Page last updated: 2024-11-13

leucovorin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

5-formyltetrahydrofolic acid : A formyltetrahydrofolic acid in which the formyl group is located at position 5. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID135403648
CHEMBL ID1679
CHEBI ID15640
SCHEMBL ID8349
SCHEMBL ID10068238
MeSH IDM0004519

Synonyms (91)

Synonym
AC-13429
(s)-2-{4-[(2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydro-pteridin-6-ylmethyl)-amino]-benzoylamino}-pentanedioic acid
bdbm50039121
2-{4-[(2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydro-pteridin-6-ylmethyl)-amino]-benzoylamino}-pentanedioic acid
5-formyl-5,6,7,8-tetrahydropteroyl-l-glutamic acid
n-[4-({[2-amino-5-formyl-4-oxo-3,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-l-glutamic acid
n5-formyltetrahydrofolic acid
leucovorinum
5-formyl-5,6,7,8-tetrahydrofolic acid
5-formyltetrahydrofolic acid
(5-formyl-5,6,7,8-tetrahydropteroyl)glutamate
n-(5-formyl-5,6,7,8-tetrahydropteroyl)-l-glutamic acid
acide folinique
CHEBI:15640 ,
n5-formyl-5,6,7,8-tetrahydrofolic acid
KBIO1_000222
DIVK1C_000222
SPECTRUM_000859
BSPBIO_000696
IDI1_000222
dw385
sd-204098
folinic acid-sf
n-[4-[[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6(rs)-pteridinyl)methyl]amino]benzoyl]-l-glutamic acid
welcovorin
leucal
l-(+)-folinic acid
citrovoeum factor
PRESTWICK2_000738
SPECTRUM5_000910
BSPBIO_002218
folinate
folinic acid
DB00650
leucovorin [usan]
l-glutamic acid, n-(4-(((2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-
einecs 200-361-6
hsdb 6544
leucovorinum (acid)
glutamic acid, n-(p-(((2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-, l-
KBIO2_003907
KBIO2_001339
KBIO2_006475
KBIOSS_001339
KBIOGR_000461
KBIO3_001438
SPECTRUM2_000116
SPBIO_000132
SPECTRUM4_000031
SPECTRUM3_000479
PRESTWICK1_000738
PRESTWICK0_000738
NINDS_000222
SPBIO_002635
PRESTWICK3_000738
BPBIO1_000766
5-formyl-tetrahydrofolate
leukovorin
leukovorum
CHEMBL1679
AKOS015961207
leucoverin
unii-q573i9dvlp
q573i9dvlp ,
S5790
(2s)-2-[(4-{[(2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl)methyl]amino}phenyl)formamido]pentanedioic acid
gtpl4816
[3h]folinic acid
gtpl6690
BRD-A75919782-238-01-8
leucovorin [hsdb]
folinic acid [mi]
folinic acid [mart.]
folinic acid [who-dd]
leucovorin [vandf]
n-(p-((((6rs)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-l-glutamate
HY-17556
SCHEMBL8349
DTXSID0048216
SCHEMBL10068238
l-glutamic acid, n-[4-[[(2-amino-5-formyl-3,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-
SBI-0051427.P003
(2s)-2-(4-((2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl)methylamino)benzamido)pentanedioic acid
Q45435667
5-formyltetrahydro-folic acid
mfcd00867488
D93089
(2s)-2-[[4-[(2-amino-5-formyl-4-oxo-3,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
EN300-27068710
(2s)-2-[(4-{[(2-amino-5-formyl-4-oxo-3,4,5,6,7,8-hexahydropteridin-6-yl)methyl]amino}phenyl)formamido]pentanedioic acid
acido folinico

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35

Bioavailability

ExcerptReferenceRelevance
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
formyltetrahydrofolic acid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
Fluoropyrimidine activity015
Disorders of folate metabolism and transport1827

Protein Targets (6)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bile salt export pumpHomo sapiens (human)IC50 (µMol)1,000.00000.11007.190310.0000AID1449628
Dihydrofolate reductaseHomo sapiens (human)Ki2.37000.00000.37564.9000AID43379
Solute carrier organic anion transporter family member 1A3Rattus norvegicus (Norway rat)Ki8.20000.50003.30008.2000AID681604
Canalicular multispecific organic anion transporter 1Rattus norvegicus (Norway rat)Ki132.00000.84004.968210.0000AID681175
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Multidrug resistance-associated protein 4Homo sapiens (human)Km640.00001.90004.27259.6900AID680355
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (45)

Processvia Protein(s)Taxonomy
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
tetrahydrobiopterin biosynthetic processDihydrofolate reductaseHomo sapiens (human)
one-carbon metabolic processDihydrofolate reductaseHomo sapiens (human)
negative regulation of translationDihydrofolate reductaseHomo sapiens (human)
axon regenerationDihydrofolate reductaseHomo sapiens (human)
response to methotrexateDihydrofolate reductaseHomo sapiens (human)
dihydrofolate metabolic processDihydrofolate reductaseHomo sapiens (human)
tetrahydrofolate metabolic processDihydrofolate reductaseHomo sapiens (human)
tetrahydrofolate biosynthetic processDihydrofolate reductaseHomo sapiens (human)
folic acid metabolic processDihydrofolate reductaseHomo sapiens (human)
positive regulation of nitric-oxide synthase activityDihydrofolate reductaseHomo sapiens (human)
regulation of removal of superoxide radicalsDihydrofolate reductaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (27)

Processvia Protein(s)Taxonomy
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
mRNA regulatory element binding translation repressor activityDihydrofolate reductaseHomo sapiens (human)
mRNA bindingDihydrofolate reductaseHomo sapiens (human)
dihydrofolate reductase activityDihydrofolate reductaseHomo sapiens (human)
folic acid bindingDihydrofolate reductaseHomo sapiens (human)
NADPH bindingDihydrofolate reductaseHomo sapiens (human)
sequence-specific mRNA bindingDihydrofolate reductaseHomo sapiens (human)
NADP bindingDihydrofolate reductaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (18)

Processvia Protein(s)Taxonomy
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
mitochondrionDihydrofolate reductaseHomo sapiens (human)
cytosolDihydrofolate reductaseHomo sapiens (human)
mitochondrionDihydrofolate reductaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (55)

Assay IDTitleYearJournalArticle
AID679299TP_TRANSPORTER: uptake in membrane vesicles from MRP3-expressing HEK293 cells2001Cancer research, Oct-01, Volume: 61, Issue:19
Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID681604TP_TRANSPORTER: inhibition of MTX uptake in OAT-K1-expressing MDCK cells2000The Journal of pharmacology and experimental therapeutics, Jun, Volume: 293, Issue:3
Trans-stimulation effects of folic acid derivatives on methotrexate transport by rat renal organic anion transporter, OAT-K1.
AID46774Tested for inhibition of [14C]-DDATHF influx in CEM/MTX cells of human leukemic lymphoblasts1994Journal of medicinal chemistry, Jul-08, Volume: 37, Issue:14
Synthesis and biological activity of N omega-hemiphthaloyl-alpha,omega- diaminoalkanoic acid analogues of aminopterin and 3',5-dichloroaminopterin.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID282412Protection against methotrexate-induced effect in human CCRF-CEM cells assessed as growth inhibition at 0.1 mM2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Benzoyl ring halogenated classical 2-amino-6-methyl-3,4-dihydro-4-oxo-5-substituted thiobenzoyl-7H-pyrrolo[2,3-d]pyrimidine antifolates as inhibitors of thymidylate synthase and as antitumor agents.
AID404304Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID680355TP_TRANSPORTER: uptake in membrane vesicles from MRP4-expressing Sf9 cells2002Cancer research, Jun-01, Volume: 62, Issue:11
Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system.
AID139776Number of mice infected to tat of total number of mice (11/11)1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID680779TP_TRANSPORTER: uptake (vesicle) in membrane vesicle from MRP2-expressing HEK293 cells2003Cancer research, Jul-15, Volume: 63, Issue:14
Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID681914TP_TRANSPORTER: inhibition of MTX uptake (MTX: 20 uM, Leucovorin: 300 uM) in membrane vesicles from MRP4-expressing Sf9 cells2002Cancer research, Jun-01, Volume: 62, Issue:11
Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID138418Effect on Pneumocystis carinii pneumonia in SCID mice1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID362433Inhibition of human RFC-mediated [3H]MTX transport in Chinese hamster PC43-10 cells at 10 uM2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Synthesis and discovery of high affinity folate receptor-specific glycinamide ribonucleotide formyltransferase inhibitors with antitumor activity.
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID282413Protection against methotrexate-induced effect in human CCRF-CEM cells assessed as growth inhibition at 10 mM2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Benzoyl ring halogenated classical 2-amino-6-methyl-3,4-dihydro-4-oxo-5-substituted thiobenzoyl-7H-pyrrolo[2,3-d]pyrimidine antifolates as inhibitors of thymidylate synthase and as antitumor agents.
AID459867Displacement of [3H]MTX from human RFC expressed in Chinese hamster PC43-10 cells at 10 uM2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduc
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID231680Ratio between Ki values of CCRF-CEM and CEM/MTX1994Journal of medicinal chemistry, Jul-08, Volume: 37, Issue:14
Synthesis and biological activity of N omega-hemiphthaloyl-alpha,omega- diaminoalkanoic acid analogues of aminopterin and 3',5-dichloroaminopterin.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID621136Inhibition of human RFC-mediated [3H]MTX uptake in chinese hamster PC43-10 cells at 10 uM after 2 mins relative to control2011Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20
Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits β-gl
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID43379Tested for the inhibition of [14C]-DDATHF influx in CCRF-CEM cells of human leukemic lymphoblast1994Journal of medicinal chemistry, Jul-08, Volume: 37, Issue:14
Synthesis and biological activity of N omega-hemiphthaloyl-alpha,omega- diaminoalkanoic acid analogues of aminopterin and 3',5-dichloroaminopterin.
AID681175TP_TRANSPORTER: inhibition of DNP-SG uptake in bile canalicular membrane vesicles from SD rat2002Drug metabolism and pharmacokinetics, , Volume: 17, Issue:1
The potential for an interaction between MRP2 (ABCC2) and various therapeutic agents: probenecid as a candidate inhibitor of the biliary excretion of irinotecan metabolites.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID680413TP_TRANSPORTER: uptake (vesicle) in membrane vesicles from MRP3-expressing HEK293 cells2003Cancer research, Jul-15, Volume: 63, Issue:14
Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (20)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (10.00)18.2507
2000's10 (50.00)29.6817
2010's8 (40.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (5.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other19 (95.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1226)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Multi-center, Open-label, Randomized, Phase 2 Clinical Trial Evaluating Safety and Efficacy of FOLFIRI With Either Panitumumab or Bevacizumab as Second-Line Treatment in Subjects With Metastatic Colorectal Cancer With Wild-type KRAS Tumors [NCT00418938]Phase 2266 participants (Actual)Interventional2006-11-01Completed
Phase 2 Study of Hepatic Arterial Infusion With Oxaliplatin, Folinic Acid and 5 Fluorouracil Alone or in Combination With Intravenous Chemotherapy in Heavily Pre-Treated Patients With Liver-Predominant Metastasis From Colorectal Cancer [NCT02345746]Phase 20 participants (Actual)Interventional2012-12-31Withdrawn(stopped due to patient population)
Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer [NCT01333033]Phase 2257 participants (Actual)Interventional2011-07-31Completed
Phase I Trial of FOLFIRI in Combination With Sorafenib and Bevacizumab in Patients With Advanced Gastrointestinal Malignancies [NCT01383343]Phase 117 participants (Actual)Interventional2011-08-31Completed
Phase II, Randomized, Controlled, Clinical Trial Exploring Efficacy and Safety of ERY001 (L-asparaginase Encapsulated in Red Blood Cells) in Association With Gemcitabine or FOLFOX4 in Second-line Therapy for Patients With Progressive Metastatic Pancreatic [NCT02195180]Phase 2141 participants (Actual)Interventional2014-07-31Completed
Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage Hepatocellular Carcinoma Out Up-to-seven: a Multi-center Randomized Controlled Trial. [NCT05171166]Phase 2/Phase 3156 participants (Anticipated)Interventional2021-12-24Recruiting
A Phase Ib/II Study of MBP-426 in Patients With Second Line Gastric, Gastro Esophageal, or Esophageal Adenocarcinoma [NCT00964080]Phase 1/Phase 262 participants (Anticipated)Interventional2009-05-31Active, not recruiting
CPT-SIOP-2009: Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Patients With Choroid Plexus Tumors [NCT01014767]Phase 327 participants (Actual)Interventional2009-11-30Terminated(stopped due to PI departure from coordinating institution)
Pilot Trial of Hyper-CVAD and Methotrexate/ARA C Plus Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma [NCT00041132]Phase 256 participants (Actual)Interventional2002-09-30Completed
Pilot Study of CS-1008 in Combination With FOLFIRI (Irinotecan, Leucovorin, and 5-fluorouracil [5-FU]) in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Failed First-line Treatment That Was Not Irinotecan-based. [NCT01124630]Phase 121 participants (Actual)Interventional2010-05-31Completed
A Comparative, Multicenter, Open-Label, Randomized, Phase 2 Study of the Safety and Antitumor Activity of Oral Eniluracil + 5 Fluorouracil + Leucovorin Versus Capecitabine Monotherapy in Subjects With Metastatic Breast Cancer [NCT01231802]Phase 2140 participants (Anticipated)Interventional2011-04-30Recruiting
Liposomal Doxorubicin(LD) Plus Gemcitabine Versus Oxaliplatin Plus Fluorouracil/Leucovorin(FOLFOX4) As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma(HCC) [NCT02527772]Phase 2/Phase 30 participants (Actual)Interventional2015-09-30Withdrawn(stopped due to It doesn't meet the requirements of randomized trials)
A Pilot Study of Pre-Operative Treatment of Newly-Diagnosed, Surgically-Resectable Osteosarcoma With Doxorubicin, Ifosfamide, Etoposide, and Cisplatin With Early Metabolic Assessment of Response [NCT01258634]Phase 12 participants (Actual)Interventional2010-07-31Terminated(stopped due to PI no longer affiliated with institution; only 2 subjects enrolled)
Open-label, Multicenter, Phase II Study Of First-line Biweekly Irinotecan, Oxaliplatin And Infusional 5-FU/LV (FOLFOXIRI) In Combination With Bevacizumab In Patients With Metastatic Colorectal Cancer [NCT01163396]Phase 257 participants (Actual)Interventional2007-07-31Completed
Randomized Phase II Trial of 4-regimen (SP, FL/Tax, FL/Doc, FOLFOX) in Patients With Recurrent or Metastatic Gastric Cancer [NCT01283204]Phase 2180 participants (Actual)Interventional2010-03-09Completed
Randomized Phase II Study of ECF-C, IC-C, or FOLFOX-C in Metastatic Esophageal and GE Junction Cancer [NCT00381706]Phase 2245 participants (Actual)Interventional2006-09-15Completed
A Phase I/II Pharmacodynamic Study of Hydroxychloroquine in Combination With FOLFOX Plus Bevacizumab to Inhibit Autophagy in Colorectal Cancer [NCT01206530]Phase 1/Phase 250 participants (Actual)Interventional2010-09-30Completed
A Phase II Study of MOAD (Methotrexate, Vincristine, L-asparaginase and Dexamethasone) With Subcutaneous Campath for Adults With Relapsed or Refractory Acute Leukemia (ALL) [NCT00262925]Phase 212 participants (Actual)Interventional2006-06-30Terminated(stopped due to slow accrual)
A Multicenter Trial Investigating the Duration of Adjuvant Therapy(3 vs. 6 Months) With the FOLFOX 4 or XELOX Regimen for Patients With High Risk Stage II or Stage III Colon Cancer [NCT01308086]Phase 32,000 participants (Actual)Interventional2010-10-31Active, not recruiting
A Randomized Phase II Study of Perioperative Atezolizumab +/- Chemotherapy in Resectable MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer [NCT05836584]Phase 2240 participants (Anticipated)Interventional2024-06-08Recruiting
A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer [NCT05379595]Phase 1/Phase 2225 participants (Anticipated)Interventional2022-07-29Recruiting
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair [NCT02912559]Phase 3700 participants (Anticipated)Interventional2017-10-16Active, not recruiting
Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI With PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer [NCT02890355]Phase 2123 participants (Actual)Interventional2016-09-01Active, not recruiting
Proposed Investigator-Initiated Clinical Trial of Pyrimethamine as a Treatment for Late-Onset GM2-gangliosidosis (Tay-Sachs and Sandhoff Disease) [NCT01102686]Phase 1/Phase 220 participants (Anticipated)Interventional2009-08-31Completed
Phase III Study Evaluating the Use of Systemic Chemotherapy and Chemohyperthemia Intraperitoneal Preoperatively (CHIP) and After Maximum Resection of Peritoneal Carcinomatosis Originating With Colorectal Cancer [NCT00769405]Phase 3264 participants (Actual)Interventional2008-02-29Completed
Efficacy and Safety of Alternating Systemic and Hepatic Artery Infusion Therapy Versus Systemic Chemotherapy Alone As Adjuvant Treatment After Resection of Liver Metastases From Colorectal Cancer: A Randomized, Parallel-Group, Open-Labelled, Active-Contro [NCT02529774]Phase 2/Phase 3432 participants (Anticipated)Interventional2015-09-30Not yet recruiting
A Randomized Multicenter Phase II/III Study Comparing 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced Resectable Adenocarcinoma of the Esophagogastreal Junction or the Stomac [NCT01216644]Phase 2/Phase 3716 participants (Actual)Interventional2010-08-31Completed
Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin and Irinotecan (FOLFIRI) as First-line Treatment for Metastatic Colorectal Cancer [NCT01219920]Phase 3244 participants (Actual)Interventional2001-11-30Completed
A Phase I Study of Riluzole in Combination With mFOLFOX6/Bevacizumab in Patients With Metastatic Colorectal Cancer [NCT04761614]Phase 113 participants (Actual)Interventional2021-04-02Active, not recruiting
BrUOG 318: FOLFOX-A For Locally Advanced Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial [NCT02578732]Phase 228 participants (Actual)Interventional2016-07-12Completed
Treatment of Advanced Colorectal or Pancreatic Cancer With Anti-CD3 x Anti-EGFR-Armed Activated T-Cells (Phase Ib) [NCT01420874]Phase 115 participants (Actual)Interventional2011-08-17Completed
A Randomized Phase II Study of PEP02 or Irinotecan in Combination With Leucovorin and 5-Fluorouracil in Second Line Therapy of Metastatic Colorectal Cancer [NCT01375816]Phase 255 participants (Actual)Interventional2011-05-31Terminated(stopped due to efficacy interim analysis as per protocol)
ESSAI DE PHASE III RANDOMISE EVALUANT LE FOLFOX AVEC OU SANS DOCETAXEL (TFOX) EN 1ère LIGNE DE CHIMIOTHERAPIE DES ADENOCARCINOMES OESO-GASTRIQUES LOCALEMENT AVANCES OU METASTATIQUES [NCT03006432]Phase 3507 participants (Actual)Interventional2016-12-19Active, not recruiting
A Phase I Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer and Good Performance Status [NCT01835041]Phase 121 participants (Actual)Interventional2013-04-30Completed
A Randomized Phase II Study of Neoadjuvant Chemoradiotherapy With 5-FU/Leucovorin (FL) vs. TS-1/Irinotecan in Patients With Locally Advanced Rectal Cancer [NCT01269216]Phase 2136 participants (Actual)Interventional2008-10-31Completed
PERIOP-FOLFIRINOX: A Pilot Trial of Perioperative Genotype-guided Irinotecan Dosing of gFOLFIRINOX for Locally Advanced Gastroesophageal Adenocarcinoma [NCT02366819]Phase 436 participants (Anticipated)Interventional2014-12-11Recruiting
A Phase I Study of FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma [NCT01383538]Phase 115 participants (Actual)Interventional2011-08-23Completed
Phase I Trial of Radioimmunotherapy (Y-90 M5A) in Combination With FOLFIRI and Bevacizumab Chemotherapy for Metastatic Colorectal Carcinoma [NCT01205022]Phase 13 participants (Actual)Interventional2011-04-30Completed
Hepatic Arterial Infusion Chemotherapy of Irinotecan, Oxaliplatin, 5-Fluorouracil and Leucovorin Versus Systemic Chemotherapy of Gemcitabine and Oxaliplatin for Unresectable Intrahepatic Cholangiocarcinoma [NCT03771846]Phase 3188 participants (Anticipated)Interventional2018-08-01Recruiting
Phase II Clinical Trial to Evaluate the Efficacy of Second-line FOLFIRI + Panitumumab in Subjects With Wild Type RAS Metastatic Colorectal Cancer Who Have Received FOLFOX + Panitumumab in First-line [NCT03751176]Phase 231 participants (Actual)Interventional2018-11-08Active, not recruiting
Phase II Study of the Combination of Low-Intensity Chemotherapy and Blinatumomab in Patients With Philadelphia Chromosome Negative Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) [NCT03518112]Phase 26 participants (Actual)Interventional2018-04-18Terminated(stopped due to Due to Competing Studies)
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer [NCT01399684]Phase 2127 participants (Actual)Interventional2011-11-30Completed
Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL) [NCT02101853]Phase 3669 participants (Actual)Interventional2014-12-17Active, not recruiting
Intensified Methotrexate, Nelarabine (Compound 506U78) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (ALL) or T-cell Lymphoblastic Lymphoma [NCT00408005]Phase 31,895 participants (Actual)Interventional2007-01-22Active, not recruiting
H-9926-LCH III: Treatment Protocol of the Third International Study for Langerhans Cell Histiocytosis [NCT00488605]Phase 30 participants (Actual)Interventional2023-08-01Withdrawn(stopped due to This is a duplicate record and the sponsor has registered the study.)
Modified FLOT Chemotherapy as First-line Treatment in Advanced or Metastatic Gastric Cancer [NCT03606928]Phase 1/Phase 218 participants (Actual)Interventional2018-07-01Completed
A Stratified Phase II Study of Neoadjuvant Chemotherapy Given Before SCPRT as Treatment for Patients With MRI-Staged Operable Rectal Cancer at High Risk of Metastatic Relapse [NCT01263171]Phase 260 participants (Actual)Interventional2012-04-30Completed
Molecularly Informed Integrated Immunotherapy Combining Innate High-affinity Natural Killer (haNK) Cell Therapy w/ Adenoviral & Yeast-based Vaccines to Induce T-cell Responses in Subjects w/ Advanced, Unresectable & Untransplantable HCC [NCT03563170]Phase 1/Phase 20 participants (Actual)Interventional2018-05-25Withdrawn(stopped due to Enrollment not initiated)
A Randomized Phase II Study of Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Patients With Metastatic Colorectal Cancer. [NCT01622543]Phase 2109 participants (Actual)Interventional2012-10-26Completed
Total Neoadjuvant Chemotherapy With 5-fluoruracil, Leucovorin, Oxaliplatin and Docetaxel in Locally Advanced Gastric and Gastroesophageal Junction Cancer (OCTASUR): Randomized, Single Center, Open Label Trial, Phase 2/3 [NCT06028737]Phase 2/Phase 3758 participants (Anticipated)Interventional2023-08-25Recruiting
Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy Compared With Standard of Care Therapy as First-line Intervention in Participants With Advanced/Metastatic Gastroeso [NCT04662710]Phase 3890 participants (Anticipated)Interventional2020-12-30Active, not recruiting
Trial Evaluating the Efficacy and Tolerance of Perioperative Chemotherapy With 5FU-Cisplatin-Cetuximab in Adenocarcinomas of the Stomach and Gastroesophageal Junction. Phase II Single Arm, Multicenter. [NCT01360086]Phase 265 participants (Actual)Interventional2011-06-30Completed
S-1 Plus Oxaliplatin Compared With Fluorouracil, Leucovorin Calcium Plus Oxaliplatin as Perioperative Chemotherapy for Advanced Gastric Carcinoma: a Multi-center, Open-labeled, Randomized Controlled Trial [NCT01364376]583 participants (Actual)Interventional2011-06-30Completed
A Phase Ib, Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Humanized Anti-VEGF Monoclonal Antibody(Sevacizumab) Injection Plus FOLFIRI in Chinese Patients With Metastatic Colorectal Cancer [NCT02453464]Phase 136 participants (Anticipated)Interventional2015-08-31Recruiting
NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy [NCT03197584]Phase 1/Phase 20 participants (Actual)Interventional2017-12-31Withdrawn(stopped due to Trial not initiated)
Phase II, Multicentric Randomized Trial, Evaluating the Efficacy of Fluoropyrimidine-based Standard Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receivi [NCT01442649]Phase 2133 participants (Actual)Interventional2010-12-31Completed
NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy [NCT03175666]Phase 1/Phase 20 participants (Actual)Interventional2017-12-31Withdrawn(stopped due to Trial not initiated)
NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With Programmed Cell Death Protein 1 (PD-1)/Programmed Death-ligand 1 (PD-L1) Inhibitors [NCT03169738]Phase 1/Phase 20 participants (Actual)Interventional2018-02-28Withdrawn(stopped due to Trial not initiated)
A Randomized, Phase 3 Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment of Patients With Pancreatic Adenocarcinoma [NCT03665441]Phase 3512 participants (Actual)Interventional2018-09-15Completed
NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After Anti-programmed Death-ligand 1 (PD-L1) Therapy [NCT03167164]Phase 1/Phase 20 participants (Actual)Interventional2017-12-31Withdrawn(stopped due to Trial not initiated)
A Randomized, Open-Label, Multicenter Phase 3 Trial of Domvanalimab, Zimberelimab, and Chemotherapy Versus Nivolumab and Chemotherapy in Participants With Previously Untreated Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, [NCT05568095]Phase 3970 participants (Anticipated)Interventional2022-11-21Recruiting
A Phase 1/2, Open-Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723) [NCT03085914]Phase 1/Phase 270 participants (Actual)Interventional2017-05-02Completed
A Phase II Trial to Evaluate the Efficacy and Safety of FOLFIRI + Panitumumab as First-line Treatment in Elderly Patients With RAS/BRAF Wild-type Unresectable Metastatic Colorectal Cancer and Good Performance Status [NCT03142516]Phase 220 participants (Actual)Interventional2017-10-31Completed
mFOLFOXIRI Compared to mFOLFOX6 or CapeOx as Adjuvant Chemotherapy for Stage IIIB or Stage IIIC Colorectal Cancer: A Randomized Controlled Clinical Research [NCT05200299]Phase 2100 participants (Anticipated)Interventional2022-02-01Recruiting
Phase 1b Trial of 5-fluorouracil, Leucovorin, Irinotecan in Combination With Temozolomide (FLIRT) and Bevacizumab for the First-line Treatment of Patients With MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer. [NCT04689347]Phase 118 participants (Anticipated)Interventional2021-01-01Recruiting
A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in Combination With Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX as Neoadjuvant Treatment in Patients With Locally Advanced, Unresectable Pancreatic Cancer [NCT03941093]Phase 3284 participants (Actual)Interventional2019-05-10Active, not recruiting
Timing of Rectal Cancer Response to Chemoradiation [NCT00335816]Phase 2248 participants (Anticipated)Interventional2008-08-31Active, not recruiting
Phase II Trial of Modified FOLFIRINOX in Patients With Metastatic Biliary Tract Cancer After Failure of Gemcitabine/Cisplatin Chemotherapy [NCT03778593]Phase 234 participants (Actual)Interventional2019-03-01Completed
A Phase 1b Trial of LY2606368 in Combination With Chemotherapy or Targeted Agents in Advanced and/or Metastatic Tumors [NCT02124148]Phase 1167 participants (Actual)Interventional2014-06-18Completed
Phase II Study of Intensified CVP, Rituximab, and High Dose Cyclophosphamide for Adult Burkitt or Burkitt-Like Lymphoma [NCT00133991]Phase 223 participants (Actual)Interventional2005-07-31Completed
Preoperative Induction Therapy With 12 Weeks of Panitumumab in Combination With mFOLFOX-6 in an Enriched Population (Quadruple Wild-Type) of Patients With mrT3 Rectal Cancer of the Middle Third With Clear Mesorectal Fascia [NCT03000374]Phase 234 participants (Actual)Interventional2017-05-30Completed
QUILT-3.088 NANT Pancreatic Cancer Vaccine: Phase II Randomized Trial of the NANT Pancreatic Cancer Vaccine vs. Standard-of-Care as First- Line Treatment for Patients With Metastatic Pancreatic Cancer [NCT03563144]Phase 20 participants (Actual)Interventional2018-08-31Withdrawn(stopped due to Trial not initiated)
A Phase IIa, Multicenter, Open-label Study to Assess the Safety and Efficacy of the Combination of BL-8040 and Pembrolizumab in Patients With Metastatic Pancreatic Cancer, the COMBAT Study [NCT02826486]Phase 280 participants (Actual)Interventional2016-09-30Completed
Avelumab Added to FOLFIRI Plus Cetuximab Followed by Avelumab Maintenance in Patients With Previously Untreated RAS Wild-type Colorectal Cancer. The Phase II FIRE-6 Study [NCT05217069]Phase 257 participants (Actual)Interventional2019-09-27Active, not recruiting
A Phase 2, Single-Arm, Open-Label, Multicenter, Study of Folotyn® (Pralatrexate Injection) in Combination With Oral Leucovorin to Prevent or Reduce Mucositis in Patients With Hematological Malignancies Including PTCL and CTCL [NCT02106650]Phase 236 participants (Actual)Interventional2014-07-31Completed
Prospective Phase II Study of Neoadjuvant mFOLFOXIRI for Potentially Resectable Cholangiocarcinoma [NCT03603834]Phase 225 participants (Anticipated)Interventional2018-09-19Recruiting
The Effect of FOLFIRINOX and Stereotactic Body Radiation Therapy for Locally Advanced, Non-Resectable Pancreatic Cancer [NCT02128100]Phase 228 participants (Anticipated)Interventional2014-05-31Recruiting
A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old With First Relapse [NCT04546399]Phase 2550 participants (Anticipated)Interventional2020-12-04Suspended(stopped due to Other - FDA Partial Clinical Hold)
Randomised, Multicentre, Phase II Pilot Study to Assess the Efficacy and Safety of Treatment With FOLFIRI-aflibercept Compared to Initial Treatment With FOLFIRI-aflibercept (for 6 Cycles) Followed by Maintenance With 5FU-aflibercept, in an Elderly Populat [NCT03279289]Phase 2170 participants (Actual)Interventional2017-10-25Completed
An Open Randomized Single Site Pharmacokinetic and Pharmacodynamic Study, of Calciumfolinat 60 mg/m², 200 mg/m² or 500 mg/ m² in Blood, Tumor and Adjacent Mucosa From Patients With Colon Cancer [NCT02959541]48 participants (Actual)Interventional2016-09-30Active, not recruiting
Open-label, Randomized, Comparative Phase 2 Study of Combination Immunotherapy Plus Standard-of-care Chemotherapy Versus Standard-of-care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer [NCT04390399]Phase 2328 participants (Anticipated)Interventional2020-07-21Recruiting
Pilot Study Evaluating An Allogeneic GM-CSF-Transduced Pancreatic Tumor Cell Vaccine (GVAX) and Low Dose Cyclophosphamide Integrated With Fractionated Stereotactic Body Radiation Therapy (SBRT) and FOLFIRINOX Chemotherapy in Patients With Resected Adenoca [NCT01595321]19 participants (Actual)Interventional2012-10-29Active, not recruiting
A Phase II Study of ORZEL (UFT + Leucovorin) in Elderly (at Least 75 Years Old) Patients With Colorectal Cancer [NCT00004860]Phase 20 participants Interventional2000-10-09Completed
Randomized Phase II Study of FOLFOXIRI Plus Bevacizumab Plus Atezolizumab Versus FOLFOXIRI Plus Bevacizumab as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patients. [NCT03721653]Phase 2218 participants (Actual)Interventional2018-11-30Completed
Randomized PhIII Trial of Cetuximab, Bevacizumab & Biweekly Infusional 5FU/Leucovorin (FOLF-CB) vs. Oxaliplatin, Bevacizumab, & Biweekly Infusional 5FU/Leucovorin (Bev-FOLFOX) in First Line Treatment of Metastatic Colorectal Cancer [NCT00252564]Phase 3247 participants (Actual)Interventional2005-09-30Completed
A Randomized , Open-label, Multicenter, Phase II Study to Compare the Efficacy of S-1 and S-1 Plus Leucovorin as Second Line Treatment on Gemcitabine-refractory Patients With Inoperable or Advanced Pancreatic Cancers [NCT01074996]Phase 292 participants (Actual)Interventional2010-02-28Active, not recruiting
A Randomized Phase II Study of Comparing S-1/Leucovorin With sLV5FU2 as the First-line Treatment for Elderly Patients With Colorectal Cancer [NCT01193452]Phase 2100 participants (Anticipated)Interventional2010-08-31Recruiting
Sorafenib Plus Hepatic Artery Infusion Chemotherapy of Oxaliplatin, Fluorouracil/Leucovorin Versus Sorafenib Plus Hepatic Artery Infusion Chemotherapy of Oxaliplatin for Advanced Hepatocellular Carcinoma [NCT03812770]Phase 2150 participants (Anticipated)Interventional2018-08-04Recruiting
A Phase II Study of Punctual, Cyclic, and Intensive Chemotherapy With Liposomal Cytarabine (Depocyt®) CNS Prophylaxis for Adults With Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma [NCT02043587]Phase 231 participants (Actual)Interventional2014-01-31Terminated(stopped due to Original investigator for the trial has left)
A Phase III Clinical Trial Comparing Infusional 5-Fluorouracil (5-FU), Leucovorin, and Oxaliplatin (mFOLFOX6) Every Two Weeks With Bevacizumab to the Same Regimen Without Bevacizumab for the Treatment of Patients With Resected Stages II and III Carcinoma [NCT00096278]Phase 32,710 participants (Actual)Interventional2004-09-15Completed
"An Open-Label Randomized Phase III Study of Intermittent Oral Capecitabine in Combination With Intravenous Oxaliplatin (Q3W) (XELOX) Versus Bolus and Continuous Infusion Fluorouracil/ Intravenous Leucovorin With Intravenous Oxaliplatin (Q2W) (FOLFOX4) as [NCT00069108]Phase 3627 participants (Actual)Interventional2003-07-31Completed
Intensive Chemotherapy And Immunotherapy In Patients With Newly Diagnosed Primary CNS Lymphoma [NCT00098774]Phase 247 participants (Actual)Interventional2004-10-31Completed
Treatment of Late Isolated Extramedullary Relapse From Acute Lymphoblastic Leukemia (ALL) (Initial CR1≥ 18 Months) [NCT00096135]168 participants (Actual)Interventional2004-11-30Completed
A Randomized Phase III Trial of Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) With or Without Cetuximab (C225) After Curative Resection for Patients With Stage III Colon Cancer [NCT00079274]Phase 33,397 participants (Actual)Interventional2004-02-29Completed
A Pilot Study of FOLFOX in Combination With Bevacizumab in Patients With Advanced Neuroendocrine Tumors [NCT00227617]Phase 2/Phase 336 participants (Actual)Interventional2005-06-08Terminated(stopped due to Low accrual)
A Phase Ib/II Study of Regorafenib and Nivolumab Plus Chemotherapy in Patients With Unresectable Advanced/Recurrent Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma [NCT05394740]Phase 1/Phase 230 participants (Actual)Interventional2022-06-06Active, not recruiting
A Phase II Trial of Modified FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Response Based Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Adenocarcinoma of the Esophagus, Gastro-esophageal Junction, and [NCT02037048]Phase 263 participants (Anticipated)Interventional2014-02-10Active, not recruiting
Phase II Study of Treatment Selection Based Upon Tumor Thymidylate Synthase Expression in Previously Untreated Patients With Metastatic Colorectal Cancer [NCT00098787]Phase 2247 participants (Actual)Interventional2005-09-08Completed
A Phase I Study Of Hepatic Arterial Infusion With Floxuridine And Dexamethasone In Combination With Intravenous Oxaliplatin Plus 5-Fluorouracil And Leucovorin As Adjuvant Treatment After Resection Of Hepatic Metastases From Colorectal Cancer [NCT00059930]Phase 138 participants (Actual)Interventional2003-01-31Active, not recruiting
A Randomised, Double-blind, Phase III Study to Compare the Efficacy and Safety of Cediranib (AZD2171, RECENTIN™) When Added to 5 Fluorouracil, Leucovorin and Oxaliplatin (FOLFOX) or Capecitabine and Oxaliplatin (XELOX) With the Efficacy and Safety of Plac [NCT00399035]Phase 31,254 participants (Actual)Interventional2006-11-30Completed
A Phase 1 Study of Alisertib (MLN8237) in Combination With mFOLFOX in Gastrointestinal Tumors [NCT02319018]Phase 114 participants (Actual)Interventional2015-08-27Completed
Perioperative Chemotherapy (FLOT Protocol) Compared To Neoadjuvant Chemoradiation (CROSS Protocol) in Patients With Adenocarcinoma of the Esophagus [NCT02509286]Phase 3438 participants (Actual)Interventional2016-01-31Active, not recruiting
[NCT02500940]Phase 354 participants (Anticipated)Interventional2015-05-31Recruiting
An Open Label, Multi-Center Phase 1b/2a Trial Investigating Different Doses of Sym004 in Combination With FOLFIRI in Patients With Metastatic Colorectal Cancer Progressing After First-Line Therapy [NCT02568046]Phase 1/Phase 210 participants (Actual)Interventional2016-03-15Terminated(stopped due to Discontinued development of Sym004 in combination with FOLFIRI)
FOLFOX6 Versus mFOLFIRINOX as First Line Chemotherapy in Metastatic Gastric or Esophagogastric Junction Adenocarcinoma (Type II-III): Open-label Randomized Phase 2/3 Trial [NCT04442984]Phase 2326 participants (Anticipated)Interventional2019-11-03Recruiting
Clinical Phase II Study Evaluating Systemic Chemotherapy in Combination With Cetuximab as Adjuvant Treatment in Patients With Completely Surgically Resected Peritoneal Carcinomatosis of Colorectal Origin [NCT00766142]Phase 218 participants (Actual)Interventional2007-05-01Terminated(stopped due to In 2008, new data highlighted that Cetuximab had no efficacy in case of KRAS mutation. As such, eligibility criteria were revised and limited to KRAS wild-type. Inclusions were thus slown down considerably, and the trial was stopped.)
No Operation After Short Course Equivalent Dose (Ht) Radiation Therapy Followed By Consolidation Chemotherapy In Locally Advanced Rectal Cancer: The Prospective, Single Arm NOAHS-ARC Trial [NCT04864067]Phase 273 participants (Anticipated)Interventional2021-06-09Recruiting
Phase II Study of Combination of Hyper-CVAD and Dasatinib (NSC-732517) With or Without Allogeneic Stem Cell Transplant in Patients With Philadelphia (Ph) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) (A BMT Study) [NCT00792948]Phase 297 participants (Actual)Interventional2009-09-01Active, not recruiting
Randomized Phase 2 Study Comparing Second Look Laparoscopy to Standard Follow up in Patients With no Radiologic Evidence of Disease at 6 Months After Complete Resection of Colorectal Mucinous Carcinoma [NCT01628211]Phase 2140 participants (Anticipated)Interventional2012-04-30Recruiting
A Prospective, Multicenter, Phase III Clinical Study Comparing Continuous Hepatic Arterial Infusion of Raltetrexed With Oxaliplatin(SALOX) Versus FOLFOX in Advanced Hepatocellular Carcinoma [NCT05231382]Phase 3426 participants (Anticipated)Interventional2022-03-28Recruiting
A Randomized Phase II Trial of Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in Patients With Previously Untreated Metastatic or Unresectable Colorectal Cancer [NCT03050814]Phase 230 participants (Actual)Interventional2017-04-05Terminated(stopped due to Terminated after an unplanned interim efficacy analysis.)
Hepatic Arterial Infusion Chemotherapy Plus Targeted Therapy and/or PD-1 Inhibitors as Conversion Treatment for Unresectable Intrahepatic Cholangiocarcinoma [NCT05489692]43 participants (Actual)Observational2017-09-01Completed
The Impact on Recurrence Risk of Adjuvant Transarterial Chemoinfusion (TAI) Versus Adjuvant Transarterial Chemoembolization (TACE) for Patients With Hepatocellular Carcinoma And Portal Vein Tumor Thrombosis (PVTT) After Hepatectomy : A Random, Controlled, [NCT03192644]Phase 3162 participants (Anticipated)Interventional2017-07-01Recruiting
Hepatic Arterial Infusion Chemotherapy Using Oxaliplatin Plus Fluorouracil/Leucovorin for Patients With Locally Advanced Hepatocellular Carcinoma [NCT02436044]0 participants Expanded AccessApproved for marketing
RFA Combined With Oxaliplatin + 5-FluoroUracil/LeucoVorin (5-FU/LV) (FOLFOX4) for Recurrent HCC:an Open Lable, Single-arm, Prospective Study [NCT02426450]Phase 228 participants (Anticipated)Interventional2015-04-30Active, not recruiting
Personalized Therapy for Esophagogastric Cancer Using Thymidylate Synthase Genetic Markers [NCT02296671]Phase 20 participants (Actual)Interventional2015-02-28Withdrawn(stopped due to Was unable to accrue any patients)
NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL [NCT03169790]Phase 1/Phase 20 participants (Actual)Interventional2017-12-31Withdrawn(stopped due to Trial not initiated)
A Multi-center Randomized Controlled Trial: Intraportal Chemotherapy Combined With Adjuvant Chemotherapy (mFOLFOX6) for Stage II and III Colon Cancer [NCT02402972]Phase 3700 participants (Anticipated)Interventional2015-02-28Recruiting
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5745 Combined With mFOLFOX6 as First Line Treatment in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma [NCT02545504]Phase 3432 participants (Actual)Interventional2015-10-13Completed
Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen [NCT02923921]Phase 3567 participants (Actual)Interventional2017-03-01Completed
Preoperative Hypofractionated Radiotherapy With FOLFOX for Esophageal/Gastroesophageal Junction Adenocarcinoma (PHOX) [NCT06078709]Phase 299 participants (Anticipated)Interventional2023-11-20Recruiting
Effects of Concomitant Administration of BMS-986195 on the Single-dose Pharmacokinetics of Methotrexate and Probe Substrates for Cytochrome P450 1A2, 2C8, 2C9, 2C19, 3A4, Organic Anion Transporter Polypeptide 1B1 and P-glycoprotein in Healthy Participants [NCT03131973]Phase 126 participants (Actual)Interventional2017-05-13Completed
A Phase IB Study FOLFIRINOX and NIS793 in Patients With Pancreatic Cancer [NCT05417386]Phase 150 participants (Anticipated)Interventional2022-08-09Recruiting
A Phase II Study of AK112 With or Without AK117 for Patients With Metastatic Colorectal Cancer [NCT05382442]Phase 2114 participants (Anticipated)Interventional2022-07-27Recruiting
Comparative Analysis of Immune Profile Following Neoadjuvant Chemotherapy in Colorectal Liver Metastases (CRLM): A Prospective Pilot Clinical Trial [NCT03698461]Phase 220 participants (Actual)Interventional2019-05-15Active, not recruiting
A Phase II Study of Dasatinib (Sprycel®) (NSC #732517) as Primary Therapy Followed by Transplantation for Adults >/= 18 Years With Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia by CALGB, ECOG and SWOG [NCT01256398]Phase 266 participants (Actual)Interventional2010-12-14Completed
Peri-operative S-1/Leucovorin, Oxaliplatin and Gemcitabine (SLOG) for Localized Pancreatic Cancer [NCT05048524]Phase 240 participants (Anticipated)Interventional2021-09-03Recruiting
Phase II Study of 2-weekly Raltitrexed Plus Irinotecan Regimen (RAILIRI) Versus Fluorouracil, Leucovorin, and Irinotecan Regimen (FOLFIRI) as Second-line Treatment in Advanced Colorectal Cancer Patients [NCT02376452]Phase 2100 participants (Anticipated)Interventional2014-09-30Recruiting
Sorafenib Plus Hepatic Artery Infusion Chemotherapy of Oxaliplatin, Fluorouracil/Leucovorin Versus Sorafenib Plus Hepatic Artery Infusion Chemotherapy of Oxaliplatin for Hepatocellular Carcinoma With Major Portal Vein Tumor Thrombosis [NCT03468231]Phase 3300 participants (Anticipated)Interventional2018-03-09Recruiting
A Phase II Evaluation of Five Fractions of Radiotherapy Followed by Full Dose FOLFOX Chemotherapy as Preoperative Treatment for Rectal Cancer [NCT01060007]Phase 280 participants (Actual)Interventional2009-11-30Completed
"A Novel Pediatric-Inspired Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia" [NCT01920737]Phase 239 participants (Actual)Interventional2013-08-31Active, not recruiting
QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Molecularly Informed Integrated Immunotherapy Combining (haNK) Cell Therapy With Adenoviral and Yeast-based Vaccines to Induce T-cell Responses in Subjects With SCC Who Have Progressed on or After P [NCT03387111]Phase 1/Phase 265 participants (Anticipated)Interventional2018-01-13Active, not recruiting
Randomized Double-Blind, Placebo-Controlled Parallel Multi-Center Study to Assess the Efficacy of Cannabidiol (BRCX014) Combined With Standard-Of-Care Treatment in Subjects With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies [NCT03607643]Phase 1/Phase 2160 participants (Anticipated)Interventional2019-01-15Not yet recruiting
A Randomized Controlled Study of the Efficacy of Hepatic Arterial Perfusion Chemotherapy Concurrently Compared to Sequentially Combined With Targeted and Immunotherapy in Potentially Resectable Intermediate and Advanced HCC [NCT06041477]Phase 3540 participants (Anticipated)Interventional2023-09-30Recruiting
Phase I/II Study of the Combination of Irinotecan and POF (Paclitaxel Plus Oxaliplatin Plus 5-fluorouracil Plus Leucovorin) and Tislelizumab [NCT05319639]Phase 1/Phase 220 participants (Anticipated)Interventional2023-02-16Recruiting
A Phase 1b/2a Dose Escalation Study of BOLD-100 in Combination With FOLFOX Chemotherapy in Patients With Advanced Solid Tumours [NCT04421820]Phase 1/Phase 2117 participants (Actual)Interventional2020-08-28Active, not recruiting
Randomized, Double-Blind, Phase II Study of FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment for Patients With Metastatic Colorectal Cancer [NCT01418222]Phase 2194 participants (Actual)Interventional2011-09-14Completed
A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer Who Have Not [NCT04456699]Phase 3335 participants (Actual)Interventional2020-08-19Completed
Treatment of Social and Language Deficits With Leucovorin for Young Children With Autism [NCT04060030]Phase 280 participants (Anticipated)Interventional2020-10-08Recruiting
METIMMOX: Colorectal Cancer METastasis - Shaping Anti-tumor IMMunity by OXaliplatin [NCT03388190]Phase 280 participants (Actual)Interventional2018-05-29Active, not recruiting
A Phase III Multicenter Open-label Randomized Trial to Evaluate Efficacy and Safety of Folfirinox (FFX) Versus Combination of CPI-613 With Modified Folfirinox (mFFX) in Patients With Metastatic Adenocarcinoma of the Pancreas [NCT03504423]Phase 3528 participants (Actual)Interventional2018-11-09Completed
To Observe the Pathological Remission Rate and Safety of FOLFOXIRI for Neoadjuvant Treatment of High-risk Locally Advanced Colorectal Cancer With a Single-arm, Open, Prospective Phase II Exploratory Clinical Study [NCT05018182]Phase 269 participants (Anticipated)Interventional2021-08-02Recruiting
Cadonilimab Plus mFOLFIRINOX as Conversion Therapy in Patients With Locally Advanced Pancreatic Cancer:A Prospective, Single-arm, Phase II Trial [NCT06153368]Phase 230 participants (Anticipated)Interventional2023-12-19Not yet recruiting
Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX in Patients With Initially Unresectable Colorectal Liver Metastasis [NCT03493048]Phase 2140 participants (Actual)Interventional2018-04-15Active, not recruiting
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors [NCT03314935]Phase 1/Phase 2149 participants (Actual)Interventional2017-11-21Completed
Efficacy and Safety of Hepatic Artery Infusion Chemotherapy in Patients With Advanced or Unresectable Hepatocellular Carcinoma Who Have Progressed or Are Intolerant to Systemic Therapy [NCT04994236]Phase 249 participants (Anticipated)Interventional2021-07-01Recruiting
[NCT03067792]Phase 352 participants (Actual)Interventional2014-12-31Completed
Alternating Neoadjuvant Gemcitabine-Nab-Paclitaxel and Nanoliposomal Irinotecan (Nal-IRI) With 5-Fluorouracil and Folinic Acid (Leucovorin) Regimens in Resectable and Borderline Resectable Pancreatic Cancer [NCT03703063]Phase 130 participants (Anticipated)Interventional2018-09-17Recruiting
Prospective, Single-arm, Multicenter Clinical Study of Hepatic Artery Infusion Chemotherapy With Donafenib for Adjuvant Treatment of HCC Patients With High Risk of Recurrence After Hepatectomy. [NCT04962958]Phase 230 participants (Anticipated)Interventional2023-07-01Not yet recruiting
Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer Prospective, Randomized, Open, Multicenter Phase III Trial to Investigate the Efficacy of Active Post-resection/Ablation Therapy in Patients With Metastatic Colorectal Canc [NCT05008809]Phase 3507 participants (Anticipated)Interventional2021-12-06Recruiting
A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia [NCT02723994]Phase 2171 participants (Actual)Interventional2016-09-30Active, not recruiting
A Phase II Study of 5-Fluorouracil, Bevacizumab (Avastin), and Radiation in the Preoperative or Adjuvant Treatment of Patients With Stage II / III Rectal Cancer [NCT00308516]Phase 266 participants (Actual)Interventional2006-03-31Completed
A Randomized, Open Labeled Phase II Pilot Study of Total Neoadjuvant Chemotherapy With FLOT ( FLOT-TNT) VS Standard Perioperative FLOT ( FLOTPOP) in Patients With Gastric or GEJ Cancer, and Assessment of CTDNA as Correlative Biological Response [NCT05567835]Phase 250 participants (Anticipated)Interventional2023-12-31Not yet recruiting
A Phase II Study to Evaluate the Surgical Conversion Rate in Patients Receiving FOLFOXIRI +/- Cetuximab for Unresectable Wild-Type KRAS/NRAS Colorectal Cancer With Metastases Confined to the Liver [NCT02063529]Phase 2101 participants (Actual)Interventional2014-02-28Completed
Phase II Study of Ziv-Aflibercept Followed by the Addition of 5-FU in the Third Line Setting of Metastatic Colorectal Cancer [NCT02235324]Phase 20 participants (Actual)Interventional2015-03-31Withdrawn(stopped due to Lack of funding)
A Phase 2 Study of Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Patients With Metastatic Pancreatic Ductal Adenocarcinoma [NCT04752696]Phase 243 participants (Actual)Interventional2021-02-03Active, not recruiting
Systemic Therapy With a Loco-regional Treatment in Patients With Locally Advanced Pancreatic Cancer: The SMART Study [NCT04276857]27 participants (Anticipated)Interventional2024-01-01Not yet recruiting
Short-course Radiotherapy Versus Chemoradiotherapy, Followed by Consolidation Chemotherapy, and Selective Organ Preservation for MRI-defined Intermediate and High-risk Rectal Cancer Patients [NCT04246684]Phase 3702 participants (Anticipated)Interventional2020-10-15Active, not recruiting
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial: PRIME [NCT03878524]Phase 12 participants (Actual)Interventional2020-04-01Active, not recruiting
Phase I Trial of huA33 Plus 5-fluorouracil (5-FU), Leucovorin and Oxaliplatin in Patients With Metastatic Colorectal Cancer [NCT00199797]Phase 120 participants (Actual)Interventional2005-04-18Completed
Conversion From Unresectable To Resectable Liver Metastases In Patients With Liver-Only Metastatic Colorectal Cancer Treated With FOLFOXIRI Plus Bevacizumab. The Conversion Trial. [NCT03401294]Phase 232 participants (Anticipated)Interventional2024-01-01Not yet recruiting
A Phase II Randomized Study of SLOG vs mFOLFIRINOX as the First-line Treatment in Locally Advanced Uncresectable or Metastatic Pancreatic Cancer [NCT03443492]Phase 2130 participants (Anticipated)Interventional2018-03-26Enrolling by invitation
An Open-label, Multicenter, Single-arm, Phase 1b/2 Study of NANT-008 in Combination With 5-fluorouracil, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma. [NCT03127124]Phase 1/Phase 264 participants (Anticipated)Interventional2018-02-27Suspended(stopped due to IRB Recommendation)
An Open-Label Randomized Phase 2 Trial Of The NANT NEOADJUVANT Triple-Negative Breast Cancer (TNBC) VACCINE VS Standard-Of-Care For The Neoadjuvant Treatment Of Subjects With TNBC [NCT03554109]Phase 20 participants (Actual)Interventional2018-09-30Withdrawn(stopped due to Trial not initiated)
Phase II Randomized Controlled Trial of FOLFOXIRI Compared to FOLFOX in First Line Treatment of Chemo-naive Metastatic Colorectal Cancer [NCT02128425]Phase 2162 participants (Anticipated)Interventional2014-04-30Recruiting
The Effect of Monosialotetrahexosylganglioside (GM1) in Prevention of Oxaliplatin Induced Neurotoxicity in Colorectal Cancer Patients Who Received Oxaliplatin-based Adjuvant Chemotherapy: A Multi-center, Randomized, Placebo-controlled Trial [NCT02251977]Phase 3196 participants (Actual)Interventional2014-09-30Completed
NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy Combining Innate High-affinity Natural Killer (haNK) Cell Therapy With Adenoviral and Yeast-based Vaccines to Induce T-cell Responses in Subjects With Pancreatic Cancer Who Have [NCT03387098]Phase 1/Phase 2173 participants (Anticipated)Interventional2018-01-02Active, not recruiting
A Phase Ib Study of hPV19, a Novel Humanized Monoclonal Antibody Against Vascular Endothelial Growth Factor (VEGF),in Combination With Chemotherapy in Patients With Advanced Solid Tumors Refractory to Standard Therapy. [NCT03503604]Phase 118 participants (Anticipated)Interventional2018-05-01Not yet recruiting
A Randomized Phase III Study of 5-Fluorouracil-based Regimen With or Without Oxaliplatin as 2nd Line Treatment of Advanced or Metastatic Pancreatic Cancer in Patients Who Have Previously Received Gemcitabine-based Chemotherapy [NCT01121848]Phase 3108 participants (Actual)Interventional2010-07-31Completed
Adjuvant Chemotherapy Combined With Huaier Granule for Treating High-risk Stage II, Stage III Colorectal Cancer [NCT02785146]Phase 3230 participants (Anticipated)Interventional2016-06-30Recruiting
The Efficacy and Safety of Retreatment With Transcatheter Arterial Infusion (TAI) for Patients Who Showed TACE-resistant: a Randomized Controlled Trial [NCT02220088]Phase 2/Phase 379 participants (Actual)Interventional2014-12-31Terminated(stopped due to protocol violation)
"A 2x2 Factorial Randomized Phase III Study of Intermittent Oral Capecitabine in Combination With Intravenous Oxaliplatin (Q3W) (XELOX) With/Without Intravenous Bevacizumab (Q3W) Versus Bolus and Continuous Infusion Fluorouracil/Intravenous Leucovorin Wit [NCT00069095]Phase 32,035 participants (Actual)Interventional2003-07-31Completed
A Phase II Trial of Sequential Chemotherapy, Imatinib Mesylate (Gleevec, STI571) (NSC # 716051), and Transplantation for Adults With Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia by the CALGB and SWOG [NCT00039377]Phase 258 participants (Actual)Interventional2002-04-30Completed
Open, Randomized, Controlled, Multicenter Phase III Study Comparing 5FU/ FA Plus Irinotecan Plus Cetuximab Versus 5FU/FA Plus Irinotecan as First-line Treatment for Epidermal Growth Factor Receptor-expressing Metastatic Colorectal Cancer [NCT00154102]Phase 31,221 participants (Actual)Interventional2004-05-31Completed
Phase II Evaluation of the Effect of 2 Versus 6 Hour Oxaliplatin Infusions on Neuropathy and Pharmacokinetics in Patients With Gastrointestinal Cancers [NCT03800693]Phase 260 participants (Anticipated)Interventional2019-03-14Recruiting
Randomized Phase II Study of SOX vs mFOLFOX6 as Neoadjuvant Chemotherapy in Patients With Resectable Rectal Cancer (KSCC1301). [NCT02280070]Phase 2110 participants (Anticipated)Interventional2013-09-30Recruiting
A Phase 2 Study of Futibatinib in Combination With PD-1 Antibody-based Standard of Care Therapy in Patients With Solid Tumors. [NCT05945823]Phase 226 participants (Anticipated)Interventional2023-07-13Recruiting
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating Combination of TST001, Nivolumab and Chemotherapy as First-Line Treatment in Subjects With Claudin18.2 Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (G [NCT06093425]Phase 3950 participants (Anticipated)Interventional2023-10-31Not yet recruiting
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy) [NCT02112916]Phase 3847 participants (Actual)Interventional2014-10-04Active, not recruiting
A Multicenter, Randomized Double-blind Placebo Controlled Phase III Study of the Efficacy of Xaliproden in Preventing the Neurotoxicity of Oxaliplatin in First-line Treatment of Patients With Metastatic Colorectal Cancer Treated With Oxaliplatin / 5-FU/LV [NCT00305188]Phase 3879 participants (Actual)Interventional2005-12-31Completed
Orzel (UFT+Leucovorin) as First-Line Therapy for Metastatic Breast Cancer [NCT00005608]Phase 20 participants Interventional2000-02-29Terminated(stopped due to Drug was pulled from the market.)
A Phase II Study Assessing Efficacy and Safety of TS-1 in Combination With Calcium Folinate in Patients With Heavily Pre-treated Metastatic Colorectal Cancer [NCT03517618]Phase 241 participants (Actual)Interventional2014-07-05Completed
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones [NCT03007147]Phase 3475 participants (Anticipated)Interventional2017-08-08Recruiting
A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL) [NCT02981628]Phase 280 participants (Anticipated)Interventional2017-06-19Active, not recruiting
A Multi-center, Single-arm Study of Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab as Second-line Therapy in Metastatic Colorectal Cancer [NCT06184698]Phase 250 participants (Anticipated)Interventional2024-01-01Not yet recruiting
A Phase Ib, Open-label, Dose-escalation Study of the Safety and Pharmacology of Ipatasertib (GDC-0068) in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Patients With Advanced Solid Tumors [NCT01362374]Phase 1122 participants (Actual)Interventional2011-07-11Completed
Phase I Clinical Trial With LBH589 and Infusional 5-FU/LV in Patients With Metastatic Colorectal Cancer Who Failed 5-FU Based Chemotherapy [NCT01238965]Phase 17 participants (Actual)Interventional2010-10-31Terminated(stopped due to Adverse Events)
Perioperative Chemotherapy With FOLFOX Plus Cetuximab Versus Adjuvant FOLFOX Plus Cetuximab for Patients With Resectable Liver Metastases of Colorectal Carcinoma [NCT01266187]16 participants (Actual)Interventional2011-07-31Terminated(stopped due to Recruitment difficulities)
High Risk B-Precursor Acute Lymphoblastic Leukemia (ALL) [NCT00075725]Phase 33,154 participants (Actual)Interventional2003-12-29Completed
[NCT01160419]Phase 249 participants (Anticipated)Interventional2009-12-31Active, not recruiting
A Multicentre, Randomized, Open Label, Phase III Study of Gemcitabine Versus FOLFOX in the First Line Setting for Metastatic Pancreatic Cancer Patients Using Human Equilibrative Nucleoside Transporter 1 (hENT1) Biomarker Testing. [NCT01586611]Phase 3175 participants (Anticipated)Interventional2012-06-30Recruiting
An Open-Label Randomized Phase III Study Comparing Xeloda (Capecitabine) With IV Bolus 5-Fluorouracil in Combination With Low-Dose Leucovorin as Adjuvant Chemotherapy in Patients Who Underwent Surgery for Dukes C Colon Cancer [NCT00009737]Phase 31,987 participants (Actual)Interventional1998-11-30Completed
Study to Investigate Efficacy of Bevacizumab Combined With Modified-FOLFOXIRI in Patients With Borderline Resectable Colorectal Liver Metastases [NCT03711240]Phase 240 participants (Anticipated)Interventional2019-01-08Recruiting
An Open Label, Phase II Study Assessing Potential Predictive Tumor Markers in Patients With Metastatic Colorectal Cancer and Wild Type K-RAS Tumor Treated With FOLFOX Plus Panitumumab as First-line Therapy [NCT01288339]Phase 278 participants (Actual)Interventional2010-11-08Completed
A Phase I Study of Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-fluorouracil, Leucovorin, Oxaliplatin (FOLFOX) in Patients With Advanced Cancers [NCT01183663]Phase 1180 participants (Actual)Interventional2010-08-31Completed
A Multicenter Feasibility Study With S-1, Oxaliplatin and Oral Leucovorin (SOL) for the Patients With Untreated Metastatic Colorectal Cancer [NCT01110941]Phase 1/Phase 220 participants (Actual)Interventional2009-09-30Completed
A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB598 Monotherapy and Combination Therapy in Participants With Advanced Malignancies [NCT05891171]Phase 181 participants (Anticipated)Interventional2023-10-13Recruiting
Phase II Study of Salvage mFOLFOX(5-fluorouracil, Leucovorin, Oxaliplatin) in Patients With Unresectable Biliary Tract Cancer (BTC) Who Had Failed Gemcitabine [NCT01127555]Phase 230 participants (Actual)Interventional2010-04-30Completed
A Pilot and Phase II Study of Altered Chemotherapy Sequencing During Neoadjuvant Therapy for Patients With Stage II or III Rectal Adenocarcinoma [NCT01302613]Phase 1/Phase 20 participants (Actual)Interventional2011-03-31Withdrawn(stopped due to Drug shortage)
Phase 2 Study Comparing Efficacy and Safety of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and Bevacizumab [NCT03368859]Phase 270 participants (Actual)Interventional2018-03-20Terminated(stopped due to Study may continue)
Intensive Treatment For T-CELL Acute Lymphoblastic Leukemia and Advanced Stage Lymphoblastic Non-Hodgkin's Lymphoma: A Pediatric Oncology Group Phase III Study [NCT01230983]Phase 3573 participants (Actual)Interventional1996-06-30Completed
A Phase II Randomized Trial of PET Imaging in Assessing Response to Induction Chemotherapy in Esophageal Squamous Cell Carcinoma Treated With Definitive Chemoradiotherapy [NCT03791905]Phase 2216 participants (Anticipated)Interventional2019-01-15Recruiting
Post Marketing Surveillance Study for ONIVYDE® in South Korea [NCT03446872]94 participants (Actual)Observational2018-03-08Completed
Hepatic Artery Infusion Chemotherapy Plus Recombinant Human Type-5 Adenovirus vs Hepatic Artery Infusion Chemotherapy Alone for Unresectable Hepatocellular Carcinoma at Barcelona Clinic Liver Cancer A-B Stage [NCT03780049]Phase 3304 participants (Anticipated)Interventional2018-10-01Recruiting
A Randomized Phase II Study of mFOLFOX vs. mFOLFIRI in Advanced or Recurrent Biliary Tract Cancer Refractory to First Line Gemcitabine Plus Cisplatin [NCT03464968]Phase 2120 participants (Actual)Interventional2015-07-29Completed
SAMSUNG MEDICAL CENTER [NCT03110510]Phase 20 participants (Actual)Interventional2019-09-06Withdrawn(stopped due to institution problem)
Organ Preservation for Patients With Locally Advanced Rectal Adenocarcinoma: Evaluating the Efficacy of Short Course Radiation Therapy Followed by FOLFOX or CapeOX [NCT04703101]Phase 125 participants (Anticipated)Interventional2021-02-11Recruiting
A Randomized Phase II Study Comparing Treatment Intensification With CIAH Plus Systemic Chemotherapy to Systemic Chemotherapy Alone in Patients With Liver-only Colorectal Metastases Considered Still Non Resectable After at Least Two Months of Systemic Ind [NCT03164655]Phase 220 participants (Actual)Interventional2018-07-25Completed
A Phase II Trial on Ofatumumab With IVAC Salvage Chemotherapy in Diffuse Large B Cell Lymphoma Patients Progressing or Relapsed After Prior R-CHOP Treatment Not Suitable for Autologous Stem Cell Transplant [NCT01481272]Phase 277 participants (Actual)Interventional2011-11-30Completed
A Phase III, Randomized, Two-armed, Triple Blinded, Parallel, Active Controlled Non-Inferiority Clinical Trial of Stivant (AryoGen Trastuzumab) Efficacy and Safety in Comparison to Avastin in Metastatic Colorectal Cancer [NCT03288987]Phase 3126 participants (Actual)Interventional2016-10-04Completed
Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated According to UGT1A1 Genotyping Versus Regorafenib Monotherapy in Patients With Previously Treated Metastatic Colorectal Cancer: A Prospective, Randomized, Controlled Study [NCT03880877]Phase 2153 participants (Anticipated)Interventional2019-02-26Recruiting
Multicenter Study Investigating Utilization of Pharmacokinetic-Guided 5-Fluorouracil in Patients Receiving mFOLFOX6 With or Without Bevacizumab [NCT01164215]Phase 176 participants (Actual)Interventional2010-02-28Completed
A Single Centre, Open-label, Parallel-group, Single Oral Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pyrimethamine in Healthy Japanese and Caucasian Male Subjects [NCT03258762]Phase 114 participants (Actual)Interventional2017-09-25Completed
Adjuvant Modified FOLFOXIRI Versus mFOLFOX6 in Patients With Postoperative MRD Positive Stage II-III Colorectal Cancer: A Multicenter, Open Lable Randomized Phase 3 Study (AFFORD) [NCT05427669]Phase 3340 participants (Anticipated)Interventional2022-10-09Not yet recruiting
A Randomized Phase II Trial of Capecitabine and Temozolomide (CAPTEM) or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomas and Exploratory Analysis of Predictive Role of Positron Emission Tomography (PET) Imaging and Biological Markers [NCT03387592]Phase 2112 participants (Anticipated)Interventional2017-03-06Recruiting
Pilot / Phase III Randomized Trial Comparing Standard Systemic Therapy to Cytoreduction + Hyperthermic Intraperitoneal Mitomycin C + Standard Systemic Therapy in Patients With Limited Peritoneal Dissemination of Colon Adenocarcinoma [NCT01167725]Phase 3340 participants (Anticipated)Interventional2010-08-31Active, not recruiting
A Real World Study of Efficacy and Safety for Apatinib Treatment as the Neoadjuvant Therapy in Advanced Colorectal Cancer [NCT03377842]Phase 2100 participants (Anticipated)Interventional2018-01-31Not yet recruiting
Randomized, Double Blind Phase II Study of FOLFOX/Bevacizumab Combined With MK-0646 Versus FOLFOX/Bevacizumab Combined With Placebo in First-Line Treatment of Metastatic Colorectal Cancer [NCT01175291]Phase 20 participants (Actual)Interventional2010-09-30Withdrawn(stopped due to treatment deemed ineffective so accrual was closed)
A Randomized Phase II Study of Irinotecan, 5-Fluorouracil and Folinic Acid (FOLFIRI) With or Without the Addition of an Endothelin Receptor Antagonist in Patients With Metastatic Colorectal Cancer After Failure of Oxaliplatin-Containing Chemotherapy [NCT01205711]Phase 2111 participants (Actual)Interventional2010-04-30Completed
Treatment Protocol of the Third International Study For Langerhans Cell Histiocytosis [NCT00276757]376 participants (Anticipated)Interventional2001-04-30Completed
A Pilot Study in Gastric Cancer of Assignment to Postoperative Chemoradiation or Chemotherapy Based Upon Surgical Lymph Node Assessment After Preoperative Chemotherapy, With Gene Assay as Correlate of Biologic Response [NCT03515941]Early Phase 16 participants (Actual)Interventional2018-06-22Terminated(stopped due to The PI has decided to close the study due to the outdated study design.)
NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy Combining Innate High-affinity Natural Killer (haNK) Cell Therapy With Adaptive T-cell Therapy (Adenovirus, Yeast, Fusion Protein Vaccine) in Subjects With Pancreatic Cancer Who [NCT03329248]Phase 1/Phase 280 participants (Anticipated)Interventional2017-11-06Active, not recruiting
Optimizing Ultrasound Enhanced Delivery of Therapeutics [NCT04821284]Phase 1/Phase 2120 participants (Anticipated)Interventional2021-12-06Recruiting
PIONEER-Panc: Phase II Investigations of New and Emerging Therapies for Pancreatic Cancer [NCT04481204]Phase 2105 participants (Actual)Interventional2023-04-18Active, not recruiting
A Phase II Study of Induction Systemic mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone Given Concurrently With Systemic mFOLFIRI as a First-Line Therapy in Patients With Unresectable Liver-Dominant Intrahepatic Cholangio [NCT04251715]Phase 230 participants (Anticipated)Interventional2021-04-28Recruiting
A Phase IIa (Pilot) Study of Neoadjuvant Chemotherapy With Folinic Acid, 5-FU, Irinotecan and Oxaliplatin (FOLFIRINOX) With Digoxin in Patients With Resectable Pancreatic Cancer [NCT04141995]Phase 220 participants (Anticipated)Interventional2021-02-12Recruiting
A Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of Oleclumab (MEDI9447) With or Without Durvalumab in Combination With Chemotherapy in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma [NCT03611556]Phase 1/Phase 2213 participants (Actual)Interventional2018-06-21Completed
Liposomal iRInotecan, Carboplatin or oXaliplatin in the First Line Treatment of Esophagogastric Cancer: a Randomized Phase 2 Study [NCT03764553]Phase 2310 participants (Anticipated)Interventional2019-05-01Recruiting
Phase II Study of Low-dose RAD001(Everolimus) Plus Cisplatin and HDFL (Weekly 24-Hour Infusion of High-dose 5-Fluorouracil and Leucovorin) Chemotherapy for First-line Treatment of Unresectable, Recurrent or Metastatic Gastric Cancer [NCT00632268]Phase 240 participants (Actual)Interventional2008-02-29Completed
Chemotherapy With FOLFIRI Plus Bevacizumab (AvastinR) in Patients With Metastatic Colorectal Cancer Bearing Genotype UGT1A1*1/UGT1A1*1 or UGT1A1*1/UGT1A1*1/UGT1A1*28: Prospective, Phase II, Multicenter Study [NCT00628810]Phase 286 participants (Actual)Interventional2007-01-31Completed
[NCT02870036]Phase 1243 participants (Anticipated)Interventional2016-10-31Recruiting
A Multicentre Randomised Phase II Study to Assess the Safety and Resectability in Patients With Initially Unresectable Liver Metastases Secondary to Colorectal Cancer Receiving First-line Treatment Either With mFOLFOX-6 Plus Bevacizumab or FOLFOXIRI Plus [NCT00778102]Phase 280 participants (Actual)Interventional2008-10-31Completed
A PHASE III RANDOMIZED TRIAL OF FOLFOXIRI + BEVACIZUMAB VERSUS FOLFIRI + BEVACIZUMAB AS FIRST- LINE TREATMENT FOR METASTATIC COLORECTAL CANCER [NCT00719797]Phase 3509 participants (Actual)Interventional2008-07-31Completed
Phase I Trial of Escalating High Dose Methotrexate Supported by Glucarpidase to Treat Patients With Primary Central Nervous Lymphoma (PCNSL) [NCT00727831]Phase 1/Phase 24 participants (Actual)Interventional2008-07-31Completed
Pilot Study of FOLFOX6 Plus Sir-Spheres® Microspheres (Chemo-radiotherapy) in Combination With Bevacizumab (Avastin) as a First Line Treatment in Patients With Nonresectable Liver Metastases From Primary Colorectal Carcinoma [NCT00735241]Phase 2/Phase 30 participants (Actual)Interventional2008-07-31Withdrawn(stopped due to Withdrawn by the study sponsor.)
Randomized, Active-Controlled, Open-Label Phase 2 Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy [NCT00967616]Phase 2100 participants (Actual)Interventional2009-09-30Completed
A Phase II Randomized Study of Induction Chemotherapy Followed by Concurrent Chemo-radiotherapy in Locally Advanced Pancreatic Cancer [NCT01867892]Phase 286 participants (Anticipated)Interventional2013-06-30Enrolling by invitation
Phase II Study of Rituximab in Combination With Methotrexate, Doxorubicin, Cyclophosphamide, Leucovorin, Vincristine, Ifosfamide, Etoposide, Cytarabine and Mesna (R-MACLO/VAM) in Patients With Previously Untreated Mantle Cell Lymphoma [NCT00878254]Phase 225 participants (Actual)Interventional2009-03-25Active, not recruiting
Feasibility and Dose Discovery Analysis of Zoledronic Acid With Concurrent Chemotherapy in the Treatment of Newly Diagnosed Metastatic Osteosarcoma [NCT00742924]Phase 124 participants (Actual)Interventional2008-08-31Completed
A Dose-Escalation Study to Evaluate the Safety and Tolerability of SCH 717454 in Combination With Different Treatment Regimens in Subjects With Advanced Solid Tumors (Phase 1B/2; Protocol No. P04722) [NCT00954512]Phase 1/Phase 215 participants (Actual)Interventional2009-09-25Terminated(stopped due to This study was terminated for business reasons.)
A Multi Center Phase II Study of 5-Fluorouracil/ Folinic Acid Plus Gemcitabine in Patients With Advanced Pancreatic Cancer. [NCT00919282]Phase 278 participants (Actual)Interventional1997-09-30Completed
A Randomized Phase II Study of Two Dose-Levels of Vorinostat in Combination With 5-FU and Leucovorin in Patients With Refractory Metastatic Colorectal Cancer [NCT00942266]Phase 258 participants (Actual)Interventional2009-07-31Completed
A Phase II Study Of Sunitinib In Combination With Irinotecan, L-leucovorin, And 5-Fluorouracil In Patients With Unresectable Or Metastatic Colorectal Cancer [NCT00668863]Phase 271 participants (Actual)Interventional2008-05-31Completed
Phase Ib Study of Gevokizumab in Combination With Standard of Care Anti-cancer Therapies in Patients With Metastatic Colorectal Cancer, Gastroesophageal Cancer and Renal Cell Carcinoma [NCT03798626]Phase 1167 participants (Actual)Interventional2019-05-22Active, not recruiting
Phase II Study of Oxaliplatin in Combination With 5-fluorouracil (5-FU) and Folinic Acid (FA) in Patients Who Have Failed First-line Treatment for Locally Advanced or Metastatic Cervical Cancer. [NCT00782041]Phase 211 participants (Actual)Interventional2003-01-31Terminated(stopped due to protocol violation)
Maintenance and Reinduction Chemotherapy With Avastin in Metastatic Colon Cancer: The MARTHA (SICOG 0803) Trial [NCT00797485]Phase 3672 participants (Anticipated)Interventional2008-07-31Recruiting
"PsyCARE Trial - Efficiency of a Composite Personalised Care on Functional Outcome in Early Psychosis : A Prospective Randomised Controlled Trial " [NCT05796401]Phase 3500 participants (Anticipated)Interventional2023-06-15Not yet recruiting
A Randomized Phase II Study of Second Line Treatment With Liposomal Irinotecan and S1 Versus Liposomal Irinotecan and 5-fluorouracil in Patients With Metastatic Pancreatic Cancer Who Failed on First Line Gemcitabine-based Chemotherapy [NCT03986294]Phase 2122 participants (Anticipated)Interventional2019-12-01Recruiting
Randomized Phase II Study Assessing the Efficacy and Safety of 2 Therapeutic Strategies Combining Bevacizumab With Chemotherapy: De-escalation Versus Escalation in Patients With Non-pretreated Unresectable Metastatic Colorectal Cancer [NCT02842580]Phase 220 participants (Actual)Interventional2016-09-30Terminated(stopped due to Inclusion rythm too slow.)
A Non-randomized Phase 2 Study of Alvocidib (Flavopiridol) Plus Oxaliplatin With or Without 5-FU and Leucovorin for Relapsed or Refractory Germ-Cell Tumors [NCT00957905]Phase 236 participants (Actual)Interventional2009-06-30Completed
An Open-label, Multicenter, Phase 1a/1b Study of IGM-8444 as a Single Agent and in Combination in Subjects With Relapsed, Refractory, or Newly Diagnosed Cancers [NCT04553692]Phase 1430 participants (Anticipated)Interventional2020-09-23Recruiting
A Phase 1b/2 Dose Escalation and Expansion Study of Tucatinib in Combination With Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers [NCT04430738]Phase 1/Phase 2120 participants (Anticipated)Interventional2020-09-15Recruiting
A Phase Ib Adaptive Study Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab [NCT04164069]Phase 19 participants (Anticipated)Interventional2020-09-02Active, not recruiting
A Phase 1 Study Combining MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer [NCT02785068]Phase 1/Phase 20 participants (Actual)Interventional2016-07-31Withdrawn
Perioperative FOLFIRINOX for Patients With Resectable Pancreatic Adenocarcinoma: A Pilot Study [NCT02782182]Phase 11 participants (Actual)Interventional2016-06-28Terminated(stopped due to Closed early due to poor accrual.)
A Phase I, Open-Label, Dose-Seeking Study of AZD2171 Given Daily Orally in Combination With Selected Standard Chemotherapy Regimens (CT) in Patients With Advanced Incurable Non-Small Cell Lung Cancer (NSCLC) or Colorectal Cancer [NCT00343408]Phase 131 participants (Actual)Interventional2005-11-29Completed
A Study to Characterize and Evaluate Biomarkers of Chemotherapy in Patients With Metastatic Colorectal Cancer In The First-line Setting [NCT03532711]264 participants (Actual)Observational2012-01-01Completed
A Phase III, Randomized Study of Adjuvant Chemotherapy for Patients With Rectal Adenocarcinoma Who Achieved Suboptimal Response After Neoadjuvant Chemo-radiotherapy. [NCT01941979]Phase 3309 participants (Anticipated)Interventional2011-09-30Recruiting
A Prospective, Single-armed, Multicentric, Explorative Phase II Clinical Research of Conversional Therapy With Combination of Hepatic Arterial Infusion Chemotherapy and Donafenib and Toripalimab for Unresectable Hepatocellular Carcinoma [NCT05493332]Phase 293 participants (Anticipated)Interventional2022-09-30Not yet recruiting
A Phase II Study Assessing Tumor Blood Flow as Measured by Dynamic Contrast Enhanced MRI in Patients With Metastatic Colorectal Cancer Receiving FOLFOX Alone Versus Patients Randomized to Receive FOLFOX Plus Bevacizumab at 5mg/kg or 10mg/kg. [NCT00602329]Phase 25 participants (Actual)Interventional2006-02-28Terminated(stopped due to Due to Poor accrual)
PFL-Alpha Chemotherapy Followed by Surgery or FHX for Early Stage Esophageal Cancer - A Pilot Project [NCT00004897]Phase 20 participants Interventional1999-10-31Terminated(stopped due to Institutional Review Board requested termination - all patients deceased and no new accrual.)
Phase II Study of Multimodality Therapy in Mantle Cell Lymphoma [NCT00004231]Phase 20 participants Interventional1999-10-31Completed
A Pilot and Feasibility Study of PD-1 Blockade With Nivolumab in Combination With Chemotherapy in Patients With Borderline Resectable Pancreatic Adenocarcinoma [NCT03970252]Early Phase 136 participants (Anticipated)Interventional2019-07-24Recruiting
Phase 1b/2 Clinical Trial of Neoadjuvant Pembrolizumab Plus Concurrent Chemoradiotherapy With Weekly Carboplatin and Paclitaxel in Adult Patients With Resectable, Locally Advanced Adenocarcinoma of the Gastroesophageal Junction or Gastric Cardia [NCT02730546]Phase 1/Phase 231 participants (Actual)Interventional2016-06-24Active, not recruiting
NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy [NCT03136406]Phase 1/Phase 23 participants (Actual)Interventional2017-08-14Active, not recruiting
Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma Beyond Milan/UCSF Criteria Who Underwent Liver Transplantation [NCT04595864]Phase 340 participants (Anticipated)Interventional2020-11-01Recruiting
Determination of the UGT1A1 Polymorphism as Guidance for Irinotecan Dose Escalation in Metastatic Colorectal Cancer Treated With First-Line Bevacizumab and FOLFIRI (PURE FIST) [NCT02256800]213 participants (Actual)Interventional2014-08-13Completed
Evaluation of Pathological Response in Patient With Resectable Gastric Cancer and Perioperative Chemotherapy FLOT Versus XELOX; Phase 2 [NCT04937738]Phase 2284 participants (Anticipated)Interventional2021-07-21Active, not recruiting
A Phase 1B/2A Trial Of CEND-1 In Combination With Neoadjuvant FOLFIRINOX Based Therapies In Pancreatic, Colon And Appendiceal Cancers (CENDIFOX) [NCT05121038]Phase 1/Phase 250 participants (Anticipated)Interventional2021-10-20Recruiting
A Multinational, Randomized, Phase III Study of FOLFIRI With/Without Bevacizumab Versus Irinotecan With/Without Bevacizumab As Second-line Therapy in Patients With Metastatic Colorectal Cancer [NCT03303495]Phase 3280 participants (Anticipated)Interventional2011-11-14Recruiting
Randomized Phase III Trial of 5-FU Based Maintenance Therapy With or Without Panitumumab in Patients With RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX + Panitumumab [NCT03300609]Phase 34 participants (Actual)Interventional2018-02-27Terminated(stopped due to Insufficient Accrual)
"Preventive HIPEC in Combination With Perioperative FLOT Versus FLOT Alone for Resectable Diffuse Type Gastric and Gastroesophageal Junction Type II/III Adenocarcinoma - The Phase III PREVENT Trial of the AIO /CAOGI /ACO" [NCT04447352]Phase 3200 participants (Anticipated)Interventional2020-12-17Recruiting
Randomised Study to Investigate FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab as First-line Treatment of BRAF-mutated Metastatic Colorectal Cancer [NCT04034459]Phase 2109 participants (Actual)Interventional2016-11-25Active, not recruiting
Effect of Chemotherapy Alone vs. Chemotherapy Followed by Surgical Resection on Survival and Quality of Life in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction - A Phase III Trial of Arbeitsgemeinschaft Internist [NCT02578368]Phase 3271 participants (Anticipated)Interventional2016-02-29Recruiting
Phase II Study of Peri-Operative Modified Folfirinox in Localized Pancreatic Cancer [NCT02047474]Phase 246 participants (Actual)Interventional2014-03-25Active, not recruiting
Randomized Phase Ⅱ Study of Second-line Treatment Comparing Hepatic Arterial Infusion Chemotherapy of Oxaliplatin, 5-fluorouracil and Leucovorin With Sorafenib in Hepatocellular Carcinoma Refractory to Transarterial Chemoembolization [NCT03722498]Phase 20 participants (Actual)Interventional2018-06-01Withdrawn(stopped due to No patients join)
Role of Folinic Acid in Improving the Adaptive Skills and Language Impairment in Children With Autism Spectrum Disorder [NCT05013164]Phase 244 participants (Actual)Interventional2020-10-01Completed
NEOadjuvant Chemotherapy Only Compared With Standard Treatment for Locally Advanced Rectal Cancer: a Randomized Phase II Trial [NCT03280407]Phase 2124 participants (Anticipated)Interventional2017-03-01Recruiting
Randomized Controlled Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer [NCT02128243]Phase 2242 participants (Actual)Interventional2014-09-30Completed
A Randomized, Multicenter Phase II Study of Panitumumab Plus FOLFIRI With or Without Hepatic Arterial Infusion as Second-Line Treatment in Patients With Wild Type RAS Who Have Unresectable Hepatic Metastases From Colorectal Cancer [NCT03069950]Phase 20 participants (Actual)Interventional2017-02-28Withdrawn(stopped due to Lack of accrual)
Single-arm Phase II Study of Maintenance Therapy With Aflibercept After First-line Treatment With FOLFIRI Plus Aflibercept in Metastatic Colorectal Cancer Patients [NCT02129257]Phase 273 participants (Actual)Interventional2014-05-26Completed
The Purpose of This Study is to Evaluate the Effectiveness of MB-6 as Adjuvant Therapy in Reducing Neutropenia When Given Oxaliplatin-based Chemotherapy in Patients With Stage 3 Colorectal Cancer Previously Treated With Surgery. [NCT02135887]184 participants (Anticipated)Observational2013-11-04Recruiting
A Phase 2 Study of Cabiralizumab (BMS-986227, FPA008) Administered in Combination With Nivolumab (BMS-936558) With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer [NCT03336216]Phase 2206 participants (Actual)Interventional2017-12-19Completed
A Prospective, Open-lable, Multicenter, Randomized, Controlled Phase II Clinical Trial to Evaluate the Efficacy of Irinotecan Versus Oxaliplatin in the First-line Treatment of Refractory Metastatic Colorectal Cancer [NCT03567629]Phase 2130 participants (Anticipated)Interventional2018-05-29Active, not recruiting
A Phase II Study of Double Induction Chemotherapy for Newly Diagnosed Non-L3 Adult Acute Lymphoblastic Leukemia With Investigation of Minimal Residual Disease and Risk of Relapse Following Maintenance Chemotherapy [NCT00109837]Phase 279 participants (Actual)Interventional2005-04-30Completed
QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and Anti-programmed Cell Death Protein 1 (PD-1)/Programmed Death-ligand 1 (PD-L1) Therapy [NCT03197571]Phase 1/Phase 20 participants (Actual)Interventional2017-12-31Withdrawn(stopped due to Trial not initiated)
A Randomized, Parallel Control Trial to Compare mFOLFOX Versus mFOLFIRI Versus FOLFPTX (a Combination of Paclitaxel, Fluorouracil) as First-line Treatment in Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction [NCT03045770]150 participants (Anticipated)Interventional2017-02-10Not yet recruiting
Phase II Study of S-1 Plus Leucovorin (1 Week on and 1 Week Off) as First-line Treatment for Patients With Metastatic and Recurrent Gastric Cancer [NCT02090153]Phase 239 participants (Actual)Interventional2011-07-31Completed
A Phase 2 Randomized Study Comparing the Efficacy and Safety of mFOLFOX6+Panitumumab Combination Therapy and 5-FU/LV+Panitumumab Combination Therapy in the Patients With Chemotherapy-Naive Unresectable Advanced Recurrent Colorectal Carcinoma of KRAS Wild- [NCT02337946]Phase 2164 participants (Actual)Interventional2014-10-16Completed
Early Treatment of Language Impairment in Young Children With Autism Spectrum Disorder With Leucovorin Calcium [NCT04060017]Phase 280 participants (Anticipated)Interventional2020-09-22Recruiting
Leucovorin for the Treatment of Language Impairment in Children With Autism Spectrum Disorder [NCT02839915]Phase 2134 participants (Anticipated)Interventional2020-08-13Recruiting
An Exploratory Study to Evaluate the Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy (HAIC) Combine With Sintilimab and Bevacizumab for BCLC-C Hepatocellular Carcinoma [NCT05617430]Phase 243 participants (Anticipated)Interventional2022-11-02Recruiting
Infusional FOLFOX Plus Camrelizumab and Apatinib Versus HAIC-FOLFOX Plus Camrelizumab and Apatinib for Hepatocellular Carcinoma of BCLC C Stage: A Multi-center Randomized Phase III Trial [NCT06172205]Phase 3192 participants (Anticipated)Interventional2023-07-01Recruiting
A Phase 1/2 Open-Label, Multicenter Study to Assess the Safety, Pharmacokinetics, and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors [NCT04393298]Phase 1/Phase 295 participants (Actual)Interventional2020-07-09Active, not recruiting
A Phase II Study of Metformin Plus Modified FOLFOX 6 in Patients With Metastatic Pancreatic Cancer [NCT01666730]Phase 250 participants (Actual)Interventional2013-02-21Completed
Standard Risk B-precursor Acute Lymphoblastic Leukemia (ALL) [NCT00103285]Phase 35,377 participants (Actual)Interventional2005-04-11Completed
Randomized Controlled Trial Comparing DC-CIK Immunotherapy Combined With Adjuvant Chemotherapy and Adjuvant Chemotherapy Alone in Stage III Colorectal Cancer. [NCT02415699]Phase 2/Phase 3100 participants (Anticipated)Interventional2015-08-31Not yet recruiting
An Open-Label, Randomized Phase 2 Study of ABT-869 in Combination With mFOLFOX6 (Oxaliplatin, 5-Fluorouracil, and Folinic Acid) Versus Bevacizumab in Combination With mFOLFOX6 as Second-line Treatment of Subjects With Advanced Colorectal Cancer [NCT00707889]Phase 2159 participants (Actual)Interventional2008-10-31Completed
Adjuvant Chemotherapy With FOLFOX After Total Mesorectal Excision for Locally Advanced Rectal Cancer; an Open-label, Multicenter, Prospective, Randomized Phase 3 Trial [NCT02167321]Phase 290 participants (Actual)Interventional2014-12-31Active, not recruiting
A Phase II Study Of Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Overexpressing Gastroesophageal Cancers [NCT06109467]Phase 236 participants (Anticipated)Interventional2023-10-24Recruiting
Phase II Trial of 5-FU, Leucovorin, Gemcitabine, and Cisplatin for Adenocarcinomas of the Urothelial Tract and Urachal Remnant [NCT00082706]Phase 246 participants (Actual)Interventional2003-04-23Active, not recruiting
Phase II Study of Isolated Hepatic Perfusion With Melphalan Followed By Postoperative Hepatic Arterial Chemotherapy in Patients With Unresectable Colorectal Cancer Metastatic to the Liver [NCT00019760]Phase 20 participants Interventional1999-04-30Completed
Phase II Study of Intensive Chemotherapy and Rituximab in Burkitt Lymphoma [NCT00126191]Phase 210 participants (Actual)Interventional2005-07-31Terminated(stopped due to closed due to slow accrual)
The Effect of Oral Folinic Acid Rescue Therapy on Pemetrexed Induced Neutropenia: A Randomized Open-label Trial [NCT06010277]Phase 450 participants (Anticipated)Interventional2023-02-06Recruiting
A Phase I/II Clinical Trial of FOLFOX Bevacizumab Plus Botensilimab and Balstilimab (3B-FOLFOX) in Patients With MSS Metastatic Colorectal Cancer [NCT05627635]Phase 1/Phase 286 participants (Anticipated)Interventional2023-05-03Recruiting
Phase II Study Evaluating the Efficacy of M9241 in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer or Intrahepatic Cholangiocarcinoma [NCT05286814]Phase 248 participants (Anticipated)Interventional2022-10-24Recruiting
Perioperative FLOT Versus Adjuvant XELOX for Locally Advanced Gastric Cancer - a Randomized Controlled Study [NCT05264896]Phase 3110 participants (Anticipated)Interventional2022-03-21Recruiting
A Phase 0 Study of EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer [NCT06011772]Early Phase 142 participants (Anticipated)Interventional2023-12-02Recruiting
Modified FOLFIRINOX Alternated With Biweekly Gemcitabine Plus Nab-Paclitaxel in Untreated Metastatic Adenocarcinoma of the Pancreas [NCT04672005]Phase 230 participants (Anticipated)Interventional2021-01-06Recruiting
A Phase III Study of Consolidative Radiotherapy in Patients With Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA) [NCT04248452]Phase 3314 participants (Anticipated)Interventional2020-05-26Recruiting
A Phase Ib Clinical Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Metastatic Pancreatic Adenocarcinoma [NCT02231723]Phase 1139 participants (Actual)Interventional2014-08-31Completed
A Multinational, Randomized, Double-blind Study, Comparing the Efficacy of Aflibercept Once Every 2 Weeks Versus Placebo in Patients With Metastatic Colorectal Cancer (MCRC) Treated With Irinotecan / 5-FU Combination (FOLFIRI) After Failure of an Oxalipla [NCT00561470]Phase 31,226 participants (Actual)Interventional2007-11-30Completed
Folate Absorption Across the Large Intestine, Study #2: Capsule Study [NCT00941174]Phase 19 participants (Actual)Interventional2008-09-30Completed
Randomized, Phase III, Multicenter Trial Comparing Two Different Sequences of therapyFOLFOX-4 vs FOLFOX-4 Followed by Irinotecan/Cetuximab in Metastatic Colorectal Patients Treated With FOLFIRI /Bevacizumab as First Line Chemotherapy [NCT01030042]Phase 3110 participants (Actual)Interventional2009-09-30Completed
A Phase II Trial of Integrated Preoperative Radiotherapy and Chemotherapy With Oxaliplatin 5-FU and Folinic Acid in Patients With Locally Advanced Rectal Cancer [NCT01013805]Phase 241 participants (Actual)Interventional2009-11-30Completed
A Feasibility Pilot and Phase II Study Of Chemoimmunotherapy With Epratuzumab (IND #12034) for Children With Relapsed CD22-Positive Acute Lymphoblastic Leukemia (ALL) [NCT00098839]Phase 1/Phase 2134 participants (Actual)Interventional2005-02-28Completed
A Phase II Single Arm Study of the Use of CODOX-M/IVAC With Rituximab (R-CODOX-M/IVAC) in the Treatment of Patients With Diffuse Large B-Cell Lymphoma (International Prognostic Index High or High-Intermediate Risk) [NCT00974792]Phase 2150 participants (Anticipated)Interventional2006-01-31Recruiting
"An Open-Label Randomized Phase III Study of Intermittent Oral Capecitabine in Combination With Intravenous Oxaliplatin (Q3W) (XELOX) Versus Fluorouracil/Leucovorin as Adjuvant Therapy for Patients Who Have Undergone Surgery for Colon Carcinoma, AJCC/UICC [NCT00069121]Phase 31,886 participants (Actual)Interventional2003-04-18Completed
A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB T [NCT00057811]Phase 297 participants (Actual)Interventional2004-06-30Completed
An Open-Label, Multicenter Phase Ib Study of The Safety and Efficacy of Atezolizumab (Anti-PD-L1 Antibody) Administered in Combination With Bevacizumab and/or Other Treatments in Patients With Solid Tumors [NCT02715531]Phase 1243 participants (Actual)Interventional2016-04-06Completed
A Phase I/II Dose Escalation Study of Subcutaneous Campath-1H (NSC #715969, IND #10864) During Intensification Therapy in Adults With Untreated Acute Lymphoblastic Leukemia (ALL) [NCT00061945]Phase 1/Phase 2302 participants (Actual)Interventional2003-06-30Completed
A Phase II Trial of Radioimmunotherapy (Y-90 M5A) Following Hepatic Resection and FOLFIRI or FOLFOX Chemotherapy [+/-BEVACIZUMAB], or Xelox for Metastatic Colorectal Carcinoma to the Liver [NCT01320683]Phase 21 participants (Actual)Interventional2011-03-31Terminated(stopped due to Slow accrual.)
A Pilot Study of Neoadjuvant Chemotherapy With Selective Use of Radiation for Locally Advanced Rectal Cancer [NCT00462501]35 participants (Actual)Interventional2007-03-31Completed
Phase II Study of Rituximab in Combination With Methotrexate, Doxorubicin, Cyclophosphamide, Leucovorin, Vincristine, Ifosfamide, Etoposide, Cytarabine and Mesna (MACLO/IVAM) in Patients With Previously Untreated Mantle Cell Lymphoma [NCT00450801]Phase 222 participants (Actual)Interventional2004-04-30Completed
Phase II Study of Avastin, Irinotecan, High Dose 24 Hour Continuous Intravenous Infusion of Floxuridine and Leucovorin in Patients With Previously Untreated Metastatic Colorectal Cancer [NCT00449163]Phase 225 participants (Actual)Interventional2006-03-01Terminated(stopped due to Study terminated by University of Miami Institutional Review Board)
Multi-Centre Phase III Open Label Randomized Trial Comparing CPT-11 In Combination With A 5-FU/FA Infusional Regimen To The Same 5-FU/FA Infusional Regimen Alone, As Adjuvant Treatment After Resection Of Liver Metastases For Colorectal Cancer. [NCT00143403]Phase 3321 participants (Actual)Interventional2001-12-31Completed
Randomized Phase III Study for the Treatment of Newly Diagnosed Disseminated Lymphoblastic Lymphoma or Localized Lymphoblastic Lymphoma [NCT00004228]Phase 3393 participants (Actual)Interventional2000-06-30Completed
A Phase II Trial of Neoadjuvant Paclitaxel - Cisplatin Chemotherapy, Surgery and Adjuvant Radiation Therapy and 5-FU/Leucovorin for Gastric Cancer [NCT00003298]Phase 239 participants (Actual)Interventional1999-06-01Completed
Hepatic Resection Followed by Concurrent Adjuvant Portal Vein Infusion of Fluorodeoxyuridine and Systemic 5-Fluorouracil and Folinic Acid for Metastatic Colorectal Carcinoma [NCT00002842]Phase 249 participants (Actual)Interventional1994-09-30Completed
A Phase III, Randomized, Open-Label Clinical Study of Napabucasin (GB201) in Combination With FOLFIRI Versus Napabucasin in Adult Patients With Previously Treated Metastatic Colorectal Cancer (CRC) [NCT03522649]Phase 3668 participants (Anticipated)Interventional2018-04-12Recruiting
Characterization and Research of Predictive Markers of Neurotoxicity During Treatment With Oxaliplatin in Colorectal Carcinoma: a Genetic and Proteomic Approach. Phase II Multicenter Study [NCT00884767]Phase 2206 participants (Anticipated)Interventional2007-09-30Recruiting
iMmunoscore Associated Decision GuIdance for adjuvaNt Chemotherapy and Physical Exercise in Stage III Colon Cancer (iMAGINE): a Prospective, Randomized, Open-label, Multicenter, Phase III Clinical Trial [NCT04488159]Phase 31,638 participants (Anticipated)Interventional2023-12-01Not yet recruiting
Open Comparative Study With a Cross-over According to Patients'Preference Receiving Xeloda or UFT With Folinic Acid in Advanced or Metastatic Colo-rectal Cancer [NCT00905047]Phase 389 participants (Actual)Interventional2005-09-30Completed
FIRE-5 -Study: Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation [NCT04034173]Phase 2120 participants (Anticipated)Interventional2019-08-01Not yet recruiting
A Phase 2 Study of POF(Paclitaxel/Oxaliplatin/5-Fluorouracil/Leucovorin) Versus FOLFOX Versus FOLFOX Plus Intraperitoneal Paclitaxel as a First-line Treatment in Advanced Gastric Cancer [NCT02845908]Phase 290 participants (Actual)Interventional2015-11-30Completed
A Phase I Dose Escalation Study of Eryaspase in Combination With Modified FOLFIRINOX in Locally Advanced and Metastatic Pancreatic Ductal Adenocarcinoma [NCT04292743]Phase 119 participants (Actual)Interventional2020-12-02Active, not recruiting
A Phase II Study Of Systemic High-Dose Methotrexate For The Treatment Of Glioblastoma Multiforme In Newly Diagnosed Patients With Measurable Disease [NCT00082797]Phase 236 participants (Anticipated)Interventional2005-07-12Completed
A ComboMATCH Treatment Trial: FOLFOX in Combination With Binimetinib as 2nd Line Therapy for Patients With Advanced Biliary Tract Cancers With MAPK Pathway Alterations [NCT05564403]Phase 266 participants (Anticipated)Interventional2024-05-07Recruiting
A Pilot Study of Dose Intensification of Methotrexate in Patients With Advanced-Stage (III/IV) Small Non-Cleaved Cell Non-Hodgkins Lymphoma and B-Cell All [NCT00005977]Phase 383 participants (Actual)Interventional2000-09-30Completed
An Open Label, Single-arm, Phase II Study to Evaluate the Efficacy and the Feasibility of Bevacizumab (Avastin) Based on a FOLFOXIRI Regimen Until Progression in Patients With Previously Untreated Metastatic Colorectal Carcinoma(OPAL-Study) [NCT00940303]Phase 297 participants (Actual)Interventional2009-06-30Completed
Phase III Study of An Optimized LV-5FU-Oxaliplatin Regimen in Metastatic Colorectal Cancer. C99-1. [NCT00006468]Phase 30 participants Interventional2000-01-31Active, not recruiting
A Randomized Investigation of Side Effects to FOLFOXIRI in Combination With Tocotrienol or Placebo as First Line Treatment of Metastatic Colorectal Cancer [NCT02705300]Phase 270 participants (Actual)Interventional2016-05-06Active, not recruiting
Induction Chemotherapy Before or After Preoperative Chemoradiotherapy and Surgery for Locally Advanced Rectal Cancer: A Randomized Phase II Trial of the German Rectal Cancer Study Group [NCT02363374]Phase 2311 participants (Actual)Interventional2015-03-25Completed
A Randomized Phase II Trial of Nal-IRI and 5-Fluorouracil Compared to 5-Fluorouracil in Patients With Cholangio- and Gallbladder Carcinoma Previously Treated With Gemcitabine-based Therapies [NCT03043547]Phase 2100 participants (Actual)Interventional2017-10-24Completed
NEO-adjuvant Chemo-Immunotherapy in Pancreatic Cancer [NCT06094140]Phase 220 participants (Anticipated)Interventional2022-05-20Recruiting
A Phase I Study of Intraperitoneal Oxaliplatin Alone and in Combination With Intraperitoneal Floxuridine and Leucovorin in Patients With Advanced Metastatic Cancer Confined to the Peritoneal Cavity [NCT00005860]Phase 10 participants Interventional2000-04-30Completed
FLOX + Cetuximab (Erbitux®): First Line Treatment for Patients With Metastatic Colorectal Cancer and Wild Type K-RAS Tumor, A Phase II Study [NCT00660582]Phase 2152 participants (Actual)Interventional2008-04-30Completed
Randomized Phase III Study of UFT+Leucovorin vs. TS-1 as Adjuvant Treatment for Stage III Colon Cancer , and Investigate Predictive Factors Based on Gene Expression [NCT00660894]Phase 31,535 participants (Actual)Interventional2008-04-30Completed
A Phase II Pilot Trial of Bortezomib (PS-341, Velcade) in Combination With Intensive Re-Induction Therapy for Children With Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL) [NCT00873093]Phase 2148 participants (Actual)Interventional2009-03-31Completed
A Phase Ib Feasibility Study of Personalized Kinase Inhibitor Therapy Combined With Induction in Acute Leukemias Who Exhibit In Vitro Kinase Inhibitor Sensitivity [NCT02779283]Phase 17 participants (Actual)Interventional2016-01-13Completed
Phase II Study on NIVolumab in Combination With FOLFOXIRI/Bevacizumab in First Line Chemotherapy of Advanced COloRectal Cancer RASm/BRAFm Patients [NCT04072198]Phase 270 participants (Anticipated)Interventional2019-09-26Recruiting
A Phase II Study of Modified FOLFOX-6 Chemotherapy as First-line Treatment of Metastatic Colorectal Cancer in Patients Who Have Received Oxaliplatin-based Adjuvant Chemotherapy [NCT00988897]Phase 20 participants (Actual)Interventional2009-10-31Withdrawn
Phase I Study Of SU011248 In Combination With Oxaliplatin, Leucovorin, And 5-Fluorouracil In Patients With Advanced Solid Malignancies [NCT00599924]Phase 153 participants (Actual)Interventional2005-09-30Completed
The Possible Protective Effect of Pentoxifylline Against Chemotherapy Induced Toxicities in Patients With Colorectal Cancer [NCT05590117]Early Phase 148 participants (Anticipated)Interventional2022-10-11Enrolling by invitation
Effect of Short-duration Preoperative Neoadjuvant Therapy With FOLFOX Based Therapy on Morbidity After Liver Resection for Colorectal Cancer Metastases [NCT00537823]Phase 29 participants (Actual)Interventional2007-06-30Terminated(stopped due to Poor accrual.)
Multi-Center, Randomized, Placebo-Controlled Phase II Study of Regorafenib in Combination With FOLFIRI Versus Placebo With FOLFIRI as Second-Line Therapy in Patients With Metastatic Colorectal Cancer [NCT01298570]Phase 2181 participants (Actual)Interventional2011-04-07Completed
A Phase 1 Dose Finding Study of the gFOLFOXIRITAX Regimen Using UGT1A1 Genotype-directed Irinotecan With Fluorouracil, Leucovorin, Oxaliplatin and Taxotere in Patients With Untreated Advanced Upper Gastrointestinal Adenocarcinomas: The I-FLOAT Study [NCT04361708]Phase 154 participants (Anticipated)Interventional2020-05-08Recruiting
A Genotype-Guided Dosing Study of FOLFIRABRAX in Previously Untreated Patients With Advanced Gastrointestinal Malignancies [NCT02333188]Phase 150 participants (Actual)Interventional2014-12-31Completed
A Controlled Randomized Double-blind Multi-center Phase II Study of FOLFOX6 or FOLFIRI Combined With Sorafenib Versus Placebo in Second-line Metastatic Colorectal Carcinoma [NCT00889343]Phase 2101 participants (Actual)Interventional2009-03-31Terminated
A Phase 2 Trial of Chemotherapy, Pembrolizumab, and Propranolol in Advanced Esophageal/Gastroesophageal Junction Adenocarcinoma Patients [NCT05651594]Phase 240 participants (Anticipated)Interventional2023-03-07Recruiting
A Phase 2/3, Randomized, Open-Label Study of Maintenance GRT-C901/GRT-R902, A Neoantigen Vaccine, in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer [NCT05141721]Phase 2/Phase 3700 participants (Anticipated)Interventional2022-02-12Active, not recruiting
A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared With Standard of Care as First-line Intervention in Participants With Metastatic Esophageal Carcinoma [NCT04949256]Phase 3862 participants (Anticipated)Interventional2021-07-28Recruiting
A Phase III, Randomized, Double-Blind, Clinical Trial of Pembrolizumab (MK-3475) Plus Chemotherapy (XP or FP) Versus Placebo Plus Chemotherapy (XP or FP) as Neoadjuvant/Adjuvant Treatment for Subjects With Gastric and Gastroesophageal Junction (GEJ) Adeno [NCT04882241]Phase 3120 participants (Anticipated)Interventional2020-07-29Active, not recruiting
Phase II Trial of Sequential Systemic Therapy Plus Intraperitoneal Paclitaxel in Gastric/GEJ Cancer Peritoneal Carcinomatosis (STOPGAP) [NCT04762953]Phase 235 participants (Anticipated)Interventional2021-02-18Recruiting
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphom [NCT03914625]Phase 36,720 participants (Anticipated)Interventional2019-07-03Recruiting
Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan-1 Levels [NCT03117972]Phase 2177 participants (Anticipated)Interventional2017-08-04Active, not recruiting
mFOLFIRINOX or Gemcitabine / Nab-paclitaxel Followed by Pancreatectomy for Patients With Borderline Resectable Pancreatic Adenocarcinoma. A Pilot Feasibility Study. [NCT04452461]Phase 230 participants (Anticipated)Interventional2021-03-01Recruiting
A Phase III, Randomized, Double-Blind, Clinical Trial of Pembrolizumab (MK-3475) Plus Chemotherapy (XP or FP) Versus Placebo Plus Chemotherapy (XP or FP) as Neoadjuvant/Adjuvant Treatment for Subjects With Gastric and Gastroesophageal Junction (GEJ) Adeno [NCT03221426]Phase 31,007 participants (Actual)Interventional2017-10-09Active, not recruiting
Pharmacogenomically Selected Treatment for Gastric and Gastroesophageal (GEJ) Tumors: A Phase II Study [NCT00515216]Phase 226 participants (Actual)Interventional2007-08-31Completed
Single-Institution Phase II Trial of Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab (Folfox-B) for Initially Unresectable Colorectal Liver Metastases: Downstaging Followed By Hepatic Resection [NCT00508872]Phase 22 participants (Actual)Interventional2005-11-30Terminated(stopped due to Slow accrual, study terminated.)
Pharmacogenomically Selected Treatment for Gastric and Gastroesophageal Junction (GEJ) Tumors: A Phase II Study [NCT00514020]Phase 233 participants (Actual)Interventional2007-08-31Completed
NANT Colorectal Cancer (CRC) Vaccine: A Phase 1b/2 Trial of the NANT CRC Vaccine vs Regorafenib in Subjects With Metastatic CRC Who Have Been Previously Treated With Standard-of-Care Therapy [NCT03563157]Phase 1/Phase 2332 participants (Anticipated)Interventional2018-05-25Active, not recruiting
A Phase II, Double-blind, Placebo Controlled, Randomized Study to Assess the Efficacy and Safety of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer in Patients Who Have Failed Therapy With a [NCT00500292]Phase 2109 participants (Actual)Interventional2007-03-31Completed
Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil and Leucovorin vs Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab for Patients With Stage II or III Rectal Cancer Receiving Pre-operative Chemoradiation [NCT00303628]Phase 3355 participants (Actual)Interventional2006-05-11Terminated(stopped due to The study was terminated before reaching its accrual goal due to slow accrual.)
Phase II Study Evaluating the Efficacy and Tolerance to Chemotherapy With 5-fluorouracil, Folinic Acid, Irinotecan and Bevacizumab as First-line Treatment in Patients With Metastatic Colorectal Cancer [NCT00467142]Phase 262 participants (Actual)Interventional2007-01-23Completed
A Phase II Randomized Study of Induction Chemotherapy Followed by Concurrent Chemo-radiotherapy in Locally Advanced Pancreatic Cancer [NCT01063192]Phase 273 participants (Anticipated)Interventional2009-11-30Enrolling by invitation
Gemcitabine Plus Oxaliplatin (GEMOX) Versus Oxaliplatin Plus Fluorouracil/Leucovorin(FOLFOX4) As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma(HCC) [NCT02534337]Phase 2/Phase 30 participants (Actual)Interventional2015-09-30Withdrawn(stopped due to It doesn't meet the requirements of randomized trials)
A Clinical Trial of the Safety and Efficacy of ABX-EGF in Combination With Irinotecan, Leucovorin, and 5-Fluorouracil in Subjects With Metastatic Colorectal Cancer [NCT00111761]Phase 243 participants (Actual)Interventional2002-07-31Completed
An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Phase III, Randomized, Controlled Study Comparing the Efficacy and Safety of mFOLFOX6 + Bevacizumab Therapy vs. mFOLFOX6 + Panitumumab Therapy in Patients With Chemotherapy-naïve Wi [NCT02394834]757 participants (Actual)Observational2015-05-29Active, not recruiting
A Phase II Trial of Preoperative FOLFIRINOX Followed by Gemcitabine Based Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Adenocarcinoma [NCT01897454]Phase 223 participants (Actual)Interventional2012-01-27Terminated(stopped due to Study was terminated due to slower than anticipated accrual)
ICARuS (Intraperitoneal Chemotherapy After cytoReductive Surgery): A Multi-center, Randomized Phase II Trial of Early Post-operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surg [NCT01815359]Phase 2292 participants (Anticipated)Interventional2013-03-31Recruiting
Randomized, Multicenter Phase II Study of Monoclonal FOLFOX6m + mAb Alone or in Combination With Liver Chemoembolization (Lifepearls-Irinotecan) in Patients With Colorectal Cancer and Metastatic Disease Limited to the Liver With Poor Prognosis [NCT04595266]Phase 248 participants (Anticipated)Interventional2021-06-29Recruiting
A Open Label, Non Randomized, Phase Two Trial in Metastatic Colorectal Cancer (mCRC) With the Combination of m FOLFIRI Plus Aflibercept as First Line Treatment: MINOAS Trial [NCT02624726]Phase 231 participants (Actual)Interventional2016-01-31Active, not recruiting
A Triplet Combination With Irinotecan Plus Oxaliplatin,Continuous Infusion 5-Fluorouracil And Leucovorin Plus Cetuximab As First Line Treatment In Metastatic Colorectal Cancer. A Pilot Phase II Trial [NCT00689624]Phase 230 participants (Actual)Interventional2007-07-31Completed
Phase III Trial of Irinotecan-Based Chemotherapy Plus Cetuximab (NSC-714692) or Bevacizumab (NSC-704865) as Second-Line Therapy for Patients With Metastatic Colorectal Cancer Who Have Progressed on Bevacizumab With Either FOLFOX, OPTIMOX or XELOX [NCT00499369]Phase 372 participants (Actual)Interventional2007-06-30Terminated(stopped due to Due to inadequate accrual, study was terminated and limited outcome data was reported.)
A Two Part Study in Japanese Patients With mCRC, Consisting of an Open-label Phase I Part to Assess the Safety and Tolerability of Cediranib (AZD2171) in Combination With FOLFOX Followed by a Phase II, Randomised, Double-blind, Parallel Group Study to Ass [NCT00494221]Phase 1/Phase 2172 participants (Actual)Interventional2007-06-30Completed
A Pilot Phase II Study of Triplet Chemotherapy Regimen in Neoadjuvant Chemotherapy of Patients With Resectable Colorectal Cancer [NCT02688023]Phase 250 participants (Anticipated)Interventional2014-03-31Recruiting
A Phase I and Dose Expansion Cohort Study of Panobinostat in Combination With Fludarabine and Cytarabine in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome [NCT02676323]Phase 119 participants (Actual)Interventional2016-05-03Terminated(stopped due to Slow accrual)
Evaluation of an Alternative Schedule for CRLX101 Alone in Combination With Bevacizumab and in Combination With mFOLFOX6 in Subjects With Advanced Solid Tumor Malignancies [NCT02648711]Phase 141 participants (Actual)Interventional2015-10-31Terminated(stopped due to Company decision)
A Phase Ib Dose Escalation Study of MM-398 Plus Irinotecan in Patients With Unresectable Advanced Cancer - DOUBLIRI [NCT02640365]Phase 110 participants (Actual)Interventional2015-11-18Completed
A Randomized Phase III Study of Systemic Therapy With or Without Hepatic Arterial Infusion for Unresectable Colorectal Liver Metastases: The PUMP Trial [NCT05863195]Phase 3408 participants (Anticipated)Interventional2023-12-19Not yet recruiting
An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma [NCT04083235]Phase 3770 participants (Actual)Interventional2020-02-11Active, not recruiting
An Open Labeled Phase 2 Study of Gemcitabine in Combination With Cisplatin, 5-FU (24h CI) and Folinic Acid in Patients With Inoperable Esophageal Cancer [NCT00759226]Phase 292 participants (Actual)Interventional2002-07-31Completed
A Pilot Study of Combined Immunochemotherapy Followed by Reduced Dose RT for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma [NCT00594815]52 participants (Actual)Interventional2002-08-28Completed
Randomized, Multinational, Study Of Aflibercept And Modified FOLFOX6 As First-Line Treatment In Patients With Metastatic Colorectal Cancer [NCT00851084]Phase 2268 participants (Actual)Interventional2009-02-28Completed
Quadruplet 1st Line Treatment of CAPOXIRI Plus Bevacizumab Versus FOLFOXIRI Plus Bevacizumab for mCRC, Multicenter Randomised Phase II Study (QUATTRO-II) [NCT04097444]Phase 2112 participants (Anticipated)Interventional2019-10-11Recruiting
Phase 2b, DB, Randomized Study Evaluating Efficacy & Safety of Sorafenib Compared With Placebo When Administered in Combination With Modified FOLFOX6 for the Treatment of Metastatic CRC Subjects Previously Untreated for Stage IV Disease [NCT00865709]Phase 2198 participants (Actual)Interventional2009-03-31Completed
A Phase I Study Evaluating the Safety and Efficacy of TGR 1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors [NCT02574663]Phase 166 participants (Actual)Interventional2015-09-11Completed
Phase II Randomized Open-Label Trial of Atovaquone Plus Pyrimethamine and Atovaquone Plus Sulfadiazine for the Treatment of Acute Toxoplasmic Encephalitis [NCT00000794]Phase 2100 participants InterventionalCompleted
A Multicenter, Randomised Phase II Trial on the Therapy of Advanced Gastric Cancer or Adenocarcinoma of the Esophagogastric Junction in Patients Older Than 65 Years With Specific Regard of Quality of Life and Pharmacogenetic Risk Profile [NCT00737373]Phase 2143 participants (Actual)Interventional2007-08-31Completed
Outpatient Chemotherapy in Pediatric Osteosarcoma: Doxorubicin With Cisplatin, High-Dose Methotrexate, and Additional Risk-Adapted Outpatient Chemotherapy [NCT00673179]7 participants (Actual)Interventional2008-05-31Terminated(stopped due to Low accrual.)
A Randomized Trial of the I-BFM-SG for the Management of Childhood Non-B Acute Lymphoblastic Leukemia [NCT00764907]Phase 34,000 participants (Anticipated)Interventional2002-11-30Recruiting
A Phase I Study of BBI608 Administered With FOLFIRI + Bevacizumab in Adult Patients With Metastatic Colorectal Cancer [NCT02641873]Phase 14 participants (Actual)Interventional2015-12-31Completed
A Two-arm Phase II Randomised Trial of Intermittent Chemotherapy Plus Continuous Cetuximab and of Intermittent Chemotherapy Plus Intermittent Cetuximab in First Line Treatment of Patients With K-ras-normal (Wild-type) Metastatic Colorectal Cancer [NCT00640081]Phase 2169 participants (Actual)Interventional2007-07-31Completed
A Prospective, Randomized Trial Of Simultaneous Pancreatic Cancer Treatment With Enoxaparin and ChemoTherapy (PROSPECT) [NCT00785421]Phase 2/Phase 3312 participants (Actual)Interventional2004-04-30Completed
Phase I Hyperthermic Intraperitoneal Oxaliplatin for Peritoneal Malignancies [NCT00625092]Phase 117 participants (Actual)Interventional2007-10-31Completed
Phase III Randomized Trial of Autologous and Allogeneic Stem Cell Transplantation Versus Intensive Conventional Chemotherapy in Acute Lymphoblastic Leukemia in First Remission [NCT00002514]Phase 31,929 participants (Actual)Interventional1993-05-07Completed
seconD-line Folfiri/aflIbercept in proSpecTIvely Stratified, Anti-EGFR resistaNt, Metastatic coloreCTal Cancer patIents With RAS Validated Wild typE Status [NCT04252456]150 participants (Anticipated)Interventional2018-04-23Recruiting
A Randomized Phase I/III Study Of Systematic Chemotherapy With Or Without Hepatic Chemoembolization For Liver-Dominant Metastatic Adenocarcinoma Of The Colon And Rectum [NCT00023868]Phase 30 participants Interventional2001-11-01Terminated(stopped due to redesign)
A Phase 1/2a, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of PEN-866 in Patients With Advanced Solid Malignancies [NCT03221400]Phase 1/Phase 2340 participants (Anticipated)Interventional2017-08-29Recruiting
Phase 3 Study of Lobaplatin,5-Fluorouracil and Leucovorin for the Treatment of Recurrent or Metastatic Esophageal Carcinoma [NCT01034683]Phase 3120 participants (Anticipated)Interventional2009-12-31Active, not recruiting
The Possible Protective Role of Ketotifen Against Oxaliplatin Induced Peripheral Neuropathy in Patients With Colorectal Cancer [NCT05624138]Phase 364 participants (Anticipated)Interventional2022-11-09Recruiting
Biomarker-oriented Study of Pembrolizumab in Combination With Chemotherapy in Chemotherapy -naïve Advanced Pancreatic Cancer [NCT04447092]Phase 277 participants (Anticipated)Interventional2020-07-01Active, not recruiting
Selective Treatment With Magnetic Resonance Image Guided Pelvic Adaptive Radiation Therapy Combined With Total Neoadjuvant ChemoTherapy for the Conservative Management of Locally Advanced Rectal Cancer [NCT05412082]Phase 125 participants (Anticipated)Interventional2022-10-05Recruiting
Randomized Phase 3 Study on the Optimization of Bevacizumab With mFOLFOX/mOXXEL in the Treatment of Patients With Metastatic Colorectal Cancer [NCT01718873]Phase 3230 participants (Actual)Interventional2012-05-31Completed
A UGT1A1 Genotype-Guided Dosing Study of Irinotecan Administered in Combination With 5-Fluorouracil/Leucovorin (FOLFIRI) and Cetuximab as First-Line Therapy in RAS Wild-Type Metastatic Colorectal Cancer Patients [NCT02573220]Phase 10 participants (Actual)Interventional2015-06-30Withdrawn(stopped due to Study terminated by PI due to inability to accrue.)
Randomized Phase II Study of S-1, Oral Leucovorin, and Oxaliplatin Combination Therapy (SOL) Versus 5-FU, l-LV and Oxaliplatin Combination Therapy (mFOLFOX6) in Patients With Untreated Metastatic Colorectal Cancer [NCT00721916]Phase 2107 participants (Actual)Interventional2008-07-31Completed
Phase II-III Study Comparing Radiochemotherapy With the FOLFOX Regimen Versus Radiochemotherapy With 5FU-cisplatin (Herskovic Regimen) in First Line Treatment of Patients With Inoperable Oesophageal Cancer. [NCT00861094]Phase 2/Phase 3266 participants (Actual)Interventional2008-03-31Completed
A Phase III, Randomized, Open-Label Multicenter, International Study Comparing The Combination Of SU5416/Irinotecan/5-Fluorouracil/Leucovorin Versus Irinotecan/Fluorouracil/Leucovorin Alone As First-Line Therapy Of Patient With Previously Untreated Metast [NCT00021281]Phase 30 participants Interventional2000-12-31Active, not recruiting
Nintedanib Plus mFOLFOX6 for Previously Untreated Metastatic Esophagogastric Adenocarcinoma (MEGAN): A Randomized, Placebo-controlled, Triple-blind Phase II Study [NCT02856867]Phase 20 participants (Actual)Interventional2016-12-31Withdrawn
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer) [NCT03193190]Phase 1/Phase 2340 participants (Anticipated)Interventional2017-07-05Active, not recruiting
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies [NCT02419495]Phase 1221 participants (Actual)Interventional2015-06-26Active, not recruiting
A Multicenter Study of the Anti-VEGF Monoclonal Antibody Bevacizumab (Avastin®) Plus 5-Fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancers That Have Progressed After Standard Chemotherapy [NCT00066846]Phase 20 participants Interventional2003-08-31Completed
Drug Treatment for Bowel Cancer: Making the Best Choices When a Milder Treatment is Needed [NCT00070213]Phase 3460 participants (Actual)Interventional2003-09-30Completed
Totally Neoadjuvant Chemoradiation Therapy With mFOLFOX6 in Locally Advanced Rectal Cancer: A Real World Study [NCT02887313]Phase 2200 participants (Anticipated)Interventional2016-07-31Recruiting
A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study of Enzastaurin With 5-FU/LV Plus Bevacizumab as Maintenance Regimen Following First Line Therapy for Metastatic Colorectal Cancer [NCT00612586]Phase 2117 participants (Actual)Interventional2008-02-29Completed
Treatment of Peripheral T-cell Lymphoma With Aggressive Induction Chemotherapy Followed by Autologous Stem Cell Transplant Using Denileukin Diftitox (Ontak) for In-vivo Purging and Post-Transplant Therapy: A Multicenter Phase II Clinical Trial [NCT00632827]Phase 221 participants (Actual)Interventional2008-07-01Terminated(stopped due to Manufacturing shortage of both Diftitox and Doxil)
Phase I/II Study of S-1, Oral Leucovorin, and Oxaliplatin Combination Therapy (SOL) in Patients With Untreated Metastatic Colorectal Cancer [NCT00524706]Phase 1/Phase 242 participants (Anticipated)Interventional2007-08-31Active, not recruiting
A Phase 1b Study of Pembrolizumab (KEYTRUDA®) in Combination With REOLYSIN® (Pelareorep) and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma [NCT02620423]Phase 111 participants (Actual)Interventional2015-12-31Completed
Prospective Randomized Trial Comparing Gastrectomy, Metastasectomy Plus Systemic Therapy Versus Systemic Therapy Alone: GYMSSA Trial [NCT00941655]Phase 315 participants (Actual)Interventional2009-07-22Completed
[NCT02941562]Phase 2150 participants (Anticipated)Interventional2016-12-31Not yet recruiting
A Prospective Multicenter Study With 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) in Patients With Locally Advanced, Limited Metastatic or Extensive Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction [NCT00849615]Phase 2252 participants (Actual)Interventional2009-02-28Completed
A Phase II Study of Panitumumab in Combination With FOLFIRI After Progression on FOLFIRI Plus Bevacizumab in KRAS(Kirsten Rat Sarcoma) and NRAS Wild-Type Metastatic Colorectal Cancer. [NCT01814501]Phase 216 participants (Actual)Interventional2013-02-01Active, not recruiting
Phase II Study of Oxaliplatin + 5-FluoroUracil/Leucovorin (Eloxatin+5-FU/LV) in Patients With Unresectable Hepatocellular Carcinoma [NCT00559455]Phase 238 participants (Actual)Interventional2007-09-30Completed
NAPOLI-2: Phase II Study of Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Previously Treated Advanced Biliary Tract Cancer [NCT04005339]Phase 244 participants (Anticipated)Interventional2019-07-29Recruiting
Phase II Study Of Weekly Administration Oxaliplatin Plus 5-Fu/Lv (Aio Regimen) Plus Bevacizumab, Alternative With Irinotecan Plus 5-Fu/Lv(Aio Regimen) Plus Cetuximab, As Salvage Treatment In Pretreated Patients With Mcrc [NCT00755118]Phase 224 participants (Actual)Interventional2008-10-31Terminated(stopped due to Due to poor Accrual)
TAC vs TACE Plus folfox4 as the Treatment of Unresectalbe Liver Metastasis of Colorectal Cancer With Resection of the Primary Tumor: a Prospective, Randomized, Control Trial [NCT00868569]Phase 4200 participants (Anticipated)Interventional2008-01-31Recruiting
Neoadjuvant Chemotherapy for Non-metastatic Locally Advanced Colon Cancer: A Prospective Multicenter Randomized Controlled Trial [NCT03426904]Phase 3560 participants (Anticipated)Interventional2018-10-24Recruiting
Does Folinic Acid Supplementation Decrease Homocysteine Concentrations in Newborns [NCT00877227]Phase 137 participants (Actual)Interventional2003-01-31Completed
An Uncontrolled, Open-label, Phase II Study in Subjects With Metastatic Adenocarcinoma of the Colon or Rectum Who Are Receiving First Line Chemotherapy With mFOLFOX6 (Oxaliplatin/ Folinic Acid/5-fluorouracil [5-FU]) in Combination With Regorafenib [NCT01289821]Phase 254 participants (Actual)Interventional2011-02-28Completed
A Phase I Dose Escalation Trial of Preoperative Chemoradiotherapy Utilizing Intensity Modulated Radiation Therapy(IMRT)in Combination With Bevacizumab-FOLFOX for Patients With Locally Advanced Rectal Cancer [NCT01395667]Phase 115 participants (Actual)Interventional2011-06-30Completed
Chemotherapy for Patients With Locally Advanced Pancreatic Cancer With Additional Chemo-radiotherapy for Patients With Borderline Resectable Tumours [NCT01397019]Phase 256 participants (Actual)Interventional2011-04-30Completed
Circulating Tumor DNA Methylation Guided Postoperative Adjuvant Chemotherapy for High-risk Stage II/III Colorectal Cancer: A Multicenter, Prospective, Randomized Controlled Cohort Study (FINE Trial) [NCT05954078]Phase 3340 participants (Anticipated)Interventional2023-07-31Recruiting
Phase I Study of Escalating Doses of Carfilzomib With Hyper-CVAD in Patients With Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma [NCT02293109]Phase 110 participants (Actual)Interventional2015-12-17Completed
A Phase 1b Clinical Trial of LDE225 in Combination With Fluorouracil, Leucovorin, Oxaliplatin and Irinotecan (FOLFIRINOX) in Previously Untreated Locally Advanced or Metastatic Pancreatic Adenocarcinoma, With an Expansion Cohort at the Recommended Phase 2 [NCT01485744]Phase 139 participants (Actual)Interventional2011-12-31Completed
PreOperative Treatment With chEmotheRapy or chemoRAdiatioN in esophaGeal or gastroEsophageal adenocaRcinoma [NCT01404156]Phase 2/Phase 360 participants (Anticipated)Interventional2015-09-30Recruiting
Postoperative folfox4 Only vs folfox4 Plus TAC in the Treatment Unresectable Liver Metastasis of Colorectal Cancer: a Randomized,Prospective,Control Trial [NCT00869271]Phase 4200 participants (Actual)Interventional2005-01-31Completed
A Randomized, Phase 2 Study Of FOLFOX Or FOLFIRI With AG-013736 Or Bevacizumab (Avastin) In Patients With Metastatic Colorectal Cancer After Failure Of An Irinotecan Or Oxaliplatin-Containing First-Line Regimen [NCT00615056]Phase 2171 participants (Actual)Interventional2008-03-31Completed
Preoperative Transhepatic Arterial Chemotherapy in the Treatment of Liver Metastasis of Resectable Colorectal Cancer [NCT00874406]Phase 4100 participants (Anticipated)Interventional2008-01-31Recruiting
Phase 3 Study of Adjuvant Chemoradiotherapy of Advanced Resectable Rectal Cancer Comparing Modulation of 5-FU With Folinic Acid or With Interferon-alpha [NCT01060501]Phase 3796 participants (Actual)Interventional1992-07-31Completed
Multimodality Management of Head and Neck Cancer: A Phase II Trial of Induction Chemotherapy, Organ Preservation Surgery, and Concurrent Chemoradiotherapy [NCT00544414]Phase 231 participants (Actual)Interventional2000-06-07Active, not recruiting
Sorafenib Alone Versus Sorafenib Combined With Hepatic Arterial Chemoinfusion for Advanced HCC With Portal Vein Tumor Thrombosis: a Multicentre Randomised Controlled Trial [NCT02774187]Phase 3247 participants (Actual)Interventional2016-05-31Completed
Hepatic Arterial Infusion of Oxaliplatin in Combination With Systemic Fluorouracil, Leucovorin and Bevacizumab With/Without Cetuximab by K-RAS Mutational Status and Liver Function for Advanced Cancers Metastatic to the Liver [NCT00941499]Phase 1140 participants (Actual)Interventional2009-07-31Completed
Multicenter Phase III Randomized Study of FOLFIRI Plus Bevacizumab Following or Not by a Maintenance Therapy With Bevacizumab in Patients With Non-Pretreated Metastatic Colorectal Cancer [NCT00952029]Phase 2/Phase 3492 participants (Actual)Interventional2010-03-31Completed
A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafe [NCT02928224]Phase 3702 participants (Actual)Interventional2016-10-13Completed
Phase II Study of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin and Bevacizumab Followed by Surgery and Postoperative 5-FU, Leucovorin, Oxaliplatin (FOLFOX) and Bevacizumab in Patients With Locally Advanced Rectal Cancer [NCT00321685]Phase 257 participants (Actual)Interventional2006-07-25Completed
Intensified Tyrosine Kinase Inhibitor Therapy (Dasatinib NSC# 732517) in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (ALL) [NCT00720109]Phase 2/Phase 363 participants (Actual)Interventional2008-07-14Completed
A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients With Treatment Naïve Metastatic Pancreatic Cancer (GIANT) [NCT04233866]Phase 2176 participants (Actual)Interventional2020-08-26Active, not recruiting
A Pilot Study of Molecularly Tailored Therapy for Patients With Metastatic Pancreatic Cancer [NCT01888978]Phase 219 participants (Actual)Interventional2012-12-31Completed
Evaluation of Bevacizumab in Combination With First-Line Chemotherapy in Patients Aged 75 Years of Older With Metastatic Colorectal Adenocarcinoma [NCT01900717]Phase 2102 participants (Actual)Interventional2011-07-31Completed
Hypofractionated Radiotherapy Combined With Chemotherapy and Toripalimab for Locally Recurrent Rectal Cancer: a Single-arm, Two-cohort, Phase II Trial (TORCH-R) [NCT05628038]Phase 293 participants (Anticipated)Interventional2022-08-18Recruiting
A Phase III Open-label, Multicenter Trial of Maintenance Therapy With Avelumab (MSB0010718C) Versus Continuation of First-line Chemotherapy in Subjects With Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro-esop [NCT02625610]Phase 3499 participants (Actual)Interventional2015-12-24Completed
A Randomised, Cross-over Phase II Study to Investigate the Efficacy and Safety of Glucarpidase for Routine Use After High Dose Methotrexate in Patients With Bone Sarcoma [NCT02022358]Phase 234 participants (Actual)Interventional2007-07-31Terminated(stopped due to Recruitment almost complete, has been slow and challenging)
AIDS-Related Primary Central Nervous System Lymphoma: A Phase II Pilot Study of High-Dose Intravenous Methotrexate With Rituximab Leucovorin Rescue and Highly Active Antiretroviral Therapy [NCT00267865]Phase 212 participants (Actual)Interventional2006-09-14Completed
Phase II Study of Preoperative Chemotherapy With Ziv-aflibercept (Zaltrap) Followed by Postoperative Chemotherapy With or Without Ziv-aflibercept (Zaltrap) in Patients With Advanced Resectable Colorectal Cancer [NCT02046538]Phase 20 participants (Actual)Interventional2014-02-28Withdrawn(stopped due to Investigator terminated due to funding issues)
Phase III Randomized Study of Intensive Adjuvant Chemotherapy for Resected Colon Cancer at High Risk of Recurrence [NCT00005979]Phase 30 participants Interventional1998-07-22Completed
A Phase I Open-Label, Safety Study of Haploidentical Bone Marrow Transplantation (BMT) After Ex Vivo Treatment of Bone Marrow With Anti-B7.1 and Anti-B7.2 Antibodies [NCT00005988]Phase 15 participants (Actual)Interventional2000-02-29Completed
Phase II Study Evaluating the Combination of 5-Fluorouracil, Leucovorin, Oxaliplatin, and Herceptin in the Treatment of Patients With Metastatic Colorectal Cancer Who Have Progressed After 5-FU and/or Irinotecan-Containing Therapy [NCT00006015]Phase 226 participants (Actual)Interventional2000-05-31Terminated(stopped due to lack of sufficient accrual)
Primary Prophylaxis of Cerebral Toxoplasmosis in HIV-Infected Patients [NCT00000643]Phase 2150 participants InterventionalCompleted
Pyrimethamine Pharmacokinetics in HIV Positive Patients Seropositive for Toxoplasma Gondii [NCT00000973]Phase 126 participants InterventionalCompleted
A Phase I Study of Isolated Hepatic Perfusion With Escalating Dose Melphalan Followed by Postoperative Hepatic Arterial Floxuridine and Leucovorin for Metastatic Unresectable Colorectal Cancers of the Liver [NCT00001576]Phase 128 participants Interventional1997-07-31Completed
FOCUS 3 - A Study to Determine the Feasibility of Molecular Selection of Therapy Using KRAS, BRAF and Topo-1 in Patients With Metastatic or Locally Advanced Colorectal Cancer [NCT00975897]Phase 2/Phase 33,240 participants (Anticipated)Interventional2009-07-31Completed
A Randomized, Comparative, Double-Blind Trial of Trimetrexate (CI-898) With Leucovorin Calcium Rescue Versus Trimethoprim / Sulfamethoxazole for Moderately Severe Pneumocystis Carinii Pneumonia in Patients With AIDS [NCT00001014]Phase 3302 participants InterventionalCompleted
Study Of The Survival Without Degradation To The Quality Of Life During Chemotherapy For Metastatic Breast Cancer In Women [NCT00010075]Phase 20 participants Interventional2000-01-31Active, not recruiting
A Randomized, Multicenter, Phase II Study Of Bolus/Infusion 5-FU/LV (de Gramont Regimen) Versus Oxaliplatin And Bolus/Infusion 5-FU/LV (de Gramont Regimen) As Third-Line Treatment Of Patients With Metastatic Colorectal Carcinoma [NCT00016198]Phase 20 participants Interventional2001-05-31Completed
A Phase II Trial of Neoadjuvant Cisplatin-Fluorouracil-Docetaxel Chemotherapy, Surgery, and Intraperitoneal (IP) Floxuridine (FUdR) Plus Leucovorin in Patients With Locally Advanced Gastric Cancer [NCT00006038]Phase 20 participants Interventional2000-02-29Completed
A Phase II Evaluation of Preoperative Chemoradiotherapy Utilizing Intensity Modulated Radiation Therapy (IMRT) in Combination With Capecitabine and Oxaliplatin for Patients With Locally Advanced Rectal Cancer [NCT00613080]Phase 279 participants (Actual)Interventional2008-04-30Completed
Toripalimab Combined With FLOT Regimen for Perioperative Treatment of PD-L1 Positive Locally Advanced Resectable Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GEJ): a Prospective, Single-center Clinical Study [NCT05466019]Phase 230 participants (Anticipated)Interventional2021-05-01Recruiting
Phase II Study of Erlotinib (Tarceva) Alternating With Chemotherapy for Second-line Treatment of Metastatic Colorectal Cancer With Molecular Correlates for p53 Pathway [NCT00642746]Phase 216 participants (Actual)Interventional2008-03-31Terminated(stopped due to Terminated due to poor enrollment and grade 3 toxicities noted during an interim analysis.)
Open, Randomized, Multicenter, Randomized Phase II Trial Comparing the Combination of Cetuximab With Oxaliplatin/5-FU/FA Versus the Combination of Cetuximab With Irinotecan/5-FU/FA as Neoadjuvant Treatment in Patients With Non-Resectable Colorectal Liver [NCT00153998]Phase 2135 participants (Actual)Interventional2004-11-30Completed
A Phase I, Open Label, Multi-center Study to Assess the Efficacy and Safety of JMT101 in Patients With Advanced Solid Tumor. [NCT04689100]Phase 1259 participants (Anticipated)Interventional2017-04-11Recruiting
A Phase I Trial of HDFL48(Weekly 48-Hour Infusion of High-Dose 5-Fluorouracil and Leucovorin) in Recurrent or Metastatic Colorectal Cancers [NCT00155558]Phase 116 participants (Actual)Interventional2001-03-31Completed
A Three-Arm Randomised Controlled Trial Comparing Either Continuous Chemotherapy Plus Cetuximab or Intermittent Chemotherapy With Standard Continuous Palliative Combination Chemotherapy With Oxaliplatin and a Fluoropyrimidine in First Line Treatment of Me [NCT00182715]Phase 32,421 participants (Anticipated)Interventional2005-03-31Active, not recruiting
Phase I Study of Vorinostat [Suberoylanilide Hydroxamic Acid (VORINOSTAT)] With Irinotecan, 5-Fluorouracil (5-FU) and Leucovorin (FOLFIRI) for Advanced Upper Gastrointestinal Cancers [NCT00537121]Phase 123 participants (Actual)Interventional2006-11-30Completed
Randomized Phase III Trial Comparing Adjuvant Oral UFT/LV to 5-FU/l-LV in Stage III Colorectal Cancer (JCOG-0205-MF) [NCT00190515]Phase 31,101 participants (Actual)Interventional2003-02-28Completed
Pancreatic Adenocarcinoma Signature Stratification for Treatment [NCT04469556]Phase 2150 participants (Anticipated)Interventional2020-10-14Recruiting
A Phase II Study of Surgical Debulking With Peritonectomy and Biweekly Intraperitoneal 5FU With Systemic Oxaliplatin/5FU/Leucovorin in Patients With Pseudomyxoma Peritonei or Peritoneal Carcinomatosis [NCT00352755]Phase 218 participants (Actual)Interventional2006-05-31Terminated(stopped due to after interim analysis it was determined that the risks were too great in comparision to the results)
A Nonrandomized Phase II Study: Feasibility and Outcome of Neo Adjuvant Chemotherapy With Oxaliplatin, Fluorodeoxyuridine (FUdR), Taxotere and Leucovorin in the Treatment of Previously Untreated Advanced Esophago-Gastric Carcinoma [NCT00448760]Phase 229 participants (Actual)Interventional2004-10-31Completed
A Study to Compare the Efficacy of AZD2171 in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX) and the Efficacy of Bevacizumab in Combination With FOLFOX in the Second-line Treatment of Patients With Metastatic Colorectal Cancer [NCT00278889]Phase 2215 participants (Actual)Interventional2006-01-31Completed
A Phase III Study of New Chemotherapy Regimen in the Treatment of Advanced Gallbladder Carcinoma [NCT01053390]Phase 3216 participants (Actual)Interventional2009-10-31Completed
A Multicentre Randomised Phase II Clinical Study of UFT/Leucovorin, Radiotherapy With or Without Cetuximab Following Induction Gemcitabine Plus Capecitabine in Patients With Locally Advanced Pancreatic Cancer (PERU) [NCT01050426]Phase 217 participants (Actual)Interventional2009-03-31Terminated(stopped due to Data from other trials failed to demonstrate meaningful survival advantage)
A Phase Ib Multiple Ascending Dose Study to Evaluate the Safety of Brivanib in Combination With 5-Fluorouracil/Leucovorin (5FU/LV) and Brivanib in Combination With 5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI) in Subjects With Advanced or Metastatic Gast [NCT01046864]Phase 149 participants (Actual)Interventional2010-02-28Completed
A Phase II Study of Docetaxel, Cisplatin, and Fluorouracil (Modified DCF) With Bevacizumab in Patients With Unresectable or Metastatic Gastroesophageal Adenocarcinoma [NCT00390416]Phase 248 participants (Actual)Interventional2006-10-31Completed
A Phase II Trial of Preoperative Chemotherapy and Chemoradiotherapy for Potentially Resectable Adenocarcinoma of the Stomach and Gastroesophageal Junction [NCT00525785]Phase 258 participants (Actual)Interventional2004-01-31Completed
A Phase 3, Randomized, Open-label, Multi-center Study to Evaluate the Efficacy and Safety of Surufatinib Plus Toripalimab Versus FOLFIRI as a Secondline Treatment in Patients With Advanced Neuroendocrine Carcinoma [NCT05015621]Phase 3194 participants (Anticipated)Interventional2021-09-18Recruiting
An Open Label, Multicenter, Single Arm, Phase 1/2 Trial of Metronomic 5-fluorouracil in Combination With Nab-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma. [NCT02620800]Phase 112 participants (Actual)Interventional2016-01-18Completed
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Pat [NCT00384176]Phase 2/Phase 31,814 participants (Actual)Interventional2006-08-30Completed
Intensive Treatment for Intermediate-Risk Relapse of Childhood B-precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies [NCT00381680]Phase 3275 participants (Actual)Interventional2007-03-31Completed
A Phase II Trial of 5-Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) Chemotherapy Plus Bevacizumab for Patients With Unresectable Stage IV Colon Cancer and a Synchronous Asymptomatic Primary Tumor [NCT00321828]Phase 290 participants (Actual)Interventional2006-03-31Completed
Intergroup Randomized Phase III Study of Postoperative Irinotecan, 5-Fluorouracil and Leucovorin vs. Oxaliplatin, 5-Fluorouracil and Leucovorin vs. 5-Fluorouracil and Leucovorin for Patients With Stage II or III Rectal Cancer Receiving Either Preoperative [NCT00068692]Phase 3225 participants (Actual)Interventional2003-10-15Completed
A Multicenter, Randomised, Double-Blind, Phase 3 Study Of Sunitinib In Metastatic Colorectal Cancer Patients Receiving Irinotecan, 5-Fluorouracil And Leucovorin (FOLFIRI) As First Line Treatment [NCT00457691]Phase 3768 participants (Actual)Interventional2007-06-30Completed
SEQUENTIAL TREATMENT STRATEGY FOR METASTATIC COLORECTAL CANCER: A PHASE III PROSPECTIVE RANDOMIZED MULTICENTER STUDY OF CHEMOTHERAPY (CT) WITH OR WITHOUT BEVACIZUMAB AS FIRST-LINE THERAPY FOLLOWED BY TWO PHASE III RANDOMIZED STUDIES OF CT ALONE OR CT PLUS [NCT01878422]Phase 3350 participants (Anticipated)Interventional2007-11-30Completed
A Randomized Phase II Trial of Induction Regimen With mFOLFOX6 and Ziv-aflibercept for First-line Therapy of Metastatic Colorectal Cancer Followed by Continuation Regimen With 5-FU/LV Alone or With Ziv-aflibercept Until Disease Progression [NCT01889680]Phase 20 participants (Actual)Interventional2014-11-30Withdrawn
Ph 2 Trial of G-FLIP (Low Doses Gemcitabine, 5FU, Leucovorin, Irinotecan & Oxaliplatin), Followed by G-FLIP-DM (G-FLIP + Low Doses Docetaxel & MitomycinC), When Used in Combination With Vitamin C, in Patients With Advanced Pancreatic Cancer [NCT01905150]Phase 234 participants (Actual)Interventional2014-07-31Completed
A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Aflibercept in Combination With FOLFIRI Administrated Every 2 Weeks in Chinese Patients With Advanced Solid Malignancies [NCT01930552]Phase 120 participants (Actual)Interventional2013-09-30Completed
NEoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma Versus Definitive Chemoradiotherapy With Salvage Surgery as Needed (NEEDS Trial) [NCT04460352]Phase 31,020 participants (Anticipated)Interventional2020-11-27Recruiting
Post-Approved Phase III Study of 1-LV/5FU Therapy [NCT00195572]Phase 3200 participants (Anticipated)Interventional2002-05-31Completed
Open-label, Phase II, Randomised, Pilot Study to Evaluate the Safety and Efficacy of Combination Therapy With Cetuximab and FOLFOX4 or FOLFOX4 Alone in Patients Colorectal Cancer and Initially Non-resectable [NCT00202787]Phase 2136 participants (Actual)Interventional2005-02-28Completed
Randomized Phase II Trial Followed by Phase III Trial With Molecular Biology Study, Comparing a Standard Bi-therapy vs 3 Arms of Intensified Chemotherapy in Patients With Unresectable or Not Optimally Resectable Colorectal Cancer Liver Metastases. [NCT00208260]Phase 2/Phase 3124 participants (Actual)Interventional2004-04-30Completed
A Phase II Study of Oxaliplatin, 5-fluorouracil, and Leucovorin in Combination With Oral Capecitabine in Patients With Metastatic Colorectal Cancer [NCT00205322]Phase 245 participants (Actual)Interventional2004-04-30Completed
A Prospective Study of Short Infusion of Ziv-Aflibercept in Combination With FOLFIRI in Patients With Metastatic Colorectal Cancer [NCT01941173]0 participants (Actual)Interventional2014-01-31Withdrawn(stopped due to Lack of accrual)
A Phase I and Randomized Phase II Double Blinded Placebo Controlled Study of mFOLFOX6 +/- AMG 337 in the First Line Treatment of Patients With Her2/Neu Negative and High MET Expressing Advanced Gastric and Esophageal Adenocarcinoma [NCT02344810]Phase 1/Phase 20 participants (Actual)Interventional2015-03-06Withdrawn(stopped due to The study did not open to accrual. No start date and no completion dates.)
A Phase II Trial of Isolated Hepatic Perfusion (IHP) and Systemic FOLFOX4 for Subjects With Metastatic Unresectable Colorectal Cancers of the Liver With ≥ 40% Hepatic Tumor Burden [NCT00103298]Phase 20 participants Interventional2004-12-31Completed
A Phase II Trial Evaluating Irinotecan With 5_fluorouracil Plus Leucovorin in Patients With Relapsed/Refractory Upper Gastrointestinal Tumours [NCT00220064]Phase 265 participants (Actual)Interventional2000-07-31Completed
Phase I Study to Determine the Safety, Maximum Tolerated Dose, and Efficacy of Biweekly Oxaliplatin (Eloxatin) in Combination With Gemcitabine, Irinotecan, and 5-FU/Leucovorin (G-Flie) in Patients With Metastatic Solid Tumors or Adenocarcinoma of the Exoc [NCT00220649]Phase 125 participants (Actual)Interventional2004-03-31Completed
Phase I-II Trial of Gemcitabine Plus Nab-paclitaxel (GemBrax) Followed by Folfirinox as First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma. [NCT01964287]Phase 1/Phase 278 participants (Actual)Interventional2013-09-24Completed
A Phase 3 Randomized Clinical Trial of Nivolumab Alone, Nivolumab in Combination With Ipilimumab, or Investigator's Choice Chemotherapy in Participants With Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic Colorectal [NCT04008030]Phase 3831 participants (Anticipated)Interventional2019-08-05Recruiting
A Safety and Efficacy Study of S-1, Oxaliplatin, and Leucovorin (SOL) in Patients With Advanced Gastric Cancer [NCT01980407]Phase 249 participants (Anticipated)Interventional2013-11-30Recruiting
A Multinational, Randomized, Phase III Study of XELIRI With/Without Bevacizumab Versus FOLFIRI With/Without Bevacizumab As Second-line Therapy in Patients With Metastatic Colorectal Cancer [NCT01996306]Phase 3650 participants (Actual)Interventional2013-12-02Completed
Single-center Randomized Study Evaluating of Oncological Benifits of Pressured Intraperitoneal Aerosol Chemotherapy (PIPAC) in Patients With Locally Advanced Gastric Cancer in Patients With Cyt-. [NCT04595929]304 participants (Anticipated)Interventional2020-02-10Recruiting
Modified Folinic Acid-Fluorouracil-Oxaliplatin (FOLFOX) Followed by Capecitabine as First-line Chemotherapy for Elderly or Frail Patients With Metastatic or Recurrent Gastric Cancer [NCT02002195]47 participants (Anticipated)Observational2013-11-30Recruiting
A Single Part, Open-Label, Randomised, Three-Way Crossover Study Designed to Evaluate the Pharmacokinetic Parameters and Relative Bioavailability of Sorafenib From Sorafenib (XS005) Tablets and Capsules Compared With Nexavar® (Reference Product) in Health [NCT05967377]Phase 115 participants (Actual)Interventional2018-11-16Completed
Phase II Study of Rituximab Given in Conjunction With Standard Chemotherapy in Primary Central Nervous System (CNS) Lymphoma [NCT00335140]Phase 226 participants (Actual)Interventional2007-08-23Terminated(stopped due to slow accrual)
Phase II Study of the Efficacy of Amifostine (Ethyol) in Reducing the Incidence and Severity of Oxaliplatin-Induced Neuropathy in Patients With Colorectal Cancer [NCT00601198]Phase 24 participants (Actual)Interventional2006-10-31Terminated(stopped due to Funding support withdrawn)
A Study of the Application of Hepatic Arterial Infusion in Advanced Hepatocellular Carcinoma Previously Treated With Immune Checkpoint Inhibitors and Antiangiogenic Agents [NCT05718492]100 participants (Anticipated)Interventional2022-10-18Recruiting
An Open-label, Randomized, Controlled, Multicenter Phase III Trial to Compare Cetuximab in Combination With FOLFOX-4 Versus FOLFOX-4 Alone in the First Line Treatment of Metastatic Colorectal Cancer in Chinese Subjects With RAS Wild-type Status [NCT01228734]Phase 3553 participants (Actual)Interventional2010-09-09Completed
A Phase II Study of Methotrexate and Thiotepa Chemotherapy for Patients With Newly Diagnosed Primary CNS Lymphoma [NCT00045539]Phase 20 participants Interventional2002-10-31Completed
A Phase I Clinical Trial of MEK162 in Combination With FOLFOX in Patients With Advanced Metastatic Colorectal Cancer Who Failed Prior Standard Therapy [NCT02041481]Phase 126 participants (Actual)Interventional2014-06-30Completed
Study of Second Look Surgery With or Without Chemotherapy Intraperitoneally, in the Event of Risk of Intraperitoneal Recurrence [NCT00005944]Phase 20 participants Interventional1999-07-01Terminated(stopped due to insuffisient recruitment)
A Multi-Center Phase Ib Study of Oxaliplatin (NSC #266046) in Combination With Fluorouracil and Leucovorin in Pediatric Patients With Advanced Solid Tumors [NCT00281944]Phase 142 participants (Actual)Interventional2005-09-30Completed
Phase II Trial of Fluorouracil (5-FU), Leucovorin (LV), Irinotecan (CPT-11) and Bevacizumab (Anti-VEGF) in Previously Untreated Patients With Advanced Colorectal Cancer [NCT00006786]Phase 20 participants Interventional2000-11-30Completed
Interracial Study of CPT-11 (Irinotecan) Pharmacokinetics in 5-Fluorouracil Refractory Colorectal Cancer: A Population Pharmacokinetic/Pharmacodynamic Study of CPT-11 [NCT00006103]Phase 3400 participants (Actual)Interventional2000-07-31Completed
Randomized Therapeutic Study Comparing Tumor Resection Followed Immediately by Intraperitoneal Chemotherapy and Systemic Chemotherapy VS Systemic Chemotherapy Alone for the Treatment of Colorectal Cancer Metastatic to the Peritoneum [NCT00006112]Phase 20 participants Interventional1996-01-31Active, not recruiting
Alternation of FOLFOX6 (Oxaliplatin - Leucovorin - Fluorouracil) and FOLFIRI (Irinotecan - Leucovorin - Fluorouracil) as Second Line Treatment of Metastatic Colorectal Cancer [NCT00006115]Phase 20 participants Interventional1999-04-30Active, not recruiting
A Phase I Study of PS-341 in Combination With 5-FU/LV in Solid Tumors [NCT00007878]Phase 130 participants (Actual)Interventional2000-09-30Completed
A Multicenter, Open-Label, Randomized, Three-Arm Study Of 5-Fluorouracil (5-FU) Plus Leucovorin (LV) Or Oxaliplatin Or A Combination Of (5-Fu) LV + Oxaliplatin As Second-Line Treatment Of Metastatic Colorectal Carcinoma [NCT00008281]Phase 30 participants Interventional2000-10-31Active, not recruiting
A Dose-Escalation, Phase I/II Study of Oral Azithromycin and Pyrimethamine for the Treatment of Toxoplasmic Encephalitis in Patients With AIDS [NCT00000966]Phase 145 participants InterventionalCompleted
Vitamin B12 and Folinic Acid Supplementation in Mitochondrial DNA Deletion Syndromes [NCT06186154]Phase 125 participants (Anticipated)Interventional2024-01-31Not yet recruiting
A Phase 3 Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer (MK-3475-C66) [NCT05239741]Phase 3100 participants (Anticipated)Interventional2022-04-02Recruiting
Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment of Stage III and High-risk Stage II Resected Colon Cancer Patients With Adjuvant FOLFOXIRI and/or Post-adjuvant Trifluridine/Tipiracil [NCT05062889]Phase 2477 participants (Anticipated)Interventional2023-05-17Recruiting
A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy (KEYNOTE 975) [NCT04210115]Phase 3700 participants (Anticipated)Interventional2020-02-28Recruiting
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repai [NCT02997228]Phase 3120 participants (Anticipated)Interventional2018-01-19Recruiting
Randomized Phase II Trial of Cetuximab/Bevacizumab (CB) as Palliative First-Line Therapy in Patients With Advanced Colorectal Cancer Followed by FOLFOX+CB vs. FOLFOX+B [NCT00571740]Phase 20 participants (Actual)InterventionalWithdrawn(stopped due to The study was not activated)
A Randomized Trial Investigating the Role of FOLFOX-4 Regimen Duration (3 Versus 6 Months) and Bevacizumab as Adjuvant Therapy for Patients With Stage II/III Colon Cancer [NCT00646607]Phase 33,756 participants (Actual)Interventional2007-06-30Completed
A Multicenter, Randomized Phase II Trial of Avastin Plus Gemcitabine Plus 5FU/Folinic Acid (A + FFG) vs. Avastin Plus Oxaliplatin Plus 5FU/Folinic Acid (A + FOLFOX 4) as Therapy for Patients With Metastatic Colorectal Cancer [NCT00192075]Phase 284 participants (Actual)Interventional2003-06-30Completed
Sequential Administration of Oral 6-Thioguanine (6-TG) After Methotrexate (MTX) in Patients With Relapsed Hodgkin's Disease (Phase II) [NCT00587873]Phase 218 participants (Actual)Interventional1994-03-31Completed
CINJALL: Treatment for Children With Acute Lymphocytic Leukemia [NCT00176462]Phase 260 participants (Actual)Interventional2001-02-28Completed
An Open Label Study to Assess the Effect of FOLFIRI Plus Avastin and Cetuximab on Progression-free Survival in Patients With Previously Untreated Metastatic Colorectal Cancer. [NCT00577109]Phase 20 participants (Actual)Interventional2007-12-31Withdrawn(stopped due to Study was cancelled before patient enrollment)
A Genotype-guided Dosing Study of mFOLFIRINOX in Previously Untreated Patients With Advanced Gastrointestinal Malignancies [NCT01643499]Phase 179 participants (Actual)Interventional2012-03-26Completed
Efficacy and Safety of Two Neoadjuvant Strategies With Bevacizumab in Locally Advanced Resectable Rectal Cancer: A Randomized, Non-Comparative Phase II Study [NCT00865189]Phase 291 participants (Actual)Interventional2007-10-23Completed
Preoperative ChemoRadiation And FOLFOXIRI To Escalate Complete Response for Rectal Cancer (CRAFTER) [NCT05358704]Phase 238 participants (Anticipated)Interventional2022-05-13Recruiting
A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer [NCT02921256]Phase 2363 participants (Actual)Interventional2017-01-11Completed
S1313, A Phase IB/II Randomized Study of Modified FOLFIRINOX + Pegylated Recombinant Human Hyaluronidase (PEGPH20) Versus Modified FOLFIRINOX Alone in Patients With Good Performance Status Metastatic Pancreatic Adenocarcinoma [NCT01959139]Phase 1/Phase 2126 participants (Actual)Interventional2014-01-23Active, not recruiting
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy) [NCT01190930]Phase 39,350 participants (Actual)Interventional2010-08-09Active, not recruiting
An Open-Label, Single-Sequence Crossover, Drug-Drug Interaction Study to Assess the Effect of Steady-State BMS-986322 on the Pharmacokinetics of Rosuvastatin (Part 1), the Pharmacokinetics and Pharmacodynamics of Metformin (Part 2) and the Pharmacokinetic [NCT05615012]Phase 176 participants (Anticipated)Interventional2022-11-11Recruiting
AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE 3 STUDY OF FIRST-LINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEAD-IN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC [NCT04607421]Phase 3815 participants (Anticipated)Interventional2020-12-21Recruiting
A Prospective, Randomized, Crossover Evaluation of the Effect of Atorvastatin on the Pharmacokinetics of Irinotecan in Colorectal Cancer Patients Receiving FOLFIRI [NCT01605344]Phase 10 participants (Actual)Interventional2012-04-30Withdrawn(stopped due to Study was withdrawn due to lack of patient enrollment.)
Phase I Study of Neoadjuvant Short Course Radiotherapy Concurrent With Infusional 5-Fluorouracil for the Treatment of Locally Advanced Rectal Cancer [NCT02270606]Phase 114 participants (Actual)Interventional2014-12-04Completed
A Single-arm Open-label Phase II Study: Treatment Beyond Progression by Adding Bevacizumab to XELOX or FOLFOX Chemotherapy in Patients With Metastatic Colorectal Cancer and Disease Progression Under First-line FOLFIRI + Bevacizumab Combination [NCT01077739]Phase 275 participants (Actual)Interventional2009-07-31Completed
Intensive Chemotherapy and Immunotherapy in Patients With Newly Diagnosed Primary CNS Lymphoma: A Pilot Study [NCT00416819]10 participants (Actual)Interventional2003-09-30Completed
Randomized Phase II Study of NaliCap (Irinotecan Liposome/Capecitabine) Compared to NAPOLI (Irinotecan Liposome/5-fluorouracil/Leucovorin) in Gemcitabine-pretreated Advanced Pancreatic Cancer [NCT04371224]Phase 2200 participants (Anticipated)Interventional2020-06-23Recruiting
AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE III STUDY OF SECOND-LINE CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB IN METASTATIC COLORECTAL CANCER PATIENTS WHO HAVE RECEIVED FIRST-LINE CHEMOTHERAPY PLUS BEVACIZUMAB. [NCT00720512]Phase 3184 participants (Actual)Interventional2008-06-30Terminated
A Randomized, Open-label, Controlled, Multi-center Phase II Study to Evaluate the Efficacy and Safety of Adecatumumab Alone or Sequentially to FOLFOX Relative to FOLFOX After R0 Resection of Colorectal Liver Metastases [NCT00866944]Phase 235 participants (Actual)Interventional2009-03-31Completed
Phase III Trial of Bevacizumab (NSC 704865), Oxaliplatin (NSC 266046), Fluorouracil and Leucovorin Versus Oxaliplatin, Fluorouracil and Leucovorin Versus Bevacizumab Alone in Previously Treated Patients With Advanced Colorectal Cancer [NCT00025337]Phase 3880 participants (Actual)Interventional2001-09-30Completed
A Phase II Double-blind and Randomized Trial Comparing Concurrent Chemoradiotherapy Plus PG2 Injection Versus Concurrent Chemoradiotherapy Plus Placebo in Advanced Pharyngeal or Laryngeal Squamous Cell Carcinoma [NCT01720563]Phase 217 participants (Actual)Interventional2012-12-31Terminated(stopped due to Change study drug dosage form)
A Phase II Study of Bi-Weekly Docetaxel Plus 24-Hour Infusion of High-Dose 5-Fluorouracil and Leucovorin(HDFL)for Inoperable Advanced or Metastatic Gastric Cancer [NCT00270543]Phase 254 participants (Anticipated)InterventionalNot yet recruiting
Neoadjuvant mFOLFOXIRI Plus Bevacizumab Versus Induction FOLFOX Followed by Concomitant Chemoradiotherapy in Patients With High-Risk Locally Advanced Rectal Cancer: Multicenter Randomized Phase III Trial [NCT04215731]Phase 3500 participants (Anticipated)Interventional2020-03-27Recruiting
Treatment Protocol for Relapsed Anaplastic Large Cell Lymphoma of Childhood and Adolescence [NCT00317408]96 participants (Anticipated)Interventional2004-04-30Active, not recruiting
A Phase I Study of Venetoclax in Combination With Cytotoxic Chemotherapy, Including Calaspargase Pegol, for Children, Adolescents and Young Adults With High-Risk Hematologic Malignancies [NCT05292664]Phase 192 participants (Anticipated)Interventional2023-03-29Recruiting
An Open-label, Multi-center, ph II Platform Study Evaluating the Efficacy and Safety of NIS793 and Other New Investigational Drug Combinations With SOC Anti-cancer Therapy for the 2L Treatment of Metastatic Colorectal Cancer (mCRC) [NCT04952753]Phase 2205 participants (Actual)Interventional2021-11-15Active, not recruiting
Phase II Study of Metronomic Chemotherapy Using POLF Regimen in the Treatment of Advanced Gastric Cancer [NCT02855788]Phase 240 participants (Anticipated)Interventional2015-05-31Recruiting
Phase 1/2 Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer [NCT02735239]Phase 1/Phase 273 participants (Actual)Interventional2016-06-24Completed
A Randomized, Open Label Study to Compare the Effect of First-line Treatment With Avastin in Combination With Irinotecan + 5-fluorouracil/Folinic Acid, and Irinotecan + 5-fluorouracil/Folinic Acid Alone, on Progression-free Survival in Chinese Patients Wi [NCT00642577]Phase 3214 participants (Actual)Interventional2007-07-31Completed
A Multi-Center, Open-Label Phase I Dose-Escalation Study of PEP02 in Combination With 5-fluorouracil (5-FU) and Leucovorin (LV) in Advanced Solid Tumors [NCT02884128]Phase 116 participants (Actual)Interventional2006-01-31Completed
A Sequential Phase I Study Of The Combination Of Everolimus (Rad001) With 5-Fu/Lv (De Gramont), Folfox6, And Folfox6/Panitumumab In Patients With Refractory Solid Malignancies [NCT00610948]Phase 174 participants (Actual)Interventional2008-03-31Completed
Phase I Study to Evaluate the Safety and Tolerability of ASLAN001 in Combination With Cisplatin and 5-Fluorouracil or Cisplatin and Capecitabine [NCT02648425]Phase 131 participants (Actual)Interventional2014-08-05Completed
A Single Dose, Within Subject, 3 Period, Pharmacokinetic Bridging Study of CoFactor Formulations and of Leucovorin Administered Intravenously in Healthy, Adult Subjects. [NCT00663481]Phase 115 participants (Anticipated)Interventional2008-04-30Completed
Evaluation and Comparison of the Efficacy of a New Standard Pre-operative Chemotherapy for Stage II and III Colorectal Cancer According to the FOLFOX4 Regimen With Routine Chemoradiation Therapy [NCT05378919]Phase 2250 participants (Anticipated)Interventional2015-06-01Recruiting
Unrelated Donor Hematopoietic Stem Cell Transplantation After Nonmyeloablative Conditioning For Patients With Hematological Malignancies [NCT00627666]Phase 252 participants (Anticipated)Interventional2003-01-31Completed
A Phase II Open-labeled, Prospective Study to Determine the Efficacy of Preoperative Chemoradiation With Oxaliplatin/5-FU in Locally Advanced Rectal Cancer Followed by Total Mesorectal Excision and FOLFOX6 [NCT00831181]Phase 227 participants (Actual)Interventional2004-07-31Completed
Phase II Randomized Study of BAX2398 in Combination With 5-Fluorouracil and Calcium Levofolinate in Japanese Patients With Metastatic Pancreatic Cancer, Which Progressed or Recurred After Prior Gemcitabine-Based Therapy [NCT02697058]Phase 284 participants (Actual)Interventional2016-03-30Completed
A Phase Ib Study to Evaluate the Safety and Tolerability of Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Patients With Advanced Solid Tumors. [NCT02658214]Phase 132 participants (Actual)Interventional2016-04-28Completed
A Pharmacogenetic-Based Phase I Trial of Irinotecan, 5-Fluorouracil, and Leucovorin (FOLFIRI) in Patients With Advanced Gastrointestinal Cancer [NCT00654160]Phase 17 participants (Actual)Interventional2008-06-30Completed
A Phase II Clinical Trial of High Dose Vitamin D3 Supplementation in Combination With FOLFOX + Bevacizumab in the 1st Line Treatment of Metastatic Colorectal Cancer [NCT01198548]Phase 210 participants (Actual)Interventional2010-08-31Terminated(stopped due to Lack of funding)
A Phase 2 Study of AZD2171 (Cediranib) With Modified FOLFOX6 in Patients With Advanced Biliary Cancers [NCT01229111]Phase 214 participants (Actual)Interventional2010-10-31Terminated(stopped due to Lack of Drug Supply)
An Open-label Study to Assess the Effect of Combination Treatment With Avastin and Xeloda, Plus Pre-operative Standard Radiotherapy, on Response Rate in Patients With Locally Advanced Rectal Cancer. [NCT01227707]Phase 243 participants (Actual)Interventional2005-11-30Completed
Primary Surgery Plus Single Course Methotrexate Versus Primary Methotrexate for Treatment of Gestational Trophoblastic Neoplasms in Low Risk Cases Above 40y: a Randomized Controled Trial [NCT02606539]Phase 2/Phase 320 participants (Anticipated)Interventional2015-09-30Recruiting
A Phase IB Study in Patients With Metastatic Colorectal Cancer to Evaluate Pharmacodynamic Effects of Erlotinib and Safety and Efficacy of Erlotinib in Combination With Modified FOLFOX6 (mFOLFOX6) and Bevacizumab [NCT00118261]Phase 117 participants (Actual)Interventional2005-03-31Completed
Phase II Study Evaluating the Efficacy and Safety of cétuximab Associated With the Protocol FOLFIRINOX (LV5FU Simplified Combined With Irinotecan and Oxaliplatin) in the First Line Treatment in Patients With Metastatic Colorectal Cancer Expressing EGFR or [NCT00556413]Phase 242 participants (Actual)Interventional2005-09-30Completed
Effect of Folic Acid on Homocysteine Levels and Flow-mediated Dilation in HIV and HIV-HCV Coinfected Patients: a Randomized Controlled Trial [NCT02810275]Phase 369 participants (Actual)Interventional2012-10-31Completed
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy Wit [NCT01183780]Phase 31,072 participants (Actual)Interventional2010-12-02Completed
Chemotherapy Intra-Arterial Hepatic With Oxaliplatin Combined With Leucovorin Calcium and Fluorouracil IV [NCT00006050]Phase 20 participants Interventional1999-04-04Completed
Phase II Multicenter Study of the Impact of the Therapeutic Sequence of Radiochemotherapy (50 Gy + Capecitabine + Oxaliplatin + Cetuximab) Followed by Total Mesorectal Excision Surgery Then Post-surgery Chemotherapy (FOLFOX 4 + Cetuximab) in Synchronous L [NCT00541112]Phase 219 participants (Actual)Interventional2007-10-29Terminated(stopped due to Toxicity and lack of efficacy)
Phase II Study Evaluating the Effectiveness of the Association of Chemotherapy LV5FU2 Simplified and Cetuximab With Intra-arterial Hepatic Chemotherapy Using Oxaliplatin in Patients With Colorectal Cancer and Nonresectable Hepatic Metastases [NCT00544349]Phase 245 participants (Anticipated)Interventional2006-10-31Completed
A Phase Ib/II, Open-Label, Multicenter, Randomized, Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction [NCT03281369]Phase 1/Phase 2410 participants (Anticipated)Interventional2017-10-13Active, not recruiting
Phase IB Study of FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma [NCT01413022]Phase 144 participants (Anticipated)Interventional2012-04-30Completed
Phase I/II Trial of Biweekly S-1, Leucovorin, Oxaliplatin and Gemcitabine (SLOG) in Metastatic Pancreatic Adenocarcinoma [NCT01415713]Phase 1/Phase 273 participants (Actual)Interventional2012-03-31Completed
Evaluation of Bevacizumab Combined With First Line Chemotherapy in Patients Aged 75 and Over Suffering From Metastatic Colorectal Adenocarcinoma. Phase II Randomized - Intergroup Trial: FFCD, FNCLCC, GERICO [NCT01417494]Phase 2102 participants (Actual)Interventional2011-07-31Completed
Phase II Randomized Trial of S-1, Leucovorin, Oxaliplatin and Gemcitabine (SLOG) vs Gemcitabine and Cisplatin (GC) in Locally Advanced or Metastatic Biliary Tract Cancer [NCT03406299]Phase 292 participants (Actual)Interventional2018-04-19Active, not recruiting
A Phase I Open Label Study to Asses the Safety and Tolerability of ZD6474 (Vandetanib)in Combination With Irinotecan, 5-Fluorouracil and Leucovorin (FOLFIRI) as First or Second Line Therapy in Patients With Metastatic Colorectal Adenocarcinoma. [NCT00507091]Phase 124 participants (Actual)Interventional2005-08-31Completed
Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors: Phase II Study of Chemotherapy, Surgery, Photon and Heavy Ion Radiotherapy Integration for More Effective and Less Toxic Treatment in Operable Patients [NCT02099175]Phase 241 participants (Actual)Interventional2013-11-30Active, not recruiting
Randomized Phase II Study of First-Line FOLFOX Plus Panitumumab Versus 5FU Plus Panitumumab in RAS And BRAF Wild-Type Metastatic Colorectal Cancer Elderly Patients [NCT02904031]Phase 2180 participants (Anticipated)Interventional2016-07-31Active, not recruiting
A Randomized, Open Label, Phase II Study of OSI-7904L Versus 5-FU/LV as First-Line Treatment in Patients With Unresectable, Locally Advanced or Metastatic Adenocarcinoma of the Biliary Tract [NCT00088270]Phase 258 participants Interventional2004-08-31Completed
A Phase I Study to Evaluate the Safety and Tolerability of Irinotecan Liposome in Combination With Oxaliplatin and 5-FU/LV in the Treatment of Advanced Pancreatic Cancer [NCT04796948]Phase 141 participants (Actual)Interventional2021-04-08Active, not recruiting
A Phase 3 Multicenter, Open Label, Randomized Study of XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects With Advanced Biliary Tumors Not Amenable to Conventional Surgery [NCT00090025]Phase 3248 participants (Actual)Interventional2004-09-30Terminated(stopped due to Futility reasons after Independent Data Monitoring Committee interim analysis)
The Ondansetron Premedication Trial in Juvenile Idiopathic Arthritis [NCT04169828]176 participants (Anticipated)Interventional2019-08-02Recruiting
Randomized Phase III Intergroup Trial in Resected Stage 2 (Dukes B) Colon Cancer: 6-Month Infusional 5FU-CPT11 (+/- Folinic Acid) Versus Observation - Determination of Biologic Predictive and Response Factors [NCT00091312]Phase 31,976 participants (Anticipated)Interventional2004-06-30Active, not recruiting
Phase II Study of S-1 Plus LV (1 Week on and 1 Week Off) as First-line Treatment for Patients With Metastatic Colorectal Cancer [NCT00891332]Phase 273 participants (Actual)Interventional2008-10-31Completed
A Phase II, Multicenter, Open-Label, Randomized Study Evaluating the Efficacy and Safety of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI in Second Line in Patients With KRAS Wildtype Metastatic Colorectal Cancer [NCT01652482]Phase 2135 participants (Actual)Interventional2012-10-31Completed
A Phase II Study of Induction Chemotherapy Followed by Concurrent Chemotherapy With Radiotherapy in Locally Advanced Pancreatic Cancer [NCT00149578]Phase 245 participants (Anticipated)Interventional2004-10-31Recruiting
Bevacizumab Plus mFOLFOXIRI or mFOLFOX-6 as First-line Treatment for Patients With Unresectable Metastatic Colorectal Cancer: a Randomised, Open-label, Phase 3 Trial [NCT04230187]Phase 3528 participants (Anticipated)Interventional2020-06-01Recruiting
A Pilot Trial of Irinotecan, 5-Fluorouracil, and Leucovorin Combined With the Anti-Angiogenesis Agent Tetrathiomolybdate in Metastatic Colorectal Carcinoma (UMCC 0075) [NCT00176774]Phase 224 participants (Actual)Interventional2001-02-28Completed
Gleevec (Imatinib) Plus Multi-Agent Chemotherapy For Newly-Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia [NCT00618501]Phase 250 participants (Anticipated)Interventional2005-10-31Completed
Phase II Randomized Study of First-Line Therapy Comprising Bevacizumab and Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil (FOLFIRI) Versus Bevacizumab and Irinotecan Hydrochloride and Capecitabine (XELIRI) in Patients With Unresectable Met [NCT00423696]Phase 2145 participants (Actual)Interventional2006-03-23Completed
Phase 2 Study to Improve Tolerance of Chemotherapy Involving Cetuximab and Multidrug FOLFIRI, With Pharmacokinetic and Pharmacogenetic Studies, in Patients With Metastatic Colorectal Cancer [NCT00559741]Phase 280 participants (Anticipated)Interventional2005-10-31Completed
A Multicenter Phase III Trial Comparing Induction Chemotherapy Followed by Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy Alone in Stage IV Nasopharyngeal Carcinoma (NPC) [NCT00201396]Phase 3480 participants (Actual)Interventional2003-08-31Completed
A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and in Combination With Pembrolizumab in Subjects With KRAS G12C Mutant Advanced Solid Tumors [NCT05067283]Phase 1450 participants (Anticipated)Interventional2021-12-17Recruiting
Phase I Study of Irinotecan Liposome (Nal-IRI), Fluorouracil and Rucaparib in the Treatment of Select Gastrointestinal Metastatic Malignancies Followed by a Phase Ib of First and Second Line Treatment of Both Unselected and Selected (for BRCA 1/2 and PALB [NCT03337087]Phase 1/Phase 218 participants (Anticipated)Interventional2018-11-02Active, not recruiting
A Phase II Multicenter Randomized Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Managem [NCT02008656]Phase 2358 participants (Actual)Interventional2013-11-30Active, not recruiting
A Phase II Study Of Oxaliplatin (OXAL), 5-Fluorouracil (5-FU), Leucovorin (CF), and Cetuximab (C225) For Patients With Unresectable Hepatic Metastases From Metastatic Adenocarcinoma Of The Colon Or Rectum [NCT00056030]Phase 273 participants (Anticipated)Interventional2004-12-31Completed
A Phase II Multi-Institutional Efficacy and Safety Study of Chemotherapy With Selective Internal Radiation Treatment Using Y-90 Microspheres (CHEMO-SIRT) in Patients With Colorectal Cancer Liver Metastasis [NCT00408551]Phase 220 participants (Anticipated)Interventional2005-11-30Recruiting
Phase I / II Study of Irinotecan (CPT-11) Combined With l-Leucovorin (l-LV) and 5-FU in Patients With Advanced Colorectal Cancer:Hokkaido Gastrointestinal Cancer Study Group:HGCSG0001 [NCT00209625]Phase 1/Phase 223 participants Interventional2000-04-30Completed
Feasibility Study of mFOLFOX6 (Oxaliplatin Combined With l-Leucovorin (l-LV) and 5-Fluorouracil) in Patients With Advanced Colorectal Cancer [NCT00209703]Phase 230 participants Interventional2005-01-31Terminated
Randomized Phase III Clinical Study Comparing Postoperative UFT+LV, UFT+LV/UFT and UFT+LV+PSK/UFT+PSK Therapies for Stage III Colorectal Cancer [NCT00209742]Phase 3340 participants (Anticipated)Interventional2005-04-30Active, not recruiting
A Randomized Crossover Trial Comparing Oral Capecitabine and Intravenous Fluorouracil + Folinic Acid (Nordic FU/FA Regimen) for Patient Preference in Colorectal Cancer [NCT00212589]Phase 360 participants Interventional2002-12-31Completed
[NCT01851941]Phase 252 participants (Actual)Interventional2004-10-31Completed
Treatment of Acute Lymphoblastic Leukemia in Children [NCT00400946]Phase 3800 participants (Actual)Interventional2005-04-30Completed
Randomised Phase 2 Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX or FOLFIRI in RAS and B-RAF WT Tumors [NCT01858662]Phase 24 participants (Actual)Interventional2014-01-31Terminated(stopped due to due to poor recrutment)
AZD8931, an Inhibitor of EGFR, ERBB2 and ERBB3 Signalling, in Combination With FOLFIRI: a Phase I/II Study to Determine the Importance of Schedule and Activity in Colorectal Cancer [NCT01862003]Phase 224 participants (Actual)Interventional2014-05-31Completed
Potentially Resectable Metastatic Colorectal Cancer With Wild-type KRAS and BRAF: Alternating Chemotherapy Plus Cetuximab - A Randomised Phase II Trial [NCT01867697]Phase 2173 participants (Actual)Interventional2012-05-31Completed
HIGH INTENSITY, BRIEF DURATION CHEMOTHERAPY FOR RELAPSED OR REFRACTORY ALL: A PHASE II STUDY OF A MULTIDRUG REGIMEN [NCT00002865]Phase 225 participants (Actual)Interventional1995-04-30Completed
Perioperative Immunotherapy vs. Chemo-immunotherapy Stratified by Early Response Evaluation in Patients With Advanced Gastric Cancer (GC) and Adenocarcinoma of the Esophago-gastric Junction (AEG) [NCT04062656]Phase 221 participants (Actual)Interventional2019-09-26Active, not recruiting
Phase III Study of Fluorouracil, Leucovorin, and Irinotecan Regimen (FOLFIRI) Versus Irinotecan Monodrug as Second-line Treatment in Metastatic Colorectal Cancer Patients [NCT02935764]Phase 3164 participants (Anticipated)Interventional2016-10-31Not yet recruiting
Assessment of Ramucirumab Plus Paclitaxel as Switch MANteInance Versus Continuation of First-line Chemotherapy in Patients With Advanced HER-2 Negative Gastric or Gastroesophageal Junction Cancers: the ARMANI Phase III Trial [NCT02934464]Phase 3280 participants (Anticipated)Interventional2016-12-31Recruiting
Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach [NCT01246960]Phase 2168 participants (Actual)Interventional2011-04-30Completed
International Collaborative Treatment Protocol for Infants Under One Year With Acute Lymphoblastic or Biphenotypic Leukemia [NCT00550992]445 participants (Anticipated)Interventional2006-01-31Recruiting
"Frontline Chemotherapy Reinforced for Cancers of the Colon and Rectum With Potentially Resectable Hepatic and/or Pulmonary Metastases: Association of FOLFIRI and ERBITUX" [NCT00557102]Phase 224 participants (Actual)Interventional2007-09-30Completed
Randomized, Blinded, Placebo-Controlled Trial of High Dose Methotrexate With Leucovorin Rescue (HDMTX-LV) With or Without Glucarpidase in Osteosarcoma [NCT00634322]Phase 27 participants (Actual)Interventional2008-10-31Terminated(stopped due to Lack of enrollment)
Open Label, Multicenter, Phase II Study Evaluating the Efficacy and Safety of IMC-11F8 in Combination With 5-FU/FA and Oxaliplatin (mFOLFOX-6) in Patients With Treatment-naïve, Locally-advanced or Metastatic Colorectal Cancer [NCT00835185]Phase 244 participants (Actual)Interventional2007-08-31Completed
An Open-Label, Single-Sequence Study to Investigate the Effects of BMS-986165 on the Single-Dose Pharmacokinetics of Methotrexate in Healthy Male Subjects [NCT03402087]Phase 130 participants (Actual)Interventional2018-01-08Completed
Systemic Chemotherapy Plus HAI(FUDR)vs Systemic Chemotherapy Alone As Adjuvant Therapy in Patients With Resectable Colorectal Liver Metastasis [NCT03500874]Phase 3288 participants (Anticipated)Interventional2018-02-28Recruiting
Phase II Study of the Hyper-CVAD Regimen in Sequential Combination With Inotuzumab Ozogamicin as Frontline Therapy for Adults With B-Cell Lineage Acute Lymphocytic Leukemia [NCT03488225]Phase 24 participants (Actual)Interventional2018-03-28Terminated(stopped due to the study was closed early due to competing trials)
A Phase II Study of FOLFOX Combined With Nab-Paclitaxel (FOLFOX-A) in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma. Big Ten Cancer Research Consortium: BTCRC-GI15-015 [NCT03283761]Phase 239 participants (Actual)Interventional2017-09-21Completed
An Open, Prospective, Multicenter Study of Trimetrexate With Leucovorin Rescue for AIDS Patients With Pneumocystis Carinii Pneumonia (PCP) and Serious Intolerance to Approved Therapies [NCT00000714]Phase 30 participants InterventionalCompleted
A Phase II Trial of Infusional 5-Fluorouracil (5-FU), Calcium Leucovorin (LV), Mitomycin-C (Mito-C), and Dipyridamole (D) in Patients With Locally Advanced Unresected Pancreatic Adenocarcinoma [NCT00003018]Phase 254 participants (Actual)Interventional1997-09-30Completed
A Randomized Phase III Trial of Paclitaxel, Carboplatin and Etoposide Vs. 5-Fluorouracil and Folinic Acid in the Treatment of Patients With Adenocarcinoma of Unknown Primary Site [NCT00003558]Phase 3140 participants (Anticipated)Interventional1998-08-31Active, not recruiting
Phase IB/Randomized Phase II Study of Folfirinox Plus AMG-479 (Ganitumab) or Placebo in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma [NCT01473303]Phase 1/Phase 20 participants (Actual)Interventional2012-08-31Withdrawn(stopped due to CALGB 81003 closed about a week after it was activated because of withdrawal of support. No patients were registered on this study.)
Multicenter Phase II Study of Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) in Patients With Locally Advanced or Metastatic Biliary Tract Cancer [NCT01494363]Phase 253 participants (Anticipated)Interventional2011-10-31Recruiting
A Randomized Phase III Study of Irinotecan Plus 5-fluorouracil Plus Leucovorin and Bevacizumab (FOLFIRI+Avastin) Versus Irinotecan Plus Capecitabine and Bevacizumab (XELIRI+Avastin) as 1st Line Treatment of Locally Advanced or Metastatic Colorectal Cancer [NCT00469443]Phase 3330 participants (Anticipated)Interventional2006-12-31Completed
Randomized Phase II Trial Evaluating the Feasibility and Tolerance of the Combination of FOLFOX With Cetuximab and the Combination of FOLFOX With Cetuximab and Bevacizumab as Perioperative Treatment in Patients With Resectable Liver Metastases From Colore [NCT00438737]Phase 2100 participants (Anticipated)Interventional2007-01-31Active, not recruiting
PALLIATIVE LOCAL CHEMOTHERAPY FOR NON-RESECTABLE LIVER METASTASES FROM COLORECTAL CARCINOMA, A RANDOMISED PHASE III STUDY [NCT00002793]Phase 3336 participants (Anticipated)Interventional1991-01-31Active, not recruiting
A Phase 2 Open Label Extension Study of Conatumumab and AMG 479 [NCT01327612]Phase 212 participants (Actual)Interventional2011-03-03Completed
A Phase I Open-Label Study of Picoplatin in Combination With 5-Fluorouracil and Leucovorin as Initial Therapy in Subjects With Metastatic Colorectal Cancer [NCT00478946]Phase 1/Phase 243 participants (Anticipated)Interventional2006-04-30Active, not recruiting
Phase I Trial of Combination of FOLFIRI and SOM 230 in Advanced Gastrointestinal Malignancies [NCT01434069]Phase 116 participants (Actual)Interventional2011-09-30Completed
Phase I Study Of Oral Etoposide In Combination With ORZEL (UFT + Leucovorin) For Advanced Non-Hematological Malignancies [NCT00009815]Phase 10 participants (Actual)Interventional1999-12-31Withdrawn
A Phase 1 and Pharmacokinetic Study of Uproleselan (GMI-1271, NSC #801708) in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia Myelodysplastic Syndrome or Mixed Phenotype Acute Leukemia That Expresses E-Selectin Ligand [NCT05146739]Phase 118 participants (Anticipated)Interventional2023-12-23Recruiting
Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients With Stage IIA Colon Cancer (COBRA) [NCT04068103]Phase 2/Phase 31,408 participants (Anticipated)Interventional2019-12-16Recruiting
A Phase III Prospective Random Assignment Trial of Regional and Systemic Chemotherapy With or Without Initial Isolated Hepatic Perfusion for Patients With Metastatic Unresectable Colorectal Cancers of the Liver [NCT00020501]Phase 30 participants Interventional2001-03-31Completed
A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A (MLL) Gene Rearrangement [NCT02828358]Phase 278 participants (Actual)Interventional2017-04-01Active, not recruiting
A Phase I Study of Hepatic Arterial Infusion of Oxaliplatin in Combination With Systemic Fluorouracil, Leucovorin and Avastin for Patients With Advanced Solid Tumors Metastatic to the Liver [NCT00507585]Phase 163 participants (Actual)Interventional2006-06-30Completed
Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined With FOLFOX Chemotherapy in Metastatic Colorectal Cancer (CA180048) [NCT00501410]Phase 186 participants (Actual)Interventional2007-04-23Completed
MEGA (Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma): FOLFOX Alone or in Combination With AMG 102 or Panitumumab as First-line Treatment in Patients With Advanced Gastroesophageal Adenocarcinoma FNCLCC-FFCD-AGEO PRODIGE 17-ACCORD 20 Randomized [NCT01443065]Phase 2162 participants (Actual)Interventional2011-01-31Completed
Phase I Study of Sunitinib With FOLFIRI (Irinotecan, 5-Fluorouracil and Leucovorin) for Advanced Gastroesophageal Cancers [NCT00524186]Phase 123 participants (Actual)Interventional2007-05-31Terminated(stopped due to PI left institute)
A Prospective,Multicenter,Randomized Trial of Biweekly Single-dose Actinomycin-D Versus Multi-day Methotrexate Protocol for the Treatment of Low-risk Gestational Trophoblastic Neoplasia [NCT04562558]228 participants (Anticipated)Interventional2020-09-29Recruiting
Phase II Randomized Study Comparing FOLFIRINOX + Panitumumab Versus mFOLFOX6 + Panitumumab in Metastatic Colorectal Cancer Patients Selected by RAS and B-RAF Status From Circulating DNA Analysis [NCT02980510]Phase 2219 participants (Actual)Interventional2016-12-31Active, not recruiting
A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; NSC#617807) [NCT00557193]Phase 3218 participants (Actual)Interventional2008-01-15Active, not recruiting
Methotrexate Infusion Into the Fourth Ventricle in Children With Malignant Fourth Ventricular Brain Tumors: A Pilot Study [NCT01737671]Early Phase 17 participants (Actual)Interventional2012-12-27Completed
A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus mFOLFOX6 Compared With Placebo Plus mFOLFOX6 as First-line Treatment of Subjects With Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unr [NCT03504397]Phase 3566 participants (Actual)Interventional2018-06-21Active, not recruiting
Chemoradiation OR Brachytherapy for RECTal Cancer [NCT02017704]Phase 29 participants (Actual)Interventional2014-06-12Completed
Phase II, Multicenter Study Evaluating G-CSF as Primary Prophylaxis for Neutropenia Associated With First-line Chemotherapy Regimen FOLFIRI and Bevacizumab in Patients With Metastatic Colorectal Cancer Who Are Homozygous for UGT1A1*28 Polymorphism, the Pr [NCT00541125]Phase 220 participants (Actual)Interventional2007-11-30Completed
Hepatic Arterial Infusion With Oxaliplatin & 23h Fluorouracil Versus Hepatic Arterial Infusion With Oxaliplatin & 46h Fluorouracil for Unresectable Hepatocellular Carcinoma:a Non-inferiority Study [NCT05476432]Phase 3300 participants (Anticipated)Interventional2022-07-26Recruiting
Phase 4 Study to Characterize and Evaluate Markers of Chemoresistance in Patients With Metastatic Colorectal Cancer [NCT00559676]Phase 4200 participants (Anticipated)Interventional2005-03-31Completed
A Clinical Trial Comparing Oral Uracil/Ftorafur (UFT) Plus Leucovorin (LV) With 5-Fluorouracil (5-FU) Plus LV in the Treatment of Patients With Stages II And III Carcinoma of the Colon [NCT00378716]Phase 31,608 participants (Actual)Interventional1997-02-28Completed
Randomized Phase II Trial Of Neoadjuvant Combined Modality Therapy For Locally Advanced Rectal Cancer [NCT00081289]Phase 2146 participants (Actual)Interventional2004-03-31Completed
Phase II Study of 5-Fluorouracil, Oxaliplatin Plus Dasatinib (FOLFOX-D) in First-line Metastatic Pancreatic Adenocarcinoma [NCT01652976]Phase 244 participants (Actual)Interventional2012-07-31Completed
A Randomized, Open Label Phase 3 Study of MM-398, With or Without 5-Fluorouracil and Leucovorin, Versus 5 Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer Who Have Failed Prior Gemcitabine-based Therapy [NCT01494506]Phase 3417 participants (Actual)Interventional2011-11-30Completed
A Multi-center, Open-label Clinical Trial to Evaluate the Objective Response Rate of Bevacizumab in Combination With Modified FOLFOX-6 Followed by One Year of Maintenance With Bevacizumab Alone in Patients With Initially Not or Borderline Resectable Color [NCT01383707]Phase 277 participants (Actual)Interventional2011-08-12Completed
HIGH INTENSITY, BRIEF DURATION CHEMOTHERAPY FOR DIFFUSE SMALL NONCLEAVED CELL LYMPHOMA AND THE L-3 SUBTYPE OF ALL: A PILOT STUDY OF A MULTIDRUG REGIMEN [NCT00002494]Phase 2134 participants (Actual)Interventional1992-05-31Completed
Pilot Study in AIDS-Related Lymphomas [NCT00002524]Phase 246 participants (Actual)Interventional1993-06-30Completed
A Multicenter, Clinical Phase II Study of FOLFOXIRI With Bevacizumab As First-line Therapy in Patients With Metastatic Colorectal Cancer [NCT02246049]Phase 269 participants (Actual)Interventional2014-05-31Completed
RANDOMIZED PHASE II STUDY OF A WEEKLY 24H-INFUSION OF HIGH-DOSE 5-FU PLUS OR MINUS FOLINIC ACID (HD-FU/FA) VERSUS HD-FU/FA PLUS BIWEEKLY CISPLATIN VERSUS FAMTX (5-FU/ADRIAMYCIN/METHOTREXATE) IN ADVANCED GASTRIC CANCER, AN EORTC/AIO INTERGROUP TRIAL [NCT00002722]Phase 2135 participants (Anticipated)Interventional1996-01-31Completed
A Randomized Phase III Trial Comparing Chemotherapy With Folfirinox to Gemcitabine in Locally Advanced Pancreatic Carcinoma [NCT02539537]Phase 3171 participants (Actual)Interventional2015-10-23Active, not recruiting
Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer [NCT00100841]Phase 266 participants (Actual)Interventional2004-11-30Completed
Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study [NCT02345460]Phase 21 participants (Actual)Interventional2015-09-30Terminated(stopped due to Competing studies)
TREATMENT OF ADULT PATIENTS WITH RELAPSING ACUTE LYMPHOCYTIC LEUKEMIA, A MULTICENTER TRIAL [NCT00002532]Phase 20 participants Interventional1993-01-31Active, not recruiting
A RANDOMIZED PHASE III TRIAL COMPARING DEXAMETHASONE WITH PREDNISONE IN INDUCTION TREATMENT AND BONE MARROW TRANSPLANTATION WITH INTENSIVE MAINTENANCE TREATMENT IN ADOLESCENT AND ADULT ACUTE LYMPHOBLASTIC LEUKEMIA (ALL-4) [NCT00002700]Phase 3392 participants (Anticipated)Interventional1995-08-31Completed
A Randomized Phase III Trial of Three Different Regimens of CPT-11 Plus 5-Fluorouracil and Leucovorin Compared to 5-Fluorouracil and Leucovorin in Patients With Advanced Adenocarcinoma of the Colon and Rectum [NCT00003594]Phase 31,691 participants (Actual)Interventional1998-10-31Completed
A Phase II Study of Patients With Unresectable Metastatic Adenocarcinoma of the Colon or Rectum (Per 04/99 Amendment) Old Title: A Phase II Study of Patients With Unresectable Metastatic Adenocarcinoma of the Colon or Rectum Confined to the Liver [NCT00003834]Phase 244 participants (Actual)Interventional1999-03-31Completed
A Phase II Trial of Docetaxel, Cisplatin, 5-FU, and Leucovorin for Carcinoma of the Nasopharnyx [NCT00004164]Phase 20 participants Interventional1999-08-31Active, not recruiting
Phase II Study of Oxaliplatin and 5 Fluorouracil in the Treatment of Advanced Ovarian Cancer [NCT00004206]Phase 20 participants Interventional1999-09-30Active, not recruiting
Pan-European Trials in Adjuvant Colon Cancer (PETACC-2): Randomized Phase III Intergroup Trial of High-Dose Infusional 5-FU (+ or - Folinic Acid) Versus Standard Bolus 5-FU/Folinic Acid [NCT00004150]Phase 30 participants Interventional1999-03-31Completed
A Phase 1, Open-Label Dose Escalation First-in-Human Study to Evaluate the Tolerability, Safety, Maximum Tolerated Dose, Preliminary Clinical Activity and Pharmacokinetics of AM0010 in Patients With Advanced Solid Tumors [NCT02009449]Phase 1350 participants (Actual)Interventional2013-11-15Active, not recruiting
A UKCCCR Study of Adjuvant Chemotherapy for Colorectal Cancer [NCT00005586]Phase 32,500 participants (Anticipated)Interventional1997-10-31Completed
Biomarkers and Clinical Outcomes in Localized Rectal Adenocarcinoma Treated With Neoadjuvant Therapy [NCT04418895]Phase 20 participants (Actual)Interventional2021-08-13Withdrawn(stopped due to lack of resources)
[NCT00378456]0 participants InterventionalCompleted
[NCT01271166]Phase 110 participants (Actual)Interventional2007-10-31Terminated
A Phase III Study of Chemotherapy With or Without Algenpantucel-L (HyperAcute®-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer [NCT01836432]Phase 3302 participants (Actual)Interventional2013-05-31Terminated(stopped due to Company decision)
Open, Randomized, Multicenter Phase II Trial With Cetuximab /5-FU/FA/Irinotecan or Cetuximab/5-FU/FA /Irinotecan/Oxaliplatin in K-ras/B-raf Wild Type Patients or With Irinotecan/Oxaliplatin/5-FU/FA With or Without Bevacizumab in K-ras Mutant Patients as N [NCT01802645]Phase 291 participants (Actual)Interventional2013-03-31Active, not recruiting
A Phase 1 Study of Hypofractionated Stereotactic Radiotherapy and Concurrent HIV Protease Inhibitor Nelfinavir as Part of a Neoadjuvant Regimen in Patients With Locally Advanced Pancreatic Cancer [NCT01068327]Phase 146 participants (Actual)Interventional2007-11-05Completed
Phase III Intergroup Trial of Adjuvant Chemoradiation After Resection of Gastric or Gastroesophageal Adenocarcinoma [NCT00052910]Phase 3546 participants (Actual)Interventional2002-12-31Completed
Multicenter, Explorative Phase II Study of Perioperative 5-FU, Leucovorin, Docetaxel, and Oxaliplatin (FLOT) in Combination With Trastuzumab in Patients With HER2-positive, Locally Advanced, Resectable Adenocarcinoma of the Gastroesophageal Junction or St [NCT01472029]Phase 253 participants (Actual)Interventional2011-12-31Completed
A Phase 1b/2 Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors [NCT03184870]Phase 1/Phase 2332 participants (Actual)Interventional2017-08-08Completed
Phase II Study Of 5FU-Irinotecan-Cisplatin As First-Line Treatment In Patients With Metastatic Carcinoma Of The Esophagus [NCT00075738]Phase 20 participants Interventional2003-10-31Active, not recruiting
Irinotecan Combined With Infusional 5-FU/Folinic Acid or Capecitabine and the Role of Celecoxib in Patients With Metastatic Colorectal Cancer [NCT00064181]Phase 386 participants (Actual)Interventional2003-05-31Completed
Study of Endostar Combined With mFOLFOX6 for First-line Treatment of Metastatic Colorectal Cancer and Efficacy Prediction [NCT01832948]Phase 230 participants (Anticipated)Interventional2013-01-31Recruiting
A Randomised, Non-Comparative, Multicentre, Phase II, Parallel-Group Trial Of ZD1839 (Iressa™) In Combination With 5 Fluorouracil, Leucovorin And Cpt-11 (Irinotecan) In Patients With Metastatic Colorectal Cancer [NCT00233623]Phase 2190 participants Interventional2004-07-31Withdrawn
[NCT00065117]Phase 2180 participants Interventional2003-09-30Terminated
Phase I Study of PS-341 (VELCADE) in Combination With 5FU/LV Plus Oxaliplatin in Patients With Advanced Colorectal Cancer [NCT00098982]Phase 116 participants (Actual)Interventional2004-09-30Completed
Phase II Study of Recurrent Ganglionic Colorectal Cancer Not Accessible By Surgery Treated Using Chemotherapy With Simplified FOLFOX7 Followed By Radiotherapy Combined With 5FU and Oxaliplatin [NCT00268333]Phase 239 participants (Anticipated)Interventional2005-08-31Completed
A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers [NCT03279237]Phase 125 participants (Actual)Interventional2017-10-24Active, not recruiting
Study of First-Line Therapy Comprising Leucovorin Calcium, Fluorouracil, and Irinotecan (FOLFIRI) in Patients With Progressive Locally Advanced or Metastatic Duodenal-Pancreatic Endocrine Tumors [NCT00416767]Phase 220 participants (Actual)Interventional2004-05-31Completed
A Single-Arm Phase II Study in Japan to Assess the Efficacy and Safety of Aflibercept Administered Every Two Weeks in Combination With FOLFIRI in Patients With Metastatic Colorectal Cancer Who Progressed During or Following an Oxaliplatin-Based Regimen [NCT01882868]Phase 262 participants (Actual)Interventional2013-07-31Completed
Phase I Study of High Dose Methotrexate With Simultaneous Trimetrexate and Leucovorin in Patients With Recurrent Osteosarcoma [NCT00119301]Phase 118 participants (Anticipated)Interventional2005-04-30Completed
A Randomized, Phase III, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Onartuzumab (MetMAb) in Combination With 5-Fluorouracil, Folinic Acid, and Oxaliplatin (mFOLFOX6) in Patients With Metastatic HER2-Negative, [NCT01662869]Phase 3564 participants (Actual)Interventional2012-11-30Completed
Phase II Trial Of Irinotecan + 5-Fluorouracil + Leucovorin + Oxaliplatin As First-Line Treatment For Metastatic Colorectal Cancer [NCT00080951]Phase 214 participants (Actual)Interventional2004-03-31Completed
An Open-Labeled, Non-Randomized Phase I Study of Alvocidib (Flavopiridol) Administered With Oxaliplatin and Fluorouracil/Leucovorin in Patients With Advanced Solid Tumors [NCT00080990]Phase 146 participants (Actual)Interventional2004-02-29Completed
A Prospectively Randomized Study on Neoadjuvant Radio-Chemotherapy in Patients With Operated Rectal Carcinoma Dukes B and C (pT2, pN1-3; pT3-4, pN0-3; M0. [NCT00309517]Phase 3700 participants Interventional1997-07-31Terminated
Preoperative Radiotherapy With or Without Concurrent Chemotherapy (5-Fluorouracil and Leucovorin) in T3-4 Rectal Cancers - Randomized Trial [NCT00296608]Phase 3762 participants (Actual)Interventional1993-04-30Completed
A Randomized Pilot Study of the Activation of the Hemostatic Pathway by FOLFIRI + Bevacizumab With or Without Dalteparin in First Line Treatment of Advanced Colorectal Cancer [NCT00323011]Phase 25 participants (Actual)Interventional2006-05-31Terminated(stopped due to drug not available)
A Phase II Study of 5-FU, Irinotecan, Bevacizumab and Hydroxychloroquine in Drug-Tolerant Persister (DTP)-Selected Patients With Metastatic Colorectal Cancer [NCT05843188]Phase 2155 participants (Anticipated)Interventional2023-08-09Recruiting
Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver [NCT02885753]Phase 3348 participants (Anticipated)Interventional2016-12-31Recruiting
Phase II Study Of Rituximab And Short Duration, High Intensity Chemotherapy With G-CSF Support In Previously Untreated Patients With Burkitt Lymphoma/Leukemia [NCT00039130]Phase 2105 participants (Actual)Interventional2002-05-31Completed
A Clinical Trial to Assess the Relative Efficacy of 5-FU + Leucovorin, 5-FU + Levamisole, and 5-FU + Leucovorin + Levamisole in Patients With Dukes' B and C Carcinoma of the Colon [NCT00425152]Phase 32,151 participants (Actual)Interventional1989-07-31Completed
A Pilot Study of Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy [NCT03883919]Phase 120 participants (Actual)Interventional2019-07-11Completed
Multicenter, Double-Blind, Placebo-Controlled Randomized Phase III Study of Adjuvant Therapy With Celecoxib in Combination With Chemotherapy in Patients With Curatively Resected Stage III Colon Cancer [NCT00085163]Phase 30 participants Interventional2004-03-31Completed
Neo-AEGIS (NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study): Randomised Clinical Trial of Neoadjuvant and Adjuvant Chemotherapy (Modified MAGIC or FLOT Regimen) vs. Neoadjuvant Chemoradiation (CROSS [NCT01726452]Phase 3377 participants (Actual)Interventional2013-01-24Completed
Multicenter Randomized Trial Evaluating FOLFIRI Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment of Metastatic Colorectal Cancer. [NCT00433927]Phase 3568 participants (Anticipated)Interventional2007-01-31Active, not recruiting
A Phase II Combination Trial of PS-341 and 5-FU/LV in Gastric and/or GE Junction Adenocarcinoma [NCT00103103]Phase 20 participants Interventional2005-03-31Terminated
A Phase I Study of Suberoylanilide Hydroxamic Acid (Vorinostat) in Combination With 5-Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX) in Patients With Colorectal Cancer and Other Solid Tumors [NCT00138177]Phase 154 participants (Actual)Interventional2005-07-31Completed
Randomized Phase II/III Trial Comparing Folririnox Association [Oxaliplatin / Irinotecan / LV5FU2] Versus Gemcitabine in First Line of Chemotherapy in Metastatics Pancreas Cancers Patients [NCT00112658]Phase 2/Phase 3342 participants (Actual)Interventional2004-11-30Completed
A Randomized Phase II Study of Irinotecan and Oxaliplatin Versus the Combination of 5-FU/LV and Oxaliplatin, as First-Line Treatment in Patients With Locally Advanced or Metastatic Gastric Cancer [NCT00447967]Phase 2110 participants (Anticipated)Interventional2004-07-31Completed
A Phase I Study of 5-FU (Plus Leucovorin) and Arsenic Trioxide for Patients With Refractory/Relapsed Metastatic Colorectal Carcinoma [NCT00449137]Phase 113 participants (Actual)Interventional2005-06-30Completed
FOLFOXIRI in Combination With GM-CSF and IL-2 (FOLFOXIGIL) Versus FOLFOXIRI as First-line Treatment for Patients With Metastatic Colorectal Cancer: a Phase II Trial by the FNF Team. [NCT03222089]Phase 20 participants (Actual)Interventional2017-07-20Withdrawn(stopped due to Another study enrolling the similar group of patient are ongoing)
5-Fluorouracil/Folinate/Oxaliplatin (Eloxatin) (FLOX Regimen), Given Continuously or Intermittently, in Combination With Cetuximab (Erbitux), in First-line Treatment of Metastatic Colorectal Cancer. A Phase III Multicenter Trial. [NCT00145314]Phase 3571 participants (Actual)Interventional2005-05-31Completed
Phase III Randomized Controlled Clinical Study of UFT/LV Therapy Versus UFT/LV + PSK Therapy as Postoperative Adjuvant Therapy for Histological Stage IIIa and IIIb Colorectal Cancer [NCT00497107]Phase 3300 participants (Anticipated)Interventional2007-07-31Recruiting
A Phase 1, Open Label Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD2171 and Selected Chemotherapy Regimens When Given in Combination to Patients With Advanced Solid Tumors [NCT00502567]Phase 1104 participants (Actual)Interventional2005-01-31Completed
TPLF-4, Compressed TPLF for Locally Advanced Squamous Cell Carcinoma [NCT00139230]Phase 230 participants Interventional1997-01-31Completed
Bi-Weekly Docetaxel Plus 24-Hour Infusion of High-Dose 5-Fluorouracil / Leucovorin (HDFL) for Inoperable Advanced or Metastatic Gastric Cancer [NCT00155883]Phase 254 participants (Anticipated)Interventional2004-06-30Terminated(stopped due to slow a accrul due to many competitive trials.)
The ADAPTA Study: ADjuvant chemotherAPy After Curative Intent resecTion of Ampullary Cancer. A Pan-European Prospective Multicenter Double Single Arm Cohort Study. [NCT06068023]400 participants (Anticipated)Observational2023-07-01Recruiting
Molecular Analysis for Combination Therapy Choice (ComboMATCH) [NCT05564377]Phase 22,900 participants (Anticipated)Interventional2023-04-07Recruiting
Phase I/Ib Trial of ATR Inhibitor BAY 1895344 in Combination With FOLFIRI in GI Malignancies With a Focus on Metastatic Colorectal and Gastric/Gastroesophageal Cancers [NCT04535401]Phase 190 participants (Anticipated)Interventional2021-08-13Active, not recruiting
RACE-trial: Neoadjuvant Radiochemotherapy Versus Chemotherapy for Patients With Locally Advanced, Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) A Randomized Phase III Joint Study of the AIO, ARO and DGAV [NCT04375605]Phase 3342 participants (Actual)Interventional2020-06-03Active, not recruiting
mFOLFOXIRI Versus mFOLFOX6 as Adjuvant Chemotherapy for Locally Advanced Colorectal Cancer Patients After Preoperative Treatment With Oxaliplatin (FANTASTIC): a Multicenter, Phase 3 Randomized Controlled Trial [NCT04338191]Phase 3638 participants (Anticipated)Interventional2020-04-01Recruiting
A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy and in Combination With Chemotherapy and/or Immunotherapy in Subjects With Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and Locoregional Gast [NCT03505320]Phase 2143 participants (Anticipated)Interventional2018-06-29Recruiting
Phase III Intergroup Prospectively Randomized Trial of Perioperative 5-FU After Curative Resection, Followed by 5-FU/Leucovorin for Patients With Colon Cancer [NCT00002525]Phase 3859 participants (Actual)Interventional1993-10-01Terminated(stopped due to The study was stopped before reaching its accrual goal due to slow accrual)
A Compassionate Treatment Protocol for the Use of Trimetrexate Glucuronate With Leucovorin Protection for Patients With Pneumocystis Carinii Pneumonia. [NCT00002102]0 participants InterventionalCompleted
A Phase II Window Study of Trimetrexate With Simultaneous Leucovorin Protection in the Treatment of Newly Diagnosed Patients With Metastatic Osteosarcoma [NCT00003776]Phase 20 participants Interventional1998-12-31Completed
A PHASE II TRIAL OF NEOADJUVANT CISPLATIN-FLUOROURACIL CHEMOTHERAPY, SURGERY, AND INTRAPERITONEAL (IP) FLOXURIDINE (FUdR) PLUS LEUCOVORIN IN PATIENTS WITH GASTRIC CANCER [NCT00002783]Phase 250 participants (Anticipated)Interventional1996-05-31Completed
A Phase I Study of Talimogene Laherparepvec (Talimogene Laherparepvec) With Neoadjuvant Chemotherapy and Radiation in Adenocarcinoma of the Rectum [NCT03300544]Phase 13 participants (Actual)Interventional2017-09-20Active, not recruiting
Applicability of Patient Derived Orthotopic Xenograft (PDOX) in Patients With Primary Liver Cancer: A Randomized Controlled Trial [NCT05766605]Phase 390 participants (Anticipated)Interventional2023-01-01Recruiting
A Multi-center, Phase II Study to Evaluate Efficacy and Safety of Perioperative Chemotherapy With Fluorouracil, Leucovorin, Oxaliplatin, Docetaxel (FLOT) and Trastuzumab in Combination With Toripalimab in Patients With HER2 Positive Locally Advanced Gastr [NCT05715931]Phase 230 participants (Anticipated)Interventional2023-02-28Recruiting
Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors: Phase II Study of Chemotherapy, Photon and Heavy Ion Radiotherapy Integration for More Effective and Less Toxic Treatment in Inoperable Patients [NCT02099188]Phase 227 participants (Actual)Interventional2013-11-30Active, not recruiting
Phase II Study of Toripalimab Combined With Fluorouracil, Leucovorin, Oxaliplatin and Docetaxel (FLOT) in Patients With Locally Advanced, Resectable Gastric Cancer or Gastroesophageal Junction Adenocarcinoma [NCT04354662]Phase 235 participants (Anticipated)Interventional2019-09-26Recruiting
Phase Ⅱ Study of FOLFIRI as Second-Line Chemotherapy for Metastatic Esophageal Carcinoma [NCT02023593]Phase 235 participants (Actual)Interventional2012-03-31Completed
An Open Label, Multicenter, Dose Finding, Phase 1 Study of Fusilev® (Levoleucovorin) to Prevent or Reduce Mucositis in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Receiving Folotyn® (Pralatrexate) [NCT01789723]Phase 10 participants (Actual)Interventional2013-03-31Withdrawn
Phase II Open-Label Trial of Neoadjuvant Atezolizumab in Combination With CAPEOX for Resectable Non-Metastatic Proficient Mismatch Repair (PMMR) Colon Cancer [NCT05870800]Phase 230 participants (Anticipated)Interventional2023-09-01Not yet recruiting
Treatment of Atypical Teratoid/Rhabdoid Tumors (AT/RT) of the Central Nervous System With Surgery, Intensive Chemotherapy, and 3-D Conformal Radiation [NCT00653068]Phase 370 participants (Actual)Interventional2008-12-08Active, not recruiting
A Phase II Study of Oxaliplatin (OXAL), 5-Fluorouracil (5-FU), and Leucovorin (CF) in Patients With Metastatic Colorectal Carcinoma Previously Treated With Irinotecan (CPT-11) [NCT00016978]Phase 240 participants (Actual)Interventional2001-04-30Completed
The First-line Treatment of RCLM With RAS Mutation Was Local Short-course Radiotherapy (SCRT) + PD-1+ Standard Therapy [NCT05640726]Phase 230 participants (Anticipated)Interventional2023-05-01Not yet recruiting
An Open,Multi-Center,Phase II Clinical Trial tO Evaluate Efficacy and Safety oF TAXOL(PACLITAXEL),UFT,and LEUCOVORIN in Patients With Advanced Gastric Cancer [NCT00154778]Phase 255 participants (Actual)Interventional2003-03-31Completed
Post-Approved Phase III Study of 1-LV/5FU Therapy [NCT00195585]Phase 3650 participants Interventional2002-10-31Completed
A Phase III Study to Evaluate the 3-year Disease-free Survival in Patients With Locally Advanced Colon Cancer Receiving Either Perioperative or Postoperative Chemotherapy With FOLFOX or CAPOX Regimens [NCT02572141]Phase 3738 participants (Anticipated)Interventional2015-01-01Active, not recruiting
Phase II Study of Adjuvant Intraperitoneal FUDR Treatment Added to Chemoradiation (5-Fluorouracil/Leucovorin Plus Total Dose 4500 cGy of External Beam Radiotherapy) in Patients With Fully Resected Locally Advanced Gastric Adenocarcinoma [NCT00183911]Phase 225 participants (Anticipated)Interventional2003-11-30Completed
A Phase I-II Study of the Combination of Ruxolitinib or Dasatinib With Chemotherapy in Patients With Philadelphia Chromosome (Ph)-Like Acute Lymphoblastic Leukemia (ALL) [NCT02420717]Phase 211 participants (Actual)Interventional2015-07-15Terminated(stopped due to Study was closed early due to low accrual and lack of response.)
An Open, Single.Centre, Phase I/II Study of ZD1839 (Iressa) in Combination With 5-Fluorouracil, Leucovorin and Radiotherapy in Subjects With Resectable Gastric Cancer [NCT00237900]Phase 1/Phase 234 participants Interventional2003-07-31Terminated
A Phase 1 Trial of MK-4280 as Monotherapy and in Combination With Pembrolizumab With or Without Chemotherapy or Lenvatinib (E7080/MK-7902) in Subjects With Advanced Solid Tumors [NCT02720068]Phase 1576 participants (Anticipated)Interventional2016-05-02Active, not recruiting
A Randomized, Double-blind, Parallel-group, Placebo- and Active Calibrator-controlled Study Assessing the Clinical Benefit of SAR153191 Subcutaneous (SC) on Top of MTX in Patients With Active RA Who Have Failed Previous TNF-α Antagonists [NCT01217814]Phase 216 participants (Actual)Interventional2010-11-30Terminated(stopped due to Due to delay in the study and the impact on the development timelines, not due to any identified safety concerns)
Induction Chemotherapy With Taxotere, Cisplatin and 5-Fluorouracil Followed by Concomitant Cetuximab and Radiation for Locoregionally Advanced Squamous Cell Cancer of the Head and Neck: A Phase II Trial [NCT01467115]Phase 21 participants (Actual)Interventional2010-03-31Completed
Oxaliplatin(Eloxatin®) + 5-FU/LV (FOLFOX4) Compared With Single Agent Doxorubicin (Adriamycin®) as Palliative Chemotherapy in Advanced Hepatocellular Carcinoma Patients Ineligible for Curative Resection or Local Treatment [NCT00471965]Phase 3371 participants (Actual)Interventional2007-03-31Completed
A Prospective Randomised Open Label Trial of Oxaliplatin/Fluoropyrimidine Versus Oxaliplatin/Fluoropyrimidine Plus Cetuximab Pre and Post Operatively in Patients With Resectable Colorectal Liver Metastasis Requiring Chemotherapy [NCT00482222]Phase 3340 participants (Anticipated)Interventional2007-02-28Recruiting
An Open Label, Multi-cohort, Multicenter Phase II Study to Evaluate the Efficacy and Safety of Envofolimab in Combination With BD0801 Injection With/Without Chemotherapy in Patients With Advanced Solid Tumors [NCT05148195]Phase 2110 participants (Anticipated)Interventional2021-12-22Recruiting
A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab Plus Ipilimumab or Nivolumab in Combination With Oxaliplatin Plus Fluoropyrimidine Versus Oxaliplatin Plus Fluoropyrimidine in Subjects With Previously Untreated Advanced or Metastatic Gast [NCT02872116]Phase 32,031 participants (Actual)Interventional2016-10-12Active, not recruiting
A Phase I,Open Label Study to Assess the Safety and Tolerability of ZD6474 in Combination With 5-Fluorouracil, Leucovorin and Oxaliplatin (mFOLFOX6) as First and Second Line Therapy in Patients With Advanced Colorectal Adenocarcinoma. [NCT00499850]Phase 118 participants (Actual)Interventional2005-08-31Completed
Study to Determine the Maximum Tolerated Time of Infusion for High-Dose Methotrexate, Administered as a Continuous Intravenous Infusion at a Dose of 6g/m² Per 24 Hours of Infusion Time [NCT00513981]Phase 136 participants (Anticipated)Interventional2007-03-31Completed
A Pilot Study of the Efficacy of the Chop-Montak Regimen in Patients With Newly Diagnosed Peripheral T Cell Lymphoma [NCT00513188]0 participants (Actual)Interventional2007-02-28Withdrawn
Oxaliplatin-CPT-11-5-FU-Leucovarin + Bevacizumab and Cetuximab (OCFL-BC) as a Combination Regimen for Systemic Treatment of Advanced Colorectal Carcinoma With Potentially Resectable Liver and/or Lung Metastases. A Phase II Study [NCT00513266]Phase 235 participants (Anticipated)Interventional2007-06-30Active, not recruiting
Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer - An Open Label, Non-comparative, Randomized, Multicenter Phase II Trial [NCT03044587]Phase 293 participants (Actual)Interventional2018-01-24Active, not recruiting
Treatment of Patients With KRAS Wild Type Advanced Colorectal Cancer (CRC) With 5-Fluorouracil (5-FU) or 5- FU Plus an Epidermal Growth Factor Receptor (EGFR) Inhibitor (Cetuximab) Based on a Comprehensive Geriatric Assessment (CGA). [NCT01522612]Phase 25 participants (Actual)Interventional2013-04-30Terminated(stopped due to poor accrual)
Influence of Individual Dosage Selection of Irinotecan (CPT-11) Based on UGT1A1 Genotype on Clinical Outcomes and Pharmacokinetics in Chinese Patients With Metastatic Colorectal Cancer [NCT01523431]Phase 2/Phase 3583 participants (Actual)Interventional2012-03-08Completed
A Randomised Phase-III Study Comparing Cytoreductive Surgery Plus Intraperitoneal Chemotherapy Versus Modern Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis. [NCT01524094]Phase 349 participants (Actual)Interventional2003-06-30Completed
"Phase-2 Study Evaluating Overall Response Rate (Efficacy) and Autonomy Daily Living Preservation (Tolerance) of FOLFIRINOX Pharmacogenetic Dose Adjusted, in Elderly Patients (70 yo. or Older) With a Metastatic Pancreatic Adenocarcinoma." [NCT02143219]Phase 272 participants (Actual)Interventional2014-07-31Completed
A Phase I/II Trial of the c-Met Inhibitor, Tivantinib, in Combination With FOLFOX for the Treatment of Patients With Advanced Solid Tumors (Phase I) and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal (GE) Junction [NCT01611857]Phase 1/Phase 249 participants (Actual)Interventional2012-07-31Completed
A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children < 36 Months Old With Intensive Induction Chemotherapy With Methotrexate Followed by Consolidation With Stem Cell Rescue vs. [NCT00336024]Phase 391 participants (Actual)Interventional2007-08-06Active, not recruiting
A Phase II Study of Weekly 24-hour Infusion 5-fluoro-deoxyuridine (FUdR)/Leucovorin With Oxaliplatin and Docetaxel (Taxotere) as First-line Treatment in Patients With Metastatic Gastric Adenocarcinoma (IIT# 14065) [NCT00448682]Phase 225 participants (Actual)Interventional2005-06-30Terminated
Phase II Study of Recombinant Endostatin Combined With Modified FOLFOX6 in Advanced Colorectal Cancer [NCT01529164]Phase 251 participants (Anticipated)Interventional2011-10-31Recruiting
A Treatment Protocol for the Use of Trimetrexate With Leucovorin Rescue for AIDS Patients With Pneumocystis Carinii Pneumonia and Serious Intolerance to Approved Therapies [NCT00001016]Phase 30 participants InterventionalCompleted
Phase II Study of S-1 Combined With Calcium Folinate to Treat Advanced Hepatocellular Carcinoma [NCT01533324]Phase 232 participants (Anticipated)Interventional2011-11-30Recruiting
Observational Study of the Impact of Circulating T Regulatory Cells (Tregs) on Clinical Outcome of Metastatic Colorectal Cancer (MCRC) Patients Treated With Standard Fluorouracil/Irinotecan/Bevacizumab First Line Therapy [NCT01533740]31 participants (Actual)Observational2012-03-31Completed
Applicability of 3D Histoculture Drug Response Assay(3D-HDRA) in Patients With Primary Liver Cancer: A Randomized Controlled Trial [NCT05701436]Phase 3144 participants (Anticipated)Interventional2022-09-01Recruiting
A Phase III Study of Large Cell Lymphomas in Children and Adolescents: Comparison of APO vs APO + IDMTX/HDARA-C and Continuous vs Bolus Infusion of Doxorubicin [NCT00002618]Phase 3242 participants (Anticipated)Interventional1994-12-31Completed
A TACL Phase 1/2 Study of PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma IND# 140730 [NCT03817320]Phase 1/Phase 231 participants (Anticipated)Interventional2019-02-12Recruiting
Pre- and Post-Operative Chemotherapy With Oxaliplatin 5FU/LV Versus Surgery Alone in Resectable Liver Metastases From Colorectal Origin - Phase III Study [NCT00006479]Phase 30 participants Interventional2000-09-30Active, not recruiting
An Open-Label, Multi-Center Phase II Trial of Neoadjuvant Irinotecan in Combination With Infusional 5-FU, Leucovorin (Folfiri) Plus Bevacizumab in Patients With Unresectable Hepatic-Only Metastases of Colorectal Carcinoma [NCT00106054]Phase 22 participants (Actual)Interventional2006-01-31Terminated(stopped due to After 1 year only 2 subjects enrolled and treated thus no meaningful efficacy analyses could be performed.)
A Prospective, Randomized Trial of Extended Lymphadenectomy in the Management of Resectable Pancreatic Cancer [NCT00003049]Phase 3100 participants (Anticipated)Interventional1997-05-31Completed
Fluorouracil, Oxaliplatin and Irinotecan: Use and Sequencing: A Randomized Trial to Assess the Role of Irinotecan and Oxaliplatin in Advanced Colorectal Cancer [NCT00008060]Phase 30 participants Interventional2000-05-31Completed
A Phase I Study Of Hepatic Arterial Infusion With Floxuridine And Dexamethasone In Combination With Intravenous Oxaliplatin Plus 5-Fluorouracil And Leucovorin In Patients With Unresectable Hepatic Metastases From Colorectal Cancer [NCT00008294]Phase 10 participants Interventional2000-08-31Completed
Phase I Study Of Weekly Paclitaxel In Combination With ORZEL (UFT + Leucovorin) For Advanced Non-Hematological Malignancies [NCT00009828]Phase 10 participants (Actual)Interventional1999-12-31Withdrawn
A Phase I Study of Weekly Gemcitabine in Combination With Infusional 5-Fluorouracil and Oral Calcium Leucovorin in Adult Cancer Patients [NCT00019513]Phase 1108 participants (Anticipated)Interventional1998-08-31Completed
Osteosarcoma: Outcome of Therapy Based on Histologic Response. A Collaborative Effort of the POB/NCI, Texas Children's Hospital and University of Oklahoma. [NCT00019864]Phase 2100 participants (Anticipated)Interventional2000-03-31Terminated
A Phase I & Pharmacologic Trial Of Sequential Irinotecan As A 24-Hour IV Infusion, Leucovorin, & Flurouracil As A 48-Hour IV Infusion In Adult Cancer Patients [NCT00020488]Phase 10 participants Interventional2001-02-28Completed
Pilot Study of an Anti-Epidermal Growth Factor Receptor (EGFR) Antibody, Cetuximab, in Combination With Irinotecan, Fluorouracil, and Leucovorin, and in Patients With Newly Diagnosed Stage IV Colorectal Carcinoma [NCT00020917]Phase 20 participants Interventional2001-02-28Completed
Phase I Study of Flavopiridol in Combination With 5-Fluorouracil, Leucovorin and Irinotecan in Patients With Advanced Malignancies [NCT00021073]Phase 190 participants (Anticipated)Interventional2001-05-31Completed
Open-Label, Phase 2 Study of GM-CT-01 When Added to a Regimen of Leucovorin, 5-FU, and Avastin as First Line Treatment for Locally Advanced, Unresectable or Metastatic Colorectal Cancer in Subjects Unable to Tolerate Intensive Chemotherapy [NCT00388700]Phase 20 participants (Actual)Interventional2006-10-31Withdrawn(stopped due to Financing and re-organization)
A Groupwide Phase II Study of Trastuzumab (Herceptin) in Metastatic Osteosarcoma Patients With Tumors That Overexpress HER2 [NCT00023998]Phase 280 participants (Actual)Interventional2001-07-31Completed
Mechanisms of Antifolate Efficacy in Arthritis [NCT00000395]Phase 240 participants (Actual)Interventional1996-09-30Completed
A Randomized Phase III Study Evaluating Modified FOLFIRINOX (mFFX) With or Without Stereotactic Body Radiotherapy (SBRT) in the Treatment of Locally Advanced Pancreatic Cancer: A Pancreatic Cancer Radiotherapy Study Group (PanCRS) Trial [NCT01926197]Phase 327 participants (Actual)Interventional2013-08-14Completed
A Pilot Study of Zimberelimab and Quemliclustat Combination With Chemotherapy in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma [NCT05688215]Phase 1/Phase 256 participants (Anticipated)Interventional2023-03-07Recruiting
A Pilot Study of Oral Clindamycin and Pyrimethamine for the Treatment of Toxoplasmic Encephalitis in Patients With AIDS [NCT00000674]30 participants InterventionalCompleted
Phase I Trial of mBACOD and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in AIDS-Associated Large Cell, Immunoblastic, and Small Non-cleaved Lymphoma [NCT00000689]Phase 118 participants InterventionalCompleted
Phase II, Randomized, Double-Blind, Multicenter Trial Of Celecoxib Vs Placebo For The Prevention Of Diarrhea Associated With CPT-11/5fu/LV Chemotherapy In Patients With Previously Untreated Metastatic Colorectal Cancer [NCT00037180]Phase 2212 participants Interventional2002-04-30Terminated
Evaluation of Escalating Doses of Intravenous Trimetrexate as Therapy for Previously Untreated Pneumocystis Carinii Pneumonia in AIDS Patients With Subsequent Comparison of Intravenous and Oral Pharmacokinetics [NCT00000998]Phase 150 participants InterventionalCompleted
A Randomized, Comparative, Double-Blind Trial of Trimetrexate (CI-898) With Leucovorin Calcium Rescue Versus Trimethoprim / Sulfamethoxazole for Moderately Severe Pneumocystis Carinii Pneumonia in Patients With AIDS [NCT00001013]Phase 3364 participants InterventionalCompleted
The Use of Modified BFM +/- Compound 506U78 (Nelarabine) (NSC# 686673, IND #52611) in an Intensive Chemotherapy Regimen for the Treatment of T-Cell Leukemia [NCT00016302]100 participants (Actual)Interventional2001-04-30Completed
Time Finding Study of Chronomodulated Irinotecan, 5 Fluorouracil, Leucovorin and Oxaliplatin as First or Second Chemotherapy Line Against Metastatic Colorectal Cancer [NCT00039208]Phase 20 participants Interventional2002-02-28Completed
A Clinicopathological Study In Burkitts's And Burkitt-Like Non-Hodgkin's Lymphoma [NCT00040690]Phase 2120 participants (Anticipated)Interventional2008-11-30Completed
An Open-Labeled, Non-Randomized Phase I Study of Alvocidib (Flavopiridol) Administered With Irinotecan (CPT-11) and Fluorouracil/Leucovorin in Patients With Advanced Solid Tumors [NCT00042874]Phase 177 participants (Actual)Interventional2002-05-31Completed
Phase 1b Study of 5-FU/FA and Oxaliplatin (FOLFOX4) Plus Ramucirumab (LY3009806) in Patients With Advanced Hepatocellular Carcinoma [NCT02069041]Phase 18 participants (Actual)Interventional2014-04-30Completed
A Phase I Study of Escalating Doses of CPT-11 and 5fluorouracil (5FU) Plus PN401 With a Fixed Dose of Leucovorin in Patients With Solid Tumor Malignancies. [NCT00044785]Phase 124 participants Interventional2002-08-31Terminated
A Phase II Trial Of IRESSA (NSC 715055, IND 61187) In Combination With 5-FU/LV/ CPT-11 In Patients With Advanced Or Recurrent Colorectal Cancer [NCT00052585]Phase 250 participants (Actual)Interventional2002-10-31Terminated(stopped due to Administratively complete.)
A Phase I/II Study of Oblimersen Sodium (G3139, Genasense) in Combination With Oxaliplatin, 5FU and Leucovorin (FOLFOX4) Regimen in Advanced Colorectal Cancer [NCT00055822]Phase 1/Phase 216 participants (Actual)Interventional2002-10-31Completed
European Study Group For Pancreatic Cancer - Trial 3 [NCT00058201]Phase 31,030 participants (Anticipated)Interventional2001-07-31Completed
Randomized Phase II Study Evaluating Three Chemotherapies: [Irinotecan + Oxaliplatin (Irinox)], [Irinotecan + LV5FU2] and [Oxaliplatin + LV5FU2] as First Intention Treatment in Subjects With Metastatic Colorectal Cancer [NCT00066274]Phase 20 participants Interventional2002-07-23Completed
A Phase II Of An Optimized LV-5FU-Oxaliplatin Strategy With Celebrex In Metastatic Colorectal Cancer, Optimox2-Celecoxib Study [NCT00072553]Phase 20 participants Interventional2003-09-30Active, not recruiting
Phase II Study of 5FU/Folinic Acid and Irinotecan as Second or Third Line Treatment in Patients With Metastatic, Unresectable, Colorectal Cancer [NCT00075595]Phase 20 participants Interventional2002-06-30Active, not recruiting
A Phase II Trial Of Irinotecan /5-FU/ Leucovorin Or Oxaliplatin /5-FU / Leucovorin With And Without Cetuximab (C225) For Patients With Untreated Metastatic Adenocarcinoma Of The Colon or Rectum [NCT00077233]Phase 3238 participants (Actual)Interventional2003-12-31Terminated(stopped due to Poor accrual)
A Phase I/II Study of Taxotere, Cisplatin, 5-Fluorouracil and Leucovorin for Squamous Cell Carcinoma of the Head and Neck [NCT00139243]Phase 1/Phase 230 participants Interventional1997-10-31Completed
A Multi-centre, Randomised, Parallel Group, Open-label, Phase II, Single-stage Selection Trial of Liposomal Irinotecan (Nal-IRI) and 5-fluorouracil (5-FU)/Folinic Acid or Docetaxel as Second-line Therapy in Patients With Progressive Poorly Differentiated [NCT03837977]Phase 2102 participants (Anticipated)Interventional2018-11-13Active, not recruiting
A Phase Ib/II Study of AK112 and AK119 in Combination With or Without Chemotherapy in the Treatment of Patients With Advanced Microsatellite Stabilized (pMMR/MSS) Colorectal Cancer [NCT05846867]Phase 1/Phase 272 participants (Anticipated)Interventional2023-05-10Not yet recruiting
Phase II Trial Of Gemcitabine, 5-Fluorouracil, And Leucovorin In Patients With Measurable Unresectable Or Metastatic Biliary Tract Carcinoma (Intrahepatic, Extrahepatic, Ampulla Of Vater) And Gallbladder Carcinoma [NCT00009893]Phase 242 participants (Actual)Interventional2001-05-31Completed
Study Of Gemcitabine, Leukovorin, And Fluorouracil Used To Treat Locally Advanced And Metastatic Pancreatic And Biliary Adenocarcinomas [NCT00010088]Phase 20 participants Interventional1999-01-31Active, not recruiting
Treatment Protocol for T-Cell and B-Precursor Cell Lymphoblastic Lymphoma of the European Inter-group Co-operation on Childhood Non-Hodgkin-Lymphoma (EICNHL) [NCT00275106]Phase 3600 participants (Anticipated)Interventional2004-09-30Terminated(stopped due to Withdrawn due to an excess of toxic deaths)
A Non-Randomized Multicenter Phase I/II Study Of Active Specific Immunotherapy In Patients With Stage II and Stage III Colon Cancer [NCT00016133]Phase 1/Phase 20 participants Interventional2001-03-31Completed
Phase II Study in Patients With Metastatic Colorectal Carcinoma Previously Treated With Oxaliplatin (OXAL) or a Combination of Irinotecan (CPT-11) and OXAL [NCT00016952]Phase 219 participants (Actual)Interventional2001-04-30Completed
A Phase II Study Of Intensive Induction Chemotherapy Followed By Autologous Stem Cell Transplantation Plus Immunotherapy For Mantle Cell Lymphoma [NCT00020943]Phase 279 participants (Actual)Interventional2001-06-30Completed
A Children's Oncology Group Pilot Study for the Treatment of Very High Risk Acute Lymphoblastic Leukemia in Children and Adolescents (Imatinib (STI571, GLEEVEC) NSC#716051) [NCT00022737]Phase 3220 participants (Actual)Interventional2002-10-31Completed
A Phase II Study of Local Excision Alone or Local Excision Plus Adjuvant Chemoradiation Therapy for Small Distal Rectal Cancers [NCT00023751]Phase 2320 participants (Actual)Interventional2001-07-31Completed
A Phase I Study Of ZD1839 (Iressa) In Combination With Irinotecan, Leucovorin, And 5-Fluorouracil In Previously Untreated, Stage IV Colorectal Cancer [NCT00026364]Phase 122 participants (Actual)Interventional2001-11-30Completed
An Examination of Changes in Urinary Metabolites With Use of Folinic Acid in Children With Autism Spectrum Disorder (ASD) [NCT03771560]Phase 2/Phase 318 participants (Actual)Interventional2018-02-15Completed
Phase II Study: Hyperfractionated Pre-Op Chemo-Radiation for Locally Advanced Rectal Cancer [NCT00021398]Phase 223 participants (Actual)Interventional1996-07-31Completed
A Phase I/II Study Of OSI-774 In Combination With Oxaliplatin, And 5-Fluourouracil In Patients With Metastatic Colorectal Carcinoma [NCT00049101]Phase 1/Phase 20 participants Interventional2002-08-31Completed
Intensive Induction Therapy for Children With Acute Lymphoblastic Leukemia (ALL) Who Experience a Bone Marrow Relapse [NCT00049569]126 participants (Anticipated)Interventional2003-01-31Completed
A Phase III, Randomized, Two-armed, Parallel, Double-blind, Active-controlled, Equivalency Clinical Trial of Cetuximab (CinnaGen Co.) Efficacy and Safety Compared With Erbitux (Merck Co.) and FOLFIRI for RAS Wild-type mCRC [NCT03391934]Phase 3234 participants (Anticipated)Interventional2018-01-20Recruiting
A Study of ZD1839 (Iressa) in Combination With Oxaliplatin, 5-Fluorouracil (5-FU) and Leucovorin (LV) in Advanced Solid Malignancies (Phase I) and Advanced Colorectal Cancers (Phase II) [NCT00025142]Phase 20 participants Interventional2001-07-31Completed
Multicenter Phase III Open Label Randomized Trial Comparing CPT-11 In Combination With A 5-FU/FA Infusional Regimen To The Same 5-FU/FA Infusional Regimen Alone As Adjuvant Treatment Of Stage III Colon Cancer [NCT00026273]Phase 30 participants Interventional2001-01-31Completed
Pilot Phase II Study of Safety and Immunogenicity of an ALVAC-CEA/B7.1 Vaccine Administered With Chemotherapy, Alone or in Combination With Tetanus Toxoid, as Compared to Chemotherapy Alone, in Patients With Metastatic Colorectal Adenocarcinoma [NCT00027833]Phase 20 participants Interventional2001-12-31Active, not recruiting
LSA5 PROTOCOL FOR THE TREATMENT OF ADVANCED PEDIATRIC AND ADOLESCENT NON-HODGKIN'S LYMPHOMA (NHL) [NCT00002691]Phase 20 participants Interventional1995-08-31Completed
Non-Operative Radiation Management of Adenocarcinoma of the Lower Rectum (NORMAL-R) [NCT02641691]Phase 220 participants (Actual)Interventional2016-05-27Completed
A Phase I, Pharmacological, and Biological Study of OSI-774 in Combination With FOLFOX 4 (5-FU, Leucovorin, and Oxaliplatin) and Bevacizumab (Avastin) in Patients With Advanced Colorectal Cancer [NCT00060411]Phase 124 participants (Actual)Interventional2003-06-30Completed
A Phase 2 Trial to Evaluate the Safety and Efficacy of Combination Therapies in Patients With Advanced Upper Gastrointestinal Tract Malignancies (EDGE-Gastric) [NCT05329766]Phase 2200 participants (Anticipated)Interventional2022-06-10Recruiting
Phase 2 Study of ZW25 Plus First-line Combination Chemotherapy in HER2-Expressing Gastrointestinal (GI) Cancers, Including Gastroesophageal Adenocarcinoma (GEA), Biliary Tract Cancer (BTC), and Colorectal Cancer (CRC) [NCT03929666]Phase 2362 participants (Anticipated)Interventional2019-08-29Recruiting
A Randomized, Open-label Phase II/III Efficacy and Safety Study of Atezolizumab in Combination With FLOT Versus FLOT Alone in Patients With Gastric Cancer and Adenocarcinoma of the Oesophago-gastric Junction and High Immune Responsiveness (MO30039/MO43340 [NCT03421288]Phase 2674 participants (Anticipated)Interventional2018-09-14Recruiting
A Phase 3 Randomized Multicenter Study of Cetuximab, Oxaliplatin, 5-Fluorouracil, and Leucovorin vs. Oxaliplatin, 5-Fluorouracil, and Leucovorin in Subjects With Previously Treated Metastatic, EGFR-Positive Colorectal Carcinoma [NCT00061815]Phase 3102 participants (Actual)Interventional2003-03-31Completed
A Phase III Trial of Modified FOLFOX6 Versus CAPOX, With Bevacizumab (NSC-704865) or Placebo, as First-Line Therapy in Patients With Previously Untreated Advanced Colorectal Cancer [NCT00070122]Phase 32,200 participants (Actual)Interventional2004-04-30Terminated(stopped due to Administratively complete.)
A Phase II Feasibility Translational Research Trial of Induction Chemotherapy Followed by Concomitant Chemoradiation in Patients With Clinical T4 Rectal Cancer [NCT00070434]Phase 20 participants (Actual)Interventional2004-08-31Withdrawn(stopped due to poor accrual)
Oxaliplatin (NSC 266046) in Combination With 5-Fluorouracil and Leucovorin (FOLFOX4) for Patients Who Have Not Received Prior Chemotherapy for Advanced Colorectal Cancer [NCT00039611]0 participants Interventional2002-05-31Completed
A Phase II, Randomized, Open-label, Controlled, Dose-elevation, Multicenter Trial of an Investigational Drug for the Prevention of Diarrhea Associated With Irinotecan/5FU/Leucovorin Chemotherapy in Patients With Previously Untreated Metastatic Colorectal [NCT00040391]Phase 20 participants Interventional2002-06-30Terminated
CLOCC Trial (Chemotherapy + Local Ablation Versus Chemotherapy) Randomized Phase II Study Of Local Treatment Of Liver Metastases By Radiofrequency Combined With Chemotherapy Versus Chemotherapy Alone In Patients With Unresectable Colorectal Liver Metastas [NCT00043004]Phase 2119 participants (Actual)Interventional2002-05-31Terminated(stopped due to low accrual)
A Phase I Study of Oxaliplatin, 5-Fluorouracil, and Leucovorin in Combination With Oral Capecitabine in Patients With Advanced Malignancy [NCT00043121]Phase 150 participants (Actual)Interventional2002-06-30Completed
Randomized Trial of Treatment Strategy for Chemotherapy in Colorectal Cancer, FFCD 2000-05 [NCT00126256]Phase 3570 participants (Anticipated)Interventional2002-02-28Completed
A Phase I Pharmacologic Trial Of Infusional UCN-01 Given With A Weekly Schedule Of 5-Fluorouracil And Leucovorin [NCT00042861]Phase 10 participants Interventional2002-08-31Completed
Treatment of Acute Lymphoblastic Leukemia in Children [NCT00165178]Phase 3498 participants (Actual)Interventional2000-09-30Completed
A Phase I Dose-Finding Study and a Randomized Phase II Study of ALIMTA Plus Oxaliplatin Versus Oxaliplatin Plus 5-Fluorouracil and Leucovorin (FOLFOX 4 Regimen) in the First-Line Treatment of Patients With Locally Advanced Unresectable or Stage IV Colorec [NCT00166465]Phase 1/Phase 2200 participants Interventional2003-08-31Completed
Multicenter, Randomized Controlled Trial Designed to Evaluate the Efficacy and Safety of Adjuvant Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Raltitrexed or Oxaliplatin Versus no HIPEC in Locally Advanced Colorectal Cancer (APEC Study) [NCT02965248]Phase 3147 participants (Anticipated)Interventional2016-11-30Recruiting
5-Fluorouracil-Leucovorin With or Without Carboplatin as Adjuvant Treatment for Primary Dukes B2-C Colon Cancer; Chronomodulated Versus Standard Administration. A Multicenter Randomized Phase III Trial of the GRECCR-Belgium (Study 03). [NCT00046995]Phase 3800 participants (Anticipated)Interventional2001-05-31Active, not recruiting
Prospective Phase II Randomized Trial of Postoperative Adjuvant Chemotherapy in Patients With High Risk Colon Cancer [NCT00201331]Phase 2162 participants Interventional2002-04-30Recruiting
A Randomized, Prospective Study Comparing Three Regimens Of Eloxatin ™ Plus Fluoropyrimidine For Evaluation Of Safety And Tolerability In First Line Treatment Of Patients With Advanced Colorectal Cancer (Tree Study) [NCT00062426]Phase 30 participants Interventional2003-05-31Completed
CHEMOTHERAPY CHOICES IN ADVANCED COLORECTAL CANCER: A RANDOMISED TRIAL COMPARING 2 DURATIONS AND 3 SYSTEMIC CHEMOTHERAPY REGIMENS IN THE PALLIATIVE TREATMENT OF ADVANCED COLORECTAL CANCER [NCT00002893]Phase 3900 participants (Anticipated)Interventional1995-06-30Active, not recruiting
Phase I Study of Gemcitabine (Gemzar) and UFT/Leucovorin [NCT00003925]Phase 136 participants (Anticipated)Interventional1998-05-31Completed
A Phase I Study of Docetaxel Plus 5-FU, Cisplatin and Leucovorin in Patients With Advanced Solid Tumors [NCT00004913]Phase 10 participants Interventional2000-01-31Completed
A Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Patients With Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma [NCT00515411]Phase 2111 participants (Actual)Interventional2006-10-23Completed
A Phase II Study of Combination Nilotinib and Hyper-CVAD in Patients Newly Diagnosed With Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia or Chronic Myeloid Leukemia Blast-Phase Lymphoid Lineage [NCT01670084]Phase 20 participants (Actual)Interventional2012-12-31Withdrawn(stopped due to No Accrual)
The TRIPLETE Study RANDOMIZED PHASE III STUDY OF TRIPLET mFOLFOXIRI PLUS PANITUMUMAB Versus mFOLFOX6 PLUS PANITUMUMAB AS INITIAL THERAPY FOR UNRESECTABLE RAS AND BRAF WILDTYPE METASTATIC COLORECTAL CANCER PATIENTS [NCT03231722]Phase 3435 participants (Actual)Interventional2017-09-13Completed
Randomized Phase III Trial of mFOLFOX7 or XELOX Plus Bevacizumab Versus 5-Fluorouracil/Leucovorin or Capecitabine Plus Bevacizumab as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer [NCT01279681]Phase 332 participants (Actual)Interventional2011-01-31Terminated(stopped due to Slow accrual)
The Effect of Folinic Acid Rescue Following Methotrexate (MTX) Graft-versus-host Disease (GVHD) Prophylaxis on Regimen Related Toxicity and Transplantation Outcome: a Double Blind Randomized Controlled Study [NCT02506231]Phase 2/Phase 3160 participants (Anticipated)Interventional2015-10-31Not yet recruiting
A Phase 2 Study of Neoadjuvant NIS793 in Combination With mFOLFIRINOX in Resectable and Borderline Resectable Pancreatic Adenocarcinoma (PDAC) [NCT05546411]Phase 28 participants (Actual)Interventional2023-01-06Terminated(stopped due to Novartis, the drug manufacturer of NIS793, notified Dana Farber Cancer Institute that they are stopping all clinical development of NIS793 in pancreatic cancer, effective immediately.)
Phase II Study of Gamma Interferon (IFN-γ) Added to Bolus + Infusional 5-Fluorouracil (5-FU) and Leucovorin (LV) +/- Bevacizumab (BV) in Metastatic Colorectal Carcinoma [NCT00786643]Phase 248 participants (Actual)Interventional2006-02-28Completed
Single-Arm, Multicenter, Prospective, Phase 2 Study for the Evaluation of Biomarkers in Patients With Advanced &/or Metastatic Colorectal Cancer With Wild Type KRAS Treated Biweekly With Chemotherapy and Cetuximab as First-Line Treatment [NCT01276379]Phase 2221 participants (Actual)Interventional2011-01-31Completed
A Phase II Study to Determine the Surgical Conversion Rate in Patients Receiving Neoadjuvant mFOLFOX7 + Cetuximab for Unresectable Wild-Type K-RAS Colorectal Cancer With Metastases Confined to the Liver [NCT00803647]Phase 220 participants (Actual)Interventional2010-01-31Completed
A Phase II Study of Erlotinib and Modified FOLFOX-6 (5-Fluorouracil, Leucovorin and Oxaliplatin) in Previously Untreated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Gastric Cardia [NCT00591123]Phase 238 participants (Actual)Interventional2007-12-31Completed
Bevacizumab With Pelvic Radiotherapy And Primary Chemotherapy in Patients With Poor-Risk Rectal Cancer: the BRANCH Trial [NCT01481545]Phase 262 participants (Actual)Interventional2006-12-31Completed
Randomized Phase III Trial of mFOLFIRINOX vs. FOLFOX With Nivolumab for First-Line Treatment of Metastatic HER2- Gastroesophageal Adenocarcinoma [NCT05677490]Phase 3382 participants (Anticipated)Interventional2023-01-23Recruiting
Association of Radiochemotherapy and Immunotherapy for the Treatment of Unresectable Oesophageal caNcer: a Comparative Randomized Phase II Trial [NCT03777813]Phase 2120 participants (Anticipated)Interventional2018-12-05Recruiting
A Phase Ib/II Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of KRAS p. G12C Mutated Advanced Pancreatic Cancer [NCT05251038]Phase 1/Phase 20 participants (Actual)Interventional2022-09-13Withdrawn(stopped due to Funder Decision)
A Phase Ib/II Open Label, Multi-arm, Parallel Cohort Dose Finding and Expansion Study to Assess the Safety, Pharmacokinetics and Efficacy of NUC-3373, a Nucleotide Analogue, Given in Combination With Standard Approved Agents in Patients With Advanced Soli [NCT05714553]Phase 1/Phase 291 participants (Anticipated)Interventional2023-03-08Recruiting
A Phase II Trial of Neoadjuvant FOLFOX4 and Cetuximab for Localized Adenocarcinoma of the Rectum [NCT00580073]Phase 26 participants (Actual)Interventional2007-12-31Terminated(stopped due to Loss of funding)
Phase II Study of Methotrexate, Mechlorethamine, Vincristine, Prednisone, and Procarbazine (MMOPP) as Primary Therapy in Infants or Young Children With Primitive Neuroectodermal Tumors or High-Grade Astrocytoma [NCT00002463]Phase 24 participants (Actual)Interventional1989-02-28Completed
Phase Ib/II Study of the Combination of Low-Intensity Chemotherapy and Tagraxofusp in Patients With Acute Lymphoblastic Leukemia (ALL) [NCT05032183]Phase 1/Phase 240 participants (Anticipated)Interventional2022-02-17Recruiting
Study of Promace-Cytabom With Trimethoprim Sulfamethoxazole, Zidovudine (AZT), and Granulocyte Colony Stimulating Factor (G-CSF) in Patients With AIDS-Related Lymphoma, Phase II [NCT00002571]Phase 252 participants (Actual)Interventional1994-06-30Completed
A Randomized Phase II Study of Modified FOLFOX6 (Infusional 5-Fluorouracil/Leucovorin, Oxaliplatin) and Bevacizumab With or Without Cetuximab in Patients With Metastatic Colorectal Cancer [NCT00193219]Phase 236 participants (Actual)Interventional2005-07-31Completed
Prospective Phase II Randomized Trial-Weekly Gemcitabine Plus High-Dose 5-Fluorouracil/ Leucovorin in the Treatment of Advanced or Metastatic Carcinoma of the Biliary Tract [NCT00201305]Phase 250 participants Interventional2002-07-31Completed
A Phase III Study of Radiotherapy With or Without Adjuvant Chemotherapy in Advanced Stage Nasopharyngeal Carcinoma Patients [NCT00201344]Phase 3320 participants Interventional1994-11-30Terminated
Essai De Phase III De Chimiotherapie Par FOLFOX 4 Ou Par Une Succession FOLFOX 7 - FOLFIRI Chez Des Patients Ayant Des Metastases Resecables D'Origine Colorectale - MIROX [NCT00268398]Phase 3284 participants (Actual)Interventional2002-07-31Completed
A Multi-Center, Open Label, Parallel Group, Randomised, Phase IIB Clinical Trial to Evaluate the Safety and Efficacy of CoFactor and 5-FU Versus Leucovorin and 5-FU in Subjects With Metastatic Colorectal Carcinoma [NCT00235898]Phase 2300 participants (Actual)Interventional2005-05-31Completed
Phase II-III Study of an Optimized LV-5FU-Oxaliplatin Strategy in Metastatic Colorectal Cancer. Optimox2 Study. C02-2 [NCT00274872]Phase 2/Phase 3600 participants (Anticipated)Interventional2004-01-31Active, not recruiting
Open Label, Randomised, Multicenter Phase III Study of Adjuvant Chemotherapy in Radically Resected Adenocarcinoma of the Stomach or Gastroesophageal Junction: Comparison of a Sequential Treatment (CPT-11+5-FU/LV --> TXT+CDDP) Versus a 5-FU/LV Regimen [NCT01640782]Phase 31,100 participants (Actual)Interventional2005-02-28Completed
A Phase I Pharmacokinetic, Pharmacodynamic and Feasibility Study of Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies (ARO-008) [NCT02270788]Phase 110 participants (Actual)Interventional2015-04-02Completed
Phase II Pilot Study of FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer [NCT04169347]Phase 227 participants (Actual)Interventional2019-12-02Active, not recruiting
A PHASE II Study of GM-CSF As Pre- And Post-operative Adjuvant Therapy For Stage II And III Colon Cancer [NCT00262808]Phase 250 participants (Anticipated)Interventional2004-03-31Completed
A Phase 2, Open-label, Randomized, Multicenter, Platform Study of Novel Oncology Therapies in Combination With Adjuvant Chemotherapy in High-risk, Microsatellite-stable Colorectal Cancer (COLUMBIA-2) [NCT04145193]Phase 20 participants (Actual)Interventional2020-10-01Withdrawn(stopped due to Study withdrawn prior to enrollment due to changing standard of care landscape.)
A Phase I Open Label, Multicenter, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Dose Limiting Toxicity, Safety and Pharmacokinetics of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab o [NCT00705874]Phase 1172 participants (Actual)Interventional2006-05-31Completed
A Prospectively Randomized Study on Adjuvant Chemotherapy in Patients With Operated Colon Carcinoma Dukes B (Stage II; T3-4, N0, M0). [NCT00309543]Phase 3636 participants Interventional1993-11-30Completed
A Randomised, Open-label Phase II Study Evaluating the Efficacy and Safety of Folfox6 + Cetuximab as First-line Therapy in Patients With Metastatic Colorectal Cancer [NCT00286130]Phase 2150 participants (Actual)Interventional2005-07-31Completed
Open, Randomized, Controlled, Multicenter Phase III Study Comparing CMAB009 Plus FOLFIRI Versus FOLFIRI Alone as First-line Treatment for Epidermal Growth Factor Receptor-expressing, RAS/BRAF Wild-type, Metastatic Colorectal Cancer [NCT03206151]Phase 3520 participants (Actual)Interventional2017-12-12Active, not recruiting
A Phase Ib/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of JS015 Combination Therapy in Patients With Advanced Solid Tumors [NCT06139211]Phase 1/Phase 2186 participants (Anticipated)Interventional2023-11-30Not yet recruiting
Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer and Low Risk for Local Failure: A Randomized Phase III Trial of the German Rectal Cancer Study Group [NCT04495088]Phase 3818 participants (Anticipated)Interventional2020-09-30Recruiting
A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 When Used in Combinations With Selected Anti-Cancer Treatment Regimens in Patients With Selected Advanced Solid Tumors [NCT03872947]Phase 1169 participants (Anticipated)Interventional2019-04-26Recruiting
An Open-Label Exploratory Phase 2/3 Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Metastatic Colorectal Cancer [NCT03414983]Phase 2/Phase 3196 participants (Actual)Interventional2018-02-20Completed
Open, Multi-center Phase I/II Trial With Mitomycin C in Combination With 5-Fluorouracil and Folinic Acid in Pretreated Patients With Metastatic Gastrointestinal Cancer [NCT00289445]Phase 1/Phase 20 participants Interventional1999-09-30Completed
Phase II Study of Paclitaxel, Oxaliplatin, Leucovorin and 5-Fluorouracil (POLF) in Gemcitabine-Refractory Advanced Pancreatic Cancer [NCT00323583]Phase 280 participants (Anticipated)Interventional2006-05-31Recruiting
Randomized Study of Classic vs Simplified Leucovorin Calcium and Fluorouracil With or Without Irinotecan in Patients Aged At Least 75 Years With Advanced Colorectal Cancer [NCT00303771]Phase 3282 participants (Actual)Interventional2003-06-30Completed
Phase I/II Study of CT-2106 in Combination With Infusional 5-fluorouracil/Folinic Acid (5-FU/FA)(de Gramont Schedule) as Second Line in Patients With Metastatic Colorectal Cancer Failing an Oxaliplatin Plus 5-FU/FA Regimen [NCT00291785]Phase 1/Phase 248 participants (Actual)Interventional2004-01-31Completed
One-year Double-blind Placebo-controlled Phase 2-3 Study to Evaluate the Effect of Oral Folinic Acid Treatment (1mg/kg/d) on the Psychomotor Development of Young Down Syndrome Patients [NCT00294593]Phase 2/Phase 3120 participants Interventional2000-10-31Completed
Effect of Add-on Anti-Toxoplasmosis Treatment on Parameters Defining Toxoplasma Gondii Infection and on Psychopathology in Patients With Schizophrenia or Major Depression Serologically Positive for Toxoplasma Gondii - Phase 3 Study [NCT00300404]Phase 340 participants Interventional2002-01-31Completed
Essai Randomise Comparant Deux Stategies De Chimiotherapie Dans Les Cancers Pancreatiques Avances: LV5FU2 Simplifie + Cisplatine Suivi de Gemcitabine, Versus Gemcitabine Suivi de LV5FU2 Simplifie + Cisplatine en Can de Progression [NCT00303758]Phase 3202 participants (Actual)Interventional2005-10-31Completed
A Phase III Multi-Center Randomized Clinical Trial to Evaluate the Safety and Efficacy of CoFactor and 5-Fluorouracil (5-FU) Plus Bevacizumab Versus Leucovorin and 5-FU Plus Bevacizumab as Initial Treatment for Metastatic Colorectal Carcinoma [NCT00337389]Phase 31,200 participants (Anticipated)Interventional2006-05-31Active, not recruiting
A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination With Anticancer Agents in Patients With Advanced/Metastatic Solid Tumours [NCT05489211]Phase 2670 participants (Anticipated)Interventional2022-09-06Recruiting
A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Bevacizumab and FOLFIRI Versus Bevacizumab and FOLFIRI in Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC) [NCT05330429]Phase 2135 participants (Anticipated)Interventional2022-07-08Recruiting
Pazopanib With 5-Fluorouracil, Leucovorin and Oxaliplatin (FLO) as 1st-line Treatment in Advanced Gastric Cancer; a Randomized Phase-II-study of the Arbeitsgemeinschaft Internistische Onkologie [NCT01503372]Phase 275 participants (Actual)Interventional2011-11-30Completed
Explorative Trial to Investigate Catumaxomab (Anti-EpCAM x Anti-CD3) for Treatment of Peritoneal Carcinomatosis in Patients With Gastric Adenocarcinomas Prior to Gastrectomy [NCT01504256]Phase 242 participants (Anticipated)Interventional2011-10-31Completed
An Observational Study of Avastin® (Bevacizumab) in Combination With Chemotherapy for Treatment of First-line Metastatic Colorectal Adenocarcinoma [NCT01506167]719 participants (Actual)Observational2012-07-06Completed
A Phase II Study of Oxaliplatin in Combination With Fluorouracil and Leucovorin in Carcinoma of the Esophagus and Gastric Cardia [NCT00004127]Phase 235 participants (Actual)Interventional2000-02-29Completed
A Phase Ib Study of the Safety and Pharmacology of Atezolizumab (Anti-PD-L1 Antibody) Administered With Bevacizumab and/or Chemotherapy in Patients With Advanced Solid Tumors [NCT01633970]Phase 1240 participants (Actual)Interventional2012-07-11Completed
A Clinical Trial Comparing 5-Fluorouracil (5-FU) Plus Leucovorin (LV) and Oxaliplatin With 5-FU Plus LV for the Treatment of Patients With Stages II and III Carcinoma of the Colon [NCT00004931]Phase 32,472 participants (Anticipated)Interventional2000-02-29Completed
A Phase 2, Randomized Study to Evaluate Safety, Efficacy, and Optimal Dose of ABBV-400 in Combination With Fluorouracil, Folinic Acid, and Bevacizumab in Previously Treated Subjects With Unresectable Metastatic Colorectal Cancer [NCT06107413]Phase 2206 participants (Anticipated)Interventional2023-11-12Recruiting
A Phase II Study of the Combination of Aflibercept (VEGF-Trap) Plus Modified FOLFOX 6 in Patients With Previously Untreated Metastatic Colorectal Cancer [NCT01652196]Phase 256 participants (Actual)Interventional2012-11-14Active, not recruiting
Prospective Phase II Study of a High Dose, Short Course Regimen (R-CODOX-M/IVAC) Including CNS Penetration and Intensive IT Prophylaxis in HIV-Associated Burkitt's and Atypical Burkitt's Lymphoma [NCT00392834]Phase 234 participants (Actual)Interventional2006-09-30Completed
A Phase Ib Ascending Multi-arm, Dose Escalation Study of BMS-906024 Combined With Several Chemotherapy Regimens in Subjects With Advanced or Metastatic Tumors [NCT01653470]Phase 1141 participants (Actual)Interventional2012-10-12Completed
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors [NCT01803282]Phase 1236 participants (Actual)Interventional2013-03-29Completed
Phase II Study of Bevacizumab Plus Modified FOLFOX6 Regimen as the Salvage Treatment in Patients With Metastatic Breast Cancer [NCT01658033]Phase 272 participants (Actual)Interventional2012-05-31Completed
Phase II Study to Evaluate Neoadjuvant Modified FOLFIRINOX and Stereotactic Body Radiation Therapy in Borderline Resectable Pancreatic Adenocarcinoma [NCT03099265]Phase 29 participants (Actual)Interventional2017-06-26Terminated(stopped due to Paused due to COVID. A determination was made to stop the study because it would be impossible to reach the 65% resection rate as outlined in the protocol.)
An Open-Label Study to Assess the Pharmacokinetics of Leucovorin in Patients Receiving High Dose Methotrexate, With or Without Voraxaze Treatment [NCT00634504]Phase 120 participants (Actual)Interventional2008-05-31Completed
Phase II Clinical Study on Efficacy and Safety of PD-1 Inhibitor Combined With Bevacizumab and FOLFIRI Regimen in the Second-line Treatment of Unresectable Recurrent or Metastatic MSI-H Colorectal Cancer [NCT05035381]Phase 210 participants (Anticipated)Interventional2019-01-01Recruiting
Total Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction (GEJ) and Gastric Cancers: A Pilot Trial [NCT05296005]Phase 120 participants (Anticipated)Interventional2022-05-31Not yet recruiting
Phase II Trial of Low Dose Whole Pelvic Radiotherapy With Concurrent Neoadjuvant FOLFOX for Patients With Newly Diagnosed T3N0M0, T2N1M0, or T3N1M0 Rectal Adenocarcinoma [NCT02319304]Phase 23 participants (Actual)Interventional2015-03-31Terminated(stopped due to Slow accrual, PI left instituion)
Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases CAIRO5 a Randomized Phase 3 Study of the Dutch Colorectal Cancer Group (DCCG) [NCT02162563]Phase 3564 participants (Anticipated)Interventional2014-07-31Recruiting
A Phase III Trial of 6 Versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients With Resected Stage III Colon Cancer [NCT01150045]Phase 32,527 participants (Actual)Interventional2010-06-30Active, not recruiting
Feasibility of an Immediate Preoperative Chemotherapy Before Resection of Colorectal Cancer and Research of Gene Expressions Changes Induced in the Tumor, Predictive of Chemotherapy Efficiency [NCT01715363]Phase 23 participants (Actual)Interventional2012-07-31Terminated(stopped due to Recruitment difficulties)
Randomized, Double-Blind, Placebo Controlled Phase II Study of FOLFOX +/- Ziv-Aflibercept in Patients With Advanced Esophageal and Gastric Cancer [NCT01747551]Phase 264 participants (Actual)Interventional2013-01-31Completed
An Open-label Randomized Phase 3 Study of Tucatinib in Combination With Trastuzumab and mFOLFOX6 Versus mFOLFOX6 Given With or Without Either Cetuximab or Bevacizumab as First-line Treatment for Subjects With HER2+ Metastatic Colorectal Cancer [NCT05253651]Phase 3400 participants (Anticipated)Interventional2022-10-24Recruiting
A Single Arm, Multi-center Phase 2 Trial of mFOLFOX6 + Trastuzumab + Avelumab in First-line, Metastatic, HER2-amplified Gastric and Esophageal Adenocarcinomas [NCT03783936]Phase 218 participants (Actual)Interventional2019-01-24Completed
Phase 2 Single-Arm Study of Nanoliposomal Irinotecan With Fluorouracil and Leucovorin in Refractory Advanced High Grade Neuroendocrine Cancer of GI, Unknown or Pancreatic Origin [NCT03736720]Phase 211 participants (Actual)Interventional2019-06-17Active, not recruiting
A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin Versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients With Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Ma [NCT00217737]Phase 33,610 participants (Anticipated)Interventional2005-09-06Active, not recruiting
[NCT01758666]40 participants (Anticipated)Interventional2012-09-30Active, not recruiting
Multi-Modality Therapy for Untreated Patients With Resectable or Marginally Resectable Pancreatic Cancer [NCT01760694]6 participants (Actual)Interventional2013-01-31Terminated(stopped due to Lack of enrollment)
Short-term Folinic Acid Supplementation Improves Vascular Reactivity in HIV-infected Individuals: a Randomized Trial [NCT01768182]30 participants (Actual)Interventional2009-08-31Completed
Randomized Phase III Study of Oxaliplatin, Fluorouracil and Leucovorin (FOLFOX) With or Without Regorafenib in Patients With Metastatic Colorectal Cancer Progressed After First-line Irinotecan Plus Fluoropyrimidines [NCT01786538]Phase 30 participants (Actual)Interventional2013-06-30Withdrawn
A Phase II/I Open-Label Clinical Trial of CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer and Good Performance Status [NCT03699319]Phase 1/Phase 249 participants (Actual)Interventional2018-12-07Active, not recruiting
Evaluate the Safety of Combination of Orectalip® (Oxaliplatin), Fluorouracil and Leucovorin as Adjuvant Treatment for High-risk Stage-Ⅱ Colorectal Cancer [NCT02284529]Phase 420 participants (Actual)Interventional2012-10-31Completed
Neoadjuvant FOLFIRINOX and Chemoradiation Followed by Definitive Surgery and Postoperative Gemcitabine for Patients With Borderline Resectable Pancreatic Adenocarcinoma: An Intergroup Single-Arm Pilot Study [NCT01821612]Early Phase 123 participants (Actual)Interventional2013-05-31Completed
An Investigator Initiated Phase 1 Trial To Evaluate mFOLFOX6 With Selinexor (KPT-330), An Oral Selective Inhibitor Of Nuclear Export (SINE), In Patients With Metastatic Colorectal Cancer [NCT02384850]Phase 110 participants (Actual)Interventional2015-03-31Terminated
A Phase 1 / 2 Study of CAN04, a Fully Humanized Monoclonal Antibody Against IL1RAP, in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumours [NCT05116891]Phase 1/Phase 240 participants (Actual)Interventional2021-09-22Completed
Phase Ib/II Treatment of Advanced Pancreatic Cancer With Anti-CD3 x Anti-EGFR-Bispecific Antibody Armed Activated T-Cells (BATs) in Combination With Low Dose IL-2 and GM-CSF [NCT02620865]Phase 1/Phase 22 participants (Actual)Interventional2015-12-31Completed
Intermittent or Continuous Panitumumab Plus FOLFIRI for First-line Treatment of Patients With RAS/B-RAF Wild-type Metastatic Colorectal Cancer: a Randomized Phase 2 Trial [NCT04425239]Phase 2151 participants (Actual)Interventional2018-05-21Completed
A Pilot Study of Molecular Profile-Directed Chemotherapy for Metastatic HER2(-) Esophagogastric Adenocarcinoma [NCT02358863]13 participants (Actual)Interventional2015-02-28Terminated(stopped due to Issues with recruitment.)
Phase I Study to Evaluate the Safety and Tolerability of ASLAN001 in Combination With Oxaliplatin and Capecitabine or Oxaliplatin and 5-FU With Leucovorin [NCT02435927]Phase 160 participants (Anticipated)Interventional2014-08-31Active, not recruiting
Phase II Study of Hepatic Arterial Infusion Chemotherapy Using Oxaliplatin,Leucovorin and 5-Fluorouracil [NCT02987699]Phase 254 participants (Anticipated)Interventional2016-11-30Recruiting
Phase II Single Arm Clinical Trial of FOLFIRINOX for Unresectable Locally Advanced and Borderline Resectable Pancreatic Cancer [NCT01688336]Phase 29 participants (Actual)Interventional2012-01-31Terminated(stopped due to Results unlikely to impact treatment patterns. Time to complete not justified.)
A Phase II Study of 5-Fluorouracil (5-FU), Aflibercept, and Radiation for the Preoperative and Adjuvant Treatment of Patients With Stage II/III Rectal Cancer [NCT01749956]Phase 239 participants (Actual)Interventional2013-01-31Completed
An Exploratory Study of Chemotherapy for Metastatic Colorectal Cancer Based Upon Thymidine Phosphorylase Expression, KRAS and BRAF Mutation Status, and ERCC1 Expression [NCT01280643]3 participants (Actual)Interventional2010-03-31Terminated(stopped due to Slow accrual)
A Phase II Open- Labeled, Prospective Study to Determine the Efficacy of Pre- Operative Chemotherapy With Six Cycles of Modified FOLFOX 6 Followed by Total Mesorectal Excision (TME) Followed by an Additional Six Cycles of FOLFOX 6 [NCT00832299]Phase 22 participants (Actual)Interventional2009-01-31Terminated(stopped due to terminated for lack of enrollment)
Study Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma [NCT05546853]Phase 152 participants (Anticipated)Interventional2023-03-28Recruiting
A Compassionate Treatment Protocol for the Use of Trimetrexate Glucuronate (Neutrexin) With Leucovorin Protection for European Adult Patients (>= 13 Years Old) With Pneumocystis Carinii Pneumonia [NCT00002103]0 participants InterventionalCompleted
A Phase I Study of Weekly Gemcitabine in Combination With Infusional Fluorodeoxyuridine and Oral Calcium Leucovorin in Adult Cancer Patients [NCT00001449]Phase 160 participants Interventional1995-09-30Completed
PRODIGE 22-ECKINOXE : Randomized Phase II Trial of Neoadjuvant FOLFOX 4 Versus FOLFOX 4 With Cetuximab Versus Immediate Surgery in Locally Advanced Colon Cancer [NCT01675999]Phase 2186 participants (Anticipated)Interventional2012-05-31Recruiting
An Open-Label Multicenter Phase 1b Study of E7046 in Combination With Radiotherapy/Chemoradiotherapy (RT/CRT) in Preoperative Treatment of Subjects With Rectum Cancer [NCT03152370]Phase 129 participants (Actual)Interventional2017-05-17Completed
FOUR ARMS PHASE III CLINICAL TRIAL FOR T3-T4 RESECTABLE RECTAL CANCER COMPARING PRE-OPERATIVE PELVIC IRRADIATION TO PRE-OPERATIVE IRRADIATION COMBINED WITH FLUOROURACIL AND LEUCOVORIN WITH OR WITHOUT POST-OPERATIVE ADJUVANT CHEMOTHERAPY [NCT00002523]Phase 31,011 participants (Actual)Interventional1993-04-30Completed
A Multicenter Study of Prognosis and the Efficacy Comparison of Perioperative Chemotherapy Plus Cetuximab Versus Chemotherapy Alone for High Risk Patients(Clinical Risk Score≥3) of Resectable Colorectal Liver Metastasis [NCT03031444]Phase 2/Phase 3135 participants (Actual)Interventional2016-01-31Completed
Chemotherapy, Radiotherapy, and Azidothymidine for AIDS-Related Primary CNS Lymphoma [NCT00000723]45 participants InterventionalTerminated
A Phase II Study Investigating CHFR Methylation Status As A Biomarker For Taxane Sensitivity Using Modified Docetaxel, Cisplatin and 5 Fluorouracil In Patients With Metastatic Esophageal, Gastroesophageal And Gastric Cancer. [NCT01715233]Phase 227 participants (Actual)Interventional2012-12-31Completed
Phase II Multicentric Randomized Trial, Evaluating the Best Protocol of Chemotherapy, Associated With Targeted Therapy According to the Tumor KRAS Status, in Metastatic Colorectal Cancer (CCRM) Patients With Initially Non-resectable Hepatic Metastases [NCT01442935]Phase 2256 participants (Actual)Interventional2011-02-28Completed
Adjuvant Chemoimmunotherapy for Colorectal Cancer [NCT00003063]Phase 31,050 participants (Anticipated)Interventional1991-11-30Active, not recruiting
A Pilot Phase II, Single Arm, Open Label, Investigator-initiated Clinical Trial of Regorafenib Plus 5-Fluorouracil/Leucovorin (5FU/LV) Beyond Progression on Regorafenib Monotherapy in Metastatic Colorectal Cancer (mCRC) [NCT03099486]Phase 22 participants (Actual)Interventional2017-10-06Terminated(stopped due to Administrative change)
RAVEN: A Phase I/II Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax [NCT05192889]Phase 1/Phase 290 participants (Anticipated)Interventional2022-08-25Recruiting
A Randomized, Phase II, Placebo-controlled Study of Ipatasertib (GDC-0068), an Inhibitor to Akt, in Combination With Fluoropyrimidine Plus Oxaliplatin in Patients With Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma [NCT01896531]Phase 2153 participants (Actual)Interventional2013-08-14Completed
Phase Ⅱ Trial to Investigate the Efficacy and Safety of mFOLFIRINOX in Patients With Metastatic Pancreatic Cancer in China [NCT02028806]Phase 240 participants (Actual)Interventional2013-02-28Completed
A Randomised, Open-label, Phase II, Dose/Schedule Optimisation Study of NUC-3373/Leucovorin/Irinotecan Plus Bevacizumab (NUFIRI-bev) Versus 5-FU/Leucovorin/Irinotecan Plus Bevacizumab (FOLFIRI-bev) for the Treatment of Patients With Previously Treated Unr [NCT05678257]Phase 2171 participants (Anticipated)Interventional2023-04-18Recruiting
Risk-Stratified Adjuvant Therapy: ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver Metastases [NCT05062317]Phase 2120 participants (Anticipated)Interventional2022-04-26Recruiting
A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer [NCT05026905]Phase 286 participants (Anticipated)Interventional2021-12-28Recruiting
A Randomised Phase II/III Trial of Preoperative Chemoradiotherapy Versus Preoperative Chemotherapy for Resectable Gastric Cancer [NCT01924819]Phase 2/Phase 3574 participants (Actual)Interventional2009-09-30Active, not recruiting
A Phase III, Randomised, Multicentre Open-label Study of Active Symptom Control (ASC) Alone or ASC With Oxaliplatin/ 5F-U Chemotherapy for Patients With Locally Advanced/ Metastatic Biliary Tract Cancers Previously Treated With Cisplatin/ Gemcitabine Chem [NCT01926236]Phase 3162 participants (Actual)Interventional2014-02-28Completed
Ensayo Fase II de selección Individualizada Del Tratamiento de Quimioterapia en Pacientes Con Carcinoma de páncreas Avanzado en función de la determinación de Dianas terapéuticas en el Tejido Tumoral [NCT01454180]Phase 231 participants (Actual)Interventional2011-10-31Completed
A Phase Ib/II Open Label Study to Assess the Safety and Pharmacokinetics of NUC-3373, a Nucleotide Analogue, Given in Combination With Standard Agents Used in Colorectal Cancer Treatment [NCT03428958]Phase 1/Phase 2225 participants (Anticipated)Interventional2018-10-16Recruiting
A Folinic Acid Intervention for ASD: Links to Folate Receptor-alpha Autoimmunity & Redox Metabolism [NCT01602016]Phase 299 participants (Actual)Interventional2012-05-31Terminated(stopped due to Non-compliance)
mFOLFOX6 Combined With Dalpiciclib(SHR6390) in Patients With Metastatic Colorectal Cancer (FIND): A Single-arm, Phase IIa Study. [NCT05480280]Phase 218 participants (Anticipated)Interventional2022-07-20Recruiting
A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection, in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only [NCT01226719]Phase 215 participants (Actual)Interventional2010-12-31Completed
A Randomized, Double-Blind, Placebo Controlled Study of l-Leucovorin in Combination With Trimethoprim / Sulfamethoxazole in the Therapy of Pneumocystis Carinii Pneumonia in Patients With the Acquired Immunodeficiency Syndrome [NCT00002002]0 participants InterventionalCompleted
Phase Ib Trial of mFOLFOX6 and Everolimus (NSC-733504) in Patients With Metastatic Gastroesophageal Adenocarcinoma [NCT01231399]Phase 1/Phase 26 participants (Actual)Interventional2012-02-29Completed
A Pilot Trial of Sequential Chemotherapy With Antimetabolite Induction, High-Dose Alkylating Agent Consolidation With Peripheral Blood Progenitor Cell Support, and Intensification With Paclitaxel and Doxorubicin for Patients With High-Risk Breast Cancer [NCT00001498]Phase 255 participants Interventional1996-02-29Completed
A Phase III Randomized Trial of Low-Dose Versus Standard-Dose mBACOD Chemotherapy With rGM-CSF for Treatment of AIDS-Associated Non-Hodgkin's Lymphoma [NCT00000658]Phase 3250 participants InterventionalCompleted
A Study of Trimetrexate With Leucovorin Rescue for AIDS Patients Who Are Refractory to Standard Therapies for Pneumocystis Carinii Pneumonia [NCT00000724]Phase 30 participants InterventionalCompleted
A Randomized, Comparative Trial of Trimetrexate With Leucovorin Rescue Versus Standard Anti-Pneumocystis Therapy Versus Standard Anti-Pneumocystis Therapy With High Dose Steroids for AIDS Patients With Pneumocystis Pneumonia Who Appear to Be Refractory to [NCT00000730]Phase 3240 participants InterventionalTerminated
Neoadjuvant Treatment With mFOLFOXIRI Plus Cadonilimab (AK104) Versus mFOLFOX6 Alone in Locally Advanced Colorectal Cancer: a Randomized Control Phase II Study (OPTICAL-2) [NCT05571644]Phase 282 participants (Anticipated)Interventional2022-12-15Not yet recruiting
HR070803 in Combination With Oxaliplatin, 5-fluorouracil, Calcium Folinate Versus Nab-paclitaxel in Combination With Gemcitabine for First-line Treatment of Advanced Pancreatic Cancer: an Open, Randomized, Multicenter Phase III Trial. [NCT05751850]Phase 3522 participants (Anticipated)Interventional2023-06-13Recruiting
A Study of Trimetrexate Glucuronate (Neutrexin) With Leucovorin Protection for Patients With Pneumocystis Carinii Pneumonia [NCT00002434]0 participants InterventionalCompleted
Phase III Randomized Study of Radiotherapy Alone vs With Concurrent Chemotherapy With MTX or VBMF (VCR/BLEO/MTX/5-FU) vs Subsequent Chemotherapy vs Concurrent and Subsequent Chemotherapy in Patients With Advanced Head and Neck Cancer [NCT00002476]Phase 30 participants Interventional1990-01-31Completed
A Single-Arm Prospective Trial Evaluating The Local And Systemic Benefits Of Oxaliplatin And 5FU With Concurrent Radiation In Patients With Metastatic Rectal Cancer [NCT00422864]Phase 226 participants (Actual)Interventional2006-10-31Completed
Phase II Trial of Biweekly S-1, Leucovorin and Gemcitabine in Elderly Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma [NCT03559348]Phase 249 participants (Actual)Interventional2018-04-03Completed
Phase II Evaluation of Gallium Nitrate (NSC 15200) in Non-Hodgkin's Lymphoma in Patients With Acquired Immunodeficiency Syndrome [NCT00002578]Phase 235 participants (Anticipated)Interventional1994-08-31Completed
A RANDOMISED TRIAL OF INTRAVENOUS VERSUS INTRAHEPATIC ARTERIAL 5-FU AND LEUCOVORIN FOR COLORECTAL LIVER METASTASES [NCT00002692]Phase 3312 participants (Anticipated)Interventional1994-12-31Active, not recruiting
TREATMENT OF ISOLATED CNS RELAPSE OF ACUTE LYMPHOBLASTIC LEUKEMIA -- A PEDIATRIC ONCOLOGY GROUP-WIDE PHASE II STUDY [NCT00002704]Phase 2156 participants (Actual)Interventional1996-01-31Completed
PHASE III STUDY OF HEPATIC ARTERY FLOXURIDINE (FUDR), LEUCOVORIN (LV), AND DEXAMETHASONE (DEX) VERSUS SYSTEMIC 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) AS TREATMENT FOR HEPATIC METASTASES FROM COLORECTAL CANCER [NCT00002716]Phase 3135 participants (Actual)Interventional1996-01-31Completed
A Pilot Study For The Treatment of Newly-Diagnosed Disseminated Anaplastic Large Cell Ki-1 Lymphoma and T-Large Cell Lymphoma [NCT00002590]Phase 2221 participants (Actual)Interventional1994-07-31Completed
RANDOMIZED TRIAL OF CONCOMITANT PREOPERATIVE RADIO-CHEMOTHERAPY WITH OR WITHOUT POSTOPERATIVE CHEMOTHERAPY IN LOCALLY ADVANCED RECTAL CARCINOMA [NCT00002896]Phase 3774 participants (Anticipated)Interventional1993-09-30Active, not recruiting
A Phase III Randomized Trial of Pulse Actinomycin-D Versus Multi-day Methotrexate for the Treatment of Low-Risk Gestational Trophoblastic Neoplasia [NCT01535053]Phase 357 participants (Actual)Interventional2012-06-18Completed
Phase II Study in Adults With Untreated Acute Lymphoblastic Leukemia Testing Increased Doses of Daunorubicin During Induction, and Cytarabine During Consolidation, Followed by High-Dose Methotrexate and Intrathecal Methotrexate in Place of Cranial Irradia [NCT00003700]Phase 2163 participants (Actual)Interventional1999-01-31Completed
A Phase II Trial of Preoperative Chemotherapy and Chemoradiotherapy for Potentially Resectable Adenocarcinoma of the Stomach [NCT00003862]Phase 20 participants Interventional1999-11-30Completed
A Phase II Trial of Eloxatin in Combination With 5-Fluorouracil and Leucovorin in Patients With Advanced Colorectal Carcinoma [NCT00004102]Phase 20 participants Interventional1999-01-31Completed
Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents [NCT03020030]Phase 3560 participants (Actual)Interventional2017-03-03Active, not recruiting
A Randomized, Open-Label, Multicenter Phase III Study of 5-FU/Leucovorin With or Without Concomitant SU5416 in Patients With Metastatic Colorectal Cancer [NCT00004252]Phase 30 participants Interventional1999-11-30Completed
ALinC 17: Protocol for Patients With Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia (ALL): A Phase III Study [NCT00005596]Phase 31,076 participants (Actual)Interventional2000-04-30Completed
A Phase I Study of Oxaliplatin, CPT-11, 5-FU and Leucovorin in Patients With Solid Tumors [NCT00005068]Phase 10 participants Interventional2000-01-31Completed
A Phase II Study Evaluating the Rate of R0 Resection (Microscopically Negative Margins) After Induction Therapy With 5- Fluorouracil, Leucovorin, Oxaliplatin, Irinotecan (FOLFIRINOX) in Patients With Borderline Resectable or Locally Advanced Inoperable Pa [NCT01359007]Phase 25 participants (Actual)Interventional2011-05-31Terminated(stopped due to The principal investigator terminated the study due to inactivity and low enrollment)
Complete Neoadjuvant Treatment for REctal Cancer (CONTRE) [NCT01363843]Phase 239 participants (Actual)Interventional2010-05-31Completed
A Pilot Trial of GI-4000 Plus Bevacizumab and Either FOLFOX or FOLFIRI in Patients With Ras Mutant Positive Metastatic Colorectal Cancer, Either Newly Diagnosed or Previously Treated. [NCT01322815]Phase 211 participants (Actual)Interventional2010-10-31Terminated(stopped due to Poor accrual rate)
A Phase III Trial of Irinotecan / 5-FU / Leucovorin or Oxaliplatin / 5-FU/ Leucovorin With Bevacizumab, or Cetuximab (C225), or With the Combination of Bevacizumab and Cetuximab for Patients With Untreated Metastatic Adenocarcinoma of the Colon or Rectum [NCT00265850]Phase 32,334 participants (Actual)Interventional2005-11-30Completed
A Randomized, Three Arm Multinational Phase III Study to Investigate Bevacizumab (q3w or q2w) in Combination With Either Intermittent Capecitabine Plus Oxaliplatin (XELOX) (q3w) or Fluorouracil/Leucovorin With Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 Regime [NCT00112918]Phase 33,451 participants (Actual)Interventional2004-12-31Completed
An Open Labelled Phase III Adjuvant Trial of Disease-free Survival in Patients With Resected Pancreatic Ductal Adenocarcinoma Randomized to Allocation of Oxaliplatin- or Gemcitabine-based Chemotherapy by Standard Clinical Criteria or by a Transcriptomic T [NCT05314998]Phase 3394 participants (Anticipated)Interventional2023-07-01Not yet recruiting
A Phase II Study of the Rate of Conversion to Complete Resection in Patients With Initially Inoperable Hepatic-Only Metastases From Colorectal Cancer After Treatment With Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Bes [NCT00492999]Phase 264 participants (Anticipated)Interventional2007-05-31Active, not recruiting
Hepatic Arterial Infusion Chemotherapy Combined With PD-1 Inhibitor in Treating Potentially Resectable Locally Advanced Hepatocellular Carcinoma: A Prospective, Phase II Clinical Study [NCT03869034]Phase 240 participants (Actual)Interventional2019-03-25Active, not recruiting
An Exploratory Phase 2 Study of Neoadjuvant Chemotherapy Followed by Stereotactic Body Radiation Therapy (SBRT) With Algenpantucel-L (HyperAcute®-Pancreas) Immunotherapy in Subjects With Borderline Resectable Pancreatic Cancer [NCT02405585]Phase 210 participants (Actual)Interventional2015-04-30Terminated
Study of Bevacizumab Plus Chemotherapy in Patients With Metastatic Colorectal Cancer [NCT01679327]Phase 2100 participants (Anticipated)Interventional2012-03-31Recruiting
Clinical Efficacy of Chemotherapy Combined With Cytokine-induced Killer in Treatment of Patients With Colon Cancer [NCT03084809]Phase 446 participants (Actual)Interventional2012-05-06Completed
Hepatic Arterial Infusion Chemotherapy of Oxaliplatin, 5-Fluorouracil and Leucovorin Versus Systemic Chemotherapy of Gemcitabine and Cisplatin for Unresectable Intrahepatic Cholangiocarcinoma [NCT04961970]Phase 3188 participants (Anticipated)Interventional2021-07-09Recruiting
A Randomized Open-Label Phase 2b Study of Hepatic Infusions of Anti-CEA CAR-T Cells Alternating With Systemic Chemotherapy Versus Chemotherapy Alone In Patients With Liver Metastases Due To CEA-Expressing Pancreatic Adenocarcinoma [NCT04037241]Phase 2/Phase 30 participants (Actual)Interventional2021-11-01Withdrawn(stopped due to Sponsor terminated)
Spleen Irradiation With Nanoliposomal Irinotecan Plus 5-FU and Leucovorin in Metastatic Pancreatic Adenocarcinoma: a Phase II Study (SINAI) [NCT05363007]Phase 260 participants (Anticipated)Interventional2022-05-01Recruiting
Randomized Phase II Study for Evaluation of Efficacy and Safety of Maintenance Treatment With 5-FU/FA Plus Panitumumab vs. 5-FU/FA Alone After Prior Induction Treatment With mFOLFOX6 Plus Panitumumab and Re-induction With mFOLFOX6 Plus Panitumumab in Case [NCT01991873]Phase 2387 participants (Actual)Interventional2014-04-30Completed
A Randomised Phase III Trial Comparing Hepatic Arterial Injection of Yttrium-90 Resin Microspheres (SIR-spheres) Plus Systemic Maintenance Therapy Versus Systemic Maintenance Therapy Alone for Patients With Unresectable Liver Metastases From Colorectal Ca [NCT01895257]Phase 3162 participants (Anticipated)Interventional2013-08-31Recruiting
Phase III Study in mCRC Patients With RAS/BRAF Wild Type Tissue and RAS Mutated in LIquid BIopsy to Compare in First-line Therapy FOLFIRI Plus CetuxiMAb or BevacizumaB (LIBImAb Study) [NCT04776655]Phase 3280 participants (Anticipated)Interventional2021-04-30Recruiting
A Phase I, Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD0156 Monotherapy or in Combination With Either Cytotoxic Chemotherapies or Novel Anti-Cancer Agents in Patients With Advance [NCT02588105]Phase 184 participants (Actual)Interventional2015-11-10Completed
An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib With Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients With Gastric Cancer [NCT04745988]Phase 243 participants (Anticipated)Interventional2021-11-11Recruiting
The Impact on Recurrence Risk of Adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial. [NCT03192618]Phase 3290 participants (Anticipated)Interventional2017-07-01Recruiting
Open-label, Single Arm Phase II Trial Investigating the Efficacy, Safety and Quality of Life of Neoadjuvant Chemotherapy With Liposomal Irinotecan Combined With Oxaliplatin and 5-Fluorouracil/Folinic Acid Followed by Curative Surgical Resection in Patient [NCT04617457]Phase 2150 participants (Anticipated)Interventional2021-10-10Recruiting
NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and Anti-programmed Cell Death Protein 1 (PD-1)/Programmed Death-ligand 1 (PD-L1) Therapy [NCT03169764]Phase 1/Phase 20 participants (Actual)Interventional2017-12-31Withdrawn(stopped due to Trial not initiated)
A Non-comparative Randomized Phase 2 Study, Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for Metastatic Pancreatic Ductal Adenocarcinoma (PDAC), Progressive After Gemcitabine-Abraxane or Gemcitabine Monotherapy [NCT05472259]Phase 2134 participants (Anticipated)Interventional2022-05-25Recruiting
Phase II Study to Evaluatate the Efficacy of Gemcitabine Plus Erlotinib for RASH-positive Patients With Metastatic Pancreatic Cancer and Friendly Risk Circumstances [NCT01729481]Phase 2150 participants (Actual)Interventional2012-07-31Active, not recruiting
Induction Chemotherapy for Locally Advanced Esophageal Cancer: A Phase II Study [NCT03110926]Phase 240 participants (Anticipated)Interventional2017-06-19Active, not recruiting
A Phase I Study of BKM120 With mFOLFOX6 in Patients With Advanced Solid Tumors With Expansion Cohort in Metastatic Pancreatic Cancers. [NCT01571024]Phase 117 participants (Actual)Interventional2012-05-31Completed
Phase II Study of Hepatic Arterial Infusion With Oxaliplatin and Fluorouracil in Patients With Unresectable Biliary Tract Carcinomas [NCT01572324]Phase 237 participants (Actual)Interventional2012-03-31Completed
Phase II Study of Irinotecan, Leucovorin, 5-Fluorouracil (FOLFIRI) Plus Bevacizumab as First-Line Treatment for Metastatic Colorectal Cancer [NCT00354978]Phase 249 participants (Actual)Interventional2005-01-31Completed
Maintenance of Chemotherapy Following Neoadjuvant Chemoradiation Therapy for Distal Rectal Cancer [NCT01613469]Phase 25 participants (Actual)Interventional2011-08-31Terminated(stopped due to Re-eval of patient population)
Perioperative Chemotherapy With FOLFIRINOX Regimen or FLOT Regimen for Resectable Gastric or Esophagogastric Junction Adenocarcinoma (Type II-III): Open-label Randomized Phase 2/3 Trial [NCT04393584]Phase 2/Phase 3538 participants (Anticipated)Interventional2019-01-29Recruiting
A Randomized Prospective Study of Early Intensification Versus Alternating Triple Therapy for Patients With Poor Prognosis Lymphoma [NCT00002835]Phase 3116 participants (Actual)Interventional1995-10-30Completed
Phase II Trial of Pre-operative Bevacizumab and FOLFOX Chemotherapy in Locally Advanced Esophageal Cancer [NCT01212822]Phase 220 participants (Actual)Interventional2011-04-27Completed
A Phase 1b Study of Irinotecan, Levofolinate, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab (IMC-1121B) Drug Product in Japanese Subjects With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, [NCT01286818]Phase 16 participants (Actual)Interventional2011-02-28Completed
Irinotecan Combined With S-1( IRIS ) Followed by mFOLFOX6 Regimen Versus mFOLFOX6 Followed by IRIS Regimen in Advanced Colorectal Cancer [NCT00316745]Phase 3200 participants (Anticipated)Interventional2006-04-30Suspended(stopped due to Because of approval of Bevacizumab, it was difficult to perform clinical study in 1st line setting.)
A Phase I/II Study of RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma [NCT01047293]Phase 1/Phase 247 participants (Actual)Interventional2010-05-31Completed
A Novel Phase I/IIa Open Label Study of IMM 101 in Combination With Selected Standard of Care (SOC) Regimens in Patients With Metastatic Cancer or Unresectable Cancer at Study Entry [NCT03009058]Phase 1/Phase 22 participants (Actual)Interventional2017-05-24Terminated(stopped due to Commercial reasons)
A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-Paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma [NCT02551991]Phase 256 participants (Actual)Interventional2015-10-19Completed
A Pilot Study of Neoadjuvant and Adjuvant mFOLFIRINOX in Localized, Resectable Pancreatic Adenocarcinoma [NCT01660711]Phase 222 participants (Actual)Interventional2012-07-31Completed
Randomized Phase I Study of Trimetrexate Glucuronate (TMTX) With Leucovorin (LCV) Protection Plus Dapsone Versus Trimethoprim / Sulfamethoxazole (TMP/SMX) for Treatment of Moderately Severe Episodes of Pneumocystis Carinii Pneumonia [NCT00002120]Phase 120 participants InterventionalCompleted
AUTOLOGOUS, ALLOGENEIC, OR SYNGENEIC BONE MARROW TRANSPLANTATION IN HODGKIN'S DISEASE, NON-HODGKIN'S LYMPHOMA, AND MULTIPLE MYELOMA [NCT00002552]Phase 240 participants (Anticipated)Interventional1993-10-31Completed
A Phase III Study of Immediate Versus Delayed Chemotherapy for Asymptomatic Advanced Colorectal Cancer [NCT00002570]Phase 367 participants (Actual)Interventional1994-07-15Completed
Phase II Trial of Trimetrexate and Leucovorin in The Treatment of Recurrent Childhood Acute Lymphoblastic Leukemia [NCT00002738]Phase 225 participants (Anticipated)Interventional1996-01-31Completed
Steam (Sequencing Triplet With Avastin and Maintenance): FOLFOXIRI/Bevacizumab Regimens (Concurrent and Sequential) vs. FOLFOX/Bevacizumab in First-Line Metastatic Colorectal Cancer [NCT01765582]Phase 2280 participants (Actual)Interventional2013-01-23Terminated
A Study of Neutrexin (Trimetrexate Glucuronate) With Leucovorin Protection for Pediatric Patients (Ages 2-12) With Pneumocystis Carinii Pneumonia [NCT00002317]0 participants InterventionalCompleted
A Phase I Trial of 5-Fluorouracil Given With 776C85 (GW776) and Low-Dose Leucovorin in Adult Patients With Solid Tumors [NCT00001579]Phase 150 participants Interventional1997-06-30Completed
Postoperative Evaluation of 5-FU by Bolus Injection vs. 5-FU by Prolonged Venous Infusion Prior to and Following Combined Prolonged Venous Infusion Plus Pelvic XRT vs. Bolus 5-FU Plus Leucovorin Plus Levamisole Prior to and Following Combined Pelvic XRT P [NCT00002551]Phase 31,917 participants (Actual)Interventional1994-03-31Completed
EXTRAMEDULLARY RELAPSE AND OCCULT BONE MARROW INVOLVEMENT IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA: A PHASE III GROUP-WIDE STUDY [NCT00002816]Phase 3120 participants (Anticipated)Interventional1996-12-31Completed
PROTOCOL FOR THE MANAGEMENT OF MYCOSIS FUNGOIDES AND THE SEZARY SYNDROME [NCT00002557]Phase 23 participants (Anticipated)Interventional1993-06-30Active, not recruiting
A Randomised Trial Comparing Pre-Operative Radiotherapy and Selective Post-Operative Chemoradiotherapy in Rectal Cancer [NCT00003422]Phase 31,800 participants (Anticipated)Interventional1998-01-31Completed
Phase III Randomized Trial of 5-FU/Leucovorin/Levamisole Versus 5-FU Continuous Infusion/Levamisole as Adjuvant Therapy for High-Risk Resectable Colon Cancer [NCT00002593]Phase 31,135 participants (Actual)Interventional1994-12-31Completed
Phase II Trial of Trimetrexate (Neutrexin), 5-Fluorouracil and Leucovorin in Metastatic Colorectal Cancer [NCT00003446]Phase 20 participants Interventional1997-12-31Completed
A Phase I Study of Continuous Oral Administration of SCH 66336 and 5-Fluorouracil/Leucovorin (5FU/LV) in Patients With Advanced Cancer [NCT00003956]Phase 125 participants (Anticipated)Interventional1999-04-30Completed
Multicentre Phase III Comparing To Therapeutic Sequence: Folfiri Following of Folfox6 (Group A) and Folfox6 Following Of (Group B) For Metastatic Colorectal Cancer [NCT00003260]Phase 3109 participants (Anticipated)Interventional1998-01-31Active, not recruiting
TREATMENT OF ADULT ACUTE LYMPHOBLASTIC LEUKEMIA: PHASE II TRIALS OF AN INDUCTION REGIMEN INCLUDING PEG-L-ASPARAGINASE, WITH OR WITHOUT PIXY, IN PREVIOUSLY UNTREATED PATIENTS, FOLLOWED BY ALLOGENEIC BONE MARROW TRANSPLANTATION OR FURTHER CHEMOTHERAPY IN FI [NCT00002665]Phase 250 participants (Anticipated)Interventional1995-07-31Completed
The Value of Dexamethasone Versus Prednisolone During Induction and Maintenance Therapy of Prolonged Versus Conventional Duration of L-Asparaginase Therapy During Consolidation and Late Intensification, and of Corticosteroid + VCR Pulses During Maintenanc [NCT00003728]Phase 31,500 participants (Anticipated)Interventional1998-12-31Active, not recruiting
A Phase II Study of Cetuximab Plus P-HDFL (Cisplatin and Weekly 24-Hour Infusion of High-Dose 5-Fluorouracil and Leucovorin) for the First-Line Treatment of Advanced Gastric Cancer [NCT00384878]Phase 235 participants (Anticipated)Interventional2006-06-30Recruiting
A Randomized Phase III Equivalence Trial of Irinotecan (CPT-11) Versus Oxaliplatin (OXAL)/5-Fluorouracil (5-FU)/Leucovorin (CF) in Patients With Advanced Colorectal Carcinoma Previously Treated With 5-FU [NCT00005036]Phase 3560 participants (Actual)Interventional1999-11-30Completed
A 24-Week Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose Finding Study to Evaluate the Efficacy and Safety of 3 Doses of Namilumab (20 mg, 80 mg and 150 mg) in Combination With Methotrexate (MTX) in Subjects With Moderate to Severe Rheumatoid [NCT02379091]Phase 2108 participants (Actual)Interventional2014-12-17Completed
A Phase III Trial Comparing UFT+PSK to UFT+LV in Stage IIB, III Colorectal Cancer [NCT00385970]Phase 3380 participants (Anticipated)Interventional2006-03-31Active, not recruiting
Randomized Phase III Study of Preoperative Chemotherapy Followed by Surgery Versus Surgery Alone in Locally Advanced Gastric Cancer (cT3 and cT4NxM0) [NCT00004099]Phase 3144 participants (Actual)Interventional1999-07-31Terminated(stopped due to low accrual)
Phase I Study of Preoperative Radiation Therapy With Concurrent Protracted Continuous Infusion 5-FU and Dose Escalating Oxaliplatin Followed by Surgery, 5-FU, and Leucovorin for Locally Advanced (T3 and T4) Rectal Adenocarcinoma [NCT00003799]Phase 120 participants (Anticipated)Interventional1999-05-31Completed
Phase III Intergroup Trial of Irinotecan (CPT-11) (NSC# 616348) Plus Fluorouracil/Leucovorin (5-FU/LV) Versus Fluorouracil/Leucovorin Alone After Curative Resection for Patients With Stage III Colon Cancer [NCT00003835]Phase 31,260 participants (Anticipated)Interventional1999-05-31Completed
ChronoFOLFOX Plus Avastin for Patients With Metastatic Colorectal Cancer [NCT00385021]Phase 220 participants (Anticipated)Interventional2006-10-31Terminated
A Phase I Study of Low Dose Continuous Infusion Topotecan in Combination With 5-Fluorouracil and Leucovorin for Advanced Malignancies [NCT00003331]Phase 130 participants (Anticipated)Interventional1998-01-31Completed
CPT-11 in Combination With Weekly 24 Hour Infusion 5-FU Plus Folinic Acid Relative to Weekly 24 Hour Infusion 5-FU Plus Folinic Acid Alone in Patients With Advanced Colorectal Cancer [NCT00004885]Phase 3430 participants (Actual)Interventional1999-07-31Completed
Phase II Trial of Intensive, Short-Course Combination Chemotherapy in the Treatment of Newly Diagnosed Patients With Poor-Risk Nonlymphoblastic Lymphoma and Acute B-Lymphoblastic Leukemia and in Patients With Recurrent Non-Hodgkin's Lymphoma [NCT00002471]Phase 20 participants Interventional1990-02-28Completed
PROTOCOL FOR THE TREATMENT OF MALIGNANT NON-TESTICULAR GERM CELL TUMORS [NCT00002489]Phase 20 participants Interventional1991-10-31Completed
COordinated Nivolumab and IntraperiToneal IL-2 for Gastric CanceR With PeritOneaL Metastasis (CONTROL) Phase 1b Pilot Study [NCT05802056]Phase 115 participants (Anticipated)Interventional2023-11-29Recruiting
Modulation of 5-Fluorouracil With Trimetrexate and Leucovorin in Advanced Pancreatic Cancer [NCT00002955]Phase 221 participants (Actual)Interventional1995-08-31Completed
A Prospective Study of FOLFIRI Plus Panitumumab in Extended RAS Wild Type and BRAF Wild Type Metastatic Colorectal Cancer With Acquired Resistance to Prior Cetuximab (or Panitumumab) Plus Irinotecan-Based Therapy and Who Failed at Least One Subsequent Non [NCT02508077]Phase 21 participants (Actual)Interventional2016-02-16Terminated(stopped due to Poor Accrual)
Multicentric Phase II Trial: Evaluation of Efficacy and Safety of FOLFIRI Association Treatment in Patients 70 Years Old and More Presenting Gastric Cancer Locally Advanced or Metastatic [NCT00210184]Phase 242 participants (Actual)Interventional2004-07-21Completed
Perioperative RAMucirumab in Combination With FLOT Versus FLOT Alone for reSEctable eSophagogastric Adenocarcinoma - RAMSES - a Phase II/III Trial of the AIO [NCT02661971]Phase 2/Phase 3180 participants (Actual)Interventional2016-06-30Completed
A Pilot Study of Intravenous Ascorbic Acid and Folfirinox in the Treatment of Advanced Pancreatic Cancer [NCT02896907]Early Phase 18 participants (Actual)Interventional2016-10-18Completed
A Single-arm Exploratory Clinical Study of Conversion Treatment of Hepatic Arterial Infusion Chemotherapy Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma [NCT05099848]Phase 221 participants (Actual)Interventional2021-03-17Active, not recruiting
A Randomized, Double-blind, Single-dummy, Parallel-controlled, Multicentre, Phase III Clinical Study of Irinotecan Hydrochloride Liposome in Combination With 5-FU/LV as Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer After Treat [NCT05074589]Phase 3298 participants (Actual)Interventional2018-01-25Completed
Perioperative Versus Adjuvant FOLFIRINOX for Resectable Pancreatic Cancer: the PREOPANC-3 Study [NCT04927780]Phase 3378 participants (Anticipated)Interventional2021-09-07Recruiting
A Prospective Phase II Trial of Molecular Profiling to Guide Neoadjuvant Therapy for Resectable and Borderline Resectable Adenocarcinoma of the Pancreas [NCT01726582]Phase 2229 participants (Actual)Interventional2011-11-30Completed
A Phase 1, Two-part, Open-label, Drug-drug Interaction Study in Healthy Male Adult Participants to Evaluate the Effects of BMS-986371 on the Pharmacokinetics of Methotrexate in the Presence and Absence of Sulfasalazine [NCT05445440]Phase 130 participants (Actual)Interventional2022-09-06Completed
Precision Chemotherapy Based on Organoid for Colorectal CancerPatient-Derived Tumor Organoid Drug Sensitivity for Colorectal Cancer: A Prospective, Multicentre,Randomized, Controlled Trial [NCT05832398]186 participants (Anticipated)Interventional2023-05-01Recruiting
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotep [NCT00003273]Phase 20 participants (Actual)Interventional1997-11-30Withdrawn
Irinotecan and 5-Fluorouracil/Leucovorin for Patients With Colorectal Carcinoma and Other Refractory Tumors [NCT00004005]Phase 212 participants (Actual)Interventional1998-09-30Completed
A Phase II Study of PN-401, 5-FU and Leucovorin in Unresectable or Metastatic Adenocarcinoma of the Stomach [NCT00004233]Phase 265 participants (Actual)Interventional2001-02-28Completed
Phase IV Randomized Study of Pyrimethamine, Sulfadiazine, and Leucovorin Calcium for Congenital Toxoplasmosis [NCT00004317]Phase 4600 participants (Anticipated)Interventional2000-07-31Recruiting
ALinC 17: Continuous Intensification for Very High Risk Acute Lymphocytic Leukemia (A.L.L.): A Pediatric Oncology Group Pilot Study [NCT00003783]Phase 236 participants (Actual)Interventional1999-03-31Completed
A Phase II Study of CPT-11 and 5-FU/LCV in Patients With Previously Untreated Gastric Adenocarcinoma [NCT00005607]Phase 20 participants Interventional2000-02-29Active, not recruiting
FUDR/Oxaliplatin HAI Plus Irinotecan Chemotherapy vs. FOLFOXIRI Chemotherapy in Treating Initially Unresectable CRCLM [NCT03678428]Phase 392 participants (Actual)Interventional2021-12-31Terminated(stopped due to Production halt of FUDR in China)
Phase I/II Study of LY2090314 and Chemotherapy in Metastatic Pancreatic Cancer Patients With Metastases Amenable to Biopsy [NCT01632306]Phase 1/Phase 213 participants (Actual)Interventional2013-03-31Terminated(stopped due to Study has been terminated due to slow enrollment.)
A Phase II Clinical Trial Evaluating Overall Survival With Therasphere® In Conjunction With 2nd-Line FOLFOX In Patients With Gemcitabine-Refractory Pancreatic Carcinoma With Liver Metastases [NCT01581307]Phase 29 participants (Actual)Interventional2012-04-30Completed
Efficacy Assessment of Systematic Treatment With Folinic Acid and Thyroid Hormone on Psychomotor Development of Down Syndrome Young Children [NCT01576705]Phase 3175 participants (Actual)Interventional2012-04-02Completed
A Randomized Phase II Pilot Study Prospectively Evaluating Treatment for Patients Based on ERCC1(Excision Repair Cross-Complementing 1) for Advanced/Metastatic Esophageal, Gastric or Gastroesophageal Junction (GEJ) Cancer [NCT01498289]Phase 2213 participants (Actual)Interventional2012-02-29Completed
Pilot Study of Correlation Between Molecular Phenotype and Response to Two Independent Treatment Regimens, Carboplatin and Paclitaxel vs. 5-Fluorouracil and Oxaliplatin Chemotherapy in Patients With Localized Esophageal Adenocarcinoma [NCT02392377]Phase 21 participants (Actual)Interventional2015-02-28Terminated(stopped due to Slow accrual)
A Randomized, Multicenter, Parallel-group, Phase III Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal Cancer [NCT03750786]Phase 3490 participants (Actual)Interventional2018-12-18Completed
A Phase II Study of Neo-adjuvant Therapy With Oxaliplatin, Leucovorin, 5-Fluorouracil, Panitumumab (Vectibix) and Radiation in Patients With Locally Advanced Adenocarcinoma of the Esophagus or Gastroesophageal Junction [NCT01307956]Phase 211 participants (Actual)Interventional2011-02-28Terminated(stopped due to Drug manufacturer - Amgen requested study stop, per DSMB observation in POWER trial)
Systemic Chemotherapy With or Without Hepatic Arterial Infusion With Floxuridine in Patients With Initially Unresectable Colorectal Liver Metastasis: A Prospective, Randomised, Controlled Study [NCT02102789]Phase 3142 participants (Anticipated)Interventional2014-03-31Recruiting
A Multicenter, Single Arm, Open Label Clinical Trial Evaluating Safety and Health Related Quality of Life of Aflibercept in Combination With Irinotecan/5-FU Chemotherapy (FOLFIRI) in Patients With Metastatic Colorectal Cancer (mCRC) Previously Treated Wit [NCT01670721]Phase 3175 participants (Actual)Interventional2012-08-31Completed
Neoadjuvant Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer - A Norwegian Population Based Observational Study [NCT04423731]251 participants (Actual)Observational2018-01-01Active, not recruiting
Docetaxel, Oxaliplatin, Fluorouracil (FLOT Regimen) Combined With Teriprizumab (PD-1) in the First-line Treatment of Patients With Advanced Gastric Cancer and Peritoneal Metastasis: an Open, One-arm, Exploratory Study [NCT04886193]20 participants (Anticipated)Interventional2021-04-16Recruiting
Induction Intensification in Infant ALL: A Children's Oncology Group Study [NCT00002756]Phase 2221 participants (Actual)Interventional1996-06-30Completed
A Single-Arm, Phase II Study of Tarceva Plus FOLFOX6 in Patients With Unresectable or Metastatic Cancer of Esophagus or Gastroesophageal Junction [NCT00539617]Phase 27 participants (Actual)Interventional2007-10-05Terminated(stopped due to For slow accrual)
Open-label, Randomized, Multicenter, Phase II Trial to Compare Efficacy of CAPTEM Versus FOLFIRI as Second Line in Patients Progressed on or After First-line Oxaliplatin Chemo for Advanced, MGMT Methylated, RAS Mutated Colorectal Cancer [NCT02414009]Phase 282 participants (Actual)Interventional2014-09-30Completed
PRIMIER*: Randomized Phase II Trial of mFOLFOX6/Bevacizumab With or Without PRI-724 as First Line Treatment for Metastatic Colorectal Cancer [NCT02413853]Phase 20 participants (Actual)Interventional2015-11-30Withdrawn(stopped due to Study drug supply issues)
Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Infants Less Than 1 Year of Age. [NCT00002785]Phase 20 participants Interventional1996-07-31Completed
Chemotherapy and Azidothymidine, With or Without Radiotherapy, for High Grade Lymphoma in AIDS-Risk Group Members [NCT00000703]45 participants InterventionalCompleted
NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed on or After Chemotherapy and Anti-programmed Cell Death Protein 1 (PD-1)/Programmed Death Ligand 1 (PD-L1) Therapy [NCT03167177]Phase 1/Phase 20 participants (Actual)Interventional2017-12-31Withdrawn(stopped due to Trial not initiated)
MAVERICC (Marker Evaluation for Avastin Research in CRC): A Randomized Phase II Study of Bevacizumab+mFOLFOX6 Vs. Bevacizumab+FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer [NCT01374425]Phase 2376 participants (Actual)Interventional2011-08-31Completed
A Randomized Non-comparative Phase II Study of Maintenance Therapy With OSE2101 Plus FOLFIRI, or FOLFIRI After Induction Therapy With FOLFIRINOX in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (TEDOPaM-D17-01 PRODIGE 63 St [NCT03806309]Phase 2106 participants (Anticipated)Interventional2019-07-31Recruiting
Phase I/II Study of 5-Fluorouracil/Folinic Acid/Gemcitabine in Patients With Advanced Colorectal Carcinoma [NCT00003001]Phase 1/Phase 263 participants (Anticipated)Interventional1997-04-30Active, not recruiting
T-Cell Depletion for Graft-Versus-Host Disease (GVHD) Prevention in High Risk Matched and Mismatched Allogeneic Bone Marrow Transplantation [NCT00005641]Phase 20 participants Interventional1997-09-30Terminated(stopped due to low study accrual)
Phase II Study to Evaluate Postoperative Chemotherapy in High-Grade Appendiceal Adenocarcinoma With Peritoneal Carcinomatosis [NCT02420509]2 participants (Actual)Observational2015-08-27Terminated(stopped due to unable to accrue)
An Open-Label, Multicenter, Phase I/II Clinical Trial to Identify the Modufolin® Dose With Most Favorable Safety Prospect and Confirmed Ability to Mitigate High-Dose Methotrexate Induced Toxicity During Treatment of Osteosarcoma Patients [NCT01987102]Phase 1/Phase 218 participants (Actual)Interventional2013-12-31Completed
NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC [NCT03169777]Phase 1/Phase 20 participants (Actual)Interventional2018-08-31Withdrawn(stopped due to Trial not initiated)
A Multicenter, Randomized, Open-lable, Parallel-controlled, Phase II Study to Evaluate the Differences of Safety and Efficacy of Irinotecan Liposome Injection-containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated [NCT05047991]Phase 2153 participants (Anticipated)Interventional2021-10-31Not yet recruiting
MULTICENTRE TRIAL OF INTENSIFIED THERAPY FOR ADULT ALL (O5/93) [NCT00002531]Phase 20 participants Interventional1993-01-31Active, not recruiting
Lenvatinib Combined With Hepatic Arterial Infusion of Modified FOLFOX Regimen Versus Lenvatinib Combined With Hepatic Arterial Infusion of ROX Regimen in the Treatment of Advanced Hepatocellular Carcinoma [NCT05007587]Early Phase 160 participants (Anticipated)Interventional2021-07-01Enrolling by invitation
Randomized Phase II Selection Study of Ramucirumab and Paclitaxel Versus FOLFIRI in Refractory Small Bowel Adenocarcinoma [NCT04205968]Phase 294 participants (Anticipated)Interventional2020-06-01Recruiting
A Single Arm Phase Ib/II Multi-Center Study of Nivolumab in Combination With Nanoliposomal-Irinotecan, 5-Fluorouracil, and Leucovorin as Second Line Therapy for Patients With Advanced Biliary Tract Cancer [NCT03785873]Phase 1/Phase 234 participants (Actual)Interventional2019-05-22Active, not recruiting
Phase I Study of Escalated Pharmacologic Dose, of Oral Folinic Acid in Combination With Temozolomide, According to Stupp R. Regimen, in Patients With Operated Grade-IV Astocytoma and a Non-methylated Gene Status of MGMT. [NCT01700569]Phase 124 participants (Actual)Interventional2013-01-31Terminated(stopped due to changing the standard of care)
A Randomized Phase II Trial of R-HCVAD/MTX/ARA-C Induction Followed by Consolidation With an Autologous Stem Cell Transplant Vs. R-Bendamustine Induction Followed by Consolidation With an Autologous Stem Cell Transplant for Patients ≤ 65 Years of Age With [NCT01412879]Phase 253 participants (Actual)Interventional2011-11-30Completed
Impact of Tumor and Stromal Subtypes on Efficacy of Neoadjuvant FOLFIRINOX in Subjects With Non-Metastatic Pancreatic Cancer [NCT03977233]Phase 245 participants (Anticipated)Interventional2019-06-12Recruiting
A Phase Ib Study to Evaluate Tolerability, Safety and Pharmacokinetics of Irinotecan Hydrochloride Liposome Injection in Combination With 5-FU/LV in Patients With Advanced Solid Tumors [NCT05086848]Phase 115 participants (Actual)Interventional2016-05-05Completed
MASTERPLAN: A Randomised Phase II Study of MFOLFIRINOX And Stereotactic Radiotherapy (SBRT) for Pancreatic Cancer With High Risk and Locally Advanced Disease [NCT04089150]Phase 2120 participants (Anticipated)Interventional2019-10-01Recruiting
A Multicenter Phase II Study in Adults With Untreated Acute Lymphoblastic Leukemia: Testing Pharmacokinetically Individualized Doses of L-Asparaginase Following the DFCI Pediatric Consortium Protocol [NCT00136435]Phase 2100 participants (Anticipated)Interventional2002-06-30Active, not recruiting
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Concomitant Systemic Oxaliplatin, Fluorouracil and Leucovorin Chemotherapy, and Anti-Angiogenic Therapy [NCT00932438]Phase 1/Phase 270 participants (Actual)Interventional2009-06-30Completed
A Randomized, Double Blind Placebo Controlled Phase 2 Study of FOLFOX Plus or Minus GDC-0449 in Patients With Advanced Gastric and Gastroesophageal Junction (GEJ) Carcinoma [NCT00982592]Phase 2124 participants (Actual)Interventional2009-09-30Completed
Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I [NCT02553460]Phase 1/Phase 250 participants (Actual)Interventional2016-01-29Active, not recruiting
A Phase II Study of Intrathecal and Systemic Chemotherapy With Radiation Therapy for Children With Central Nervous System Atypical Teratoid/Rhabdoid Tumor (AT/RT) Tumor [NCT00084838]Phase 225 participants (Actual)Interventional2003-02-28Completed
LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma [NCT03684980]Early Phase 144 participants (Anticipated)Interventional2018-11-14Recruiting
Front-line Combination Therapy of Sunitinib Malate Plus Chemotherapy With Leucovorin/5-Fluorouracil and Irinotecan (FOLFIRI) for Rectal Cancer Patients With Synchronous Non-Resectable Metastases: A Phase II Non Controlled Study. (SUREMETS) [NCT00936832]Phase 20 participants (Actual)Interventional2009-04-30Withdrawn(stopped due to because the sunitinib showed futility in anotehr trial)
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma That Has Progressed Following a First Line Oxal [NCT01479465]Phase 2266 participants (Actual)Interventional2011-12-31Terminated
Cetuximab and Envafolimab Plus mFOLFOXIRI Versus Cetuximab Plus mFOLFOX6/FOLFIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancer: A Randomized Controlled Phase II Trial (CEIL) [NCT05959356]Phase 2198 participants (Anticipated)Interventional2023-11-09Active, not recruiting
A Phase II, Prospective, Multicenter Study of Cadonilimab in Combination With FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer. [NCT05839470]Phase 220 participants (Anticipated)Interventional2023-11-19Recruiting
A Phase II Trial of Perioperative Chemotherapy With Leucovorin, Oxaliplatin, Docetaxel and S-1 (LOTS) For Patients With Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma [NCT04999332]Phase 258 participants (Anticipated)Interventional2021-12-10Recruiting
An Open-Label Phase 1/2 Multi-Arm Study of DS-1594b as a Single-Agent and in Combination With Azacitidine and Venetoclax or Mini-HCVD for the Treatment of Patients With Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) [NCT04752163]Phase 1/Phase 217 participants (Actual)Interventional2021-03-25Completed
NeoOPTIMIZE: An Open-Label, Phase II Trial to Assess the Efficacy of Adaptive Switching of FOLFIRINOX or Gemcitabine/Nab-Paclitaxel as a Neoadjuvant Strategy for Patients With Resectable and Borderline Resectable/Locally Advanced Unresectable Pancreatic C [NCT04539808]Phase 260 participants (Anticipated)Interventional2021-05-27Recruiting
A Randomised Study to Assess the Efficacy of Cetuximab Rechallenge in Patients With Metastatic Colorectal Cancer (RAS Wild-type) Responding to First-line Treatment With FOLFIRI Plus Cetuximab [NCT02934529]Phase 3673 participants (Actual)Interventional2015-03-31Active, not recruiting
A Phase 3 Study of BBI-608 in Combination With 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients With Previously Treated Metastatic Colorectal Cancer (CRC). [NCT02753127]Phase 31,253 participants (Actual)Interventional2016-06-30Completed
A Phase Ib/II Clinical Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer [NCT02024607]Phase 1/Phase 2495 participants (Actual)Interventional2014-01-31Completed
A Multi-Center, Trial to Evaluate the Efficacy & Tolerability of Aprepitant and Palonosetron for the Prevention of CINV in Colorectal Cancer (CRC) Patients Receiving FOLFOX [NCT00381862]Phase 254 participants (Actual)Interventional2006-06-30Completed
A Phase I, Randomised, Open-Label, Single-Dose, Two-Treatment, Two-Way Crossover, Two-Stage Study to Evaluate the Bioequivalence of Onivyde (Irinotecan Liposome Injection) Manufactured at Two Different Sites Administered in Combination With Anti-Cancer Ag [NCT05383352]Phase 1122 participants (Anticipated)Interventional2022-05-30Recruiting
A Phase 2, Multicenter, Open-Label Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy as First-Line or Second-Line Therapy in Adult Patients With Inoperable, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma ( [NCT04363801]Phase 2232 participants (Anticipated)Interventional2020-07-29Recruiting
NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy Combining Innate High-affinity Natural Killer (haNK) Cell Therapy With Adenoviral and Yeast-based Vaccines to Induce T-cell Responses in Subjects With TNBC Wh [NCT03387085]Phase 1/Phase 279 participants (Anticipated)Interventional2018-03-16Active, not recruiting
A Phase 1b Multi-cohort Study of the Combination of Pembrolizumab (MK-3475) Plus Binimetinib Alone or the Combination of Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Participants With Metastatic Colorectal Cancer (KEYNOTE-651) [NCT03374254]Phase 1114 participants (Actual)Interventional2018-02-16Completed
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations [NCT02883049]Phase 35,937 participants (Actual)Interventional2012-02-29Active, not recruiting
A Phase II Study Of Neo-Adjuvant Chemotherapy And Radiation In Patients With Locally Advanced Pancreatic Cancer [NCT00089024]Phase 229 participants (Actual)Interventional2004-02-25Completed
A Phase 2 Study of RO4929097 (NSC 749225) in Combination With FOLFOX Plus Bevacizumab Versus FOLFOX Plus Bevacizumab Alone for the First-Line Treatment of Patients With Metastatic Colorectal Cancer (NCI #8467) [NCT01270438]Phase 20 participants (Actual)Interventional2010-12-31Withdrawn
QUILT-3.080: Phase 1B/2 Trial Of The NANT Pancreatic Cancer Vaccine As Treatment For Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-Of-Care Therapy [NCT03586869]Phase 1/Phase 2173 participants (Anticipated)Interventional2018-07-28Active, not recruiting
A Phase II Study of Neoadjuvant FOLFIRINOX in Patients With Resectable Pancreatic Ductal Adenocarcinoma With Tissue Collection [NCT02178709]Phase 248 participants (Actual)Interventional2014-06-03Completed
Phase II Study of FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer [NCT01913639]Phase 239 participants (Actual)Interventional2013-07-31Completed
A Single-Blind, Randomized Phase I/II Study of Pharmacokinetic and Pharmacodynamic Investigation of Modufolin® (60 or 200mg/m2) Compared to Levoleucovorin (60 or 200mg/m2) in Tumor, Adjacent Mucosa and Plasma for Patients With Colon Cancer [NCT01681472]Phase 1/Phase 232 participants (Actual)Interventional2012-09-30Completed
A Randomized International Phase 3 Trial of Imatinib and Chemotherapy With or Without Blinatumomab in Patients With Newly-Diagnosed Philadelphia Chromosome-Positive or Philadelphia Chromosome-Like ABL-Class B-Cell Acute Lymphoblastic Leukemia [NCT06124157]Phase 3680 participants (Anticipated)Interventional2024-01-22Not yet recruiting
A Phase 1 Study of NBTXR3 Activated by Radiotherapy With Concurrent Chemotherapy for Adenocarcinoma of the Esophagus [NCT04615013]Phase 124 participants (Anticipated)Interventional2020-11-23Recruiting
An Open-label, Multicentre, Phase II Study to Evaluate the Safety and Efficacy of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer [NCT05009953]Phase 266 participants (Anticipated)Interventional2021-09-30Not yet recruiting
A Phase I, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumors [NCT05647122]Phase 1108 participants (Anticipated)Interventional2022-12-22Recruiting
A Prospective, Randomised, Controlled, Open-label, Multicentre Study to Evaluate Efficacy, Safety and Patient-Reported Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-Edotreotide Compared to Best Standard of Care in Patients With Well- [NCT04919226]Phase 3202 participants (Anticipated)Interventional2021-12-21Recruiting
A Phase I Study of the NovoTTF-100L(P) System to Enhance Antitumor Activity in Patients With Predominant Hepatic Metastatic Cancer [NCT03203525]Phase 152 participants (Anticipated)Interventional2020-06-23Recruiting
PHASE I TRIAL OF POST-OPERATIVE COMBINED ORAL UFT PLUS LEUCOVORIN AND RADIATION THERAPY FOR RECTAL CANCER [NCT00002801]Phase 130 participants (Anticipated)Interventional1996-04-30Completed
Standard Chemotherapy (CHOP Regimen) Versus Sequential High-Dose Chemotherapy With Autologous Stem Cell Transplantation in Patients With Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas and Poor Prognostic Factors: A Randomized Phase III Study (MISTRAL) [NCT00003215]Phase 3400 participants (Anticipated)Interventional1997-04-30Completed
First Line Infusional 5-Fluorouracil, Folinic Acid and Oxaliplatin for Metastatic Colorectal Cancer or Loco-Regional Recurrency - Role of Chronomodulated Delivery Upon Survival - A Multicenter Randomized Phase III Trial [NCT00003287]Phase 3554 participants (Anticipated)Interventional1998-03-31Completed
A Phase II Trial of Aminopterin in Adults and Children With Refractory Acute Leukemia Grant Application Title: A Phase II Trial of Aminopterin in Acute Leukemia [NCT00003305]Phase 275 participants (Anticipated)Interventional1997-07-31Completed
The Experimental Treatment of Transfusion Dependent 5q Minus Syndrome With Leucovorin [NCT00004997]Phase 214 participants Interventional1998-04-30Completed
ALINC #17 Treatment for Patients With Low Risk Acute Lymphoblastic Leukemia: A Pediatric Oncology Group Phase III Study [NCT00005585]Phase 3838 participants (Actual)Interventional2000-04-30Completed
Development of a Novel Folic Acid Wound Dressing to Enhance Nitric Oxide Bioactivity Required for Diabetic Foot Ulcer Wound Healing [NCT04723134]Phase 230 participants (Anticipated)Interventional2021-12-01Recruiting
Protocol for Patients With Newly Diagnosed Better Risk Acute Lymphoblastic Leukemia (ALL): A POG Pilot Study [NCT00003671]Phase 259 participants (Actual)Interventional1998-12-31Completed
Study of Sequential Administration of Oral 6-Thioguanine After Methotrexate in Patients With Langerhans Cell in Histiocytosis (LCH) [NCT00588536]Phase 25 participants (Actual)Interventional1995-01-31Completed
Investigation of Association Between UGT1A1 Polymorphisms and Irinotecan Toxicity in Korean Patients With Advanced Colorectal or Gastric Cancer Treated With FOLFIRI Regimen [NCT01271582]Phase 41,500 participants (Anticipated)Interventional2009-01-31Active, not recruiting
A Multicenter Phase 1 Study of Intravenous Administration of REOLYSIN® (Reovirus Type 3 Dearing) in Combination With Irinotecan/Fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer [NCT01274624]Phase 136 participants (Actual)Interventional2010-12-31Completed
An Open Label, Multicenter, Phase 2 Study Evaluating the Safety and Efficacy of IMC-1121B in Combination With 5-FU/FA and Oxaliplatin (Modified FOLFOX-6) as First-line Therapy in Patients With Metastatic Colorectal Cancer [NCT00862784]Phase 248 participants (Actual)Interventional2009-04-30Completed
A Phase I Study of Cytosine Deaminase-Expressing Neural Stem Cells in Combination With Oral 5-Fluorocytosine and Leucovorin for the Treatment of Recurrent High-Grade Gliomas [NCT02015819]Phase 116 participants (Actual)Interventional2014-10-07Completed
Adjuvant Hyperthermic Intraperitoneal Chemotherapy in Patients With Colon Cancer at High Risk of Peritoneal Carcinomatosis [NCT02231086]Phase 3204 participants (Actual)Interventional2015-03-31Completed
A Randomized Phase II Study to Investigate the Deepness of Response of FOLFOXIRI Plus Cetuximab (Erbitux) Versus FOLFOXIRI Plus Bevacizumab as the First-line Therapy in Metastatic Colorectal Cancer Patients With RAS Wild-type Tumors: DEEPER [NCT02515734]Phase 2360 participants (Anticipated)Interventional2015-08-31Not yet recruiting
A Prospective, Multi-centric, Phase Ⅲ, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Second-Line Adjuvant Therapy With Nab-Paclitaxel Plus Gemcitabine (AG) Versus Oxaliplatin Plus Folinic Acid and Fluorouracil (OFF) for Gemcitabine-R [NCT02506842]Phase 3300 participants (Anticipated)Interventional2015-06-30Recruiting
Phase II Study of AVELUMAB and CETUXIMAB and Modified FOLFOXIRI as Initial Therapy for RAS Wild-type Unresectable Metastatic Colorectal Cancer Patients [NCT04513951]Phase 258 participants (Anticipated)Interventional2020-04-01Active, not recruiting
Safety and Efficacy of Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Ovarian, Uterine, Appendiceal, Colorectal, and Gastric Cancer Patients With Peritoneal Carcinomatosis (PC) [NCT04329494]Phase 149 participants (Anticipated)Interventional2020-08-21Recruiting
Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer (SOLARIS) [NCT04094688]Phase 3455 participants (Actual)Interventional2019-09-30Active, not recruiting
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy [NCT03959085]Phase 34,772 participants (Anticipated)Interventional2019-10-31Recruiting
Genotype-Directed Phase II Study Of Higher Dose Of Irinotecan In First-Line Metastatic Colorectal Cancer Patients Treated With Folfiri Plus Bevacizumab [NCT02138617]Phase 2100 participants (Actual)Interventional2014-05-31Active, not recruiting
Mature B-Cell Lymphoma And Leukemia Study III [NCT01046825]Phase 2/Phase 3128 participants (Actual)Interventional2010-09-09Active, not recruiting
Phase II Trial of Sorafenib in Combination With Modified FOLFOX in Patients With Advanced Hepatocellular Carcinoma [NCT01775501]Phase 240 participants (Actual)Interventional2013-01-31Completed
Phase II Study of FOLFIRINOX Chemotherapy for Treatment of Advanced Gastric, Gastro-esophageal Junction, and Esophageal Tumors [NCT01928290]Phase 267 participants (Actual)Interventional2013-11-08Completed
Phase II Trial Of Neoadjuvant Bevacizumab With Modified FOLFOX7 In Patients With Stage II And III Rectal Cancer [NCT01871571]Phase 217 participants (Actual)Interventional2013-08-02Active, not recruiting
Phase I / II Dose Escalation of Oxaliplatin Via a Laparoscopic Approach of Aerosol Pressurized Intraperitoneal Chemotherapy for Nonresectable Peritoneal Metastases of Digestive Cancers (Stomach, Hail and Colorectal) [NCT03294252]Phase 1/Phase 234 participants (Actual)Interventional2017-05-24Terminated(stopped due to The 34 patients included had all completed their treatment period under the protocol and the data could be collected to assess the main objective and the secondary objectives before the last theoretical follow-up.)
Open Label Randomized Bioequivalence Study to Evaluate the Pharmacokinetic and Safety Profile of Bevacizumab Biosimilar (BEVZ92) vs Bevacizumab (AVASTIN®), Both With FOLFOX or FOLFIRI, in First-line Treatment for mCRC Patients [NCT02069704]Phase 1142 participants (Actual)Interventional2014-10-29Completed
Effects of BMS-986142 on the Single-dose Pharmacokinetics of Methotrexate and Probe Substrates Montelukast (CYP2C8), Flurbiprofen (CYP2C9), Midazolam (CYP3A4), Digoxin (P-gp), and Pravastatin (OATP1B1) in Healthy Subjects [NCT02456844]Phase 124 participants (Actual)Interventional2015-05-31Completed
The Janus Rectal Cancer Trial: A Randomized Phase II Trial Testing The Efficacy of Triplet Versus Doublet Chemotherapy to Achieve Clinical Complete Response in Patients With Locally Advanced Rectal Cancer [NCT05610163]Phase 2312 participants (Anticipated)Interventional2022-12-08Recruiting
A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer [NCT04340141]Phase 3352 participants (Anticipated)Interventional2020-07-01Recruiting
A Phase III, Randomized, Controlled Study of mFOLFOX6 + Bevacizumab Combination Therapy Versus mFOLFOX6 + Panitumumab Combination Therapy in Chemotherapy-naive Patients With KRAS/NRAS Wild-type, Incurable/Unresectable, Advanced/Recurrent Colorectal Cancer [NCT02394795]Phase 3823 participants (Actual)Interventional2015-05-29Completed
A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating The Efficacy And Safety Of Onartuzumab (MetMAb) In Combination With 5-Fluorouracil, Folinic Acid, And Oxaliplatin (mFOLFOX6) In Patients With Metastatic HER2-Negative G [NCT01590719]Phase 2123 participants (Actual)Interventional2012-07-31Completed
A Randomized, Double-Blind, Phase II Trial of CT-322 (BMS-844203) Plus Irinotecan, 5-FU and Leucovorin (FOLFIRI) Versus Bevacizumab Plus FOLFIRI as Second-Line Treatment for Metastatic Colorectal Cancer [NCT00851045]Phase 217 participants (Actual)Interventional2009-10-31Completed
Phase I Study of Ursodeoxycholic Acid (Ursodiol)in Combination With 5-Fluorouracil, Leucovorin, Oxaliplatin and Bevacizumab in Patients With Metastatic Colorectal Cancer [NCT00873275]Phase 111 participants (Actual)Interventional2009-03-11Active, not recruiting
"A Phase II Study of Liposomial IrinoTecan (Nal-IRI) With 5-Fluorouracil, Levofolinic Acid and Oxaliplatin in Patients With Resectable Pancreatic Cancer nITRo Trial" [NCT03528785]Phase 267 participants (Anticipated)Interventional2018-03-02Recruiting
FOLFOX + Immunotherapy With Intrahepatic Administration of Oxaliplatin for Patients With Multiple Non-resectable Liver Metastasis From Colorectal Cancer [NCT04430985]Phase 20 participants (Actual)Interventional2020-09-30Withdrawn(stopped due to Problems identifying eligble patients)
Efficacy of Adjuvant Chemotherapy in Patients With Clinical Stage III Rectal Cancer Undergoing Neoadjuvant Chemoradiotherapy: A Pathology-oriented, Prospective, Multicenter, Randomized, Open-label, Parallel Group Clinical Trial [NCT03415763]Phase 3764 participants (Anticipated)Interventional2018-11-05Recruiting
International Protocol for the Treatment of Childhood Anaplastic Large Cell Lymphoma [NCT00006455]Phase 3885 participants (Actual)Interventional1999-11-26Completed
A Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Napabucasin Protocols [NCT04299880]Phase 17 participants (Actual)Interventional2020-02-24Completed
An Open-Label, Multicenter, Randomized Phase Ib/II Study of FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer [NCT01133990]Phase 1/Phase 25 participants (Actual)Interventional2010-03-04Terminated(stopped due to The study was terminated early as the combination of E7820 and FOLFIRI was deemed to be not tolerable, hence no efficacy analysis was conducted.)
A Randomized, Double-Masked and Placebo-Controlled Study to Evaluate the Efficacy and Safety of Sarilumab Administered Subcutaneously Every 2 Weeks in Patients With Non-Infectious, Intermediate, Posterior or Pan-Uveitis (NIU) [NCT01900431]Phase 258 participants (Actual)Interventional2013-10-31Completed
A Phase II Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC) [NCT01490866]Phase 270 participants (Actual)Interventional2012-01-31Completed
Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) Vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer [NCT02042443]Phase 253 participants (Actual)Interventional2014-02-28Completed
Phase II Feasibility Study of FOLFIRINOX-Losartan Followed by Accelerated Short Course Radiation Therapy With Capecitabine for Locally Advanced Pancreatic Cancer [NCT01821729]Phase 250 participants (Actual)Interventional2013-07-31Active, not recruiting
Phase II Study of Chemotherapy (Doxorubicin, Methotrexate and Leucovorin) in Combination With Antiviral-Based Therapy (Zidovudine + Hydroxyurea) for AIDS, Immunocompromised, or Immunocompetent Patients With Relapsed or CNS Positive Epstein Barr Virus Asso [NCT01964755]Phase 26 participants (Actual)Interventional2009-04-21Terminated(stopped due to Investigator Decision)
mFOLFOX6 vs. mFOLFOX6 + Aflibercept as Neoadjuvant Treatment in MRI-defined T3-rectal Cancer: a Randomized Phase-II-trial [NCT03043729]Phase 2119 participants (Actual)Interventional2017-03-06Completed
Tocotrienol and Bevacizumab in Metastatic Colorectal Cancer. A Randomized Phase II Marker Trial [NCT04245865]Phase 274 participants (Anticipated)Interventional2020-06-26Recruiting
A Pilot Study of Home Parenteral Nutrition for Malnourished Patients With Unresectable Stage IV Gastric Receiving Salvage Chemotherapy [NCT03121807]25 participants (Actual)Interventional2014-09-01Completed
First-line FOLFOX-4 Plus Panitumumab Followed by 5-FU/LV Plus Panitumumab or Single-agent Panitumumab as Maintenance Therapy in Patients With RAS Wild-type, Metastatic Colorectal Cancer: the VALENTINO Study [NCT02476045]Phase 2224 participants (Anticipated)Interventional2015-06-30Recruiting
FOLFOX Via Hepatic Artery Infusion Chemotherapy (HAI) Plus Systemic Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Patients With Initially Unresectable RAS-mutated Colorectal Cancer With Liver Metastases: A [NCT05727163]Phase 2194 participants (Anticipated)Interventional2022-07-29Recruiting
A Randomized Controlled Study on the Effect of Postoperative Adjuvant Chemotherapy With FOLFOX4 After Hepatocarcinoma Resection Based on Folate Receptor-positive Circulating Tumor Cells [NCT04521491]184 participants (Anticipated)Interventional2020-12-01Not yet recruiting
BrUOG 292: FOLFOX-A For Metastatic Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial [NCT02080221]Phase 250 participants (Actual)Interventional2014-08-31Completed
Phase II Trial of FOLFOXIRI + Bevacizumab in Patients With Untreated Metastatic Colorectal Cancer [NCT02497157]Phase 245 participants (Anticipated)Interventional2015-05-21Completed
A Phase II Study of Neoadjuvant Chemotherapy With and Without Immunotherapy to CA125 (Oregovomab) Followed by Hypofractionated Stereotactic Radiotherapy & Concurrent HIV Protease Inhibitor Nelfinavir in Locally Advanced Pancreatic Cancer [NCT01959672]Phase 211 participants (Actual)Interventional2013-09-06Completed
A Study of Preoperative FOLFIRINOX For Potentially Curable Pancreatic Cancer [NCT03167112]Phase 220 participants (Anticipated)Interventional2017-07-03Recruiting
Induction FOLFOX With or Without Aflibercept Followed by Chemoradiation in High Risk Locally Advanced Rectal Cancer. Phase II Randomized, Multicenter, Open Label Trial [NCT02340949]Phase 2180 participants (Actual)Interventional2015-01-31Completed
A Phase II, Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of RO5520985 (Vanucizumab) Plus FOLFOX Versus Bevacizumab Plus FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer [NCT02141295]Phase 2197 participants (Actual)Interventional2014-06-30Terminated
An Australian Translational Study to Evaluate the Prognostic Role of Inflammatory Markers in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab (Avastin™) [NCT01588990]Phase 4128 participants (Actual)Interventional2012-06-26Completed
A Study to Evaluate the Potential of Concomitant Ramucirumab to Affect the Pharmacokinetics of Irinotecan and Its Metabolite SN-38 When Coadministered With Folinic Acid and 5 Fluorouracil in Patients With Advanced Malignant Solid Tumors [NCT01634555]Phase 229 participants (Actual)Interventional2012-10-31Completed
Randomized, Double-Blind, Phase II Trial of Vitamin D Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer [NCT01516216]Phase 2139 participants (Actual)Interventional2012-04-13Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00002525 (4) [back to overview]5-year Overall Survival Rate in Patients With Dukes' B3/C Disease
NCT00002525 (4) [back to overview]5-year Disease-free Survival Rate in Patients With Dukes' B3/C Disease
NCT00002525 (4) [back to overview]5-year Disease-free Survival Rate in Patients With Dukes' B2 Disease
NCT00002525 (4) [back to overview]5-year Overall Survival Rate in Patients With Dukes' B2 Disease
NCT00002842 (1) [back to overview]2 Year Disease-free Survival .
NCT00003298 (4) [back to overview]Best Confirmed Response to Neoadjuvant Therapy
NCT00003298 (4) [back to overview]Progression Free Survival
NCT00003298 (4) [back to overview]Overall Survival
NCT00003298 (4) [back to overview]Grade 3 or Higher Toxicity Incidence on Step 1
NCT00004228 (2) [back to overview]Percentage of Patients With Overall Survival as Assessed by Time to Death
NCT00004228 (2) [back to overview]Event-free Survival
NCT00009737 (6) [back to overview]Number of Participants With Any Adverse Events and Serious Adverse Events
NCT00009737 (6) [back to overview]Overall Survival
NCT00009737 (6) [back to overview]Mean Change From Baseline in Global Health Status at Week 25
NCT00009737 (6) [back to overview]Disease-free Survival
NCT00009737 (6) [back to overview]Relapse-Free Survival
NCT00009737 (6) [back to overview]Number of Participants With Abnormalities for Blood Chemistry and Hematological Parameters
NCT00039130 (3) [back to overview]2 Year Event Free Survival
NCT00039130 (3) [back to overview]2 Year Overall Survival
NCT00039130 (3) [back to overview]Complete Response Rate
NCT00039377 (5) [back to overview]Number of Participants Who Achieved a BCR-ABL Response at 12 Months
NCT00039377 (5) [back to overview]Overall Survival
NCT00039377 (5) [back to overview]Disease Free Survival
NCT00039377 (5) [back to overview]5 Year Overall Survival for Autologous & Allogeneic Transplant Groups
NCT00039377 (5) [back to overview]5 Year Disease-free Survival for Autologous & Allogeneic Transplant Groups
NCT00041132 (3) [back to overview]Response
NCT00041132 (3) [back to overview]Progression-free Survival
NCT00041132 (3) [back to overview]Overall Survival
NCT00052910 (2) [back to overview]Overall Survival
NCT00052910 (2) [back to overview]Disease Free Survival
NCT00057811 (4) [back to overview]Response Rate
NCT00057811 (4) [back to overview]Minimal Residual Disease
NCT00057811 (4) [back to overview]Grade ≥ 3 Stomatitis
NCT00057811 (4) [back to overview]Toxic Death
NCT00061945 (6) [back to overview]Disease-free Survival, for Only Complete Response Patients
NCT00061945 (6) [back to overview]Overall Survival
NCT00061945 (6) [back to overview]Number of Participants Who Proceed to Course V Within 2-6 Weeks of the Last Dose of Alemtuzumab (Phase II)
NCT00061945 (6) [back to overview]Minimal Residual Disease (MRD) During Treatment With Alemtuzumab (Phase II)
NCT00061945 (6) [back to overview]Maximum Tolerated Dose (MTD) of Alemtuzumab (Phase I)
NCT00061945 (6) [back to overview]Number of Participants Achieving Complete Remission
NCT00068692 (4) [back to overview]Proportion of Sphincter Preservation
NCT00068692 (4) [back to overview]Failure Pattern
NCT00068692 (4) [back to overview]3-year Overall Survival Rate
NCT00068692 (4) [back to overview]3-year Disease Free Survival
NCT00069095 (22) [back to overview]PFS as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) by General Approach (Participants With Curative Surgery Censored) - Superiority of Chemotherapy Plus BV Over Chemotherapy Alone
NCT00069095 (22) [back to overview]PFS as Assessed by the Independent Review Committee (IRC) (General Approach, Participants With Curative Surgery Censored) - Superiority of Chemotherapy Plus BV Over Chemotherapy Alone
NCT00069095 (22) [back to overview]PFS as Assessed by the Independent Review Committee (IRC) (General Approach, Participants With Curative Surgery Censored) - Non-inferiority of XELOX Versus FOLFOX-4
NCT00069095 (22) [back to overview]PFS (On-treatment Approach): Non-inferiority of XELOX Versus FOLFOX-4
NCT00069095 (22) [back to overview]Overall Survival: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone
NCT00069095 (22) [back to overview]Overall Survival: Non-inferiority of XELOX Versus FOLFOX-4
NCT00069095 (22) [back to overview]Duration of Overall Response as Assessed by the Investigator According to RECIST: Superiority Analysis of Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone
NCT00069095 (22) [back to overview]Duration of Overall Response as Assessed by the Investigator According to RECIST: Non-inferiority of XELOX Versus FOLFOX-4
NCT00069095 (22) [back to overview]Time to Treatment Failure as Assessed by the Investigator According to RECIST: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone
NCT00069095 (22) [back to overview]Time to Response as Assessed by the Investigator According to RECIST: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone
NCT00069095 (22) [back to overview]Time to Response as Assessed by the Investigator According to RECIST: Non-inferiority of XELOX Versus FOLFOX-4
NCT00069095 (22) [back to overview]Progression-free Survival (PFS) as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) by General Approach (Participants With Curative Surgery Censored): Non-inferiority of XELOX Versus FOLFOX-4
NCT00069095 (22) [back to overview]PFS by General Approach, Participants With Curative Surgery Not Censored: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone
NCT00069095 (22) [back to overview]Duration of Complete Response as Assessed by the Investigator According to RECIST: Non-inferiority of XELOX Versus FOLFOX-4
NCT00069095 (22) [back to overview]BOR as Assessed by the IRC According to RECIST: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone
NCT00069095 (22) [back to overview]BOR as Assessed by the IRC According to RECIST: Non-inferiority of XELOX Versus FOLFOX-4
NCT00069095 (22) [back to overview]Best Overall Response (BOR) as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST): Non-inferiority of XELOX Versus FOLFOX-4
NCT00069095 (22) [back to overview]Best Overall Response (BOR) as Assessed by the Investigator According to RECIST: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone
NCT00069095 (22) [back to overview]Time to Treatment Failure (TTF) as Assessed by the Investigator According to RECIST: Non-inferiority of XELOX Versus FOLFOX-4
NCT00069095 (22) [back to overview]PFS (On-treatment Approach): Superiority of Chemotherapy Plus BV Over Chemotherapy Alone
NCT00069095 (22) [back to overview]PFS by General Approach, Participants With Curative Surgery Not Censored: Non-inferiority of XELOX Versus FOLFOX-4
NCT00069095 (22) [back to overview]Duration of Complete Response as Assessed by the Investigator According to RECIST: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone
NCT00069108 (11) [back to overview]Duration Of Response
NCT00069108 (11) [back to overview]Progression Free Survival
NCT00069108 (11) [back to overview]Progression Free Survival Based on Independent Review Committee Assessment
NCT00069108 (11) [back to overview]Progression Free Survival Based on Treatment Analysis- Intent To Treat Population
NCT00069108 (11) [back to overview]Progression Free Survival Based on Treatment Analysis- Per Population
NCT00069108 (11) [back to overview]Time To Treatment Failure
NCT00069108 (11) [back to overview]Best Overall Response, Independent Review Committee Assessment
NCT00069108 (11) [back to overview]Best Overall Response, Investigators' Assessments
NCT00069108 (11) [back to overview]Number of Participants With Marked Post-baseline Laboratory Abnormalities by Trial Treatment
NCT00069108 (11) [back to overview]Time To Response
NCT00069108 (11) [back to overview]Overall Survival
NCT00069121 (7) [back to overview]Overall Survival [Number of Events]
NCT00069121 (7) [back to overview]Disease-Free Survival (DFS) [Time to Event]
NCT00069121 (7) [back to overview]Number of Participants With at Least One Adverse Event by Most Severe Intensity
NCT00069121 (7) [back to overview]Disease-Free Survival (DFS) [Number of Events]
NCT00069121 (7) [back to overview]Relapse-Free Survival (RFS) [Time to Event]
NCT00069121 (7) [back to overview]Overall Survival [Time to Event]
NCT00069121 (7) [back to overview]Relapse-Free Survival (RFS) [Number of Events]
NCT00075725 (7) [back to overview]Correlation of Minimal Residual Disease (MRD) Negative With Event Free Survival (EFS).
NCT00075725 (7) [back to overview]Correlation of Minimal Residual Disease (MRD) Negative With Overall Survival (OS).
NCT00075725 (7) [back to overview]Correlation of Minimal Residual Disease (MRD) Positive With Event Free Survival (EFS)
NCT00075725 (7) [back to overview]Correlation of Minimal Residual Disease (MRD) Positive With Overall Survival (OS)
NCT00075725 (7) [back to overview]Correlation of Early Marrow Response Status With MRD Positive.
NCT00075725 (7) [back to overview]Comparison of the Increase in Cure Rate of High Risk ALL Without Causing More Serious Side Effects Between Interventions
NCT00075725 (7) [back to overview]Correlation of Early Marrow Response Status With MRD Negative.
NCT00079274 (6) [back to overview]Disease-free Survival (Arms A and D: Mutant KRAS Patients)
NCT00079274 (6) [back to overview]Disease-free Survival (Arms A and D: Wild-type KRAS Patients)
NCT00079274 (6) [back to overview]Overall Survival as Measured by the 3-year Event-free Rate (Arms A and D: Mutant KRAS Patients)
NCT00079274 (6) [back to overview]Overall Survival as Measured by the 3-year Event-free Rate (Arms A and D: Wild-type KRAS Patients)
NCT00079274 (6) [back to overview]Toxicity, Assessed Using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 (v3) (Arms A and D: Wild-type KRAS Patients)
NCT00079274 (6) [back to overview]Toxicity, Assessed Using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 (v3) (Arms A and D: Mutant KRAS Patients)
NCT00081289 (18) [back to overview]Pathologic Complete Response Rate
NCT00081289 (18) [back to overview]Second Primary Rate at 4 Years
NCT00081289 (18) [back to overview]Survival Rate at 4 Years
NCT00081289 (18) [back to overview]Number of Participants With Grade 3+ Treatment-related Adverse Events
NCT00081289 (18) [back to overview]Number of Participants With Grade 3+ Treatment-related Adverse Events Postoperatively
NCT00081289 (18) [back to overview]Number of Participants With Grade 3+ Treatment-related Adverse Events Preoperatively
NCT00081289 (18) [back to overview]Change From Baseline in EORTC QLQ-CR38 Gastro-intestinal Symptom Score at Completion of Chemoradiation
NCT00081289 (18) [back to overview]Change From Baseline in EORTC QLQ-CR38 Defecation Symptom Score at Two Years
NCT00081289 (18) [back to overview]Change From Baseline in QLQ-C30 Global Health Status Score at Completion of Chemoradiation
NCT00081289 (18) [back to overview]Change From Baseline in EORTC QLQ-CR38 Gastro-intestinal Symptom Score at Two Years
NCT00081289 (18) [back to overview]Change From Baseline in QLQ-C30 Global Health Status Score at Completion of Post-operative Chemotherapy
NCT00081289 (18) [back to overview]Change From Baseline in QLQ-C30 Global Health Status Score at Two Years
NCT00081289 (18) [back to overview]Change From Baseline in EORTC QLQ-CR38 Defecation Symptom Score at Completion of Chemoradiation
NCT00081289 (18) [back to overview]Change From Baseline in EORTC QLQ-CR38 Defecation Symptom Score at Post-operative Chemotherapy
NCT00081289 (18) [back to overview]Change From Baseline in EORTC QLQ-CR38 Gastro-intestinal Symptom Score at Completion of Post-operative Chemotherapy
NCT00081289 (18) [back to overview]Disease-free Survival Rate at 4 Years
NCT00081289 (18) [back to overview]Distant Failure Rate at 4 Years
NCT00081289 (18) [back to overview]Local-regional Failure Rate at 4 Years
NCT00084838 (19) [back to overview]Grade 3-4 Blood/Bone Marrow Events
NCT00084838 (19) [back to overview]Grade 3-4 Cardiovascular Events
NCT00084838 (19) [back to overview]Grade 3-4 Constitutional Events
NCT00084838 (19) [back to overview]Grade 3-4 Dermatology Events
NCT00084838 (19) [back to overview]Grade 3-4 Gastrointestinal Events
NCT00084838 (19) [back to overview]Grade 3-4 Hemorrhage Events
NCT00084838 (19) [back to overview]Grade 3-4 Hepatic Events
NCT00084838 (19) [back to overview]Grade 3-4 Infection/Febrile Neutropenia Events
NCT00084838 (19) [back to overview]Grade 3-4 Metabolic/Laboratory Events
NCT00084838 (19) [back to overview]Grade 3-4 Muscloskeletal Events
NCT00084838 (19) [back to overview]Grade 3-4 Neurology Events
NCT00084838 (19) [back to overview]Grade 3-4 Pain Events
NCT00084838 (19) [back to overview]Grade 3-4 Pulmonary Events
NCT00084838 (19) [back to overview]Grade 3-4 Renal/Genitourinary Events
NCT00084838 (19) [back to overview]Grade 3/4 Events
NCT00084838 (19) [back to overview]Pre-Radiation Therapy Chemotherapeutic Response
NCT00084838 (19) [back to overview]Grade 3-4 Allergy/Immunology
NCT00084838 (19) [back to overview]2-yr Overall Survival
NCT00084838 (19) [back to overview]Grade 3-4 Auditory/Hearing Events
NCT00089024 (2) [back to overview]Number of Participants Experiencing Grade 3-4 Toxicity While Receiving the Study Treatment
NCT00089024 (2) [back to overview]Surgical Exploration
NCT00096135 (1) [back to overview]Event-free Survival
NCT00096278 (2) [back to overview]Disease-free Survival
NCT00096278 (2) [back to overview]Survival
NCT00098774 (4) [back to overview]Complete Response Rate After Remission Induction
NCT00098774 (4) [back to overview]4 Year Overall Survival Rate
NCT00098774 (4) [back to overview]4 Year Progression Free Rate
NCT00098774 (4) [back to overview]Change From Baseline in Mini-Mental Status Evaluation at 4 Months
NCT00098787 (3) [back to overview]Objective Response Rate
NCT00098787 (3) [back to overview]Overall Survival (OS)
NCT00098787 (3) [back to overview]Progression-Free Survival (PFS)
NCT00098839 (4) [back to overview]Rate of Minimal Residual Disease (MRD) < 0.01%
NCT00098839 (4) [back to overview]Remission Re-induction (CR2) Rate
NCT00098839 (4) [back to overview]Pharmacokinetics
NCT00098839 (4) [back to overview]Event-free Survival Rate
NCT00100841 (2) [back to overview]Severe Adverse Event (SAE) Rate
NCT00100841 (2) [back to overview]Progression Free Survival Rate
NCT00103285 (10) [back to overview]Optimal Time Point for Advance Health Related Quality of Life Intervention
NCT00103285 (10) [back to overview]Overall Survival Probability (OS) According to Induction Day 29 MRD Status
NCT00103285 (10) [back to overview]Event-Free Survival Probability According to MRD Status End Induction (Day 29)
NCT00103285 (10) [back to overview]Event-free Survival (EFS) for SR-Low Patients
NCT00103285 (10) [back to overview]Event-Free Survival (EFS) for Low MRD (Negative) Subjects by Genetic Subset (TEL/Trisomy Positive vs Negative)
NCT00103285 (10) [back to overview]Early Marrow Status (EMS) by MRD Status End Induction (Day 29)
NCT00103285 (10) [back to overview]Health-related Quality of Life Relative to Physical, Social and Emotional Impairment
NCT00103285 (10) [back to overview]Event-free Survival (EFS) for SR-High Patients.
NCT00103285 (10) [back to overview]Event-free Survival (EFS) for SR-Average ALL Patients
NCT00103285 (10) [back to overview]Event-free Survival (EFS) for SR-Average ALL Patients
NCT00109837 (2) [back to overview]Toxicity
NCT00109837 (2) [back to overview]Continuous Complete Remission at 1 Year
NCT00111761 (13) [back to overview]Time to Treatment Failure (Part 1)
NCT00111761 (13) [back to overview]Number of Participants With Objective Tumor Response (Part 1)
NCT00111761 (13) [back to overview]Number of Participants With Grade 3 or Grade 4 Diarrhea (Part 2)
NCT00111761 (13) [back to overview]Time to Disease Progression (Part 1)
NCT00111761 (13) [back to overview]Survival Time (Part 1)
NCT00111761 (13) [back to overview]Survival Time (Part 2)
NCT00111761 (13) [back to overview]Number of Participants Who Died (Part 2)
NCT00111761 (13) [back to overview]Progression-free Survival Time (Part 2)
NCT00111761 (13) [back to overview]Progression-free Survival Time (Part 1)
NCT00111761 (13) [back to overview]Time to Disease Progression (Part 2)
NCT00111761 (13) [back to overview]Time to Initial Objective Tumor Response (Part 1)
NCT00111761 (13) [back to overview]Number of Participants With an Objective Tumor Response (Part 2)
NCT00111761 (13) [back to overview]Number of Participants With Grade 3 or Grade 4 Diarrhea (Part 1)
NCT00112918 (6) [back to overview]Disease-free Survival in Stage III Cancer Patients - Time to Event
NCT00112918 (6) [back to overview]Overall Survival in Stage III Cancer Patients - Time to Event
NCT00112918 (6) [back to overview]Overall Survival in Stage III Cancer Patients - Number of Events
NCT00112918 (6) [back to overview]Overall Survival in Stage III Cancer Patients - Time to Event: Final Analysis
NCT00112918 (6) [back to overview]Overall Survival in Stage III Cancer Patients - Number of Events: Final Analysis
NCT00112918 (6) [back to overview]Disease-free Survival in Stage III Cancer Patients - Number of Events
NCT00126191 (2) [back to overview]Disease Free Survival
NCT00126191 (2) [back to overview]Response Rates (CR and PR) in Adults With Burkitt/Atypical Burkitt
NCT00133991 (5) [back to overview]Percentage of Participants Experiencing Grade 3-5 Toxicity
NCT00133991 (5) [back to overview]Event-free Survival
NCT00133991 (5) [back to overview]Overall Response Rate
NCT00133991 (5) [back to overview]Overall Survival
NCT00133991 (5) [back to overview]Relapse Pattern
NCT00143403 (2) [back to overview]Overall Survival Rates
NCT00143403 (2) [back to overview]Disease Free Survival (DFS)
NCT00154102 (15) [back to overview]Duration of Response - Independent Review Committee (IRC) Assessments
NCT00154102 (15) [back to overview]Best Overall Response Rate - Independent Review Committee (IRC) Assessments
NCT00154102 (15) [back to overview]Best Overall Response Rate (KRAS Mutant Population) - Independent Review Committee (IRC) Assessments
NCT00154102 (15) [back to overview]Best Overall Response Rate (KRAS Wild-Type Population) - Independent Review Committee (IRC) Assessments
NCT00154102 (15) [back to overview]Disease Control Rate - Independent Review Committee (IRC) Assessments
NCT00154102 (15) [back to overview]Progression-free Survival Time (KRAS Mutant Population) - Independent Review Committee (IRC) Assessments
NCT00154102 (15) [back to overview]Overall Survival Time (KRAS Mutant Population)
NCT00154102 (15) [back to overview]Overall Survival Time (KRAS Wild-Type Population)
NCT00154102 (15) [back to overview]Overall Survival Time (OS)
NCT00154102 (15) [back to overview]Participants With No Residual Tumor After Metastatic Surgery
NCT00154102 (15) [back to overview]Progression-free Survival (PFS) Time - Independent Review Committee (IRC) Assessments
NCT00154102 (15) [back to overview]Progression-free Survival Time (Chinese V-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Wild-Type Population) - Independent Review Committee (IRC) Assessments
NCT00154102 (15) [back to overview]Safety - Number of Patients Experiencing Any Adverse Event
NCT00154102 (15) [back to overview]Quality of Life (QOL) Assessment European Organisation for the Research and Treatment of Cancer (EORTC) QLQ-C30 Global Health Status
NCT00154102 (15) [back to overview]Quality of Life Assessment (EORTC QLQ-C30) Social Functioning
NCT00176462 (1) [back to overview]Percentage of Patients With ALL at High Risk of Relapse (Arm 2) Who Were Relapse-free at 5 Years
NCT00192075 (11) [back to overview]Progression-Free Survival
NCT00192075 (11) [back to overview]Progression-Free Survival - Avastin Subgroup
NCT00192075 (11) [back to overview]Tumor Response by Response Evaluation Criteria In Solid Tumors (RECIST)
NCT00192075 (11) [back to overview]Time to Progressive Disease
NCT00192075 (11) [back to overview]Duration of Response
NCT00192075 (11) [back to overview]Duration of Response - A+FOLFOX4 - Avastin Subgroup
NCT00192075 (11) [back to overview]Overall Survival
NCT00192075 (11) [back to overview]Time to Progressive Disease - Avastin Subgroup
NCT00192075 (11) [back to overview]Survival at 12 Months and 24 Months - Avastin Subgroup
NCT00192075 (11) [back to overview]Toxicity - Avastin Subgroup
NCT00192075 (11) [back to overview]Tumor Response - Avastin Subgroup
NCT00193219 (4) [back to overview]Progression Free Survival (PFS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Worsening of Their Disease
NCT00193219 (4) [back to overview]Overall Survival (OS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Death
NCT00193219 (4) [back to overview]Overall Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment
NCT00193219 (4) [back to overview]Number of Patients With Adverse Events as a Measure of Safety With FOLFOX6 Combined With Bevacizumab and Cetuximab
NCT00199797 (1) [back to overview]Safety as Measured by the Number of Patients With Treatment Emergent Adverse Events (TEAEs), Grade 3 TEAEs, TEAEs Resulting in Death, TEAEs Related to Treatment and Serious TEAEs in Patients With Metastatic Colorectal Cancer.
NCT00210184 (3) [back to overview]2-month Response Rate
NCT00210184 (3) [back to overview]Overall Survival
NCT00210184 (3) [back to overview]Progression-free Survival
NCT00227617 (6) [back to overview]Best Objective Response
NCT00227617 (6) [back to overview]Time to Progression
NCT00227617 (6) [back to overview]Rate of Discontinuation Due to Adverse Events Possibly Related to Study Treatment
NCT00227617 (6) [back to overview]Overall Time to Treatment Failure
NCT00227617 (6) [back to overview]Overall Median Survival
NCT00227617 (6) [back to overview]Biochemical Marker Response
NCT00252564 (4) [back to overview]Overall Survival (OS)
NCT00252564 (4) [back to overview]Objective Response Rate
NCT00252564 (4) [back to overview]Progression-free Survival (PFS) Rate at 1 Year.
NCT00252564 (4) [back to overview]Progression-Free Survival (PFS)
NCT00262925 (2) [back to overview]Overall Survival
NCT00262925 (2) [back to overview]Complete Response Rate
NCT00265850 (2) [back to overview]Progression-free Survival (PFS)
NCT00265850 (2) [back to overview]Overall Survival
NCT00267865 (6) [back to overview]Change From Baseline in Cluster of Differentiation 4 (CD4) T Cell Count at up to 2.5 Years
NCT00267865 (6) [back to overview]Estimated Percentage of Participants Overall Survival
NCT00267865 (6) [back to overview]Number of Patients Alive at 2 Years Without Recurrent Brain Lymphoma or Severe Neurocognitive Defects
NCT00267865 (6) [back to overview]Median Mini Mental Status Exam (MMSE) Score in Surviving Participants After Rituximab, High-Dose Methotrexate & Leucovorin ( R-HD-MTX) Treatment
NCT00267865 (6) [back to overview]Number of Participants With Serious and Non-serious Adverse Events
NCT00267865 (6) [back to overview]Number of Participants With Response to Treatment After Rituximab, High-Dose Methotrexate (R-HD-MTX) Induction
NCT00278889 (7) [back to overview]Quality Of Live(QOL) : Time to Worsening of Tissue Oxygen Index (TOI)
NCT00278889 (7) [back to overview]QOL: Time to Worsening of Treatment-free Survival (TFS)
NCT00278889 (7) [back to overview]QOL: Time to Worsening of FACT Colorectal Cancer Symptom Index(FCSI)
NCT00278889 (7) [back to overview]QOL: Time to Worsening of Clear Cell Sarcoma (CCS)
NCT00278889 (7) [back to overview]Progression Free Survival
NCT00278889 (7) [back to overview]Overall Survival
NCT00278889 (7) [back to overview]Objective Response Rate
NCT00303628 (6) [back to overview]Proportion of Patients Who Completed 12 Cycles of Treatment
NCT00303628 (6) [back to overview]Patterns of Failure
NCT00303628 (6) [back to overview]Change in Rectal Function Between Baseline and 12 Months
NCT00303628 (6) [back to overview]Change in Oxaliplatin-related Neurotoxicity Between Baseline and 12 Months
NCT00303628 (6) [back to overview]5-year Overall Survival Rate
NCT00303628 (6) [back to overview]5-year Disease-free Survival Rate
NCT00308516 (2) [back to overview]Disease-Free Survival (DFS), The Proportion of Patients Predicted to be Alive Without Evidence of Disease Recurrence 24 Months After Completion of Protocol Treatment
NCT00308516 (2) [back to overview]Overall Survival (OS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Death
NCT00321685 (5) [back to overview]Resection Rate for T3 Rectal Cancers
NCT00321685 (5) [back to overview]Resection Rate for T4 Rectal Cancers
NCT00321685 (5) [back to overview]5-year Recurrence-free Survival Rate
NCT00321685 (5) [back to overview]5-year Overall Survival Rate
NCT00321685 (5) [back to overview]Pathologic Complete Response Rate
NCT00321828 (1) [back to overview]Major Morbidity Related to the Intact Primary Tumor
NCT00335140 (1) [back to overview]Complete Response Rate - Locally Reviewed
NCT00336024 (10) [back to overview]Percentage of Participants With Any Acute Adverse Events
NCT00336024 (10) [back to overview]Number of Participants With Secondary Malignancies
NCT00336024 (10) [back to overview]Number of Participants With Chronic Primary Hypothyroidism/Subclinical Compensatory HypothyroidismHypothyroidism/Subclinical Compensatory Hypothyroidism
NCT00336024 (10) [back to overview]Number of Participants With Chronic Low Somatomedin C
NCT00336024 (10) [back to overview]Number of Participants With Chronic Diabetes Insipidus
NCT00336024 (10) [back to overview]Number of Participants With Chronic Central Hypothyroidism
NCT00336024 (10) [back to overview]Median/Range of Patients for Total Quality of Life (QOL) Score, Intelligence Quotient (IQ) and Processing Speed Index (PSI).
NCT00336024 (10) [back to overview]Rates of Nutritional Toxicities
NCT00336024 (10) [back to overview]Rates of Gastrointestinal Toxicities
NCT00336024 (10) [back to overview]Percentage of Participants With Event Free Survival (EFS)
NCT00352755 (5) [back to overview]Overall Survival
NCT00352755 (5) [back to overview]Safety and Tolerability of the Planned Treatment Regimen as Measured by Number of Participants With Grade 3 or Higher Adverse Events
NCT00352755 (5) [back to overview]Progression-free Survival
NCT00352755 (5) [back to overview]Progression Rate
NCT00352755 (5) [back to overview]Number of Participants Who Experience Surgical Complications Associated With This Regimen
NCT00354978 (1) [back to overview]Median Progression-free Survival (PFS)
NCT00381680 (6) [back to overview]Frequency and Severity of Adverse Effects
NCT00381680 (6) [back to overview]Event Free Survival (EFS)
NCT00381680 (6) [back to overview]Adjusted Event Free Survival
NCT00381680 (6) [back to overview]Rate of Minimal Residual Disease (MRD) < 0.01% at End Block 3
NCT00381680 (6) [back to overview]Rate of Minimal Residual Disease (MRD) < 0.01% at End Block 1
NCT00381680 (6) [back to overview]Event Free Survival. EFS
NCT00381706 (5) [back to overview]Tumor Response Rate (Complete and Partial) in Patients With Squamous Cell Carcinoma
NCT00381706 (5) [back to overview]Overall Survival in Patients With Adenocarcinoma
NCT00381706 (5) [back to overview]Progression-free Survival in Patients With Adenocarcinoma
NCT00381706 (5) [back to overview]Response Rate (Complete and Partial) in Patients With Measurable Esophageal or GE Junction Adenocarcinoma
NCT00381706 (5) [back to overview]Time to Treatment Failure in Patients With Adenocarcinoma
NCT00381862 (1) [back to overview]Number of Participants With no Emesis and no Rescue Therapy Within 5 Days of Receiving FOLFOX and FOLFIRI in the First Cycle of Chemotherapy.
NCT00384176 (6) [back to overview]Overall Survival
NCT00384176 (6) [back to overview]Objective Response Rate
NCT00384176 (6) [back to overview]Duration of Response
NCT00384176 (6) [back to overview]Progression Free Survival
NCT00384176 (6) [back to overview]Percentage Change in Tumour Size
NCT00384176 (6) [back to overview]Time to Worsening of Health Related Quality of Life (QOL) Based on the FACT Colorectal Symptom Index (FCSI)
NCT00390416 (3) [back to overview]6 Month Progression Free Survival
NCT00390416 (3) [back to overview]Patients With Measurable Disease the Confirmed Response Rate
NCT00390416 (3) [back to overview]1-year Survival
NCT00392834 (1) [back to overview]Overall Survival (OS) at 1 Year
NCT00399035 (7) [back to overview]Time to Wound Healing Complications
NCT00399035 (7) [back to overview]Rate of Resection of Liver Metastases
NCT00399035 (7) [back to overview]Progression-free Survival
NCT00399035 (7) [back to overview]Overall Survival
NCT00399035 (7) [back to overview]Overall Response Rate
NCT00399035 (7) [back to overview]Duration of Response
NCT00399035 (7) [back to overview]Best Percentage Change in Tumour Size
NCT00400946 (10) [back to overview]5-year Disease-Free Survival by CNS Directed Treatment Group
NCT00400946 (10) [back to overview]Induction Infection Toxicity Rate
NCT00400946 (10) [back to overview]5-Year Disease-Free Survival
NCT00400946 (10) [back to overview]Post-Induction Therapeutic Nadir Serum Asparaginase Activity Rate
NCT00400946 (10) [back to overview]Induction Serum Asparaginase Activity Level
NCT00400946 (10) [back to overview]Induction Therapeutic Nadir Serum Asparaginase Activity Rate
NCT00400946 (10) [back to overview]Post-Induction Nadir Serum Asparaginase Activity Level
NCT00400946 (10) [back to overview]5-Year Disease-Free Survival by Bone Marrow Day 18 Status
NCT00400946 (10) [back to overview]5-Year Disease-Free Survival by MRD Day 32 Status
NCT00400946 (10) [back to overview]Asparaginase-Related Toxicity Rate
NCT00408005 (8) [back to overview]Disease-free Survival (DFS) for Randomized Nelarabine T-ALL Cohort (Arm I vs. Arm II vs. Arm III vs. Arm IV)
NCT00408005 (8) [back to overview]Cumulative Incidence of CNS Relapse for T-ALL by Risk Group
NCT00408005 (8) [back to overview]Cumulative Incidence of CNS Relapse for T-ALL by Risk Group
NCT00408005 (8) [back to overview]Disease-free Survival (DFS) for T-cell Lymphoblastic Lymphoma (T-LLy) Cohort
NCT00408005 (8) [back to overview]Disease-free Survival (DFS) for Randomized Nelarabine T-ALL Cohort (Arm I + Arm III vs. Arm II + Arm IV)
NCT00408005 (8) [back to overview]Disease-free Survival (DFS) for T-cell Lymphoblastic Lymphoma (T-LLy) Cohort
NCT00408005 (8) [back to overview]Disease-free Survival (DFS) for Randomized Methotrexate T-ALL Cohort (Arm I + Arm II vs. Arm III + Arm IV)
NCT00408005 (8) [back to overview]Disease-free Survival (DFS) for Randomized Methotrexate T-ALL Cohort (Arm I vs. Arm II vs. Arm III vs. Arm IV)
NCT00418938 (7) [back to overview]Time to Response
NCT00418938 (7) [back to overview]Objective Response Rate
NCT00418938 (7) [back to overview]Time to Progression
NCT00418938 (7) [back to overview]Overall Survival
NCT00418938 (7) [back to overview]Progression-free Survival (PFS)
NCT00418938 (7) [back to overview]Disease Control
NCT00418938 (7) [back to overview]Duration of Response
NCT00448760 (4) [back to overview]Overall Survival
NCT00448760 (4) [back to overview]Pathologic Complete Response
NCT00448760 (4) [back to overview]Clinical Response
NCT00448760 (4) [back to overview]Median Progression-free Survival (PFS)
NCT00449163 (4) [back to overview]Median Progression-free Survival in Months
NCT00449163 (4) [back to overview]Response Rate (Complete Response and Partial Response)
NCT00449163 (4) [back to overview]Overall Survival up to 2 Years
NCT00449163 (4) [back to overview]Rate of Toxicity in Study Participants
NCT00450801 (4) [back to overview]Progression-free Survival Rate
NCT00450801 (4) [back to overview]Overall Survival Rate
NCT00450801 (4) [back to overview]Response Rate
NCT00450801 (4) [back to overview]Number of Patients Experiencing Adverse Events.
NCT00457691 (8) [back to overview]Progression-free Survival (PFS)
NCT00457691 (8) [back to overview]Overall Survival (OS)
NCT00457691 (8) [back to overview]Number of Participants With Overall Confirmed Objective Response
NCT00457691 (8) [back to overview]Change From Baseline in MDASI-GI Symptom Interference Score
NCT00457691 (8) [back to overview]Change From Baseline in Monroe Dunaway (MD) Anderson Symptom Assessment Inventory of Gastrointestinal Symptoms (MDASI-GI) Symptom Intensity Score
NCT00457691 (8) [back to overview]Change From Baseline in EuroQol (EQ) Visual Analog Scale (VAS) (EQ-VAS)
NCT00457691 (8) [back to overview]Change From Baseline in European Quality of Life (EuroQol) EQ-5D Self-Report Questionnaire
NCT00457691 (8) [back to overview]Duration of Response (DR)
NCT00462501 (1) [back to overview]Complete Pathologic Response
NCT00467142 (2) [back to overview]Percentage of Participants in Objective Response (Partial or Complete Responses)
NCT00467142 (2) [back to overview]Median Duration of Response
NCT00494221 (5) [back to overview]Best Percentage Change in Tumour Size
NCT00494221 (5) [back to overview]Duration of Response
NCT00494221 (5) [back to overview]Objective Tumour Response Rate
NCT00494221 (5) [back to overview]Overall Survival
NCT00494221 (5) [back to overview]Progression Free Survival
NCT00499369 (2) [back to overview]Toxicity
NCT00499369 (2) [back to overview]Progression-free Survival (PFS)
NCT00500292 (1) [back to overview]Number of Patients With an Objective Disease Progression Event
NCT00514020 (1) [back to overview]"Number of Patients With Each Response in Good Risk Genotype (Thymidylate Synthase Promoter Enhancer Region [TSER]*2/*2 or TSER*2/*3 Genotype [Low TS Expression])"
NCT00515216 (18) [back to overview]Genetic Polymorphisms That May Alter Treatment Outcomes (Stable Disease)
NCT00515216 (18) [back to overview]Genetic Polymorphisms That May Alter Treatment Outcomes (Stable Disease)
NCT00515216 (18) [back to overview]Genetic Polymorphisms That May Alter Treatment Outcomes (Stable Disease)
NCT00515216 (18) [back to overview]Overall Survival
NCT00515216 (18) [back to overview]Progression-free Survival (PFS)
NCT00515216 (18) [back to overview]Genetic Polymorphisms That May Alter Treatment Outcomes (Partial Response)
NCT00515216 (18) [back to overview]Genetic Polymorphisms That May Alter Treatment Outcomes (Partial Response)
NCT00515216 (18) [back to overview]Genetic Polymorphisms That May Alter Treatment Outcomes (Partial Response)
NCT00515216 (18) [back to overview]Genetic Polymorphisms That May Alter Treatment Outcomes (Partial Response)
NCT00515216 (18) [back to overview]Genetic Polymorphisms That May Alter Treatment Outcomes (Partial Response)
NCT00515216 (18) [back to overview]Genetic Polymorphisms That May Alter Treatment Outcomes (Partial Response)
NCT00515216 (18) [back to overview]Genetic Polymorphisms That May Alter Treatment Outcomes (Partial Response)
NCT00515216 (18) [back to overview]Genetic Polymorphisms That May Alter Treatment Outcomes (Stable Disease)
NCT00515216 (18) [back to overview]Disease Control Rate (DCR)
NCT00515216 (18) [back to overview]Overall Response Rate (ORR)
NCT00515216 (18) [back to overview]Genetic Polymorphisms That May Alter Treatment Outcomes (Stable Disease)
NCT00515216 (18) [back to overview]Genetic Polymorphisms That May Alter Treatment Outcomes (Stable Disease)
NCT00515216 (18) [back to overview]Genetic Polymorphisms That May Alter Treatment Outcomes (Stable Disease)
NCT00515411 (2) [back to overview]6 Month Progression Free Survival (PFS)
NCT00515411 (2) [back to overview]Overall Survival
NCT00525785 (1) [back to overview]Complete Pathologic Response Rate
NCT00537823 (8) [back to overview]All-cause Mortality
NCT00537823 (8) [back to overview]Postoperative Recurrence Patterns
NCT00537823 (8) [back to overview]Nonalcoholic Steatohepatitis Score (0-3)
NCT00537823 (8) [back to overview]Postoperative Complication Rate
NCT00537823 (8) [back to overview]Effect of Preoperative Chemotherapy on Tumor Size
NCT00537823 (8) [back to overview]Major Postoperative Complication Rate
NCT00537823 (8) [back to overview]Change in Tumor Size From Pretreatment to Preoperative CT Scan
NCT00537823 (8) [back to overview]Histologic Hepatic Toxicity at Surgery
NCT00544414 (2) [back to overview]Progression-free Survival
NCT00544414 (2) [back to overview]Overall Response
NCT00557193 (10) [back to overview]Describe FLT3 Protein Expression as a Molecular Mechanism of Primary Resistance to Lestaurtinib in Leukemic Blasts
NCT00557193 (10) [back to overview]Describe in Vitro Sensitivity as a Molecular Mechanism of Acquired Resistance to Lestaurtinib in Leukemic Blasts
NCT00557193 (10) [back to overview]Percent Probability for Event-free Survival (EFS) for Patients on Arm A
NCT00557193 (10) [back to overview]Percent Probability for Event-free Survival (EFS) for Patients on Arm C at Dose Level 2 (DL2)
NCT00557193 (10) [back to overview]Percent Probability for Event-free Survival (EFS) of MLL-R Infants Treated With Combination Chemotherapy With or Without Lestaurtinib at DL2
NCT00557193 (10) [back to overview]Percent Probability of Event Free Survival (EFS) by MRD Status and Treatment Arm
NCT00557193 (10) [back to overview]Pharmacodynamics PIA Levels in Infants Given Lestaurtinib at DL2 in Combination With Chemotherapy
NCT00557193 (10) [back to overview]Describe FLT3 Protein Expression as a Molecular Mechanism of Acquired Resistance to Lestaurtinib in Leukemic Blasts
NCT00557193 (10) [back to overview]Number of Patients Who Experienced Lestaurtinib-related Dose Limiting Toxicity (DLT)
NCT00557193 (10) [back to overview]Describe in Vitro Sensitivity as a Molecular Mechanism of Primary Resistance to Lestaurtinib in Leukemic Blasts
NCT00561470 (5) [back to overview]Number of Participants With Adverse Events (AE)
NCT00561470 (5) [back to overview]Progression-free Survival (PFS) Assessed by Independent Review Committee (IRC)
NCT00561470 (5) [back to overview]Overall Survival (OS)
NCT00561470 (5) [back to overview]Overall Objective Response Rate (ORR) Based on the Tumor Assessment by the Independent Review Committee (IRC) as Per Response Evaluation Criteria in Solid Tumours (RECIST) Criteria
NCT00561470 (5) [back to overview]Immunogenicity Assessment: Number of Participants With Positive Sample(s) in the Anti-drug Antibodies (ADA) Assay and in the Neutralizing Anti-drug Antibodies (NAb) Assay
NCT00580073 (2) [back to overview]Down-staging of the Tumor; Response to Therapy
NCT00580073 (2) [back to overview]Progression Free Survival
NCT00588536 (1) [back to overview]Determine the Incidence of Complete and Partial Response and the Duration of Response in Patients With Langerhans Cell Histiocytosis (LCH) Treated With Sequential Administration of Oral 6-TG After MTX.
NCT00591123 (2) [back to overview]Overall Response Rate of Previously-untreated Patients With Unresectable or Metastatic Adenocarcinomas of the Upper Gastrointestinal Tract When Treated With the Combination of 5-fluorouracil, Leucovorin, Oxaliplatin, and Erlotinib.
NCT00591123 (2) [back to overview]Toxicity of the Combination of FOLFOX, 5-FU, and Erlotinib
NCT00594815 (2) [back to overview]Total Number of Participants Who Experienced Acute Treatment Related Adverse Events
NCT00594815 (2) [back to overview]Progression Free Survival
NCT00599924 (20) [back to overview]Area Under Plasma Concentration-Time Profile From Time Zero to Twenty-Four Hours Postdose (AUC24) of Sunitinib
NCT00599924 (20) [back to overview]Steady State Clearance (CLss) of 5-FU
NCT00599924 (20) [back to overview]Steady State Concentration (Css) of Fluorouracil (5-FU)
NCT00599924 (20) [back to overview]T1/2 for Free Platinum
NCT00599924 (20) [back to overview]Tmax of Free Platinum
NCT00599924 (20) [back to overview]Tmax of SU-012662 (Sunitinib's Metabolite)
NCT00599924 (20) [back to overview]Tmax of Total Platinum
NCT00599924 (20) [back to overview]Area Under the Plasma Concentration-Time Profile From Time Zero to Forty-Eight Hours (AUC48) for Total Platinum
NCT00599924 (20) [back to overview]Time to Cmax (Tmax) of Sunitinib
NCT00599924 (20) [back to overview]Maximum Plasma Concentration (Cmax) of Sunitinib
NCT00599924 (20) [back to overview]Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT00599924 (20) [back to overview]Minimum Plasma Concentration (Cmin) of Sunitinib
NCT00599924 (20) [back to overview]Cmin of SU-012662 (Sunitinib's Metabolite)
NCT00599924 (20) [back to overview]Cmax of Total Platinum
NCT00599924 (20) [back to overview]Cmax of SU-012662 (Sunitinib's Metabolite)
NCT00599924 (20) [back to overview]Cmax of Free Platinum
NCT00599924 (20) [back to overview]Clearance (CL/F) of Sunitinib
NCT00599924 (20) [back to overview]AUC24 for SU-012662 (Sunitinib's Metabolite)
NCT00599924 (20) [back to overview]Area Under the Plasma Concentration-Time Profile From Time Zero to Infinity (AUCinf) for Free Platinum
NCT00599924 (20) [back to overview]Objective Response (OR)
NCT00612586 (5) [back to overview]Progression Free Survival (PFS)
NCT00612586 (5) [back to overview]PFS From Start of First Line Therapy
NCT00612586 (5) [back to overview]Overall Survival (OS) From Start of First Line Therapy
NCT00612586 (5) [back to overview]Overall Survival (OS)
NCT00612586 (5) [back to overview]Number of Participants With Adverse Events (AEs)
NCT00613080 (9) [back to overview]Local-regional Failure: 4-year Rate
NCT00613080 (9) [back to overview]Number of Patients in Protocol Adherence Categories for Intensity-modulated Radiotherapy (IMRT) Planning
NCT00613080 (9) [back to overview]Number of Patients With Pathologic Complete Response
NCT00613080 (9) [back to overview]Number of Patients Who Underwent Abdominoperineal Resection
NCT00613080 (9) [back to overview]Distant Failure: 4-year Rate
NCT00613080 (9) [back to overview]Disease-free Survival: 4-year Rate
NCT00613080 (9) [back to overview]Percentage of Patients With Grade 3 or Higher Treatment-related Adverse Events as Assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v3.0
NCT00613080 (9) [back to overview]The Percentage of Patients Experiencing Treatment-related Gastrointestinal Adverse Events ≥ Grade 2 Per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v. 3.0, Occurring Preoperatively
NCT00613080 (9) [back to overview]Overall Survival: 4-year Rate
NCT00615056 (6) [back to overview]Overall Survival (OS)
NCT00615056 (6) [back to overview]Duration of Response (DR)
NCT00615056 (6) [back to overview]Change From Baseline in MDASI-D Symptom Interference Score at Day 1 of Cycles 2-5, Day 1 of Every Odd-numbered Cycle Throughout the Study and End of Treatment (Cycle 65) or Withdrawal
NCT00615056 (6) [back to overview]Change From Baseline in MD Anderson Symptoms Inventory Diarrhea (MDASI-D) Symptom Severity Score at Day 1 of Cycles 2-5, Day 1 of Every Odd-numbered Cycle Throughout the Study and End of Treatment (Cycle 65) or Withdrawal
NCT00615056 (6) [back to overview]Progression Free Survival (PFS)
NCT00615056 (6) [back to overview]Percentage of Participants With Objective Response (OR)
NCT00632827 (4) [back to overview]Complete Response Rate
NCT00632827 (4) [back to overview]Median Time to Response
NCT00632827 (4) [back to overview]Overall Survival Rate
NCT00632827 (4) [back to overview]Progression Free Survival
NCT00634504 (1) [back to overview]Pharmacokinetics (PK) of Leucovorin
NCT00642746 (3) [back to overview]Second-line Progression Free Survival
NCT00642746 (3) [back to overview]Response Rates of Radiographically Measurable Disease
NCT00642746 (3) [back to overview]Time to Second Progression (From Start of First-Line Regimen)
NCT00653068 (4) [back to overview]Toxic Death
NCT00653068 (4) [back to overview]Overall Survival (OS)
NCT00653068 (4) [back to overview]Non-hematological Toxicity Associated With Chemotherapy: Grade 3 or Higher During Protocol Therapy
NCT00653068 (4) [back to overview]Event-free Survival
NCT00668863 (15) [back to overview]Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Measurable Concentration (AUC Last) and Area Under the Plasma Concentration Versus Time Curve From Time 0 to Infinity (AUC ∞) of Irinotecan
NCT00668863 (15) [back to overview]Maximum Observed Plasma Concentration (Cmax) and Predose Concentration (Ctrough) of Sunitinib.
NCT00668863 (15) [back to overview]Area Under the Plasma Concentration Versus Time Curve From Time 0 to 24 Hours Postdose (AUC 0-24) of Sunitinib
NCT00668863 (15) [back to overview]Volume of Distribution at Steady State (Vss) of Irinotecan
NCT00668863 (15) [back to overview]Terminal Phase Elimination Half-life (t1/2) of Irinotecan
NCT00668863 (15) [back to overview]Time to Reach Maximum Plasma Concentration (Tmax) of Sunitinib
NCT00668863 (15) [back to overview]Maximum Observed Plasma Concentration (Cmax) of Irinotecan
NCT00668863 (15) [back to overview]Time to Reach Maximum Plasma Concentration (Tmax) of Irinotecan
NCT00668863 (15) [back to overview]Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and Grade 3 or Higher Adverse Events According to Common Terminology Criteria (CTCAE).
NCT00668863 (15) [back to overview]Apparent Oral Clearance (CL/F) of Sunitinib
NCT00668863 (15) [back to overview]Progression-Free Survival (PFS)
NCT00668863 (15) [back to overview]Plasma Concentration at Steady State (Css) of 5-FU
NCT00668863 (15) [back to overview]Percentage of Participants Who Presented Objective Response: Objective Response Rate (ORR)
NCT00668863 (15) [back to overview]Duration of Response (DR)
NCT00668863 (15) [back to overview]Clearance of Irinotecan
NCT00705874 (1) [back to overview]Maximum Tolerated Dose (MTD)
NCT00720109 (5) [back to overview]Percent of Patients MRD Positive (MRD > 0.01%) at End of Consolidation
NCT00720109 (5) [back to overview]Overall EFS Rate for the Combined Cohort of Standard- and High-Risk Patients (Who Receive the Final Chosen Dose of Dasatinib)
NCT00720109 (5) [back to overview]Feasibility and Toxicity of an Intensified Chemotherapeutic Regimen Incorporating Dasatinib for Treatment of Children and Adolescents With Ph+ ALL Assessed by Examining Adverse Events
NCT00720109 (5) [back to overview]Event-Free Survival (EFS) of Patients With Standard-risk Disease Treated With Dasatinib in Combination With Intensified Chemotherapy
NCT00720109 (5) [back to overview]Contribution of Dasatinib on Minimal Residual Disease (MRD) After Induction Therapy
NCT00742924 (1) [back to overview]Limiting Toxicity
NCT00766142 (4) [back to overview]Overall Survival (OS) Time
NCT00766142 (4) [back to overview]30-day Mortality Rate
NCT00766142 (4) [back to overview]Mean Number of Adverse Events Per Patient, Within 30 Days of Surgery
NCT00766142 (4) [back to overview]Median Progression-free Survival (PFS) Time
NCT00778102 (14) [back to overview]Percentage of Participants With a Confirmed Best Overall Response of Complete Response (CR) or Partial Response (PR) According to RECIST Version 1.0
NCT00778102 (14) [back to overview]Percentage of Participants Who Died
NCT00778102 (14) [back to overview]Percentage of Participants Experiencing Relapse Following Curative Resection
NCT00778102 (14) [back to overview]Percentage of Participants Experiencing Death or Disease Progression
NCT00778102 (14) [back to overview]Overall Survival (OS)
NCT00778102 (14) [back to overview]Percentage of Participants With Complete Resection or Residual (Microscopic or Macroscopic) Tumor
NCT00778102 (14) [back to overview]Relapse-Free Survival (RFS)
NCT00778102 (14) [back to overview]Percentage of Participants With Histopathological Response
NCT00778102 (14) [back to overview]Percentage of Participants With Complications Related to Second Resective Surgery
NCT00778102 (14) [back to overview]Percentage of Participants With Complications Related to First Resective Surgery
NCT00778102 (14) [back to overview]Time to Response
NCT00778102 (14) [back to overview]Time to Resection
NCT00778102 (14) [back to overview]Progression-Free Survival (PFS)
NCT00778102 (14) [back to overview]Percentage of Participants With Complete or Major Histopathological Response
NCT00786643 (3) [back to overview]Time to Progression
NCT00786643 (3) [back to overview]Best Response (BR)
NCT00786643 (3) [back to overview]Early Response Rate (RR) (Stratum 1 Only)
NCT00792948 (3) [back to overview]Continuous Complete Remission (CCR) Rate
NCT00792948 (3) [back to overview]Overall Survival (OS)
NCT00792948 (3) [back to overview]Relapse-free Survival (RFS) After Allogeneic Stem Cell Transplantation
NCT00803647 (5) [back to overview]Objective Clinical Response Rate (cRR). Measureable Lesions That Can be Accurately Measured in at Least One Dimension With Conventional Radiologic Techniques or Spiral CT.
NCT00803647 (5) [back to overview]Overall Survival (OS). Time From Study Entry Until Death From Any Cause.
NCT00803647 (5) [back to overview]Recurrence-free Survival (RFS). Time From Study Entry Until First Recurrence.
NCT00803647 (5) [back to overview]Reported Adverse Events.
NCT00803647 (5) [back to overview]The Percentage of Patients Who Had a Curative (R0) Liver Metastasectomy Following Protocol Treatment, i.e., Metastatic Disease That Can be Completely Resected and/or Ablated With no Postoperative Evidence of Residual Malignant Disease (R0 Resection).
NCT00831181 (8) [back to overview]Treatment Toxicity
NCT00831181 (8) [back to overview]Local Regional Control
NCT00831181 (8) [back to overview]Number of Participants With Comparison of Preoperative Stage With Post-treatment Pathologic Stage
NCT00831181 (8) [back to overview]Complete Resectability Rates
NCT00831181 (8) [back to overview]Overall Survival
NCT00831181 (8) [back to overview]Pathologic Response and Complete Response
NCT00831181 (8) [back to overview]Patterns of Disease Failure, Including Local Recurrence and Distant Metastasis Assessed by CT Scan
NCT00831181 (8) [back to overview]Disease-free Survival
NCT00835185 (12) [back to overview]Area Under the Concentration-Time Curve From Time 0 to Infinity [AUC(0-∞)] of IMC-11F8 at Study Day 1 of Cycle 1
NCT00835185 (12) [back to overview]Clearance (CL) of IMC-11F8 at Study Day 1 of Cycle 1
NCT00835185 (12) [back to overview]Duration of Response
NCT00835185 (12) [back to overview]Half-Life (t1/2) of IMC-11F8 at Study Day 1 of Cycle 1
NCT00835185 (12) [back to overview]Maximum Concentration (Cmax) of IMC-11F8 at Study Day 1 of Cycle 1
NCT00835185 (12) [back to overview]Overall Survival (OS)
NCT00835185 (12) [back to overview]Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response )
NCT00835185 (12) [back to overview]Number of Participants With Adverse Events (AEs), Serious AEs (SAEs) or Death
NCT00835185 (12) [back to overview]Kirsten Rat Sarcoma (KRAS) Mutation Status
NCT00835185 (12) [back to overview]Volume of Distribution (Vss) of IMC-11F8 at Study Day 1 of Cycle 1
NCT00835185 (12) [back to overview]Serum Anti-IMC-11F8 Antibody Assessment (Immunogenicity)
NCT00835185 (12) [back to overview]Progression-Free Survival (PFS)
NCT00851084 (6) [back to overview]Immunogenicity of Intravenous (IV) Aflibercept
NCT00851084 (6) [back to overview]Number of Participants With Treatment-emergent Adverse Events (TEAE)
NCT00851084 (6) [back to overview]Overall Objective Response Rate (ORR)
NCT00851084 (6) [back to overview]Overall Survival (OS)
NCT00851084 (6) [back to overview]Progression Free Survival (PFS)
NCT00851084 (6) [back to overview]Progression Free Survival (PFS) Rate at 12 Months
NCT00862784 (7) [back to overview]Number of Participants With IMC-1121B (Ramucirumab)-Related Severe Adverse Events (SAEs)
NCT00862784 (7) [back to overview]Duration of Response
NCT00862784 (7) [back to overview]Serum Anti-IMC-1121B (Immunogenicity) at Day 1
NCT00862784 (7) [back to overview]Number of Participants With IMC-1121B (Ramucirumab)-Related Adverse Events (AEs)
NCT00862784 (7) [back to overview]Progression-Free Survival (PFS)
NCT00862784 (7) [back to overview]Percentage of Participants With Complete Response or Partial Response [Objective Response Rate (ORR)]
NCT00862784 (7) [back to overview]Overall Survival (OS)
NCT00865189 (11) [back to overview]Percentage of Participants With Surgery
NCT00865189 (11) [back to overview]Percentage of Participants With Tumor Sterilization Defined by ypT0-N0
NCT00865189 (11) [back to overview]Percentage of Participants With Local and Distant Recurrences
NCT00865189 (11) [back to overview]Percentage of Participants With Tumor Down-Staging (ypT0-pT2)
NCT00865189 (11) [back to overview]Number of Cycles of Radiotherapy
NCT00865189 (11) [back to overview]Disease-Free Survival (DFS)
NCT00865189 (11) [back to overview]Number of Cycles of Chemotherapy
NCT00865189 (11) [back to overview]Number of Cycles of Induction Chemotherapy
NCT00865189 (11) [back to overview]Overall Survival
NCT00865189 (11) [back to overview]Percentage of Participants Who Died
NCT00865189 (11) [back to overview]Percentage of Participants With Second Cancer, Local or Regional Recurrence, Distant Metastasis, or Death
NCT00865709 (5) [back to overview]Overall Response
NCT00865709 (5) [back to overview]Overall Survival (OS)
NCT00865709 (5) [back to overview]Progression-Free Survival (PFS)
NCT00865709 (5) [back to overview]Time to Progression (TTP)
NCT00865709 (5) [back to overview]Duration of Response
NCT00873093 (7) [back to overview]Rate of Minimal Residual Disease (MRD) < 0.01% at End Block 3
NCT00873093 (7) [back to overview]Toxic Death Rate
NCT00873093 (7) [back to overview]Severe Adverse Events (SAE) Rate.
NCT00873093 (7) [back to overview]Second Complete Remission Rate at the End of Block 1 Reinduction Chemotherapy
NCT00873093 (7) [back to overview]Event Free Survival
NCT00873093 (7) [back to overview]Rate of Minimal Residual Disease (MRD) < 0.01% at End Block 1
NCT00873093 (7) [back to overview]Rate of Minimal Residual Disease (MRD) < 0.01% at End Block 2
NCT00932438 (2) [back to overview]Tumor Response
NCT00932438 (2) [back to overview]Number of Serious Adverse Events
NCT00941655 (9) [back to overview]Completeness of Cytoreduction (CCR) Score
NCT00941655 (9) [back to overview]12 Months Disease Free Survival (DFS)
NCT00941655 (9) [back to overview]Overall Survival in Patients With Limited Metastatic Gastric Carcinoma: Arm I
NCT00941655 (9) [back to overview]Median Blood Loss During Surgery
NCT00941655 (9) [back to overview]Median Duration of Cytoreduction Surgery and Heated Intraperitoneal Chemotherapy (HIPEC)
NCT00941655 (9) [back to overview]Median Hospital Stay After Initial Surgery
NCT00941655 (9) [back to overview]Gillys Stage Before and After Surgery
NCT00941655 (9) [back to overview]Number of Participants With Serious and Non-Serious Adverse Events
NCT00941655 (9) [back to overview]Overall Survival in Patients With Limited Metastatic Gastric Carcinoma: Arm II
NCT00942266 (7) [back to overview]Response Rate
NCT00942266 (7) [back to overview]Disease Control Rate (Stable Disease or Objective Response)
NCT00942266 (7) [back to overview]Vorinostat Pharmacokinetics
NCT00942266 (7) [back to overview]Toxicity
NCT00942266 (7) [back to overview]Overall Survival
NCT00942266 (7) [back to overview]Median Progression-free Survival
NCT00942266 (7) [back to overview]Fluorouracil Steady-state Pharmacokinetics
NCT00954512 (2) [back to overview]Part 1: Number of Participants Who Experienced One or More Adverse Events (AEs)
NCT00954512 (2) [back to overview]Part 2: Number of Participants With Each Type of Response Evaluation Criteria in Solid Tumors (RECIST)-Determined Overall Best Response
NCT00957905 (1) [back to overview]Objective Response Rate
NCT00967616 (5) [back to overview]Best Overall Response and Objective Response Rate Following Administration of CS-7017 in Combination With Irinotecan, Leucovorin, and 5-Fluorouracil (FOLFIRI) After Failure of First-line Therapy in Treatment of Metastatic Colorectal Cancer
NCT00967616 (5) [back to overview]Percentage of Participants With Progression-Free Survival at 16 Weeks After Administration of CS-7017 Combined With Irinotecan, Leucovorin, and 5-Fluorouracil (5-FU) After Failure of First-line Therapy in Treatment of Metastatic Colorectal Cancer
NCT00967616 (5) [back to overview]Median Overall Progression-Free Survival: Sensitivity Analysis Including Clinical Progression After Administration of CS-7017 and Irinotecan, Leucovorin, and 5-Fluorouracil After Failure of First-line Therapy of Metastatic Colorectal Cancer
NCT00967616 (5) [back to overview]Median Overall Progression-Free Survival Following Administration of CS-7017 in Combination With Irinotecan, Leucovorin, and 5-Fluorouracil (5-FU) (FOLFIRI) After Failure of First-line Therapy in Treatment of Metastatic Colorectal Cancer
NCT00967616 (5) [back to overview]Treatment-Emergent Adverse Events Occurring in ≥10% of Participants Following Administration of CS-7017 Combined With Irinotecan, Leucovorin, and 5-Fluorouracil (FOLFIRI) After Failure of First-line Therapy in Treatment of Metastatic Colorectal Cancer
NCT00982592 (5) [back to overview]Median Progression-free Survival (PFS)
NCT00982592 (5) [back to overview]Incidence of Toxicities (grades1 and 2)
NCT00982592 (5) [back to overview]Incidence of Toxicities (Grade 3 and Higher)
NCT00982592 (5) [back to overview]Objective Response Rate
NCT00982592 (5) [back to overview]Overall Survival
NCT01047293 (2) [back to overview]Progression Free Survival at Six Months
NCT01047293 (2) [back to overview]Evaluate Safety of the Combination at a Daily Dosing of 2.5mg RAD001, 5 mg RAD001 or 10 mg RAD001 (Phase 1 Part)
NCT01060007 (9) [back to overview]Preoperative Gastrointestinal Morbidity
NCT01060007 (9) [back to overview]Incidence of Post Chemoradiotherapy Grade 3 or Higher Morbidity
NCT01060007 (9) [back to overview]Freedom From Disease Relapse
NCT01060007 (9) [back to overview]Local Control
NCT01060007 (9) [back to overview]Rate of Locoregional Control
NCT01060007 (9) [back to overview]Incidence of Any Late Grade 3 or Higher Morbidity
NCT01060007 (9) [back to overview]Determine Quality of Anorectal Function
NCT01060007 (9) [back to overview]Rate of T Stage Downstaging
NCT01060007 (9) [back to overview]Rate of Overall Control
NCT01077739 (4) [back to overview]PFS From the Start of First-Line Therapy
NCT01077739 (4) [back to overview]Geometric Mean Values of Pro-Angiogenic Cytokine Concentrations at Baseline and Prior to Progression
NCT01077739 (4) [back to overview]Progression-Free Survival (PFS) From the Start of Treatment Beyond Progression
NCT01077739 (4) [back to overview]Percentage of Participants With an Overall Response of Complete Response (CR) or Partial Response (PR)
NCT01133990 (5) [back to overview]Phase 1b: Number of Participants With Eastern Cooperative Oncology Group Performance Status (ECOG-PS)
NCT01133990 (5) [back to overview]Phase 1b: Number of Participants With Any Treatment-emergent Adverse Events (TEAEs)
NCT01133990 (5) [back to overview]Phase 1b: Number of Participants With Clinically Significant Change From Baseline in Electrocardiograms (ECGs) Parameter
NCT01133990 (5) [back to overview]Phase 1b: Number of Participants With Clinically Significant Changes in Physical Examinations
NCT01133990 (5) [back to overview]Phase 1b: Number of Participants With Dose-limiting Toxicities (DLTs)
NCT01150045 (2) [back to overview]Disease-free Survival
NCT01150045 (2) [back to overview]Overall Survival
NCT01183780 (7) [back to overview]Progression-free Survival (PFS) Time
NCT01183780 (7) [back to overview]Observed Maximum Concentration (Cmax) and Observed Minimum Concentration (Cmin) of Ramucirumab
NCT01183780 (7) [back to overview]Change From Baseline in EuroQol- 5D (EQ-5D)
NCT01183780 (7) [back to overview]Change From Baseline in European Organisation for Research and Treatment of Cancer [EORTC] QLQ-C30 Global Health Status
NCT01183780 (7) [back to overview]Overall Survival (OS)
NCT01183780 (7) [back to overview]Percentage of Participants Achieving an Objective Response (Objective Response Rate)
NCT01183780 (7) [back to overview]Percentage of Participants With Treatment-Emergent Anti-Ramucirumab Antibodies
NCT01190930 (41) [back to overview]Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL at End of Maintenance Cycle 1: Right
NCT01190930 (41) [back to overview]Burden of Therapy in Boy AR Patients Overall at End of Therapy: Emotional
NCT01190930 (41) [back to overview]Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL at End of Consolidation Therapy-Right
NCT01190930 (41) [back to overview]Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL at End of Consolidation Therapy-Left
NCT01190930 (41) [back to overview]Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL 12 Months Post Therapy: Right
NCT01190930 (41) [back to overview]Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL 12 Months Post Therapy: Left
NCT01190930 (41) [back to overview]Burden of Therapy in Boy AR Patients Overall at End of Therapy: Social Functioning
NCT01190930 (41) [back to overview]Burden of Therapy in Boy AR Patients Overall at End of Therapy: Physical
NCT01190930 (41) [back to overview]Burden of Therapy in Boy AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Therapy: Social Functioning
NCT01190930 (41) [back to overview]Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 4: Emotional
NCT01190930 (41) [back to overview]Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 1: Social Functioning
NCT01190930 (41) [back to overview]Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 1: Physical
NCT01190930 (41) [back to overview]Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 1: Emotional
NCT01190930 (41) [back to overview]Burden of Therapy in AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 4: Emotional
NCT01190930 (41) [back to overview]Burden of Therapy in AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 4: Physical
NCT01190930 (41) [back to overview]Burden of Therapy in AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 4: Social Functioning
NCT01190930 (41) [back to overview]Burden of Therapy in AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Emotional
NCT01190930 (41) [back to overview]Burden of Therapy in AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Physical
NCT01190930 (41) [back to overview]Burden of Therapy in AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Social Functioning
NCT01190930 (41) [back to overview]Burden of Therapy in AR Patients Overall at End of Consolidation Therapy: Emotional
NCT01190930 (41) [back to overview]Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 4: Physical
NCT01190930 (41) [back to overview]Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 4: Social Functioning
NCT01190930 (41) [back to overview]Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Emotional
NCT01190930 (41) [back to overview]Burden of Therapy in AR Patients Overall at End of Consolidation Therapy: Social Functioning
NCT01190930 (41) [back to overview]Burden of Therapy in Boy AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Therapy: Physical
NCT01190930 (41) [back to overview]Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Physical
NCT01190930 (41) [back to overview]Burden of Therapy in Boy AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Therapy: Emotional
NCT01190930 (41) [back to overview]Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Social Functioning
NCT01190930 (41) [back to overview]Burden of Therapy in AR Patients Overall at End of Consolidation Therapy: Physical
NCT01190930 (41) [back to overview]Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL at End of Maintenance Cycle 1: Left
NCT01190930 (41) [back to overview]Sample Collection of Central Path Review Slides in B-LLy Patients
NCT01190930 (41) [back to overview]Overall Survival (OS) for B-LLy Patients
NCT01190930 (41) [back to overview]Event Free Survival (EFS) for B-LLy Patients
NCT01190930 (41) [back to overview]Disease Free Survival (DFS) in Average Risk (AR) Patients Based on the Methotrexate Dose Randomization
NCT01190930 (41) [back to overview]DFS in Low Risk (LR) Patients Based on Randomization to 1 of 2 Low-intensity Regimens
NCT01190930 (41) [back to overview]DFS in Average Risk (AR) Patients Based on the Pulse Frequency Randomization
NCT01190930 (41) [back to overview]DFS for SR Down Syndrome Patients With Standardized Treatment and Enhanced Supportive Care
NCT01190930 (41) [back to overview]Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Right
NCT01190930 (41) [back to overview]Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Left
NCT01190930 (41) [back to overview]Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Right
NCT01190930 (41) [back to overview]Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Left
NCT01212822 (4) [back to overview]Progression Free Survival
NCT01212822 (4) [back to overview]Disease-free Survival
NCT01212822 (4) [back to overview]Complete and Partial Response to Neoadjuvant Therapy Based on the Response Evaluation Criteria in Solid Tumors (RECIST)
NCT01212822 (4) [back to overview]Overall Survival
NCT01217814 (1) [back to overview]Pharmacokinetic (PK) Parameter: Serum Concentration of Functional and Bound Sarilumab
NCT01226719 (5) [back to overview]Progression-free Survival (PFS)
NCT01226719 (5) [back to overview]To Determine the Acute Toxicity Produced by This Regimen.
NCT01226719 (5) [back to overview]R0 Resection Rate
NCT01226719 (5) [back to overview]Overall Survival (OS)
NCT01226719 (5) [back to overview]Overall Response Rate (ORR)
NCT01227707 (13) [back to overview]Percentage of Participants With New Lesions at the Primary Tumor Site at the End of Neoadjuvant Treatment
NCT01227707 (13) [back to overview]Percentage of Participants With Pathological Complete Response (pCR)
NCT01227707 (13) [back to overview]DFS - Time to Event
NCT01227707 (13) [back to overview]Time to Disease Progression (TTP) - Percentage of Participants With an Event
NCT01227707 (13) [back to overview]Disease-Free Survival (DFS) - Percentage of Participants With an Event
NCT01227707 (13) [back to overview]OS - Time to Event
NCT01227707 (13) [back to overview]Overall Survival (OS) - Percentage of Participants With an Event
NCT01227707 (13) [back to overview]Percentage of Participants With an Overall Response of CR at the End of Neoadjuvant Treatment
NCT01227707 (13) [back to overview]TTP - Time to Event
NCT01227707 (13) [back to overview]Percentage of Participants by Primary Tumor (T), Regional Lymph Nodes (N), and Distant Metastasis (M) Clinical Stage at Baseline and at the End of Neo-Adjuvant Treatment (NAT)
NCT01227707 (13) [back to overview]Percentage of Participants Undergoing Sphincter-Saving Surgery by Type of Procedure
NCT01227707 (13) [back to overview]Percentage of Participants With Complete Response (CR) at the End of Neoadjuvant Treatment
NCT01227707 (13) [back to overview]Percentage of Participants With Relapse During Follow-Up
NCT01228734 (5) [back to overview]Best Overall Response Rate (ORR)
NCT01228734 (5) [back to overview]Overall Survival (OS) Time
NCT01228734 (5) [back to overview]Progression Free Survival (PFS) Time
NCT01228734 (5) [back to overview]Time to Treatment Failure (TTF)
NCT01228734 (5) [back to overview]Number of Subjects With Curative Surgery of Liver Metastases
NCT01229111 (4) [back to overview]Progression Free Survival
NCT01229111 (4) [back to overview]Estimation of Overall Survival
NCT01229111 (4) [back to overview]Tabulation of the Toxicity Profile of the Combination Therapy
NCT01229111 (4) [back to overview]The Response Rate of Patients Evaluated Using the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
NCT01231399 (4) [back to overview]Number of Subject With Overall Response
NCT01231399 (4) [back to overview]Maximum Tolerated Dose (MTD) of Everolimus
NCT01231399 (4) [back to overview]Progression-free Survival
NCT01231399 (4) [back to overview]Overall Survival
NCT01246960 (7) [back to overview]Progression-Free Survival (PFS)
NCT01246960 (7) [back to overview]Duration of Response
NCT01246960 (7) [back to overview]Time to Disease Progression (TTP)
NCT01246960 (7) [back to overview]Number of Participants With Adverse Events (AEs)
NCT01246960 (7) [back to overview]Number of Participants With Treatment-Emergent Anti-Ramucirumab Antibodies
NCT01246960 (7) [back to overview]Overall Survival (OS)
NCT01246960 (7) [back to overview]Percentage of Participants Achieving an Objective Response (Objective Response Rate)
NCT01256398 (6) [back to overview]Response
NCT01256398 (6) [back to overview]Disease Free Survival Defined From the Date of First Induction Complete Response (CR) to Relapse or Death Due to Any Cause
NCT01256398 (6) [back to overview]Feasibility of Maintenance Therapy in This Patient Population (Restricted to Those Patients Achieving a CR). Feasibility Will be Defined as the Number of Deaths Ocuring.
NCT01256398 (6) [back to overview]Probability of Being BCR-ABL Negative in the Bone Marrow and Peripheral Blood at the Completion of the CNS Prophylaxis Course (Restricted to Those Patients Achieving a CR)
NCT01256398 (6) [back to overview]Overall Survival (OS)
NCT01256398 (6) [back to overview]Disease Free Survival (DFS)
NCT01276379 (5) [back to overview]Response Duration
NCT01276379 (5) [back to overview]Overall Survival
NCT01276379 (5) [back to overview]Frequency of Adverse Events
NCT01276379 (5) [back to overview]Progression Free Survival
NCT01276379 (5) [back to overview]Secondary Biomarkers Analysis
NCT01279681 (4) [back to overview]Number of Participants With Grade 3 Adverse Events At Least Possibly Related to Treatment
NCT01279681 (4) [back to overview]Response Rate, Defined as the Percentage of Patients in Each Arm Who Have an Objective Status of Complete Response or Partial Response, Confirmed by a Second Assessment Measured at Least 6 Weeks From the Initial Assessment
NCT01279681 (4) [back to overview]Progression-Free Survival
NCT01279681 (4) [back to overview]Overall Survival
NCT01286818 (9) [back to overview]Steady State Volume of Distribution (Vss) of Ramucirumab
NCT01286818 (9) [back to overview]Number of Participants With Serum Anti-IMC-1121B Antibodies (Immunogenicity)
NCT01286818 (9) [back to overview]Number of Participants With Ramucirumab Drug-Related Adverse Events or Serious Adverse Events
NCT01286818 (9) [back to overview]Maximum Concentration (Cmax) of Ramucirumab
NCT01286818 (9) [back to overview]Half Life (t1/2) of Ramucirumab
NCT01286818 (9) [back to overview]Clearance (CL) of Ramucirumab
NCT01286818 (9) [back to overview]Area Under the Curve (AUC) of Ramucirumab
NCT01286818 (9) [back to overview]Best Overall Response [Anti-Tumor Activity of FOLFIRI Plus Ramucirumab (IMC-1121B)]
NCT01286818 (9) [back to overview]Number of Participants That Experienced Any Dose-Limiting Toxicities (DLT) During the DLT Assessment Period
NCT01289821 (6) [back to overview]Duration of Response (DOR)
NCT01289821 (6) [back to overview]Overall Survival (OS)
NCT01289821 (6) [back to overview]Progression-free Survival (PFS)
NCT01289821 (6) [back to overview]Duration of Stable Disease (DOSD)
NCT01289821 (6) [back to overview]Objective Response (OR)
NCT01289821 (6) [back to overview]Disease Control (DC)
NCT01298570 (4) [back to overview]Percentage of Patients With Severe Adverse Events
NCT01298570 (4) [back to overview]Progression Free Survival (PFS)
NCT01298570 (4) [back to overview]Overall Survival (OS)
NCT01298570 (4) [back to overview]Drug Metabolism
NCT01307956 (4) [back to overview]Complete Pathological Response (pCR) Rate
NCT01307956 (4) [back to overview]Number of Patients Who Can Undergo Resection
NCT01307956 (4) [back to overview]Overall Survival
NCT01307956 (4) [back to overview]Progression-free Survival
NCT01322815 (1) [back to overview]Number of Participants Alive and Free of Progression at 4 Months (Patients Who Have Undergone Prior Therapy) and 10 Months (Untreated Patients)
NCT01327612 (6) [back to overview]Number of Participants With CTCAE Grade 3 or Higher Clinical Laboratory Toxicities
NCT01327612 (6) [back to overview]Maximum Change From Baseline in Blood Pressure
NCT01327612 (6) [back to overview]Minimum Change From Baseline in Blood Pressure
NCT01327612 (6) [back to overview]Number of Participants With Disease Progression or Death Due to Disease Progression
NCT01327612 (6) [back to overview]Number of Participants With Adverse Events
NCT01327612 (6) [back to overview]Number of Participants With Serious Adverse Events
NCT01333033 (5) [back to overview]Complete Pathological Response (pCR) of PET/CT Non-responders
NCT01333033 (5) [back to overview]Progression Free Survival (PFS) Among PET/CT Non-responders Within Each Induction Treatment Group
NCT01333033 (5) [back to overview]PET/CT Response Between Treatment Arms
NCT01333033 (5) [back to overview]pCR Compared Between Induction Treatment Arms Among PET/CT Responders
NCT01333033 (5) [back to overview]pCR Compared Among Non-responders Between Induction Treatment Arms if Treatment Regimens Are Found to be Efficacious
NCT01359007 (1) [back to overview]Number of Participants Who Experienced Toxicity
NCT01363843 (2) [back to overview]Evaluate the Toxicity of Study Therapy
NCT01363843 (2) [back to overview]Incidence of Complete Resection
NCT01374425 (37) [back to overview]OS in Participants With High ERCC-1 Levels
NCT01374425 (37) [back to overview]OS in Participants With High ERCC-1 Levels Versus Participants With Low ERCC-1 Levels
NCT01374425 (37) [back to overview]OS in Participants With High VEGF-A Levels Versus Participants With Low VEGF-A Levels
NCT01374425 (37) [back to overview]OS in Participants With Low ERCC-1 Levels
NCT01374425 (37) [back to overview]OS in Participants With Wild-Type KRAS Versus Participants With Mutant KRAS
NCT01374425 (37) [back to overview]Overall Survival (OS)
NCT01374425 (37) [back to overview]Percentage of Participants With Complete Liver Metastasis Resection
NCT01374425 (37) [back to overview]Percentage of Participants With Complete Liver Metastasis Resection in Participants With High ERCC-1 Levels
NCT01374425 (37) [back to overview]Percentage of Participants With Disease Control According to RECIST Version 1.1 in Participants With High VEGF-A Levels Versus Participants With Low VEGF-A Levels
NCT01374425 (37) [back to overview]Percentage of Participants With Disease Control According to RECIST Version 1.1 in Participants With High ERCC-1 Levels Versus Participants With Low ERCC-1 Levels
NCT01374425 (37) [back to overview]Percentage of Participants With Disease Control According to RECIST Version 1.1 in Participants With High ERCC-1 Levels
NCT01374425 (37) [back to overview]Percentage of Participants With Objective Response According to RECIST Version 1.1 in Participants With Low ERCC-1 Levels
NCT01374425 (37) [back to overview]Percentage of Participants With Disease Control According to RECIST Version 1.1
NCT01374425 (37) [back to overview]Percentage of Participants With Objective Response According to RECIST Version 1.1 in Participants With Wild-Type KRAS Versus Participants With Mutant KRAS
NCT01374425 (37) [back to overview]PFS According to RECIST Version 1.1 in Participants With High ERCC-1 and High VEGF-A Levels
NCT01374425 (37) [back to overview]Percentage of Participants With Complete Liver Metastasis Resection in Participants With Low ERCC-1 Levels
NCT01374425 (37) [back to overview]Percentage of Participants With Complete Liver Metastasis Resection in Participants With High VEGF-A Levels Versus Participants With Low VEGF-A Levels
NCT01374425 (37) [back to overview]Percentage of Participants With Complete Liver Metastasis Resection in Participants With High ERCC-1 Levels Versus Participants With Low ERCC-1 Levels
NCT01374425 (37) [back to overview]PFS According to RECIST Version 1.1 in Participants With High ERCC-1 and Low VEGF-A Levels
NCT01374425 (37) [back to overview]PFS According to RECIST Version 1.1 in Participants With High ERCC-1 Levels
NCT01374425 (37) [back to overview]PFS According to RECIST Version 1.1 in Participants With High ERCC-1 Levels Versus Participants With Low ERCC-1 Levels
NCT01374425 (37) [back to overview]PFS According to RECIST Version 1.1 in Participants With High Vascular Endothelial Growth Factor (VEGF)-A Levels Versus Participants With Low VEGF-A Levels
NCT01374425 (37) [back to overview]PFS According to RECIST Version 1.1 in Participants With Low ERCC-1 and High VEGF-A Levels
NCT01374425 (37) [back to overview]PFS According to RECIST Version 1.1 in Participants With Low ERCC-1 and Low VEGF-A Levels
NCT01374425 (37) [back to overview]PFS According to RECIST Version 1.1 in Participants With Low ERCC-1 Levels
NCT01374425 (37) [back to overview]PFS According to RECIST Version 1.1 in Participants With Wild-Type V-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Versus Participants With Mutant KRAS
NCT01374425 (37) [back to overview]Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
NCT01374425 (37) [back to overview]Percentage of Participants With Objective Response According to RECIST Version 1.1 in Participants With High ERCC-1 Levels Versus Participants With Low ERCC-1 Levels
NCT01374425 (37) [back to overview]Percentage of Participants With Objective Response According to RECIST Version 1.1 in Participants With High VEGF-A Levels Versus Participants With Low VEGF-A Levels
NCT01374425 (37) [back to overview]Percentage of Participants With Objective Response According to RECIST Version 1.1 in Participants With High ERCC-1 Levels
NCT01374425 (37) [back to overview]Percentage of Participants With Objective Response According to RECIST Version 1.1
NCT01374425 (37) [back to overview]Percentage of Participants With Liver Metastasis Resection in Participants With Low ERCC-1 Levels
NCT01374425 (37) [back to overview]Percentage of Participants With Liver Metastasis Resection in Participants With High VEGF-A Levels Versus Participants With Low VEGF-A Levels
NCT01374425 (37) [back to overview]Percentage of Participants With Liver Metastasis Resection in Participants With High ERCC-1 Levels Versus Participants With Low ERCC-1 Levels
NCT01374425 (37) [back to overview]Percentage of Participants With Liver Metastasis Resection in Participants With High ERCC-1 Levels
NCT01374425 (37) [back to overview]Percentage of Participants With Liver Metastasis Resection
NCT01374425 (37) [back to overview]Percentage of Participants With Disease Control According to RECIST Version 1.1 in Participants With Low ERCC-1 Levels
NCT01383707 (6) [back to overview]Progression-Free Survival (PFS)
NCT01383707 (6) [back to overview]Percentage of Participants Achieving No Residual Tumor (R0)/Surgical Margin With Microscopic Residual Tumor (R1) Liver Resection
NCT01383707 (6) [back to overview]Overall Survival (OS)
NCT01383707 (6) [back to overview]Objective Response Rate (ORR) in the Per-protocol Analysis Set (PPAS)
NCT01383707 (6) [back to overview]Disease-free Interval (DFI)
NCT01383707 (6) [back to overview]Objective Response Rate (ORR) in the Intent-to-treat (ITT) Analysis Set
NCT01412879 (4) [back to overview]Progression-Free Survival (PFS) at 2 Years
NCT01412879 (4) [back to overview]Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug
NCT01412879 (4) [back to overview]5-year Overall Survival (OS)
NCT01412879 (4) [back to overview]Response Rate (Complete and Partial Response)
NCT01479465 (3) [back to overview]Progression Free Survival (PFS)
NCT01479465 (3) [back to overview]Objective Response Rate (ORR)
NCT01479465 (3) [back to overview]Overall Survival (OS)
NCT01481545 (7) [back to overview]Number of Participants With Adverse Events
NCT01481545 (7) [back to overview]Clinical Response Rate
NCT01481545 (7) [back to overview]Percentage of Patients With Complete Tumor Regression Rate (TRG1)
NCT01481545 (7) [back to overview]Progression Free Survival (PFS)
NCT01481545 (7) [back to overview]Patients With Metastatic Lymphnodes at Pathology Exam After Surgery
NCT01481545 (7) [back to overview]Overall Survival (OS)
NCT01481545 (7) [back to overview]Number of Patients With Sphincter Preservation
NCT01490866 (5) [back to overview]Overall Survival (OS)
NCT01490866 (5) [back to overview]Progression-free Survival
NCT01490866 (5) [back to overview]Time To Progression (TTP)
NCT01490866 (5) [back to overview]Frequency of Adverse Events as a Measure of Safety
NCT01490866 (5) [back to overview]Objective Response Rate
NCT01494506 (8) [back to overview]EORTC-QLQ-C30
NCT01494506 (8) [back to overview]Time to Treatment Failure
NCT01494506 (8) [back to overview]Progression Free Survival
NCT01494506 (8) [back to overview]Pharmacokinetic Measurements of Total Irinotecan
NCT01494506 (8) [back to overview]Objective Response Rate
NCT01494506 (8) [back to overview]Overall Survival
NCT01494506 (8) [back to overview]Percentage of Patients With Clinical Benefit Response
NCT01494506 (8) [back to overview]Percentage of Patients With Tumor Marker (CA 19-9) Response
NCT01498289 (6) [back to overview]PFS Variation by ERCC1
NCT01498289 (6) [back to overview]Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs
NCT01498289 (6) [back to overview]Overall Response Rate (ORR)
NCT01498289 (6) [back to overview]Overall Survival (OS)
NCT01498289 (6) [back to overview]PFS in Low-ERCC1 Participants
NCT01498289 (6) [back to overview]Progression-free Survival (PFS) in High-ERCC1 Patients
NCT01516216 (9) [back to overview]Plasma 25-hydroxyvitamin D Levels
NCT01516216 (9) [back to overview]Grade 3-5 Treatment-Related Neutropenia Toxicity Rate
NCT01516216 (9) [back to overview]Hazard Ratio Between Baseline Plasma 25(OH)D Level and PFS
NCT01516216 (9) [back to overview]Hazard Ratio Between Baseline Plasma 25(OH)D Levels and OS
NCT01516216 (9) [back to overview]Median Overall Survival (OS)
NCT01516216 (9) [back to overview]Median Progression-free Survival (PFS)
NCT01516216 (9) [back to overview]Number of Participants With Vitamin D Deficiency at Baseline
NCT01516216 (9) [back to overview]Objective Response Rate
NCT01516216 (9) [back to overview]Vitamin D Sufficiency Rate
NCT01535053 (6) [back to overview]Percentage of Participants With Complete Response
NCT01535053 (6) [back to overview]The Number of Participants With Post Protocol Multi-agent Chemotherapy Treatment for Each Arm.
NCT01535053 (6) [back to overview]The Number of Participants With Post Protocol Surgical Treatment for Each Arm.
NCT01535053 (6) [back to overview]Number of Participants With CTCAE v4 Graded Adverse Events With Low-risk Gestational Trophoblastic Neoplasia by Arm
NCT01535053 (6) [back to overview]Patient-reported Quality of Life (QOL) After Baseline Visit.
NCT01535053 (6) [back to overview]Patient-reported Quality of Life (QOL) at Baseline
NCT01576705 (2) [back to overview]GMDS (Griffiths Mental Development Scale)
NCT01576705 (2) [back to overview]BL (Brunet Lezine Revised Scale)
NCT01581307 (3) [back to overview]Overall Response Rate (ORR)
NCT01581307 (3) [back to overview]Median Overall Survival (OS)
NCT01581307 (3) [back to overview]Rate of Progression Free Survival (PFS)
NCT01588990 (22) [back to overview]PFS Until Second Disease Progression as Assessed by the Investigator Based on Routine Clinical Practice: Phase B
NCT01588990 (22) [back to overview]OS: Phase B
NCT01588990 (22) [back to overview]Functional Assessment of Cancer Therapy-Colorectal (FACT-C) Score: Phase A
NCT01588990 (22) [back to overview]Percentage of Participants With Confirmed Complete or Partial Response as Assessed by the Investigator Based on Routine Clinical Practice: Overall
NCT01588990 (22) [back to overview]Percentage of Participants With Confirmed Complete or Partial Response as Assessed by the Investigator Based on Routine Clinical Practice: Phase A
NCT01588990 (22) [back to overview]Percentage of Participants With Confirmed Complete or Partial Response as Assessed by the Investigator Based on Routine Clinical Practice: Phase B
NCT01588990 (22) [back to overview]Duration of Disease Control (DDC) as Assessed by the Investigator Based on Routine Clinical Practice: Overall
NCT01588990 (22) [back to overview]Association Between NLR Normalization (First NLR Post-Baseline ≤5 Versus NLR >5) and PFS as Assessed by Hazard Ratio
NCT01588990 (22) [back to overview]Association Between Longitudinal NLR (Longitudinal NLR ≤5 Versus NLR >5) and OS as Assessed by Hazard Ratio
NCT01588990 (22) [back to overview]Association Between NLR (NLR ≤5 Versus NLR >5) and OS as Assessed by Hazard Ratio
NCT01588990 (22) [back to overview]Association Between Neutrophil to Lymphocyte Ratio (NLR) [NLR ≤5 Versus NLR >5] and Progression-Free Survival (PFS) as Assessed by Hazard Ratio
NCT01588990 (22) [back to overview]Overall Survival (OS) From the Start of Treatment to Study Completion: Overall
NCT01588990 (22) [back to overview]Percentage of Participants Who Underwent Liver Resection: Overall
NCT01588990 (22) [back to overview]PFS Until First Disease Progression as Assessed by the Investigator Based on Routine Clinical Practice: Phase A
NCT01588990 (22) [back to overview]Association Between Longitudinal NLR (Longitudinal NLR ≤5 Versus NLR >5) and PFS as Assessed by Hazard Ratio
NCT01588990 (22) [back to overview]Survival Beyond First Disease Progression: Overall
NCT01588990 (22) [back to overview]Time to Failure of Strategy (TFS): Overall
NCT01588990 (22) [back to overview]AQoL-8D Global Utility Score: Phase B
NCT01588990 (22) [back to overview]FACT-C Score: Phase B
NCT01588990 (22) [back to overview]EuroQol-5D Utility Score: Phase B
NCT01588990 (22) [back to overview]European Quality of Life 5-Dimension (EuroQol-5D) Utility Score: Phase A
NCT01588990 (22) [back to overview]Assessment of Quality of Life - Eight Dimensions (AQoL-8D) Global Utility Score: Phase A
NCT01611857 (4) [back to overview]Progression Free Survival in Phase II Dose Expansion
NCT01611857 (4) [back to overview]The Incidence of Dose Limiting Toxicities (DLT) in Phase I Dose Escalation
NCT01611857 (4) [back to overview]Time to Progression in Phase II Dose Expansion
NCT01611857 (4) [back to overview]Overall Survival in Phase II Dose Expansion
NCT01622543 (4) [back to overview]Objective Response Rate
NCT01622543 (4) [back to overview]Changes in CEA Levels
NCT01622543 (4) [back to overview]Overall Survival
NCT01622543 (4) [back to overview]Progression Free Survival
NCT01632306 (4) [back to overview]Progression Free Survival (PFS)
NCT01632306 (4) [back to overview]Percentage of Participants With Complete Response (CR) or Partial Response (PR) [Overall Response Rate (ORR)]
NCT01632306 (4) [back to overview]Overall Survival (OS)
NCT01632306 (4) [back to overview]Percentage of Participants Who Survived at 6 Months
NCT01634555 (6) [back to overview]Pharmacokinetics: Dose-Normalized Maximum Observed Drug Concentration (Cmax) of Irinotecan and Its Metabolite SN-38 in Cycle 1
NCT01634555 (6) [back to overview]Pharmacokinetics: Dose-Normalized Area Under the Concentration Versus Time Curve of Irinotecan and Its Metabolite SN-38 From Time Zero to Infinity [AUC(0-∞)] in Cycle 1
NCT01634555 (6) [back to overview]Pharmacokinetics: Cmax of Ramucirumab (IMC-1121B)
NCT01634555 (6) [back to overview]Pharmacokinetics: Dose-Normalized Cmax of Irinotecan and Its Metabolite SN-38 in Cycle 2
NCT01634555 (6) [back to overview]Pharmacokinetics: Dose-Normalized AUC(0-∞) of Irinotecan and Its Metabolite SN-38 in Cycle 2
NCT01634555 (6) [back to overview]Number of Participants With Treatment Emergent Anti-Drug Antibodies (TE-ADA)
NCT01652976 (11) [back to overview]Progression Free Survival (PFS)
NCT01652976 (11) [back to overview]Median Time To Progression
NCT01652976 (11) [back to overview]Median Overall Survival
NCT01652976 (11) [back to overview]Freedom From Metastasis
NCT01652976 (11) [back to overview]Drug Compliance
NCT01652976 (11) [back to overview]Clinical Benefit Rate
NCT01652976 (11) [back to overview]Safety and Tolerability
NCT01652976 (11) [back to overview]Quality of Life, as Measured by the Cancer Therapy Satisfaction Questionnaire (CTSQ), 2007
NCT01652976 (11) [back to overview]Quality of Life, as Measured by the Functional Assessment of Chronic Illness Therapy; Hepatobiliary Cancer (FACT-Hep) Questionnaire (Version 4.0)
NCT01652976 (11) [back to overview]Site of Failure
NCT01652976 (11) [back to overview]Response Rate
NCT01660711 (2) [back to overview]Percentage Able to Complete Full Course of Preoperative Chemotherapy
NCT01660711 (2) [back to overview]Percentage Able to Complete Full Course of Therapy
NCT01666730 (5) [back to overview]Median Overall Survival (OS)
NCT01666730 (5) [back to overview]Response Rate (RR) Objective Tumor Response Based on Computed Tomography (CT) Scans or Magnetic Resonance Imaging (MRI) Scans According to Response Evaluation Criteria in Solid Tumors (RECIST)
NCT01666730 (5) [back to overview]Number of Grade 3 and 4 Toxicities According to NCI CTCAE Version 4.0
NCT01666730 (5) [back to overview]Progression Free Survival According to RECIST 1.1 Criteria
NCT01666730 (5) [back to overview]Clinical Benefit Rate (CBR) Based on Computed Tomography (CT) Scans or Magnetic Resonance Imaging (MRI) Scans According to RECIST
NCT01670721 (4) [back to overview]Change From Baseline in Health Related Quality of Life (HRQL) European Organization for Research and Treatment for Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)
NCT01670721 (4) [back to overview]Change From Baseline in HRQL EQ-5D-3L VAS Score
NCT01670721 (4) [back to overview]Percentage of Participants With Adverse Events (AEs)
NCT01670721 (4) [back to overview]Change From Baseline in HRQL European-Quality of Life-5 Dimension Instrument-3 Levels (EQ-5D-3L) Index Score
NCT01681472 (43) [back to overview]Concentration of [6S]-5-THF in Adjacent Mucosa Tissue
NCT01681472 (43) [back to overview]Concentration of [6S]-5-methyl-THF in Tumor Tissue
NCT01681472 (43) [back to overview]Concentration of [6S]-5-methyl-THF in Adjacent Mucosa Tissue
NCT01681472 (43) [back to overview]Concentration of [6S]-5-formyl-THF in Tumor Tissue
NCT01681472 (43) [back to overview]Concentration of [6S]-5-formyl-THF in Adjacent Mucosa Tissue
NCT01681472 (43) [back to overview]Concentration of [6R]-5,10-methylene-THF in Tumor Tissue
NCT01681472 (43) [back to overview]Concentration of [6R]-5,10-methylene-THF in Adjacent Mucosa Tissue
NCT01681472 (43) [back to overview]Cmax of [6S]-5-THF in Plasma
NCT01681472 (43) [back to overview]Cmax of [6S]-5-methyl-THF in Plasma
NCT01681472 (43) [back to overview]Cmax of [6S]-5-formyl-THF in Plasma
NCT01681472 (43) [back to overview]AUC(Last) of [6R]-5,10-methylene-THF
NCT01681472 (43) [back to overview]Cmax of [6R]-5,10-methylene-THF
NCT01681472 (43) [back to overview]Gene Expression Ratios (Mucosa:Tumor)
NCT01681472 (43) [back to overview]Correlation of Gene Expression in Tumor and Adjacent Mucosa
NCT01681472 (43) [back to overview]Correlation Between Plasma and Tissue Concentration (Tumor and Mucosa) for [6S]-5-THF
NCT01681472 (43) [back to overview]Correlation Between Plasma and Tissue Concentration (Tumor and Mucosa) for [6S]-5-methyl-THF
NCT01681472 (43) [back to overview]Correlation Between Plasma and Tissue Concentration (Tumor and Mucosa) for [6S]-5-formyl-THF
NCT01681472 (43) [back to overview]Correlation Between Plasma and Tissue Concentration (Tumor and Mucosa) for [6R]-5,10-methylene-THF
NCT01681472 (43) [back to overview]Change in S-Folate Concentration From Screening
NCT01681472 (43) [back to overview]Change in Homocystein Concentration From Screening
NCT01681472 (43) [back to overview]Tmax of [6S]-5-THF
NCT01681472 (43) [back to overview]Tmax of [6S]-5-methyl-THF
NCT01681472 (43) [back to overview]Tmax of [6S]-5-formyl-THF
NCT01681472 (43) [back to overview]Tmax of [6R]-5,10-methylene-THF
NCT01681472 (43) [back to overview]T(Last) of [6S]-5-THF
NCT01681472 (43) [back to overview]T(Last) of [6S]-5-methyl-THF
NCT01681472 (43) [back to overview]AUC(0-2h) of [6R]-5,10-methylene-THF
NCT01681472 (43) [back to overview]AUC(0-2h) of [6S]-5-methyl-THF
NCT01681472 (43) [back to overview]AUC(0-2h) of [6S]-5-THF
NCT01681472 (43) [back to overview]AUC(0-2h) of [6SR]-5-formyl-THF
NCT01681472 (43) [back to overview]AUC(Last) of [6S]-5-THF
NCT01681472 (43) [back to overview]AUC(Last) of [6S]-5-methyl-THF
NCT01681472 (43) [back to overview]AUC(Last) of [6S]-5-formyl-THF
NCT01681472 (43) [back to overview]T(Last) of [6S]-5-formyl-THF
NCT01681472 (43) [back to overview]T(Last) of [6R]-5,10-methylene-THF
NCT01681472 (43) [back to overview]T(1/2) of [6S]-5-THF
NCT01681472 (43) [back to overview]T(1/2) of [6S]-5-methyl-THF
NCT01681472 (43) [back to overview]T(1/2) of [6S]-5-formyl-THF
NCT01681472 (43) [back to overview]T(1/2) of [6R]-5,10-methylene-THF
NCT01681472 (43) [back to overview]Concentration of [6S]-5-THF in Tumor Tissue
NCT01681472 (43) [back to overview]S-Folate Concentration
NCT01681472 (43) [back to overview]Number of AEs Per Severity
NCT01681472 (43) [back to overview]Homocystein Concentration
NCT01688336 (6) [back to overview]Progression Free Survival (PFS)
NCT01688336 (6) [back to overview]Overall Survival for Borderline Resectable Patients
NCT01688336 (6) [back to overview]Objective Response Rate
NCT01688336 (6) [back to overview]Median Overall Survival (OS) of FOLFIRINOX in Patients With Unresectable Locally Advanced (ULA) Pancreatic Cancer
NCT01688336 (6) [back to overview]Disease Control Rate (DCR)
NCT01688336 (6) [back to overview]Rate of Resectability (RR)
NCT01715233 (3) [back to overview]Response
NCT01715233 (3) [back to overview]CHFR Methylation Status
NCT01715233 (3) [back to overview]Overall Survival
NCT01718873 (5) [back to overview]Objective Response Rate
NCT01718873 (5) [back to overview]Overall Survival
NCT01718873 (5) [back to overview]Progression-free Survival (PFS)
NCT01718873 (5) [back to overview]Toxic Effects
NCT01718873 (5) [back to overview]Disease Control Rate
NCT01726582 (4) [back to overview]Number of Subjects Completing Therapy Including Surgical Resection.
NCT01726582 (4) [back to overview]Overall Survival in Months
NCT01726582 (4) [back to overview]Progression-free Survival
NCT01726582 (4) [back to overview]Use of Biomarkers to Determine Course of Treatment
NCT01747551 (4) [back to overview]Objective Response Rate (ORR)
NCT01747551 (4) [back to overview]6-month Progression-free Survival (PFS)
NCT01747551 (4) [back to overview]Duration of Objective Response
NCT01747551 (4) [back to overview]Grade 4 Treatment-Related Toxicity Rate
NCT01749956 (7) [back to overview]Disease-Free Survival
NCT01749956 (7) [back to overview]The Number of Participants Who Experienced Serious or Non-Serious Adverse Events as a Measure of Safety.
NCT01749956 (7) [back to overview]Overall Survival Probability at 6 and 12 Months
NCT01749956 (7) [back to overview]Disease Free Survival Probability at 6 and 12 Months
NCT01749956 (7) [back to overview]Sphincter Preservation Rate
NCT01749956 (7) [back to overview]Pathologic Complete Response Rate
NCT01749956 (7) [back to overview]Overall Survival
NCT01765582 (7) [back to overview]Proportion of Participants Who Underwent Liver Metastases Resections
NCT01765582 (7) [back to overview]Time to PFS2
NCT01765582 (7) [back to overview]Overall Survival (OS)
NCT01765582 (7) [back to overview]Percentage of Participants With Adverse Events
NCT01765582 (7) [back to overview]Percentage of Participants With Overall Response During First-Line Therapy (ORR1)
NCT01765582 (7) [back to overview]Progression-Free Survival During First-Line Therapy (PFS1)
NCT01765582 (7) [back to overview]Proportion of Participants Considered by the Investigator to be Unresectable on Study Enrollment Who Subsequently Underwent Attempted Curative Resections of Metastases
NCT01775501 (6) [back to overview]Time to Progression
NCT01775501 (6) [back to overview]Overall Response Rate
NCT01775501 (6) [back to overview]Duration of Response
NCT01775501 (6) [back to overview]Median Overall Survival
NCT01775501 (6) [back to overview]Median Progression Free Survival
NCT01775501 (6) [back to overview]Number of Patients Experiencing Adverse Events
NCT01803282 (2) [back to overview]Percentage of Participants Experiencing Laboratory Abnormalities
NCT01803282 (2) [back to overview]Percentage of Participants Experiencing Treatment-Emergent Adverse Events
NCT01821729 (2) [back to overview]Number of Participants With R0 Resection
NCT01821729 (2) [back to overview]Progression-Free Survival
NCT01882868 (27) [back to overview]Maximum Observed Plasma Concentration (Cmax) for Free and Vascular Endothelial Growth Factor (VEGF)-Bound Aflibercept: Participants With Additional Blood Sampling for Detailed PK Analysis
NCT01882868 (27) [back to overview]Area Under the Concentration Time Curve From Time 0 to the Time of Last Quantifiable Concentration (AUClast) for Irinotecan and Its Active Metabolite SN-38: Participants With Additional Blood Sampling for Detailed PK Analysis
NCT01882868 (27) [back to overview]Area Under the Concentration Time Curve From Time 0 to the Time of Last Quantifiable Concentration (AUClast) for Free and VEGF-Bound Aflibercept: Participants With Additional Blood Sampling for Detailed PK Analysis
NCT01882868 (27) [back to overview]Area Under the Concentration Time Curve From Time 0 to 14 Days Post Start of Infusion (AUC0-14 Day) for Free and VEGF-Bound Aflibercept: Participants With Additional Blood Sampling for Detailed PK Analysis
NCT01882868 (27) [back to overview]Area Under the Concentration Time Curve (AUC) for Irinotecan and Its Active Metabolite SN-38: Participants With Additional Blood Sampling for Detailed PK Analysis
NCT01882868 (27) [back to overview]Aflibercept Immunogenicity Assessment: Number of Participants With Positive Sample(s) in the Anti-drug Antibodies (ADA) Assay and in the Neutralizing Anti-drug Antibodies (NAb) Assay
NCT01882868 (27) [back to overview]Volume of Distribution at the Steady State (Vss) for Irinotecan: Participants With Additional Blood Sampling for Detailed PK Analysis
NCT01882868 (27) [back to overview]Volume of Distribution at the Steady State (Vss) for Free Aflibercept: Participants With Additional Blood Sampling for Detailed PK Analysis
NCT01882868 (27) [back to overview]Volume of Distribution at the Steady State (Vss) for Free Aflibercept: ITT Population
NCT01882868 (27) [back to overview]Total Body Clearance (CL) for Irinotecan: Participants With Additional Blood Sampling for Detailed PK Analysis
NCT01882868 (27) [back to overview]Total Body Clearance (CL) for Free Aflibercept: ITT Population
NCT01882868 (27) [back to overview]Terminal Elimination Half-life (t1/2z) for Free Aflibercept: Participants With Additional Blood Sampling for Detailed PK Analysis
NCT01882868 (27) [back to overview]Steady State Drug Concentration (Css) for 5-FU: Participants With Additional Blood Sampling for Detailed PK Analysis
NCT01882868 (27) [back to overview]Percentage of Participants With Overall Response
NCT01882868 (27) [back to overview]Area Under the Concentration Time Curve (AUC) for Free Aflibercept: ITT Population
NCT01882868 (27) [back to overview]Progression Free Survival (PFS)
NCT01882868 (27) [back to overview]Number of Participants With Treatment Emergent Adverse Events (TEAEs)
NCT01882868 (27) [back to overview]Total Body Clearance (CL) for Free Aflibercept: Participants With Additional Blood Sampling for Detailed PK Analysis
NCT01882868 (27) [back to overview]Time to Reach Maximum Plasma Concentration Observed (Tmax) for Free and VEGF-Bound Aflibercept in Cycle 1: Participants With Additional Blood Sampling for Detailed PK Analysis
NCT01882868 (27) [back to overview]Terminal Elimination Half-life (t1/2z) for Irinotecan and Its Active Metabolite SN-38: Participants With Additional Blood Sampling for Detailed PK Analysis
NCT01882868 (27) [back to overview]Overall Survival (OS)
NCT01882868 (27) [back to overview]Maximum Observed Plasma Concentration (Cmax) for Free Aflibercept: ITT Population
NCT01882868 (27) [back to overview]Clearance at Steady State (CLss) for 5-FU: Participants With Additional Blood Sampling for Detailed PK Analysis
NCT01882868 (27) [back to overview]Area Under the Concentration Time Curve From Time 0 to 14 Days Post Start of Infusion (AUC0-14 Day) for Free Aflibercept: ITT Population
NCT01882868 (27) [back to overview]Area Under the Concentration Time Curve (AUC) for Free Aflibercept: Participants With Additional Blood Sampling for Detailed PK Analysis
NCT01882868 (27) [back to overview]Maximum Observed Plasma Concentration (Cmax) for Irinotecan and Its Active Metabolite SN-38: Participants With Additional Blood Sampling for Detailed PK Analysis
NCT01882868 (27) [back to overview]Active Metabolite SN-38 / Irinotecan Ratio on Area Under the Concentration Time Curve (Rmet): Participants With Additional Blood Sampling for Detailed PK Analysis
NCT01896531 (6) [back to overview]Serum Concentration of Ipatasertib
NCT01896531 (6) [back to overview]Progression-Free Survival (PFS) in All Randomized Participants and Participants With PTEN Loss Tumors at Primary Analysis
NCT01896531 (6) [back to overview]Overall Survival (OS)
NCT01896531 (6) [back to overview]Objective Response Rate (ORR)
NCT01896531 (6) [back to overview]Duration of Objective Tumor Response
NCT01896531 (6) [back to overview]Number of Participants With Adverse Events (AEs)
NCT01897454 (7) [back to overview]Percentage of Participants Achieving R0 Resection (R0 Resection Rate)
NCT01897454 (7) [back to overview]Progression Free Survival (PFS)
NCT01897454 (7) [back to overview]Percentage of Patients Able to Undergo Resection
NCT01897454 (7) [back to overview]Overall Response Rate
NCT01897454 (7) [back to overview]Overall Survival (OS)
NCT01897454 (7) [back to overview]Toxicities Associated With Chemotherapy and Radiotherapy
NCT01897454 (7) [back to overview]Vascular Reconstruction
NCT01900431 (8) [back to overview]Change From Baseline in Central Retinal Thickness (CRT) At Week 16
NCT01900431 (8) [back to overview]Percentage of Participants With Anterior Chamber (AC) Cell Score = 0 or At Least 2-step Reduction in Score at Week 16
NCT01900431 (8) [back to overview]Pharmacokinetics (PK) Assessment: Serum Functional Sarilumab Concentration
NCT01900431 (8) [back to overview]Percentage of Participants With Prednisone Dose of ≤5 mg/Day (or Equivalent Oral Corticosteroid) at Week 16
NCT01900431 (8) [back to overview]Percentage of Participants With at Least 2-step Reduction in Vitreous Haze (VH) or Prednisone Dose <10 mg/Day at Week 16
NCT01900431 (8) [back to overview]Change From Baseline in Best Corrected Visual Acuity (BCVA) Score at Week 16
NCT01900431 (8) [back to overview]Change From Baseline in VH Scale at Week 16
NCT01900431 (8) [back to overview]Percent Change From Baseline in CRT at Week 16
NCT01913639 (4) [back to overview]Progression Free Survival (PFS)
NCT01913639 (4) [back to overview]Participants Evaluated for Toxicity
NCT01913639 (4) [back to overview]Overall Survival (OS)
NCT01913639 (4) [back to overview]Overall Response Rate
NCT01926197 (6) [back to overview]Progression-free Survival (PFS) at 1 Year
NCT01926197 (6) [back to overview]Grade 2 or Greater Gastrointestinal (GI) Toxicity
NCT01926197 (6) [back to overview]Local Progression-free Survival (Local PFS)
NCT01926197 (6) [back to overview]Metastasis-free Survival (MFS)
NCT01926197 (6) [back to overview]Overall Survival (OS)
NCT01926197 (6) [back to overview]Progression-free Survival (PFS)
NCT01928290 (7) [back to overview]Toxicity and Tolerability (Arm A and Arm B) as Measured by the Number of Participants With Grade 3 or Higher Adverse Events
NCT01928290 (7) [back to overview]Progression Free Survival
NCT01928290 (7) [back to overview]Overall Survival (OS)
NCT01928290 (7) [back to overview]Number of Participants With an Objective Response
NCT01928290 (7) [back to overview]Duration of Response
NCT01928290 (7) [back to overview]Clinical Benefit Rate
NCT01928290 (7) [back to overview]Time to Progression (TTP)
NCT01959139 (5) [back to overview]Progression Free Survival (PFS) (Phase II)
NCT01959139 (5) [back to overview]Phase II: Overall Survival
NCT01959139 (5) [back to overview]Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs
NCT01959139 (5) [back to overview]Objective Tumor Response Rate (Confirmed and Unconfirmed, Complete and Partial)
NCT01959139 (5) [back to overview]Phase I: Maximum Tolerated Dose (MTD) of PEGPH20 in Combination With mFOLFIRINOX
NCT01959672 (5) [back to overview]Distant Failure-free Survival
NCT01959672 (5) [back to overview]Number of Participants With CA-125-Specific T-cell Signal.
NCT01959672 (5) [back to overview]Number of Participants With Progressive Disease,
NCT01959672 (5) [back to overview]Overall Survival
NCT01959672 (5) [back to overview]Surgical Complete Resection (Negative Margin) Rate
NCT01964755 (6) [back to overview]Rate of Toxicity Related to Protocol Therapy
NCT01964755 (6) [back to overview]One-year Rate of Overall Survival
NCT01964755 (6) [back to overview]T-Cell Subset Levels in Peripheral Blood in Positive Participants Before, During and After Protocol Therapy
NCT01964755 (6) [back to overview]One-Year Rate of Failure-Free Survival (FFS)
NCT01964755 (6) [back to overview]Rate of Complete Response to Protocol Therapy
NCT01964755 (6) [back to overview]HIV Viral Load in Positive Subjects Before, During and After Protocol Therapy
NCT01987102 (14) [back to overview]Number of HDMTX Related AEs Per Severity (All Courses)
NCT01987102 (14) [back to overview]Number of Ongoing AEs Per HDMTX Course
NCT01987102 (14) [back to overview]Number of Ongoing HDMTX Related AEs Per HDMTX Course
NCT01987102 (14) [back to overview]Time to Successful MTX Elimination (Definition C)
NCT01987102 (14) [back to overview]Number of AEs Per Severity (All Courses)
NCT01987102 (14) [back to overview]Characterization (Number/Severity) of All Reported AEs During the ENTIRE STUDY PERIOD.
NCT01987102 (14) [back to overview]Number of Administered HDMTX Courses Classified as Having Met the Criteria for Successful Advancement According to Definition A and/or Definition B
NCT01987102 (14) [back to overview]Number of Administered MAP Cycles Classified as Having Met the Criteria for Successful Advancement From First to Second HDMTX Course Within the Same MAP Cycle According to Definition A.
NCT01987102 (14) [back to overview]Number of Administered MAP Cycles Classified as Having Met the Criteria for Successful Advancement to Next MAP Cycle According to Definition B.
NCT01987102 (14) [back to overview]Number of Grade A1, Grade A2, Grade B, Grade C, or Grade D Excretion Toxicities as Listed in the MTX-toxicity Management Instructions
NCT01987102 (14) [back to overview]Number of HDMTX Courses in Which the Initial Hydration Was Increased
NCT01987102 (14) [back to overview]Number of HDMTX Courses With Delayed Early MTX Elimination (Definition E).
NCT01987102 (14) [back to overview]Number of HDMTX Courses With Delayed Late MTX Elimination (Definition F).
NCT01987102 (14) [back to overview]Number of HDMTX Courses With Delayed MTX Elimination (Definition D).
NCT02015819 (6) [back to overview]Comparison of 5-FC in the Brain to 5-FC in the Plasma
NCT02015819 (6) [back to overview]Average Steady State Levels of 5-FC Concentrations in Plasma
NCT02015819 (6) [back to overview]Number of Participants With Mechanical Issues With Repeat Administrations of NSCs Via Rickham
NCT02015819 (6) [back to overview]Average Steady State Levels of 5-FC and 5-FU in the Brain
NCT02015819 (6) [back to overview]Number of Participants Developing Antibodies Against NSCs
NCT02015819 (6) [back to overview]Number of Participants With Dose Limiting Toxicities (DLTs) and Maximum Tolerated Dose (MTD)
NCT02017704 (4) [back to overview]Number of Patients With Pathologic Complete Response
NCT02017704 (4) [back to overview]Change in EORTC QLQ-C30 Global Health Status Score
NCT02017704 (4) [back to overview]Change in EORTC QLQ-C30 Global Health Status Score
NCT02017704 (4) [back to overview]Number of Participants With Grade 3 or Higher Adverse Events
NCT02024607 (6) [back to overview]Number of Participants With Adverse Events and Serious Adverse Events
NCT02024607 (6) [back to overview]Disease Control Rate
NCT02024607 (6) [back to overview]Disease Control Rate of Patients With FOLFIRI/XELIRI-refractory Metastatic Colorectal Cancer
NCT02024607 (6) [back to overview]The Objective Response Rate of Napabucasin Administered in Combination in FOLFIRI in Patients With FOLFIRI/XELIRI-refractory Metastatic Colorectal Cancer
NCT02024607 (6) [back to overview]Progression Free Survival of Patients With FOLFIRI/XELIRI-refractory Metastatic Colorectal Cancer
NCT02024607 (6) [back to overview]Overall Survival of Patients With FOLFIRI/XELIRI-refractory Metastatic Colorectal Cancer
NCT02042443 (4) [back to overview]Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug
NCT02042443 (4) [back to overview]Objective Response Rate
NCT02042443 (4) [back to overview]Progression-free Survival
NCT02042443 (4) [back to overview]Overall Survival
NCT02069041 (5) [back to overview]PK:Area Under the Concentration-Time Curve (AUC[0-∞]) of Ramucirumab
NCT02069041 (5) [back to overview]Pharmacokinetics (PK): Maximum Concentration (Cmax) of Ramucirumab
NCT02069041 (5) [back to overview]Percentage of Participants With Best Response of Complete Response (CR) or Partial Response (PR) (Overall Response Rate [ORR])
NCT02069041 (5) [back to overview]Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
NCT02069041 (5) [back to overview]Number of Participants With Anti-Ramucirumab Antibodies
NCT02069704 (13) [back to overview]Elimination Half-life (t1/2) of BEVZ92 and Avastin®
NCT02069704 (13) [back to overview]Ctrough,sd of BEVZ92 and Avastin®
NCT02069704 (13) [back to overview]Cmax,ss of BEVZ92 and Avastin®
NCT02069704 (13) [back to overview]Cmax,sd of BEVZ92 and Avastin®
NCT02069704 (13) [back to overview]AUC at Steady State (AUCss) of BEVZ92 and Avastin®
NCT02069704 (13) [back to overview]Area Under the Concentration-versus-time Curve (AUC) at Cycle 1 (AUC0-336h) of BEVZ92 and Avastin®
NCT02069704 (13) [back to overview]Ctrough,ss of BEVZ92 and Avastin®
NCT02069704 (13) [back to overview]Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) Reported With BEVZ92 and Avastin®
NCT02069704 (13) [back to overview]Objective Response Rate (ORR) of BEVZ92 and Avastin®
NCT02069704 (13) [back to overview]Anti-Drug Antibody (ADA) of BEVZ92 and Avastin®
NCT02069704 (13) [back to overview]Volume of Distribution (Vd) of BEVZ92 and Avastin®
NCT02069704 (13) [back to overview]Progression-free Survival (PFS) of BEVZ92 and Avastin®
NCT02069704 (13) [back to overview]Elimination Rate Constant (Kel) of BEVZ92 and Avastin®
NCT02080221 (1) [back to overview]Survival for Patients With Metastatic Pancreatic Cancer With First-line Treatment With FOLFOX-A as Compared to Historical Controls of Gemcitabine Alone.
NCT02101853 (4) [back to overview]Overall Survival (OS) of LR Relapse Patients
NCT02101853 (4) [back to overview]Disease Free Survival (DFS) of High-risk (HR) and Intermediate-risk (IR) Relapse Patients
NCT02101853 (4) [back to overview]Disease Free Survival (DFS) of Low Risk (LR) Relapse Patients
NCT02101853 (4) [back to overview]Overall Survival (OS) of HR and IR Relapse Patients
NCT02112916 (6) [back to overview]Cumulative Incidence Rates of Isolated Central Nervous System (CNS) Relapse for SR and IR T-ALL Patients on the Non-bortezomib Containing Arm on This Study (no CRT) and Similar Patients on AALL0434 (Receive CRT)
NCT02112916 (6) [back to overview]Toxicity Rates Associated With Modified Standard Therapy, Including Dexamethasone and Additional Pegaspargase
NCT02112916 (6) [back to overview]Event-free Survival (EFS) for Modified Augmented Berlin-Frankfurt-Munster Backbone With or Without Bortezomib in All Randomized Patients
NCT02112916 (6) [back to overview]EFS for Very High Risk (VHR) T-ALL Patients Treated With High Risk (HR) Berlin-Frankfurt-Munster (BFM) Intensification Blocks Who Become Minimal Residual Disease (MRD) Negative and Those Who Remain MRD Positive at the End of HR Block 3
NCT02112916 (6) [back to overview]EFS for Very High Risk (VHR) T-LLy Patients Treated With HR Berlin-Frankfurt-Munster (BFM) Intensification Blocks Who Have Complete or Partial Remission and Those Who do Not Respond
NCT02112916 (6) [back to overview]EFS for Standard (SR) and Intermediate Risk (IR) T-ALL Patients on the Non-bortezomib Containing Arm on This Study (no Cranial Radiation Therapy [CRT]) and Similar Patients on AALL0434 (Received CRT)
NCT02141295 (14) [back to overview]Percentage of Participants With Objective Response (ORR) as Assessed Using RECIST v. 1.1
NCT02141295 (14) [back to overview]Overall Survival (OS)
NCT02141295 (14) [back to overview]Number of Participants With Human Anti-human Antibodies (HAHAs) Against Vanucizumab
NCT02141295 (14) [back to overview]Time to Reach Cmax (Tmax) of Vanucizumab
NCT02141295 (14) [back to overview]Duration of Objective Response, as Assessed Using RECIST v. 1.1
NCT02141295 (14) [back to overview]Cmax Accumulation Ratio (AR) of Vanucizumab
NCT02141295 (14) [back to overview]Plasma Clearance at Steady State (CLss) of Vanucizumab
NCT02141295 (14) [back to overview]Plasma Terminal Half-Life (t1/2) of Vanucizumab
NCT02141295 (14) [back to overview]Progression-free Survival (PFS), Time to Event
NCT02141295 (14) [back to overview]Volume of Distribution at Steady State (Vss) of Vanucizumab
NCT02141295 (14) [back to overview]Area Under the Plasma Concentration-Time Curve (AUC) of Vanucizumab
NCT02141295 (14) [back to overview]Maximum Observed Plasma Concentration (Cmax) of Vanucizumab
NCT02141295 (14) [back to overview]Minimum Observed Plasma Concentration (Clast) of Vanucizumab
NCT02141295 (14) [back to overview]Percentage of Participants With Adverse Events (AEs)
NCT02178709 (8) [back to overview]Disease Free Survival
NCT02178709 (8) [back to overview]Objective Response Rate (Percentage of Patients With Complete Response or Partial Response)
NCT02178709 (8) [back to overview]Disease Control Rate (Percentage of Patients With Complete Response, Partial Response, or Stable Disease)
NCT02178709 (8) [back to overview]Number of Patients With Treatment-Related Adverse Events Grade 3 or Above
NCT02178709 (8) [back to overview]Overall Survival
NCT02178709 (8) [back to overview]Percentage of Patients Who Successfully Underwent Surgery After Neoadjuvant FOLFIRINOX
NCT02178709 (8) [back to overview]Percentage of Patients With Pathologic Complete Response
NCT02178709 (8) [back to overview]Rate of R0 Resection
NCT02231086 (2) [back to overview]Peritoneal Recurrence Free Survival at 18 Months
NCT02231086 (2) [back to overview]Treatment Related Toxicity of Adjuvant HIPEC
NCT02319304 (2) [back to overview]Secondary Outcome Measure (Number of Adverse Events)
NCT02319304 (2) [back to overview]Primary Outcome Measure (Overall Survival Rate)
NCT02337946 (9) [back to overview]Overall Survival (OS)
NCT02337946 (9) [back to overview]Response Rate (RR)
NCT02337946 (9) [back to overview]Time to Treatment Failure (TTF)
NCT02337946 (9) [back to overview]Percentage of Participants With Grade 3 or Higher Skin Toxicity
NCT02337946 (9) [back to overview]Percentage of Participants With Grade 2 or Higher Peripheral Neuropathy
NCT02337946 (9) [back to overview]Percentage of Participants With Adverse Events
NCT02337946 (9) [back to overview]Progression-Free Survival (PFS)
NCT02337946 (9) [back to overview]Percentage of Participants With Adverse Events by Severity Graded Using the Common Terminology Criteria for Adverse Events (CTCAE) Grade
NCT02337946 (9) [back to overview]Progression-Free Survival Rate (PFS Rate) at 9 Months After Randomization
NCT02340949 (4) [back to overview]Number of Patients Reporting Adverse Events (AEs)
NCT02340949 (4) [back to overview]Disease Free Survival (DFS) Rate at 3 Years
NCT02340949 (4) [back to overview]Number of Patients Reporting Surgical Complications
NCT02340949 (4) [back to overview]Number of Patients Achieving Pathological Parameters of Efficacy: R0 Resection, Tumor Regression Grade, and Circular Radial Margin Rate
NCT02358863 (1) [back to overview]The Number of Patients With Tumor Size Reduction (Objective Response Rate)
NCT02379091 (7) [back to overview]ACR Numeric (N) Index (ACRn) at Week 24
NCT02379091 (7) [back to overview]Change From Baseline in DAS28-CRP at Week 24
NCT02379091 (7) [back to overview]ACR Numeric (N) Index (ACRn) at Week 12
NCT02379091 (7) [back to overview]Change From Baseline in Disease Activity Score 28 C-Reactive Protein (DAS28-CRP) at Week 12
NCT02379091 (7) [back to overview]Change From Baseline in DAS28-CRP at Weeks 2, 6, and 10
NCT02379091 (7) [back to overview]Percentage of Participants Achieving American College of Rheumatology 20% (ACR20), 50% (ACR 50) and 70% (ACR70) Response at Weeks 12 and 24
NCT02379091 (7) [back to overview]Percentage of Participants With a Reduction of Pain as Measured Using a Visual Analog Scale (VAS) at Weeks 2, 12 and 24
NCT02384850 (5) [back to overview]Numbers of Patients With Dose Limiting Toxicities
NCT02384850 (5) [back to overview]Number of Patients Experiencing Adverse Events
NCT02384850 (5) [back to overview]Progression Free Survival (PFS)
NCT02384850 (5) [back to overview]Number of Patients Still Alive at End of Study (Overall Survival)
NCT02384850 (5) [back to overview]Overall Response Rate
NCT02394795 (7) [back to overview]Progression-Free Survival (PFS) in All Participants
NCT02394795 (7) [back to overview]Progression-Free Survival (PFS) in Participants With Left-sided Tumors
NCT02394795 (7) [back to overview]Duration of Response (DOR)
NCT02394795 (7) [back to overview]Number of Participants With Treatment-emergent Adverse Events (TEAE)
NCT02394795 (7) [back to overview]Overall Survival (OS) in All Participants
NCT02394795 (7) [back to overview]OS in Participants With Left-sided Tumors
NCT02394795 (7) [back to overview]Number of Participants Treated With Curative Surgical Resection After Chemotherapy
NCT02420717 (4) [back to overview]Overall Survival
NCT02420717 (4) [back to overview]Participants With Complete Response (Complete Response [CR]/CR With Incomplete Marrow Recovery [CRi]) (Phase II)
NCT02420717 (4) [back to overview]Progression-free Survival
NCT02420717 (4) [back to overview]Maximal Tolerated Dose (MTD) of Ruxolitinib in Combination With Chemotherapy Defined as the Highest Dose Level at Which no More Than 1 Out of 6 Patients Experience a Dose Limiting Toxicity (Phase I)
NCT02508077 (1) [back to overview]4-month Progression-free Survival (PFS) Rate
NCT02545504 (5) [back to overview]Objective Response Rate (ORR)
NCT02545504 (5) [back to overview]Percentage of Participants With Clinically Relevant Treatment-emergent Laboratory Abnormalities
NCT02545504 (5) [back to overview]Progression-free Survival (PFS)
NCT02545504 (5) [back to overview]Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)
NCT02545504 (5) [back to overview]Overall Survival (OS)
NCT02551991 (7) [back to overview]Median Overall Survival (OS)
NCT02551991 (7) [back to overview]Median Progression Free Survival (PFS)
NCT02551991 (7) [back to overview]Overall Response Rate (ORR)
NCT02551991 (7) [back to overview]Median Duration of Response (DoR)
NCT02551991 (7) [back to overview]Part 1A: Number of Participants With Dose-Limiting Toxicities (DLT)
NCT02551991 (7) [back to overview]Disease Control Rate (DCR)
NCT02551991 (7) [back to overview]Best Overall Response (BOR)
NCT02553460 (1) [back to overview]Percentage of Treatment-related Mortality (TRM)
NCT02568046 (1) [back to overview]Number of Participants With Adverse Events (AEs) by Nature, Severity, and Occurrence Measured From Baseline to End of Trial Participation, as Assessed by the Common Terminology Criteria for AEs (Version 4.03) (CTCAE v4.03).
NCT02578732 (2) [back to overview]Response Rate of FOLFOX-A for Patients With Locally Advanced Pancreatic Cancer.
NCT02578732 (2) [back to overview]Overall Survival for Patients With Locally Advanced Pancreatic Cancer Treated With FOLFOX-A
NCT02620865 (3) [back to overview]Progression Free Survival (PFS)
NCT02620865 (3) [back to overview]Incidence of Toxicity (CTCAE Version 4.0)
NCT02620865 (3) [back to overview]Median Overall Survival (OS)
NCT02625610 (12) [back to overview]Change From Baseline in European Quality of Life 5-dimensions Health Outcome Questionnaire Through Visual Analogue Scale up to Safety Follow-up (Up to 152.3 Weeks)
NCT02625610 (12) [back to overview]Overall Survival (OS)
NCT02625610 (12) [back to overview]Objective Response Rate (ORR) by Investigator Assessment
NCT02625610 (12) [back to overview]Maintenance Phase: Number of Participants With Grade Change From Baseline to Worst On-Treatment Grade 4 Hematology Values
NCT02625610 (12) [back to overview]Maintenance Phase: Number of Participants With Shift in Eastern Cooperative Oncology Group (ECOG) Performance Status Score to 1 or Higher Than 1
NCT02625610 (12) [back to overview]Progression Free Survival (PFS) by Independent Review Committee (IRC)
NCT02625610 (12) [back to overview]Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30) Global Health Status Scale Score up to Safety Follow-up (Up to 152.3 Weeks)
NCT02625610 (12) [back to overview]Change From Baseline in European Quality of Life 5-dimensions (EQ-5D-5L) Health Outcome Questionnaire Through Composite Index Score up to Safety Follow-up (Up to 152.3 Weeks)
NCT02625610 (12) [back to overview]Maintenance Phase: Number of Participants With Potentially Clinically Significant Abnormalities in Vital Signs
NCT02625610 (12) [back to overview]Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Stomach Cancer Specific (EORTC QLQ-STO22 ) Questionnaire Scores up to Safety Follow-up (Up to 152.3 Weeks)
NCT02625610 (12) [back to overview]Maintenance Phase: Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Abnormalities
NCT02625610 (12) [back to overview]Maintenance Phase: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs According to National Cancer Institute-Common Terminology Criteria for Adverse Events Version 4.03 (NCI-CTCAE v4.03)
NCT02641691 (9) [back to overview]Prospective Patient Reported Outcomes as Measured by FACT-C Questionnaire
NCT02641691 (9) [back to overview]Prospective Patient Reported Outcomes as Measured by FACT-C Questionnaire
NCT02641691 (9) [back to overview]Number of Any Grade 3 or Higher Toxicities
NCT02641691 (9) [back to overview]Number of Post Chemotherapy Grade 3 or Higher Toxicities
NCT02641691 (9) [back to overview]Complete Response Rate
NCT02641691 (9) [back to overview]Quality of Anorectal Function as Measured by the FACT-C Questionnaire
NCT02641691 (9) [back to overview]Quality of Anorectal Function as Measured by the FACT-C Questionnaire
NCT02641691 (9) [back to overview]Quality of Anorectal Function as Measured by the FACT-C Questionnaire
NCT02641691 (9) [back to overview]Prospective Patient Reported Outcomes as Measured by FACT-C Questionnaire
NCT02730546 (1) [back to overview]Pathological Complete Response (PathCR) Rate
NCT02753127 (7) [back to overview]Progression-Free Survival (PFS)
NCT02753127 (7) [back to overview]Number of Patients With Adverse Events in the General Population
NCT02753127 (7) [back to overview]Overall Survival (OS)
NCT02753127 (7) [back to overview]Disease Control Rate (DCR)
NCT02753127 (7) [back to overview]Mean Change From Baseline for Global Health Status at Time 2 (Cycle 5 Day 1) and Time 4 (Cycle 9 Day 1).
NCT02753127 (7) [back to overview]Mean Change From Baseline for Physical Functioning Status at Time 2 (Cycle 5 Day 1) and Time 4 (Cycle 9 Day 1).
NCT02753127 (7) [back to overview]Objective Response Rate (ORR)
NCT02828358 (5) [back to overview]Biologic Activity, Defined as Global Deoxyribonucleic Acid (DNA) Methylation Change in Peripheral Blood Mononuclear Cells (PBMC)s; Day 5 of Second Course of Azacitidine
NCT02828358 (5) [back to overview]Biologic Activity, Defined as Global Deoxyribonucleic Acid (DNA) Methylation Change in Peripheral Blood Mononuclear Cells (PBMC)s; Day 5 of First Course of Azacitidine
NCT02828358 (5) [back to overview]Biologic Activity, Defined as Global Deoxyribonucleic Acid (DNA) Methylation Change in Peripheral Blood Mononuclear Cells (PBMC)s; Day 1 Prior to Second Course of Azacitidine
NCT02828358 (5) [back to overview]Biologic Activity, Defined as Global Deoxyribonucleic Acid (DNA) Methylation Change in Peripheral Blood Mononuclear Cells (PBMC)s; Day 1 Prior to First Course of Azacitidine
NCT02828358 (5) [back to overview]Tolerability of Azacitidine in Combination With Interfant-06 Standard Chemotherapy in Evaluable Infant Patients With Newly Diagnosed ALL With KMT2A Gene Rearrangement (KMT2A-R). KMT2A Gene Rearrangement (KMT2A-R)
NCT02872116 (7) [back to overview]Progression Free Survival (PFS) in Participants Treated With Nivolumab Plus Chemotherapy vs Chemotherapy With PD-L1 CPS ≥ 5
NCT02872116 (7) [back to overview]OS in Participants Treated With Nivolumab Plus Ipilimumab vs Chemotherapy
NCT02872116 (7) [back to overview]Overall Survival (OS) in Participants Treated With Nivolumab Plus Chemotherapy vs Chemotherapy With PD-L1 CPS ≥ 5
NCT02872116 (7) [back to overview]OS in Participants Treated With Nivolumab Plus Chemotherapy vs Chemotherapy
NCT02872116 (7) [back to overview]Objective Response Rate
NCT02872116 (7) [back to overview]PFS in Participants Treated With Nivolumab Plus Ipilimumab vs Chemotherapy
NCT02872116 (7) [back to overview]PFS in Participants Treated With Nivolumab Plus Chemotherapy vs Chemotherapy
NCT02890355 (6) [back to overview]Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs
NCT02890355 (6) [back to overview]Disease Control Rate
NCT02890355 (6) [back to overview]Duration of Response (DoR)
NCT02890355 (6) [back to overview]Overall Response Rate, ORR
NCT02890355 (6) [back to overview]Overall Survival (OS)
NCT02890355 (6) [back to overview]Progression Free Survival (PFS)
NCT02896907 (1) [back to overview]Change in Quality of Life as Defined by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C-30
NCT02921256 (3) [back to overview]Neoadjuvant Rectal Cancer (NAR) Score
NCT02921256 (3) [back to overview]Rate of Pathologic Complete Response (Nodes and Tumor) ypT0 and ypN0
NCT02921256 (3) [back to overview]Rate of Sphincter Preservation
NCT02923921 (6) [back to overview]Percentage of Participants Alive at 1 Year (12-Month Survival Rate)
NCT02923921 (6) [back to overview]Percentage of Participants With a Best Overall Response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD): Disease Control Rate (DCR)
NCT02923921 (6) [back to overview]Progression Free Survival
NCT02923921 (6) [back to overview]Duration of Response (DOR)
NCT02923921 (6) [back to overview]Overall Survival
NCT02923921 (6) [back to overview]Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) [Objective Response Rate (ORR)] That Assessed by Investigator
NCT02928224 (78) [back to overview](Phase 3) Change From Baseline in the Participant Global Impression of Change (PGIC) in Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet
NCT02928224 (78) [back to overview](Phase 3) Change From Baseline in the Participant Global Impression of Change (PGIC) in Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet
NCT02928224 (78) [back to overview](Phase 3) Change From Baseline in the Functional Assessment of Cancer Therapy-Colon Cancer (FACT-C) in Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet
NCT02928224 (78) [back to overview](Phase 3) Change From Baseline in the Functional Assessment of Cancer Therapy-Colon Cancer (FACT-C) in Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet
NCT02928224 (78) [back to overview](Phase 3) Change From Baseline in the Functional Assessment of Cancer Therapy-Colon Cancer (FACT-C) in Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet
NCT02928224 (78) [back to overview](Phase 3) Change From Baseline in the EuroQol-5D-5L Visual Analog Scale (EQ-5D-5L VAS) in Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet
NCT02928224 (78) [back to overview](Phase 3) Change From Baseline in the EuroQol-5D-5L Visual Analog Scale (EQ-5D-5L VAS) in Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet
NCT02928224 (78) [back to overview](Phase 3) Change From Baseline in the EuroQol-5D-5L Visual Analog Scale (EQ-5D-5L VAS) in Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet
NCT02928224 (78) [back to overview](Phase 3) Change From Baseline in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire for Cancer Participants (QLQ-C30) Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet
NCT02928224 (78) [back to overview](Phase 3) Change From Baseline in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire for Cancer Participants (QLQ-C30) Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet
NCT02928224 (78) [back to overview](Phase 3) Change From Baseline in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire for Cancer Participants (QLQ-C30) Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet
NCT02928224 (78) [back to overview]Phase 3: Number of Participants With Clinically Notable Shifts in Urinalysis Laboratory Parameters
NCT02928224 (78) [back to overview](Safety Lead-in) Time to Response by Investigator
NCT02928224 (78) [back to overview](Safety Lead-in) Time to Response by BICR
NCT02928224 (78) [back to overview](Safety Lead-in) Progression-Free Survival (PFS) by Investigator
NCT02928224 (78) [back to overview](Safety Lead-in) Progression-Free Survival (PFS) by BICR
NCT02928224 (78) [back to overview](Safety Lead-in) Objective Response Rate (ORR) by Investigator
NCT02928224 (78) [back to overview](Safety Lead-in) Objective Response Rate (ORR) by BICR
NCT02928224 (78) [back to overview](Safety Lead-in) Number of Participants With Dose-Limiting Toxicities (DLTs)
NCT02928224 (78) [back to overview](Safety Lead-in) Number of Participants With Adverse Events (AEs)
NCT02928224 (78) [back to overview](Safety Lead-in) Incidence of Dose Interruptions, Dose Modifications and Discontinuations Due to Adverse Events (AEs) - Interim Analysis
NCT02928224 (78) [back to overview](Safety Lead-in) Evaluation of the Steady-State Concentration Measured Just Before the Next Dose of Study Drug (Ctrough) for Encorafenib
NCT02928224 (78) [back to overview](Safety Lead-in) Evaluation of the Steady-State Concentration Measured Just Before the Next Dose of Study Drug (Ctrough) for Cetuximab
NCT02928224 (78) [back to overview](Safety Lead-in) Evaluation of the Steady-State Concentration Measured Just Before the Next Dose of Study Drug (Ctrough) for Binimetinib
NCT02928224 (78) [back to overview](Safety Lead-in) Incidence of Dose Interruptions, Dose Modifications and Discontinuations Due to Adverse Events (AEs) - Final Analysis
NCT02928224 (78) [back to overview](Safety Lead-in) Duration of Response (DOR) by Investigator
NCT02928224 (78) [back to overview](Safety Lead-in) Duration of Response (DOR) by BICR
NCT02928224 (78) [back to overview](Phase 3) Overall Survival (OS) of Triplet Arm vs. Control Arm - Interim Analysis
NCT02928224 (78) [back to overview](Phase 3) Overall Survival (OS) of Triplet Arm vs. Control Arm - Final Analysis
NCT02928224 (78) [back to overview](Phase 3) Overall Survival (OS) in Triplet Arm vs. Doublet Arm
NCT02928224 (78) [back to overview](Safety Lead-in) Evaluation of the Steady-State Concentration Measured Just Before the Next Dose of Study Drug (Ctrough) for a Metabolite of Binimetinib
NCT02928224 (78) [back to overview](Phase 3) Overall Survival (OS) in Doublet Arm vs. Control Arm
NCT02928224 (78) [back to overview](Phase 3) Objective Response Rate (ORR) by Blinded Independent Central Review (BICR) Per Response Evaluation Criteria in Solid Tumors (RECIST), v1.1 of Triplet Arm vs. Control Arm
NCT02928224 (78) [back to overview](Phase 3) Evaluation of the Model-Based Oral Clearance (CL/F) for Encorafenib
NCT02928224 (78) [back to overview](Phase 3) Evaluation of the Model-Based Oral Clearance (CL/F) for Binimetinib
NCT02928224 (78) [back to overview](Phase 3) Evaluation of the Model-Based Clearance (CL) for Cetuximab
NCT02928224 (78) [back to overview](Phase 3) Comparison of Time to Response in Triplet Arm vs Doublet Arm Per Investigator
NCT02928224 (78) [back to overview](Phase 3) Comparison of Time to Response in Triplet Arm vs Doublet Arm Per BICR
NCT02928224 (78) [back to overview](Phase 3) Comparison of Time to Response in Triplet Arm vs Control Arm Per Investigator
NCT02928224 (78) [back to overview](Phase 3) Comparison of Time to Response in Triplet Arm vs Control Arm Per BICR
NCT02928224 (78) [back to overview](Phase 3) Comparison of Time to Response in Doublet Arm vs Control Arm Per Investigator
NCT02928224 (78) [back to overview](Phase 3) Comparison of Time to Response in Doublet Arm vs Control Arm Per BICR
NCT02928224 (78) [back to overview](Phase 3) Comparison of Progression-Free Survival (PFS) in Triplet Arm vs Doublet Arm Per Investigator
NCT02928224 (78) [back to overview](Phase 3) Comparison of Progression-Free Survival (PFS) in Triplet Arm vs Doublet Arm Per BICR
NCT02928224 (78) [back to overview](Phase 3) Comparison of Progression-Free Survival (PFS) in Triplet Arm vs Control Arm Per BICR
NCT02928224 (78) [back to overview](Phase 3) Comparison of Progression-Free Survival (PFS) in Doublet Arm vs Control Arm Per Investigator
NCT02928224 (78) [back to overview](Phase 3) Comparison of Progression-Free Survival (PFS) in Doublet Arm vs Control Arm Per BICR
NCT02928224 (78) [back to overview](Phase 3) Comparison of Objective Response Rate (ORR) in Triplet Arm vs Doublet Arm Per Investigator
NCT02928224 (78) [back to overview](Phase 3) Comparison of Objective Response Rate (ORR) in Triplet Arm vs Doublet Arm Per BICR
NCT02928224 (78) [back to overview](Phase 3) Comparison of Progression-free Survival (PFS) in Triplet Arm vs Control Arm Per Investigator
NCT02928224 (78) [back to overview]Phase 3: Number of Participants With Shifts in Left Ventricular Ejection Fraction (LVEF) From Baseline to Maximum Grade On-treatment
NCT02928224 (78) [back to overview]Phase 3: Number of Participants With Shift in Visual Acuity Logarithm of the Minimum Angle of Resolution (LogMAR) Score
NCT02928224 (78) [back to overview]Phase 3: Number of Participants With Newly Occurring Clinically Notable Vital Sign Abnormalities
NCT02928224 (78) [back to overview]Phase 3: Number of Participants With Newly Occurring Clinically Notable Electrocardiogram (ECG) Values
NCT02928224 (78) [back to overview]Phase 3: Number of Participants With Clinically Notable Shifts in Serum Chemistry Laboratory Parameters
NCT02928224 (78) [back to overview]Phase 3: Number of Participants With Clinically Notable Shifts in Hematology and Coagulation Laboratory Parameters
NCT02928224 (78) [back to overview](Safety Lead-in) Evaluation of the Time of Maximum Observed Concentration (Tmax) for Metabolite of Binimetinib (AR00426032)
NCT02928224 (78) [back to overview](Safety Lead-in) Evaluation of the Time of Maximum Observed Concentration (Tmax) for Encorafenib
NCT02928224 (78) [back to overview](Safety Lead-in) Evaluation of the Time of Maximum Observed Concentration (Tmax) for Cetuximab
NCT02928224 (78) [back to overview](Safety Lead-in) Evaluation of the Time of Maximum Observed Concentration (Tmax) for Binimetinib
NCT02928224 (78) [back to overview](Safety Lead-in) Evaluation of the Maximum Concentration (Cmax) for Metabolite of Binimetinib (AR00426032)
NCT02928224 (78) [back to overview](Safety Lead-in) Evaluation of the Maximum Concentration (Cmax) for Encorafenib
NCT02928224 (78) [back to overview](Safety Lead-in) Evaluation of the Maximum Concentration (Cmax) for Cetuximab
NCT02928224 (78) [back to overview](Safety Lead-in) Evaluation of the Maximum Concentration (Cmax) for Binimetinib
NCT02928224 (78) [back to overview](Safety Lead-in) Evaluation of the Area Under the Concentration-time Curve From Zero to the Last Measurable Time Point (AUClast) for Metabolite of Binimetinib (AR00426032)
NCT02928224 (78) [back to overview](Safety Lead-in) Evaluation of the Area Under the Concentration-Time Curve From Zero to the Last Measurable Time Point (AUClast) for Encorafenib
NCT02928224 (78) [back to overview](Safety Lead-in) Evaluation of the Area Under the Concentration-Time Curve From Zero to the Last Measurable Time Point (AUClast) for Cetuximab
NCT02928224 (78) [back to overview](Phase 3) Comparison of Duration of Response (DOR) in Doublet Arm vs Control Arm Per BICR
NCT02928224 (78) [back to overview](Safety Lead-in) Evaluation of the Area Under the Concentration-Time Curve From Zero to the Last Measurable Time Point (AUClast) for Binimetinib
NCT02928224 (78) [back to overview](Phase 3) Comparison of Objective Response Rate (ORR) in Triplet Arm vs Control Arm Per Investigator
NCT02928224 (78) [back to overview](Phase 3) Comparison of Objective Response Rate (ORR) in Doublet Arm vs Control Arm Per Investigator
NCT02928224 (78) [back to overview](Phase 3) Comparison of Objective Response Rate (ORR) in Doublet Arm vs Control Arm Per BICR
NCT02928224 (78) [back to overview](Phase 3) Comparison of Duration of Response (DOR) in Triplet Arm vs Doublet Arm by Investigator
NCT02928224 (78) [back to overview](Phase 3) Comparison of Duration of Response (DOR) in Triplet Arm vs Doublet Arm by BICR
NCT02928224 (78) [back to overview](Phase 3) Comparison of Duration of Response (DOR) in Triplet Arm vs Control Arm Per Investigator
NCT02928224 (78) [back to overview](Phase 3) Comparison of Duration of Response (DOR) in Triplet Arm vs Control Arm Per BICR
NCT02928224 (78) [back to overview](Phase 3) Comparison of Duration of Response (DOR) in Doublet Arm vs Control Arm Per Investigator
NCT02928224 (78) [back to overview](Phase 3) Change From Baseline in the Participant Global Impression of Change (PGIC) in Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet
NCT03050814 (3) [back to overview]Number of Participants That Are Hospitalized Because of Adverse Events Attributed to Disease Progression
NCT03050814 (3) [back to overview]Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)
NCT03050814 (3) [back to overview]Progression Free Survival Between the Standard of Care (SOC) Arm A, and Standard of Care (SOC) Arm B + lead-in
NCT03085914 (3) [back to overview]Phases 1 and 2: Number of Participants With Dose Limiting Toxicities (DLTs)
NCT03085914 (3) [back to overview]Phases 1 and 2: Objective Response Rate (ORR)
NCT03085914 (3) [back to overview]Phases 1 & 2: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs
NCT03099265 (1) [back to overview]Grade 3 or Greater Acute and Late Gastrointestinal Toxicity
NCT03099486 (4) [back to overview]Best Overall Response
NCT03099486 (4) [back to overview]Number of Toxicities Due to Regorafenib and 5-FU/LV Combination Therapy
NCT03099486 (4) [back to overview]Overall Survival Rate
NCT03099486 (4) [back to overview]Progression Free Survival (PFS) at 2 Months
NCT03258762 (36) [back to overview]Change From Baseline of Clinical Chemistry Parameters: Alkaline Phosphatase, Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST)
NCT03258762 (36) [back to overview]Change From Baseline of Clinical Chemistry Parameters: Direct Bilirubin, Bilirubin, Creatinine.
NCT03258762 (36) [back to overview]Change From Baseline of Clinical Chemistry Parameters: Glucose, Sodium, Calcium, Potassium, and Urea.
NCT03258762 (36) [back to overview]Change From Baseline of Clinical Chemistry Parameters: Protein
NCT03258762 (36) [back to overview]Change From Baseline of ECG Parameter: ECG Mean Heart Rate
NCT03258762 (36) [back to overview]Change From Baseline of Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval, and QT Interval Corrected for Heart Rate by Fredericia's Formula (QTcF) Interval
NCT03258762 (36) [back to overview]Number of Participants With Abnormal Urinalysis Parameter
NCT03258762 (36) [back to overview]Change From Baseline in Hematology Parameter: Mean Corpuscular Hemoglobin
NCT03258762 (36) [back to overview]Change From Baseline in Hematology Parameter: Hemoglobin
NCT03258762 (36) [back to overview]Change From Baseline in Hematology Parameter: Hematocrit
NCT03258762 (36) [back to overview]Change From Baseline in Hematology Parameter: Erythrocytes
NCT03258762 (36) [back to overview]Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)
NCT03258762 (36) [back to overview]Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)
NCT03258762 (36) [back to overview]Vd/F of Pyrimethamine in Healthy Caucasian Male Participants
NCT03258762 (36) [back to overview]Time to Maximum Observed Concentration (Tmax) of Pyrimethamine in Healthy Japanese Male Participants
NCT03258762 (36) [back to overview]Terminal Half-life (t1/2) of Pyrimethamine in Healthy Japanese Male Participants
NCT03258762 (36) [back to overview]T1/2 of Pyrimethamine in Healthy Caucasian Male Participants
NCT03258762 (36) [back to overview]Specific Gravity at Indicated Time Points
NCT03258762 (36) [back to overview]Urine Potential of Hydrogen (pH) at Indicated Time Points
NCT03258762 (36) [back to overview]Maximum Observed Concentration (Cmax) of Pyrimethamine in Healthy Japanese Male Participants
NCT03258762 (36) [back to overview]Cmax of Pyrimethamine in Healthy Caucasian Male Participants
NCT03258762 (36) [back to overview]CL/F of Pyrimethamine in Healthy Caucasian Male Participants
NCT03258762 (36) [back to overview]AUC (0-t) of Pyrimethamine in Healthy Caucasian Male Participants
NCT03258762 (36) [back to overview]AUC (0-inf) of Pyrimethamine in Healthy Caucasian Male Participants
NCT03258762 (36) [back to overview]AUC (0-24) of Pyrimethamine in Healthy Caucasian Male Participants
NCT03258762 (36) [back to overview]Change From Baseline in Hematology Parameter: Mean Corpuscular Volume
NCT03258762 (36) [back to overview]Area Under the Concentration-time Curve From Time 0 to Infinity (AUC[0-inf]) of Pyrimethamine in Healthy Japanese Male Participants
NCT03258762 (36) [back to overview]Area Under the Concentration-time Curve From Time 0 to t (AUC[0-t]) of Pyrimethamine in Healthy Japanese Male Participants
NCT03258762 (36) [back to overview]Area Under the Concentration-time Curve From Time 0 to 24 (AUC[0-24]) of Pyrimethamine in Healthy Japanese Male Participants
NCT03258762 (36) [back to overview]Apparent Volume of Distribution Following Oral Dosing (Vd/F) of Pyrimethamine in Healthy Japanese Male Participants
NCT03258762 (36) [back to overview]Apparent Clearance Following Oral Dosing (CL/F) of Pyrimethamine in Healthy Japanese Male Participants
NCT03258762 (36) [back to overview]Tmax of Pyrimethamine in Healthy Caucasian Male Participants
NCT03258762 (36) [back to overview]Change From Baseline in Temperature
NCT03258762 (36) [back to overview]Change From Baseline in Pulse Rate
NCT03258762 (36) [back to overview]Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet and Leukocytes
NCT03258762 (36) [back to overview]Change From Baseline in Hematology Parameter: Reticulocytes
NCT03279237 (4) [back to overview]Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0
NCT03279237 (4) [back to overview]Clinical Response Rate
NCT03279237 (4) [back to overview]Pathologic Complete Response Rate
NCT03279237 (4) [back to overview]The Completion Rate of Chemotherapy in Combination With Chemoradiation
NCT03288987 (6) [back to overview]Number of Positive Anti-drug Antibody (ADA) Samples Among Patients (Immunogenicity)
NCT03288987 (6) [back to overview]Progression Free Survival (PFS)
NCT03288987 (6) [back to overview]Incidence of the Adverse Events
NCT03288987 (6) [back to overview]Objective Response Rate
NCT03288987 (6) [back to overview]Overall Survival (OS)
NCT03288987 (6) [back to overview]Time to Treatment Failure
NCT03314935 (13) [back to overview]Tmax of INCB001158 in Participants Treated With INCB001158 in Combination With Chemotherapy Following the First Dose on Cycle 1 Day 1 and on Cycle 2 Day 1 Following Repeated Dose Administration
NCT03314935 (13) [back to overview]Phase 1: ORR
NCT03314935 (13) [back to overview]Cmin of INCB001158 in Participants Treated With INCB001158 in Combination With Chemotherapy on Cycle 2 Day 1 Following Repeated Dose Administration
NCT03314935 (13) [back to overview]Tlast of INCB001158 in Participants Treated With INCB001158 in Combination With Chemotherapy Following the First Dose on Cycle 1 Day 1 and on Cycle 2 Day 1 Following Repeated Dose Administration
NCT03314935 (13) [back to overview]Cmax of INCB001158 in Participants Treated With INCB001158 in Combination With Chemotherapy Following the First Dose on Cycle 1 Day 1 and on Cycle 2 Day 1 Following Repeated Dose Administration
NCT03314935 (13) [back to overview]Phase 1: Number of Participants With Any Dose-limiting Toxicity (DLT)
NCT03314935 (13) [back to overview]Phases 1 and 2: Disease Control Rate
NCT03314935 (13) [back to overview]Phases 1 and 2: Progression-free Survival
NCT03314935 (13) [back to overview]Recommended Phase 2 Dose (RP2D) of INCB001158 When Given in Combination With Each Chemotherapy Regimen
NCT03314935 (13) [back to overview]AUC0-t of INCB001158 in Participants Treated With INCB001158 in Combination With Chemotherapy Following the First Dose on Cycle 1 Day 1 and on Cycle 2 Day 1 Following Repeated Dose Administration
NCT03314935 (13) [back to overview]Phase 2: Objective Response Rate (ORR)
NCT03314935 (13) [back to overview]Phases 1 and 2: Duration of Response
NCT03314935 (13) [back to overview]Phases 1 and 2: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)
NCT03368859 (3) [back to overview]Overall Survival (OS)
NCT03368859 (3) [back to overview]Objective Response Rate (ORR)
NCT03368859 (3) [back to overview]Progression Free Survival (PFS)
NCT03414983 (17) [back to overview]Overall Survival (OS)
NCT03414983 (17) [back to overview]Objective Response Rate (ORR) Per Investigator Assessment
NCT03414983 (17) [back to overview]Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR)
NCT03414983 (17) [back to overview]Number of Participants With Serious Adverse Events (SAEs)
NCT03414983 (17) [back to overview]Number of Participants With Adverse Events (AEs)
NCT03414983 (17) [back to overview]Number of Participants Experiencing Death
NCT03414983 (17) [back to overview]Duration of Response (DoR) Per Investigator Assessment
NCT03414983 (17) [back to overview]Duration of Response (DoR) Per Blinded Independent Central Review (BICR)
NCT03414983 (17) [back to overview]Disease Control Rate (DCR) Per Investigator
NCT03414983 (17) [back to overview]Disease Control Rate (DCR) Per Blinded Independent Central Review (BICR)
NCT03414983 (17) [back to overview]Number of Participants With Laboratory Abnormalities in Specific Thyroid Tests
NCT03414983 (17) [back to overview]Number of Participants With Laboratory Abnormalities in Specific Liver Tests
NCT03414983 (17) [back to overview]Time to Objective Response Per Investigator Assessment
NCT03414983 (17) [back to overview]Time to Objective Response Per Blinded Independent Central Review (BICR)
NCT03414983 (17) [back to overview]Progression Free Survival (PFS) Per Investigator Assessment
NCT03414983 (17) [back to overview]Progression Free Survival (PFS) Per Blinded Independent Central Review (BICR) - Extended Collection
NCT03414983 (17) [back to overview]Progression Free Survival (PFS) Per Blinded Independent Central Review (BICR)
NCT03488225 (5) [back to overview]Event-Free Survival
NCT03488225 (5) [back to overview]Number of Participants With Minimal Residual Disease (MRD) Negativity
NCT03488225 (5) [back to overview]Number of Participants With Adverse Events
NCT03488225 (5) [back to overview]Participants to Achieve Complete Remission (CR):
NCT03488225 (5) [back to overview]Overall Survival
NCT03504423 (3) [back to overview]Progression Free Survival (PFS)
NCT03504423 (3) [back to overview]Overall Response Rate (ORR)
NCT03504423 (3) [back to overview]Overall Survival (OS)
NCT03515941 (2) [back to overview]Median Time to Recurrence
NCT03515941 (2) [back to overview]Number of Participants Who Complete the Recommended Therapy From Each Arm
NCT03518112 (5) [back to overview]Duration of Response
NCT03518112 (5) [back to overview]Number of Participants Negative for Minimal Residual Disease (MRD)
NCT03518112 (5) [back to overview]Overall Survival
NCT03518112 (5) [back to overview]Participants With a Response
NCT03518112 (5) [back to overview]Event Free Survival (EFS) Where Events Defined as no Response, Loss of Response, or Death
NCT03611556 (31) [back to overview]Serum Concentrations of Durvalumab
NCT03611556 (31) [back to overview]Serum Concentrations of Oleclumab
NCT03611556 (31) [back to overview]Serum Concentrations of Oleclumab
NCT03611556 (31) [back to overview]Number of Participants With TEAEs and TESAEs in Dose Expansion Phase
NCT03611556 (31) [back to overview]Serum Concentrations of Durvalumab
NCT03611556 (31) [back to overview]Progression-free Survival According to RECIST v1.1 in Dose Expansion Phase
NCT03611556 (31) [back to overview]Number of Participants With Positive Anti-drug Antibodies (ADA) to Oleclumab
NCT03611556 (31) [back to overview]Number of Participants With Positive ADA to Durvalumab
NCT03611556 (31) [back to overview]Number of Participants With Abnormal Vital Signs Reported as TEAEs in Dose Expansion Phase
NCT03611556 (31) [back to overview]Number of Participants With Abnormal Vital Signs Reported as TEAEs in Dose Escalation Phase
NCT03611556 (31) [back to overview]Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs in Dose Escalation Phase
NCT03611556 (31) [back to overview]Number of Participants With Abnormal ECG Parameters Reported as TEAEs in Dose Expansion Phase
NCT03611556 (31) [back to overview]Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs in Dose Expansion Phase
NCT03611556 (31) [back to overview]Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs in Dose Escalation Phase
NCT03611556 (31) [back to overview]Progression-free Survival According to RECIST v1.1 by CD73 Expression at Baseline in Dose Expansion Phase
NCT03611556 (31) [back to overview]Percentage of Participants With OR According to RECIST v1.1 in Dose Escalation Phase
NCT03611556 (31) [back to overview]Percentage of Participants With OR According to RECIST v1.1 by CD73 Expression at Baseline in Dose Expansion Phase
NCT03611556 (31) [back to overview]Percentage of Participants With Objective Response (OR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in Dose Expansion Phase
NCT03611556 (31) [back to overview]Percentage of Participants With Disease Control (DC) According to RECIST v1.1 in Dose Escalation Phase
NCT03611556 (31) [back to overview]Percentage of Participants With DC According to RECIST v1.1 in Dose Expansion Phase
NCT03611556 (31) [back to overview]Overall Survival in Dose Expansion Phase
NCT03611556 (31) [back to overview]Overall Survival by CD73 Expression at Baseline in Dose Expansion Phase
NCT03611556 (31) [back to overview]Number of Participants With Progression-free Survival Events According to RECIST v1.1 in Dose Expansion Phase
NCT03611556 (31) [back to overview]Number of Participants With Progression-free Survival Events According to RECIST v1.1 by CD73 Expression at Baseline in Dose Expansion Phase
NCT03611556 (31) [back to overview]Number of Participants With Overall Survival Events in Dose Expansion Phase
NCT03611556 (31) [back to overview]Number of Participants With Overall Survival Events by CD73 Expression at Baseline in Dose Expansion Phase
NCT03611556 (31) [back to overview]Number of Participants With Dose-limiting Toxicities (DLTs) in Dose Escalation Phase
NCT03611556 (31) [back to overview]Duration of Response (DoR) According to RECIST v1.1 in Dose Expansion Phase
NCT03611556 (31) [back to overview]Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) in Dose Escalation Phase
NCT03611556 (31) [back to overview]Plasma Concentrations of Gemcitabine and Metabolite 2',2'-Difluorodeoxyuridine (dFdU)
NCT03611556 (31) [back to overview]Plasma Concentrations of Nab-paclitaxel
NCT03665441 (7) [back to overview]Disease Control Rate (DCR)
NCT03665441 (7) [back to overview]Incidence of Treatment Emergent Adverse Events as Assessed by CTCAE v5.0
NCT03665441 (7) [back to overview]Time to Quality of Life Questionnaire EORTC QLQ-C30 First Worsening in Global Health Status Analysis
NCT03665441 (7) [back to overview]Progression Free Survival (PFS)
NCT03665441 (7) [back to overview]Overall Survival (OS)
NCT03665441 (7) [back to overview]Objective Response Rate (ORR)
NCT03665441 (7) [back to overview]Duration of Response (DoR)
NCT03736720 (4) [back to overview]Overall Survival
NCT03736720 (4) [back to overview]Progression-free Survival Assessed by RECIST 1.1
NCT03736720 (4) [back to overview]Time-to Treatment Failure
NCT03736720 (4) [back to overview]Quality of Life (QOL) as Assessed by European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30)
NCT03750786 (2) [back to overview]Duration of Response
NCT03750786 (2) [back to overview]Progression Free Survival
NCT03771560 (5) [back to overview]Social Responsiveness Scale (SRS) - Parent Reported Change
NCT03771560 (5) [back to overview]Social Responsiveness Scale (SRS) - Teacher Reported Change
NCT03771560 (5) [back to overview]Aberrant Behavior Checklist (ABC) - Parent Reported Change
NCT03771560 (5) [back to overview]Aberrant Behavior Checklist (ABC) - Teacher Reported Change
NCT03771560 (5) [back to overview]Pediatric Quality of Life (PedsQL) - Parent Reported Change
NCT03783936 (6) [back to overview]Disease Control Rate (DCR)
NCT03783936 (6) [back to overview]Progression Free Survival (PFS)
NCT03783936 (6) [back to overview]Progression Free Survival by iRECIST(iPFS)
NCT03783936 (6) [back to overview]Best Objective Response Rate (bORR)
NCT03783936 (6) [back to overview]Number of Participants With Grade 3-4 Treatment Related Adverse Events
NCT03783936 (6) [back to overview]Overall Survival (OS)

5-year Overall Survival Rate in Patients With Dukes' B3/C Disease

Overall survival (OS) is defined as time from randomization to death from any cause or last date known alive. Kaplan-Meier method was used to estimate 5-year OS rate (NCT00002525)
Timeframe: every 3 months for 2 years, then every 6 months for 2 years, and then annually until year 15 after randomization

Interventionproportion of participants (Number)
Perioperative 5-FU0.666
No Perioperative 5-FU0.612

[back to top]

5-year Disease-free Survival Rate in Patients With Dukes' B3/C Disease

Disease-free survival (DFS) was defined as time from randomization to recurrence, second invasive primary cancer, or deaths, whichever occurred first. Patients who were still alive and had no DFS events were censored at the last disease assessment date known to be free of DFS events. Patients without any follow up data were censored at random assignment. Kaplan-Meier method was used to estimate the 5-year DFS rate. (NCT00002525)
Timeframe: every 3 months for 2 years, then every 6 months for 2 years, and then annually until year 15 after randomization

Interventionproportion of participants (Number)
Perioperative 5-FU0.582
No Perioperative 5-FU0.543

[back to top]

5-year Disease-free Survival Rate in Patients With Dukes' B2 Disease

Disease-free survival (DFS) was defined as time from randomization to recurrence, second invasive primary cancer, or deaths, whichever occurred first. Patients who were still alive and had no DFS events were censored at the last disease assessment date known to be free of DFS events. Patients without any follow up data were censored at random assignment. Kaplan-Meier method was used to estimate the 5-year DFS rate. (NCT00002525)
Timeframe: every 3 months for 2 years, then every 6 months for 2 years, and then annually until year 15 after randomization

Interventionproportion of participants (Number)
Perioperative 5-FU0.749
No Perioperative 5-FU0.724

[back to top]

5-year Overall Survival Rate in Patients With Dukes' B2 Disease

Overall survival (OS) is defined as time from randomization to death from any cause or last date known alive. Kaplan-Meier method was used to estimate 5-year OS rate (NCT00002525)
Timeframe: every 3 months for 2 years, then every 6 months for 2 years, and then annually until year 15 after randomization

Interventionproportion of participants (Number)
Perioperative 5-FU0.851
No Perioperative 5-FU0.780

[back to top]

2 Year Disease-free Survival .

Estimated using the product-limit method of Kaplan and Meier. Disease free survival, defined as first documented evidence of treatment failure. Acceptable evidence includes: Anastomotic - positive cytology or biopsy; Abdominal, pelvic and retroperitoneal nodes - progressively enlarging node as evidenced by 2 CT scans separated by at least a 4 week interval, ureteral obstruction in the presence of a mass as documented on CT scan; Peritoneum - positive cytology or biopsy, progressively enlarged intraperitoneal solid mass as evidenced by 2 CT scans separated by at least 4 weeks; Ascites - positive cytology or biopsy; Liver - positive cytology or biopsy; Pelvic mass - positive cytology or biopsy, progressively enlarging intrapelvic solid mass as evidenced by 2 CT scans separated by at least 4 weeks; Abdominal wall - positive cytology or biopsy; Lung - positive cytology or biopsy or presence of multiple pulmonary nodules; Bone marrow - positive cytology, aspiration or biopsy. (NCT00002842)
Timeframe: 2 years after treatment

Interventionpercentage of participants (Number)
Hepatic Resection/Portal Vein FUdr/Systemic 5-FU & Leucovorin9

[back to top]

Best Confirmed Response to Neoadjuvant Therapy

Response was based on pathology at surgery. A patient achieved complete response if no gross or microscopic tumor were identified with the surgical specimen and nodal tissue. Stable response was defined as a response that did not qualify as complete response or progressive disease (PD), where PD indicated metastatic spread. Best confirmed response rate was defined as the proportion of patients with complete response (CR). A patient was considered unevaluable if the patient did not have surgery, the pathologist did not examine at least 15 lymph nodes, or the pathology report was unavailable. (NCT00003298)
Timeframe: Assessed at surgery time (surgery performed during week 8-10 after registration to the study)

Interventionpercentage of participants (Number)
Experimental Arm0

[back to top]

Progression Free Survival

Progression-free survival (PFS) was defined as time from registration until progression, recurrence, or death, whichever occurred first. If date of death occurred beyond three months from the date of last disease assessment, then PFS was censored at date of last disease assessment. Patients who were alive and progression-free were censored at the date of last disease evaluation. (NCT00003298)
Timeframe: assessed every month for the first 3 months, every 3 months for the next 21 months, every 6 months for the next year, and annually thereafter up to year 10

Interventionyears (Median)
Experimental Arm0.68

[back to top]

Overall Survival

Overall survival was defined as the time from registration to death, where a subject was censored on date of last record alive. (NCT00003298)
Timeframe: assessed every month for the first 3 months, every 3 months for the next 21 months, every 6 months for the next year, and annually thereafter up to year 10

Interventionyears (Median)
Experimental Arm1.55

[back to top]

Grade 3 or Higher Toxicity Incidence on Step 1

Incidence is defined as proportion of patients with any grade 3 or higher treatment-related toxicities among all treated patients. (NCT00003298)
Timeframe: assessed at the end of every cycle (cycle=21 days) during treatment (3 cycles in total)

Interventionpercentage of participants (Number)
Experimental Arm65.8

[back to top]

Percentage of Patients With Overall Survival as Assessed by Time to Death

Overall survival will be computed by measuring the rate of deaths during induction due primarily to treatment toxicity and cumulative incidence of toxic deaths in induction or deaths in remission overall and separately for treatment groups defined by the two design factors. (NCT00004228)
Timeframe: 5 years

Interventionpercentage of participants (Number)
A0 (Localized Disease Stg I/II) Modified CCG BFM96
A1 (Disseminated, No CNS - CCG Mod BFM w/Out Intens84
A2 (Disseminated, No CNS - CCG Mod BFM w/Intens88
B2 (CNS+) NHL/BFM-95 w/Intens Delayed Radiation Therapy81
B2 (Disseminated,CNS- (< Amend 7B)) NHL/BFM-95 w/Intens85
B1 (Disseminated CNS-) NHL/BFM-95 w/Out Intens85
B1 (NHL/BFM-95 w/Out Intens) Additional Enrollment92

[back to top]

Event-free Survival

Assessed by time to treatment failure, occurrence of second malignant neoplasm, or death from any cause. Statistical analysis will be to estimate the difference in the proportion of patients treated with each therapy who are long-term event-free survivors due either to the difference between the backbone therapy regimens (CCG BFM vs NHL/BFM-95), or due to the intensification. (NCT00004228)
Timeframe: 5 years

Interventionpercentage of particpants (Number)
A0 (Localized Disease Stg I/II) Modified CCG BFM88
A1 (Disseminated, No CNS - CCG Mod BFM w/Out Intens82
A2 (Disseminated, No CNS - CCG Mod BFM w/ Intens80
B2 (CNS+) NHL/BFM-95 w/Intens Delayed Radiation Therapy63
B2 (Disseminated,CNS- (< Amend 7B)) NHL/BFM-95 w/Intens82
B1 (Disseminated CNS-) NHL/BFM-95 w/Out Intens84
B1 (NHL/BFM-95 w/Out Intens) Additional Enrollment90

[back to top]

Number of Participants With Any Adverse Events and Serious Adverse Events

An Adverse Event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered to be related to the medicinal product. An Serious Adverse Events (SAEs) is any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or results in a congenital anomaly/birth defect. (NCT00009737)
Timeframe: Up to Week 29

,
InterventionParticipants (Number)
All adverse eventsSerious adverse events
5-Fluorouracil + Leucovorin885182
Capecitabine910181

[back to top]

Overall Survival

Participants with overall survival were reported. Overall survival was assessed as the number of days between randomization and death or the last time at which a participant was known to be alive (censoring time). (NCT00009737)
Timeframe: Approximately 3 years

InterventionParticipants (Number)
Capecitabine804
5-Fluorouracil + Leucovorin756

[back to top]

Mean Change From Baseline in Global Health Status at Week 25

Global health status was assessed as a sub scale of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30. It was scored on a scale of 0-100; where higher score indicates better quality of life. Wherever the scores for the participants were not available, the last value carried forward (LVCF) were used. (NCT00009737)
Timeframe: Baseline (Days -7 to 1) and at Week 25

InterventionScore on a scale (Mean)
Capecitabine2.1
5-Fluorouracil + Leucovorin2.6

[back to top]

Disease-free Survival

Participants with disease-free survival were reported. Disease-free survival was assessed as the number of days between randomization and the first time at which relapse, a new occurrence of colon cancer, or death was recorded, or the last time at which a participant was known to be disease free (censoring time). (NCT00009737)
Timeframe: Approximately 3 years

InterventionParticipants (Number)
Capecitabine656
5-Fluorouracil + Leucovorin603

[back to top]

Relapse-Free Survival

Participants with relapse-free survival were reported. Relapse-free survival was assessed as the number of days between randomization and the first time at which relapse, a new occurrence of colon cancer, or death was recorded, or the last time at which a participants was known to be disease free (censoring time), excluding deaths that were not related to treatment or to disease progression. (NCT00009737)
Timeframe: Approximately 3 years

InterventionParticipants (Number)
Capecitabine677
5-Fluorouracil + Leucovorin621

[back to top]

Number of Participants With Abnormalities for Blood Chemistry and Hematological Parameters

Laboratory abnormalities were categorized according to the National Cancer Institute of Canada Common Toxicity Criteria (NCIC - CTC) grading system (May 1991 revised) as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe) and Grade 4 (life- threatening). Participants with abnormalities in hemoglobin, granulocytes, lymphocytes, neutrophils, neutrophils/granulocytes, platelets, white blood cell, potassium, serum creatinine, sodium, total bilirubin, alanine transaminase, aspartate aminotransferase, alkaline phosphatase, calcium (hyper), and calcium (hypo) with Grades 1-4 were presented. (NCT00009737)
Timeframe: Up to Week 25

,
InterventionParticipants (Number)
Alanine transaminaseAspartate aminotransferaseAlkaline PhosphataseCalcium (Hyper)Calcium (Hypo)GranulocytesHemoglobinLymphocytesNeutrophilsNeutrophils/GranulocytesPlateletsPotassiumSerum CreatinineSodiumTotal BilirubinWhite blood cell
5-Fluorouracil + Leucovorin3332882896811243650744596612160156138184185409
Capecitabine3273003346715020691778308316182209157189501220

[back to top]

2 Year Event Free Survival

Percentage of patients who were event free at 2 years. The 2-year event free rate was estimated using the Kaplan Meier method. An event is defined as death, progression or treatment failure. (NCT00039130)
Timeframe: 2 years

Interventionpercentage of participants (Number)
Rituximab With High Intensity Chemotherapy78

[back to top]

2 Year Overall Survival

Percentage of participants who were alive at 2 years. The 2 year survival, with 95% confidence interval, was estimated using the Kaplan Meier method. (NCT00039130)
Timeframe: 2 years

Interventionpercentage of participants (Number)
Rituximab With High Intensity Chemotherapy80

[back to top]

Complete Response Rate

Response is assessed by investigator according to Revised Response Criteria for Malignant Lymphoma. Complete response requires disappearance of all evidence of disease. (NCT00039130)
Timeframe: 6 months

Interventionpercentage of participants (Number)
Rituximab With High Intensity Chemotherapy83

[back to top]

Number of Participants Who Achieved a BCR-ABL Response at 12 Months

"BCR-ABL response is defined in two ways: complete molecular response (CMR) and major molecular response (MMR).~Complete Molecular Response is defined as a Bcr-Abl (a fusion of gene of Bcr and ABl genes) ratio ≤0.0032% on the International Scale Bcr = breakpoint cluster gene Abl = abelson proto-oncogene~MMR is defined as Bcr-Abl (A fusion gene of the breakpoint cluster region [Bcr] gene and Abelson proto-oncogene [Abl] genes) transcript ratio ≤0.1% (≥ 3 log reduction of BCR-ABL transcripts from a standardized baseline), as detected by reverse transcriptase polymerase chain reaction [RT-PCR] (performed centrally)." (NCT00039377)
Timeframe: 12 months

Interventionparticipants (Number)
Complete Molecular ResponseMajor Molecular Response
Entire Cohort94

[back to top]

Overall Survival

Overall survival (OS) as the interval from the on-study date until death. OS was estimated using the Kaplan Meier method. (NCT00039377)
Timeframe: Duration of study (up to 10 years)

Interventionyears (Median)
Entire Cohort3.6

[back to top]

Disease Free Survival

"Disease-free survival (DFS) was measured as the interval from achievement of complete remission (CR) until relapse or death, regardless of cause; patients alive and in CR were censored at last follow-up. DFS was estimated using the Kaplan Meier method.~A complete remission (CR) was defined as recovery of morphologically normal bone marrow and blood counts (i.e., neutrophils >= 1.5 x 10^9/L and platelets > 100 x 10^9/L) and no circulating leukemic blasts or evidence of extramedullary leukemia and persisting for at least one month." (NCT00039377)
Timeframe: Duration of treatment (up to 10 years)

Interventionyears (Median)
Entire Cohort1.7

[back to top]

5 Year Overall Survival for Autologous & Allogeneic Transplant Groups

Percentage of patients who were alive at 5 years. The 5-year progression free survival was estimated using the Kaplan Meier method. (NCT00039377)
Timeframe: 5 years from registration

Interventionpercentage of patients (Number)
Patients With HLA-matched Sibling Donor53
Patients Without HLA-matched Sibling Donors51

[back to top]

5 Year Disease-free Survival for Autologous & Allogeneic Transplant Groups

Percentage of patients who achieved a complete remission (CR) and were alive and relapse free at 5 years. The 5-year progression free survival was estimated using the Kaplan Meier method. (NCT00039377)
Timeframe: 5 years from CR

Interventionpercentage of patients (Number)
Patients With HLA-matched Sibling Donor46
Patients Without HLA-matched Sibling Donors47

[back to top]

Response

Complete (CR), complete unconfirmed (CRU) and partial responses (PR). CR is complete disappearance of all measurable and non-measurable disease with the exception of nodes; no new lesions; previously enlarged organs must have regressed in size; and if bone marrow positive at baseline, it must be negative. CRU is complete disappearance of all measurable and non-measurable disease; regressed, non-palpable organs; and one or more exceptions not qualifying for CR (see protocol section 10). PR applies to patients with at least one measurable lesion who do not qualify for CR or CRU. PR is a 50% decrease in sum of products of greatest diameters (SPD) for up to six identified dominant lesions identified at baseline; no new lesions; no increase in the size of liver, spleen or other nodes; and splenic and hepatic nodules must have regressed in size by at least 50% in SPD. (NCT00041132)
Timeframe: assessed after cycle 4 and after completion of treatment (168 days)

Interventionparticipants (Number)
Hyper-CVAD + MTX/Ara-C + Rituximab42

[back to top]

Progression-free Survival

Progression-Free Survival (PFS) rate at 1 year. PFS measured from date of registration to date of first observation of progressive disease or death due to any cause. Progressive disease is a 50% increase in the sum of products of greatest diameters (SPD) of target measurable lesions over the smallest sum observed if a complete response (confirmed, or unconfirmed) was not previously achieved; appearance of a new lesion/site; unequivocal progression of non-measurable disease; or death due to disease without prior documentation of progression. (NCT00041132)
Timeframe: assessed after cycle 4, after completion of treatment, then every 3 months until 1 year after registration

Interventionpercentage of participants (Number)
Hyper-CVAD + MTX/Ara-C + Rituximab90

[back to top]

Overall Survival

Overall Survival rate at 1 year. Time to death is from date of registration to date of death due to any cause. (NCT00041132)
Timeframe: assessed after cycle 4, after completion of treatment, then every 3 months for 2 years, then every 6 months thereafter until 5 years

Interventionpercentage of participants (Number)
Hyper-CVAD + MTX/Ara-C + Rituximab92

[back to top]

Overall Survival

Overall survival is defined as the time from study enrollment to death due to any cause. The distribution of survival time will be estimated using the method of Kaplan-Meier. (NCT00052910)
Timeframe: From study enrollment until death from any cause; up to 3 years

Interventionyears (Median)
Arm I (5-FU/LV)3.6
Arm II (ECF)3.5

[back to top]

Disease Free Survival

Disease free survival is defined as the time from the date of study enrollment to death or documented second primary tumor, or cancer recurrence.The distribution of disease free survival time will be estimated using the method of Kaplan-Meier. (NCT00052910)
Timeframe: From the date of study enrollment until death or documented second primary tumor, or cancer recurrence; up to 4 years

Interventionyears (Median)
Arm I (5-FU/LV)2.7
Arm II (ECF)2.3

[back to top]

Response Rate

Response includes both complete and partial responses. Per protocol, complete Response is defined as the complete disappearance of all clinical evidence of disease by physical examination, by imaging studies, by bone marrow biopsy (where indicated), by CNS evaluation (where indicated) and by biopsy where there is a residual abnormality on an imaging study. Bone marrow must contain <5% blasts. CSF WBC must be <5/μL with no blasts or lymphomatous cells present. Partial response is defined as: at least a 50% reduction in the size of all measurable tumor areas. Each site is to be defined by the product of the maximum length, width and depth (3 dimensions). No lesion may progress. No new lesion may appear. Bone marrow must contain <5% blasts. CSF WBC must be <5/μL with no blasts or lymphomatous cells present.. (NCT00057811)
Timeframe: Up to 5 years

Interventionpercentage of participants analyzed (Number)
Group B (Chemotherapy, Protective Therapy, Monoclonal Antib.)88
Group C (Chemotherapy, Monoclonal Antibody Therapy)83

[back to top]

Minimal Residual Disease

The presence or absence of tumor cells at the end of induction assessed by studying tissue and/or blood/marrow. Details of methods and criteria used can be found in Shiramizu at al. BJH 153:758-763, 2011 (full citation in the citation section). (NCT00057811)
Timeframe: Not Provided

Interventionpercentage of samples analyzed (Number)
Group B (Chemotherapy, Protective Therapy, Monoclonal Antib.)22
Group C (Chemotherapy, Monoclonal Antibody Therapy)70

[back to top]

Grade ≥ 3 Stomatitis

The incidence of grade ≥ 3 stomatitis. Grade 3 stomatitis: Confluent ulcerations or pseudomembranes; bleeding with minor trauma. Grade 4 stomatitis: Tissue necrosis; Significant spontaneous bleeding; life-threatening consequences (NCT00057811)
Timeframe: Up to 1 year

,
Interventionparticipants (Number)
Incidence of grade ≥ 3 stomatitisNo incidence of grade ≥ 3 stomatitis
Group B (Chemotherapy, Protective Therapy, Monoclonal Antib.)441
Group C (Chemotherapy, Monoclonal Antibody Therapy)634

[back to top]

Toxic Death

Implementation of the toxic death rate stopping rule, a death must be possibly, probably or definitely attributable to Rituximab and/or chemotherapy to be considered a toxic death. (NCT00057811)
Timeframe: Up to 1 year

,
Interventionparticipants (Number)
Toxic deathNo toxic death
Group B (Chemotherapy, Protective Therapy, Monoclonal Antib.)045
Group C (Chemotherapy, Monoclonal Antibody Therapy)238

[back to top]

Disease-free Survival, for Only Complete Response Patients

Disease Free Survival (DFS) is defined as the time from a Complete Response (CR) until death or relapse. The date of last clinical assesment will be used as the censor date for patients with no death or relapse. The DFS will be estimated using the Kaplan-Meier method with confidence intervals presented. (NCT00061945)
Timeframe: 9 years 4 months

Interventionmonths (Median)
Phase I - Alemtuzumab and Combination Chemotherapy58.6
Phase II - Alemtuzumab and Combination Chemotherapy19.8

[back to top]

Overall Survival

Overall Survival is defines as the time from registration to death due to any cause. It is estimated using the Kaplan-Meier method with confidence intervals presented. (NCT00061945)
Timeframe: 9 years 4 months

Interventionmonths (Median)
Phase I - Alemtuzumab and Combination Chemotherapy33.6
Phase II - Alemtuzumab and Combination Chemotherapy23.1

[back to top]

Number of Participants Who Proceed to Course V Within 2-6 Weeks of the Last Dose of Alemtuzumab (Phase II)

The primary endpoint is the number of participants who are able to proceed to course V within two - six weeks of completion of course IV. (NCT00061945)
Timeframe: 8 months

Interventionparticipants (Number)
Phase II - Alemtuzumab and Combination Chemotherapy30

[back to top]

Minimal Residual Disease (MRD) During Treatment With Alemtuzumab (Phase II)

Minimal Residual Disease measures the presence of of circulating leukemia cells in the body. Patients that report a Complete Response (CR) during treatment are further tested to determine the presence of small amounts of circulating leukemia cells. Here we report the number of patients who were MRD negative. (NCT00061945)
Timeframe: 9 years 4 months

InterventionParticipants (Count of Participants)
Phase II - Alemtuzumab and Combination Chemotherapy16

[back to top]

Maximum Tolerated Dose (MTD) of Alemtuzumab (Phase I)

The maximum tolerated dose is defined as the highest alemtuzumab dose at which less than 40% of patients develop the dose limiting toxicity (DLT), where DLT is defined as the inability to proceed (due to medical complications) with the protocol treatment within six weeks of receiving the last dose of alemtuzumab. Groups of six patients will be enrolled into each cohort at the time of re-registration prior to starting Course IV. After a cohort has accrued 6 patients and at least 3 have completed the 2-6 week post alemtuzumab observation period without DLT, the incoming patients will be assigned to the next cohort in the table while the DLT and other toxicities continue to be assessed for the newly closed cohort. If less than 3 out of 6 enrolled patients in a cohort have completed the 2-6 week post alemtuzumab observation period without DLT, additional patients may continue to enroll in that same cohort, i.e., accrual will not be suspended while waiting for patient follow-up data. (NCT00061945)
Timeframe: 6 weeks

Interventionmg (Number)
Phase I - Alemtuzumab and Combination Chemotherapy30

[back to top]

Number of Participants Achieving Complete Remission

A complete remission (CR) requires the following: an absolute neutrophil count (segs and bands) > 1500/μl, no circulating blasts, platelets > 100,000/μl; bone marrow cellularity > 20% with trilineage hematopoiesis, and < 5% marrow blast cells, none of which appear neoplastic. All previous extramedullary manifestations of disease must be absent (e.g., lymphadenopathy, splenomegaly, skin or gum infiltration, testicular masses, or CNS involvement). (NCT00061945)
Timeframe: 9 years

Interventionparticipants (Number)
Phase I - Alemtuzumab and Combination Chemotherapy92
Phase II - Alemtuzumab and Combination Chemotherapy145

[back to top]

Proportion of Sphincter Preservation

Proportion of sphincter preservation was defined as number of patients with sphincter preservation divided by total number of patients randomized to the arm (NCT00068692)
Timeframe: assessed at primary surgery time

Interventionproportion of patients (Number)
Irinocetan (Arm I)0.814
Oxaliplatin (Arm II)0.724
Control (Arm III)0.655

[back to top]

Failure Pattern

Type of failures (local/regional recurrence vs. distant recurrence vs. concurrent recurrence vs. second primary cancer vs. deaths) in the analysis population (NCT00068692)
Timeframe: assessed every 3 months withihn 2 years of study entry, every 6 monhts between years 3-5 and then annually for 5 years

,,
InterventionParticipants (Count of Participants)
Local/regional recurrence onlyDistant recurrence onlyBoth local/regional and distant recurrenceAny recurrenceSecond primary cancerDeath
Control (Arm III)510116221
Irinocetan (Arm I)315220319
Oxaliplatin (Arm II)511420521

[back to top]

3-year Overall Survival Rate

Overall survival (OS) was defined as time from randomization to death from any cause. 3-year OS rate was estimated using Kaplan-Meier method. (NCT00068692)
Timeframe: assessed every 3 months withihn 2 years of study entry, every 6 monhts between years 3-5 and then annually for 5 years, estimated at 3 years

Interventionproportion of patients (Number)
Irinocetan (Arm I)0.965
Oxaliplatin (Arm II)0.843
Control (Arm III)0.870

[back to top]

3-year Disease Free Survival

Disease free survival (DFS) was defined as time from randomization to recurrence, second invasive primary cancer and death from any cause, whichever occurred first. 3-year DFS rate was estimated using Kaplan-Meier method. (NCT00068692)
Timeframe: assessed every 3 months withihn 2 years of study entry, every 6 monhts between years 3-5 and then annually for 5 years, estimated at 3 years

Interventionproportion of patients (Number)
Irinocetan (Arm I)0.670
Oxaliplatin (Arm II)0.717
Control (Arm III)0.704

[back to top]

PFS as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) by General Approach (Participants With Curative Surgery Censored) - Superiority of Chemotherapy Plus BV Over Chemotherapy Alone

PFS was defined as the time from randomization to progressive disease or death. Participants with neither disease progression nor death were censored at the last date of the last tumor assessment that confirmed that their disease had not progressed. Participants with no tumor assessments after baseline who were alive at the time of clinical cutoff were censored at the date of randomization. Participants who underwent surgical resection with curative intent without prior progression were censored at the date of surgery. PFS was based on tumor assessments made by the investigators according to the RECIST criteria. Superiority analysis that followed the general approach took into account all tumor assessments obtained during the primary study treatment phase, the post-study treatment phase and those obtained during the follow-up phase. Superiority of the BV-containing arms was compared with the chemotherapy alone arms. (NCT00069095)
Timeframe: Baseline until disease progression or death, approximately 2 years 6 months

Interventiondays (Median)
FOLFOX-4+P/XELOX+P244.0
FOLFOX-4+BV/XELOX+BV285.0

[back to top]

PFS as Assessed by the Independent Review Committee (IRC) (General Approach, Participants With Curative Surgery Censored) - Superiority of Chemotherapy Plus BV Over Chemotherapy Alone

PFS is defined as the time from randomization to disease progression (PD) or death due to any cause. Participants with neither disease progression nor death were censored at the last date of the last tumor assessment that confirmed that their disease had not progressed. Participants who underwent surgical resection with curative intent without prior progression were censored at the date of surgery. PFS was analyzed on the basis of the tumor response assessments made by the IRC. Superiority analysis that followed the general approach took into account all tumor assessments obtained during the primary study treatment phase, the post-study treatment phase and those obtained during the follow-up phase. Superiority of the bevacizumab-containing arms was compared with the placebo-containing arms. (NCT00069095)
Timeframe: Baseline until disease progression or death, approximately 2 years 6 months

Interventiondays (Median)
FOLFOX-4+P/XELOX+P259.0
FOLFOX-4+BV/XELOX+BV335.0

[back to top]

PFS as Assessed by the Independent Review Committee (IRC) (General Approach, Participants With Curative Surgery Censored) - Non-inferiority of XELOX Versus FOLFOX-4

PFS is defined as the time from randomization to disease progression (PD) or death due to any cause. Participants with neither disease progression nor death were censored at the last date of the last tumor assessment that confirmed that their disease had not progressed. Participants who underwent surgical resection with curative intent without prior progression were censored at the date of surgery. PFS was analyzed on the basis of the tumor response assessments made by the IRC. Non-inferiority analysis that followed the general approach took into account all tumor assessments obtained during the primary study treatment phase, the post-study treatment phase and those obtained during the follow-up phase. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms. (NCT00069095)
Timeframe: Baseline until disease progression or death, approximately 2 years 6 months

Interventiondays (Median)
FOLFOX-4/FOLFOX-4+P/FOLFOX-4+BV304.0
XELOX/XELOX+P/XELOX+BV261.0

[back to top]

PFS (On-treatment Approach): Non-inferiority of XELOX Versus FOLFOX-4

PFS is defined as the time from randomization to disease progression (PD) or death due to any cause. The on-treatment analysis included only tumor assessments and death events that occurred no later than 28 days after the last confirmed intake of any study medication in the primary study treatment phase. Participants who did not have an event during this interval were censored at the date of the last tumor assessment within this time window, or on day 1 if no tumor assessment was available after baseline. Participants who underwent surgical resection with curative intent without prior progression within 28 days after the last confirmed intake of any study medication in the primary study treatment phase were censored at the date of surgery. The on-treatment approach excluded the possible impact of other treatments that might have been started before disease progression. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms. (NCT00069095)
Timeframe: Baseline until disease progression or death, approximately 2 years 6 months

Interventiondays (Median)
FOLFOX-4/FOLFOX-4+P/FOLFOX-4+BV268.0
XELOX/XELOX+P/XELOX+BV234.0

[back to top]

Overall Survival: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone

Overall survival was defined as the time from the date of randomization to the date of death. Participants who were not reported to have died at the time of the clinical cut-off date for the analysis were censored using the date they were last known to be alive. Superiority of the BV-containing arms was compared with the chemotherapy alone arms. (NCT00069095)
Timeframe: Baseline until disease progression or death, approximately 2 years 6 months

Interventiondays (Median)
FOLFOX-4+P/XELOX+P574.0
FOLFOX-4+BV/XELOX+BV551.0

[back to top]

Overall Survival: Non-inferiority of XELOX Versus FOLFOX-4

Overall survival was defined as the time from the date of randomization to the date of death. Participants who were not reported to have died at the time of the clinical cut-off date for the analysis were censored using the date they were last known to be alive. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms. (NCT00069095)
Timeframe: Baseline until disease progression or death, approximately 2 years 6 months

Interventiondays (Median)
FOLFOX-4/FOLFOX-4+P/FOLFOX-4+BV549.0
XELOX/XELOX+P/XELOX+BV577.0

[back to top]

Duration of Overall Response as Assessed by the Investigator According to RECIST: Superiority Analysis of Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone

Duration of overall response was measured from the time that measurement criteria were first met for CR or PR (whichever status was recorded first) until the first date when progressive disease or death was documented. It was based on tumor assessments made by the investigators according to the RECIST criteria. Participants who neither progressed nor died were censored at the date of the last tumor assessment. Participants undergoing surgical resection with curative intent were censored at the date of surgery. Superiority of the BV-containing arms was compared with the chemotherapy alone arms. (NCT00069095)
Timeframe: From baseline until disease progression/recurrence, approximately 2 years 6 months

Interventiondays (Median)
FOLFOX-4+P/XELOX+P225.0
FOLFOX-4+BV/XELOX+BV257.0

[back to top]

Duration of Overall Response as Assessed by the Investigator According to RECIST: Non-inferiority of XELOX Versus FOLFOX-4

Duration of overall response was measured from the time that measurement criteria were first met for CR or PR (whichever status was recorded first) until the first date when progressive disease or death was documented. It was based on tumor assessments made by the investigators according to the RECIST criteria. Participants who neither progressed nor died were censored at the date of the last tumor assessment. Participants undergoing surgical resection with curative intent were censored at the date of surgery. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms. (NCT00069095)
Timeframe: From baseline until disease progression/recurrence, approximately 2 years 6 months

Interventiondays (Median)
FOLFOX-4/FOLFOX-4+P/FOLFOX-4+BV239.0
XELOX/XELOX+P/XELOX+BV226.0

[back to top]

Time to Treatment Failure as Assessed by the Investigator According to RECIST: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone

Time to treatment failure was defined as the time from the date of randomization to the date of discontinuation of the primary study treatment phase due to adverse event/intercurrent illness, insufficient therapeutic response, death, failure to return, refusing treatment/being unwilling to cooperate, or withdrawing consent; discontinuation of the post study treatment phase due to adverse event, progressive disease, death, participant refusal/administrative reasons, or withdrawing consent; documented disease progression; or death due to any cause, whichever occurred first. The general approach included all tumor assessments or deaths that occurred during the primary study treatment phase, the post-study treatment phase, or the follow-up phase. The on-treatment approach included only tumor assessments and deaths that occurred no later than 28 days after the last confirmed intake of any study medication in the primary study treatment phase only. (NCT00069095)
Timeframe: From baseline until disease progression/recurrence, approximately 2 years 6 months

,
Interventiondays (Median)
General ApproachOn-treatment Approach
FOLFOX-4+BV/XELOX+BV209.0208.0
FOLFOX-4+P/XELOX+P183.0182.0

[back to top]

Time to Response as Assessed by the Investigator According to RECIST: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone

For participants whose BOR was CR or PR, time to response was measured as the time from randomization to the first time when the measurement criteria for CR or PR (whichever status was recorded first) was met. It was based on tumor assessments made by the investigators according to the RECIST criteria. Results were reported as the number of participants achieving a response in 8 time categories from Week 1 to Week 54. Superiority of the BV-containing arms was compared with the chemotherapy alone arms. (NCT00069095)
Timeframe: Week 1 to Week 54

,
InterventionParticipants (Number)
Week 1-6Week 7-12Week 13-18Week 19-24Week 25-30Week 31-36Week 37-42Week 49-54
FOLFOX-4+P/XELOX+P58146105267210
XELOX/XELOX+P/XELOX+BV48138872912821

[back to top]

Time to Response as Assessed by the Investigator According to RECIST: Non-inferiority of XELOX Versus FOLFOX-4

For participants whose BOR was CR or PR, time to response was measured as the time from randomization to the first time when the measurement criteria for CR or PR (whichever status was recorded first) was met. It was based on tumor assessments made by the investigators according to the RECIST criteria. Results were reported as the number of participants achieving a response in 8 time categories from Week 1 to Week 54. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms. (NCT00069095)
Timeframe: Week 1 to Week 54

,
InterventionParticipants (Number)
Week 1-6Week 7-12Week 13-18Week 19-24Week 25-30Week 31-36Week 37-42Week 49-54
FOLFOX-4/FOLFOX-4+P/FOLFOX-4+BV671901552514732
XELOX/XELOX+P/XELOX+BV931911103813310

[back to top]

Progression-free Survival (PFS) as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) by General Approach (Participants With Curative Surgery Censored): Non-inferiority of XELOX Versus FOLFOX-4

PFS was defined as the time from randomization to progressive disease or death. Participants with neither disease progression nor death were censored at the last date of the last tumor assessment that confirmed that their disease had not progressed. Participants with no tumor assessments after baseline who were alive at the time of clinical cutoff were censored at the date of randomization. Participants who underwent surgical resection with curative intent without prior progression were censored at the date of surgery. PFS was based on tumor assessments made by the investigators according to the RECIST criteria. Non-inferiority analysis that followed the general approach took into account all tumor assessments obtained during the primary study treatment phase, the post-study treatment phase and those obtained during the follow-up phase. Non-inferiority of the XELOX-containing arms compared with the FOLFOX-4- containing arms was investigated. (NCT00069095)
Timeframe: Baseline until disease progression or death, approximately 2 years 6 months

Interventiondays (Median)
FOLFOX-4/FOLFOX-4+P/FOLFOX-4+BV259
XELOX/XELOX+P/XELOX+BV241

[back to top]

PFS by General Approach, Participants With Curative Surgery Not Censored: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone

PFS is defined as the time from randomization to disease progression (PD) or death due to any cause. Participants who underwent curative surgery after experiencing a sufficient shrinkage of their tumor were not censored at the date of surgery, but any relapse, new occurrence of colorectal cancer, or death was considered as an event. Superiority analysis that followed the general approach took into account all tumor assessments obtained during the primary study treatment phase, the post-study treatment phase and those obtained during the follow-up phase. Superiority of the BV-containing arms was compared with the chemotherapy alone arms. (NCT00069095)
Timeframe: Baseline until disease progression or death, approximately 2 years 6 months

Interventiondays (Median)
FOLFOX-4+P/XELOX+P245.0
FOLFOX-4+BV/XELOX+BV287.0

[back to top]

Duration of Complete Response as Assessed by the Investigator According to RECIST: Non-inferiority of XELOX Versus FOLFOX-4

For complete responders, the duration of complete response was measured from the time measurement criteria were first met for complete response until the date that progressive disease (or death) was documented. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms. (NCT00069095)
Timeframe: From baseline until disease progression/recurrence, approximately 2 years 6 months

Interventiondays (Median)
FOLFOX-4/FOLFOX-4+P/FOLFOX-4+BV347.0
XELOX/XELOX+P/XELOX+BV589.0

[back to top]

BOR as Assessed by the IRC According to RECIST: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone

According to the RECIST criteria, the BOR in an individual participant was the best response recorded from the start of the treatment until disease progression/recurrence (taking the smallest measurements recorded since the baseline assessment as a reference for PD). The BOR as assessed by the IRC was determined based on tumor assessments that were made up to and including 28 days after last intake of study medication in the primary study treatment phase. Responders were defined as the percentage of participants with a complete response (CR) or partial response (PR). Superiority of the BV-containing arms was compared with the chemotherapy alone arms. (NCT00069095)
Timeframe: From baseline until disease progression/recurrence, approximately 2 years 6 months

InterventionPercentage of responders (Number)
FOLFOX-4+P/XELOX+P37.5
FOLFOX-4+BV/XELOX+BV37.5

[back to top]

BOR as Assessed by the IRC According to RECIST: Non-inferiority of XELOX Versus FOLFOX-4

According to the RECIST criteria, the BOR in an individual participant was the best response recorded from the start of the treatment until disease progression/recurrence (taking the smallest measurements recorded since the baseline assessment as a reference for PD). The BOR as assessed by the IRC was determined based on tumor assessments that were made up to and including 28 days after last intake of study medication in the primary study treatment phase. Responders were defined as the percentage of participants with a complete response (CR) or partial response (PR). Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms. (NCT00069095)
Timeframe: From baseline until disease progression/recurrence, approximately 2 years 6 months

InterventionPercentage of responders (Number)
FOLFOX-4/FOLFOX-4+P/FOLFOX-4+BV38.6
XELOX/XELOX+P/XELOX+BV37.1

[back to top]

Best Overall Response (BOR) as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST): Non-inferiority of XELOX Versus FOLFOX-4

According to the RECIST criteria, BOR in an individual participant was defined as the best response recorded from the start of the treatment until disease progression or recurrence. Only tumor assessments as assessed by the investigator and made up to and including 28 days after last intake of study medication in the primary study treatment phase not later than date of first curative surgery were included in these analyses. Responders were defined as the percentage of participants with a confirmed best overall response of complete response (CR) or partial response (PR). Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms. (NCT00069095)
Timeframe: From baseline until disease progression/recurrence, approximately 2 years 6 months

InterventionPercentage of responders (Number)
FOLFOX-4/FOLFOX-4+P/FOLFOX-4+BV49.4
XELOX/XELOX+P/XELOX+BV46.4

[back to top]

Best Overall Response (BOR) as Assessed by the Investigator According to RECIST: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone

According to the RECIST criteria, BOR in an individual participant was defined as the best response recorded from the start of the treatment until disease progression or recurrence. Only tumor assessments as assessed by the investigator and made up to and including 28 days after last intake of study medication in the primary study treatment phase not later than date of first curative surgery were included in these analyses. Responders were defined as the percentage of participants with a confirmed best overall response of complete response (CR) or partial response (PR). Superiority of the BV-containing arms was compared with the chemotherapy alone arms. (NCT00069095)
Timeframe: From baseline until disease progression/recurrence, approximately 2 years 6 months

InterventionPercentage of responders (Number)
FOLFOX-4+P/XELOX+P49.2
FOLFOX-4+BV/XELOX+BV46.5

[back to top]

Time to Treatment Failure (TTF) as Assessed by the Investigator According to RECIST: Non-inferiority of XELOX Versus FOLFOX-4

Time to treatment failure was defined as the time from the date of randomization to the date of discontinuation of the primary study treatment phase due to adverse event/intercurrent illness, insufficient therapeutic response, death, failure to return, refusing treatment/being unwilling to cooperate, or withdrawing consent; discontinuation of the post study treatment phase due to adverse event, progressive disease, death, participant refusal/administrative reasons, or withdrawing consent; documented disease progression; or death due to any cause, whichever occurred first. The general approach took into account all tumor assessments obtained during the primary study treatment phase, the post-study treatment phase and those obtained during the follow-up phase.The on-treatment approach included only tumor assessments and deaths that occurred no later than 28 days after the last confirmed intake of any study medication in the primary study treatment phase only. (NCT00069095)
Timeframe: From baseline until disease progression/recurrence, approximately 2 years 6 months

,
Interventiondays (Median)
General ApproachOn-treatment Approach
FOLFOX-4/FOLFOX-4+P/FOLFOX-4+BV191.0190.0
XELOX/XELOX+P/XELOX+BV179.0176.0

[back to top]

PFS (On-treatment Approach): Superiority of Chemotherapy Plus BV Over Chemotherapy Alone

PFS is defined as the time from randomization to disease progression (PD) or death due to any cause. The on-treatment analysis included only tumor assessments and death events that occurred no later than 28 days after the last confirmed intake of any study medication in the primary study treatment phase. Participants who did not have an event during this interval were censored at the date of the last tumor assessment within this time window, or on day 1 if no tumor assessment was available after baseline. Participants who underwent surgical resection with curative intent without prior progression within 28 days after the last confirmed intake of any study medication in the primary study treatment phase were censored at the date of surgery. The on-treatment approach excluded the possible impact of other treatments that might have been started before disease progression. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms. (NCT00069095)
Timeframe: Baseline until disease progression or death, approximately 2 years 6 months

Interventiondays (Median)
FOLFOX-4+P/XELOX+P241.0
FOLFOX-4+BV/XELOX+BV316.0

[back to top]

PFS by General Approach, Participants With Curative Surgery Not Censored: Non-inferiority of XELOX Versus FOLFOX-4

PFS is defined as the time from randomization to disease progression (PD) or death due to any cause. Participants who underwent curative surgery after experiencing a sufficient shrinkage of their tumor were not censored at the date of surgery, but any relapse, new occurrence of colorectal cancer, or death was considered as an event. Non-inferiority analysis that followed the general approach took into account all tumor assessments obtained during the primary study treatment phase, the post-study treatment phase and those obtained during the follow-up phase. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms. (NCT00069095)
Timeframe: Baseline until disease progression or death, approximately 2 years 6 months

Interventiondays (Median)
FOLFOX-4/FOLFOX-4+P/FOLFOX-4+BV260.0
XELOX/XELOX+P/XELOX+BV244.0

[back to top]

Duration of Complete Response as Assessed by the Investigator According to RECIST: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone

For complete responders, the duration of complete response was measured from the time measurement criteria were first met for complete response until the date that progressive disease (or death) was documented. Superiority of the BV-containing arms was compared with the chemotherapy alone arms. (NCT00069095)
Timeframe: From baseline until disease progression/recurrence, approximately 2 years 6 months

Interventiondays (Median)
FOLFOX-4+P/XELOX+P403.0
FOLFOX-4+BV/XELOX+BV386.0

[back to top]

Duration Of Response

Duration of response (DOR) is defined as the time when CR or PR was first met up to first date that PD or death is documented. CR is defined as disappearance of all TLs and non TLs, PR is defined as at least 30% decrease in the sum of the LD of TLs, taking as reference the baseline sum LD. PD was defined as at least a 20% increase in the sum of the LD of the TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions for the TLs or the appearance of one or more new lesions and/or unequivocal progression of existing non-TLs. (NCT00069108)
Timeframe: Up to 3 years

Interventiondays (Median)
XELOX169
FOLFOX-4190

[back to top]

Progression Free Survival

Progression free survival (PFS) is defined as the time from the date of randomization to the day of documented disease progression or death from any cause. It was based on tumor assessments made according to the Response Evaluation Criteria In Solid Tumors (RECIST) version 1.0, wherein progressive disease (PD) was defined as at least a 20% increase in the sum of the longest diameter (LD) of the target lesions (TLs), taking as reference the smallest sum LD recorded since the treatment started or appearance of one or more new lesions or unequivocal progression of existing non-target lesions. Participants with neither disease progression nor death were censored at the last date of the last tumor assessment confirming that they had not progressed. Participants with no tumor assessments after baseline but who were still alive at the time of the clinical cut-off were censored at date of randomization (NCT00069108)
Timeframe: Up to 3 years

Interventiondays (Median)
XELOX154
FOLFOX-4168

[back to top]

Progression Free Survival Based on Independent Review Committee Assessment

Progression free survival (PFS) is defined as the time from the date of randomization to the day of documented disease progression or death from any cause. It was based on tumor assessments made according to the RECIST version 1.0, wherein PD was defined as at least a 20% increase in the sum of the LD of the TLs, taking as reference the smallest sum LD recorded since the treatment started or appearance of one or more new lesions or unequivocal progression of existing non-TLs. Participants with neither disease progression nor death were censored at the last date of the last tumor assessment confirming that they had not progressed. Participants with no tumor assessments after baseline but who were still alive at the time of the clinical cut-off were censored at date of randomization. This PFS evaluation was based on Independent Review Committee Assessment. (NCT00069108)
Timeframe: Up to 3 years

Interventiondays (Median)
XELOX168
FOLFOX-4162

[back to top]

Progression Free Survival Based on Treatment Analysis- Intent To Treat Population

Progression free survival (PFS) is defined as the time from date of randomization to day of documented disease progression or death from any cause. It was based on tumor assessments made according to the RECIST version 1.0, wherein PD was defined as at least a 20% increase in the sum of LD of the TLs, taking as reference the smallest sum LD recorded since the treatment started or appearance of one or more new lesions or unequivocal progression of existing non-TLs. Participants with neither disease progression nor death were censored at the last date of the last tumor assessment confirming that they had not progressed. Participants with no tumor assessments after baseline but who were still alive at the time of the clinical cut-off were censored at date of randomization. PFS was analyzed using an on-treatment approach included only disease progression and death that occurred no later than 28 days after the last confirmed intake of study medication in the primary study treatment phase. (NCT00069108)
Timeframe: Up to 3 years

Interventiondays (Median)
XELOX145
FOLFOX-4152

[back to top]

Progression Free Survival Based on Treatment Analysis- Per Population

Progression free survival (PFS) is defined as the time from the date of randomization to the day of documented disease progression or death from any cause. It was based on tumor assessments made according to the RECIST version 1.0, wherein PD was defined as at least a 20% increase in the sum of the LD of the TLs, taking as reference the smallest sum LD recorded since the treatment started or appearance of one or more new lesions or unequivocal progression of existing non-TLs. Participants with neither disease progression nor death were censored at the last date of the last tumor assessment confirming that they had not progressed. Participants with no tumor assessments after baseline but who were still alive at the time of the clinical cut-off were censored at date of randomization (NCT00069108)
Timeframe: Up to 3 years

Interventiondays (Median)
XELOX153
FOLFOX-4164

[back to top]

Time To Treatment Failure

Time to treatment failure was defined as the time from the date of randomization to the first occurrence of adverse event (AE), insufficient therapeutic response, death, failure to return, or refusing treatment/being uncooperative/withdrawing consent. (NCT00069108)
Timeframe: Up to 3 years

Interventiondays (Median)
XELOX125
FOLFOX-4121.5

[back to top]

Best Overall Response, Independent Review Committee Assessment

Best overall response is best response recorded from start of treatment until disease progression/recurrence where responses include CR, PR, or SD. CR was defined as disappearance of all TLs, non-TLs along with normalization of tumor marker level. PR is at least 30% decrease in sum of the LD of TLs, taking as reference baseline sum LD. SD defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking reference of smallest sum LD since treatment started. It was dependent on achievement of measurement and confirmation criteria. BOR .i.e. CR or PR was confirmed by repeat assessments performed within 4 weeks, for SD, follow-up assessments had to meet the SD criteria at least once after study entry within 6 to 8 weeks. This PFS evaluation was based on Independent Review Committee Assessment. (NCT00069108)
Timeframe: Up to 3 years

,
Interventionparticipants (Number)
IRC Assessed, RespondersIRC assessed-CRIRC assessed-PR
FOLFOX-439039
XELOX48048

[back to top]

Best Overall Response, Investigators' Assessments

Best overall response is best response recorded from start of treatment until disease progression/recurrence where responses include complete response (CR), partial response (PR), or stable disease (SD). CR was defined as disappearance of all TLs, non-TLs along with normalization of tumor marker level. PR is at least 30% decrease in sum of the LD of TLs, taking as reference baseline sum LD. SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking reference of smallest sum LD since treatment started. It was dependent on achievement of measurement and confirmation criteria. BOR .i.e. CR or PR was confirmed by repeat assessments performed within 4 weeks. For SD, follow-up assessments had to meet the SD criteria at least once after study entry within 6 to 8 weeks. (NCT00069108)
Timeframe: Up to 3 years

,
Interventionparticipants (Number)
Investigator Assessed, RespondersInvestigator assessed-CRInvestigator assessed-PR
FOLFOX-455253
XELOX63063

[back to top]

Number of Participants With Marked Post-baseline Laboratory Abnormalities by Trial Treatment

Laboratory abnormalities were defined as those values that were outside the Roche defined reference range and showed a clinically relevant change from baseline. All laboratory parameters were categorized according to the National Cancer Center Common Toxicity Criteria (NCI-CTCAE) grading system. Incidence of Grade 1 to 4 laboratory abnormalities are presented in the table below. (NCT00069108)
Timeframe: Up to 3 years

,
Interventionparticipants (Number)
Serum Glutamic-Pyruvic Transaminase (SGPT)Serum Glutamic Oxaloacetic Transaminase (SGOT)Alkaline PhosphataseCalcium (hyper)Calcium (hypo )Glucose (hyper)Glucose (hypo)GranulocytesHaemoglobinNeutrophilsNeutrophils/GranulocytesPlateletsPotassium (hyper)Potassium (hypo)Serum AlbuminSerum CreatinineSodium (hyper)Sodium (hypo)Total BilirubinWhite blood cell (WBC)
FOLFOX-411017420197020796240199202212269213832217395205
XELOX901931847682011212161131141681768116181464107124

[back to top]

Time To Response

Time to response (TOR) (best response of CR or PR) was measured as the time from randomization to the first date on which the measurement criteria for CR or PR (whichever status was recorded first) were met. CR for TLs was defined as disappearance of all TLs and for non-TLs as disappearance of all non-TLs and normalization of tumor marker level. PR was defined as at least 30% decrease in the sum of the LD of TLs, taking as reference the baseline sum LD. (NCT00069108)
Timeframe: Up to 3 years

,
Interventionparticipants (Number)
Week 1-6Week 7-12Week 13-18Week 19-24
FOLFOX-41123183
XELOX1326222

[back to top]

Overall Survival

Overall survival was measured as the time from the date of randomization to the date of death. Participant who were not reported to have died at the time of the analysis were censored using the date they were last known to be alive. (NCT00069108)
Timeframe: Up to 3 years

Interventiondays (Median)
XELOX363
FOLFOX-4382

[back to top]

Overall Survival [Number of Events]

Overall survival was measured as the time from randomization to the date of death, irrespective of the cause of death. Participants who were not reported as having died at the time of the analysis were censored using the date they were last known to be alive. (NCT00069121)
Timeframe: Time from randomization date to date of death/date last known to be alive. Median observation time was 83 months (range: 0-95 months).

,
InterventionParticipants (Count of Participants)
Patients With EventPatients Without Events
5-FU/LV286656
XELOX242702

[back to top]

Disease-Free Survival (DFS) [Time to Event]

Determination of an event was based on tumor assessments and survival follow-up assessments. A disease-free survival (DFS) event was defined as any recurrence of the original colon cancer or appearance of a new colon or rectal cancer (proven by cytology or histology, when possible) or death due to any cause, whichever was earliest. Participants who had not had any such event at the time of data analysis were censored at the last date they were known to be event-free. Participants with no tumor assessments after baseline were censored at Day 1. An isolated event of increased CEA, or unexplained clinical deterioration were not considered to be evidence of relapse without support of other objective measurements. The date of relapse was defined as the date of the definitive assessment by objective measurements. The median was estimated by the Kaplan-Meier method. The full range values include censored observations. (NCT00069121)
Timeframe: Time from randomization date to date of first DFS event/date last known to be event-free. Median observation time for DFS was 74 months (range: 0-95 months).

Interventionmonths (Median)
5-FU/LVNA
XELOX88.6

[back to top]

Number of Participants With at Least One Adverse Event by Most Severe Intensity

"The intensity of all adverse events (AEs) was categorized according to the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) (version 3.0) grading system. If an AE had occurred which was not contained in the NCI-CTC, a four-point scale (mild, moderate, severe, life-threatening) was used. The terms severe and serious are not synonymous and are independently assessed for each AE. Only the most severe intensity was counted for multiple occurrences of an AE in one individual. See the AEs results table for details." (NCT00069121)
Timeframe: From time of very first drug intake to 28 days after very last drug intake (median [full range] duration of study treatment per arm: 5-FU/LV MAYO CLINIC: 145 [4-208] days; 5-FU/LV ROSWELL PARK: 204 [1-239] days; XELOX: 163 [1-275] days).

,,
InterventionParticipants (Count of Participants)
Mild AEsModerate AEsSevere AEsLife-Threatening
5-FU/LV MAYO CLINIC55749329983
5-FU/LV ROSWELL PARK25621714621
XELOX85579254863

[back to top]

Disease-Free Survival (DFS) [Number of Events]

Determination of an event was based on tumor assessments and survival follow-up assessments. A disease-free survival (DFS) event was defined as any recurrence of the original colon cancer or appearance of a new colon or rectal cancer (proven by cytology or histology, when possible) or death due to any cause, whichever was earliest. Participants who had not had any such event at the time of data analysis were censored at the last date they were known to be event-free. Participants with no tumor assessments after baseline were censored at Day 1. An isolated event of increased CEA, or unexplained clinical deterioration were not considered to be evidence of relapse without support of other objective measurements. The date of relapse was defined as the date of the definitive assessment by objective measurements. (NCT00069121)
Timeframe: Time from randomization date to date of first DFS event/date last known to be event-free. Median observation time for DFS was 74 months (range: 0-95 months).

,
InterventionParticipants (Count of Participants)
Patients with EventPatients without Events
5-FU/LV379563
XELOX320624

[back to top]

Relapse-Free Survival (RFS) [Time to Event]

A relapse-free survival (RFS) event included recurrence of the original colon cancer, development of a new colon or rectal cancer, and deaths related to any of the following: treatment, recurrence of the original colon cancer, or development of a new colon or rectal cancer. Participants who had not had any such event at the time of data analysis were censored at the last date they were known to be event-free. Participants whose cause of death was unrelated to treatment or disease recurrence were censored at the time of the last tumor assessment. The median was estimated by the Kaplan-Meier method. The full range values include censored observations. (NCT00069121)
Timeframe: Time from randomization date to date of first RFS event/date last known to be event-free. Median observation time for RFS was 74 months (range: 0-95 months).

Interventionmonths (Median)
5-FU/LVNA
XELOX88.6

[back to top]

Overall Survival [Time to Event]

Overall survival was measured as the time from randomization to the date of death, irrespective of the cause of death. Participants who were not reported as having died at the time of the analysis were censored using the date they were last known to be alive. The median was estimated by the Kaplan-Meier method. The full range values include censored observations. (NCT00069121)
Timeframe: Time from randomization date to date of death/date last known to be alive. Median observation time was 83 months (range: 0-95 months).

Interventionmonths (Median)
5-FU/LVNA
XELOXNA

[back to top]

Relapse-Free Survival (RFS) [Number of Events]

A relapse-free survival (RFS) event included recurrence of the original colon cancer, development of a new colon or rectal cancer, and deaths related to any of the following: treatment, recurrence of the original colon cancer, or development of a new colon or rectal cancer. Participants who had not had any such event at the time of data analysis were censored at the last date they were known to be event-free. Participants whose cause of death was unrelated to treatment or disease recurrence were censored at the time of the last tumor assessment. (NCT00069121)
Timeframe: Time from randomization date to date of first RFS event/date last known to be event-free. Median observation time for RFS was 74 months (range: 0-95 months).

,
InterventionParticipants (Count of Participants)
Patients With EventPatients Without Events
5-FU/LV356586
XELOX290654

[back to top]

Correlation of Minimal Residual Disease (MRD) Negative With Event Free Survival (EFS).

Bone marrow MRD status is defined as negative with < 0.1 detectable leukemia cells. (NCT00075725)
Timeframe: 5 years

Interventionpercentage of participants (Number)
Dexamethasone and Capizzi Methotrexate Patients < 10 Years86.4
Dexamethasone, High Dose Methotrexate (Non Randomly Assigned)93.6
Dexamethasone & Capizzi Methotrexate Patients => 10 Years Old80.5
Dexamethasone, High Dose Methotrexate (IM) < 10 Years93.1
Prednisone, Capizzi Methotrexate <10 Years86.5
Prednisone, Capezzi Methotrexate >= 10 Years83.4
Prednisone and High Dose Methotrexate < 10 Yrs Old84.2
Prednisone and High Dose Methotrexate >=10 Years83.9
Dexamethasone, High Dose Methotrexate (IM) >= 10 Years85.3
Prednisone, Capezzi Methotrexate (Down's Syndrome)74.4
Dexamethasone, Capizzi Methotrexate Down Syndrome (Non Random)25

[back to top]

Correlation of Minimal Residual Disease (MRD) Negative With Overall Survival (OS).

Bone marrow MRD status is defined as negative with < .01 detectable leukemia cells. (NCT00075725)
Timeframe: 5 years

Interventionpercentage of participants (Number)
Dexamethasone and Capizzi Methotrexate Patients < 10 Years95.4
Dexamethasone, High Dose Methotrexate (Non Randomly Assigned)92.9
Dexamethasone & Capizzi Methotrexate Patients => 10 Years Old87.4
Dexamethasone, High Dose Methotrexate (IM) < 10 Years98.1
Prednisone, Capizzi Methotrexate <10 Years93.3
Prednisone, Capizzi Methotrexate >= 10 Years90.2
Prednisone and High Dose Methotrexate < 10 Yrs Old94.5
Prednisone and High Dose Methotrexate >=10 Years90.5
Dexamethasone, High Dose Methotrexate (IM) >= 10 Years91.6
Prednisone, Capizzi Methotrexate (Down's Syndrome)78.3
Dexamethasone, Capizzi Methotrexate Down Syndrome (Non Random)25.0

[back to top]

Correlation of Minimal Residual Disease (MRD) Positive With Event Free Survival (EFS)

Bone marrow MRD status is defined as positive with >= 0.1 detectable leukemia cells. (NCT00075725)
Timeframe: 5 years

Interventionpercentage of participants (Number)
Dexamethasone and Capizzi Methotrexate Patients < 10 Years66.5
Dexamethasone, High Dose Methotrexate (Non Randomly Assigned)43.3
Dexamethasone & Capizzi Methotrexate Patients => 10 Years Old35.4
Dexamethasone, High Dose Methotrexate (IM) < 10 Years80
Prednisone, Capizzi Methotrexate <10 Years34.7
Prednisone, Capizzi Methotrexate >= 10 Years39
Prednisone and High Dose Methotrexate < 10 Yrs Old55
Prednisone and High Dose Methotrexate >=10 Years47.8
Dexamethasone, High Dose Methotrexate (IM) >= 10 Years49.4

[back to top]

Correlation of Minimal Residual Disease (MRD) Positive With Overall Survival (OS)

Bone marrow MRD status is defined as positive with >= 0.1 detectable leukemia cells, and negative with < 0.1 detectable leukemia cells. (NCT00075725)
Timeframe: 5 Years

Interventionpercentage of participants (Number)
Dexamethasone and Capizzi Methotrexate Patients < 10 Years79.2
Dexamethasone, High Dose Methotrexate (Non Randomly Assigned)69.9
Dexamethasone & Capizzi Methotrexate Patients => 10 Years Old65.6
Dexamethasone, High Dose Methotrexate (IM) < 10 Years86.2
Prednisone, Capizzi Methotrexate <10 Years93.8
Prednisone, Capizzi Methotrexate >= 10 Years63.1
Predisone and High Dose Methotrexate < 10 Yrs Old84.2
Prednisone and High Dose Methotrexate >=10 Years73.6
Dexamethasone, High Dose Methotrexate (IM) >= 10 Years74.6

[back to top]

Correlation of Early Marrow Response Status With MRD Positive.

Bone marrow status is defined as: M1: < 5% lymphoblasts; M2: 5-25% lymphoblasts; M3: > 25% lymphoblasts. Bone marrow MRD status is defined as positive with >= 0.1 detectable leukemia cells, and negative with < 0.1 detectable leukemia cells. (NCT00075725)
Timeframe: Day 29

Interventionparticipants (Number)
Dexamethasone and Capizzi Methotrexate Patients < 10 Years26
Dexamethasone, High Dose Methotrexate (Non Randomly Assigned)12
Dexamethasone & Capizzi Methotrexate Patients => 10 Years Old43
Dexamethasone, High Dose Methotrexate (IM) < 10 Years14
Prednisone, Capizzi Methotrexate <10 Years16
Prednisone, Capezzi Methotrexate >= 10 Years95
Prednisone and High Dose Methotrexate < 10 Yrs Old17
Prednisone and High Dose Methotrexate >=10 Years98
Dexamethasone, High Dose Methotrexate (IM) >= 10 Years39
Prednisone, Capezzi Methotrexate (Down's Syndrome)3
Dexamethasone, Capizzi Methotrexate Down Syndrome (Non Random)3
Prednisone and High Dose Methotrexate (Non Randomly Assigned)3

[back to top]

Comparison of the Increase in Cure Rate of High Risk ALL Without Causing More Serious Side Effects Between Interventions

Event Free Probability. (NCT00075725)
Timeframe: 5 years

Interventionpercentage of participants (Number)
Dexamethasone and Capizzi Methotrexate Patients < 10 Years83.2
Dexamethasone, High Dose Methotrexate (Non Randomly Assigned)81.6
Dexamethasone & Capizzi Methotrexate Patients => 10 Years Old69.1
Dexamethasone, High Dose Methotrexate (IM) < 10 Years91.2
Prednisone, Capizzi Methotrexate <10 Years82.1
Prednisone, Capezzi Methotrexate >= 10 Years73.5
Predisone and High Dose Methotrexate < 10 Yrs Old80.8
Prenisone and High Dose Methotrexate >=10 Years75.8
Dexamethasone, High Dose Methotrexate (IM) >= 10 Years77.0
Prenisone, Capezzi Methotrexate (Down's Syndrome)61.8
Dexamethasone, Capizzi Methotrexate Down Syndrome (Non Random)44.4

[back to top]

Correlation of Early Marrow Response Status With MRD Negative.

Bone marrow status is defined as: M1: < 5% lymphoblasts; M2: 5-25% lymphoblasts; M3: > 25% lymphoblasts. Bone marrow MRD status is defined as positive with >= 0.1 detectable leukemia cells, and negative with < 0.1 detectable leukemia cells. (NCT00075725)
Timeframe: Day 29

Interventionparticipants (Number)
Dexamethasone and Capizzi Methotrexate Patients < 10 Years182
Dexamethasone, High Dose Methotrexate (Non Randomly Assigned)72
Dexamethasone & Capizzi Methotrexate Patients => 10 Years Old198
Dexamethasone, High Dose Methotrexate (IM) < 10 Years188
Prednisone, Capizzi Methotrexate <10 Years195
Prednisone, Capezzi Methotrexate >= 10 Years471
Prednisone and High Dose Methotrexate < 10 Yrs Old190
Prednisone and High Dose Methotrexate >=10 Years479
Dexamethasone, High Dose Methotrexate (IM) >= 10 Years208
Prednisone, Capezzi Methotrexate (Down's Syndrome)25
Dexamethasone, Capizzi Methotrexate Down Syndrome (Non Random)3
Prednisone and High Dose Methotrexate (Non Randomly Assigned)18

[back to top]

Disease-free Survival (Arms A and D: Mutant KRAS Patients)

"A secondary endpoint for this study was to investigate the disease-free survival (DFS) in patients with stage III colon cancer who are KRAS mutant (or KRAS-nonevaluable) and randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). Participants treated according to Arms B, C, E, and F treatment schedules received treatment which included irinotecan hydrochloride and therefore were not analyzed for this endpoint.~Disease-free survival is defined as the time from randomization until tumor recurrence or death, whichever is first. Estimated by the method of Kaplan and Meier." (NCT00079274)
Timeframe: At 3 years

Interventionpercentage of participants (Number)
Mutant KRAS Arm A67.1
Mutant KRAS Arm D65.0

[back to top]

Disease-free Survival (Arms A and D: Wild-type KRAS Patients)

"The primary endpoint for this study was to compare the disease-free survival (DFS) in patients with stage III colon cancer who are KRAS wild-type randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). Participants treated according to Arms B, C, E, and F treatment schedules received treatment which included irinotecan hydrochloride and therefore were not analyzed for this endpoint.~Disease-free survival is defined as the time from randomization until tumor recurrence or death, whichever is first. Estimated by the method of Kaplan and Meier." (NCT00079274)
Timeframe: At 3 years

Interventionpercentage of participants (Number)
Wild-type KRAS Arm A74.6
Wild-type KRAS Arm D71.5

[back to top]

Overall Survival as Measured by the 3-year Event-free Rate (Arms A and D: Mutant KRAS Patients)

Evidence of death from any cause within 3 years counted as events in the time to event- Kaplan Meier analysis of overall survival for patients with stage III colon cancer who are KRAS mutant (or KRAS-nonevaluable) and randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). Participants treated according to Arms B, C, E, and F treatment schedules received treatment which included irinotecan hydrochloride and therefore were not analyzed for this endpoint. The 3-year event-free rates (percentage) are report below for mutant KRAS patients. (NCT00079274)
Timeframe: Up to 3 years

Interventionpercentage of participants (Number)
Mutant KRAS Arm A87.9
Mutant KRAS Arm D82.7

[back to top]

Overall Survival as Measured by the 3-year Event-free Rate (Arms A and D: Wild-type KRAS Patients)

Evidence of death from any cause within 3 years counted as events in the time to event- Kaplan Meier analysis of overall survival for patients with stage III colon cancer who are KRAS wild-type randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). Participants treated according to Arms B, C, E, and F treatment schedules received treatment which included irinotecan hydrochloride and therefore were not analyzed for this endpoint. The 3-year event free rates (percentage) are reported below for Wild-type KRAS Patients. (NCT00079274)
Timeframe: Up to 3 years

Interventionpercentage of participants (Number)
Wild-type KRAS Arm A87.3
Wild-type KRAS Arm D85.6

[back to top]

Toxicity, Assessed Using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 (v3) (Arms A and D: Wild-type KRAS Patients)

The maximum grade for each type of toxicity will be recorded for each patient with stage III colon cancer who are KRAS wild-type randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). The overall toxicity rates (percentages) for grade 3 or higher adverse events considered at least possibly related to treatment are reported below. (NCT00079274)
Timeframe: Assessed up to 8 years

Interventionpercentage of patients (Number)
Wild-type KRAS Arm A51.1
Wild-type KRAS Arm D73.3

[back to top]

Toxicity, Assessed Using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 (v3) (Arms A and D: Mutant KRAS Patients)

The maximum grade for each type of toxicity will be recorded for each patient with stage III colon cancer who are KRAS mutant (or KRAS-nonevaluable) and randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). The overall toxicity rates (percentages) for grade 3 or higher adverse events considered at least possibly related to treatment are reported below. (NCT00079274)
Timeframe: Assessed up to 8 years

Interventionpercentage of patients (Number)
Mutant KRAS Arm A55.6
Mutant KRAS Arm D72.3

[back to top]

Pathologic Complete Response Rate

"A pathologic complete response (pCR) was defined as no evidence of residual cancer histologically; disease progression or death before surgery was considered less than pCR (even without surgical specimen). All cases were reviewed by the study's surgical oncology co-chair for the determination of pCR.~Each arm was first analyzed alone. If the arm had 9 or more pCRs in 48 evaluable pts, then the null hypothesis (H0) of 10% pCR rate would be rejected in favor of the alternative hypothesis of 25%, providing 90% power with a two-sided 10% type I error rate. If both arms reject H0, then statistical selection theory would be used to choose the arm for further study in a phase III trial. If only one arm has acceptable pCR rate, then that arm would be pursued in a phase III trial." (NCT00081289)
Timeframe: After protocol surgery, approximately 10-16 weeks from randomization based on surgery occurring 4-8 weeks after chemoradiation

Interventionpercentage of participants (Number)
Neoadjuvant Chemoradiation With Irinotecan10.4
Neoadjuvant Chemoradiation With Oxaliplatin20.8

[back to top]

Second Primary Rate at 4 Years

Time to second primary is defined as time from randomization to date of the appearance of a second primary cancer, last known follow-up (censored), or death without second primary (competing risk). Second primary rates are estimated by the cumulative incidence method. (NCT00081289)
Timeframe: From randomization to four years

Interventionpercentage of participants (Number)
Neoadjuvant Chemoradiation With Irinotecan2
Neoadjuvant Chemoradiation With Oxaliplatin6

[back to top]

Survival Rate at 4 Years

Survival time is defined as time from registration/randomization to the date of death from any cause or last known follow-up (censored). Survival rates are estimated by the Kaplan-Meier method. (NCT00081289)
Timeframe: From randomization to four years

Interventionpercentage of participants (Number)
Neoadjuvant Chemoradiation With Irinotecan85
Neoadjuvant Chemoradiation With Oxaliplatin75

[back to top] [back to top] [back to top] [back to top]

Change From Baseline in EORTC QLQ-CR38 Gastro-intestinal Symptom Score at Completion of Chemoradiation

The gastro-intestinal (GI) symptom score is calculated from five symptom questions on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ]-CR38. The question responses range from 1 (not at all) to 4 (very much) such that a higher response indicates worse symptoms. The mean of these responses is linearly transformed to a range of 0 (best) to 100 (worst). Change from baseline is calculated as the time point value - baseline value and a decrease from baseline indicates improvement in symptoms. A negative number indicates improvement in symptoms. (NCT00081289)
Timeframe: Baseline and completion of chemoradiation approximately 6-8 weeks from randomization

Interventionscore on a scale (Mean)
Neoadjuvant Chemoradiation With Irinotecan5.9
Neoadjuvant Chemoradiation With Oxaliplatin20.3

[back to top]

Change From Baseline in EORTC QLQ-CR38 Defecation Symptom Score at Two Years

"The defecation symptom score is calculated from seven symptom questions on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ]-CR38. The question responses range from 1 not at all to 4 very much such that a higher response indicates worse symptoms. The mean of these responses is linearly transformed to a range of 0 (best) to 100 (worst). Change from baseline is calculated as the time point value - baseline value and a decrease from baseline indicates improvement in symptoms. A negative number indicates improvement in symptoms." (NCT00081289)
Timeframe: Baseline and two years

Interventionscore on a scale (Mean)
Neoadjuvant Chemoradiation With Irinotecan0.4
Neoadjuvant Chemoradiation With Oxaliplatin-1.6

[back to top]

Change From Baseline in QLQ-C30 Global Health Status Score at Completion of Chemoradiation

"Global Health Status is calculated from two questions on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ]-C30. The question responses range from 1 very poor to 7 excellent such that a higher response indicates better quality of life (QOL). The mean of these responses is linearly transformed to a range of 0 (worst) to 100 (best). Change from baseline is calculated as the time point value - baseline value and a decrease from baseline indicates decline in quality of life. A positive number indicates improvement in QOL." (NCT00081289)
Timeframe: Baseline and completion of chemoradiation, approximately 6-8 weeks from randomization

Interventionscore on a scale (Mean)
Neoadjuvant Chemoradiation With Irinotecan-10.3
Neoadjuvant Chemoradiation With Oxaliplatin-12.2

[back to top]

Change From Baseline in EORTC QLQ-CR38 Gastro-intestinal Symptom Score at Two Years

The gastro-intestinal (GI) symptom score is calculated from five symptom questions on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ]-CR38. The question responses range from 1 (not at all) to 4 (very much) such that a higher response indicates worse symptoms. The mean of these responses is linearly transformed to a range of 0 (best) to 100 (worst). Change from baseline is calculated as the time point value - baseline value and a decrease from baseline indicates improvement in symptoms. A negative number indicates improvement in symptoms. (NCT00081289)
Timeframe: Baseline and two years

Interventionscore on a scale (Mean)
Neoadjuvant Chemoradiation With Irinotecan0.4
Neoadjuvant Chemoradiation With Oxaliplatin6.7

[back to top]

Change From Baseline in QLQ-C30 Global Health Status Score at Completion of Post-operative Chemotherapy

"Global Health Status is calculated from two questions on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ]-C30. The question responses range from 1 very poor to 7 excellent such that a higher response indicates better quality of life (QOL). The mean of these responses is linearly transformed to a range of 0 (worst) to 100 (best). Change from baseline is calculated as the time point value - baseline value and a decrease from baseline indicates decline in quality of life. A positive number indicates improvement in QOL." (NCT00081289)
Timeframe: Baseline and completion of post-operative chemotherapy approximately 32 to 40 weeks from randomization based on 18 weeks of post-operative chemotherapy

Interventionscore on a scale (Mean)
Neoadjuvant Chemoradiation With Irinotecan-12.5
Neoadjuvant Chemoradiation With Oxaliplatin-7.1

[back to top]

Change From Baseline in QLQ-C30 Global Health Status Score at Two Years

"Global Health Status is calculated from two questions on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ]-C30. The question responses range from 1 very poor to 7 excellent such that a higher response indicates better quality of life (QOL). The mean of these responses is linearly transformed to a range of 0 (worst) to 100 (best). Change from baseline is calculated as the time point value - baseline value and a decrease from baseline indicates decline in quality of life. A negative number indicates improvement in symptoms." (NCT00081289)
Timeframe: Baseline and two years

Interventionscore on a scale (Mean)
Neoadjuvant Chemoradiation With Irinotecan-6.8
Neoadjuvant Chemoradiation With Oxaliplatin-1.3

[back to top]

Change From Baseline in EORTC QLQ-CR38 Defecation Symptom Score at Completion of Chemoradiation

"The defecation symptom score is calculated from seven symptom questions on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ]-CR38. The question responses range from 1 not at all to 4 very much such that a higher response indicates worse symptoms. The mean of these responses is linearly transformed to a range of 0 (best) to 100 (worst). Change from baseline is calculated as the time point value - baseline value and a decrease from baseline indicates improvement in symptoms. A negative number indicates improvement in symptoms." (NCT00081289)
Timeframe: Baseline and completion of chemoradiation, approximately 6-8 weeks from randomization

Interventionscore on a scale (Mean)
Neoadjuvant Chemoradiation With Irinotecan4.8
Neoadjuvant Chemoradiation With Oxaliplatin8.8

[back to top]

Change From Baseline in EORTC QLQ-CR38 Defecation Symptom Score at Post-operative Chemotherapy

"The defecation symptom score is calculated from seven symptom questions on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ]-CR38. The question responses range from 1 not at all to 4 very much such that a higher response indicates worse symptoms. The mean of these responses is linearly transformed to a range of 0 (best) to 100 (worst). Change from baseline is calculated as the time point value - baseline value and a decrease from baseline indicates improvement in symptoms. A negative number indicates improvement in symptoms." (NCT00081289)
Timeframe: Baseline and completion of post-operative chemotherapy, approximately 32 to 40 weeks from randomization based on 18 weeks of post-operative chemotherapy

Interventionscore on a scale (Mean)
Neoadjuvant Chemoradiation With Irinotecan-1.6
Neoadjuvant Chemoradiation With Oxaliplatin14.6

[back to top]

Change From Baseline in EORTC QLQ-CR38 Gastro-intestinal Symptom Score at Completion of Post-operative Chemotherapy

The gastro-intestinal (GI) symptom score is calculated from five symptom questions on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ]-CR38. The question responses range from 1 (not at all) to 4 (very much) such that a higher response indicates worse symptoms. The mean of these responses is linearly transformed to a range of 0 (best) to 100 (worst). Change from baseline is calculated as the time point value - baseline value and a decrease from baseline indicates improvement in symptoms. A negative number indicates improvement in symptoms. (NCT00081289)
Timeframe: Baseline and completion of post-operative chemotherapy approximately 32 to 40 weeks from randomization based on 18 weeks of post-operative chemotherapy

Interventionscore on a scale (Mean)
Neoadjuvant Chemoradiation With Irinotecan-1.5
Neoadjuvant Chemoradiation With Oxaliplatin3.9

[back to top]

Disease-free Survival Rate at 4 Years

Disease-free survival time is defined as time from randomization to date of local-regional failure, the appearance of distant metastases, the appearance of a second primary failure, or date of death from any cause/ Disease-free survival rates are estimated by the Kaplan-Meier method. Patients last known to be alive without failure are censored at the date of last contact. (NCT00081289)
Timeframe: From randomization to four years

Interventionpercentage of participants (Number)
Neoadjuvant Chemoradiation With Irinotecan68
Neoadjuvant Chemoradiation With Oxaliplatin62

[back to top]

Distant Failure Rate at 4 Years

Time to distant failure is defined as time from randomization to date of the appearance of distant metastases, last known follow-up (censored), or death without distant failure (competing risk). Distant failure rates are estimated by the cumulative incidence method. (NCT00081289)
Timeframe: From randomization to four years

Interventionpercentage of participants (Number)
Neoadjuvant Chemoradiation With Irinotecan24
Neoadjuvant Chemoradiation With Oxaliplatin30

[back to top]

Local-regional Failure Rate at 4 Years

Local-regional failure is defined as any of the following: no clinical complete response (cCR) in the primary site and/or nodes at any time after treatment completion (persistence), recurrence and/or progression in the primary site and/or nodes after cCR, and nonprotocol surgery to the primary site after cCR. Time to local-regional failure is defined as time from randomization to date of failure, last known follow-up (censored), or death without local-regional failure (competing risk). Local-regional failure rates are estimated by the cumulative incidence method. (NCT00081289)
Timeframe: From randomization to four years

Interventionpercentage of participants (Number)
Neoadjuvant Chemoradiation With Irinotecan16
Neoadjuvant Chemoradiation With Oxaliplatin18

[back to top]

Grade 3-4 Blood/Bone Marrow Events

"All Grade 3-4 Blood/Bone Marrow events based on CTCAEv2 as reported on case report forms.~Arm Name" (NCT00084838)
Timeframe: Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.

Interventionadverse events (Number)
Multi-agent Intrathecal and Systemic CT With RT (Mod IRS III)564

[back to top]

Grade 3-4 Cardiovascular Events

All Grade 3-4 Cardiovascular events based on CTCAEv2 as reported on case report forms. (NCT00084838)
Timeframe: Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.

Interventionadverse events (Number)
Multi-agent Intrathecal and Systemic CT With RT (Mod IRS III)6

[back to top]

Grade 3-4 Constitutional Events

All Grade 3-4 Constitutional events based on CTCAEv2 as reported on case report forms. (NCT00084838)
Timeframe: Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.

Interventionadverse events (Number)
Multi-agent Intrathecal and Systemic CT With RT (Mod IRS III)22

[back to top]

Grade 3-4 Dermatology Events

All Grade 3-4 Dermatology events based on CTCAEv2 as reported on case report forms. (NCT00084838)
Timeframe: Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.

Interventionadverse events (Number)
Multi-agent Intrathecal and Systemic CT With RT (Mod IRS III)3

[back to top]

Grade 3-4 Gastrointestinal Events

All Grade 3-4 Gastrointestinal events based on CTCAEv2 as reported on case report forms. (NCT00084838)
Timeframe: Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.

Interventionadverse events (Number)
Multi-agent Intrathecal and Systemic CT With RT (Mod IRS III)139

[back to top]

Grade 3-4 Hemorrhage Events

All Grade 3-4 Hemorrhage events based on CTCAEv2 as reported on case report forms. (NCT00084838)
Timeframe: Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.

Interventionadverse events (Number)
Multi-agent Intrathecal and Systemic CT With RT (Mod IRS III)1

[back to top]

Grade 3-4 Hepatic Events

All Grade 3-4 Hepatic events based on CTCAEv2 as reported on case report forms. (NCT00084838)
Timeframe: Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.

Interventionadverse events (Number)
Multi-agent Intrathecal and Systemic CT With RT (Mod IRS III)8

[back to top]

Grade 3-4 Infection/Febrile Neutropenia Events

All Grade 3-4 Infection/Febrile Neutropenia events based on CTCAEv2 as reported on case report forms. (NCT00084838)
Timeframe: Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.

Interventionadverse events (Number)
Multi-agent Intrathecal and Systemic CT With RT (Mod IRS III)49

[back to top]

Grade 3-4 Metabolic/Laboratory Events

All Grade 3-4 Metabolic/Laboratory events based on CTCAEv2 as reported on case report forms. (NCT00084838)
Timeframe: Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.

Interventionadverse events (Number)
Multi-agent Intrathecal and Systemic CT With RT (Mod IRS III)128

[back to top]

Grade 3-4 Muscloskeletal Events

All Grade 3-4 Muscloskeletal events based on CTCAEv2 as reported on case report forms. (NCT00084838)
Timeframe: Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.

Interventionadverse events (Number)
Multi-agent Intrathecal and Systemic CT With RT (Mod IRS III)8

[back to top]

Grade 3-4 Neurology Events

All Grade 3-4 Neurology events based on CTCAEv2 as reported on case report forms. (NCT00084838)
Timeframe: Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.

Interventionadverse events (Number)
Multi-agent Intrathecal and Systemic CT With RT (Mod IRS III)45

[back to top]

Grade 3-4 Pain Events

All Grade 3-4 Pain events based on CTCAEv2 as reported on case report forms. (NCT00084838)
Timeframe: Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.

Interventionadverse events (Number)
Multi-agent Intrathecal and Systemic CT With RT (Mod IRS III)31

[back to top]

Grade 3-4 Pulmonary Events

All Grade 3-4 Pulmonary events based on CTCAEv2 as reported on case report forms. (NCT00084838)
Timeframe: Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.

Interventionadverse events (Number)
Multi-agent Intrathecal and Systemic CT With RT (Mod IRS III)4

[back to top]

Grade 3-4 Renal/Genitourinary Events

All Grade 3-4 Renal/Genitourinary events based on CTCAEv2 as reported on case report forms. (NCT00084838)
Timeframe: Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.

Interventionadverse events (Number)
Multi-agent Intrathecal and Systemic CT With RT (Mod IRS III)4

[back to top]

Grade 3/4 Events

All Grade 3-4 events based on CTCAEv2 as reported on case report forms. (NCT00084838)
Timeframe: Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.

Interventionadverse events (Number)
Multi-agent Intrathecal and Systemic CT With RT (Mod IRS III)1021

[back to top]

Pre-Radiation Therapy Chemotherapeutic Response

"Response pre-RT/post-CT was defined as follows with overall response defined as achieving PR or CR.~Complete Response (CR): Complete resolution of all initially demonstrable tumor on MRI or CT evaluation w/o appearance of any new areas of disease; negative CSF cytology. Partial Response (PR): >/= 50% decrease in the sum of the products of the maximum perpendicular diameters of the tumor (sum LD) relative to baseline w/o appearance of any new areas of disease; CSF cytology unchanged from that at diagnosis or clearing after being initially positive Stable Disease (SD): <50% decrease in the sum LD w/o appearance of any new areas of disease; CSF cytology unchanged from that at diagnosis or clearing after being initially positive Progressive Disease (PD): >/= 25% increase in the sum LD relative to baseline, or the appearance of any new areas of disease or appearance of positive cytology after two consecutive negative samples." (NCT00084838)
Timeframe: Assessed at study entry and pre-RT/post-CT at week 7.

Interventionproportion of evaluable patients (Number)
Multi-agent Intrathecal and Systemic CT With RT (Modified IRS0.58

[back to top]

Grade 3-4 Allergy/Immunology

All Grade 3-4 Allergy/Immunology events based on CTCAEv2 as reported on case report forms. (NCT00084838)
Timeframe: Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.

Interventionadverse events (Number)
Multi-agent Intrathecal and Systemic CT With RT (Mod IRS III)1

[back to top]

2-yr Overall Survival

Overall survival is defined as the time from date of diagnosis to death or date of last follow-up. 2-year overall survival is the probability of patients remaining alive at 2-years from study entry estimated using Kaplan-Meier (KM) methods which censors patients at date of last follow-up. Precision of this conditional probability estimate was measured in terms of standard error. Median OS, the original primary endpoint, was not estimable based on the Kaplan-Meier method because of insufficient follow-up. (NCT00084838)
Timeframe: Patients are followed for survival up to 5 yrs post-therapy completion or death; As of this analysis, median follow-up among survivors was 31 months with the longest follow-up being 40 months.

Interventionprobability (Number)
Multi-agent Intrathecal and Systemic CT With RT (Modified IRS0.70

[back to top]

Grade 3-4 Auditory/Hearing Events

All Grade 3-4 Auditory/Hearing events based on CTCAEv2 as reported on case report forms. (NCT00084838)
Timeframe: Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.

Interventionadverse events (Number)
Multi-agent Intrathecal and Systemic CT With RT (Mod IRS III)8

[back to top]

Number of Participants Experiencing Grade 3-4 Toxicity While Receiving the Study Treatment

Toxicity event collected during Induction chemotherapy (CT) - two 3-week cycles, Concurrent CT and Radiation Therapy (CRT) (approximately 5.5 weeks), post CRT (4 weeks after the end of CRT), 2-3 months post CRT (8-12 weeks after the end of CRT) (NCT00089024)
Timeframe: From time of first dose until 30 days following final treatment, approximately 24 weeks

InterventionParticipants (Count of Participants)
Induction CT, grade 3Induction CT, grade 4CRT, grade 3CRT, grade 4Within 1 mo. post CRT, grade 3Within 1 mo. post CRT, grade 42-3 mos. post CRT, grade 32-3 mos. post CRT, grade 4
Treatment4511012190

[back to top]

Surgical Exploration

Patients who completed chemotherapy & chemo-radiation had restaging imaging studies 4 weeks after completion of chemo-radiation. If there were no contraindications for surgical resection, surgical exploration was performed 6-8 weeks after completing chemo-radiation (NCT00089024)
Timeframe: After 6 weeks of chemotherapy and then after 4 weeks of chemo-radiation.

InterventionParticipants (Count of Participants)
unresectable diseaseintra-abdominal metastasisresection of the primary tumor
Treatment469

[back to top]

Event-free Survival

Monitoring of efficacy results will be performed in comparison with historical results. (NCT00096135)
Timeframe: 3 years

Interventionpercentage of participants (Number)
CNS Patients - Treatment (Combination Chemotherapy)64.9
Testicular Relapse Patients (Combination Chemotherapy)70

[back to top]

Disease-free Survival

Where events are defined as recurrence, second primary cancer, or death from any cause (NCT00096278)
Timeframe: 3 years

Interventionpercentage of patients (Number)
Arm 1: Oxaliplatin + Leucovorin + 5-Fluorouracil75.5
Arm 2: Oxaliplatin + Leucovorin + 5-Fluorouracil + Bevacizumab77.4

[back to top]

Survival

Percentage of patients who did not experience an event where events are defined as death from any cause. (NCT00096278)
Timeframe: 5 years

Interventionpercentage of patients (Number)
Arm I (mFOLFOX6)77.6
Arm II (Bevacizumab, mFOLFOX6)78.7

[back to top]

Complete Response Rate After Remission Induction

Response is assessed by investigator according to Revised Response Criteria for Malignant Lymphoma. Complete response requires disappearance of all evidence of disease. (NCT00098774)
Timeframe: 4 months

Interventionpercentage of participants (Number)
Intensive Combination Chemo & Immunotherapy66

[back to top]

4 Year Overall Survival Rate

Percentage of patients who were alive at 4 years. The 4-year survival rate was estimated using the Kaplan Meier method. (NCT00098774)
Timeframe: 4 years

Interventionpercentage of participants (Number)
Intensive Combination Chemo & Immunotherapy65

[back to top]

4 Year Progression Free Rate

"Percentage of patients who were progression free at 4 years. The 4-year progression free rate was estimated using the Kaplan Meier method.~Relapse was assessed by investigator according to Revised Response Criteria for Malignant Lymphoma. Progression required a 25% increase of previous area of gadolinium enhancement, appearance of new areas of T1 gadolinium enhancement or new appearance of malignant cells in the spinal fluid or new tumor appearance in other sites of the body" (NCT00098774)
Timeframe: 4 years

Interventionpercentage of participants (Number)
Intensive Combination Chemo & Immunotherapy48

[back to top]

Change From Baseline in Mini-Mental Status Evaluation at 4 Months

Neurologic functioning will be assessed using the Mini-Mental Status Evaluation (MMSE), a standardized, bedside tool for evaluation of higher mental function. This assessment is based on a 30-point scale (0-30) with higher scores associated with better performance. (NCT00098774)
Timeframe: Baseline & month 4

Interventionunits on a scale (Median)
Baseline Score4 month ScoreChange from Baseline
Intensive Combination Chemo & Immunotherapy27281

[back to top]

Objective Response Rate

Objective response rate is defined as proportion of patients who achieve complete response (CR) or partial response (PR). Response was assessed using Solid Tumor Response Criteria (RECIST). CR is defined as the disappearance of all target lesions. PR is defined as at least a 30% decrease in the sum of the longest diameters of target lesions, taking as reference the baseline sum longest diameter. (NCT00098787)
Timeframe: Assessed every 3 months if the patient is within 2 years of registration and every 6 months up to 4 years post-registration.

Interventionproportion (Number)
Arm A (High TS, IROX/Bev)0.33
Arm B (High TS, FOLFOX/Bev)0.38
Arm C (Low or Intermediate TS, FOLFOX/Bev)0.49

[back to top]

Overall Survival (OS)

Overall survival is defined as time from randomization (to Arm A or Arm B) or registration (to Arm C) to death. Patients alive at last follow-up were censored. (NCT00098787)
Timeframe: Assessed every 3 months if the patient is within 2 years of registration and every 6 months once the patient is 2-4 years post-registration.

Interventionmonths (Median)
Arm A (High TS, IROX/Bev)18
Arm B (High TS, FOLFOX/Bev)21
Arm C (Low or Intermediate TS, FOLFOX/Bev)32

[back to top]

Progression-Free Survival (PFS)

Progression-free survival is defined as time from randomization (to Arm A or Arm B) or registration (to Arm C) to the earlier of disease progression or death. Patients alive and progression-free at last follow-up were censored. (NCT00098787)
Timeframe: Assessed every 3 months if the patient is within 2 years of registration and every 6 months once the patient is 2-4 years post-registration.

Interventionmonths (Median)
Arm A (High TS, IROX/Bev)10
Arm B (High TS, FOLFOX/Bev)9
Arm C (Low or Intermediate TS, FOLFOX/Bev)13

[back to top]

Rate of Minimal Residual Disease (MRD) < 0.01%

Proportion of patients (evaluable and had MRD measured at the end of Block 1) who had MRD < 0.01%. (NCT00098839)
Timeframe: At the end of Block 1 of re-induction therapy (day 36)

InterventionProportion of participants (Number)
Reinduction Chemoimmunotherapy With Epratuzumab Once Weekly.195
Reinduction Chemoimmunotherapy With Epratuzumab Twice Weekly.295

[back to top]

Remission Re-induction (CR2) Rate

The proportion of patients who achieved complete response at the end Block 1 of re-induction therapy. Complete Remission (CR) - Attainment of M1 bone marrow (<5% blasts) with no evidence of circulating blasts or extramedullary disease and with recovery of peripheral counts (ANC >1000/uL and platelet count >100,000/uL). Partial Remission (PR) - Complete disappearance of circulating blasts and achievement of M2 marrow status (5% or < 25% blast cells and adequate cellularity). Partial Remission Cytolytic (PRCL) - Complete disappearance of circulating blasts and achievement of at least 50% reduction from baseline in bone marrow blast count. Minimal Response Cytolytic (MRCL) - 50% reduction in the peripheral blast count with no increase in peripheral white blood cell count. (NCT00098839)
Timeframe: At the end of Block 1 of re-induction therapy (day 36)

Interventionproportion of participants (Number)
Reinduction Chemoimmunotherapy With Epratuzumab Once Weekly.646
Reinduction Chemoimmunotherapy With Epratuzumab Twice Weekly.660

[back to top]

Pharmacokinetics

Mean trough serum concentration measured before final dose of epratuzumab. (NCT00098839)
Timeframe: Up to day 36

Interventionug/mL (Mean)
Twice Weekly Dosing Schedule501

[back to top]

Event-free Survival Rate

Proportion of patients who were event free at 4 months (NCT00098839)
Timeframe: At 4 months after enrollment

InterventionProportion of participants (Number)
Reinduction Chemoimmunotherapy With Epratuzumab Once Weekly.604
Reinduction Chemoimmunotherapy With Epratuzumab Twice Weekly.640

[back to top]

Severe Adverse Event (SAE) Rate

The primary objective is to evaluate safety in all treated patients specifically the rate of serious adverse events which were defined as grade 5 events, grade 4 hemorrhage or thrombosis or bowel perforation (NCT00100841)
Timeframe: The duration of the study

Interventionparticipants (Number)
Grade 5 DeathGrade 4 venous thrombosis
Treatment (Combination Chemotherapy)22

[back to top]

Progression Free Survival Rate

(NCT00100841)
Timeframe: From randomization to the first documented disease progression

Interventionmonths (Median)
Treatment (Combination Chemotherapy)9.6

[back to top] [back to top]

Overall Survival Probability (OS) According to Induction Day 29 MRD Status

Overall survival by Day 29 MRD status (negative vs positive), Overall survival defined as time from study entry to death or date of last contact for patients who are alive. (NCT00103285)
Timeframe: Overall Survival Probability of 6 years

Interventionpercent probability (Number)
Induction Therapy, MRD Negative97.07
Induction Therapy, MRD Positive90.47

[back to top]

Event-Free Survival Probability According to MRD Status End Induction (Day 29)

Event-Free survival by Day 29 MRD status (negative vs positive), Event Free Probability (time from study entry to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free. (NCT00103285)
Timeframe: MRD at Day 29 of therapy

InterventionPercent Probability (Number)
Induction Therapy, MRD Negative91.39
Induction Therapy, MRD Positive79.86

[back to top]

Event-free Survival (EFS) for SR-Low Patients

Event Free Probability where EFS time is defined as time from randomization to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free. (NCT00103285)
Timeframe: 6 years

InterventionPercent probability (Number)
SR-low ALL, Arm I-combination Chemotherapy95.22
SR-low ALL, Arm II-combination Chemotherapy93.96

[back to top]

Event-Free Survival (EFS) for Low MRD (Negative) Subjects by Genetic Subset (TEL/Trisomy Positive vs Negative)

Event-free probability where EFS is defined as time from randomization to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free. (NCT00103285)
Timeframe: 6 years

InterventionPercent probability (Number)
Group 1-SR-low ALL, Arm I-combination Chemotherapy95.22
Group 2-SR-avg ALL, Arm I-combination Chemotherapy88.52

[back to top]

Early Marrow Status (EMS) by MRD Status End Induction (Day 29)

Early Marrow Status defined as M1 versus M2/M3 marrow is correlated with MRD (Positive vs. Negative) (NCT00103285)
Timeframe: Early Marrow Status at Day 15, MRD Status at Day 29 of therapy.

InterventionParticipants (Count of Participants)
All Patients for Induction, MRD Negative4378
All Patients for Induction, MRD Positive258

[back to top] [back to top]

Event-free Survival (EFS) for SR-High Patients.

Event Free Probability where EFS time is defined as time from randomization to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free. (NCT00103285)
Timeframe: 6 years

Interventionpercent probability (Number)
Group 3-SR-high ALL, Combination Chemotherapy85.58

[back to top]

Event-free Survival (EFS) for SR-Average ALL Patients

EFS for SR-Average with standard and Intensified Consolidation. Event Free Probability where EFS time is defined as time from randomization to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free. (NCT00103285)
Timeframe: 6 years

,
Interventionpercent probability (Number)
Standard and Intensified therapy
Group 2-SR-avg ALL, Arm III-combination Chemotherapy88.34
Group 2-SR-avg ALL, Arm IV-combination Chemotherapy90.51

[back to top]

Event-free Survival (EFS) for SR-Average ALL Patients

EFS for SR-Average with standard and Intensified Consolidation. Event Free Probability where EFS time is defined as time from randomization to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free. (NCT00103285)
Timeframe: 6 years

,
Interventionpercent probability (Number)
Standard and Intensified therapyStandard therapy
Group 2-SR-avg ALL, Arm I-combination Chemotherapy83.8287.41
Group 2-SR-avg ALL, Arm II-combination Chemotherapy88.8988.29

[back to top]

Toxicity

Number of patients with Grade 3-5 adverse events that are related to study drug by given type of adverse event (NCT00109837)
Timeframe: Patients were assessed for adverse events after the induction cycle

InterventionParticipants with a given type of AE (Number)
ALT, SGPT (serum glutamic pyruvic transaminase)AST, SGOT (serum glut oxaloacetic transaminase)Albumin, serum-low (hypoalbuminemia)Alkaline phosphataseAnorexiaAscites (non-malignant)Bilirubin (hyperbilirubinemia)Calcium, serum-low (hypocalcemia)CholecystitisCholesterol, serum-high (hypercholesterolemia)Coagulation-Other (Specify)Colitis, infectious (e.g., Clostridium difficile)ConstipationDIC (disseminated intravascular coagulation)Death not assoc with CTCAE term-Multi-organ failEdema: limbFatigue (asthenia, lethargy, malaise)Febrile neutropeniaFever (in the abs of neutropenia)FibrinogenGlucose, serum-high (hyperglycemia)Glucose, serum-low (hypoglycemia)HemoglobinHypertensionHypotensionHypoxiaIleus, GI (functional obstruction of bowel)Infec(doc clin or mibio) w/ Gr 3/4 neut-AnalInfec(doc clin or mibio) w/ Gr 3/4 neut-BladderInfec(doc clin or mibio) w/ Gr 3/4 neut-BloodInfec(doc clin or mibio) w/ Gr 3/4 neut-BronchusIInfec(doc clin or mibio) w/ Gr 3/4 neut-CatheterInfec(doc clin or mibio) w/ Gr 3/4 neut-Eye NOSInfec(doc clin or mibio) w/ Gr 3/4 neut-LungInfec(doc clin or mibio) w/ Gr 3/4 neut-NoseInfec(doc clin or mibio) w/ Gr 3/4 neut-PharynxInfec(doc clin or mibio) w/ Gr 3/4 neut-Ur tractInfec with nor ANC or Gr 1/2 neut-Lung (pneumonia)Infection-Other (Specify)Leukocytes (total WBC)LipaseLiver dysfunction/failure (clinical)LymphopeniaMagnesium, serum-high (hypermagnesemia)Mucositis/stomatitis (clinical exam) - Oral cavityMucositis/stomatitis (funct/symp) - Oral cavityMucositis/stomatitis (func/symp) - PharynxMuscle weak,gen spec area-Whole bodyNauseaNeuropathy: motorNeutrophils/granulocytes (ANC/AGC)Pain - Abdomen NOSPain - BonePain - NeckPancreatic endocrine: glucose intolerancePancreatitisPhosphate, serum-low (hypophosphatemia)PlateletsPotassium, serum-high (hyperkalemia)Potassium, serum-low (hypokalemia)Rash/desquamationRenal failureSodium, serum-low (hyponatremia)Thrombosis/thrombus/embolismThrombotic microangiopathyTriglyceride, serum-high (hypertriglyceridemia)Tumor lysis syndromeTyphlitis (cecal inflammation)Uric acid, serum-high (hyperuricemia)Vomiting
Induction171332216712111211318111161332321111111111122143121912112314711111144171261215111

[back to top]

Continuous Complete Remission at 1 Year

A patient has a continuous complete remission at 1 year if they achieve a CR and are alive 365 days after registering to the study. (NCT00109837)
Timeframe: After induction, after consolidation, every 3 months during maintenance, and every three months after off treatment for up to a year

Interventionparticipants (Number)
Treatment21

[back to top]

Time to Treatment Failure (Part 1)

Kaplan-Meier estimate of the median time from the date of first dose of panitumumab or chemotherapy to the date the decision was made to end treatment for any reason in Part 1 of the study. (NCT00111761)
Timeframe: Until disease progression (median 35 weeks) or 48 weeks, whichever occurred first

InterventionWeeks (Median)
Panitumumab With IFL24.3

[back to top]

Number of Participants With Objective Tumor Response (Part 1)

Objective tumor response (complete or partial) in Part 1 of the study, based on Response Evaluation Criteria in Solid Tumors (RECIST), where complete response = disappearance of all target lesions, partial response = ≥30% reduction in lesion size, progressive disease = ≥20% increase in tumor size; otherwise stable disease. (NCT00111761)
Timeframe: Until disease progression (median 35 weeks) or 48 weeks, whichever occurred first

InterventionParticipants (Number)
Panitumumab With IFL9

[back to top]

Number of Participants With Grade 3 or Grade 4 Diarrhea (Part 2)

The number of participants with grade 3 or grade 4 diarrhea in Part 2 of the study. Grading of diarrhea followed the grading scale in Version 2.0 of the National Cancer Institute Common Toxicity Criteria (NCI CTC). (NCT00111761)
Timeframe: Until disease progression (median 47 weeks)

InterventionParticipants (Number)
Panitumumab With FOLFIRI6

[back to top]

Time to Disease Progression (Part 1)

Kaplan-Meier estimate of the median time from the first dose of study drug to disease progression or death if due to disease progression (whichever comes first) in Part 1 of the study. Participants who had not progressed or died for reasons other than disease progression were censored at their last disease assessment date. (NCT00111761)
Timeframe: From enrollment until disease progression or death. Maximum follow-up time was 25 months.

Interventionweeks (Median)
Panitumumab With IFL35.0

[back to top]

Survival Time (Part 1)

Kaplan-Meier estimate of the median time from enrollment to death from any cause. Participants who did not die on study were censored at their last contact date. (NCT00111761)
Timeframe: From enrollment until death. Maximum follow-up time was 25 months.

Interventionweeks (Median)
Panitumumab With IFL73.1

[back to top]

Survival Time (Part 2)

Kaplan-Meier estimate of the median time from enrollment to death from any cause. Participants who did not die on study were censored at their last contact date. (NCT00111761)
Timeframe: From enrollment until death. Maximum follow-up time was 16 months.

Interventionweeks (Median)
Panitumumab With IFL73.1

[back to top]

Number of Participants Who Died (Part 2)

The number of participants in Part 2 who died during the study. (NCT00111761)
Timeframe: From enrollment until last contact. Maximum follow-up was 16 months.

Interventionparticipants (Number)
Panitumumab With FOLFIRI6

[back to top]

Progression-free Survival Time (Part 2)

Kaplan-Meier estimate of median time from enrollment to death or disease progression in Part 2 of the study. Participants who had not progressed and had not died were censored at their last disease assessment date. (NCT00111761)
Timeframe: From enrollment until disease progression or death. Maximum follow-up time was 16 months.

Interventionweeks (Median)
Panitumumab With FOLFIRI41.1

[back to top]

Progression-free Survival Time (Part 1)

Kaplan-Meier estimate of median time from enrollment to death or disease progression in Part 1 of the study. Participants who had not progressed and had not died were censored at their last disease assessment date. (NCT00111761)
Timeframe: From enrollment until disease progression or death. Maximum follow-up time was 25 months.

Interventionweeks (Median)
Panitumumab With IFL24.3

[back to top]

Time to Disease Progression (Part 2)

Kaplan-Meier estimate of median time from the first dose of study drug to first observed disease progression or death if the death was due to disease progression (whichever comes first) in Part 2 of the study. Participants who had not progressed or died for reasons other than disease progression were censored at their last disease assessment date. (NCT00111761)
Timeframe: From enrollment until death or diease progression. Maximum follow-up time was 16 months.

Interventionweeks (Median)
Panitumumab With FOLFIRI47.3

[back to top]

Time to Initial Objective Tumor Response (Part 1)

Median time to first observed objective tumor response (complete or partial) among responders in Part 1 of the study. (NCT00111761)
Timeframe: Until disease progression (median 35 weeks) or 48 weeks, whichever occurred first

Interventionweeks (Median)
Panitumumab With IFL5.9

[back to top]

Number of Participants With an Objective Tumor Response (Part 2)

Objective tumor response (complete or partial) in Part 2 of the study, based on Response Evaluation Criteria in Solid Tumors (RECIST), where complete response = disappearance of all target lesions, partial response = ≥30% reduction in lesion size, progressive disease = ≥20% increase in tumor size; otherwise stable disease. (NCT00111761)
Timeframe: Until disease progression (median 47 weeks)

InterventionParticipants (Number)
Panitumumab With FOLFIRI8

[back to top]

Number of Participants With Grade 3 or Grade 4 Diarrhea (Part 1)

The number of participants with grade 3 or grade 4 diarrhea in Part 1 of the study. Grading of diarrhea followed the grading scale in Version 2.0 of the National Cancer Institute Common Toxicity Criteria (NCI CTC). (NCT00111761)
Timeframe: Until disease progression (median 35 weeks) or 48 weeks, whichever occurred first

InterventionParticipants (Number)
Panitumumab With IFL11

[back to top]

Disease-free Survival in Stage III Cancer Patients - Time to Event

Disease-free survival (DFS) was defined as the time from the date of randomization to the time of a recurrence, a new occurrence of colorectal cancer or death due to any cause, whichever occurred first. Patients without an event were censored at the last date the patient was known to be disease-free. Recurrence and new occurrence of colorectal cancer were based on tumor assessments made by the investigator. Patients with no tumor assessments after baseline but still alive at the time of the clinical cut-off were censored at day 1. (NCT00112918)
Timeframe: From first patient randomized until the data cut-off date of 30 June 2010 (36 months after the last patient randomized).

Interventionmonths (Median)
FOLFOX4NA
FOLFOX4 + BvNA
XELOX+BvNA

[back to top]

Overall Survival in Stage III Cancer Patients - Time to Event

Overall survival was defined as the time between date of randomization and date of death due to any cause. Patients not reported as having died at the time of the analysis were censored at the date they were last known to be alive. (NCT00112918)
Timeframe: From first patient randomized until the clinical data cut-off date of 30 June 2010 (36 months after the last patient randomized).

Interventionmonths (Median)
FOLFOX4NA
FOLFOX4 + BvNA
XELOX+BvNA

[back to top]

Overall Survival in Stage III Cancer Patients - Number of Events

An overall survival event was death due to any cause. (NCT00112918)
Timeframe: From first patient randomized until the clinical data cut-off date of 30 June 2010 (36 months after the last patient randomized).

,,
Interventionparticipants (Number)
Patients with eventsPatients without events
FOLFOX4115840
FOLFOX4 + Bv151809
XELOX+Bv145807

[back to top]

Overall Survival in Stage III Cancer Patients - Time to Event: Final Analysis

Overall survival was defined as the time between date of randomization and date of death due to any cause. Patients not reported as having died at the time of the clinical cut-off date (30 June 2012) were censored at the date they were last known to be alive. (NCT00112918)
Timeframe: From first patient randomized until the final data cut-off date of 30 June 2012 (5 years after the last patient randomized).

Interventionmonths (Median)
FOLFOX4NA
FOLFOX4 + BvNA
XELOX+BvNA

[back to top]

Overall Survival in Stage III Cancer Patients - Number of Events: Final Analysis

An overall survival event was death due to any cause. (NCT00112918)
Timeframe: From first patient randomized until the final data cut-off date of 30 June 2012 (5 years after the last patient randomized).

,,
Interventionparticipants (Number)
Patients with eventsPatients without events
FOLFOX4161794
FOLFOX4 + Bv202758
XELOX+Bv182770

[back to top]

Disease-free Survival in Stage III Cancer Patients - Number of Events

A disease-free survival (DFS) event was composed of a recurrence, a new occurrence of colorectal cancer or death due to any cause. Recurrence and new occurrence of colorectal cancer were based on tumor assessments made by the investigator. Triggering events for DFS are reported; a patient can have both recurrence and a new occurrence of colon cancer. (NCT00112918)
Timeframe: From first patient randomized until the data cut-off date of 30 June 2010 (36 months after the last patient randomized).

,,
Interventionparticipants (Number)
Patients with a DFS eventRecurrenceNew OccurrenceDeathPatients without events
FOLFOX4237219317718
FOLFOX4 + Bv280253821680
XELOX+Bv253223625699

[back to top]

Disease Free Survival

Participants are followed after completion of protocol therapy until disease progression to determine disease free survival. (NCT00126191)
Timeframe: Until disease progression up to 120 months

InterventionMonths (Mean)
Low Risk84
High Risk52

[back to top]

Response Rates (CR and PR) in Adults With Burkitt/Atypical Burkitt

"Complete Response (CR): Disappearance of all measurable or evaluable disease confirmed.~Partial Response (PR): Reduction of 50% or greater in the sum of the products of the perpendicular diameters of all measurable.~Of 8 High Risk participants, 7 met the primary response outcome. 1 High Risk participant did not meet protocol defined primary outcome response and died two months following enrollment." (NCT00126191)
Timeframe: 3 years

Interventionparticipants (Number)
Low Risk2
High Risk7

[back to top]

Percentage of Participants Experiencing Grade 3-5 Toxicity

Percentage of participants experiencing at least one grade 3-5 adverse event (by CTCAE 3.0 criteria). (NCT00133991)
Timeframe: Up to 2 years

InterventionParticipants (Count of Participants)
R-CVP + HiCy21

[back to top]

Event-free Survival

Percentage of participants alive without relapse at 1 year and 3 years. (NCT00133991)
Timeframe: 1 year and 3 years

Interventionpercentage of participants (Number)
1 year3 years
R-CVP + HiCy5252

[back to top]

Overall Response Rate

Number of participants who have a complete or partial remission (2007 International Working Group criteria). (NCT00133991)
Timeframe: Up to 3 months

InterventionParticipants (Count of Participants)
Complete remissionPartial remission
R-CVP + HiCy112

[back to top]

Overall Survival

Percentage of participants alive at 1 year and at 3 years. (NCT00133991)
Timeframe: 1 year and 3 years

Interventionpercentage of participants (Number)
1 year3 years
R-CVP + HiCy5757

[back to top]

Relapse Pattern

Percentage of participants experiencing central nervous system (CNS) and systemic relapse. (NCT00133991)
Timeframe: Up to 6 months

InterventionParticipants (Count of Participants)
Systemic relapse onlySystemic and CNS relapse
R-CVP + HiCy32

[back to top]

Overall Survival Rates

Probability of being alive was calculated in a yearly increment. (NCT00143403)
Timeframe: Median follow-up time (42 months)

,
Interventionsurvival rate (Number)
12 months24 months36 months
5-FU/FA0.9610.8450.716
Irinotecan + 5-FU/FA0.9730.8810.727

[back to top]

Disease Free Survival (DFS)

time interval between the date of randomization and the earliest date of local, regional or distant relapse, or death due to cancer. (NCT00143403)
Timeframe: last tumor assessment date or cut-off date, whichever is earlier.

Interventionmonths (Median)
5-FU/FA21.6
Irinotecan + 5-FU/FA24.7

[back to top]

Duration of Response - Independent Review Committee (IRC) Assessments

"Time from first assessment of Complete Response or Partial Response to disease progression or death (within 60 days of last tumor assessment).~Patients without event are censored on the date of last tumor assessment. Tumor assessments based on modified WHO criteria." (NCT00154102)
Timeframe: Time from first assessment of complete response or partial response to disease progression, death or last tumor assessment reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006

Interventionmonths (Median)
Cetuximab Plus FOLFIRI9.6
FOLFIRI Alone7.7

[back to top]

Best Overall Response Rate - Independent Review Committee (IRC) Assessments

The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments (based on modified WHO criteria). (NCT00154102)
Timeframe: evaluations were performed every 6 weeks until progression reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006

Interventionpercentage of participants (Number)
Cetuximab Plus FOLFIRI46.9
FOLFIRI Alone38.7

[back to top]

Best Overall Response Rate (KRAS Mutant Population) - Independent Review Committee (IRC) Assessments

The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments (based on modified WHO criteria). (NCT00154102)
Timeframe: evaluations were performed every 6 weeks until progression reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006

Interventionpercentage of participants (Number)
Cetuximab Plus FOLFIRI31.3
FOLFIRI Alone36.1

[back to top]

Best Overall Response Rate (KRAS Wild-Type Population) - Independent Review Committee (IRC) Assessments

The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments (based on modified WHO criteria). (NCT00154102)
Timeframe: evaluations were performed every 6 weeks until progression reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006

Interventionpercentage participants (Number)
Cetuximab Plus FOLFIRI57.3
FOLFIRI Alone39.7

[back to top]

Disease Control Rate - Independent Review Committee (IRC) Assessments

The disease control rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response + Stable Disease as best overall response according to radiological assessments (based on modified WHO criteria). (NCT00154102)
Timeframe: Evaluations were performed every 6 weeks until progression reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006

Interventionpercentage of participants (Number)
Cetuximab Plus FOLFIRI84.3
FOLFIRI Alone85.5

[back to top]

Progression-free Survival Time (KRAS Mutant Population) - Independent Review Committee (IRC) Assessments

"Duration from randomization until radiological progression (based on modified WHO criteria) or death due to any cause.~Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment." (NCT00154102)
Timeframe: Time from randomisation to disease progression, death or last tumour assessment, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006

Interventionmonths (Median)
Cetuximab Plus FOLFIRI7.4
FOLFIRI Alone7.7

[back to top]

Overall Survival Time (KRAS Mutant Population)

Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whichever is later. (NCT00154102)
Timeframe: Time from randomisation to death or last day known to be alive reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 31 May 2009

Interventionmonths (Median)
Cetuximab Plus FOLFIRI16.2
FOLFIRI Alone16.7

[back to top]

Overall Survival Time (KRAS Wild-Type Population)

Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whichever is later. (NCT00154102)
Timeframe: Time from randomisation to death or last day known to be alive reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 31 May 2009

Interventionmonths (Median)
Cetuximab Plus FOLFIRI23.5
FOLFIRI Alone20.0

[back to top]

Overall Survival Time (OS)

Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whichever is later. (NCT00154102)
Timeframe: Time from randomisation to death or last day known to be alive, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 31 May 2009

Interventionmonths (Median)
Cetuximab Plus FOLFIRI19.9
FOLFIRI Alone18.6

[back to top]

Participants With No Residual Tumor After Metastatic Surgery

Participants with no residual tumor after on-study surgery for metastases (NCT00154102)
Timeframe: time from first dose up to 30 days after last dose of study treatment reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 30 Nov 2007

InterventionParticipants (Number)
Cetuximab Plus FOLFIRI29
FOLFIRI Alone10

[back to top]

Progression-free Survival (PFS) Time - Independent Review Committee (IRC) Assessments

"Duration from randomization until radiological progression (based on modified World Health Organisation (WHO) criteria) or death due to any cause.~Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment." (NCT00154102)
Timeframe: Time from randomisation to disease progression, death or last tumour assessment, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006

Interventionmonths (Median)
Cetuximab Plus FOLFIRI8.9
FOLFIRI Alone8.0

[back to top]

Progression-free Survival Time (Chinese V-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Wild-Type Population) - Independent Review Committee (IRC) Assessments

"Duration from randomization until radiological progression (based on modified WHO criteria) or death due to any cause.~Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment." (NCT00154102)
Timeframe: Time from randomisation to disease progression, death or last tumour assessment, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006

Interventionmonths (Median)
Cetuximab Plus FOLFIRI9.9
FOLFIRI Alone8.4

[back to top]

Safety - Number of Patients Experiencing Any Adverse Event

Please refer to Adverse Events section for further details (NCT00154102)
Timeframe: time from first dose up to 30 days after last dose of study treatment reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 30 Nov 2007

Interventionparticipants (Number)
Cetuximab Plus FOLFIRI599
FOLFIRI Alone597

[back to top]

Quality of Life (QOL) Assessment European Organisation for the Research and Treatment of Cancer (EORTC) QLQ-C30 Global Health Status

Mean global health status scores (EORTC QLQ-C30) against time for each treatment group. Scores were derived from mutually exclusive sets of items, with scale scores ranging from 0 to 100 after a linear transformation. Higher scores indicate a better QoL. (NCT00154102)
Timeframe: at baseline, at week 8, at week 16, at week 24, at week 32, and at week 40, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006

,
Interventionscores on a scale (Least Squares Mean)
At baselineAt week 8At week 16At week 24At week 32At week 40
Cetuximab Plus FOLFIRI58.8859.0260.7761.8359.6863.43
FOLFIRI Alone60.3361.8363.2964.0665.0764.02

[back to top]

Quality of Life Assessment (EORTC QLQ-C30) Social Functioning

Mean social functioning scores (EORTC QLQ-C30) against time for each treatment group. Scores were derived from mutually exclusive sets of items, with scale scores ranging from 0 to 100 after a linear transformation. Higher scores indicate a higher level of functioning. (NCT00154102)
Timeframe: at baseline, at week 8, at week 16, at week 24, at week 32, and at week 40, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006

,
Interventionscores on a scale (Least Squares Mean)
At baselineAt week 8At week 16At week 24At week 32At week 40
Cetuximab Plus FOLFIRI75.2174.1473.7276.3174.0476.58
FOLFIRI Alone77.2876.7176.6777.9875.6478.07

[back to top]

Percentage of Patients With ALL at High Risk of Relapse (Arm 2) Who Were Relapse-free at 5 Years

This measure looks at the percentage of patients on Arm 2 who did not experience a relapse at 5 years, where relapse is defined as the presence of progressive disease after the achievement of a complete remission. (NCT00176462)
Timeframe: 5 years

Interventionpercentage of participants (Number)
Arm 2 High Risk64.9

[back to top]

Progression-Free Survival

Defined as the time from randomization to the first observation of disease progression, or death due to any cause. (NCT00192075)
Timeframe: randomization to the first date of progression or death from any cause (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)

Interventionmonths (Median)
A+FFG8.6
A + FOLFOX 49.5

[back to top]

Progression-Free Survival - Avastin Subgroup

Defined as the time from date of first dose to the first observation of disease progression, or death due to any cause. (NCT00192075)
Timeframe: randomization to the first date of progression or death from any cause (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)

Interventionmonths (Median)
A+FFG - Avastin Subgroup13.7
A + FOLFOX 4 - Avastin Subgroup11.5

[back to top]

Tumor Response by Response Evaluation Criteria In Solid Tumors (RECIST)

Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria. (NCT00192075)
Timeframe: baseline to measured progressive disease (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)

,
Interventionparticipants (Number)
Complete Response (CR)Partial Response (PR)Overall Response Rate (CR+PR)Stable Disease (SD)Disease Control Rate (CR+PR+SD)Progressive DiseaseUnknown
A + FOLFOX 421517163372
A+FFG1342125143

[back to top]

Time to Progressive Disease

Defined as the time from study enrollment to the first date of disease progression. Time to disease progression was censored at the date of death if death was due to other cause. (NCT00192075)
Timeframe: randomization to the date of first documented disease progression or death due to disease under study, whichever comes first (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)

Interventionmonths (Median)
A+FFG8.6
A + FOLFOX 49.7

[back to top]

Duration of Response

The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause. (NCT00192075)
Timeframe: date of first response until the first date of documented progression or death from any cause (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)

Interventionmonths (Median)
A+FFG12.7
A + FOLFOX 47.9

[back to top]

Duration of Response - A+FOLFOX4 - Avastin Subgroup

The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause. (NCT00192075)
Timeframe: date of first response until the first date of documented progression or death from any cause (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)

Interventionmonths (Median)
A + FOLFOX 4 - Avastin Subgroup5.2

[back to top]

Overall Survival

Overall survival is the duration from enrollment to death. For patients who are alive, overall survival is censored at the last contact. (NCT00192075)
Timeframe: randomization to the date of death from any cause (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)

Interventionmonths (Median)
A+FFG20.6
A + FOLFOX 419.7

[back to top]

Time to Progressive Disease - Avastin Subgroup

Defined as the time from study enrollment to the first date of disease progression. Time to disease progression was censored at the date of death if death was due to other cause. (NCT00192075)
Timeframe: randomization to the date of first documented disease progression or death due to disease under study, whichever comes first (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)

Interventionmonths (Median)
A+FFG - Avastin Subgroup13.7
A + FOLFOX 4 - Avastin Subgroup13.8

[back to top]

Survival at 12 Months and 24 Months - Avastin Subgroup

Percentage of participants who were alive at 12 months and 24 months. (NCT00192075)
Timeframe: randomization to the date of death from any cause (up to 24 months)

,
Interventionpercentage of participants alive (Number)
12-Month Survival24-Month Survival
A + FOLFOX 4 - Avastin Subgroup83.366.7
A+FFG - Avastin Subgroup75.650.4

[back to top]

Toxicity - Avastin Subgroup

Includes all Grade 3-4 hematologic toxicities and all non-hematologic toxicities with either >=1 Grade 4 or >=2 Grade 3 adverse events (NCT00192075)
Timeframe: every cycle (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)

,
Interventionparticipants (Number)
Neutropenia (Grade 3)Neutropenia (Grade 4)Thrombocytopenia (Grade 3)Thrombocytopenia (Grade 4)Leukopenia (Grade 3)Leukopenia (Grade 4)Anemia (Grade 3)Anemia (Grade 4)Febrile neutropenia (Grade 3)Febrile neutropenia (Grade 4)Diarrhea (Grade 3)Diarrhea (Grade 4)Small intestinal obstruction (Grade 3)Small intestinal obstruction (Grade 4)Fatigue (Grade 3)Fatigue (Grade 4)Cerebral infarction (Grade 3)Cerebral infarction (Grade 4)Hyperglycemia (Grade 3)Hyperglycemia (Grade 4)Dehydration (Grade 3)Dehydration (Grade 4)Deep vein thrombosis (Grade 3)Deep vein thrombosis (Grade 4)Myocardial infarction (Grade 3)Myocardial infarction (Grade 4)Subdural hematoma (Grade 3)Subdural hematoma (Grade 4)Perirectal abscess (Grade 3)Perirectal abscess (Grade 4)Hypoxia (Grade 3)Hypoxia (Grade 4)
A + FOLFOX 4 - Avastin Subgroup51000000100110200000102002000000
A+FFG - Avastin Subgrouup35103100001010000000000000001000

[back to top]

Tumor Response - Avastin Subgroup

Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria. (NCT00192075)
Timeframe: baseline to measured progressive disease (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)

,
Interventionparticipants (Number)
Complete Response (CR)Partial Response (PR)Overall Response Rate (CR+PR)Stable Disease (SD)Disease Control Rate (CR+PR+SD)Progressive DiseaseUnknown
A + FOLFOX 4 - Avastin Subgroup18981710
A+FFG - Avastin Subgroup000111161

[back to top]

Progression Free Survival (PFS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Worsening of Their Disease

Progression Free Survival (PFS) is defined as the interval between the start date of treatment and the date of occurrence of progressive disease or death. (NCT00193219)
Timeframe: 18 months

Interventionmonths (Median)
Bevacizumab/Cetuximab/FOLFOX9

[back to top]

Overall Survival (OS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Death

Measured from the date of first treatment until the date of death from any cause (NCT00193219)
Timeframe: 36 months

Interventionmonths (Median)
Bevacizumab/Cetuximab/FOLFOX25.7

[back to top]

Overall Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI or CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. (NCT00193219)
Timeframe: 18 months

Interventionpercentage of patients (Number)
Bevacizumab/Cetuximab/FOLFOX55

[back to top]

Number of Patients With Adverse Events as a Measure of Safety With FOLFOX6 Combined With Bevacizumab and Cetuximab

The toxicity assessments were made according to the common terminology criteria for adverse events (CTCAE version 3.0) of the National Cancer Institute. Number of participants with Grade 1 to 5 adverse events are reported here. (NCT00193219)
Timeframe: 18 months

InterventionParticipants (Count of Participants)
Bevacizumab/Cetuximab/FOLFOX31

[back to top] [back to top]

2-month Response Rate

"Response rate is defined as the rate of participants with partial or complete responses according to RECIST V1.0.~Complete response is defined as the disappearance of all target lesions and partial response is defined as at least a 30% decrease in the sum of the longest diameters (SLD) of target lesions, taking as reference the baseline SLD (RECIST V1.0.)." (NCT00210184)
Timeframe: 2 months

Interventionpercentage of participants (Number)
Irinotecan Associated to Fluorouracil and Leucovorin25

[back to top]

Overall Survival

OS was defined as the time from trial inclusion to death due to any cause. Participants without documented death were censored at the date of the last follow-up or last patient contact. The OS was calculated using the product-limit (Kaplan-Meier) method for censored data. (NCT00210184)
Timeframe: From date of inclusion until the date of date of death from any cause, assessed up to 12 months.

Interventionmonths (Median)
Irinotecan Associated to Fluorouracil and Leucovorin10

[back to top]

Progression-free Survival

PFS was defined as time since trial inclusion to progression or death from any cause, whichever occurred first, and data from patients progression-free and lost to follow-up before the study end were censored at date of last news. The PFS was calculated using the product-limit (Kaplan-Meier) method for censored data. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT00210184)
Timeframe: From date of inclusion until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months

Interventionmonths (Median)
Irinotecan Associated to Fluorouracil and Leucovorin7

[back to top]

Best Objective Response

Best Objective Response by RECIST with Exact 95% Binomial CIs across all tumor types. The patient's best response assignment will depend on the achievement of both measurement and confirmation criteria Target lesions response + Non-Target lesions response + Evaluation of non-target lesions (Yes / No) = Overall response (NCT00227617)
Timeframe: From Baseline until disease progression, up to 8 years

Interventionpercentage of participants (Number)
UnevaluableProgressive DiseasePartial ResponseStable Disease
Combined Neuroendocrine Tumors2.82.83164

[back to top]

Time to Progression

Time to disease progression will be defined as the time from baseline until documented disease progression or death (whichever occurs first). (NCT00227617)
Timeframe: From beginning of treatment up to 18 months; Post-study survival follow-up up to 8 years

Interventionmonths (Median)
Carcinoid19.3
PNET21

[back to top] [back to top]

Overall Time to Treatment Failure

Time to treatment failure is defined as the time from the initial complete or partial response to documented disease progression or death (whichever occurs first) across treatment groups and inclusive of drug holidays and estimated using Kaplan-Meier survival analysis methods (NCT00227617)
Timeframe: From initial complete or partial response to disease progression, up to 8 years

Interventionmonths (Median)
Combined Neuroendocrine Tumors9.1

[back to top]

Overall Median Survival

The overall survival is defined as the time from baseline until death (Carcinoid, PNET, PDNEC) using Kaplan-Meier Survival analysis methods. (NCT00227617)
Timeframe: until death, up to 8 years

Interventionmonths (Median)
Combined Neuroendocrine Tumors31.0

[back to top]

Biochemical Marker Response

Biochemical marker response is defined as >=50% reduction in marker or hormone(s) that were elevated at baseline. Markers/hormones tested are: Chromagranin A (CGA), 5-HIAA, Insulin, Proinsulin, C-peptide, Pancreatic polypeptide, Gastrin, Glucagon, and Vasointestinal Peptide. (NCT00227617)
Timeframe: From Baseline until end of treatment, up to 8 years

,,,
Interventionpercentage of participants (Number)
Chromogranin A (CGA)Any hormone and/or CGAAny hormone (not including CGA)
All Neuroendocrine Tumors505233
Carcinoid253123
PDNEC000
PNET788060

[back to top]

Overall Survival (OS)

"From randomization to death (event); or last follow-up date if alive (censoring).~Kaplan-Meier OS median time." (NCT00252564)
Timeframe: up to 4 years

InterventionMonths (Median)
Arm A21.3
Arm B19.5

[back to top]

Objective Response Rate

"Percentage of patients with tumor response (by RECIST criteria, including complete response, or CR, i.e. disappearance of all target lesions; and partial response, or PR, i.e. at least a 30% decrease in the sum of the longest diameters of target lesions taking as reference the baseline sum of the longest diameters) among all per-protocol population patients." (NCT00252564)
Timeframe: 12 months

Interventionpercentage of participants (Number)
Arm A52.1
Arm B41.2

[back to top]

Progression-free Survival (PFS) Rate at 1 Year.

From randomization to first progression or death, whichever comes first (event); or first new anti-cancer treatment if before or without progression / death (censoring); or last follow-up date otherwise (censoring). (NCT00252564)
Timeframe: 12 months

Interventionproportion of participants w/ PFS at 1yr (Number)
Arm A0.45
Arm B0.32

[back to top]

Progression-Free Survival (PFS)

"From randomization to first progression or death, whichever comes first (event); or first new anti-cancer treatment if before or without progression / death (censoring); or last follow-up date otherwise (censoring).~Kaplan-Meier median PFS time and PFS rate (at 12 months)" (NCT00252564)
Timeframe: 12 months

Interventionmonths (Median)
Arm A11.0
Arm B8.3

[back to top]

Overall Survival

Time from registration to death from any cause. Patients alive were censored at follow up. (NCT00262925)
Timeframe: assessed every 3 months if patient is < 2 years from study entry and every 6 months if patient is 2-5 years from study entry

Interventionmonths (Median)
Treatment (Chemotherapy, Enzyme Inhibitor Therapy)5.2

[back to top]

Complete Response Rate

"Complete response requires that all of the following be present for at least four weeks.~1. Peripheral Blood Counts: Neutrophil count >= 1.0 x 109/L, Platelet count >= 100 x 109/L, Reduced hemoglobin concentration or hematocrit has no bearing on remission status, Leukemic blasts must not be present in the peripheral blood.~2 .Bone Marrow Aspirate and Biopsy: Cellularity of bone marrow biopsy must be > 20% with maturation of all cell lines, <= 5% blasts.~3. Extramedullary leukemia, such as CNS or soft tissue involvement, must not be present." (NCT00262925)
Timeframe: assessed before the first consolidation cycle and first cytoreduction cycle, before the first and after the last maintenance cycle; after discontinuing treatment, assessed every 3 months if < 2 years and every 6 months if 2-5 years from study entry

Interventionpercentage of participants (Number)
Treatment (Chemotherapy, Enzyme Inhibitor Therapy)33

[back to top]

Progression-free Survival (PFS)

PFS will be measured from study entry until first documented progression or death from any cause. Time to event distributions will be estimated using the Kaplan-Meier method. PFS will be compared between Arm A and Arm B. (NCT00265850)
Timeframe: Up to 5 years post-treatment

Interventionmonths (Median)
Arm A: FOLFOX or FOLFIRI + Bevacizumab10.6
Arm B: FOLFOX or FOLFIRI + Cetuximab10.5

[back to top]

Overall Survival

Survival time will be defined as the time from registration to death. Time to event distributions will be estimated using the Kaplan-Meier method. Overall Survival (OS) will be compared between Arm A and Arm B. (NCT00265850)
Timeframe: Up to 5 years post-treatment

Interventionmonths (Median)
Arm A: FOLFOX or FOLFIRI + Bevacizumab29.0
Arm B: FOLFOX or FOLFIRI + Cetuximab30.0

[back to top]

Change From Baseline in Cluster of Differentiation 4 (CD4) T Cell Count at up to 2.5 Years

An increase in CD4 cells is determined by the number of CD4+ T lymphocytes /µL of peripheral blood. (NCT00267865)
Timeframe: Baseline and up to 2.5 years

Interventioncells/µL (Median)
Rituximab, High-Dose Methotrexate & Leucovorin Treatment35

[back to top]

Estimated Percentage of Participants Overall Survival

Participants that are estimated to be alive or last known to be alive after Rituximab, High-Dose Methotrexate and Leucovorin treatment. (NCT00267865)
Timeframe: Time from treatment start date until date of death or date last known alive, approximately 60 months

Interventionpercentage of participants (Number)
Rituximab, High-Dose Methotrexate & Leucovorin Treatment66

[back to top]

Number of Patients Alive at 2 Years Without Recurrent Brain Lymphoma or Severe Neurocognitive Defects

Recurrent lymphoma as defined by the International Primary Central Nervous System (CNS) Lymphoma Collaborative Group for response assessment of aggressive Non-Hodgkin's Lymphoma (NHL) using fluorodeoxyglucose F 18 (18FDG-PET). Severe cognitive problems are defined as the inability to carry out normal activities with minimal difficulty and not requiring nursing care or hospitalization because of neurological impairment. (NCT00267865)
Timeframe: 2 years

InterventionParticipants (Count of Participants)
Rituximab, High-Dose Methotrexate & Leucovorin Treatment8

[back to top]

Median Mini Mental Status Exam (MMSE) Score in Surviving Participants After Rituximab, High-Dose Methotrexate & Leucovorin ( R-HD-MTX) Treatment

The MMSE is scored out of a maximum of 30 points. A score of >25 is considered normal, with scores <25 indicating different levels of cognitive impairment: mild (21-24) moderate (10-20), and severe (0-10). (NCT00267865)
Timeframe: up to 2.5 years

InterventionScores on a scale (Median)
Rituximab, High-Dose Methotrexate & Leucovorin Treatment28

[back to top]

Number of Participants With Serious and Non-serious Adverse Events

Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v3.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT00267865)
Timeframe: Date treatment consent signed to date off study, approximately 142 months and 11 days.

InterventionParticipants (Count of Participants)
Rituximab, High-Dose Methotrexate & Leucovorin Treatment11

[back to top]

Number of Participants With Response to Treatment After Rituximab, High-Dose Methotrexate (R-HD-MTX) Induction

Response was assessed by the International Workshop Criteria for Non-Hodgkin's Lymphoma. Complete Response is disappearance of all enhancing lesions on magnetic resonance imaging of the brain. Partial Response is a reduction of enhancing tumor volume by more than 50% for at least 4 weeks. Progressive Disease is an increase of tumor volume of more than 25% or occurrence of new lesions. (NCT00267865)
Timeframe: At the end of 6 cycles or 12 weeks of treatment

InterventionParticipants (Count of Participants)
Complete ResponsePartial ResponseProgressive Disease
Rituximab, High-Dose Methotrexate & Leucovorin Treatment541

[back to top]

Quality Of Live(QOL) : Time to Worsening of Tissue Oxygen Index (TOI)

Time when a sustained clinically important deterioration in TOI has been recorded: derived from the FACT-C questionnaires (NCT00278889)
Timeframe: Randomisation to data cut-off date of November 2007

InterventionDays (Median)
FOLFOX + Cediranib 20 mg63
FOLFOX + Cediranib 30 mg74
FOLFOX + Bevacizumab 10 mg/kg87

[back to top]

QOL: Time to Worsening of Treatment-free Survival (TFS)

Time when a sustained clinically important deterioration in TFS has been recorded: derived from the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) questionnaires (NCT00278889)
Timeframe: Randomisation to data cut-off date of November 2007

InterventionDays (Median)
FOLFOX + Cediranib 20 mg98
FOLFOX + Cediranib 30 mg112
FOLFOX + Bevacizumab 10 mg/kg147

[back to top]

QOL: Time to Worsening of FACT Colorectal Cancer Symptom Index(FCSI)

Time when a sustained clinically important deterioration in CCS has been recorded: derived from the FACT-C questionnaires (NCT00278889)
Timeframe: Randomisation to data cut-off date of November 2007

InterventionDays (Median)
FOLFOX + Cediranib 20 mg106
FOLFOX + Cediranib 30 mg92
FOLFOX + Bevacizumab 10 mg/kg155

[back to top]

QOL: Time to Worsening of Clear Cell Sarcoma (CCS)

Time when a sustained clinically important deterioration in CCS has been recorded: derived from the FACT-C questionnaires (NCT00278889)
Timeframe: Randomisation to data cut-off date of November 2007

InterventionDays (Median)
FOLFOX + Cediranib 20 mg84
FOLFOX + Cediranib 30 mg74
FOLFOX + Bevacizumab 10 mg/kg87

[back to top]

Progression Free Survival

Number of months from randomisation to the earlier date of objective progression or death (NCT00278889)
Timeframe: Randomisation to data cut-off date of November 2007

InterventionMonths (Median)
FOLFOX + Cediranib 20 mg5.8
FOLFOX + Cediranib 30 mg7.2
FOLFOX + Bevacizumab 10 mg/kg7.8

[back to top]

Overall Survival

Number of months from randomisation to the date of death from any cause (NCT00278889)
Timeframe: Randomisation to data cut-off date of 30 January 2009

InterventionMonths (Median)
FOLFOX + Cediranib 20 mg14.3
FOLFOX + Cediranib 30 mg16.8
FOLFOX + Bevacizumab 10 mg/kg19.6

[back to top]

Objective Response Rate

"Per RECIST Criteria (V1.0) and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >= ##% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.~Confirmed Partial Response (PR) or Complete Response (CR) as defined by RECIST." (NCT00278889)
Timeframe: Randomisation to data cut-off date of November 2007

InterventionParticipants (Number)
FOLFOX + Cediranib 20 mg13
FOLFOX + Cediranib 30 mg14
FOLFOX + Bevacizumab 10 mg/kg18

[back to top]

Proportion of Patients Who Completed 12 Cycles of Treatment

In the study, treatment was repeated every 2 weeks for a total of 12 cycles on both arms. The total number of cycles of treatment patient received until going off treatment due to any reason was recorded. It was a measure of the tolerance of the therapy. (NCT00303628)
Timeframe: assessed at the end of treatment

Interventionproportion of participants (Number)
Arm I (Oxaliplatin, Fluorouracil, Leucovorin)0.722
Arm II (Oxaliplatin, Fluorouracil, Leucovorin, Bevacizumab)0.615

[back to top]

Patterns of Failure

Failure included recurrence, second primary cancer and death without recurrence. (NCT00303628)
Timeframe: Follow-up assessments performed every 3 months for patients < 2 years from randomization, every 6 months for patients 2-5 years from randomization, and every 12 months for patients 5-10 years from randomization

,
Interventionparticipants (Number)
Local/regional recurrenceDistant recurrenceMutiple recurrenceUnknown siteDeath without recurrenceSecond invasive primary cancerDFS event
Arm I (Oxaliplatin, Fluorouracil, Leucovorin)6245151252
Arm II (Oxaliplatin, Fluorouracil, Leucovorin, Bevacizumab)520816441

[back to top]

Change in Rectal Function Between Baseline and 12 Months

Change in rectal function between baseline and 12 months was measuring the long-term rectal function among the patients. Rectal function was measured using the Bowel Function Questionnaire at baseline and 12 months after randomization. The total score of the questionnaire was calculated as the number of problems with bowel function (score range 0-11). Change in rectal function between baseline and 12 months= total score at 12 months - total score at baseline. A negative value indicated improved rectal function. This change in score was calculated for each individual patient who had the data. (NCT00303628)
Timeframe: assessed at baseline and 12 months after randomization

Interventionscores on a scale (Mean)
Arm I (Oxaliplatin, Fluorouracil, Leucovorin)-1.17
Arm II (Oxaliplatin, Fluorouracil, Leucovorin, Bevacizumab)1.18

[back to top] [back to top]

5-year Overall Survival Rate

Overall survival (OS) was defined as time from randomization to date of death from any cause. Patients who were still alive were censored at last date of known alive. Kaplan-Meier method was used to estimate the 5-year OS rate. (NCT00303628)
Timeframe: Follow-up assessments performed every 3 months for patients < 2 years from randomization, every 6 months for patients 2-5 years from randomization, and every 12 months for patients 5-10 years from randomization

Interventionproportion of participants (Number)
Arm I (Oxaliplatin, Fluorouracil, Leucovorin)0.883
Arm II (Oxaliplatin, Fluorouracil, Leucovorin, Bevacizumab)0.837

[back to top]

5-year Disease-free Survival Rate

Disease-free survival (DFS) was defined as time from randomization to recurrence, second invasive primary cancer or death, whichever occurred first. Patients who were still alive and had no DFS events were censored at the last disease assessment date known to be free of DFS events. Kaplan-Meier method was used to estimate 5-year DFS rate. (NCT00303628)
Timeframe: Follow-up assessments performed every 3 months for patients < 2 years from randomization, every 6 months for patients 2-5 years from randomization, and every 12 months for patients 5-10 years from randomization

Interventionproportion of participants (Number)
Arm I (Oxaliplatin, Fluorouracil, Leucovorin)0.712
Arm II (Oxaliplatin, Fluorouracil, Leucovorin, Bevacizumab)0.765

[back to top]

Disease-Free Survival (DFS), The Proportion of Patients Predicted to be Alive Without Evidence of Disease Recurrence 24 Months After Completion of Protocol Treatment

The Proportion of Patients Predicted to be Alive Without Evidence of Disease Recurrence 24 Months After Completion of Protocol Treatment (NCT00308516)
Timeframe: 24 months

Interventionpercentage of participants (Number)
Preoperative 5FU/Radiation/Bevacizumab85
Postoperative 5FU/Radiation/Bevacizumab97

[back to top]

Overall Survival (OS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Death

Overall Survival (OS) is defined ad the Length of time, in months, that patients were alive from their first date of protocol treatment until death. (NCT00308516)
Timeframe: 24 months

Interventionmonths (Median)
Preoperative 5FU/Radiation/BevacizumabNA
Postoperative 5FU/Radiation/BevacizumabNA

[back to top]

Resection Rate for T3 Rectal Cancers

Resection rate is defined as number of patients with T3 rectal cancer who underwent curative surgical resection among all eligible and treated patients with T3 rectal cancers (NCT00321685)
Timeframe: Assessed at surgery time

Interventionpercentage of participants (Number)
Arm I92

[back to top]

Resection Rate for T4 Rectal Cancers

Resection rate is defined as number of patients with T4 rectal cancer who underwent curative surgical resection among all eligible and treated patients with T4 rectal cancers (NCT00321685)
Timeframe: Assessed at surgery time

Interventionpercentage of participants (Number)
Arm I75

[back to top]

5-year Recurrence-free Survival Rate

Recurrence free survival is defined as time from surgery to disease recurrence or death without recurrence (whichever occurred first) among resected patients. 5-year recurrence-free survival rate is estimated using Kaplan-Meier method, with 90% confidence interval calculated using Greenwood's formula. (NCT00321685)
Timeframe: recurrence follow-up began after post-operative chemotherapy, assessed every 3 months for patients 3-5 years from registration, every 6 months for patients 5-10 years from registration and every 12 months for patients 10 years from registration

Interventionpercentage of participants (Number)
Arm I81

[back to top]

5-year Overall Survival Rate

Overall survival is defined as time from registration to death from any cause. 5-year overall survival rate is estimated using Kaplan-Meier method. (NCT00321685)
Timeframe: survival follow-up began after post-operative chemotherapy, assessed every 3 months for patients 3-5 years from registration, every 6 months for patients 5-10 years from registration and every 12 months for patients 10 years from registration

Interventionpercentage of participants (Number)
Arm I80

[back to top]

Pathologic Complete Response Rate

Pathologic complete response to preoperative therapy was determined at the time of surgical resection. Pathologic complete response (pCR) is defined as no evidence of invasive cells on pathologic examination of the primary rectal cancer (or tissue from the area where the tumor had been if there is a complete clinical response). Pathologic complete response rate is calculated as number of patients achieving pathologic complete response divided by all eligible and treated patients (NCT00321685)
Timeframe: Assessed at surgery time

Interventionpercentage of participants (Number)
Arm I17

[back to top] [back to top]

Complete Response Rate - Locally Reviewed

"Assessed by the ECOG-ACRIN data manager based upon local review of images and data sent by the local sites.~Treatment response was determined by calculating the sum of the maximal cross section in 2 separate axes using enhancing lesion(s) on CT or MRI imaging. The same imaging modality was to be used throughout assessment. Complete response was defined as the disappearance of all contrast enhancing tumor size on CT or MRI, patient was off all glucocorticoids, and resolution of all meningeal and vitreous involvement if present. Response must have lasted at least 4 weeks." (NCT00335140)
Timeframe: For the primary endpoint, complete response will be based on disease status at three weeks post the end of therapy (week 17).

Interventionpercentage of participants (Number)
Rituximab + Standard Chemotherapy64

[back to top]

Percentage of Participants With Any Acute Adverse Events

Event is defined as the first occurrence of any acute toxicity. Estimates will be obtained using life-table methods. Patients who have progression or recurrence of disease will be censored in this analysis. Difference in incidence for the two treatment regimens will be compared using log-rank test. (NCT00336024)
Timeframe: Beginning of treatment to the end of consolidation

Interventionpercentage of participants (Number)
Arm I (Patients Treated Without Methotrexate (MTX))97.4
Arm II (Patients Treated With MTX)97.2

[back to top]

Number of Participants With Secondary Malignancies

The number of patients who had secondary malignancy will be reported for this analysis due to small numbers. (NCT00336024)
Timeframe: Off-treatment up to 9 years

InterventionParticipants (Count of Participants)
Arm I (Patients Treated Without Methotrexate (MTX))1
Arm II (Patients Treated With MTX)0

[back to top]

Number of Participants With Chronic Primary Hypothyroidism/Subclinical Compensatory HypothyroidismHypothyroidism/Subclinical Compensatory Hypothyroidism

"Thyroid function was assessed as per ACNS0334 Endocrine Guidelines. Normal and Abnormal are defined at each institution by the laboratory standards where the blood tests are run. Primary Hypothyroidism/Subclinical Compensatory Hypothyroidism is defined as patients with Free T4 level less than Institutional Normal or equal to Institutional Normal with TSH level greater than Institutional Normal." (NCT00336024)
Timeframe: Off-treatment up to 9 years

InterventionParticipants (Count of Participants)
Arm I (Patients Treated Without Methotrexate (MTX))3
Arm II (Patients Treated With MTX)5

[back to top]

Number of Participants With Chronic Low Somatomedin C

Low Somatomedin C is defined as patients with somatomedin C value less than institutional normal. As numbers are too small, descriptive statistics such as number will be reported for this analysis. Growth hormone function was assessed as per ACNS0334 Endocrine Guidelines. Low Somatomedin C levels are defined at each institution by the laboratory standards where the blood tests are run. (NCT00336024)
Timeframe: Off-treatment up to 9 years

InterventionParticipants (Count of Participants)
Arm I (Patients Treated Without Methotrexate (MTX))2
Arm II (Patients Treated With MTX)5

[back to top]

Number of Participants With Chronic Diabetes Insipidus

"The number of patients who had Diabetes Insipidus and on DDAVP will be reported for this analysis due to small numbers.." (NCT00336024)
Timeframe: Beginning of off-treatment to up to 9 years

InterventionParticipants (Count of Participants)
Arm I (Patients Treated Without Methotrexate (MTX))1
Arm II (Patients Treated With MTX)1

[back to top]

Number of Participants With Chronic Central Hypothyroidism

"Thyroid function was assessed as per ACNS0334 Endocrine Guidelines. Normal and Abnormal are defined at each institution by the laboratory standards where the blood tests are run. Central Hypothyroidism is defined as Free T4 level less than Institutional Normal with TSH less than or equal to Institutional Normal." (NCT00336024)
Timeframe: Off-treatment up to 9 years

InterventionParticipants (Count of Participants)
Arm I (Patients Treated Without Methotrexate (MTX))1
Arm II (Patients Treated With MTX)1

[back to top]

Median/Range of Patients for Total Quality of Life (QOL) Score, Intelligence Quotient (IQ) and Processing Speed Index (PSI).

"Three tools are used to assess intelligence (IQ) depending on age. The range of IQ scores is 40-160 (mean=100, SD=15); range for the Processing Speed Index (PSI)=45-155. Higher scores represent better functioning. (1) Wechsler Preschool and Primary Scale of Intelligence-4th Edition (WPPSI-IV) is used for ages 2.5 to 6 years. Bug Search and Cancellation subtests are summed to calculate PSI. (2) Wechsler Intelligence Scales for Children-5th Edition (WISC-V) is used for ages 6 - 16 years. Symbol Search and Coding subtests are summed to calculate PSI. (3) Wechsler Adult Intelligence Scales-4th Edition (WAIS-IV) is used for ages 16 and older. Symbol Search and Coding subtests are summed to calculate PSI.~The Pediatric Quality of Life Inventory Version 4 (PedsQL) measures health-related quality of life (QOL). Parents complete the measure for children ages 2-17, and patients > 18 complete a self-report version. Total scores range from 0-100, with higher scores representing better QOL." (NCT00336024)
Timeframe: 60 months (+/- 3 months)

,
Interventionscores on a scale (Median)
Total Quality of Life ScoreIntelligence QuotientProcessing Speed Index
Arm I (Patients Treated Without Methotrexate (MTX))60.577.082.0
Arm II (Patients Treated With MTX)56.578.589.0

[back to top]

Rates of Nutritional Toxicities

Rates of nutritional toxicities reported as Adverse Events during therapy for each cycle will be summarized using standard descriptive methods (such as number of patients). The difference in number of patients with nutritional toxicities between the two treatment regimens will be compared using a Chi-square test. (NCT00336024)
Timeframe: Beginning of treatment to the end of consolidation

,
InterventionParticipants (Count of Participants)
Nutritional Disorders Induction Cycle INo Nutritional Disorders Induction Cycle INutritional Disorders Induction Cycle IINo Nutritional Disorders Induction Cycle IINutritional Disorders Induction Cycle IIINo Nutritional Disorders Induction Cycle IIINutritional Disorders Consolidation Cycle INo Nutritional Disorders Consolidation Cycle INutritional Disorders Consolidation Cycle IINo Nutritional Disorders Consolidation Cycle IINutritional Disorders Consolidation Cycle IIINo Nutritional Disorders Consolidation Cycle III
Arm I (Patients Treated Without Methotrexate (MTX))1029132673212279301029
Arm II (Patients Treated With MTX)172113251226830533533

[back to top]

Rates of Gastrointestinal Toxicities

Rates of gastrointestinal toxicities reported as Adverse Events during therapy for each cycle will be summarized using standard descriptive methods (such as number of patients). The difference in number of patients with gastrointestinal toxicities between the two treatment regimens will be compared using a Chi-square test. (NCT00336024)
Timeframe: Beginning of treatment to the end of consolidation

,
InterventionParticipants (Count of Participants)
GI Tox Induction Cycle INo GI Tox Induction Cycle IGI Tox Induction Cycle IINo GI Tox Induction Cycle IIGI Tox Induction Cycle IIINo GI Tox Induction Cycle IIIGI Tox Consolidation Cycle INo GI Tox Consolidation Cycle IGI Tox Consolidation Cycle IINo GI Tox Consolidation Phase IIGI Tox Consolidation Cycle IIINo GI Tox Consolidation Cycle III
Arm I (Patients Treated Without Methotrexate (MTX))8314354351128732534
Arm II (Patients Treated With MTX)1226102883014241028632

[back to top]

Percentage of Participants With Event Free Survival (EFS)

EFS was defined as time from enrollment to the occurrence of first event (disease progression/relapse, secondary malignancy, death from any cause) or date of last contact for patients who are event-free. The percentage of participants with EFS and 90% confidence interval were provided. The difference in incidence for the two treatment regimens were compared using a one-sided log-rank test with a significance level of 0.1. (NCT00336024)
Timeframe: Baseline to up to 5 years

Interventionpercentage of participants with EFS (Number)
Arm I (Patients Treated Without Methotrexate (MTX))43.6
Arm II (Patients Treated With MTX)54.9

[back to top]

Overall Survival

(NCT00352755)
Timeframe: Median follow-up was 32 months

Interventionmonths (Median)
Peritonectomy + IP5FU + FOLFOX32.01

[back to top]

Safety and Tolerability of the Planned Treatment Regimen as Measured by Number of Participants With Grade 3 or Higher Adverse Events

(NCT00352755)
Timeframe: 30 days after end of treatment

Interventionparticipants (Number)
HemoglobinLeukocytesLymphopeniaNeutrophilsRigors/chillsDehydrationNauseaVomitingFebrile neutropeniaAnal/perianal infectionUrinary infectionInfection (clinic or micro) with Gr. 3/4 ANCWound infectionAlanine aminotransferase (ALT)CreatinineHypermagnesemiaHypocalcemiaHypokalemiaHypomagnesemiaHyponatremiaSyncopeAbdomen painHead/headache pain
Peritonectomy + IP5FU + FOLFOX11321232111121111212131

[back to top]

Progression-free Survival

(NCT00352755)
Timeframe: Median follow-up was 32 months

Interventionmonths (Median)
Peritonectomy + IP5FU + FOLFOX21.20

[back to top]

Progression Rate

-Progressive disease - at least a 20% increase in the sum of the longest diameter of the target lesions taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new lesions. (NCT00352755)
Timeframe: Median follow-up was 32 months

Interventionpercentage of participants (Number)
Peritonectomy + IP5FU + FOLFOX62.5

[back to top]

Number of Participants Who Experience Surgical Complications Associated With This Regimen

(NCT00352755)
Timeframe: Median follow-up was 32 months

Interventionparticipants (Number)
Peritonectomy + IP5FU + FOLFOX9

[back to top]

Median Progression-free Survival (PFS)

PFS is defined as the duration of time from start of treatment to time of disease progression using Kaplan-Meier median PFS time. (NCT00354978)
Timeframe: From baseline until first documented progression or death from any cause, whichever came first, assessed up to 75 months

InterventionMonths (Median)
FOLFIRI Plus Bevacizumab12.8

[back to top]

Frequency and Severity of Adverse Effects

Percentage of patients who developed at least 1 episode of grade 2 to 4 neuropathy. (NCT00381680)
Timeframe: Up to 107 weeks

Interventionpercentage of participants (Number)
CC or CT genotypeHigh-risk CEP72 genotype (TT at rs924607)
All Patients17.344.4

[back to top]

Event Free Survival (EFS)

Percentage of patients who were event free at 3 years among those with isolated BM or combined BM relapse >= 36 months. (NCT00381680)
Timeframe: 3 years

,
Interventionpercentage of participants (Number)
MRD < 0.01% BL1MRD >= 0.01% BL1MRD < 0.01% BL3MRD >= 0.01% BL3
Regimen A88.560.083.861.5
Regimen B77.346.283.333.3

[back to top]

Adjusted Event Free Survival

Adjusted percentage of patients who were event free at 3 years. For patients who received matched donor SCT, EFS was adjusted to start from the actual SCT date. For patients who did not undergo SCT, EFS was adjusted to start from median time to SCT based on patients who received matched related SCT (where patients who had events prior to SCT date were excluded from the calculation of median time to SCT). (NCT00381680)
Timeframe: 3 years

Interventionadjusted percentage of participants (Number)
Received SCTDid not receive SCT
Regimen A: Standard Vincristine Dosing82.264.2

[back to top]

Rate of Minimal Residual Disease (MRD) < 0.01% at End Block 3

Percentage of patients who had minimal residual disease (MRD) < 0.01% among those with isolated BM or combined BM relapse >= 36 months and had successful MRD determinations at End Block 3. (NCT00381680)
Timeframe: End of Block 3 (105 days) of Induction therapy

Interventionpercentage of participants (Number)
Regimen A81.4
Regimen B88.9

[back to top]

Rate of Minimal Residual Disease (MRD) < 0.01% at End Block 1

Percentage of patients who had minimal residual disease (MRD) < 0.01% among those with isolated BM or combined BM relapse >= 36 months and had successful MRD determinations at End Block 1 (NCT00381680)
Timeframe: End of Block 1 (35 days) of Induction therapy

Interventionpercentage of participants (Number)
Regimen A50.8
Regimen B41.5

[back to top]

Event Free Survival. EFS

Percentage of patients who were event free at 3 years among those on Standard VCR dosing who did not undergo Hematopoietic Stem Cell Transplant (SCT). (NCT00381680)
Timeframe: 3 years after enrollment

Interventionpercentage of participants EFS at 3 yrs3 (Number)
Regimen A: Standard Vincristine Dosing66.0

[back to top]

Tumor Response Rate (Complete and Partial) in Patients With Squamous Cell Carcinoma

Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria: Complete Response (CR): disappearance of all target lesions; Partial Response (PR) 30% decrease in sum of longest diameter of target lesions; Progressive Disease (PD): 20% increase in sum of longest diameter of target lesions; Stable Disease (SD): small changes that do not meet above criteria. Overall tumor response is the total number of CR and PRs in participants with squamous cell carcinoma who have received at least one cycle of therapy. (NCT00381706)
Timeframe: Up to 2 years post-treatment

Interventionpercentage of participants (Number)
Arm A: Squamous Cell Carcinoma (ECF + Cetuximab)67
Arm B: Squamous Cell Carcinoma (IC + Cetuximab)13
Arm C: Squamous Cell Carcinoma (FOLFOX + Cetuximab)60

[back to top]

Overall Survival in Patients With Adenocarcinoma

Overall survival (OS) was defined as the time from study entry to death of any cause. The median OS with 95% CI was estimated using the Kaplan Meier method. (NCT00381706)
Timeframe: Up to 2 years post-treatment

Interventionmonths (Median)
Arm A: Adenocarcinoma (ECF + Cetuximab)11.6
Arm B: Adenocarcinoma (IC + Cetuximab)8.6
Arm C: Adenocarcinoma (FOLFOX + Cetuximab)11.8

[back to top]

Progression-free Survival in Patients With Adenocarcinoma

Progression free survival (PFS) was defined as the time from study entry to progression or death of any cause. The median PFS with 95% CI was estimated using the Kaplan Meier method. (NCT00381706)
Timeframe: Up to 2 years post-treatment

Interventionmonths (Median)
Arm A: Adenocarcinoma (ECF + Cetuximab)7.1
Arm B: Adenocarcinoma (IC + Cetuximab)4.9
Arm C: Adenocarcinoma (FOLFOX + Cetuximab)6.8

[back to top]

Response Rate (Complete and Partial) in Patients With Measurable Esophageal or GE Junction Adenocarcinoma

Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria: Complete Response (CR): disappearance of all target lesions; Partial Response (PR) 30% decrease in sum of longest diameter of target lesions; Progressive Disease (PD): 20% increase in sum of longest diameter of target lesions; Stable Disease (SD): small changes that do not meet above criteria. Overall tumor response is the total number of CR and PRs in participants with adenocarcinoma who have received at least one cycle of therapy. (NCT00381706)
Timeframe: Up to 2 years post-treatment

Interventionpercentage of participants (Number)
Arm A: Adenocarcinoma (ECF + Cetuximab)61
Arm B: Adenocarcinoma (IC + Cetuximab)45
Arm C: Adenocarcinoma (FOLFOX + Cetuximab)54

[back to top]

Time to Treatment Failure in Patients With Adenocarcinoma

Time to treatment failure (TTF) was measured from study entry until documented progression, death resulting from any cause, or end of protocol therapy because of unacceptable toxicity. The median TTF with 95% CI was estimated using the Kaplan Meier method. (NCT00381706)
Timeframe: Up to 2 years post-treatment

Interventionmonths (Median)
Arm A: Adenocarcinoma (ECF + Cetuximab)5.6
Arm B: Adenocarcinoma (IC + Cetuximab)4.3
Arm C: Adenocarcinoma (FOLFOX + Cetuximab)6.7

[back to top]

Number of Participants With no Emesis and no Rescue Therapy Within 5 Days of Receiving FOLFOX and FOLFIRI in the First Cycle of Chemotherapy.

(NCT00381862)
Timeframe: Up to 24 weeks

InterventionParticipants (Number)
Aprepitant and Palonosetron54

[back to top]

Overall Survival

Number of months from randomisation to the date of death from any cause (NCT00384176)
Timeframe: Randomisation until data cut-off

InterventionMonths (Median)
Cediranib 20 mg22.8
Bevacizumab 5 mg/kg21.3

[back to top]

Objective Response Rate

"Objective response rate is Complete Response (CR) + Partial Response (PR) as defined below:~CR = Disappearance of all target lesions. PR = At least a 30% decrease in the sum of longest diameters (LDs) of target lesions, taking as reference the baseline sum of LDs." (NCT00384176)
Timeframe: Up until data cut-off

InterventionParticipants (Number)
Cediranib 20 mg328
Bevacizumab 5 mg/kg337

[back to top]

Duration of Response

Duration of Response is calculated as the time from the first recording of CR/PR until the patient progresses, regardless of whether the patient was still taking study medication. Only confirmed responses are included in the calculation. For patients who had not progressed, the end date used in the calculation of duration of response is the data cut-off date of 15th November 2009. (NCT00384176)
Timeframe: Up until data cut-off date of 15/11/2007

InterventionMonths (Median)
Cediranib 20 mg8.6
Bevacizumab 5 mg/kg9.6

[back to top]

Progression Free Survival

Progression is defined as the number of months from randomisation until progressive disease based on RECIST (progression of target lesions, clear progression of existing non-target lesions or the appearance of one or more new lesions) or death in the absence of progression. (NCT00384176)
Timeframe: Baseline then at Weeks 8, 16, 24 and then every 12 weeks until progression

InterventionMonths (Median)
Cediranib 20 mg9.9
Bevacizumab 5 mg/kg10.3

[back to top]

Percentage Change in Tumour Size

Percentage change in tumour size from baseline to first RECIST assessment (Week 8) ((Week 8 - baseline)/baseline)*100 (NCT00384176)
Timeframe: Baseline to Week 8

InterventionPercentage change in tumour size (Mean)
Cediranib 20 mg-23.2
Bevacizumab 5 mg/kg-22.1

[back to top] [back to top]

6 Month Progression Free Survival

as measured from the start of the treatment to the date of either documentation of disease progression or death. As we have previously, we will define progression of disease as per RECIST criteria. As per RECIST criteria, any evidence of progression in non-measurable lesions, measurable lesions, or the development of new lesions, would qualify as disease progression .RECIST criteria as defined by CTEP (http://ctep.info.nih.gov/Policies). (NCT00390416)
Timeframe: 6 months

Interventionpercentage of participants (Number)
Docetaxel, Cisplatin, Fluorouracil, Bevacizumab, Leucovorin79

[back to top]

Patients With Measurable Disease the Confirmed Response Rate

(NCT00390416)
Timeframe: up to 2 years

Interventionpercentage of participants (Number)
Confirmed Response RateResponse Rate (proximal/GEJ tumors)
Docetaxel, Cisplatin, Fluorouracil, Bevacizumab, Leucovorin6785

[back to top]

1-year Survival

(NCT00390416)
Timeframe: 1 year

Interventionmonths (Median)
Progression Free SurvivalOverall Survival
Docetaxel, Cisplatin, Fluorouracil, Bevacizumab, Leucovorin1216.8

[back to top]

Overall Survival (OS) at 1 Year

(NCT00392834)
Timeframe: 1 year post treatment

InterventionCumulative proportion surviving at 1 yr (Number)
Regimen A (R-CODOX-M Chemotherapy)1.0
Regimen B (Rituximab and IVAC Chemotherapy)0.82

[back to top]

Time to Wound Healing Complications

Number of days from post-randomisation surgery until wound healing complications (NCT00399035)
Timeframe: Post-randomisation until end of study

InterventionDays (Median)
Cediranib 20 mg18
Placebo18

[back to top]

Rate of Resection of Liver Metastases

Number of patients undergoing liver resection, based on patients with liver disease at baseline (NCT00399035)
Timeframe: Post-randomisation until end of study

InterventionParticipants (Number)
Cediranib 20 mg21
Placebo17

[back to top]

Progression-free Survival

RECIST criteria defined as follows: Target lesions Complete Response (CR) Disappearance of all target lesions Partial Response (PR) At least a 30% decrease in the sum of LD of target lesions taking as reference the baseline sum LD.Progressive Disease (PD) At least a 20% increase in the sum of LD of target lesions taking as references the smallest sum LD recorded (either at baseline or at previous assessment since treatment began).Stable Disease (SD) Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. Non-target lesions Complete Response (CR) Disappearance of all non-target lesions Non-Complete Response (non-CR/Non- Progression [non-PD]) Persistence of one or more non-target lesion or/and maintenance of tumour marker level above the normal limits. Progression (PD) Unequivocal progression of existing nontarget lesions. (NCT00399035)
Timeframe: RECIST assessed at baseline every 6 weeks through to week 24 and 12 week thereafter through to progression or data cut off date of 21/03/10 whichever was earliest.

InterventionMonths (Median)
Cediranib 20 mg8.6
Placebo8.2

[back to top]

Overall Survival

Number of months from randomisation to the date of death from any cause (NCT00399035)
Timeframe: Baseline through to date of death upto and including data cut off date of 21/03/10

InterventionMonths (Median)
Cediranib 20 mg19.7
Placebo18.9

[back to top]

Overall Response Rate

Objective tumour response(defined as a confirmed response of CR or PR).The definition for a confirmed response was met when an initial RECIST response of PR/CR was confirmed at the next scheduled visit as a PR/CR according to an evaluable assessment.Intervening assessments of non-evaluable or stable disease were allowable as long as the initial RECIST response was confirmed.RECIST criteria defined as follows: Target lesions Complete Response(CR)Disappearance of all target lesions Partial Response (PR).At least a 30% decrease in the sum of LD of target lesions taking as reference the baseline sum LD. Progressive Disease (PD) At least a 20% increase in the sum of LD of target lesions taking as references the smallest sum LD recorded (either at baseline or at previous assessment since treatment began).Stable Disease (SD) Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.Non-target lesions Complete Response (CR) Disappearance of all non-target lesi (NCT00399035)
Timeframe: Baseline through to date of death upto and including data cut off date of 21/03/10

InterventionParticipants (Number)
Cediranib 20 mg254
Placebo178

[back to top]

Duration of Response

Based on RECIST measurements taken throughout the study and best objective tumour response at the defined analysis cut-off point. Measured from the time the criteria for CR/PR are first met (whichever is recorded first) until the patient progresses or dies. (NCT00399035)
Timeframe: Treatment period from initial response up until data cut-off date of 21/03/10

InterventionMonths (Median)
Cediranib 20 mg8.5
Placebo6.9

[back to top]

Best Percentage Change in Tumour Size

Maximum percentage reduction or minimum percentage increase in tumour size where size is the sum of the longest diameters of the target lesions (NCT00399035)
Timeframe: Baseline through to date of death upto and including data cut off date of 21/03/10

InterventionPercentage [change in tumour size (mm) ] (Mean)
Cediranib 20 mg-42.49
Placebo-40.61

[back to top]

5-year Disease-Free Survival by CNS Directed Treatment Group

Disease-free survival (DFS) in a landmark analysis is defined as the duration of time from asparaginase randomization (which occurred after patients achieved complete remission and were assigned to a final risk group) to documented relapse, death during remission or second malignant neoplasm. DFS is estimated based on the Kaplan-Meier method and 5-year DFS is the probability of patients remaining alive, relapse-free and without occurrence of second malignant neoplasm 5 years from asparaginase randomization. Disease relapse is defined as >25% lymphoblasts identified morphologically in bone marrow aspirate/biopsy, or identification of lymphoblasts in marrow (any percentage) identified to be leukemic by flow cytometry, cytogenetics, FISH, immunohistochemistry, or other tests. Appearance of leukemic cells at any extramedullary site (a single, unequivocal lymphoblast in the CSF may qualify as CNS leukemia) also qualifies if confirmed by the PI. (NCT00400946)
Timeframe: Disease evaluations occurred continuously on treatment. Suggested long-term follow-up was monthly for 6m, bi-monthly for 6m, every 4 months for 1y, semi-annually for 1y, then annually. Median follow-up in this study cohort is 6 yrs, up to 10y.

Interventionprobability (Number)
CNS-1.89
CNS-2.89
CNS-31.00
Traumatic Tap With Blasts.84
Traumatic Tap Without Blasts.87

[back to top]

Induction Infection Toxicity Rate

Infection toxicity rate is defined as the percentage of patients who experience bacterial or fungal infection of grade 3 or higher with treatment attribution of possibly, probably or definite based on CTCAEv3 during remission induction phase of combination chemotherapy. (NCT00400946)
Timeframe: Assessed daily during remission induction days 4-32.

Interventionpercentage of participants (Number)
Overall26

[back to top]

5-Year Disease-Free Survival

Disease-free survival (DFS) in a landmark analysis is defined as the duration of time from asparaginase randomization (which occurred after patients achieved complete remission and were assigned to a final risk group) to documented relapse, death during remission or second malignant neoplasm. DFS is estimated based on the Kaplan-Meier method and 5-year DFS is the probability of patients remaining alive, relapse-free and without occurrence of second malignant neoplasm 5 years from asparaginase randomization. Disease relapse is defined as >25% lymphoblasts identified morphologically in bone marrow aspirate/biopsy, or identification of lymphoblasts in marrow (any percentage) identified to be leukemic by flow cytometry, cytogenetics, FISH, immunohistochemistry, or other tests. Appearance of leukemic cells at any extramedullary site (a single, unequivocal lymphoblast in the CSF may qualify as CNS leukemia) also qualifies if confirmed by the PI. (NCT00400946)
Timeframe: Disease evaluations occurred continuously on treatment. Suggested long-term follow-up was monthly for 6m, bi-monthly for 6m, every 4 months for 1y, semi-annually for 1y, then annually. Median follow-up in this study cohort is 6 yrs, up to 10y.

Interventionprobability (Number)
Intramuscular Native E Coli L-asparaginase (IM-EC).89
Intravenous PEG-asparaginase (IV-PEG).90

[back to top]

Post-Induction Therapeutic Nadir Serum Asparaginase Activity Rate

Nadir serum asparaginase activity (NSAA) levels were estimated based on established methods. Post-Induction therapeutic NSAA rate is defined as the percentage of patients achieving a NSAA level above 0.1 IU/mL ever during post-induction therapy. (NCT00400946)
Timeframe: Samples for nadir serum asparaginase activity analyses were obtained before doses administered at weeks 5, 11, 17, 23 and 29 of post-induction asparaginase treatment.

Interventionpercentage of participants (Number)
Intramuscular Native E Coli L-asparaginase (IM-EC)71
Intravenous PEG-asparaginase (IV-PEG)99

[back to top]

Induction Serum Asparaginase Activity Level

Serum asparaginase activity (NSAA) levels were estimated based on established methods. (NCT00400946)
Timeframe: Samples for serum asparaginase activity analyses were obtained days 4, 11, 18 and 25 post one-dose of IV-PEG on day 7 of the induction phase.

InterventionIU/mL (Median)
Day 4 NSAA LevelDay 11 NSAA LevelDay 18 NSAA LevelDay 25 NSAA Level
Overall.694.505.211.048

[back to top]

Induction Therapeutic Nadir Serum Asparaginase Activity Rate

Nadir serum asparaginase activity (NSAA) levels were estimated based on established methods. Induction therapeutic NSAA rate is defined as the percentage of patients achieving a NSAA level above 0.1 IU/mL at a given timepoint. (NCT00400946)
Timeframe: Samples for serum asparaginase activity analyses were obtained days 4, 11, 18 and 25 post one-dose of IV-PEG on day 7 of the induction phase.

Interventionpercentage of participants (Number)
Day 4 NSAA RateDay 11 NSAA RateDay 18 NSAA RateDay 25 NSAA Rate
Overall97968712

[back to top]

Post-Induction Nadir Serum Asparaginase Activity Level

Nadir serum asparaginase activity (NSAA) levels were estimated based on established methods. (NCT00400946)
Timeframe: Samples for nadir serum asparaginase activity analyses were obtained before doses administered at weeks 5, 11, 17, 23 and 29 of post-induction asparaginase treatment.

,
InterventionIU/mL (Mean)
Week 5 NSAA LevelWeek 11 NSAA LevelWeek 17 NSAA LevelWeek 23 NSAA LevelWeek 29 NSAA Level
Intramuscular Native E Coli L-asparaginase (IM-EC)0.1290.1430.1590.1800.123
Intravenous PEG-asparaginase (IV-PEG)0.7260.7730.7870.7570.806

[back to top]

5-Year Disease-Free Survival by Bone Marrow Day 18 Status

Disease-free survival (DFS) in a landmark analysis is defined as the duration of time from asparaginase randomization (which occurred after patients achieved complete remission and were assigned to a final risk group) to documented relapse, death during remission or second malignant neoplasm. DFS is estimated based on the Kaplan-Meier method and 5-year DFS is the probability of patients remaining alive, relapse-free and without occurrence of second malignant neoplasm 5 years from asparaginase randomization. Disease relapse is defined as >25% lymphoblasts identified morphologically in bone marrow aspirate/biopsy, or identification of lymphoblasts in marrow (any percentage) identified to be leukemic by flow cytometry, cytogenetics, FISH, immunohistochemistry, or other tests. Appearance of leukemic cells at any extramedullary site (a single, unequivocal lymphoblast in the CSF may qualify as CNS leukemia) also qualifies if confirmed by the PI. (NCT00400946)
Timeframe: Disease evaluations occurred continuously on treatment. Suggested long-term follow-up was monthly for 6m, bi-monthly for 6m, every 4 months for 1y, semi-annually for 1y, then annually. Median follow-up in this study cohort is 6 yrs, up to 10y.

Interventionprobability (Number)
M1 Day 18 Bone Marrow Status.89
M2/M3 Day 18 Bone Marrow Status.78
Hypocellular Day 18 Bone Marrow Status.88

[back to top]

5-Year Disease-Free Survival by MRD Day 32 Status

Disease-free survival (DFS) in a landmark analysis is defined as the duration of time from asparaginase randomization (which occurred after patients achieved complete remission and were assigned to a final risk group) to documented relapse, death during remission or second malignant neoplasm. DFS is estimated based on the Kaplan-Meier method and 5-year DFS is the probability of patients remaining alive, relapse-free and without occurrence of second malignant neoplasm 5 years from asparaginase randomization. Disease relapse is defined as >25% lymphoblasts identified morphologically in bone marrow aspirate/biopsy, or identification of lymphoblasts in marrow (any percentage) identified to be leukemic by flow cytometry, cytogenetics, FISH, immunohistochemistry, or other tests. Appearance of leukemic cells at any extramedullary site (a single, unequivocal lymphoblast in the CSF may qualify as CNS leukemia) also qualifies if confirmed by the PI. (NCT00400946)
Timeframe: Disease evaluations occurred continuously on treatment. Suggested long-term follow-up was monthly for 6m, bi-monthly for 6m, every 4 months for 1y, semi-annually for 1y, then annually. Median follow-up in this study cohort is 6 yrs, up to 10y.

Interventionprobability (Number)
Low Day 32 MRD Level.79
High Day 32 MRD Level.90

[back to top] [back to top]

Disease-free Survival (DFS) for Randomized Nelarabine T-ALL Cohort (Arm I vs. Arm II vs. Arm III vs. Arm IV)

Disease Free Probability where DFS time is defined as time from randomization end of induction to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free. (NCT00408005)
Timeframe: 4 years from randomization at the end of induction

Interventionpercent probability (Number)
ARM I (Combination Chemotherapy)89.01
ARM II (Combination Chemotherapy)90.53
ARM III (Combination Chemotherapy)78.07
ARM IV (Combination Chemotherapy)86.46

[back to top]

Cumulative Incidence of CNS Relapse for T-ALL by Risk Group

Cumulative incidence of CNS relapse adjusting for DFS events, was calculated using the method Gray et. al. High risk patients receive cranial radiation and low risk patients receive no cranial radiation. (NCT00408005)
Timeframe: 4 years from randomization at the end of induction

,
Interventionpercent probability (Number)
Intermediate RiskHigh Risk
ARM II (Combination Chemotherapy)1.080
ARM IV (Combination Chemotherapy)0.853.45

[back to top]

Cumulative Incidence of CNS Relapse for T-ALL by Risk Group

Cumulative incidence of CNS relapse adjusting for DFS events, was calculated using the method Gray et. al. High risk patients receive cranial radiation and low risk patients receive no cranial radiation. (NCT00408005)
Timeframe: 4 years from randomization at the end of induction

,
Interventionpercent probability (Number)
Low RiskIntermediate RiskHigh Risk
ARM I (Combination Chemotherapy)1.851.163.64
ARM III (Combination Chemotherapy)1.929.16.52

[back to top]

Disease-free Survival (DFS) for T-cell Lymphoblastic Lymphoma (T-LLy) Cohort

Disease Free Probability where DFS time is defined as time from randomization end of induction to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free. (NCT00408005)
Timeframe: 4 years from end of induction

Interventionpercent probability (Number)
High RiskInduction Failure
ARM II (Combination Chemotherapy)85.0100

[back to top]

Disease-free Survival (DFS) for Randomized Nelarabine T-ALL Cohort (Arm I + Arm III vs. Arm II + Arm IV)

Disease Free Probability where DFS time is defined as time from randomization end of induction to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event (NCT00408005)
Timeframe: 4 years from randomization at the end of induction

Interventionpercent probability (Number)
ARM I and ARM III (Combination Chemotherapy)82.96
ARM II and ARM IV (Combination Chemotherapy)88.30

[back to top]

Disease-free Survival (DFS) for T-cell Lymphoblastic Lymphoma (T-LLy) Cohort

Disease Free Probability where DFS time is defined as time from randomization end of induction to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free. (NCT00408005)
Timeframe: 4 years from end of induction

Interventionpercent probability (Number)
Standard RiskHigh Risk
ARM I (Combination Chemotherapy)87.485.1

[back to top]

Disease-free Survival (DFS) for Randomized Methotrexate T-ALL Cohort (Arm I + Arm II vs. Arm III + Arm IV)

Disease Free Probability where DFS time is defined as time from randomization end of induction to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free. (NCT00408005)
Timeframe: 4 years from randomization at the end of induction

Interventionpercent probability (Number)
ARM I and ARM II (Combination Chemotherapy)91.45
ARM III and ARM IV (Combination Chemotherapy)85.78

[back to top]

Disease-free Survival (DFS) for Randomized Methotrexate T-ALL Cohort (Arm I vs. Arm II vs. Arm III vs. Arm IV)

Disease-free survival defined as time from randomization end of induction to first event (relapse, second malignant neoplasm, remission death) or date of last contact for those who are event-free. (NCT00408005)
Timeframe: 4 years from randomization at the end of induction

Interventionpercent probability (Number)
ARM I (Combination Chemotherapy)91.76
ARM II (Combination Chemotherapy)90.53
ARM III (Combination Chemotherapy)86.06
ARM IV (Combination Chemotherapy)84.89

[back to top]

Time to Response

Time to response is defined as time from the date of randomization to the date of first confirmed objective response (NCT00418938)
Timeframe: From randomization up to 65 months.

,
Interventionmonths (Median)
Wild-type KRAS (n=91,91)Mutant KRAS (n=36,32)
Bevacizumab Plus FOLFIRI3.71.8
Panitumumab Plus FOLFIRI2.12.2

[back to top]

Objective Response Rate

Objective response rate is defined as incidence of either a confirmed complete response (CR) or partial response (PR) on study up to starting a new anti-tumor therapy and will be based on modified RECIST version 1.0 (responder) by central assessment. (NCT00418938)
Timeframe: From randomization up to 65 months.

,
Intervention% of patients (Number)
Wild-type KRAS (n=91,91)Mutant KRAS (n=36,32)
Bevacizumab Plus FOLFIRI19.283.33
Panitumumab Plus FOLFIRI32.1811.76

[back to top]

Time to Progression

Time to progression is defined as time from the date of randomization to the date of radiographic disease progression per modified RECIST version 1.0 (per central assessment). (NCT00418938)
Timeframe: From randomization up to 65 months.

,
Interventionmonths (Median)
Wild-type KRASMutant KRAS
Bevacizumab Plus FOLFIRI9.47.4
Panitumumab Plus FOLFIRI11.14.5

[back to top]

Overall Survival

Overall survival is defined as time from the date of randomization to the date of death due to any cause. Subjects who have not died or are lost to follow-up at the analysis cutoff date will be censored at their last contact date. (NCT00418938)
Timeframe: From randomization up to 65 months.

,
Interventionmonths (Median)
Wild-type KRAS (n=91,91)Mutant KRAS (n=36,32)
Bevacizumab Plus FOLFIRI21.413.5
Panitumumab Plus FOLFIRI18.08.7

[back to top]

Progression-free Survival (PFS)

Progression-free survival is defined as time from the date of randomization to the date of first progression per modified RECIST version 1.0 (based on central review of the radiographic scans), or death within 60 days after the last evaluable tumor assessment or randomization date (whichever is later). (NCT00418938)
Timeframe: From randomization up to 65 months.

,
Interventionmonths (Median)
Wild-type KRAS (n=91,91)Mutant KRAS (n=36,32)
Bevacizumab Plus FOLFIRI9.26.4
Panitumumab Plus FOLFIRI7.73.7

[back to top]

Disease Control

Disease control is defined as incidence of objective response or stable disease on study up to starting a new anti-tumor therapy. (NCT00418938)
Timeframe: From randomization up to 65 months.

,
Intervention% of participants (Number)
Wild-type KRAS (n=91,91)Mutant KRAS (n=36,32)
Bevacizumab Plus FOLFIRI79.5266.67
Panitumumab Plus FOLFIRI72.4152.94

[back to top]

Duration of Response

Duration of response is defined as time from first confirmed objective response to disease progression per modified RECIST version 1.0 (by central assessment). (NCT00418938)
Timeframe: From randomization up to 65 months.

,
Interventionmonths (Median)
Wild-type KRAS (n=91,91)Mutant KRAS (n=36,32)
Bevacizumab Plus FOLFIRI8.915.2
Panitumumab Plus FOLFIRI12.710.2

[back to top]

Overall Survival

(NCT00448760)
Timeframe: 24 months

Interventionmonths (Median)
Single Arm21.4

[back to top]

Pathologic Complete Response

No evidence of cellular residual cancerous cells as evidenced by tumor tissue samples taken via surgery at the end of neo-adjuvant chemotherapy. (NCT00448760)
Timeframe: 8 - 16 weeks

Interventionpercentage of participants (Number)
Single Arm16.7

[back to top]

Clinical Response

"Overall response = Complete response (CR) + Partial Response (PR). Evaluated via endoscopic ultrasounds, PET and CT scans of the chest:~Complete Response (CR) applies to participants complete disappearance of all measurable and evaluable disease. No new lesion. No disease related symptoms. No evidence of non-evaluable disease, including tumor markers and other laboratory values.~Partial Response (PR) applies to participants with at least 50 percent reduction in the sum of the products of bi-dimensional perpendicular diameters of all measurable lesions. No progression of evaluable disease. No new lesions." (NCT00448760)
Timeframe: 8 - 16 weeks

Interventionpercentage of participants (Number)
Single Arm72.4

[back to top]

Median Progression-free Survival (PFS)

(NCT00448760)
Timeframe: 24 months

Interventionmonths (Median)
Single Arm13.6

[back to top]

Median Progression-free Survival in Months

Median number of months subjects achieved progression-free survival (NCT00449163)
Timeframe: 2 years

Interventionmonths (Median)
Combination Chemotherapy and Bevacizumab13

[back to top]

Response Rate (Complete Response and Partial Response)

Percentage of patients achieving complete response or partial response per RECIST criteria ver 1.0 (NCT00449163)
Timeframe: 2 years

Interventionpercentage of participants (Number)
Combination Chemotherapy and Bevacizumab67

[back to top]

Overall Survival up to 2 Years

Percentage of patients with overall survival times of up to 2 years (NCT00449163)
Timeframe: 2 years

Interventionpercentage of participants (Number)
Combination Chemotherapy and Bevacizumab61

[back to top]

Rate of Toxicity in Study Participants

Evaluation the safety and toxicities of protocol regimen as evidenced by the rate of serious adverse events in study participants. (NCT00449163)
Timeframe: 2 years

Interventionpercentage of participants (Number)
Combination Chemotherapy and Bevacizumab50

[back to top]

Progression-free Survival Rate

Percentage of participants achieving progression-free survival at 1, 3 and 5 years after the start of protocol therapy, based upon the International Working Group Response Criteria for Non-Hodgkin's Lymphoma (NHL). Progression is defined as a ≥ 50% increase from nadir in the product of the two largest perpendicular diameters (PPD-size) of any previously identified abnormal node, or appearance of any new lesion. (NCT00450801)
Timeframe: Up to 5 years

Interventionpercentage of participants (Number)
1 year progression-free survival3 year progression-free survival5-year progression-free survival
R-MACLO-IVAM-T917869

[back to top]

Overall Survival Rate

Percentage of participants who are alive up to five years after receipt of protocol therapy. (NCT00450801)
Timeframe: Up to 5 years

Interventionpercentage of participants (Number)
1-year rate overall survival Rate2-year overall survival Rate3-year overall survival rate4-year overall survival rate5-year overall survival rate
R-MACLO-IVAM-T9696968787

[back to top]

Response Rate

Percentage of participants achieving complete response (CR) to protocol therapy according to International Working Group Response Criteria for Non-Hodgkin's Lymphoma (NHL) using the CT imaging method. Patients were classified by best tumor response; CR was defined as normalization of the lactate dehydrogenase (LDH), complete disappearance of disease-related symptoms and lymph nodes, and clearance of lymphoma from involved organs; complete response unconfirmed (CRu) as a residual lymph node greater than 1.5 cm in greatest transverse diameter that had regressed by more than 75% or an indeterminate bone marrow examination; partial response (PR) as greater than 50% reduction in the involved lymph nodes, or disappearance of the involved lymph nodes but persistent bone marrow involvement; relapse/progression as new or increased lymph nodes, organomegaly, or reappearance of bone marrow involvement. (NCT00450801)
Timeframe: Up to 5 years

Interventionpercentage of participants (Number)
R-MACLO-IVAM-T100

[back to top]

Number of Patients Experiencing Adverse Events.

Number of patients experiencing adverse events during the course of protocol therapy. (NCT00450801)
Timeframe: Up to 5 years

Interventionparticipants (Number)
R-MACLO Cycles22
R-IVAM Cycles22
Thalidomide Therapy19

[back to top]

Progression-free Survival (PFS)

PFS defined as time from date of randomization to date of first documentation of objective tumour progression or death due to any cause, whichever occurred first. (NCT00457691)
Timeframe: First dose of study treatment up to 30 months

InterventionWeeks (Median)
FOLFIRI + Sunitinib33.6
FOLFIRI + Placebo36.6

[back to top]

Overall Survival (OS)

OS was defined as the time from randomization to the date of death due to any cause. OS data were censored on the day following the date of the last contact at which the patient was known to be alive. (NCT00457691)
Timeframe: Baseline up to 30 months

InterventionWeeks (Median)
FOLFIRI + Sunitinib87.9
FOLFIRI + Placebo85.9

[back to top]

Number of Participants With Overall Confirmed Objective Response

Objective disease response: participants with a confirmed complete response (CR) or partial response (PR) according to the Response Evaluation Criteria in Solid Tumors (RECIST). CR was defined as the disappearance of all target lesions. PR was defined as a greater than or equal to 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. (NCT00457691)
Timeframe: Day 28 of Cycle 1 up to 30 months

InterventionParticipants (Number)
FOLFIRI + Sunitinib124
FOLFIRI + Placebo128

[back to top]

Change From Baseline in MDASI-GI Symptom Interference Score

Symptom Interference score is comprised of the sum 6 function items from MDASI core (general activity, walking, work, mood, relations with other people, and enjoyment of life). Participant asked to rate how much symptoms have interfered in past 24 hours; each item rated from 0 to 10, with 0=did not interfere and 10=interfered completely; lower scores indicated better outcome (range: 0 to 60). (NCT00457691)
Timeframe: Day 1 of Cycles 1-3 and Day 1 of every odd-numbered cycle thereafter until EOT/withdrawal

,
Interventionscores on a scale (Mean)
Cycle 2, Day 1Cycle 3, Day 1Cycle 5, Day 1Cycle 7, Day 1Cycle 9, Day 1Cycle 11, Day 1
FOLFIRI + Placebo-1.3-1.7-1.2-0.2-1.7-1.0
FOLFIRI + Sunitinib0.0-0.10.2-0.52.13.1

[back to top]

Change From Baseline in Monroe Dunaway (MD) Anderson Symptom Assessment Inventory of Gastrointestinal Symptoms (MDASI-GI) Symptom Intensity Score

Symptom Intensity score is comprised of the sum of 13 MDASI core items (ie, pain, fatigue, nausea, disturbed sleep, distress, shortness of breath, remembering things, lack of appetite, drowsiness, dry mouth, sadness, vomiting, numbness or tingling). Participant asked to rate severity of each symptom at their worst in past 24 hours; each item rated from 0 to 10, with 0=symptom not present and 10=as bad as you can imagine; lower scores indicated better outcome (range: 0 to 130). (NCT00457691)
Timeframe: Day 1 of Cycles 1-3 and Day 1 of every odd-numbered cycle thereafter until end of treatment (EOT)/withdrawal

,
InterventionScores on a scale (Mean)
Cycle 2, Day 1Cycle 3, Day 1Cycle 5, Day 1Cycle 7, Day 1Cycle 9, Day 1Cycle 11, Day 1
FOLFIRI + Placebo0.40.91.82.71.2-2.7
FOLFIRI + Sunitinib1.70.81.00.70.85.0

[back to top]

Change From Baseline in EuroQol (EQ) Visual Analog Scale (VAS) (EQ-VAS)

EQ-5D: participant-rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state. (NCT00457691)
Timeframe: Day 1 of Cycles 1-3 and Day 1 of every odd-numbered cycle thereafter until EOT/withdrawal

,
InterventionScores on a scale (Mean)
Cycle 2, Day 1Cycle 3, Day 1Cycle 5, Day 1Cycle 7, Day 1Cycle 9, Day 1Cycle 11, Day 1
FOLFIRI + Placebo3.34.36.64.34.09.0
FOLFIRI + Sunitinib1.01.71.83.8-0.9-1.6

[back to top]

Change From Baseline in European Quality of Life (EuroQol) EQ-5D Self-Report Questionnaire

"EQ-5D: participant-rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problem); 3 indicates worst health state (eg, confined to bed). Scoring formula developed by EuroQol Group assigns a utility value for each domain. Score is transformed and results in total score range -1.11 to 1.000; higher score indicates better health state." (NCT00457691)
Timeframe: Day 1 of Cycles 1-3 and Day 1 of every odd-numbered cycle thereafter until EOT/withdrawal

,
InterventionScores on a scale (Mean)
Cycle 2, Day 1Cycle 3, Day 1Cycle 5, Day 1Cycle 7, Day 1Cycle 9, Day 1Cycle 11, Day 1
FOLFIRI + Placebo0.040.040.030.050.050.09
FOLFIRI + Sunitinib0.020.020.020.030.000.01

[back to top]

Duration of Response (DR)

DR was defined as the time from the first objective documentation of CR or PR that was subsequently confirmed to the first documentation of disease progression or to death due to any cause, whichever occurred first. (NCT00457691)
Timeframe: Day 28 of Cycle 1 up to 30 months

InterventionWeeks (Median)
FOLFIRI + Sunitinib30.1
FOLFIRI + Placebo39.0

[back to top]

Complete Pathologic Response

This will be assessed on the basis of the surgical pathology report. (NCT00462501)
Timeframe: 3 years

Interventionparticipants (Number)
Complete ResponsePartial ResponseUnknown
Chemotherapy and Bevacizumab With or Without Radiation8211

[back to top]

Percentage of Participants in Objective Response (Partial or Complete Responses)

Objective response defined as complete or partial responses according to RECIST v1.0. Complete response is defined as the disappearance of all target lesions and partial response is defined as at least a 30% decrease in the sum of the longest diameters (SLD) of target lesions, taking as reference the baseline SLD (RECIST V1.0.).Radiologic assessment was carried out every four cycles (8 weeks) with centralized external secondary review. (NCT00467142)
Timeframe: 6 months

Interventionpercentage of participants (Number)
Folfiri and Bevacizumab47.5

[back to top]

Median Duration of Response

Duration of response is defined as the delay between response (complete or partial) and disease progression according to RECIST V1.0. Therefore, this criterion can only be assessed in in subjects who have responded. Complete response is defined as the disappearance of all target lesions and partial response is defined as at least a 30% decrease in the sum of the longest diameters (SLD) of target lesions, taking as reference the baseline SLD (RECIST V1.0.). Progression is defined as a 20% increase in the sum of the longest diameters (SLD) of target lesions, taking as reference the baseline SLD, or appearance of one or several new lesions (RECIST V1.0) Radiologic assessment was carried out every four cycles (8 weeks) with centralized external secondary review. (NCT00467142)
Timeframe: 24 months

Interventionmonths (Median)
Folfiri and Bevacizumab9.5

[back to top]

Best Percentage Change in Tumour Size

Best percentage change in tumour size from baseline, based on the sum of the longest diameters of the target lesions (NCT00494221)
Timeframe: Randomisation until cut-off date 13OCT2009 (based on approximately 105 progression events observed across the 3 groups)

InterventionPercentage (Mean)
Cediranib 20 mg-36.56
Cediranib 30 mg-43.99
Placebo-40.22

[back to top]

Duration of Response

Number of months from Complete/Partial response until progression up to cut-off date 13OCT2009 (based on approximately 105 progression events observed across the 3 groups). (NCT00494221)
Timeframe: RECIST at Baseline, Weeks 6, 12, 18, 24 and then every 12 weeks until progression through to a cut-off date of 13th Oct 2009 (based on approx 105 progression events observed across the 3 groups)

InterventionMonths (Mean)
Cediranib 20 mg13.26
Cediranib 30 mg8.12
Placebo10.42

[back to top]

Objective Tumour Response Rate

Number of patients with complete (CR) /partial response (PR) (based on RECIST). CR is defined as Disappearance of all target lesions. PR is defined as at least a 30% decrease in the sum of Longest Diameter (LD) of target lesions taking as reference the baseline sum LD. (NCT00494221)
Timeframe: RECIST at Baseline, Weeks 6, 12, 18, 24 and then every 12 weeks until progression through to a cut-off date of 13th Oct 2009 (based on approx 105 progression events observed across the 3 groups)

InterventionParticipants (Number)
Cediranib 20 mg31
Cediranib 30 mg39
Placebo31

[back to top]

Overall Survival

Number of months until death (censored if still alive at date cut-off). Median non-estimable if >50% of subjects within a group are censored. (NCT00494221)
Timeframe: Randomisation until cut-off date 13OCT2009 (based on approximately 105 progression events observed across the 3 groups)

InterventionMonths (Median)
Cediranib 20 mgNA
Cediranib 30 mg20.07
Placebo19.51

[back to top]

Progression Free Survival

Number of months from randomisation until progressive disease based on RECIST (progression of target lesions, clear progression of existing non-target lesions or the appearance of one or more new lesions) or death in the absence of progression. (NCT00494221)
Timeframe: RECIST at Baseline, Weeks 6, 12, 18, 24 and then every 12 weeks until progression through to a cut-off date of 13th Oct 2009 (based on approx 105 progression events observed across the 3 groups)

InterventionMonths (Median)
Cediranib 20 mg10.23
Cediranib 30 mg8.85
Placebo8.32

[back to top]

Toxicity

Number of patients with Grade 3 through 5 adverse events that are related to study drug. Only adverse events that are possibly, probably or definitely related to study drug are reported. (NCT00499369)
Timeframe: Up to 5 years

,,,,
InterventionParticipants (Number)
Albumin, serum-low (hypoalbuminemia)Alkaline phosphataseAnorexiaBilirubin (hyperbilirubinemia)Colitis, infectious (e.g., Clostridium difficile)ConfusionConstipationCoughDehydrationDiarrheaDyspnea (shortness of breath)Edema: limbEdema: trunk/genitalEncephalopathyFatigue (asthenia, lethargy, malaise)Febrile neutropeniaHemoglobinHemorrhage, GI - StomaHypertensionInf (clin/microbio) w/Gr 3-4 neuts - Abdomen NOSInf (clin/microbio) w/Gr 3-4 neuts - BloodInf (clin/microbio) w/Gr 3-4 neuts - UTIInf w/normal ANC or Gr 1-2 neutrophils - Ab NOSInf w/normal ANC or Gr 1-2 neutrophils - BloodInf w/normal ANC or Gr 1-2 neutrophils - MucosaInf w/normal ANC or Gr 1-2 neutrophils - UTILeukocytes (total WBC)LymphopeniaMagnesium, serum-low (hypomagnesemia)Mental statusMucositis/stomatitis (clinical exam) - Oral cavityMucositis/stomatitis (functional/symp) - Oral cavMucositis/stomatitis (functional/symp) - PharynxNasal cavity/paranasal sinus reactionsNauseaNeuropathy: sensoryNeutrophils/granulocytes (ANC/AGC)Pain - Pain NOSPhosphate, serum-low (hypophosphatemia)PlateletsPneumonitis/pulmonary infiltratesPotassium, serum-low (hypokalemia)Rash/desquamationRash: acne/acneiformRash: hand-foot skin reactionSodium, serum-low (hyponatremia)Thrombosis/thrombus/embolismVomiting
Cohort I: Chemotherapy + Cetuximab100101002300010210011101005001000000400110030000
Cohort I: Chemotherapy + Cetuximab + Higher Bevacizumab010010002301103100000000002110110030700000141001
Cohort I: Chemotherapy + Cetuximab + Lower Bevacizumab001000000210001210000010114000100010700202120000
Cohort II: Chemotherapy + Bevacizumab001100111500002011100000010000001100310000000101
Cohort II: Chemotherapy + Cetuximab010000000300000010000000002000000001301001020010

[back to top]

Progression-free Survival (PFS)

PFS is measured from date of registration to first documentation of progression or symptomatic deterioration, or death due to any cause. Patients last known to be alive and progression free are censored at date of last contact. (NCT00499369)
Timeframe: Up to 5 years

Interventionmonths (Median)
Cohort I: Chemotherapy + Cetuximab3.2
Cohort I: Chemotherapy + Cetuximab + Lower Bevacizumab4.2
Cohort I: Chemotherapy + Cetuximab + Higher Bevacizumab8.5
Cohort II: Chemotherapy + Cetuximab1.4
Cohort II: Chemotherapy + Bevacizumab5.6

[back to top]

Number of Patients With an Objective Disease Progression Event

Number of patients with objective disease progression or death (by any cause in the absence of objective progression) (NCT00500292)
Timeframe: RECIST tumour assessments carried out at screening and then as per site clinical practice until objective progression. The only additional mandatory tumour assessment visit is at the point of data cut-off (5 March 2008 +/-3 days)

InterventionParticipants (Number)
Vandetanib 100 mg Plus FOLFOX23
Vandetanib 300 mg Plus FOLFOX27
Placebo Plus FOLFOX24

[back to top]

"Number of Patients With Each Response in Good Risk Genotype (Thymidylate Synthase Promoter Enhancer Region [TSER]*2/*2 or TSER*2/*3 Genotype [Low TS Expression])"

Per RECIST criteria v. 1.0: measurable lesions: complete response (CR) disappearance of target lesions, partial response (PR) > 30% decrease in the sum of the longest diameter (LD) of target lesions, progressive disease (PD) > 20% increase in the sum of the LD of target lesions or appearance of new lesions, stable disease (SD) neither sufficient decrease nor increase of the sum of smallest sum of the LD of target lesions. This is a one-time assessment. (NCT00514020)
Timeframe: every 8 weeks to progression

Interventionparticipants (Number)
Complete ResponsePartial ResponseProgressive DiseaseStable Disease
Oxaliplatin + Leucovorin + 5-Fluorouracil09114

[back to top]

Genetic Polymorphisms That May Alter Treatment Outcomes (Stable Disease)

This outcome looks at what genotypes of the TYMS 3'-UTR 1494delTTAAAG(6 bp) (rs34489327) gene had stable disease. (NCT00515216)
Timeframe: 4 years

Interventionparticipants (Number)
+6 bp/+6 bp+6 bp/-6 bp
Oxaliplatin/Leucovorin/5-FU65

[back to top]

Genetic Polymorphisms That May Alter Treatment Outcomes (Stable Disease)

This outcome looks at what genotypes of the TYMS 5'-UTR TSER + G>C (rs34743033) gene had stable disease. (NCT00515216)
Timeframe: 4 years

Interventionparticipants (Number)
TYMS, TSER*2/*2TYMS, TSER*2/*3 (G)TYMS, TSER*2/*3 (C)
Oxaliplatin/Leucovorin/5-FU146

[back to top]

Genetic Polymorphisms That May Alter Treatment Outcomes (Stable Disease)

This outcome looks at what genotypes of the XRCC1 c.1196G>A (rs25487) gene had stable disease. (NCT00515216)
Timeframe: 4 years

Interventionparticipants (Number)
A/AG/AG/G
Oxaliplatin/Leucovorin/5-FU650

[back to top]

Overall Survival

(NCT00515216)
Timeframe: 4 years

Interventionmonths (Median)
Oxaliplatin/Leucovorin/5-FU11.4

[back to top]

Progression-free Survival (PFS)

Progressive disease - at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions (NCT00515216)
Timeframe: 4 years

Interventionmonths (Median)
Oxaliplatin/Leucovorin/5-FU6.2

[back to top]

Genetic Polymorphisms That May Alter Treatment Outcomes (Partial Response)

This outcome looks at what genotypes of the ERCC1 c.354C>T (rs11615) gene had a partial tumor response. (NCT00515216)
Timeframe: 4 years

Interventionparticipants (Number)
C/CC/TT/T
Oxaliplatin/Leucovorin/5-FU243

[back to top]

Genetic Polymorphisms That May Alter Treatment Outcomes (Partial Response)

This outcome looks at what genotypes of the ERCC2 c.2251A>C (rs13181) gene had a partial response. (NCT00515216)
Timeframe: 4 years

Interventionparticipants (Number)
A/AA/CC/C
Oxaliplatin/Leucovorin/5-FU531

[back to top]

Genetic Polymorphisms That May Alter Treatment Outcomes (Partial Response)

This outcome looks at what genotypes of the GSTP1 c.313A>G (rs1695) gene had a partial response. (NCT00515216)
Timeframe: 4 years

Interventionparticipants (Number)
A/AA/GG/G
Oxaliplatin/Leucovorin/5-FU432

[back to top]

Genetic Polymorphisms That May Alter Treatment Outcomes (Partial Response)

This outcome looks at what genotypes of the XRCC1 c.1196G>A (rs25487) gene had a partial response. (NCT00515216)
Timeframe: 4 years

Interventionparticipants (Number)
A/AG/AG/G
Oxaliplatin/Leucovorin/5-FU162

[back to top]

Genetic Polymorphisms That May Alter Treatment Outcomes (Partial Response)

This outcome looks at what genotypes of the MDR1 c.3435C>T (rs1045642) gene had a partial response. (NCT00515216)
Timeframe: 4 years

Interventionparticipants (Number)
C/CC/TT/T
Oxaliplatin/Leucovorin/5-FU090

[back to top]

Genetic Polymorphisms That May Alter Treatment Outcomes (Partial Response)

This outcome looks at what genotypes of the TYMS 3'-UTR 1494delTTAAAG(6 bp) (rs34489327) gene had a partial tumor response. (NCT00515216)
Timeframe: 4 years

Interventionparticipants (Number)
+6 bp/+6 bp+6 bp/-6 bp
Oxaliplatin/Leucovorin/5-FU54

[back to top]

Genetic Polymorphisms That May Alter Treatment Outcomes (Partial Response)

This outcome looks at what genotypes of the TYMS 5'-UTR TSER + G>C (rs34743033) gene had a partial tumor response. (NCT00515216)
Timeframe: 4 years

Interventionparticipants (Number)
TYMS, TSER*2/*2TYMS, TSER*2/*3 (G)TYMS, TSER*2/*3 (C)
Oxaliplatin/Leucovorin/5-FU522

[back to top]

Genetic Polymorphisms That May Alter Treatment Outcomes (Stable Disease)

This outcome looks at what genotypes of the GSTP1 c.313A>G (rs1695) gene had stable disease. (NCT00515216)
Timeframe: 4 years

Interventionparticipants (Number)
A/AA/GG/G
Oxaliplatin/Leucovorin/5-FU821

[back to top]

Disease Control Rate (DCR)

"DCR - complete response, partial response, and stable disease~Complete response - disappearance of all target and non-target lesions~Partial response - at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter~Stable disease - neither sufficient shrinkage to qualify for partial response not sufficient increase to qualify for progressive disease" (NCT00515216)
Timeframe: 2 years

Interventionpercentage of participants (Number)
Oxaliplatin/Leucovorin/5-FU95.7

[back to top]

Overall Response Rate (ORR)

"ORR = complete response + partial response~Complete response - disappearance of all target and non-target lesions~Partial response - at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter" (NCT00515216)
Timeframe: 2 years

Interventionpercentage of participants (Number)
Oxaliplatin/Leucovorin/5-FU39.1

[back to top]

Genetic Polymorphisms That May Alter Treatment Outcomes (Stable Disease)

This outcome looks at what genotypes of the ERCC1 c.354C>T (rs11615) gene had stable disease. (NCT00515216)
Timeframe: 4 years

Interventionparticipants (Number)
C/CC/TT/T
Oxaliplatin/Leucovorin/5-FU182

[back to top]

Genetic Polymorphisms That May Alter Treatment Outcomes (Stable Disease)

This outcome looks at what genotypes of the ERCC2 c.2251A>C (rs13181) gene had stable disease. (NCT00515216)
Timeframe: 4 years

Interventionparticipants (Number)
A/AA/CC/C
Oxaliplatin/Leucovorin/5-FU362

[back to top]

Genetic Polymorphisms That May Alter Treatment Outcomes (Stable Disease)

This outcome looks at what genotypes of the MDR1 c.3435C>T (rs1045642) gene had stable disease. (NCT00515216)
Timeframe: 4 years

Interventionparticipants (Number)
C/CC/TT/T
Oxaliplatin/Leucovorin/5-FU164

[back to top]

6 Month Progression Free Survival (PFS)

"Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions, or similar definition as accurate and appropriate" (NCT00515411)
Timeframe: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months

Interventionpercentage of paticipants (Mean)
Arm A, - Modified DCF63
ARM B - Parent DCF With G-CSF53
Arm C - Modified DCF+ Trastuzumab73

[back to top]

Overall Survival

Overall survival measured in months (NCT00515411)
Timeframe: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 43 months

Interventionmonths (Median)
Arm A, - Modified DCF18.8
ARM B - Parent DCF With G-CSF12.6
Arm C - Modified DCF+ Trastuzumab24.9

[back to top]

Complete Pathologic Response Rate

"The complete pathologic response (path CR) rate after treatment calculated as the percentage of participants with path CR out of the total participants, where the path CR is defined as absence of tumor cells in the surgical specimen and all registered participants are used in the denominator for calculating the path CR rate.~Primary gastric carcinoma is not measurable by conventional criteria thus usual response criteria cannot be applied. The following criteria for response assessment applied: Pathologic Complete Response: Absence of tumor cells in the surgical specimen, 95% or more necrosis of the cancer; Complete Clinical Response: Absence of tumor on endoscopy, biopsy, cytology, or both." (NCT00525785)
Timeframe: Restaging and surgical resection at 4-6 weeks after completion of chemoradiotherapy, approximately at 16 weeks into treatment

Interventionpercentage of participants (Number)
5-Fluorouracil + Folinic Acid + Oxaliplatin14

[back to top]

All-cause Mortality

(NCT00537823)
Timeframe: 30 days following surgery

Interventionparticipants (Number)
Arm 1 - Wildtype0
Arm 2 K-Ras 12/13 Codon Mutation0

[back to top]

Postoperative Recurrence Patterns

Liver only vs distant disease (NCT00537823)
Timeframe: Up to 5 years

,
Interventionparticipants (Number)
Liver onlyDistant disease
Arm 1 - Wildtype01
Arm 2 K-Ras 12/13 Codon Mutation00

[back to top]

Nonalcoholic Steatohepatitis Score (0-3)

"NASH Scoring~Steatosis **<5% = 0~**5-33%=1~**>33-66%=2~**>66%=3~Lobular inflammation~**No foci=0~**<2 foci per x 200 field=1~**2-4 foci per x 200 field=2~**>4 foci per x 200 field=3~Hepatocellular ballooning **None=0 **Few balloon cells = 1 **Many cells/prominent ballooning=2" (NCT00537823)
Timeframe: Time of surgery (approximately 11-16 weeks)

,
Interventionparticipants (Number)
Not reported on pathology reportAborted surgeryScore 0
Arm 1 - Wildtype310
Arm 2 K-Ras 12/13 Codon Mutation001

[back to top]

Postoperative Complication Rate

Fraction of patients with any grade of complication I-V (NCT00537823)
Timeframe: 30 days following surgery

Interventionpercentage of participants (Number)
Arm 1 - Wildtype25
Arm 2 K-Ras 12/13 Codon Mutation0

[back to top]

Effect of Preoperative Chemotherapy on Tumor Size

Number of participants whose tumor size decreased from baseline to completion of preoperative chemotherapy. (NCT00537823)
Timeframe: Upon completion of neoadjuvant chemotherapy (approximately 2 months)

Interventionparticipants (Number)
Arm 1 - Wildtype4
Arm 2 K-Ras 12/13 Codon Mutation2

[back to top]

Major Postoperative Complication Rate

Fraction of patients with any complication grades IV and V (NCT00537823)
Timeframe: 30 days following surgery

Interventionpercentage of participants (Number)
Arm 1 - Wildtype25
Arm 2 K-Ras 12/13 Codon Mutation0

[back to top]

Change in Tumor Size From Pretreatment to Preoperative CT Scan

-Compare total longest diameter from baseline to preoperative CT scan. (NCT00537823)
Timeframe: Completion of neoadjuvant therapy (approximately 8 weeks)

Interventionpercentage of change of longest diameter (Median)
Arm 1 - Wildtype-23.8
Arm 2 K-Ras 12/13 Codon Mutation-14.3

[back to top]

Histologic Hepatic Toxicity at Surgery

(NCT00537823)
Timeframe: Time of surgery (approximately 11-16 weeks)

,
Interventionparticipants (Number)
Not reported on pathology reportMildAborted surgeryNone
Arm 1 - Wildtype1111
Arm 2 K-Ras 12/13 Codon Mutation0001

[back to top]

Progression-free Survival

Estimated using the product-limit method of Kaplan and Meier. Progression defined as a 50% increase or an increase of 10 cm^2 (whichever is smaller) in the sum of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, or clear worsening of any evaluable disease, or reappearance of any lesion that had disappeared, or appearance of any new lesion/site, or failure to return for evaluation due to death or deteriorating condition. Progression-free survival defined as from first day of treatment until the date of first documented progression or date of death from any cause, whichever came first. If failure has not occurred, failure time is censored at the time of last follow-up. (NCT00544414)
Timeframe: From date of initial treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 171 months

InterventionMonths (Median)
Treatment170.5

[back to top]

Overall Response

Complete response (CR): Complete disappearance of all measurable and evaluable disease. No new lesions. Partial response (PR): Greater than or equal 50% decrease under baseline in the sum of products of perpendicular diameters of all measurable lesions. No new lesions. All measurable and evaluable lesions and sites must be assessed using the same techniques as baseline. Overall Response (OR) = CR + PR. (NCT00544414)
Timeframe: 30 days after last course of treatment

InterventionParticipants (Count of Participants)
Treatment28

[back to top]

Describe FLT3 Protein Expression as a Molecular Mechanism of Primary Resistance to Lestaurtinib in Leukemic Blasts

Described via mean and standard deviation by group. (NCT00557193)
Timeframe: Sampled at the start of induction

InterventionqPCR fold expression ratio (Mean)
Arm A (Standard Risk MLL-G)1.25
Arm B (IR/HR MLL-R Chemotherapy)7.85
Arm C (IR/HR MLL-R Chemotherapy and Lestaurtinib)5.83

[back to top]

Describe in Vitro Sensitivity as a Molecular Mechanism of Acquired Resistance to Lestaurtinib in Leukemic Blasts

Described via means and standard deviations in samples which have acquired resistance to lestaurtinib (NCT00557193)
Timeframe: At relapse (up to 3 years)

InterventionProportion of cells that are viable (Mean)
Arm C (IR/HR MLL-R Chemotherapy and Lestaurtinib)0.69

[back to top]

Percent Probability for Event-free Survival (EFS) for Patients on Arm A

EFS time is defined as time from treatment assignment to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free. EFS is constructed using the Kaplan-Meier life table method with confidence interval based on standard errors computed using the method of Peto and Peto. (NCT00557193)
Timeframe: From start of post-induction therapy for up to 10 years

Interventionpercentage probability (Number)
Arm A (Standard Risk MLL-G)86.67

[back to top]

Percent Probability for Event-free Survival (EFS) for Patients on Arm C at Dose Level 2 (DL2)

EFS time is defined as time from randomization to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free. EFS is constructed using the Kaplan-Meier life table method with confidence interval based on standard errors computed using the method of Peto and Peto. (NCT00557193)
Timeframe: From start of post-induction therapy for up to 10 years

Interventionpercentage probability (Number)
Arm C (Safety/Efficacy Dose Level 2)35.82

[back to top]

Percent Probability for Event-free Survival (EFS) of MLL-R Infants Treated With Combination Chemotherapy With or Without Lestaurtinib at DL2

Event Free Probability where EFS time is defined as time from randomization to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free. EFS is constructed using the Kaplan-Meier life table method with confidence interval based on standard errors computed using the method of Peto and Peto. EFS will be compared between patients on treatment Arm C at DL2 to those on Arm B. (NCT00557193)
Timeframe: From start of post-induction therapy for up to 10 years.

Interventionpercent probability (Number)
Arm B (IR/HR MLL-R Chemotherapy)38.89
Arm C (IR/HR MLL-R Chemotherapy and Lestaurtinib)35.82

[back to top]

Percent Probability of Event Free Survival (EFS) by MRD Status and Treatment Arm

Three-year EFS estimates and 90% CI will be reported by treatment arm and end-induction MRD status. (NCT00557193)
Timeframe: 3 Years from end of Induction)

Interventionpercent probability (Number)
Arm A (MRD Negative)86.05
Arm A (MRD Positive)87.5
Arm B (MRD Negative)47.37
Arm B (MRD Positive)22.73
Arm C (MRD Negative)51.85
Arm C (MRD Positive)27.03

[back to top]

Pharmacodynamics PIA Levels in Infants Given Lestaurtinib at DL2 in Combination With Chemotherapy

Summarized with mean and standard deviation for those with available data in Arm C (NCT00557193)
Timeframe: Sampled between weeks 6-12 from start of induction

InterventionActivity percentage (Mean)
Arm C (Safety/Efficacy Dose Level 2)69.00

[back to top]

Describe FLT3 Protein Expression as a Molecular Mechanism of Acquired Resistance to Lestaurtinib in Leukemic Blasts

Described via means and standard deviations in available Arm C relapse samples (NCT00557193)
Timeframe: At relapse (up to 3 years)

InterventionqPCR fold expression ratio (Mean)
Arm C (Safety/Efficacy Dose Level 2)5.73

[back to top] [back to top]

Describe in Vitro Sensitivity as a Molecular Mechanism of Primary Resistance to Lestaurtinib in Leukemic Blasts

Described via means and standard deviations in samples which have primary resistance to lestaurtinib (NCT00557193)
Timeframe: Sampled at the start of induction

InterventionProportion of cells that are viable (Median)
Arm A (Standard Risk MLL-G)0.75
Arm B (IR/HR MLL-R Chemotherapy)0.48
Arm C (IR/HR MLL-R Chemotherapy and Lestaurtinib)0.47

[back to top]

Number of Participants With Adverse Events (AE)

"All AEs regardless of seriousness or relationship to study treatment, spanning from the first administration of study treatment until 30 days after the last administration of study treatment, were recorded, and followed until resolution or stabilization.~The number of participants with all treatment emergent adverse events (TEAE), serious adverse events (SAE), TEAE leading to death, and TEAE leading to permanent treatment discontinuation are reported." (NCT00561470)
Timeframe: From the date of the first randomization up to 30 days after the treatment discontinuation or until TEAE was resolved or stabilized

,
Interventionparticipants (Number)
Treatment-Emergent Adverse Event (TEAE)Serious TEAETEAE leading to DeathTEAE causing permanent treatment discontinuation
Aflibercept/FOLFIRI60629437164
Placebo/FOLFIRI5921982973

[back to top]

Progression-free Survival (PFS) Assessed by Independent Review Committee (IRC)

"PFS was the time interval from the date of randomization to the date of progression, or death from any cause if it occurs before tumor progression is documented. To evaluate disease progression, copies of all tumor imaging sets were systematically collected and assessed by the IRC.~PFS was analyzed using the Kaplan-Meier method, and the Hazard Ratio was estimated using the Cox Proportional Hazard Model.~The analysis for PFS was performed as planned when 561 deaths (OS events) had occurred." (NCT00561470)
Timeframe: From the date of the first randomization until the occurrence of 561 OS events, 06 May 2010 (approximately 30 months)

Interventionmonths (Median)
Placebo/FOLFIRI4.67
Aflibercept/FOLFIRI6.90

[back to top]

Overall Survival (OS)

"Overall Survival was the time interval from the date of randomization to the date of death due to any cause. Once disease progression was documented, participants were followed every 2 months for survival status, until death or until the study cutoff date, whichever came first. The final data cutoff date for the analysis of OS was the date when 863 deaths had occurred (07 February 2011).~OS was estimated using the Kaplan-Meier method, and the Hazard Ratio was estimated using the Cox Proportional Hazard Model." (NCT00561470)
Timeframe: From the date of the first randomization until the study data cut-off date, 07 February 2011 (approximately three years)

Interventionmonths (Median)
Placebo/FOLFIRI12.06
Aflibercept/FOLFIRI13.50

[back to top]

Overall Objective Response Rate (ORR) Based on the Tumor Assessment by the Independent Review Committee (IRC) as Per Response Evaluation Criteria in Solid Tumours (RECIST) Criteria

"The overall ORR was the percentage of evaluable participants who achieved complete response [CR] or partial response [PR] according to RECIST criteria version 1.0.~CR reflected the disappearance of all tumor lesions (with no new tumors)~PR reflected a pre-defined reduction in tumor burden~Tumors were assessed by the IRC using Computerized Tomography (CT) scans or Magnetic Resonance Imaging (MRI) scans; and an observed response was confirmed by repeated imaging after 4 - 6 weeks." (NCT00561470)
Timeframe: From the date of the first randomization until the study data cut-off date, 06 May 2010 (approximately 30 months)

Interventionpercentage of participants (Number)
Placebo/FOLFIRI11.1
Aflibercept/FOLFIRI19.8

[back to top]

Immunogenicity Assessment: Number of Participants With Positive Sample(s) in the Anti-drug Antibodies (ADA) Assay and in the Neutralizing Anti-drug Antibodies (NAb) Assay

Serum samples for immunogenicity assessment were analyzed using a bridging immunoassay to detect ADA. Positive samples in the ADA assay were further analyzed in the NAb assay using a validated, non-quantitative ligand binding assay. (NCT00561470)
Timeframe: Baseline, every other treatment cycle, 30 days and 90 days after the last infusion of aflibercept/placebo

,
Interventionparticipants (Number)
At least one positive sample in the ADA assayAt least one positive sample in the NAb assay
Aflibercept/FOLFIRI81
Placebo/FOLFIRI182

[back to top]

Down-staging of the Tumor; Response to Therapy

Down-staging of the tumor and tumor response rate is defined as the proportion of participant who have any evidence of complete response (CR), pathologic complete response (pCR), or partial response (PR). (NCT00580073)
Timeframe: 6 months

Interventionparticipants (Number)
PRpCRCR
FOLFOX4 + Cetuximab410

[back to top]

Progression Free Survival

Number of participants who achieve progression free survival, defined as the time from date of registration to date of disease progression, up through study closure. Progressive disease is defined as ≥ 20% increase in the sum of the longest dimensions of the primary lesion taking as a reference the smallest sum of the longest dimensions recorded since the treatment started, or the appearance of 1 or more new lesions. (NCT00580073)
Timeframe: Up to 3 years

Interventionparticipants (Number)
FOLFOX4 + Cetuximab5

[back to top]

Determine the Incidence of Complete and Partial Response and the Duration of Response in Patients With Langerhans Cell Histiocytosis (LCH) Treated With Sequential Administration of Oral 6-TG After MTX.

(NCT00588536)
Timeframe: Conclusion of the study

Interventionparticipants (Number)
Complete ResponseStable DiseaseProgression of Disease
MTX, 6-TG and Leucovorin212

[back to top]

Overall Response Rate of Previously-untreated Patients With Unresectable or Metastatic Adenocarcinomas of the Upper Gastrointestinal Tract When Treated With the Combination of 5-fluorouracil, Leucovorin, Oxaliplatin, and Erlotinib.

"Per response evaluation criteria in solid tumors criteria (RECIST) for target lesions and assessed by computerized tomography (CT) scan.~Complete Response (CR): Disappearance of all target lesions Partial Response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started Progressive Disease (PD): At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions" (NCT00591123)
Timeframe: 3.5 years

Interventionpercent of subjects that had response (Number)
FOLFOX Plus 5-FU and Erlotinib51.5

[back to top]

Toxicity of the Combination of FOLFOX, 5-FU, and Erlotinib

Adverse event assessment by investigators and as reported by subjects from time of consent to 30 days after last dose. Up to 3.5 years. (NCT00591123)
Timeframe: 3.5 years

Interventionparticipants (Number)
Diarrhea / dehydrationAnorexiaNausea/VomitingRashFatiguePeripheral neuropathyNeutropeniaNeutropenic FeverHypokalemiaAST / ALT Elevation
FOLFOX Plus 5-FU and Erlotinib9543435122

[back to top] [back to top]

Progression Free Survival

Overall Progression Free Survival at 2 years (NCT00594815)
Timeframe: 2 Years

Interventionpercentage of participants (Number)
Immunocompetent Pts With Newly Diagnosed Primary CNS Lymphoma57

[back to top]

Area Under Plasma Concentration-Time Profile From Time Zero to Twenty-Four Hours Postdose (AUC24) of Sunitinib

AUC24 = Area under the plasma concentration-time profile from time zero (pre-dose) to twenty-four hours. AUC24 was obtained by the Linear/Log trapezoidal method. (NCT00599924)
Timeframe: pre-dose, 1, 2, 4, 6, 8, 10, and 24 hours post-dose

,
Interventionng*hr/mL (Mean)
Cycle 1, Day 14Cycle 2, Day 1
37.5 mg Sunitinib + Modified FOLFOX6 (Schedule 2/2)985.43948.40
50 mg Sunitinib + Modified FOLFOX6 (Schedule 2/2)1233.731202.50

[back to top]

Steady State Clearance (CLss) of 5-FU

CLss was determined by total amount of drug received during infusion or duration of infusion (Ki) divided by Css. (NCT00599924)
Timeframe: pre-dose, 1h, 2h, 2 h 5 min, 2h 15 min, 2h 30 min, 2h 45 min, 4h, 6h, 8h, 10h, 24h, and 48h post-dose

,
InterventionL/hr (Mean)
Cycle 1, Day 1Cycle 2, Day 1
37.5 mg Sunitinib + Modified FOLFOX6 (Schedule 2/2)284.99174.51
50 mg Sunitinib + Modified FOLFOX6 (Schedule 2/2)312.63201.12

[back to top]

Steady State Concentration (Css) of Fluorouracil (5-FU)

Steady state is reached when the amount of drug getting into the system per unit time is equal to the amount of drug cleared from the system. (NCT00599924)
Timeframe: pre-dose, 1h, 2h, 2 h 5 min, 2h 15 min, 2h 30 min, 2h 45 min, 4h, 6h, 8h, 10h, 24h, and 48h post-dose

,
Interventionng/mL (Mean)
Cycle 1, Day 1Cycle 2, Day 1
37.5 mg Sunitinib + Modified FOLFOX6 (Schedule 2/2)567.52598.86
50 mg Sunitinib + Modified FOLFOX6 (Schedule 2/2)334.26647.32

[back to top]

T1/2 for Free Platinum

t1/2 = terminal phase half-life. t1/2 was obtained by ln2 divided by kel. Oxaliplatin was metabolized to platinum and free platinum was measured. (NCT00599924)
Timeframe: pre-dose, 1h, 2h, 2 h 5 min, 2h 15 min, 2h 30 min, 2h 45 min, 4h, 6h, 8h, 10h, 24h, and 48h post-dose

,
Interventionhours (Mean)
Cycle 1, Day 1Cycle 2, Day 1
37.5 mg Sunitinib + Modified FOLFOX6 (Schedule 2/2)16.1518.55
50 mg Sunitinib + Modified FOLFOX6 (Schedule 2/2)15.6031.20

[back to top]

Tmax of Free Platinum

Oxaliplatin was metabolized to platinum and free platinum was measured. (NCT00599924)
Timeframe: pre-dose, 1h, 2h, 2 h 5 min, 2h 15 min, 2h 30 min, 2h 45 min, 4h, 6h, 8h, 10h, 24h, and 48h post-dose

,
Interventionhours (Median)
Cycle 1, Day 1Cycle 2, Day 1
37.5 mg Sunitinib + Modified FOLFOX6 (Schedule 2/2)2.002.00
50 mg Sunitinib + Modified FOLFOX6 (Schedule 2/2)2.002.00

[back to top]

Tmax of SU-012662 (Sunitinib's Metabolite)

(NCT00599924)
Timeframe: pre-dose, 1, 2, 4, 6, 8, 10, and 24 hours post-dose

,
Interventionhours (Median)
Cycle 1, Day 14Cycle 2, Day 1
37.5 mg Sunitinib + Modified FOLFOX6 (Schedule 2/2)8.0015.00
50 mg Sunitinib + Modified FOLFOX6 (Schedule 2/2)10.004.00

[back to top]

Tmax of Total Platinum

Oxaliplatin was metabolized to platinum and total platinum was measured. (NCT00599924)
Timeframe: pre-dose, 1h, 2h, 2 h 5 min, 2h 15 min, 2h 30 min, 2h 45 min, 4h, 6h, 8h, 10h, 24h, and 48h post-dose

,
Interventionhours (Median)
Cycle 1, Day 1Cycle 2, Day 1
37.5 mg Sunitinib + Modified FOLFOX6 (Schedule 2/2)2.002.00
50 mg Sunitinib + Modified FOLFOX6 (Schedule 2/2)2.002.00

[back to top]

Area Under the Plasma Concentration-Time Profile From Time Zero to Forty-Eight Hours (AUC48) for Total Platinum

Oxaliplatin was metabolized to platinum and total platinum was measured. AUC48 = Area under the plasma concentration-time profile from time zero (pre-dose) to forty-eight hours. AUC48 was obtained by the Linear/Log trapezoidal method. (NCT00599924)
Timeframe: pre-dose, 1h, 2h, 2 h 5 min, 2h 15 min, 2h 30 min, 2h 45 min, 4h, 6h, 8h, 10h, 24h, and 48h post-dose

,
Interventionng*hr/mL (Mean)
Cycle 1, Day 1Cycle 2, Day 1
37.5 mg Sunitinib + Modified FOLFOX6 (Schedule 2/2)47264.0256813.62
50 mg Sunitinib + Modified FOLFOX6 (Schedule 2/2)43713.9551962.03

[back to top]

Time to Cmax (Tmax) of Sunitinib

(NCT00599924)
Timeframe: pre-dose, 1, 2, 4, 6, 8, 10, and 24 hours post-dose

,
Interventionhours (Median)
Cycle 1, Day 14Cycle 2, Day 1
37.5 mg Sunitinib + Modified FOLFOX6 (Schedule 2/2)8.007.00
50 mg Sunitinib + Modified FOLFOX6 (Schedule 2/2)10.008.00

[back to top]

Maximum Plasma Concentration (Cmax) of Sunitinib

(NCT00599924)
Timeframe: pre-dose, 1, 2, 4, 6, 8, 10, and 24 hours post-dose

,
Interventionng/mL (Mean)
Cycle 1, Day 14Cycle 2, Day 1
37.5 mg Sunitinib + Modified FOLFOX6 (Schedule 2/2)47.1344.95
50 mg Sunitinib + Modified FOLFOX6 (Schedule 2/2)61.3660.24

[back to top]

Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs)

All observed or volunteered AEs and SAEs regardless of treatment group or suspected causal relationship to the investigational product(s) were reported. (NCT00599924)
Timeframe: up to 20 weeks

,,,,,,
Interventionparticipants (Number)
AEsSAEs
25 mg Sunitinib + Modified FOLFOX6 (Continuous Dosing)84
37.5 mg Sunitinib + Modified FOLFOX6 (Continuous Dosing)62
37.5 mg Sunitinib + Modified FOLFOX6 (Schedule 2/2)40
37.5 mg Sunitinib + Modified FOLFOX6 (Schedule 4/2)127
50 mg Sunitinib + Modified FOLFOX6 (CRC Only, Schedule 2/2)50
50 mg Sunitinib + Modified FOLFOX6 (Schedule 2/2)94
50 mg Sunitinib + Modified FOLFOX6 (Schedule 4/2)93

[back to top]

Minimum Plasma Concentration (Cmin) of Sunitinib

(NCT00599924)
Timeframe: pre-dose, 1, 2, 4, 6, 8, 10, and 24 hours post-dose

,
Interventionng/mL (Mean)
Cycle 1, Day 14Cycle 2, Day 1
37.5 mg Sunitinib + Modified FOLFOX6 (Schedule 2/2)34.9530.28
50 mg Sunitinib + Modified FOLFOX6 (Schedule 2/2)38.2339.47

[back to top]

Cmin of SU-012662 (Sunitinib's Metabolite)

(NCT00599924)
Timeframe: pre-dose, 1, 2, 4, 6, 8, 10, and 24 hours post-dose

,
Interventionng/mL (Mean)
Cycle 1, Day 14Cycle 2, Day 1
37.5 mg Sunitinib + Modified FOLFOX6 (Schedule 2/2)14.4513.59
50 mg Sunitinib + Modified FOLFOX6 (Schedule 2/2)15.7017.68

[back to top]

Cmax of Total Platinum

Oxaliplatin was metabolized to platinum and total platinum was measured. (NCT00599924)
Timeframe: pre-dose, 1h, 2h, 2 h 5 min, 2h 15 min, 2h 30 min, 2h 45 min, 4h, 6h, 8h, 10h, 24h, and 48h post-dose

,
Interventionng/mL (Mean)
Cycle 1, Day 1Cycle 2, Day 1
37.5 mg Sunitinib + Modified FOLFOX6 (Schedule 2/2)2490.002905.00
50 mg Sunitinib + Modified FOLFOX6 (Schedule 2/2)2137.142641.43

[back to top]

Cmax of SU-012662 (Sunitinib's Metabolite)

(NCT00599924)
Timeframe: pre-dose, 1, 2, 4, 6, 8, 10, and 24 hours post-dose

,
Interventionng/mL (Mean)
Cycle 1, Day 14Cycle 2, Day 1
37.5 mg Sunitinib + Modified FOLFOX6 (Schedule 2/2)18.9518.75
50 mg Sunitinib + Modified FOLFOX6 (Schedule 2/2)22.8023.44

[back to top]

Cmax of Free Platinum

Oxaliplatin was metabolized to platinum and free platinum was measured. (NCT00599924)
Timeframe: pre-dose, 1h, 2h, 2 h 5 min, 2h 15 min, 2h 30 min, 2h 45 min, 4h, 6h, 8h, 10h, 24h, and 48h post-dose

,
Interventionng/mL (Mean)
Cycle 1, Day 1Cycle 2, Day 1
37.5 mg Sunitinib + Modified FOLFOX6 (Schedule 2/2)935.251043.75
50 mg Sunitinib + Modified FOLFOX6 (Schedule 2/2)634.00789.43

[back to top]

Clearance (CL/F) of Sunitinib

Drug clearance (CL/F) = dose divided by area under the plasma concentration-time profile from time zero to twenty-four hours. (NCT00599924)
Timeframe: pre-dose, 1, 2, 4, 6, 8, 10, and 24 hours post-dose

,
InterventionL/hr (Mean)
Cycle 1, Day 14Cycle 2, Day 1
37.5 mg Sunitinib + Modified FOLFOX6 (Schedule 2/2)41.1342.40
50 mg Sunitinib + Modified FOLFOX6 (Schedule 2/2)44.2949.44

[back to top]

AUC24 for SU-012662 (Sunitinib's Metabolite)

AUC24 = Area under the plasma concentration-time profile from time zero (pre-dose) to twenty-four hours. AUC24 was obtained by the Linear/Log trapezoidal method. (NCT00599924)
Timeframe: pre-dose, 1, 2, 4, 6, 8, 10, and 24 hours post-dose.

,
Interventionng*hr/mL (Mean)
Cycle 1, Day 14Cycle 2, Day 1
37.5 mg Sunitinib + Modified FOLFOX6 (Schedule 2/2)401.51395.82
50 mg Sunitinib + Modified FOLFOX6 (Schedule 2/2)468.79495.97

[back to top]

Area Under the Plasma Concentration-Time Profile From Time Zero to Infinity (AUCinf) for Free Platinum

Oxaliplatin was metabolized to platinum and free platinum was measured. AUCinf = Area under the plasma concentration-time profile from time zero (pre-dose) to infinity. AUCinf was obtained by the Linear/Log trapezoidal method. (NCT00599924)
Timeframe: pre-dose, 1h, 2h, 2 h 5 min, 2h 15 min, 2h 30 min, 2h 45 min, 4h, 6h, 8h, 10h, 24h, and 48h post-dose

,
Interventionng*hr/mL (Mean)
Cycle 1, Day 1Cycle 2, Day 1
37.5 mg Sunitinib + Modified FOLFOX6 (Schedule 2/2)7459.287942.64
50 mg Sunitinib + Modified FOLFOX6 (Schedule 2/2)6490.177092.65

[back to top]

Objective Response (OR)

From the start of treatment until disease progression/recurrence. OR=confirmed Complete Response (CR) or confirmed Partial Response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). CR = disappearance of all target lesions. CR was confirmed if it persisted on repeat imaging study ≥ 4 weeks after initial documentation of response. PR = ≥ 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. PR was confirmed if it persisted on repeat imaging study ≥ 4 weeks after initial documentation of response. (NCT00599924)
Timeframe: From start of treatment until Day 8 of Cycles 4 and 8 (2/2 Schedule), Day 8 of Cycles 3 and 6 (4/2 Schedule), and Day 1 of Cycles 3 and 7 (Continuous Dosing)

Interventionparticipants (Number)
37.5 mg Sunitinib + Modified FOLFOX6 (Schedule 2/2)0
50 mg Sunitinib + Modified FOLFOX6 (Schedule 2/2)2
50 mg Sunitinib + Modified FOLFOX6 (CRC Only, Schedule 2/2)0
37.5 mg Sunitinib + Modified FOLFOX6 (Schedule 4/2)0
50 mg Sunitinib + Modified FOLFOX6 (Schedule 4/2)0
37.5 mg Sunitinib + Modified FOLFOX6 (Continuous Dosing)0
25 mg Sunitinib + Modified FOLFOX6 (Continuous Dosing)2

[back to top]

Progression Free Survival (PFS)

PFS was defined as the time from randomization to the first observation of disease progression or death due to any cause. Progressive disease was determined using a modified version of Response Evaluation Criteria in Solid Tumor (RECIST) Assessment and was defined as at least a 20% increase in sum of longest diameter of target lesions. Time to disease progression was censored at the date of death if death was due to other cause. (NCT00612586)
Timeframe: Randomization to measured progressive disease or death up to 17.2 months

Interventionmonths (Median)
Enzastaurin + 5-FU/LV + Bev5.8
Placebo + 5FU/LV + Bev8.1

[back to top]

PFS From Start of First Line Therapy

PFS was defined as the time from first line therapy to the first observation of disease progression or death due to any cause. Progressive disease was determined using a modified version of RECIST Assessment and was defined as at least a 20% increase in sum of longest diameter of target lesions. Time to disease progression was censored at the date of death if death was due to other cause. (NCT00612586)
Timeframe: Start of first line therapy to measured progressive disease or death up to 24 months

Interventionmonths (Median)
Enzastaurin + 5-FU/LV + Bev8.9
Placebo + 5FU/LV + Bev11.3

[back to top]

Overall Survival (OS) From Start of First Line Therapy

OS was the duration from first line therapy to death due to any cause. For participants who are alive, OS is censored at the last contact. (NCT00612586)
Timeframe: Start of first line therapy (approximately 3 months prior to randomization) to date of death from any cause up to 27 months post randomization

Interventionmonths (Median)
Enzastaurin + 5-FU/LV + Bev20.0
Placebo + 5FU/LV + BevNA

[back to top]

Overall Survival (OS)

OS was the duration from enrollment to death due to any cause. For participants who are alive, OS is censored at the last contact. (NCT00612586)
Timeframe: Randomization up to 22.8 months

Interventionmonths (Median)
Enzastaurin + 5-FU/LV + BevNA
Placebo + 5FU/LV + BevNA

[back to top]

Number of Participants With Adverse Events (AEs)

A summary of serious and all other non-serious AEs is located in the Reported Adverse Event module. (NCT00612586)
Timeframe: Randomization up to 17.2 months

,
InterventionParticipants (Count of Participants)
Serious AEsOther Non-Serious AEs
Enzastaurin + 5-FU/LV + Bev1553
Placebo + 5FU/LV +Bev1152

[back to top]

Local-regional Failure: 4-year Rate

Local failure is defined as: (1) any recurrence or surgery to the primary site after a complete response (CR) reported at surgery or reported after the end of protocol treatment; or (2) persistence [failure at one day post study entry], absence of CR after protocol treatment was completed and patient lived at least 90 days from the end of treatment. Regional failure is defined as: (1) any recurrence after a nodal CR reported at surgery or reported after the end of protocol treatment; or (2) persistence, absence of nodal CR after protocol treatment was completed and patient lived at least 90 days from the end of treatment. Local-regional failure time is defined as time from registration to local or regional failure, last known follow-up (censored), or death (competing risk). Local-regional failure rates are estimated by the cumulative incidence method. (NCT00613080)
Timeframe: From registration to four years

Interventionpercentage of participants (Number)
IMRT + Chemotherapy , Resection, Postoperative Chemotherapy7.4

[back to top]

Number of Patients in Protocol Adherence Categories for Intensity-modulated Radiotherapy (IMRT) Planning

Real-time quality assurance was performed remotely by the study chair or the radiation oncology co-chair prior to initiation of treatment for the first 40 cases. The final cases enrolled were reviewed within 3 months after accrual was completed. Review included evaluation of clinical target volume (CTV) and planning target volume (PTV), Organs at Risk (OARs), and treatment plan dosimetry. (NCT00613080)
Timeframe: Pretreatment

InterventionParticipants (Count of Participants)
Tumor volume: Contouring score72417637Organs at risk: Contouring score72417637Tumor volume: Dose volume analysis score72417637Organs at risk: Dose volume analysis score72417637
Unacceptable variationPer ProtocolAcceptable variation
IMRT + Chemotherapy , Resection, Postoperative Chemotherapy58
IMRT + Chemotherapy , Resection, Postoperative Chemotherapy5
IMRT + Chemotherapy , Resection, Postoperative Chemotherapy62
IMRT + Chemotherapy , Resection, Postoperative Chemotherapy6
IMRT + Chemotherapy , Resection, Postoperative Chemotherapy0
IMRT + Chemotherapy , Resection, Postoperative Chemotherapy59
IMRT + Chemotherapy , Resection, Postoperative Chemotherapy8
IMRT + Chemotherapy , Resection, Postoperative Chemotherapy1
IMRT + Chemotherapy , Resection, Postoperative Chemotherapy48
IMRT + Chemotherapy , Resection, Postoperative Chemotherapy17
IMRT + Chemotherapy , Resection, Postoperative Chemotherapy3

[back to top]

Number of Patients With Pathologic Complete Response

Pathologic complete response is defined as no evidence of residual cancer histologically in the resection specimen. (NCT00613080)
Timeframe: At the time of surgery, which is 4-8 weeks after radiation therapy, approximately 9-13 weeks from treatment start.

InterventionParticipants (Count of Participants)
IMRT + Chemotherapy , Resection, Postoperative Chemotherapy10

[back to top]

Number of Patients Who Underwent Abdominoperineal Resection

All patients were to undergo surgery 4 to 8 weeks following the completion of radiation therapy. The choice of procedure (abdominoperineal resection (APR), low anterior resection (LAR), or LAR/coloanal anastomosis) was at the discretion of the surgeon. If more than 28 patients received abdominoperineal resection, this would result in a conclusion of an excessive number of abdominoperineal resections. (NCT00613080)
Timeframe: Surgery occurred 4 to 8 weeks following the completion of radiation therapy, approximately 9-13 weeks from start of treatment.

InterventionParticipants (Count of Participants)
IMRT + Chemotherapy , Resection, Postoperative Chemotherapy14

[back to top]

Distant Failure: 4-year Rate

Distant failure is defined as the appearance of peritoneal seeding or distant metastases. Time to distant failure is defined as time from registration to the date of distant failure, last known follow-up (censored), or death (competing risk). Distant failure rates are estimated by the cumulative incidence method. (NCT00613080)
Timeframe: From registration to four years

Interventionpercentage of participants (Number)
IMRT + Chemotherapy , Resection, Postoperative Chemotherapy29.7

[back to top]

Disease-free Survival: 4-year Rate

Disease is defined as local-regional failure or distant failure. Distant failure is defined as the appearance of peritoneal seeding or distant metastases. Local-regional failure is defined as: (1) any recurrence or surgery to the primary site after a complete response (CR) / any recurrence after a nodal CR - reported at surgery or reported after the end of protocol treatment; or (2) persistence [failure at one day post study entry], absence of primary/nodal CR after protocol treatment was completed and patient lived at least 90 days from the end of treatment. Disease-free survival time is defined as time from registration to the date of disease, death, or last known follow-up (censored). Disease-free survival rates are estimated using the Kaplan-Meier method. (NCT00613080)
Timeframe: From registration to four years

Interventionpercentage of participants (Number)
IMRT + Chemotherapy , Resection, Postoperative Chemotherapy60.6

[back to top] [back to top] [back to top]

Overall Survival: 4-year Rate

Overall survival time is defined as time from registration to the date of death from any cause. Overall survival rates are estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact. (NCT00613080)
Timeframe: From registration to four years

Interventionpercentage of participants (Number)
IMRT + Chemotherapy , Resection, Postoperative Chemotherapy82.9

[back to top]

Overall Survival (OS)

Time in months from the start of study treatment to date of death due to any cause. OS was calculated as (the death date minus the date of first dose of study medication plus 1) divided by 30.4. Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death). (NCT00615056)
Timeframe: Baseline until death or up to 1 year after the randomization of last participant

InterventionMonths (Median)
Axitinib + FOLFIRI12.9
Bevacizumab + FOLFIRI15.7
Axitinib + FOLFOX17.1
Bevacizumab + FOLFOX14.1

[back to top]

Duration of Response (DR)

Time in months from the first documentation of objective tumor response to objective tumor progression or death due to any cause. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 30.4. DR was calculated for the subgroup of participants with a confirmed objective tumor response. (NCT00615056)
Timeframe: Baseline until disease progression or discontinuation from the study due to any cause, assessed every 8 weeks up to 130 weeks

InterventionMonths (Median)
Axitinib + FOLFIRI7.52
Bevacizumab + FOLFIRI12.29
Axitinib + FOLFOX10.15
Bevacizumab + FOLFOX10.94

[back to top]

Change From Baseline in MDASI-D Symptom Interference Score at Day 1 of Cycles 2-5, Day 1 of Every Odd-numbered Cycle Throughout the Study and End of Treatment (Cycle 65) or Withdrawal

Symptom Interference score is comprised of the average of 6 items on feeling or function from the MDASI-D core (general activity, mood, work, relations with others, walking, and enjoyment of life) and ranges from 0 to 10. Participants were asked to rate how much symptoms have interfered in last week; each item rated from 0 to 10, with 0 = did not interfere and 10 = interfered completely. Lower scores indicated better outcome. Total average score range: 0 to 10. (NCT00615056)
Timeframe: Baseline, Day 1 of cycle 2-5, Day 1 of every odd-numbered cycle throughout the study and end of treatment (cycle 65) or withdrawal

,,,
InterventionUnits on a Scale (Mean)
Baseline (n=39,46,35,33)Change at Cycle 2/Day 1 (n=35, 39, 34, 28)Change at Cycle 3/Day 1 (n=36,36,33,26)Change at Cycle 4/Day 1 (n=29,37,32,25)Change at Cycle 5/Day 1 (n=28,29,24,24)Change at Cycle 7/Day 1 (n=26,30,22,20)Change at Cycle 9/Day 1 (n=18,25,19,17)Change at Cycle 11/Day 1 (n=15,24,16,15)Change at Cycle 13/Day 1 (n=13,19,15,10)Change at Cycle 15/Day 1 (n=7,17,12,8)Change at Cycle 17/Day 1 (n=6,11,11,7)Change at Cycle 19/Day 1 (n=6,10,9,5)Change at Cycle 21/Day 1 (n=6,9,7,4)Change at Cycle 23/Day 1 (n=5,7,6,4)Change at Cycle 25/Day 1 (n=5,7,6,3)Change at Cycle 27/Day 1 (n=2,7,3,3)Change at Cycle 29/Day 1 (n=2,5,2,3)Change at Cycle 31/Day 1 (n=1,5,2,2)Change at Cycle 33/Day 1 (n=1,3,2,1)Change at Cycle 35/Day 1 (n=0,4,1,1 )Change at Cycle 37/Day 1 (n=0,4,0,1)Change at Cycle 39/Day 1 (n=0,2,0,1)Change at Cycle 41/Day 1 (n=0,2,0,1)Change at Cycle 43/Day 1 (n=0,1,0,1)Change at Cycle 45/Day 1 (n=0,0,0,1 )Change at Cycle 47/Day 1 (n=0,1,0,0)Change at Cycle 49/Day 1 (n=0,1,0,0)Change at Cycle 51/Day 1 (n=0,1,0,0)Change at Cycle 53/Day 1 (n=0,1,0,0)Change at Cycle 55/Day 1 (n=0,1,0,0)Change at Cycle 57/Day 1 (n=0,1,0,0)Change at Cycle 59/Day 1 (n=0,1,0,0)Change at Cycle 61/Day 1 (n=0,1,0,0)Change at Cycle 63/Day 1 (n=0,0,0,0)Change at Cycle 65/Day 1 (n=0,1,0,0)Change at end of treatment (n=21,29,26,21)
Axitinib + FOLFIRI2.10.81.30.81.00.71.11.01.12.32.42.11.72.21.61.63.24.54.5NANANANANANANANANANANANANANANANA1.3
Axitinib + FOLFOX2.40.10.30.20.80.40.60.81.3-0.10.70.30.40.9-0.6-1.6-1.3-0.1-0.8-1.2NANANANANANANANANANANANANANANA1.5
Bevacizumab + FOLFIRI1.70.90.3-0.20.40.40.30.30.70.90.70.81.0-0.30.50.90.0-0.5-0.2-0.3-0.4-0.3-0.2-0.3NA-0.2-0.3-0.3-0.2-0.30.0-0.20.0NA-0.21.0
Bevacizumab + FOLFOX2.8-0.5-0.20.50.30.00.3-0.20.71.32.12.42.11.41.41.31.31.20.33.31.32.01.51.82.5NANANANANANANANANANA1.2

[back to top]

Change From Baseline in MD Anderson Symptoms Inventory Diarrhea (MDASI-D) Symptom Severity Score at Day 1 of Cycles 2-5, Day 1 of Every Odd-numbered Cycle Throughout the Study and End of Treatment (Cycle 65) or Withdrawal

Symptom severity score is comprised of average of 14 MDASI-D core items (pain, fatigue, nausea, disturbed sleep, distress, shortness of breath, remembering things, lack of appetite, drowsiness, dry mouth, sadness, vomiting, numbness or tingling and diarrhea) and ranges from 0 to 10. Participants were asked to rate severity of each symptom at their worst in last week; each item rated from 0 to 10, with 0 = symptom not present and 10 = as bad as you can imagine. Lower scores indicated better outcome. Total average score range: 0 to 10. (NCT00615056)
Timeframe: Baseline, Day 1 of cycles 2- 5, Day 1 of every odd-numbered cycle throughout the study and end of treatment (cycle 65) or withdrawal

,,,
InterventionUnits on a Scale (Mean)
Baseline (n=39,46,35,33)Change at Cycle 2/Day 1 (n=35, 39, 34,28)Change at Cycle 3/Day 1 (n=36,36,33,26)Change at Cycle 4/Day 1 (n=29,37,32,25)Change at Cycle 5/Day 1 (n=28,29,24,24)Change at Cycle 7/Day 1 (n=26,31,22,20)Change at Cycle 9/Day 1 (n=19,26,19,17)Change at Cycle 11/Day 1 (n=15,24,16,15)Change at Cycle 13/Day 1 (n=13,19,15,10)Change at Cycle 15/Day 1 (n=7,17,12,8)Change at Cycle 17/Day 1 (n=6,11,11,7)Change at Cycle 19/Day 1 (n=6,10,9,5)Change at Cycle 21/Day 1 (n=6,9,7,4)Change at Cycle 23/Day 1 (n=5,7,6,4)Change at Cycle 25/Day 1 (n=5,7,6,3)Change at Cycle 27/Day 1 (n=2,7,3,3)Change at Cycle 29/Day 1 (n=2,5,2,3)Change at Cycle 31/Day 1 (n=1,5,2,2)Change at Cycle 33/Day 1 (n=1,3,2,1)Change at Cycle 35/Day 1 (n=0,4,1,1)Change at Cycle 37/Day 1 (n=0,4,0,1)Change at Cycle 39/Day 1 (n=0,2,0,1)Change at Cycle 41/Day 1 (n=0,2,0,1)Change at Cycle 43/Day 1 (n=0,1,0,1)Change at Cycle 45/Day 1 (n=0,0,0,1 )Change at Cycle 47/Day 1 (n=0,1,0,0)Change at Cycle 49/Day 1 (n=0,1,0,0)Change at Cycle 51/Day 1 (n=0,1,0,0)Change at Cycle 53/Day 1 (n=0,1,0,0)Change at Cycle 55/Day 1 (n=0,1,0,0)Change at Cycle 57/Day 1 (n=0,1,0,0)Change at Cycle 59/Day 1 (n=0,1,0,0)Change at Cycle 61/Day 1 (n=0,1,0,0)Change at Cycle 63/Day 1 (n=0,0,0,0)Change at Cycle 65/Day 1 (n=0,1,0,0)Change at end of treatment (n=21,29,27,22)
Axitinib + FOLFIRI2.10.60.80.80.50.71.11.01.00.82.01.31.12.62.22.32.84.95.0NANANANANANANANANANANANANANANANA0.7
Axitinib + FOLFOX1.90.70.30.50.90.60.61.00.90.50.90.80.90.40.20.3-0.8-0.3-0.80.4NANANANANANANANANANANANANANANA1.3
Bevacizumab + FOLFIRI1.80.50.20.00.10.0-0.20.10.10.20.40.50.5-0.30.10.4-0.2-0.4-0.6-0.4-0.5-0.4-0.3-0.4NA-0.4-0.5-0.4-0.4-0.3-0.3-0.3-0.2NA-0.40.5
Bevacizumab + FOLFOX2.00.00.20.50.40.20.80.10.81.01.71.41.61.01.01.10.90.90.52.41.01.01.42.02.2NANANANANANANANANANA0.9

[back to top]

Progression Free Survival (PFS)

"Time in months from start of study treatment to first documentation of objective tumor progression or death due to any cause. PFS was calculated as (first event date minus the date of first dose of study medication plus 1) divided by 30.4. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease [PD]), or from adverse event (AE) data (where the outcome was Death)." (NCT00615056)
Timeframe: Baseline until disease progression or discontinuation from the study due to any cause, assessed every 8 week up to 130 weeks

InterventionMonths (Median)
Axitinib + FOLFIRI5.72
Bevacizumab + FOLFIRI6.87
Axitinib + FOLFOX7.59
Bevacizumab + FOLFOX6.44

[back to top]

Percentage of Participants With Objective Response (OR)

Percentage of participants with objective response based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). CR are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. PR are those with at least 30 percent decrease in sum of the longest dimensions of target lesions taking as a reference the baseline sum longest dimensions, with non target lesions not increased or absent. (NCT00615056)
Timeframe: Baseline until disease progression or discontinuation from the study due to any cause, assessed every 8 weeks up to 130 weeks

InterventionPercentage of participants (Number)
Axitinib + FOLFIRI24.5
Bevacizumab + FOLFIRI23.5
Axitinib + FOLFOX19.4
Bevacizumab + FOLFOX20.0

[back to top]

Complete Response Rate

The complete response rate will be defined as the total number of patients who have defined complete response using study regimen (intensive induction therapy/progressive chemotherapy/stem cell rescue), divided by the number of patients entered in the trial using response-evaluable patients. (NCT00632827)
Timeframe: Up to 3 years

InterventionParticipants (Count of Participants)
Treatment Plan14

[back to top]

Median Time to Response

The time to response is measured from the time measurement criteria are met for complete response or partial response (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started) in months. (NCT00632827)
Timeframe: Up to 2 years

Interventionmonths (Median)
Treatment Plan3.0

[back to top]

Overall Survival Rate

Overall Survival will be defined the percentage of participants alive at median follow up of 25 months. If the patient is lost to follow-up, survival will be censored on the last date the patient was known to be alive. The analysis is expected to occur up to 60 months after the first patient is entered the trial. (NCT00632827)
Timeframe: Up to 5 years

Interventionpercentage of participants (Number)
Treatment Plan75

[back to top]

Progression Free Survival

Progression-Free Survival will be defined the percentage of participants alive and progression-free at median follow up of 25 months. Patients will be routinely followed for disease progression and those who die without a reported prior progression will be considered to have progressed on the day of their death. Patients who did not progress or die will be censored at the day of their last treatment assessment. Patients who have not received study regimen or did not have on-study treatment assessments will be censored on the day they entered the trial. Patients who receive chemotherapy for reasons other than documented progression of disease or clinical progression without documented progression will be censored on the earliest date of subsequent therapy (NCT00632827)
Timeframe: Up to 3 years

Interventionpercentage of partcipants (Number)
Treatment Plan65

[back to top]

Pharmacokinetics (PK) of Leucovorin

Geometric mean (6S)-leucovorin area under the plasma concentration vs. time curve from time 0 to the 3-hour time point. (NCT00634504)
Timeframe: 5 minutes, 30 minutes, 1 hour, 2 hours and 3 hours post-LV administration

Interventionmicromol x hour/L (Geometric Mean)
A (High-dose Methotrexate, Leucovorin, and Glucarpidase)6.43
B (High-dose Methotrexate and Leucovorin Without Glucarpidase)1.13

[back to top]

Second-line Progression Free Survival

Time to disease progression from start of second-line experimental regimen. Disease progression will be measured per Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT scan: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), >= 30% decrease in the sum of the longest diameter of target lesions; Progressive Disease (PD), >= 20% increase in the sum of the longest diameter of target lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease. (NCT00642746)
Timeframe: Upon completion of follow-up, for an average of 99 days following the initiation of study treatment.

InterventionDays (Median)
FOLFIRI With Erlotinib83
FOLFOX With Erlotinib125

[back to top]

Response Rates of Radiographically Measurable Disease

The primary outcome measure will be the response rates of radiographically measurable disease. Response rate of disease will be assessed per Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT scan: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), >= 30% decrease in the sum of the longest diameter of target lesions; Progressive Disease (PD), >= 20% increase in the sum of the longest diameter of target lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease. (NCT00642746)
Timeframe: Disease response assessed after every 2 Treatment Cycles, or around 8 weeks.

,
InterventionNumber of Patients (Number)
Best Outcome - Complete ResponseBest Outcome - Partial ResponseBest Outcome- Stable DiseaseBest Outcome - Progressive Disease
FOLFIRI With Erlotinib0154
FOLFOX With Erlotinib0010

[back to top]

Time to Second Progression (From Start of First-Line Regimen)

"Number of days from the initiation of first line treatment to first documented progression. Progression will be assessed per Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT scan: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), >= 30% decrease in the sum of the longest diameter of target lesions; Progressive Disease (PD), >= 20% increase in the sum of the longest diameter of target lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease.~Progression free survival (time to progression or death, whichever occurs first) is the same as time to progression as all of the patients in this trial progressed." (NCT00642746)
Timeframe: Documented by Follow-up CT scans following first line treatment, average of 225 days.

InterventionDays (Median)
FOLFIRI With Erlotinib83
FOLFOX With Erlotinib125

[back to top]

Toxic Death

The number of patients who experience death that is considered to be primarily attributable to complications of treatment. (NCT00653068)
Timeframe: During and after completion of study treatment up to 1 year after enrollment.

InterventionParticipants (Count of Participants)
Stratum I3
Stratum III1

[back to top]

Overall Survival (OS)

Estimated 4-year survival, where survival is calculated as the time from study enrollment to death from any cause or last follow-up alive whichever occurs first. Kaplan-Meier method is used for estimation. Patients alive at last contact are censored. (NCT00653068)
Timeframe: Up to 4 years after study enrollment

InterventionEstimated Probability (Number)
Stratum I0.3888
Stratum III0.5486

[back to top]

Non-hematological Toxicity Associated With Chemotherapy: Grade 3 or Higher During Protocol Therapy

Number of Participants with Nonhematological Toxicity Associated With Chemotherapy: Grade 3 or Higher During Protocol Therapy. (NCT00653068)
Timeframe: During protocol therapy up to 1 year after enrollment.

InterventionParticipants (Count of Participants)
AcidosisAcute kidney injuryApneaAdult respiratory distress syndromeAspirationAtelectasisCatheter related infectionCentral nervous system necrosisDehydrationDiarrheaDissmeminated intravascular coagulation (DIC)EnterocolitisFebrile neutropeniaHearing impairmentHematuriaHydrocephalusHypernatremiaHypoalbuminemiaHypocalcemiaHypoglycemiaHypokalemiaHyponatremiaHypophosphatemiaHypotensionHypoxiaIncreased Alanine aminotransferaseIncreased Aspartate aminotransferaseIncreased LipaseIntracranial hemorrhagentraoperative venous injuryLaryngospasmLeft ventricular systolic dysfunctionLung infectionMulti-organ failureMucositis oralPoisoning and procedural complicationsOther gastrointestinal disordersOther infectionPneumonitisProductive coughPulmonary edemaRecurrent laryngeal nerve palsyRenal calculiRespiratory failureSeizureSepsisSinus tachycardiaStridorUpper respiratory infectionVascular access complicationVoice alterationVomitingWeight loss
All Patients11213121111161111132922465412111313117211113262211111

[back to top]

Event-free Survival

Estimated 4-year EFS where EFS is calculated as the time from study enrollment to disease progression, disease relapse, occurrence of a second malignant neoplasm, death from any cause or last follow-up whichever occurs first. Kaplan-Meier method is used for estimation. Patients without an event are censored at last contact. (NCT00653068)
Timeframe: Up to 4 years after study enrollment

InterventionEstimated probability (Number)
Stratum I0.3401
Stratum III0.4500

[back to top]

Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Measurable Concentration (AUC Last) and Area Under the Plasma Concentration Versus Time Curve From Time 0 to Infinity (AUC ∞) of Irinotecan

"AUC last of irinotecan and its metabolite SN-38 were calculated using the Linear/Log trapezoidal method.~AUC∞ of irinotecan was calculated using following equation; AUC last+(C*t/kel), where Ct* is the estimated concentration at the time of the last quantifiable concentration, kel is terminal phase rate constant that is estimated as the absolute value of the slope of a linear regression during the terminal phase of the natural-logarithm (ln) transformed concentration-time profile." (NCT00668863)
Timeframe: Cycle 1 Day 15

Interventionng.h/mL (Mean)
Irinotecan AUC lastIrinotecan AUC ∞SN-38 AUC last
Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI1310013800274

[back to top]

Maximum Observed Plasma Concentration (Cmax) and Predose Concentration (Ctrough) of Sunitinib.

Plasma concentrations were assessed at predose, 2, 4, 6, 8, and 24 hours postdose and Cmax and Ctrough of sunitinib, its metabolite SU012662, and the total (sunitinib + SU0122662) were determined. (NCT00668863)
Timeframe: Cycle 1 Day 15

Interventionng/mL (Mean)
Sunitinib CmaxSunitinib CtroughSU012662 CmaxSU012662 CtroughTotal (sunitinib + SU0122662) CmaxTotal (sunitinib + SU0122662) Ctrough
Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI54.341.815.811.370.053.1

[back to top]

Area Under the Plasma Concentration Versus Time Curve From Time 0 to 24 Hours Postdose (AUC 0-24) of Sunitinib

AUC 0-24 was determined using the Linear/Log trapezoidal method. (NCT00668863)
Timeframe: Cycle 1 Day 15

Interventionng.h/mL (Mean)
Sunitinib AUC 0-24SU012662 AUC 0-24Total (sunitinib + SU0122662) AUC 0-24
Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI11613461507

[back to top]

Volume of Distribution at Steady State (Vss) of Irinotecan

Vss was calculated using following equation: CL x mean residence time (MRT), where MRT = the area under the first moment curve from zero time to infinity (AUMC 0-∞)/AUC 0-∞- (infusion time/2), AUMC 0-∞ = the area under the first moment curve from zero time to time t (AUMC t)+ ((t x Ct*)/ kel) + (Ct* / kel^2), AUMC t is calculated using the linear trapezoidal method. (NCT00668863)
Timeframe: Cycle 1 Day 15

InterventionL (Mean)
Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI160

[back to top]

Terminal Phase Elimination Half-life (t1/2) of Irinotecan

Terminal phase half-life of irinotecan was calculated as ln 2/ kel. (NCT00668863)
Timeframe: Cycle 1 Day 15

Interventionhours (Mean)
Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI5.36

[back to top]

Time to Reach Maximum Plasma Concentration (Tmax) of Sunitinib

(NCT00668863)
Timeframe: Cycle 1 Day 15

Interventionhours (Mean)
Sunitinib TmaxSU012662 TmaxTotal (sunitinib + SU0122662) Tmax
Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI646

[back to top]

Maximum Observed Plasma Concentration (Cmax) of Irinotecan

Plasma samples were assessed at prior to initiation of irinotecan (and l-leucovorin) infusion, 1, 2 (predose for 5-FU bolus), 4, 8, and 24 hours after initiation of irinotecan infusion, and Cmax of irinotecan and its metabolite SN-38 were determined. (NCT00668863)
Timeframe: Cycle 1 Day 15

Interventionng/mL (Mean)
Irinotecan CmaxSN-38 Cmax
Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI196325.1

[back to top]

Time to Reach Maximum Plasma Concentration (Tmax) of Irinotecan

(NCT00668863)
Timeframe: Cycle 1 Day 15

Interventionhours (Mean)
Irinotecan tmaxSN-38 tmax
Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI24

[back to top]

Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and Grade 3 or Higher Adverse Events According to Common Terminology Criteria (CTCAE).

Any untoward medical occurrence in a patient who received study drug was considered an adverse event (AE), without regard to possibility of causal relationship. Treatment-emergent adverse events (TEAE): those which occurred or worsened after baseline. An adverse event resulting in any of the following outcomes, or deemed to be significant for any other reason, was considered to be a serious adverse event (SAE): death; initial or prolonged inpatient hospitalization; a life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. (NCT00668863)
Timeframe: Up to 11 cycles (1 cycle = 6 weeks)

InterventionParticipants (Number)
Treatment emergent adverse eventsSerious adverse eventsCTCAE grade 3 or 4 adverse eventsCTCAE grade 5 adverse events
Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI7132701

[back to top]

Apparent Oral Clearance (CL/F) of Sunitinib

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. (NCT00668863)
Timeframe: Cycle 1 Day 15

InterventionL/hour (Mean)
Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI32.9

[back to top]

Progression-Free Survival (PFS)

"PFS is defined as the time from the date of enrollment to the date of the first documentation of objective tumor progression or death due to any cause, whichever occurs first.~PFS data was censored on the day following the date of the last tumor assessment documenting absence of progressive disease for patients who 1) were given anti-tumor treatment other than the study treatment prior to observing objective tumor progression; 2) were removed from the study prior to documentation of objective tumor progression; and 3) were ongoing at the time of the analysis." (NCT00668863)
Timeframe: Up to 11 cycles (1 cycle = 6 weeks)

Interventionweeks (Median)
Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI28.9

[back to top]

Plasma Concentration at Steady State (Css) of 5-FU

Concentration at 22 hour post start of 5-FU infusion were to be used as Css if 5-FU concentrations suggested steady state at 22 hours time point. (NCT00668863)
Timeframe: Cycle 1 Day 15

Interventionng/mL (Mean)
Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI650

[back to top]

Percentage of Participants Who Presented Objective Response: Objective Response Rate (ORR)

ORR is defined as the percentage of participants with best overall response of either a confirmed complete (CR) or partial response (PR) relative to the number of participants in FAS. Based on the response evaluation criteria in solid tumors (RECIST), CR is defined as the disappearance of all target lesions and PR is defined as a greater than or equal to 30% decrease in the sum of the longest dimensions of the target lesion. (NCT00668863)
Timeframe: Up to 11 cycles (1 cycle = 6 weeks)

Interventionpercentage of participants (Median)
Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI36.6

[back to top]

Duration of Response (DR)

DR is defined as the time from the first objective documentation of complete or partial response that is subsequently confirmed to the first documentation of disease progression or to death due to any cause, whichever occurs first. The definition of censorship is the same as PFS. (NCT00668863)
Timeframe: Up to 11 cycles (1 cycle = 6 weeks)

Interventionweeks (Median)
Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI28.3

[back to top]

Clearance of Irinotecan

CL is calculated as dose divided by AUC 0-∞ (NCT00668863)
Timeframe: Cycle 1 Day 15

InterventionL/hour (Mean)
Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI23.0

[back to top]

Maximum Tolerated Dose (MTD)

"The MTD was defined as the dose below which one-third of at least 6 patients (2/6) experienced a dose limiting toxicity (DLT).~DLTs had to occur during cycle 1 of treatment and had to be considered related to PG-11047:~Any nonhematologic toxicity > Grade 3 lasting > 3 days~Grade 4 thrombocytopenia~Grade 4 Anemia on the next scheduled dosing day~Grade 4 Neutropenia (lasting > than 5 days~Any febrile neutropenia (Grade 3 or 4))~Inability to receive all scheduled doses of PG-11047 during the first dosing cycle due to drug related toxicity" (NCT00705874)
Timeframe: End of Study

Interventionmg (Number)
PG11047/GemcitabineNA
PG11047/DocetaxelNA
PG11047/Bevacizumab590
PG11047/Erlotinib590
PG11047/Cisplatin590
PG11047/5-Flurouracil590
PG11047/SunitinibNA

[back to top]

Percent of Patients MRD Positive (MRD > 0.01%) at End of Consolidation

A 1-sample Z-test of proportions (alpha=5%, 1-sided test) will be used. (NCT00720109)
Timeframe: At end of consolidation (at 11 weeks)

InterventionPercentage of participants (Number)
Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy)10.5
Standard-risk0
High-risk66.7

[back to top]

Overall EFS Rate for the Combined Cohort of Standard- and High-Risk Patients (Who Receive the Final Chosen Dose of Dasatinib)

An event is defined as: Induction failure, relapse at any site, secondary malignancy, or death. (NCT00720109)
Timeframe: From the time entry on study to first event or date of last follow-up, assessed up to 7 years

Interventionpercentage of patients (Number)
Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy)79.8
Standard-risk83.2
High-risk66.7

[back to top]

Feasibility and Toxicity of an Intensified Chemotherapeutic Regimen Incorporating Dasatinib for Treatment of Children and Adolescents With Ph+ ALL Assessed by Examining Adverse Events

Number of patients in safety cohort with dose limiting toxicity (DLT)(including treatment delay) (NCT00720109)
Timeframe: Weeks 3 through 23 of treatment (From week 3 Induction through Intensification Block 1)

InterventionPts with DLTs (Number)
Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy)1

[back to top]

Event-Free Survival (EFS) of Patients With Standard-risk Disease Treated With Dasatinib in Combination With Intensified Chemotherapy

Event-Free Survival (EFS) curves will be constructed using the Kaplan-Meier life table method with standard errors computed using the method of Peto and Peto. A 1-sided 95% confidence interval for EFS will be constructed. (NCT00720109)
Timeframe: At 3 years

InterventionPercent probability (Number)
Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy)79.8
Standard-risk83.2
High-risk66.7

[back to top]

Contribution of Dasatinib on Minimal Residual Disease (MRD) After Induction Therapy

Percent of patients MRD Positive (MRD > 0.01%) at End of Induction. (NCT00720109)
Timeframe: At the end of induction therapy (at 5 weeks)

InterventionPercentage of participants (Number)
Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy)40.7
Standard-risk29.2
High-risk100.0

[back to top]

Limiting Toxicity

"The occurrence of Limiting Toxicity defined as Any CTC AE version 4 Grade 3 and 4 non-hematologic toxicity thought to be possibly, probably or definitely related to zoledronic acid with the specific exclusion of:~Grade 3 nausea and vomiting controlled with adequate antiemetic prophylaxis.~Grade 3 transaminase (AST/ALT) that occurs during the evaluation period but resolves to ≤ Grade 2, before the planned dose of therapy after definitive surgery.~Grade 3 fever or infection.~Grade 3 or 4 hypocalcemia (see Section 5.1.1)~Grade 3 mucositis.~Grade 3 fatigue that returns to ≤ Grade 2, before the planned dose of therapy after definitive surgery.~Grade 3 joint range of motion, decreased or joint effusion that is related to the primary tumor." (NCT00742924)
Timeframe: Enrollment through the first 12 weeks of therapy.

Interventionparticipants (Number)
Arm 1- Chemotherapy and 1.2 mg/m2 Zoledronic Acid1
Arm 2 - Chemotherapy and 2.3 mg/m2 Zoledronic Acid1
Arm 3 - Chemotherapy and 3.5 mg/m2 Zoledronic Acid3
Chemotherapy and 2.3 mg/m2 Zoledronic Acid After MTD2

[back to top]

Overall Survival (OS) Time

OS is the delay between surgery and death (NCT00766142)
Timeframe: from surgery, up to five years.

Interventionmonths (Median)
Chemotherapy + Cetuximab41.5

[back to top]

30-day Mortality Rate

Rate of deaths observed within 30 days of surgery (NCT00766142)
Timeframe: from the date of surgery up to 30 days

InterventionParticipants (Count of Participants)
Chemotherapy + Cetuximab0

[back to top]

Mean Number of Adverse Events Per Patient, Within 30 Days of Surgery

(NCT00766142)
Timeframe: from the date of surgery up to 30 days

Interventionadverse events (Mean)
Chemotherapy + Cetuximab0.93

[back to top]

Median Progression-free Survival (PFS) Time

"Progression-free survival time is defined as the time from the date of surgery to the date of progression (as per RECIST v1.1) or death of any cause, whichever occurs first.~Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions." (NCT00766142)
Timeframe: Since surgery, up to 5 years

Interventionmonths (Median)
Chemotherapy + Cetuximab12.2

[back to top]

Percentage of Participants With a Confirmed Best Overall Response of Complete Response (CR) or Partial Response (PR) According to RECIST Version 1.0

Using RECIST version 1.0, participants were considered to have achieved CR upon the disappearance of all target and non-target lesions. Participants who achieved PR demonstrated at least a 30% decrease in the sum of the largest diameter of target lesions, taking as reference the Screening sum largest diameter. Responses were confirmed by repeat assessments no less than 4 weeks after criteria for response were first met. The collective percentage of participants with confirmed best overall response of CR or PR was calculated as [number of participants meeting RECIST criteria for CR or PR divided by the number of participants analyzed] multiplied by 100. Associated 95% confidence intervals were calculated for one-sample binomial using the Clopper-Pearson method. (NCT00778102)
Timeframe: Up to 5 years (at Screening; every 6 weeks, and within 4 weeks prior to surgery; 4 and 12 weeks after surgery; and at the end of Cycles 4 and 8 if assessed as R0 or R1, or every 6 weeks until progression or resectability if assessed as R2)

Interventionpercentage of participants (Number)
Bevacizumab + mFOLFOX-661.5
Bevacizumab + FOLFOXIRI80.5

[back to top]

Percentage of Participants Who Died

(NCT00778102)
Timeframe: Up to 5 years (prior to each cycle, and within 7 days prior to surgery; at time of surgery; 48 hours and 4 and 12 weeks after surgery; within 4 weeks after completion of treatment; every 3 to 6 months for 1 year; then annually)

Interventionpercentage of participants (Number)
Bevacizumab + mFOLFOX-648.7
Bevacizumab + FOLFOXIRI19.5

[back to top]

Percentage of Participants Experiencing Relapse Following Curative Resection

Among participants with curative resection (complete resection [R0] or microscopic residual tumor [R1]), relapse was defined as the first new occurrence of cancer or death. The percentage of participants who experienced relapse was calculated as [number of participants with a relapse event divided by the number of participants initially classified as R0 or R1 following resective surgery] multiplied by 100. (NCT00778102)
Timeframe: Up to 5 years (at time of surgery; 48 hours and 4 and 12 weeks after surgery; within 4 weeks after completion of treatment; every 3 to 6 months for 1 year; then annually)

Interventionpercentage of participants (Number)
Bevacizumab + mFOLFOX-676.9
Bevacizumab + FOLFOXIRI57.1

[back to top]

Percentage of Participants Experiencing Death or Disease Progression

PD was defined, using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0, as at least a 20% increase in the sum of the longest diameter of target lesions, or the appearance of one or more new lesions. The percentage of participants experiencing PD or death was calculated as [number of participants with event divided by the number of participants analyzed] multiplied by 100. (NCT00778102)
Timeframe: Up to 5 years (at Screening; every 6 weeks, and within 4 weeks prior to surgery; 4 and 12 weeks after surgery; and at the end of Cycles 4 and 8 if assessed as R0 or R1, or every 6 weeks until progression or resectability if assessed as R2)

Interventionpercentage of participants (Number)
Bevacizumab + mFOLFOX-689.7
Bevacizumab + FOLFOXIRI68.3

[back to top]

Overall Survival (OS)

OS was defined as the time from randomization to death from any cause. For participants without an event of death, OS was censored at the last-known alive date. OS was estimated by Kaplan-Meier analysis. (NCT00778102)
Timeframe: Up to 5 years (prior to each cycle, and within 7 days prior to surgery; at time of surgery; 48 hours and 4 and 12 weeks after surgery; within 4 weeks after completion of treatment; every 3 to 6 months for 1 year; then annually)

Interventionmonths (Median)
Bevacizumab + mFOLFOX-632.2
Bevacizumab + FOLFOXIRINA

[back to top]

Percentage of Participants With Complete Resection or Residual (Microscopic or Macroscopic) Tumor

Following resective surgery, participants were evaluated for complete resection (R0) or the presence of microscopic (R1) or macroscopic (R2) residual tumor. The percentage of participants within each residual tumor classification was calculated as [number of participants with R0, R1, and/or R2 divided by the total number of participants] multiplied by 100. Associated 95% confidence intervals were calculated for one-sample binomial using the Clopper-Pearson method. (NCT00778102)
Timeframe: Up to 5 years (at Screening; every 6 weeks, and within 4 weeks prior to surgery; and at time of/after surgery)

,
Interventionpercentage of participants (Number)
R0, R1, or R2R0 or R1R0
Bevacizumab + FOLFOXIRI61.051.248.8
Bevacizumab + mFOLFOX-648.733.323.1

[back to top]

Relapse-Free Survival (RFS)

RFS was defined as the time from curative resection (complete resection [R0] or microscopic residual tumor [R1]) to the date of first diagnosis of relapse. For participants with curative resection and without relapse, RFS was censored at the last known relapse-free assessment. RFS was estimated by Kaplan-Meier analysis. (NCT00778102)
Timeframe: Up to 5 years (at time of surgery; 48 hours and 4 and 12 weeks after surgery; within 4 weeks after completion of treatment; every 3 to 6 months for 1 year; then annually)

Interventionmonths (Median)
Bevacizumab + mFOLFOX-68.1
Bevacizumab + FOLFOXIRI17.1

[back to top]

Percentage of Participants With Histopathological Response

At the time of resective surgery, participants were evaluated for histopathological response as defined through pathologist review of the resected metastatic lesions, including assessment of margin status and tumor cell viability. Histopathological response classification was based upon the percentage of viable tumor cells, where 'Complete response' was considered for those with 0 percent (%) viable tumor cells, 'Major response' for those with 1% to 49% viable tumor cells, 'Minor response' for 50% to 99% viable tumor cells, and 'No response' for 100% viable tumor cells. The response could not be determined in some cases and was documented as 'Unknown.' The percentage of participants within each response category was calculated as [number of participants with a given response divided by the number of participants who completed the assessment] multiplied by 100. (NCT00778102)
Timeframe: Up to 5 years (at Screening; every 6 weeks, and within 4 weeks prior to surgery; and at time of/after surgery)

,
Interventionpercentage of participants (Number)
Complete responseMajor responseMinor responseNo responseUnknown
Bevacizumab + FOLFOXIRI4.847.633.3014.3
Bevacizumab + mFOLFOX-6057.128.6014.3

[back to top] [back to top] [back to top]

Time to Response

Time to response according to RECIST version 1.0 was defined as the time from randomization to the date of first documented CR or PR. Participants were considered to have achieved CR upon the disappearance of all target and non-target lesions. Participants who achieved PR demonstrated at least a 30% decrease in the sum of the largest diameter of target lesions, taking as reference the Screening sum largest diameter. Responses were confirmed by repeat assessments no less than 4 weeks after criteria for response were first met. For participants who did not complete a confirmatory tumor assessment, time to response was censored at the date of last tumor assessment, or if unavailable, at the date of first dose. Time to response was estimated by Kaplan-Meier analysis. (NCT00778102)
Timeframe: Up to 5 years (at Screening; every 6 weeks, and within 4 weeks prior to surgery; 4 and 12 weeks after surgery; and at the end of Cycles 4 and 8 if assessed as R0 or R1, or every 6 weeks until progression or resectability if assessed as R2)

Interventionmonths (Median)
Bevacizumab + mFOLFOX-63.1
Bevacizumab + FOLFOXIRI3.1

[back to top]

Time to Resection

Time to resection was defined as the time from randomization to the date of first resective surgery. For participants who did not undergo resective surgery, time to resection was censored at Day 1. Time to resection was estimated by Kaplan-Meier analysis. (NCT00778102)
Timeframe: Up to 5 years (at Screening; prior to each cycle, and within 7 days prior to surgery; and at time of surgery)

Interventionmonths (Median)
Bevacizumab + mFOLFOX-64.4
Bevacizumab + FOLFOXIRI4.3

[back to top]

Progression-Free Survival (PFS)

PFS was defined, using RECIST version 1.0, as the time from randomization to the date of first documented PD or death from any cause. PD was defined as at least a 20% increase in the sum of the longest diameter of target lesions, or the appearance of one or more new lesions. For participants without documented PD or death, PFS was censored at the time of last tumor assessment. PFS was estimated by Kaplan-Meier analysis. (NCT00778102)
Timeframe: Up to 5 years (at Screening; every 6 weeks, and within 4 weeks prior to surgery; 4 and 12 weeks after surgery; and at the end of Cycles 4 and 8 if assessed as R0 or R1, or every 6 weeks until progression or resectability if assessed as R2)

Interventionmonths (Median)
Bevacizumab + mFOLFOX-611.5
Bevacizumab + FOLFOXIRI18.6

[back to top]

Percentage of Participants With Complete or Major Histopathological Response

At the time of resective surgery, participants were evaluated for histopathological response as defined through pathologist review of the resected metastatic lesions, including assessment of margin status and tumor cell viability. Histopathological response classification was based upon the percentage of viable tumor cells, as described previously. The collective percentage of participants assessed as having a complete or major response was calculated as [number of participants with complete or major response divided by the number of participants who completed the assessment] multiplied by 100. Associated 95% confidence intervals were calculated for one-sample binomial using the Clopper-Pearson method. (NCT00778102)
Timeframe: Up to 5 years (at Screening; every 6 weeks, and within 4 weeks prior to surgery; and at time of/after surgery)

Interventionpercentage of participants (Number)
Bevacizumab + mFOLFOX-657.1
Bevacizumab + FOLFOXIRI52.4

[back to top]

Time to Progression

Patients were censored if they did not progress, stopped particiaption due to an adverse event, or withdrew consent following the start of study treatment. Response was evaluated by Response Evaluation Criteria In Solid Tumors (RECIST) guidelines version 1.0. Per RECIST v1.0, Progressive Disease (PD) is defined as a measurable increase in smallest diameter of any target or non-target lesion, or the appearance of new lesions, since baseline. (NCT00786643)
Timeframe: From date of study treatment start until date of first documented progression or date of death from any cause, whichever came first, assessed up to 15 months

InterventionMonths (Median)
Stratum 15.5263
Stratum 23.9145

[back to top]

Best Response (BR)

BR is recorded from start of treatment until progressive disease (PD). Imaging was repeated by same technique after every 4 cycles of treatment. Response was evaluated per Response Evaluation Criteria In Solid Tumors (RECIST) guidelines version 1.0. Per RECIST v1.0 and CT scan: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of longest diameter of target lesions; Stable Disease (SD), neither sufficient shrinkage in sum of LD of target lesions to be PR nor increase of >=20%; PD, increase in existing lesions or new lesions. (NCT00786643)
Timeframe: After every 4 cycles of treatment (approximately every 56 days for up to about 280 days)

,
InterventionParticipants (Number)
Complete response (CR)Partial response (PR)Stable disease (SD)Progressive disease (PD)Not evaluable (NE)
Stratum 106761
Stratum 2031564

[back to top]

Early Response Rate (RR) (Stratum 1 Only)

Early RR evaluated in stratum 1 to see if bevacizumab (bev) would be added to GFL treatment (tx). Patients with stable disease (SD) pre 5th cycle of tx had bev added. Response was evaluated by Response Evaluation Criteria In Solid Tumors (RECIST) version 1.0. Per RECIST and CT scan: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), >=30% decrease in sum of longest diameter (LD) of target lesions; SD, neither sufficient shrinkage in sum of LD of target lesions to be PR nor increase of >=20%; Progressive Disease (PD), increase in existing lesions or new lesions. (NCT00786643)
Timeframe: After 4 cycles of treatment (approximately 56 days)

InterventionParticipants (Number)
Complete response (CR)Partial response (PR)Stable disease (SD)Progressive disease (PD)Not evaluable (NE)
Stratum 105762

[back to top]

Continuous Complete Remission (CCR) Rate

Will be testing using an exact binomial test (NCT00792948)
Timeframe: 18 months

Interventionpercentage of participants (Number)
Treatment57

[back to top]

Overall Survival (OS)

OS will be estimated using the method of Kaplan-Meier. (NCT00792948)
Timeframe: From the date of initial registration on the study until death from any cause, assessed up to 5 years

InterventionProbability of surviving 12 months (Number)
Treatment0.88

[back to top]

Relapse-free Survival (RFS) After Allogeneic Stem Cell Transplantation

Will be estimated using the method of Kaplan-Meier. (NCT00792948)
Timeframe: 12 months

InterventionProbability of 12-month RFS (Number)
Treatment0.83

[back to top]

Objective Clinical Response Rate (cRR). Measureable Lesions That Can be Accurately Measured in at Least One Dimension With Conventional Radiologic Techniques or Spiral CT.

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by PET/CT, CT scan, MRI or spiral CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Objective clinical Response Rate (cRR) = CR + PR during the 3 preoperative cycles, among the treated patients. (NCT00803647)
Timeframe: 8 months

Interventionpercentage of participants (Number)
Treatment85

[back to top]

Overall Survival (OS). Time From Study Entry Until Death From Any Cause.

The percentage of patients alive at 18 months. (NCT00803647)
Timeframe: 18 months

Interventionpercentage of participants (Number)
Treatment83.8

[back to top]

Recurrence-free Survival (RFS). Time From Study Entry Until First Recurrence.

(NCT00803647)
Timeframe: 2 years

Interventionmonths (Median)
Treatment13.3

[back to top]

Reported Adverse Events.

19 participants experienced at least one adverse event. There were a total of 95 adverse events reported. (Note: multiple occurrences of the same adverse event in one individual are counted only once.) Refer to the Adverse Events section for specifics. The Other Adverse Events section lists only those events occurring above 5% frequency. (NCT00803647)
Timeframe: 8 months

Interventionadverse events (Number)
Treatment95

[back to top]

The Percentage of Patients Who Had a Curative (R0) Liver Metastasectomy Following Protocol Treatment, i.e., Metastatic Disease That Can be Completely Resected and/or Ablated With no Postoperative Evidence of Residual Malignant Disease (R0 Resection).

(NCT00803647)
Timeframe: 8 months

Interventionpercentage of participants (Number)
Treatment75

[back to top]

Treatment Toxicity

Toxicity was assessed weekly during neoadjuvant chemotherapy and radiation therapy, bi-weekly during adjuvant FOLFOX therapy. (NCT00831181)
Timeframe: Weekly during chemoradiation treatment (3 months). Bi-weekly during adjuvant FOLFOX therapy (3.5 months).

Interventionpatients (Number)
Chemoradiation,Surgery, Chemotherapy16

[back to top]

Local Regional Control

subjects were followed for median of 22 months post-surgery (NCT00831181)
Timeframe: median follow-up 22 months post-TME

Interventionpatient (Number)
Chemoradiation,Surgery, Chemotherapy21

[back to top]

Number of Participants With Comparison of Preoperative Stage With Post-treatment Pathologic Stage

Thin-section high resolution pelvic MRI was used to image the tumor prior to chemoradiation and repeated prior to surgery, and then compared to post-treatment pathological stage. (NCT00831181)
Timeframe: Total mesorectal excision (TME) participants were evaluated at the time of surgical resection, 3 months after beginning of chemoradiation treatment.

Interventionpatient (Number)
Chemoradiation,Surgery, Chemotherapy13

[back to top]

Complete Resectability Rates

Complete resectability rates assessed by circumferential margin. (NCT00831181)
Timeframe: Total mesorectal excision (TME) participants were evaluated at the time of surgical resection, 3 months after beginning of chemoradiation treatment.

Interventionpatient (Number)
Chemoradiation,Surgery, Chemotherapy3

[back to top]

Overall Survival

(NCT00831181)
Timeframe: median follow-up 22 months

Interventionparticipants (Number)
Chemoradiation,Surgery, Chemotherapy21

[back to top]

Pathologic Response and Complete Response

"Pathologic Response and Complete Response to preoperative therapy will be determined at the time of surgical resection. All grossly visible areas of ulceration and/or induration with be measured and submitted for histological evaluation.~The unit of measure is the tumor response rate to preoperative chemoradiation.~Pathologic complete response (pCR) is defined as no evidence of invasive tumor cells on pathologic examination of the primary rectal cancer.~Tumor regression grade (TRG) will be quantitated into five grades:~TRG 1 (complete regression) -absence of residual cancer and fibrosis extending from the site of original tumor through the layers of the rectal wall.~TRG 2 characterized by the presence of rare residual cancer cells scattered through the fibrosis.~TRG 3 characterized by an increase in the number of residual cancer cells, but fibrosis still predominant.~TRG 4 -residual cancer outgrowing fibrosis. TRG 5 characterized by absence of regressive changes." (NCT00831181)
Timeframe: Total mesorectal excision (TME) participants were evaluated at the time of surgical resection, an average of 3.5 months

InterventionParticipants (Number)
Chemoradiation,Surgery, Chemotherapy3

[back to top]

Patterns of Disease Failure, Including Local Recurrence and Distant Metastasis Assessed by CT Scan

(NCT00831181)
Timeframe: median follow-up 22 months

Interventionpatients (Number)
Chemoradiation,Surgery, Chemotherapy2

[back to top]

Disease-free Survival

(NCT00831181)
Timeframe: median 22 months follow-up

Interventionparticipants (Number)
Chemoradiation,Surgery, Chemotherapy16

[back to top]

Area Under the Concentration-Time Curve From Time 0 to Infinity [AUC(0-∞)] of IMC-11F8 at Study Day 1 of Cycle 1

(NCT00835185)
Timeframe: Cycle 1 Day 1 predose, immediately after infusion, and 1, 2, 4, 24, 72, 96, 144, 168 and 236 hours postdose

Interventionmicrograms*hour/milliliter (µg*h/mL)] (Geometric Mean)
IMC-11F8 (Necitumumab) + mFOLFOX-639400

[back to top]

Clearance (CL) of IMC-11F8 at Study Day 1 of Cycle 1

CL is the volume of plasma (or blood) from which the drug is completely removed, or cleared, in a given time. (NCT00835185)
Timeframe: Cycle 1 Day 1 predose, immediately after infusion, and 1, 2, 4, 24, 72, 96, 144, 168 and 236 hours postdose

Interventionmilliliters/hour (mL/h) (Geometric Mean)
IMC-11F8 (Necitumumab) + mFOLFOX-620.3

[back to top]

Duration of Response

The duration of response was defined as the time from first confirmed CR or PR to the first time of PD or death due to any cause. CR, PR and PD were defined using RECIST v1.0 criteria. CR was defined as the disappearance of all target and non-target lesions; PR was defined as a ≥30% decrease in the sum of the LD of the target lesions, taking as reference the baseline sum of the LD; PD was defined as a ≥20% increase in the sum of LD of target lesions, taking as reference the smallest sum of the LD recorded since treatment started or the appearance of new lesions and/or unequivocal progression of existing nontarget lesions. Participants with CR or PR who had no PD or death at the time of the data inclusion cutoff, the duration of response was censored at their last contact. (NCT00835185)
Timeframe: Time of response to time of measured PD or death up to 30 months

Interventionmonths (Median)
IMC-11F8 (Necitumumab) + mFOLFOX-610.0

[back to top]

Half-Life (t1/2) of IMC-11F8 at Study Day 1 of Cycle 1

The t1/2 is the time measured for the plasma concentration of the drug to decrease by one half. (NCT00835185)
Timeframe: Cycle 1 Day 1 predose, immediately after infusion, and 1, 2, 4, 24, 72, 96, 144, 168 and 236 hours postdose

Interventionhours (h) (Geometric Mean)
IMC-11F8 (Necitumumab) + mFOLFOX-6142

[back to top]

Maximum Concentration (Cmax) of IMC-11F8 at Study Day 1 of Cycle 1

(NCT00835185)
Timeframe: Cycle 1 Day 1 predose, immediately after infusion, and 1, 2, 4, 24, 72, 96, 144, 168 and 236 hours postdose

Interventionmicrograms/milliliter (µg/mL) (Geometric Mean)
IMC-11F8 (Necitumumab) + mFOLFOX-6344

[back to top]

Overall Survival (OS)

OS was defined as the duration from the date of first dose to the date of death from any cause. OS was estimated by the Kaplan-Meier method. Participants who were alive at the time of the data inclusion cutoff or lost to follow-up, OS was censored at the last contact. (NCT00835185)
Timeframe: First dose to date of death from any cause up to 30 months

Interventionmonths (Median)
IMC-11F8 (Necitumumab) + mFOLFOX-622.5

[back to top]

Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response )

CR and PR defined using Response Evaluation Criteria In Solid Tumors (RECIST) version (v) 1.0 criteria. CR was defined as the disappearance of all target and non-target lesions and PR defined as a ≥30% decrease in the sum of the longest diameters (LD) of the target lesions, taking as reference the baseline sum of the LD. Percentage of participants was calculated as: (total number of participants with CR or PR from start of the treatment until disease progression or recurrence) / (total number of participants treated) * 100. (NCT00835185)
Timeframe: Up to 30 Months

Interventionpercentage of participants (Number)
IMC-11F8 (Necitumumab) + mFOLFOX-663.6

[back to top]

Number of Participants With Adverse Events (AEs), Serious AEs (SAEs) or Death

The number of participants who experienced AEs, SAEs or death during the study and within 30 days of last dose. A summary of SAEs and other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module. (NCT00835185)
Timeframe: First dose to end of treatment and 30-day post treatment follow-up up to 31 months

Interventionparticipants (Number)
AEsSAEsDeaths
IMC-11F8 (Necitumumab) + mFOLFOX-644163

[back to top]

Kirsten Rat Sarcoma (KRAS) Mutation Status

Tumor tissues collected prior to study drug administration were evaluated for the presence or absence of KRAS mutations by a retrospective analysis. (NCT00835185)
Timeframe: Baseline

Interventionparticipants (Number)
KRAS Mutation PositiveKRAS Mutation Negative
IMC-11F8 (Necitumumab) + mFOLFOX-6916

[back to top]

Volume of Distribution (Vss) of IMC-11F8 at Study Day 1 of Cycle 1

Vss is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug at steady-state. (NCT00835185)
Timeframe: Cycle 1 Day 1 predose, immediately after infusion, and 1, 2, 4, 24, 72, 96, 144, 168 and 236 hours postdose

Interventionmilliliters (mL) (Geometric Mean)
IMC-11F8 (Necitumumab) + mFOLFOX-63660

[back to top]

Serum Anti-IMC-11F8 Antibody Assessment (Immunogenicity)

A participant was considered to have an anti-IMC-11F8 response if there were 2 consecutive positive samples or if the final sample tested is positive. Participants with a baseline sample positive for anti-IMC-11F8 antibodies were considered unevaluable for immunogenicity. A sample was considered positive for IMC-11F8 antibodies if it exhibited a post-baseline treatment emergent antibody level that exceeded the upper 95% confidence interval of the mean determined from the normal anti-IMC 11F8 level found in healthy treatment-naïve individuals. (NCT00835185)
Timeframe: Baseline up to last day of treatment plus 45 days after last treatment (127 weeks)

Interventionparticipants (Number)
IMC-11F8 (Necitumumab) + mFOLFOX-64

[back to top]

Progression-Free Survival (PFS)

PFS was defined as the time from date of first dose to the first observation of disease progression or death due to any cause. Progressive disease (PD) was determined using RECIST v1.0 criteria. PD was defined as ≥20% increase in the sum of LD of target lesions, taking as reference the smallest sum of the LD recorded since treatment started or the appearance of new lesions and/or unequivocal progression of existing nontarget lesions. PFS was estimated by the Kaplan-Meier method. Participants who had no PD or death at the time of the data inclusion cutoff, PFS was censored at their last tumor assessment prior to the earliest of the following events: 2 or more missed visits, additional cancer treatment or the end of the follow-up period. (NCT00835185)
Timeframe: First dose to measured PD or death up to 30 months

Interventionmonths (Median)
IMC-11F8 (Necitumumab) + mFOLFOX-610.0

[back to top]

Immunogenicity of Intravenous (IV) Aflibercept

The antidrug antibody (ADA) assay was evaluated for participants receiving aflibercept. (NCT00851084)
Timeframe: Any time post baseline and 90 days after the last infusion of aflibercept, according to baseline status

,
Interventionparticipants (Number)
ADA Negative post-baselineADA Positive (drug specific) post-baselineADA Negative 90 days after last doseADA Positive 90 days after last dose
Negative or Missing1057450
Positive1211

[back to top]

Number of Participants With Treatment-emergent Adverse Events (TEAE)

Summary of treatment-emergent adverse events in the safety population. The National Cancer Institute Common Terminology Criteria for Adverse Event (NCI-CTCAE), version 3.0 was used in this study to grade the severity of AEs. (NCT00851084)
Timeframe: From the date of the first randomization up to 30 days after the treatment discontinuation or until TEAE was resolved or stabilized

,
Interventionparticipants (Number)
Treatment Emergent Adverse Event (TEAE)Grade 3-4 TEAETreatment emergent Serious Adverse Event (SAE)TEAE leading to deathPremature treatment discontinuationPermanent treatment discontinuation
mFOLFOX6 + Aflibercept1191085583437
mFOLFOX6 Only11587322NA26

[back to top]

Overall Objective Response Rate (ORR)

"Summary of overall objective response rate based on tumor assessment by the Independent Review Committee (IRC) as per Response Evaluation Criteria in Solid Tumours (RECIST) criteria. ORR was defined as the proportion of patients with confirmed Complete Response (CR) or confirmed Partial Response (PR) relative to the total number of patients in the analysis population.~Per RECIST v 1.0 target lesions evaluation and assessed by tumor imaging: Complete Response (CR): Disappearance of all target lesions; Partial Response (PR): >=30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD.~The study was not powered for comparison of ORR between the two arms (non-comparative, open-label study)." (NCT00851084)
Timeframe: From the date of the first randomization until the study data cut-off date, 14 April 2011 (approximately 26 months)

Interventionpercentage of participants (Number)
mFOLFOX6 Only45.9
mFOLFOX6 + Aflibercept49.1

[back to top]

Overall Survival (OS)

"Overall survival was defined as the time from the date of randomization to the date of death due to any cause. In absence of confirmation of death, survival time was censored at the earliest between the last date the patient was known to be alive and the study cutoff date.~The study was not powered for comparison of OS between the two arms (non-comparative, open-label study)." (NCT00851084)
Timeframe: From the date of the first randomization until the study data cut-off date, 14 April 2011 (approximately 26 months)

Interventionmonths (Median)
mFOLFOX6 Only22.31
mFOLFOX6 + Aflibercept19.45

[back to top]

Progression Free Survival (PFS)

"PFS was defined as the time from the date of randomization to the date of tumor progression or death from any cause, whichever occurred first. PFS was based on tumor assessment by the Independent Review Committee (IRC). PFS was estimated from Kaplan-Meier Curves.~The study was not powered for comparison of PFS between the two arms (non-comparative, open-label study).~Progression was defined using Response Evaluation Criteria In Solid Tumors (RECIST v1.0), as at least a 20 percent increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non target-lesions." (NCT00851084)
Timeframe: From the date of the first randomization until the study data cut-off date, 14 April 2011 (approximately 26 months)

InterventionMonths (Median)
mFOLFOX6 Only8.77
mFOLFOX6 + Aflibercept8.48

[back to top]

Progression Free Survival (PFS) Rate at 12 Months

PFS rate at 12 months was defined as the percentage of patients alive without disease progression at 12 months after randomization. The primary efficacy analysis was based on assessment by the Independent Review Committee (IRC). The study was not powered for comparison of PFS rate at 12 months between the two arms (non-comparative, open-label study). Progression was defined using Response Evaluation Criteria In Solid Tumors (RECIST v1.0), as at least a 20 percent increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non target-lesions. (NCT00851084)
Timeframe: 12 months

Interventionpercentage of participants (Number)
mFOLFOX6 Only21.2
mFOLFOX6 + Aflibercept25.8

[back to top] [back to top]

Duration of Response

The duration of response was defined as the time from first objective status assessment of complete response (CR) or partial response (PR) to the first time of progression or death as a result of any cause. CR or PR is classified by the investigators according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.0. CR is disappearance of all target and non-target lesions; PR is a ≥30% decrease in sum of longest diameter of target lesions without new lesion and progression of non-target lesion. (NCT00862784)
Timeframe: Time of response to time of measured progressive disease up to 22.2 months

Interventionmonths (Median)
IMC-1121B (Ramucirumab) + mFOLFOX-611.0

[back to top]

Serum Anti-IMC-1121B (Immunogenicity) at Day 1

Data presented are the number of participants with treatment emergent anti-IMC-112B antibodies. (NCT00862784)
Timeframe: Day 1 (Cycles 1, 5, 9, and 30-day follow-up)

Interventionparticipants (Number)
Cycle 1 (n=39)Cycle 5 (n=33)Cycle 9 (n=25)30-day Follow-up (n=17)
IMC-1121B (Ramucirumab) + mFOLFOX-60202

[back to top] [back to top]

Progression-Free Survival (PFS)

PFS was defined as the time from date of first dose to the first observation of progression of disease (PD) or death due to any cause. PD was determined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.0. PD is ≥20% increase in sum of longest diameter of target lesions and/or unequivocal progression of non-target lesion and/or new lesion. For participants who had no PD or death or had started new therapeutic anticancer treatment, PFS was censored at their last radiographic tumor assessment. (NCT00862784)
Timeframe: First dose to measured progressive disease or death due to any cause up to 28.1 months

Interventionmonths (Median)
IMC-1121B (Ramucirumab) + mFOLFOX-611.5

[back to top]

Percentage of Participants With Complete Response or Partial Response [Objective Response Rate (ORR)]

ORR is the percentage of participants with a confirmed complete response (CR) + partial response (PR), as classified by the investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.0. CR is disappearance of all target and non-target lesions; PR is a ≥30% decrease in sum of longest diameter of target lesions without new lesion and progression of non-target lesion. ORR is calculated as a total number of participants with CR or PR from the start of study treatment until disease progression or recurrence divided by the total number of participants treated, then multiplied by 100. (NCT00862784)
Timeframe: First dose to date of objective progressive disease up to 23.8 months

Interventionpercentage of participants (Number)
IMC-1121B (Ramucirumab) + mFOLFOX-658.3

[back to top]

Overall Survival (OS)

OS was defined as the time from first dose to the date of death due to any cause. For participants who were alive or were lost to follow-up, OS was censored on the last date the participant was known to be alive. (NCT00862784)
Timeframe: First dose to death due to any cause up to 28.1 months

Interventionmonths (Median)
IMC-1121B (Ramucirumab) + mFOLFOX-620.4

[back to top]

Percentage of Participants With Surgery

The surgery involving a radical rectal excision using the TME technique. (NCT00865189)
Timeframe: Arm A: approximately 28-31 weeks after initiation of treatment; Arm B: approximately 13-15 weeks after initiation of treatment

Interventionpercentage of participants (Number)
Arm A (Bevacizumab, Induction Chemotherapy, Chemoradiotherapy)91.3
Arm B (Bevacizumab, Chemoradiotherapy)97.8

[back to top]

Percentage of Participants With Tumor Sterilization Defined by ypT0-N0

Tumor sterilization was defined as the absence of residual tumor cells in the resected specimen including lymph nodes (ypT0-N0). The rate of sterilization of the tumoral specimen was assessed after surgery on the surgical specimen by local review. Analyses were performed for participants who have been operated as defined by the protocol (within the study and TME technique) and for all participants who have been operated. Reported is the percentage of participants with tumor sterilization. (NCT00865189)
Timeframe: After surgery (Arm A: approximately 28-31 weeks after initiation of treatment; Arm B: approximately 13-15 weeks after initiation of treatment)

Interventionpercentage of participants (Number)
Arm A (Bevacizumab, Induction Chemotherapy, Chemoradiotherapy)23.8
Arm B (Bevacizumab, Chemoradiotherapy)11.4

[back to top]

Percentage of Participants With Local and Distant Recurrences

The percentage of participants with a recurrence was described by type of recurrence (local and distant recurrence). (NCT00865189)
Timeframe: After surgery (Arm A: approximately 28-31 weeks after initiation of treatment; Arm B: approximately 13-15 weeks after initiation of treatment)

,
Interventionpercentage of participants (Number)
Local recurrenceDistant recurrence
Arm A (Bevacizumab, Induction Chemotherapy, Chemoradiotherapy)2.217.4
Arm B (Bevacizumab, Chemoradiotherapy)6.713.3

[back to top]

Percentage of Participants With Tumor Down-Staging (ypT0-pT2)

A participant with a downstaging was defined as a participant with T3 (T describes the size of the original [primary] tumor) at inclusion and T2 or T1 or T0 after surgery, or with N+ (N describes lymph nodes involvement) at inclusion and N- after surgery and if T is equal at inclusion and after surgery. The clinical tumor-node-metastasis (cTNM) classification was used at inclusion and the pathological staging tumor and nodes (ypTN) classification after surgery. Reported is the percentage of participants with tumor downstaging of the surgical specimen according to the local review and centralized review. (NCT00865189)
Timeframe: After surgery (Arm A: approximately 28-31 weeks after initiation of treatment; Arm B: approximately 13-15 weeks after initiation of treatment)

,
Interventionpercentage of participants (Number)
Downstaging, local review (n=41, 44)Downstaging, centralized review (n=39, 43)
Arm A (Bevacizumab, Induction Chemotherapy, Chemoradiotherapy)65.964.1
Arm B (Bevacizumab, Chemoradiotherapy)54.555.8

[back to top]

Number of Cycles of Radiotherapy

(NCT00865189)
Timeframe: Arm A: Week 16 to Week 23; Arm B: Week 1 to Week 7

Interventioncycles (Mean)
Arm A (Bevacizumab, Induction Chemotherapy, Chemoradiotherapy)4.5
Arm B (Bevacizumab, Chemoradiotherapy)5.0

[back to top]

Disease-Free Survival (DFS)

The DFS was defined as the time from the first treatment intake to disease recurrence assessed (second primary cancer, local or distant recurrence, distant metastases) or death from any cause. The DFS was analyzed using Kaplan-Meier method. (NCT00865189)
Timeframe: From first time of the treatment administration to the date of second cancer, local or regional recurrence, distant metastasis or death from any cause (up to approximately 6 years)

Interventionmonths (Median)
Arm A (Bevacizumab, Induction Chemotherapy, Chemoradiotherapy)68.3
Arm B (Bevacizumab, Chemoradiotherapy)NA

[back to top]

Number of Cycles of Chemotherapy

(NCT00865189)
Timeframe: Arm A: Week 16 to Week 23; Arm B: Week 1 to Week 7

Interventioncycles (Mean)
Arm A (Bevacizumab, Induction Chemotherapy, Chemoradiotherapy)4.4
Arm B (Bevacizumab, Chemoradiotherapy)4.8

[back to top]

Number of Cycles of Induction Chemotherapy

(NCT00865189)
Timeframe: 6 cycles (12 weeks; cycle length = 14 days)

Interventioncycles (Mean)
Arm A (Bevacizumab, Induction Chemotherapy, Chemoradiotherapy)5.8

[back to top]

Overall Survival

The overall survival was defined as the time from the first treatment intake to death from any cause. (NCT00865189)
Timeframe: From the first treatment administration to the date of death (up to approximately 6 years)

Interventionmonths (Median)
Arm A (Bevacizumab, Induction Chemotherapy, Chemoradiotherapy)NA
Arm B (Bevacizumab, Chemoradiotherapy)NA

[back to top]

Percentage of Participants Who Died

(NCT00865189)
Timeframe: Baseline up to approximately 6 years

Interventionpercentage of participants (Number)
Arm A (Bevacizumab, Induction Chemotherapy, Chemoradiotherapy)8.7
Arm B (Bevacizumab, Chemoradiotherapy)24.4

[back to top]

Percentage of Participants With Second Cancer, Local or Regional Recurrence, Distant Metastasis, or Death

(NCT00865189)
Timeframe: Baseline up to approximately 6 years

Interventionpercentage of participants (Number)
Arm A (Bevacizumab, Induction Chemotherapy, Chemoradiotherapy)30.4
Arm B (Bevacizumab, Chemoradiotherapy)33.3

[back to top]

Overall Response

Overall response of a subject was defined as the best tumor response (Complete Response (CR) or Partial Response (PR)) observed during trial period assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. CR was defined as disappearance of tumor lesions, PR was defined as a decrease of at least 30% in the sum of tumor lesion sizes. (NCT00865709)
Timeframe: From randomization of the first subject until 23 months later, assessed every 8 weeks.

Interventionparticipants (Number)
Sorafenib (Nexavar, BAY43-9006) + mFOLFOX645
Matching Placebo + mFOLFOX661

[back to top]

Overall Survival (OS)

Overall Survival (OS) was defined as the time from date of randomization to death due to any cause. Subjects still alive at the time of analysis were censored at their last date of last contact. (NCT00865709)
Timeframe: From randomization of the first subject until 33 months later.

Interventiondays (Median)
Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6535
Matching Placebo + mFOLFOX6552

[back to top]

Progression-Free Survival (PFS)

Progression-free Survival (PFS) was defined as the time from date of randomization to disease progression or death due to any cause, whichever occurred first. Subjects without progression or death at the time of analysis were censored at their last date of tumor evaluation. Disease progression was defined as an increase of at least 20% in the sum of tumor lesions sizes. (NCT00865709)
Timeframe: From randomization of the first subject until 23 months later, assessed every 8 weeks.

InterventionMonths (Median)
Sorafenib (Nexavar, BAY43-9006) + mFOLFOX69.1
Matching Placebo + mFOLFOX68.7

[back to top]

Time to Progression (TTP)

Time to progression (TTP) was defined as the time from date of randomization to disease progression. Subjects without progression at the time of analysis were censored at their last date of tumor evaluation. Disease progression was defined as an increase of at least 20% in the sum of tumor lesions sizes. (NCT00865709)
Timeframe: From randomization of the first subject until 23 months later, assessed every 8 weeks.

InterventionMonths (Median)
Sorafenib (Nexavar, BAY43-9006) + mFOLFOX69.2
Matching Placebo + mFOLFOX69.0

[back to top]

Duration of Response

Duration of Response was defined as the time from date of first response (Complete Response (CR) or Partial Response (PR)) to the date when Progressive Disease (PD) was first documented or to the date of death, whichever occurred first according to Response Evaluation Criteria in Solid Tumors (RECIST). Subjects still having CR or PR and alive at the time of analysis were censored at their last date of tumor evaluation. CR was defined as disappearance of tumor lesions, PR as a decrease of at least 30% and PD as an increase of at least 20% in the sum of tumor lesions sizes. (NCT00865709)
Timeframe: From randomization of the first subject until 23 months later, assessed every 8 weeks

Interventionmonths (Number)
Sorafenib (Nexavar, BAY43-9006) + mFOLFOX67.5
Matching Placebo + mFOLFOX66.7

[back to top]

Rate of Minimal Residual Disease (MRD) < 0.01% at End Block 3

Percentage of eligible and evaluable patients with MRD < 0.01% among those who had successful MRD determination at the end of Block 3. (NCT00873093)
Timeframe: End of Block 3 (Day 36 of Block 3) of re-induction therapy

InterventionPercentage of participants (Number)
Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs80
Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs63.6

[back to top]

Toxic Death Rate

The proportion of toxic death rate among all eligible patients. (NCT00873093)
Timeframe: 4 months

Interventionpercentage of participants (Number)
Overall2.1

[back to top]

Severe Adverse Events (SAE) Rate.

The proportion of SAE rate among all eligible patients (NCT00873093)
Timeframe: 4 months

Interventionpercentage of participants (Number)
Overall8.2

[back to top]

Second Complete Remission Rate at the End of Block 1 Reinduction Chemotherapy

The percentage of eligible and evaluable patients who have achieved complete response at the end Block 1 of re-induction therapy. (NCT00873093)
Timeframe: The outcome is measured the end of Block 1 (Day 36 of Block 1) of re-induction therapy.

InterventionPercentage of participants (Number)
Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs72.2
Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs63

[back to top]

Event Free Survival

Percentage of patients who were event free at 4 months (NCT00873093)
Timeframe: 4 months after enrollment

InterventionPercentage of participants (Number)
Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs68.5
Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs37.8

[back to top]

Rate of Minimal Residual Disease (MRD) < 0.01% at End Block 1

Percentage of eligible and evaluable patients with MRD < 0.01% among those who had successful MRD determination at the end of Block 1. (NCT00873093)
Timeframe: End of Block 1 (Day 36 of Block 1) of re-induction therapy

Interventionpercentage of participants (Number)
Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs35.4
Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs25

[back to top]

Rate of Minimal Residual Disease (MRD) < 0.01% at End Block 2

Percentage of eligible and evaluable patients with MRD < 0.01% among those who had successful MRD determination at the end of Block 2. (NCT00873093)
Timeframe: End of Block 2 (Day 36 of Block 2) of re-induction therapy

Interventionpercentage of participants (Number)
Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs66.7
Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs42.1

[back to top]

Tumor Response

Tumor response will be determined using Modified Response Evaluation Criteria in Solid Tumors (mRECIST). Response will classified as: Complete response - disappearance of all lesions; Partial response - at least 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum of longest diameter or 30% reduction of arterial enhancement; Progressive disease - at least 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest longest diameter recorded since start of treatment or appearance of one or more new lesions greater than 1cm in size; Stable disease - neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum longest diameter since start of treatment. (NCT00932438)
Timeframe: Months 2, 4 and 6

Interventionparticipants (Number)
LC Beads Loaded With Irinotecan and FOLFOX631
FOLFOX6 and Bevacizumab16

[back to top]

Number of Serious Adverse Events

Total number of serious adverse events that occurred in both Arms of the study. (NCT00932438)
Timeframe: First treatment through one year post treatment completion

InterventionSerious Adverse Event (Number)
Irinotecan Beads With FOLFOX649
FOLFOX6/Avastin Alone21

[back to top]

Completeness of Cytoreduction (CCR) Score

CCR is assessed by Sugarbaker's criteria. CCR-0 is no residual tumor. CCR-1 is no residual nodules greater than 2.5 mm in diameter, CCR-2 is no residual nodules greater than 25 mm, and CCR-3 is residual nodules greater than 25 mm. (NCT00941655)
Timeframe: Day 1

InterventionScores on a scale (Number)
Patient 1Patient 2Patient 3Patient 4Patient 5Patient 6Patient 7Patient 8
Surgery + HIPEC + Systemic Chemotherapy00020000

[back to top]

12 Months Disease Free Survival (DFS)

Participants who were alive and disease free at 12 months. DFS was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST). Complete response was disappearance of all target lesions. Partial response was at least a 30% decrease in target lesions. Progression was at least a 20% increase in target lesions and stable disease is neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease. (NCT00941655)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Surgery + HIPEC + Systemic Chemotherapy2
Systemic Chemotherapy Alone0

[back to top]

Overall Survival in Patients With Limited Metastatic Gastric Carcinoma: Arm I

Time between the first day of treatment and the date of death. (NCT00941655)
Timeframe: 12 weeks up to 3 years

InterventionMonths (Number)
Patient #1Patient #2Patient #4Patient #6Patient #7Patient #9Patient #11Patient #15
Surgery + HIPEC + Systemic Chemotherapy1911114145120

[back to top]

Median Blood Loss During Surgery

Blood loss during surgery is related to complexity of the operation and via that to the stage of disease (more tumor to be cytoreduced, more blood loss). (NCT00941655)
Timeframe: Day 1

Interventionml (Median)
Surgery + HIPEC + Systemic Chemotherapy650

[back to top]

Median Duration of Cytoreduction Surgery and Heated Intraperitoneal Chemotherapy (HIPEC)

Time it takes to perform this complex surgery and HIPEC to reduce tumor burden overall in this disease. (NCT00941655)
Timeframe: up to 12 hours

Interventionhours (Median)
Surgery + HIPEC + Systemic Chemotherapy10.1

[back to top]

Median Hospital Stay After Initial Surgery

Recuperation period following complex surgery for this disease. (NCT00941655)
Timeframe: 1-10 weeks

InterventionDays (Median)
Surgery + HIPEC + Systemic Chemotherapy17

[back to top]

Gillys Stage Before and After Surgery

Gillys stage measures the completeness of the cytoreduction and is recorded before and after surgery. It is used to classify disease burden and determine prognosis. Stage 0 is no macroscopic signs of disease, stage 1 is nodules >5mm in one part of the abdomen, stage 2 is nodules >5 mm throughout the abdomen, stage 3 is nodules 5mm to 2 cm, and stage 4 is nodules < 2 cm. (NCT00941655)
Timeframe: Day 1

InterventionStage (Number)
Patient 1 Before SurgeryPatient 1 After SurgeryPatient 2 Before SurgeryPatient 2 After SurgeryPatient 3 Before SurgeryPatient 3 After SurgeryPatient 4 Before SurgeryPatient 4 After SurgeryPatient 5 Before SurgeryPatient 5 After SurgeryPatient 6 Before SurgeryPatient 6 After SurgeryPatient 7 Before SurgeryPatient 7 After SurgeryPatient 8 Before SurgeryPaitent 8 After Surgery
Surgery + HIPEC + Systemic Chemotherapy0010003100001030

[back to top]

Number of Participants With Serious and Non-Serious Adverse Events

Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v3.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT00941655)
Timeframe: Date treatment consent signed to date off study, approximately, 40.5 months

InterventionParticipants (Count of Participants)
Surgery + HIPEC + Systemic Chemotherapy8
Systemic Chemotherapy Alone5

[back to top]

Overall Survival in Patients With Limited Metastatic Gastric Carcinoma: Arm II

Time between the first day of treatment and the date of death (NCT00941655)
Timeframe: 12 weeks up to 3 years

InterventionMonths (Number)
Patient #3Patient #5Patient #8Patient #10Patient #12Patient #13Patient #14
Systemic Chemotherapy Alone176100080

[back to top]

Response Rate

"Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI:~Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR." (NCT00942266)
Timeframe: Every 8 weeks; up to 100 weeks.

Interventionpercentage of participants (Number)
Arm I: Low-dose Vorinostat2.3
Arm II: High-dose Vorinostat100

[back to top]

Disease Control Rate (Stable Disease or Objective Response)

"Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI:~Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR." (NCT00942266)
Timeframe: At 2 months

Interventionpercentage of participants (Number)
Arm I: Low-dose Vorinostat53
Arm II: High-dose Vorinostat53

[back to top]

Vorinostat Pharmacokinetics

Blood samples (5 ml of blood each) will be collected in red-top vacutainers (no anticoagulant) at 0 (pre- vorinostat), 0.5, 1, 2, 3, 4, 6, and 8 hours after the vorinostat dose on the first day of 5-FU infusion on cycle 1 (day 2 of cycle 1). Mean area under the curve is presented with 95% CI. (NCT00942266)
Timeframe: day 2 (cycle 1)

Interventionhr∙μM (Mean)
Arm I: Low-dose Vorinostat12.6
Arm II: High-dose Vorinostat14.7

[back to top]

Toxicity

"Number of participants with an adverse event.~Please refer to the adverse event reporting for more detail." (NCT00942266)
Timeframe: Daily

Interventionparticipants (Number)
Arm I: Low-dose Vorinostat42
Arm II: High-dose Vorinostat15

[back to top]

Overall Survival

(NCT00942266)
Timeframe: Every 12 weeks

Interventionmonths (Median)
Arm I: Low-dose Vorinostat6.5
Arm II: High-dose Vorinostat6.7

[back to top]

Median Progression-free Survival

Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT00942266)
Timeframe: Every 8 weeks, up to 100 weeks.

Interventionmonths (Median)
Arm I: Low-dose Vorinostat2.4
Arm II: High-dose Vorinostat2.9

[back to top]

Fluorouracil Steady-state Pharmacokinetics

Blood samples will be collected for determination of plasma 5-FU steady state concentration at 6 hours after start of 5-FU continuous infusion. The mean per treatment arm are presented. (NCT00942266)
Timeframe: Day 1

Interventionng/ml (Mean)
Arm I: Low-dose Vorinostat389.4
Arm II: High-dose Vorinostat423.5

[back to top]

Part 1: Number of Participants Who Experienced One or More Adverse Events (AEs)

An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of study drug, whether or not considered related to this study drug. AEs may include the onset of new illness and the exacerbation of pre-existing conditions. (NCT00954512)
Timeframe: Up to ~30 days after the final dose of robatumumab (Up to ~14 months)

InterventionParticipants (Number)
Regimen A: FOLFIRI (± Cetuximab) + Robatumumab2
Regimen B: Carboplatin + Paclitaxel + Robatumumab3
Regimen D: Trastuzumab + Robatumumab2
Regimen E: mTor Inhibitor (Everolimus) + Robatumumab4
Regimen F: Gemcitabine (± Erlotinib) + Robatumumab4

[back to top]

Part 2: Number of Participants With Each Type of Response Evaluation Criteria in Solid Tumors (RECIST)-Determined Overall Best Response

Overall best response was determined by RECIST criteria. Types of overall response could be: Complete Response (CR), Partial Response (PR), Stable Disease (SD), Progressive Disease (PD), Not Assessable (NA) or Incomplete Response/Stable Disease (IR/SD). (NCT00954512)
Timeframe: Up to ~30 days after the final dose of robatumumab (Up to ~14 months)

,,,,
InterventionParticipants (Number)
Complete Response (CR)Partial Response (PR)Stable Disease (SD)Progressive Disease (PD)Not Assessable (NA)Incomplete Response/Stable Disease (IR/SD)
Regimen A: FOLFIRI (± Cetuximab) + Robatumumab000200
Regimen B: Carboplatin + Paclitaxel + Robatumumab002100
Regimen D: Trastuzumab + Robatumumab001100
Regimen E: mTor Inhibitor (Everolimus) + Robatumumab002100
Regimen F: Gemcitabine (± Erlotinib) + Robatumumab001100

[back to top]

Objective Response Rate

"Number of Participants with Partial Response (PR), Stable Disease (SD), Progression of Disease (POD) Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI and/or CT: Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for a Partial Response nor sufficient increase to qualify for Progression of Disease (POD); POD, 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions" (NCT00957905)
Timeframe: Within 3 courses of treatment

,
Interventionparticipants (Number)
Partial ResponseStable DiseaseProgression of Disease
Part A (Alvocidib and Oxaliplatin)025
Part B (Alvocidib and FOLFOX)6109

[back to top]

Best Overall Response and Objective Response Rate Following Administration of CS-7017 in Combination With Irinotecan, Leucovorin, and 5-Fluorouracil (FOLFIRI) After Failure of First-line Therapy in Treatment of Metastatic Colorectal Cancer

As per Response Evaluation Criteria for Solid Tumors v1.0, best overall response was characterized as confirmed complete response (CR) defined as disappearance of all target lesions, confirmed partial response (PR) defined as ≥30% decrease from baseline, stable disease (SD) defined as neither progressive disease (PD) nor PR, and PD defined as ≥20% increase from smallest sum of longest diameter recorded since treatment started. Objective response rate (ORR) was defined as CR + PR. If there is no tumor assessment after the first dose of study drug, the best overall response is classified as Inevaluable. (NCT00967616)
Timeframe: Baseline to approximately 3 years postdose

,
InterventionParticipants (Count of Participants)
Confirmed CRConfirmed PRObjective response (confirmed CR+PR)Stable diseaseProgressive diseaseInevaluableBest overall response of SD or better
CS7017 + FOLFIRI010101881230
FOLFIRI0772910238

[back to top]

Percentage of Participants With Progression-Free Survival at 16 Weeks After Administration of CS-7017 Combined With Irinotecan, Leucovorin, and 5-Fluorouracil (5-FU) After Failure of First-line Therapy in Treatment of Metastatic Colorectal Cancer

Progression-free survival (PFS) was defined as the time from randomization until the first objective evidence of disease progression or death from any cause. (NCT00967616)
Timeframe: Baseline to 16 weeks postdose

Interventionpercentage of participants (Number)
FOLFIRI66.7
CS7017 + FOLFIRI59.7

[back to top]

Median Overall Progression-Free Survival: Sensitivity Analysis Including Clinical Progression After Administration of CS-7017 and Irinotecan, Leucovorin, and 5-Fluorouracil After Failure of First-line Therapy of Metastatic Colorectal Cancer

Progression-free survival (PFS) was defined as the time from randomization to the date of the first objective documentation of progressive disease (PD) or death resulting from any cause, whichever came first. The sensitivity analysis included clinical progression as an event. (NCT00967616)
Timeframe: Baseline to approximately 3 years postdose

Interventionmonths (Median)
FOLFIRI4.2
CS7017 + FOLFIRI4.4

[back to top]

Median Overall Progression-Free Survival Following Administration of CS-7017 in Combination With Irinotecan, Leucovorin, and 5-Fluorouracil (5-FU) (FOLFIRI) After Failure of First-line Therapy in Treatment of Metastatic Colorectal Cancer

Progression-free survival (PFS) was defined as the time from randomization until the first objective evidence of disease progression or death from any cause. (NCT00967616)
Timeframe: Baseline to approximately 3 years postdose

Interventionmonths (Median)
FOLFIRI4.2
CS7017 + FOLFIRI4.4

[back to top]

Treatment-Emergent Adverse Events Occurring in ≥10% of Participants Following Administration of CS-7017 Combined With Irinotecan, Leucovorin, and 5-Fluorouracil (FOLFIRI) After Failure of First-line Therapy in Treatment of Metastatic Colorectal Cancer

An adverse event (AE) >30 days after last dose of study drug was not included as a treatment-emergent adverse events (TEAE) unless considered related to treatment. (NCT00967616)
Timeframe: Baseline to 30 days post last dose, up to approximately 3 years

,
InterventionParticipants (Count of Participants)
Any TEAEBlood and Lymphatic System DisordersAnaemiaFebrile neutropeniaLeukopeniaNeutropeniaThrombocytopeniaEye DisordersGastrointestinal DisordersAbdominal painAbdominal pain upperAphthous stomatitisConstipationDiarrheaNauseaVomitingGeneral Disorders & Administration Site ConditionsAstheniaFace EdemaFatigueMucosal inflammationEdema peripheralPyrexiaInfections & InfestationsInfluenzaInjury, Poisoning, and Procedural ComplicationsInvestigationsWeight decreasedWeight increasedMetabolism and Nutrition DisordersDecreased appetiteDehydrationHypokalaemiaMusculoskeletal and Connective Tissue DisordersPain in extremityBack painNervous System DisordersDizzinessHeadachePsychiatric DisordersRenal and Urinary DisordersReproductive System and Breast DisordersRespiratory, Thoracic, and Mediastinal DisordersCoughDyspneaSkin and Subcutaneous Tissue DisordersAlopeciaVascular Disorders
CS7017 + FOLFIRI5042357113398492012133039244314915734102116286202817461263143511931956201010
FOLFIRI50241600102147176593336333922091375215416120312374184617531065175721118

[back to top]

Median Progression-free Survival (PFS)

PFS is defined as the time from randomization until objective tumor progression or death from any cause and is evaluated per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. (NCT00982592)
Timeframe: up to 4 years

Interventionmonths (Median)
Arm I (FOLFOX Regimen and Placebo)8.77
Arm II (FOLFOX Regimen and Vismodegib)8.35

[back to top]

Incidence of Toxicities (grades1 and 2)

Defined as percentage of patients who experienced a toxicity with grade 1 or 2 (worst grade) related to the protocol therapy. Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0. (NCT00982592)
Timeframe: Up to 4 years

,
Interventionpercentage of patients (Number)
Neuropathy (sensory)FatigueDiarrheaNauseaDysguesiaVomitingAnorexiaWeight lossLeukocytesAnemiaThrombocytopeniaHypoalbuminemiaHyperglycemiaElevated AST
Arm I (FOLFOX Regimen and Placebo)5654485416384130575157524129
Arm II (FOLFOX Regimen and Vismodegib)6273407142373529466056403746

[back to top]

Incidence of Toxicities (Grade 3 and Higher)

Defined as percentage of patients who experienced a toxicity with grade 3 or higher related to the protocol therapy. Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0 (NCT00982592)
Timeframe: Up to 4 years

,
Interventionpercentage of patients (Number)
Neuropathy (sensory)FatigueThrombosisNauseaHemorrhage_GIVomitingDehydrationNeutropeniaFebrile neutropeniaAnemiaThrombocytopeniaHypokalemiaHyperglycemiaHyponatremia
Arm I (FOLFOX Regimen and Placebo)1310118116632510051010
Arm II (FOLFOX Regimen and Vismodegib)19151488885021061042

[back to top]

Objective Response Rate

Defined as the percentage of the patients who had complete response (CR) or partial response (PR) per RECIST 1.1. (NCT00982592)
Timeframe: Up to 4 years

Interventionpercentage of patients (Number)
Arm I (FOLFOX Regimen and Placebo)44
Arm II (FOLFOX Regimen and Vismodegib)37

[back to top]

Overall Survival

Defined as time from randomization day until death from any cause. (NCT00982592)
Timeframe: up to 4 years

Interventionmonths (Median)
Arm I (FOLFOX Regimen and Placebo)15.38
Arm II (FOLFOX Regimen and Vismodegib)12.12

[back to top]

Progression Free Survival at Six Months

(NCT01047293)
Timeframe: 6 months

Interventionpercentage of participants (Number)
All Patients87

[back to top]

Evaluate Safety of the Combination at a Daily Dosing of 2.5mg RAD001, 5 mg RAD001 or 10 mg RAD001 (Phase 1 Part)

Number of patients who experienced a Dose Limiting Toxicity (DLT). DLT will be assessed in the first 28 days of dosing. Patients need to get dosed with 2 rounds/sessions of all chemotherapy agents in the first 28 days in order to be evaluable for DLT assessment. The primary endpoint is safety as summarized by dose limiting toxicity (DLT). (NCT01047293)
Timeframe: December 2011

Interventionparticipants (Number)
ARM 1 RAD001 5 mg QOD0
ARM 2 5mg RAD001 QD1
ARM 3 10mg RAD001 QD1

[back to top]

Preoperative Gastrointestinal Morbidity

As measured by participants who experience grade 3 or higher gastrointestinal morbidity (NCT01060007)
Timeframe: Mean number of weeks before surgery 17.3 (SD +/- 2.9 weeks)

Interventionparticipants (Number)
Neoadjuvant Radiation Followed by FOLFOX7

[back to top]

Incidence of Post Chemoradiotherapy Grade 3 or Higher Morbidity

(NCT01060007)
Timeframe: 1 year (completion of all treatment)

Interventionparticipants (Number)
Neoadjuvant Radiation Followed by FOLFOX21

[back to top]

Freedom From Disease Relapse

Kaplan-Meier projections. (NCT01060007)
Timeframe: 30 months

Interventionpercentage of participants (Number)
Neoadjuvant Radiation Followed by FOLFOX87

[back to top]

Local Control

"Kaplan-Meier projections~Local control = control of primary tumor" (NCT01060007)
Timeframe: 30 months

Interventionpercentage of participants (Number)
Neoadjuvant Radiation Followed by FOLFOX95

[back to top]

Rate of Locoregional Control

(NCT01060007)
Timeframe: 1 year

Interventionpercentage of participants (Number)
Neoadjuvant Radiation Followed by FOLFOX96

[back to top]

Incidence of Any Late Grade 3 or Higher Morbidity

(NCT01060007)
Timeframe: Preoperative (mean time from start of radiation to surgery 17.3 weeks (SD +/- 2.9 weeks)

Interventionparticipants (Number)
Non-hematologic toxicitiesHematologic toxicities
Neoadjuvant Radiation Followed by FOLFOX1621

[back to top]

Determine Quality of Anorectal Function

"Anorectal function was measured by the participant's response to the FACT-C questionnaire question I have control of my bowels. The answers ranged from 0=not at all to 4=very much." (NCT01060007)
Timeframe: Up to 1 year

,,
InterventionParticipants (Count of Participants)
0 = not at all1 = a little bit2 = somewhat3 = quite a bit4 = very much
1 Year Post-treatment241375
Pre-surgery4482122
Pre-treatment73221426

[back to top]

Rate of T Stage Downstaging

T stage downstaging is defined as clinical pretreatment American Joint Committee on Cancer T stage (cT) being greater than pathologic T stage at surgery (ypT). (NCT01060007)
Timeframe: Mean number of weeks before surgery 17.3 (SD +/- 2.9 weeks)

Interventionpercentage of participants (Number)
Neoadjuvant Radiation Followed by FOLFOX71

[back to top]

Rate of Overall Control

(NCT01060007)
Timeframe: 1 year

Interventionpercentage of participants (Number)
Neoadjuvant Radiation Followed by FOLFOX89

[back to top]

PFS From the Start of First-Line Therapy

PFS from the start of first-line therapy was defined as the interval between the start of first-line therapy and the date at which second disease progression (after the start of beyond progression therapy) was documented. Progression of disease was evaluated using RECIST version 1.1 and abdominal/pelvic CT or MRI scanning. The same method of assessment and the same technique were to be used to evaluate each lesion throughout the entire study. If more than one method was used, data from the most accurate method according to RECIST were recorded. Median PFS was estimated using the Kaplan-Meier method. (NCT01077739)
Timeframe: Baseline, every 9 weeks until disease progression, at end of treatment or withdrawal, for up to 24 months

Interventionmonths (Median)
Bevacizumab + Oxaliplatin + Capecitabine17.8
Bevacizumab + FOLFOX18.0

[back to top]

Geometric Mean Values of Pro-Angiogenic Cytokine Concentrations at Baseline and Prior to Progression

Pro-angiogenic cytokine concentrations of placental growth factor (PlGF), basic fibroblast growth factor (bFGF), and hepatocyte growth factor (HGF) in participant sera were measured and reported in units of picograms/milliliter (pg/mL). The geometric mean was calculated as exp10 (mean of log10 transformed concentration) and the standard deviation (SD) is SD of log10 transformed concentration. (NCT01077739)
Timeframe: Baseline, every 9 weeks until disease progression, at final visit or at withdrawal, for up to 24 months

,
Interventionpg/mL (Geometric Mean)
Baseline bFGF (n=13,23)bFGF, Prior to progression levels (n=12,18)Baseline HGF (n=13,23)HGF, Prior to progression levels (n=12,18)Baseline PIGF (n=13,23)PIGF, Prior to progression levels (n=12,18)
Bevacizumab + FOLFOX6.14.2186.0230.326.337.1
Bevacizumab + Oxaliplatin + Capecitabine6.83.6133.0187.329.834.7

[back to top]

Progression-Free Survival (PFS) From the Start of Treatment Beyond Progression

PFS from the start of treatment beyond progression was defined as the interval between the start of beyond-progression therapy and the date at which disease progression was documented. Progression of disease was evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1 and abdominal/pelvic computerized tomography (CT) or magnetic resonance imaging (MRI) scanning as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. The same method of assessment and the same technique were to be used to evaluate each lesion throughout the entire study. If more than one method was used, data from the most accurate method according to RECIST were recorded. Median PFS was estimated using the Kaplan-Meier method. (NCT01077739)
Timeframe: Baseline, every 9 weeks until disease progression, at end of treatment or withdrawal, for up to 24 months

Interventionmonths (Median)
Bevacizumab + Oxaliplatin + Capecitabine6.3
Bevacizumab + FOLFOX5.1

[back to top]

Percentage of Participants With an Overall Response of Complete Response (CR) or Partial Response (PR)

"Percentage of participants with an overall response of CR or PR according to RECIST criteria.~CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must have decreased to normal (short axis less than [<]10 millimeters [mm]). No new lesions. PR was defined as greater than or equal to (≥)30 percent (%) decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions." (NCT01077739)
Timeframe: Baseline, every 9 weeks until disease progression, at end of treatment or withdrawal, for up to 24 months

Interventionpercentage of participants (Number)
Bevacizumab + Oxaliplatin + Capecitabine27.3
Bevacizumab + FOLFOX6.4

[back to top]

Phase 1b: Number of Participants With Eastern Cooperative Oncology Group Performance Status (ECOG-PS)

ECOG-PS measured participant's performance status on 5 point scale: 0=Fully active/able to carry on all pre-disease activities without restriction; 1=restricted in physically strenuous activity, ambulatory/able to carry out light or sedentary work; 2=ambulatory (greater than[ >] 50 percent [%] of waking hours), capable of all self care, unable to carry out any work activities; 3=capable of only limited self care, confined to bed/chair >50% of waking hours; 4=completely disabled, cannot carry on any self care, totally confined to bed/chair; 5=dead. (NCT01133990)
Timeframe: From date of first dose up to 30 days after last dose of study treatment (up to 11.5 months)

InterventionParticipants (Count of Participants)
Participants With ECOG-PS Grade 1Participants With ECOG-PS Grade 2Participants With ECOG-PS Grade 3Participants With ECOG-PS Grade 4Participants With ECOG-PS Grade 5
Phase 1b: E7820 40 mg/Day + FOLFIRI12200

[back to top]

Phase 1b: Number of Participants With Any Treatment-emergent Adverse Events (TEAEs)

Adverse Events were defined as TEAEs if they started on or after the date and time of administration of the first dose of study drug during the study. An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product, and which did not necessarily have a causal relationship with this treatment. Any change in hematology, clinical chemistry, urine values and regular measurement of vital signs which were deemed clinically significant by the investigator were recorded as TEAE. (NCT01133990)
Timeframe: From date of first dose up to 30 days after last dose of study treatment (up to 11.5 months)

InterventionParticipants (Count of Participants)
Phase 1b: E7820 40 mg/Day + FOLFIRI5

[back to top]

Phase 1b: Number of Participants With Clinically Significant Change From Baseline in Electrocardiograms (ECGs) Parameter

ECG was to be a complete standardized 12-lead recording. The ECGs were reviewed by the investigator or designee prior to study drug administration as part of the participant's standard of care. (NCT01133990)
Timeframe: From date of first dose up to 30 days after last dose of study treatment (up to 11.5 months)

InterventionParticipants (Count of Participants)
Phase 1b: E7820 40 mg/Day + FOLFIRI1

[back to top]

Phase 1b: Number of Participants With Clinically Significant Changes in Physical Examinations

Physical examination included examination of the head, eyes, ears, nose, throat, neck, heart, chest, lungs, abdomen, extremities, skin, lymph nodes, and neurological status. (NCT01133990)
Timeframe: From date of first dose up to 30 days after last dose of study treatment (up to 11.5 months)

InterventionParticipants (Count of Participants)
Phase 1b: E7820 40 mg/Day + FOLFIRI2

[back to top]

Phase 1b: Number of Participants With Dose-limiting Toxicities (DLTs)

Dose-limiting toxicities were defined as clinically significant adverse events (AEs) occurring less than or equal to (<=) 28 days after commencing study treatment and considered by the investigator to be possibly or probably related to study treatment. Toxicity was evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (NCI CTCAE v.4.0). (NCT01133990)
Timeframe: Cycle 1 (each cycle length=28 days)

InterventionParticipants (Count of Participants)
Phase 1b: E7820 40 mg/Day + FOLFIRI2

[back to top]

Disease-free Survival

Disease-Free Survival (DFS) is defined as the time of randomization until documented progression or death from any cause. The endpoint of this trial is to compare disease-free survival of patients with stage III colon cancer randomized to standard chemotherapy only (FOLFOX; Arm A and Arm C) or standard chemotherapy (FOLFOX) with 3 years of celecoxib 400 mg daily (Arm B and Arm D). The percentage of patients who were alive and disease free after 3 years are reported here. A log-rank test stratified with the stratification factors was used to compare disease-free survival (celecoxib vs placebo) (NCT01150045)
Timeframe: At 3 years of follow-up

Interventionpercentage of participants (Number)
FOLFOX and Placebo (Arms A +C)73.4
FOLFOX Plus Celecoxib Daily (Arms B + D)76.3

[back to top]

Overall Survival

Overall Survival (DFS) is defined as the time of randomization until documented death from any cause. The endpoint is to compare overall survival of patients with stage III colon cancer randomized to standard chemotherapy only (FOLFOX; Arm A and Arm C) or standard chemotherapy (FOLFOX) with 5 years of celecoxib 400 mg daily (Arm B and Arm D). The percentage of patients who were alive after 3 years are reported here. (NCT01150045)
Timeframe: up to 3 years from registration

Interventionpercentage of participants (Number)
FOLFOX and Placebo (Arms A +C)81.6
FOLFOX Plus Celecoxib Daily (Arms B + D)84.3

[back to top]

Progression-free Survival (PFS) Time

PFS was defined as the time from the date of randomization until the date of objectively determined progressive disease (PD) [according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v). 1.1] or death due to any cause, whichever was first. PD is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeters (mm). Participants who died without a reported prior progression were considered to have progressed on the day of their death. Participants who did not progress or were lost to follow-up were censored at the day of their last radiographic tumor assessment. (NCT01183780)
Timeframe: Randomization to Measured PD or Date of Death from Any Cause Up to 38.01 Months

Interventionmonths (Median)
Ramucirumab + FOLFIRI5.7
Placebo + FOLFIRI4.5

[back to top]

Observed Maximum Concentration (Cmax) and Observed Minimum Concentration (Cmin) of Ramucirumab

(NCT01183780)
Timeframe: Preinfusion and 1 hour postinfusion in Cycles 3, 5, 9, 13, and 17

Interventionmicrograms/milliliter (ug/mL) (Geometric Mean)
Cmin Dose 3 (n=248)Cmin Dose 5 (n=154)Cmin Dose 9 (n=27)Cmin Dose 13 (n=11)Cmin Dose 17 (n=5)Cmax Dose 3 (n=88)Cmax Dose 5 (n=51)Cmax Dose 9 (n=18)Cmax Dose 13 (n=12)Cmax Dose 17 (n=7)
Ramucirumab + FOLFIRI46.365.177.975.972.0221.0243.0262.0307.0253.0

[back to top]

Change From Baseline in EuroQol- 5D (EQ-5D)

The EQ-5D is a generic, multidimensional, health status instrument. The profile allows participants to rate their health state in 5 health domains: mobility, self-care, usual activities, pain/discomfort, and mood using a 3-level scale (no problem, some problems, and major problems). These combinations of attributes were converted into a weighted health-state Index Score according to the United Kingdom (UK) population-based algorithm. The possible values for the Index Score ranged from -0.59 (severe problems in all 5 dimensions) to 1.0 (no problem in any dimension). A negative change indicated a worsening of the participant's health status. (NCT01183780)
Timeframe: Baseline and 30-Day Follow-Up (FU) up to 171 Weeks

Interventionunits on a scale (Mean)
Ramucirumab + FOLFIRI-0.097
Placebo + FOLFIRI-0.103

[back to top]

Change From Baseline in European Organisation for Research and Treatment of Cancer [EORTC] QLQ-C30 Global Health Status

The EORTC QLQ-C30 (v. 3.0) is a self-administered, cancer-specific questionnaire with multidimensional scales assessing 15 domains (5 functional domains, 9 symptoms, and global health status). A linear transformation was applied to standardize the raw scores to range between 0 and 100 per developer guidelines. For the functional domains and global health status scale, higher scores represent a better level of functioning. For symptom scales, higher scores represent a greater degree of symptoms. Maximum improvement is the best post-baseline change. (NCT01183780)
Timeframe: Baseline Up to 171 Weeks

Interventionunits on a scale (Mean)
Ramucirumab + FOLFIRI4.0
Placebo + FOLFIRI6.6

[back to top]

Overall Survival (OS)

OS was defined as the time in months from the date of randomization to the date of death from any cause. For participants not known to have died as of the cut-off date, OS was censored at the last known date alive. (NCT01183780)
Timeframe: Randomization to Date of Death from Any Cause Up to 39.36 Months

Interventionmonths (Median)
Ramucirumab + FOLFIRI13.3
Placebo + FOLFIRI11.7

[back to top]

Percentage of Participants Achieving an Objective Response (Objective Response Rate)

The objective response rate is equal to the proportion of participants achieving a best overall response of partial response or complete response (PR + CR). Response was defined using RECIST, v. 1.1 criteria. CR was defined as the disappearance of all target and non-target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm and normalization of tumor marker level of non-target lesions; PR was defined as having at least a 30% decrease in sum of longest diameter of target lesions taking as reference the baseline sum diameter. (NCT01183780)
Timeframe: Randomization until Disease Progression Up to 38.01 Months

Interventionpercentage of participants (Number)
Ramucirumab + FOLFIRI13.4
Placebo + FOLFIRI12.5

[back to top]

Percentage of Participants With Treatment-Emergent Anti-Ramucirumab Antibodies

Blood samples were tested to determine if a participant reacted to ramucirumab by producing anti-ramucirumab antibodies. Samples were identified as treatment emergent anti-drug antibody (TE ADA) if the post-treatment sample had an increase of at least 4 fold in titer from pre-treatment values. If the pre-treatment value was not detected or was not present, a 1:20 post-treatment titer was required to indicate treatment emergence. The percentage of participants with TE ADA was calculated as: (the number of participants with TE ADA / total number of participants with at least 1 post-treatment immunogenicity sample analyzed)*100. (NCT01183780)
Timeframe: Cycles 1, 3, 5, and 30-Day FU

,
Interventionpercentage of participants (Number)
Immunogenicity Any Time During Study (n=516, 512)Immunogenicity Post-Treatment (n=477, 473)
Placebo + FOLFIRI5.53.8
Ramucirumab + FOLFIRI5.63.1

[back to top]

Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL at End of Maintenance Cycle 1: Right

Strength in the right ankle dorsiflexors averaged over two measurements. Age and gender standardized mean and standard deviation for the cohort will be reported. (NCT01190930)
Timeframe: 1 Year

InterventionZ-Score (Mean)
B-ALL Average Risk-0.39

[back to top]

Burden of Therapy in Boy AR Patients Overall at End of Therapy: Emotional

Age standardized Quality of life, measured by the emotional subscale of Pediatric Quality of Life Inventory 4.0 Genetic Core Scales (PedsQL), will be calculated with mean and standard deviation reported. (NCT01190930)
Timeframe: 3.2 years

InterventionZ-Score (Mean)
B-ALL Average Risk-0.62

[back to top]

Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL at End of Consolidation Therapy-Right

Strength in the right ankle dorsiflexors averaged over two measurements. Age and gender standardized mean and standard deviation for the cohort will be reported. (NCT01190930)
Timeframe: 2 Months

InterventionZ-Score (Mean)
B-ALL Average Risk-0.87

[back to top]

Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL at End of Consolidation Therapy-Left

Strength in the left ankle dorsiflexors averaged over two measurements. Age and gender standardized mean and standard deviation for the cohort will be reported. (NCT01190930)
Timeframe: 2 Months

InterventionZ-Score (Mean)
B-ALL Average Risk-0.84

[back to top]

Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL 12 Months Post Therapy: Right

Strength in the right ankle dorsiflexors averaged over two measurements. Age and gender standardized mean and standard deviation for the cohort will be reported. (NCT01190930)
Timeframe: 4.2 Years

InterventionZ-Score (Mean)
B-ALL Average Risk-1.12

[back to top]

Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL 12 Months Post Therapy: Left

Strength in the left ankle dorsiflexors averaged over two measurements. Age and gender standardized mean and standard deviation for the cohort will be reported. (NCT01190930)
Timeframe: 4.2 Years

InterventionZ-Score (Mean)
B-ALL Average Risk-1.19

[back to top]

Burden of Therapy in Boy AR Patients Overall at End of Therapy: Social Functioning

Age standardized Quality of life, measured by the Social functioning subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported. (NCT01190930)
Timeframe: 3.2 Years

InterventionZ-Score (Mean)
B-ALL Average Risk-0.40

[back to top]

Burden of Therapy in Boy AR Patients Overall at End of Therapy: Physical

Age standardized Quality of life, measured by the physical subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported. (NCT01190930)
Timeframe: 3.2 years

InterventionZ-Score (Mean)
B-ALL Average Risk-0.67

[back to top]

Burden of Therapy in Boy AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Therapy: Social Functioning

Age standardized Quality of life, measured by the social functioning subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated for each group with mean and standard deviation reported. (NCT01190930)
Timeframe: 3.2 Years

InterventionZ-Score (Mean)
B-ALL Average Risk: VCR/DEX Pulse Every 4 Weeks-0.46
B-ALL Average Risk: VCR/DEX Pulse Every 12 Weeks-0.33

[back to top]

Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 4: Emotional

Age standardized Quality of life, measured by the emotional subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported. (NCT01190930)
Timeframe: 1.7 years

InterventionZ-Score (Mean)
B-ALL Average Risk-0.84

[back to top]

Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 1: Social Functioning

Age standardized Quality of life, measured by the social functioning subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported. (NCT01190930)
Timeframe: 1 Year

InterventionZ-Score (Mean)
B-ALL Average Risk-0.19

[back to top]

Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 1: Physical

Age standardized Quality of life, measured by the physical subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported. (NCT01190930)
Timeframe: 1 Year

InterventionZ-Score (Mean)
B-ALL Average Risk-0.59

[back to top]

Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 1: Emotional

Age standardized Quality of life, measured by the emotional subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported. (NCT01190930)
Timeframe: 1 year

InterventionZ-Score (Mean)
B-ALL Average Risk-0.86

[back to top]

Burden of Therapy in AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 4: Emotional

Age standardized Quality of life, measured by the emotional subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated for each group with means and standard deviation reported. (NCT01190930)
Timeframe: 1.7 years

InterventionZ-Score (Mean)
B-ALL Average Risk: VCR/DEX Pulse Every 4 Weeks-0.80
B-ALL Average Risk: VCR/DEX Pulse Every 12 Weeks-0.89

[back to top]

Burden of Therapy in AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 4: Physical

Age standardized Quality of life, measured by the physical subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated for each group with means and standard deviation reported. (NCT01190930)
Timeframe: 1.7 Years

InterventionZ-Score (Mean)
B-ALL Average Risk: VCR/DEX Pulse Every 4 Weeks-0.62
B-ALL Average Risk: VCR/DEX Pulse Every 12 Weeks-0.64

[back to top]

Burden of Therapy in AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 4: Social Functioning

Age standardized Quality of life, measured by the social functioning subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated for each group with means and standard deviation reported. (NCT01190930)
Timeframe: 1.7 Years

InterventionZ-Score (Mean)
B-ALL Average Risk: VCR/DEX Pulse Every 4 Weeks-0.16
B-ALL Average Risk: VCR/DEX Pulse Every 12 Weeks-0.25

[back to top]

Burden of Therapy in AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Emotional

Age standardized Quality of life, measured by the emotional subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated for each group with mean and standard deviation reported. (NCT01190930)
Timeframe: 2.4 Years

InterventionZ-Score (Mean)
B-ALL Average Risk: VCR/DEX Pulse Every 4 Weeks-0.72
B-ALL Average Risk: VCR/DEX Pulse Every 12 Weeks-0.77

[back to top]

Burden of Therapy in AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Physical

Age standardized Quality of life, measured by the physical subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated for each group with mean and standard deviation reported. (NCT01190930)
Timeframe: 2.4 Years

InterventionZ-Score (Mean)
B-ALL Average Risk: VCR/DEX Pulse Every 4 Weeks-0.64
B-ALL Average Risk: VCR/DEX Pulse Every 12 Weeks-0.67

[back to top]

Burden of Therapy in AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Social Functioning

Age standardized Quality of life, measured by the social functioning subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated for each group with mean and standard deviation reported. (NCT01190930)
Timeframe: 2.4 Years

InterventionZ-Score (Mean)
B-ALL Average Risk: VCR/DEX Pulse Every 4 Weeks-0.27
B-ALL Average Risk: VCR/DEX Pulse Every 12 Weeks-0.34

[back to top]

Burden of Therapy in AR Patients Overall at End of Consolidation Therapy: Emotional

Age standardized Quality of life, measured by the emotional subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported. (NCT01190930)
Timeframe: 2 Months

InterventionZ-Score (Mean)
B-ALL Average Risk-1.21

[back to top]

Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 4: Physical

Age standardized Quality of life, measured by the physical subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported. (NCT01190930)
Timeframe: 1.7 years

InterventionZ-Score (Mean)
B-ALL Average Risk-0.63

[back to top]

Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 4: Social Functioning

Age standardized Quality of life, measured by the social functioning subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported. (NCT01190930)
Timeframe: 1.7 Years

InterventionZ-Score (Mean)
B-ALL Average Risk-0.20

[back to top]

Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Emotional

Age standardized Quality of life, measured by the emotional subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported. (NCT01190930)
Timeframe: 2.5 years

InterventionZ-Score (Mean)
B-ALL Average Risk-0.74

[back to top]

Burden of Therapy in AR Patients Overall at End of Consolidation Therapy: Social Functioning

Age standardized Quality of life, measured by the social functioning subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported. (NCT01190930)
Timeframe: 2 Months

InterventionZ-Score (Mean)
B-ALL Average Risk-0.42

[back to top]

Burden of Therapy in Boy AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Therapy: Physical

Age standardized Quality of life, measured by the physical subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated for each group with mean and standard deviation reported. (NCT01190930)
Timeframe: 3.2 Years

InterventionZ-Score (Mean)
B-ALL Average Risk: VCR/DEX Pulse Every 4 Weeks-0.85
B-ALL Average Risk: VCR/DEX Pulse Every 12 Weeks-0.47

[back to top]

Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Physical

Age standardized Quality of life, measured by the physical subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported. (NCT01190930)
Timeframe: 2.4 Years

InterventionZ-Score (Mean)
B-ALL Average Risk-0.66

[back to top]

Burden of Therapy in Boy AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Therapy: Emotional

Age standardized Quality of life, measured by the emotional subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated for each group with mean and standard deviation reported. (NCT01190930)
Timeframe: 3.2 Years

InterventionZ-Score (Mean)
B-ALL Average Risk: VCR/DEX Pulse Every 4 Weeks-0.71
B-ALL Average Risk: VCR/DEX Pulse Every 12 Weeks-0.51

[back to top]

Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Social Functioning

Age standardized Quality of life, measured by the social functioning subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported. (NCT01190930)
Timeframe: 2.4 Years

InterventionZ-Score (Mean)
B-ALL Average Risk-0.30

[back to top]

Burden of Therapy in AR Patients Overall at End of Consolidation Therapy: Physical

Age and gender standardized Quality of life, measured by the physical subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported. (NCT01190930)
Timeframe: 2 Months

InterventionZ-Score (Mean)
B-ALL Average Risk-1.44

[back to top]

Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL at End of Maintenance Cycle 1: Left

Strength in the left ankle dorsiflexors averaged over two measurements. Age and gender standardized mean and standard deviation for the cohort will be reported. (NCT01190930)
Timeframe: 1 Year

InterventionZ-Score (Mean)
B-ALL Average Risk-0.36

[back to top]

Sample Collection of Central Path Review Slides in B-LLy Patients

Percent of B-LLy patients who had adequate/usable samples of samples collected will be reported. (NCT01190930)
Timeframe: Up to 1 month

Interventionpercentage of patients (Number)
B-LLy89.7

[back to top]

Overall Survival (OS) for B-LLy Patients

OS is calculated as the time from study enrollment to death or date of last contact. The 5-year OS and 95% confidence interval for these patients will be estimated. (NCT01190930)
Timeframe: 5 years

Interventionpercent probability (Number)
B-LLy93.97

[back to top]

Event Free Survival (EFS) for B-LLy Patients

EFS is calculated as the Time from study enrollment to first event (induction failure, relapse, second malignancy, remission death) or date of last contact. The 5-year EFS and 95% confidence interval for these patients will be estimated. (NCT01190930)
Timeframe: 5 years

Interventionpercent probability (Number)
B-LLy94.54

[back to top]

Disease Free Survival (DFS) in Average Risk (AR) Patients Based on the Methotrexate Dose Randomization

DFS is calculated as the time from randomization at the end of interim maintenance II to first event (relapse, second malignancy, remission death) or date of last contact. Five year DFS estimates will be calculated from the point of randomization for both groups. Two-sided 95% confidence intervals will be calculated. (NCT01190930)
Timeframe: 5.7 years

Interventionpercent probability (Number)
B-ALL Average Risk: MTX 20 mg/m^2/Week Starting Dose95.05
B-ALL Average Risk: MTX 40 mg/m^2/Week Starting Dose94.17

[back to top]

DFS in Low Risk (LR) Patients Based on Randomization to 1 of 2 Low-intensity Regimens

DFS is calculated as the time from randomization at the end of Induction to first event (relapse, second malignancy, remission death) or date of last contact. Five year DFS estimates will be calculated from the point of randomization for both groups. Two-sided 95% confidence intervals will be calculated. (NCT01190930)
Timeframe: 5.1 years

Interventionpercent probability (Number)
B-ALL Low Risk Arm I (LR-M)98.75
B-ALL Low Risk Arm II (LR-C)98.50

[back to top]

DFS in Average Risk (AR) Patients Based on the Pulse Frequency Randomization

DFS is calculated as the time from randomization at the end of interim maintenance II to first event (relapse, second malignancy, remission death) or date of last contact. Five year DFS estimates will be calculated from the point of randomization for both groups. Two-sided 95% confidence intervals will be calculated. (NCT01190930)
Timeframe: 5.7 years

Interventionpercent probability (Number)
B-ALL Average Risk: VCR/DEX Pulse Every 4 Weeks94.10
B-ALL Average Risk: VCR/DEX Pulse Every 12 Weeks95.13

[back to top]

DFS for SR Down Syndrome Patients With Standardized Treatment and Enhanced Supportive Care

DFS is calculated as the time from end of Induction to first event (relapse, second malignancy, remission death) or date of last contact. The 5-year DFS and 95% confidence interval for these patients will be estimated. (NCT01190930)
Timeframe: 5.1 years

Interventionpercent probability (Number)
Standard Risk With Down Syndrome89.77

[back to top]

Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Right

Strength in the right ankle dorsiflexors averaged over two measurements. Age and gender standardized mean and standard deviation for each randomization group will be reported. (NCT01190930)
Timeframe: 2.4 Years

InterventionZ-Score (Mean)
B-ALL Average Risk: VCR/DEX Pulse Every 4 Weeks-1.12
B-ALL Average Risk: VCR/DEX Pulse Every 12 Weeks-0.02

[back to top]

Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Left

Strength in the left ankle dorsiflexors averaged over two measurements. Age and gender standardized mean and standard deviation for each randomization group will be reported. (NCT01190930)
Timeframe: 2.4 Years

InterventionZ-Score (Mean)
B-ALL Average Risk: VCR/DEX Pulse Every 4 Weeks-1.19
B-ALL Average Risk: VCR/DEX Pulse Every 12 Weeks0.21

[back to top]

Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Right

Strength in the right ankle dorsiflexors averaged over two measurements. Age and gender standardized mean and standard deviation for the cohort will be reported. (NCT01190930)
Timeframe: 2.4 Years

InterventionZ-Score (Mean)
B-ALL Average Risk-0.27

[back to top]

Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Left

Strength in the left ankle dorsiflexors averaged over two measurements. Age and gender standardized mean and standard deviation for the cohort will be reported. (NCT01190930)
Timeframe: 2.4 Years

InterventionZ-Score (Mean)
B-ALL Average Risk-0.28

[back to top]

Progression Free Survival

Characterized using Kaplan-Meier curves. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions and a 5 mm absolute increase, or a measurable increase in a non-target lesion, or the appearance of new lesions (NCT01212822)
Timeframe: 3 years

Interventionmonths (Median)
Treatment (Bevacizumab, FOLFOX)19.0

[back to top]

Disease-free Survival

To investigate 2 year disease free survival in pts with resectable esophageal and GE junction cancer treated with perioperative bevaciumab and FOLFOX (NCT01212822)
Timeframe: 2 years

InterventionParticipants (Count of Participants)
Treatment (Bevacizumab, FOLFOX)4

[back to top]

Complete and Partial Response to Neoadjuvant Therapy Based on the Response Evaluation Criteria in Solid Tumors (RECIST)

To assess, by path examination after surgical resection, complete and partial response to neoadjuvant therapy. Characterized using proportions and 95% confidence intervals. (NCT01212822)
Timeframe: Up to 3 years

Interventionpercent of patients (Number)
Treatment (Bevacizumab, FOLFOX)44.4

[back to top]

Overall Survival

Characterized using Kaplan-Meier curves. (NCT01212822)
Timeframe: 4.5 years

Interventionmonths (Median)
Treatment (Bevacizumab, FOLFOX)26.0

[back to top]

Pharmacokinetic (PK) Parameter: Serum Concentration of Functional and Bound Sarilumab

(NCT01217814)
Timeframe: Week 12

Interventionng/mL (Mean)
Bound ConcentrationFunctional Concentration
Sarilumab 150 mg qw4271.4342391.43

[back to top]

Progression-free Survival (PFS)

The Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Worsening of Their Disease. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT01226719)
Timeframe: 18 months

Interventionmonths (Median)
FOLFOXIRI+Panitumumab Regimen13.3

[back to top]

To Determine the Acute Toxicity Produced by This Regimen.

The analyses of safety will be based on the frequency of adverse events and their severity for patients who received at least one dose of study treatment. (NCT01226719)
Timeframe: 18 months

Interventionparticipants (Number)
RashDiarrheaFatigueNauseaMucositisPeripheral neuropathyVomitingAnorexiaCold sensitivityConstipationDehydrationLeukopeniaAnemiaHypokalemiaHypomagnesemiaNail changesNeutropeniaTaste alterationThrombocytopeniaWeight lossAbdominal painAlopeciaDepressionDizzinessInsomniaAlkaline phosphatase increasedALT increasedAnxietyAST increasedAstheniaBack painBlood bicarbonate increasedDecreased ejection fractionDry mouthDysesthesiaDyspepsiaEdemaEpistaxisFlashersHand-foot syndromeHematocheziaHemorrhoidsHyperpigmentationHypertensionHypoalbuminemiaHyponatremiaInfection - otherInfusion related reactionMemory lossOral infectionParaphasiaPruritusSpeech impairmentSwollen tongue
FOLFOXIRI+Panitumumab Regimen1298876544444333333332222211111111111111111111111111111

[back to top]

R0 Resection Rate

To determine the rate of complete (R0) resection for patients treated with this regimen. (NCT01226719)
Timeframe: 18 months

Interventionpercentage of patients with surgery (Number)
FOLFOXIRI+Panitumumab Regimen100

[back to top]

Overall Survival (OS)

The Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Death (NCT01226719)
Timeframe: 18 months

Interventionmonths (Median)
FOLFOXIRI+Panitumumab RegimenNA

[back to top]

Overall Response Rate (ORR)

The Percentage of Patients Who Experience an Objective Benefit From Treatment. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI or CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. (NCT01226719)
Timeframe: 18 months

Interventionpercentage of evaluable participants (Number)
FOLFOXIRI+Panitumumab Regimen75

[back to top]

Percentage of Participants With New Lesions at the Primary Tumor Site at the End of Neoadjuvant Treatment

The percentage of participants with new lesions located at the primary tumor site were evaluated at the end of NAT. (NCT01227707)
Timeframe: BL and within 6 weeks after the completion of study treatment

Interventionpercentage of participants (Number)
Bv+Capecitabine/Bv+Leucovorin+5-FU4.65

[back to top]

Percentage of Participants With Pathological Complete Response (pCR)

pCR was defined as the absence of viable tumor cells, as determined by standard histologic procedure, in the tumor specimen (including regional lymph nodes) obtained at surgery. In order to minimize evaluation bias, tumor specimens were analyzed by both a central and local pathologist. The number of participants with pathological tumor stage 0 (pT0) and regional lymph nodes stage 0 (pN0) at surgery was determined. pCR was defined as the number of participants with pT0 and pN0 at surgery divided by the total number of participants with pathological tumor stage data collected. (NCT01227707)
Timeframe: 6 to 8 weeks following completion of neoadjuvant treatment

Interventionpercentage of participants (Number)
Bv+Capecitabine/Bv+Leucovorin+5-FU10.00

[back to top]

DFS - Time to Event

The time in months from date of start-of-treatment to the date of event defined as the first documented disease progression or death due to any cause. If a participant did not have an event, the time was censored at the date of last adequate tumor assessment. DFS was estimated using the Kaplan-Meier method. (NCT01227707)
Timeframe: BL, within 6 weeks after the completion of neoadjuvant treatment, every 2 weeks for 1 year following surgery, every 3 months thereafter until progression, up to 45 months

Interventionmonths (Mean)
Bv+Capecitabine/Bv+Leucovorin+5-FU27.43

[back to top]

Time to Disease Progression (TTP) - Percentage of Participants With an Event

TTP was defined as the time from date of treatment start until first documented progression of disease or death due to underlying cancer. (NCT01227707)
Timeframe: BL, within 6 weeks after the completion of neoadjuvant treatment, every 2 weeks for 1 year following surgery, every 3 months thereafter until death, up to 45 months

Interventionpercentage of participants (Number)
Bv+Capecitabine/Bv+Leucovorin+5-FU27.91

[back to top]

Disease-Free Survival (DFS) - Percentage of Participants With an Event

DFS was defined as the time from treatment start date to the date of first progression of disease or date of death due to any cause. (NCT01227707)
Timeframe: BL, within 6 weeks after the completion of neoadjuvant treatment, every 2 weeks for 1 year following surgery, every 3 months thereafter until progression, up to 45 months

Interventionpercentage of participants (Number)
Bv+Capecitabine/Bv+Leucovorin+5-FU30.23

[back to top]

OS - Time to Event

OS was defined as the time from the date of first day of treatment until death due to any cause or the last date the participant was known to be alive. OS was estimated using the Kaplan-Meier method. (NCT01227707)
Timeframe: BL, within 6 weeks after the completion of neoadjuvant treatment, every 2 weeks for 1 year following surgery, every 3 months thereafter until death, up to 45 months

Interventionmonths (Mean)
Bv+Capecitabine/Bv+Leucovorin+5-FU32.14

[back to top]

Overall Survival (OS) - Percentage of Participants With an Event

OS was defined as the time from the date of first day of treatment until death due to any cause or the last date the participant was known to be alive. (NCT01227707)
Timeframe: BL, within 6 weeks after the completion of neoadjuvant treatment, every 2 weeks for 1 year following surgery, every 3 months thereafter until death, up to 45 months

Interventionpercentage of participants (Number)
Bv+Capecitabine/Bv+Leucovorin+5-FU25.58

[back to top]

Percentage of Participants With an Overall Response of CR at the End of Neoadjuvant Treatment

Percentage of participants with an overall response of CR was evaluated as the proportion of participants with CR for the target and non-target lesions plus absence of new lesions at the end of NAT according to RECIST. CR was defined as disappearance of all target lesions, all non-target lesions, and normalization of tumor marker levels. (NCT01227707)
Timeframe: BL and within 6 weeks after the completion of study treatment

Interventionpercentage of participants (Number)
Bv+Capecitabine/Bv+Leucovorin+5-FU9.30

[back to top]

TTP - Time to Event

TTP was defined as the time from date of treatment start until first documented progression of disease or death due to underlying cancer. TTP was estimated using the Kaplan-Meier method. (NCT01227707)
Timeframe: BL, within 6 weeks after the completion of neoadjuvant treatment, every 2 weeks for 1 year following surgery, every 3 months thereafter until death, up to 45 months

Interventionmonths (Mean)
Bv+Capecitabine/Bv+Leucovorin+5-FU27.68

[back to top]

Percentage of Participants by Primary Tumor (T), Regional Lymph Nodes (N), and Distant Metastasis (M) Clinical Stage at Baseline and at the End of Neo-Adjuvant Treatment (NAT)

The frequencies of clinical tumor stage T (0, 1, 2, 3, 4, or X), regional lymph nodes stage N (0, 1, 2, 3, or 4), and distant metastasis clinical stage M (0, 1, or X) at baseline and at the end of NAT were assessed. The frequencies of pathological tumor stage T and regional lymph nodes stage N at surgery were evaluated. The clinical tumor and lymph node status was assessed by clinical examination, endosonography, and/or rectosigmoidoscopy, and pelvic and abdomen computerized tomography (CT) scan or magnetic resonance imaging (MRI). Response to treatment had to be assessed within 6 weeks after end of treatment by using the same techniques performed at baseline. (NCT01227707)
Timeframe: Baseline (BL) and end of neoadjuvant treatment (within 6 weeks after the completion of study treatment)

Interventionpercentage of participants (Number)
Baseline: T0, N0End of NAT: T0, N0Baseline: T1, N0End of NAT: T1, N0Baseline: T1, NXEnd of NAT: T1, NXBaseline: T2, N0End of NAT: T2, N0Baseline: T2, N1End of NAT: T2, N1Baseline: T2, NXEnd of NAT: T2, NXBaseline: T3, N0End of NAT: T3, N0Baseline: T3, N1End of NAT: T3, N1Baseline: T3, N2End of NAT: T3, N2Baseline: T3, NXEnd of NAT: T3, NXBaseline: T4, N0End of NAT: T4, N0Baseline: T4, N1End of NAT: T4, N1Baseline: T4, N2End of NAT: T4, N2Baseline: T4, N3End of NAT: T4, N3Baseline: TX, N0End of NAT: TX, N0Baseline: TX, N2End of NAT: TX, N2Baseline: M0End of NAT: M0Baseline: M1End of NAT: M1Baseline: MXEnd of NAT: MX
Bv+Capecitabine/Bv+Leucovorin+5-FU04.6504.6502.33018.609.309.3006.9832.5618.6046.519.3002.332.336.9804.652.3302.3302.33002.332.33097.6781.402.332.3309.30

[back to top]

Percentage of Participants Undergoing Sphincter-Saving Surgery by Type of Procedure

(NCT01227707)
Timeframe: 6 to 8 weeks after completion of study treatment

Interventionpercentage of participants (Number)
Anterior resectionAbdomen-peritoneal amputation (Miles)OtherColostomy, temporary (n=32)Colostomy, definitive (n=32)No colostomy
Bv+Capecitabine/Bv+Leucovorin+5-FU70.022.53.047.5032.5020.0

[back to top]

Percentage of Participants With Complete Response (CR) at the End of Neoadjuvant Treatment

Percentage of participants with CR was evaluated as the proportion of participants with complete response for the target and non-target lesions, separately, at the end of NAT according to the Response Evaluation Criteria in Solid Tumors (RECIST). CR was defined as disappearance of all target lesions or all non-target lesions and normalization of tumor marker levels. (NCT01227707)
Timeframe: BL and within 6 weeks after the completion of study treatment

Interventionpercentage of participants (Number)
CR of target lesion(s)CR of non-target lesion(s)
Bv+Capecitabine/Bv+Leucovorin+5-FU11.6318.60

[back to top]

Percentage of Participants With Relapse During Follow-Up

The percentage of participants with local and/or regional relapse during follow-up. New lesions located at rectum or at colon or at lymph node detected at the end of NAT were evaluated as local and/or regional relapse. (NCT01227707)
Timeframe: BL, within 6 weeks after the completion of neoadjuvant treatment, every 2 weeks for 1 year following surgery, every 3 months thereafter until progression, up to 45 months

Interventionpercentage of participants (Number)
No Relapse1 Relapse2 Relapses
Bv+Capecitabine/Bv+Leucovorin+5-FU84.217.897.89

[back to top]

Best Overall Response Rate (ORR)

The Best ORR was defined as the percentage of subjects having achieved complete response (CR) or partial response (PR) according to RECIST version 1.0 as determined by the IRC. CR: defined as disappearance of all target and all non-target lesions and no new lesions. PR: defined as at least a 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters, no progression of non-target lesions and no new lesions. (NCT01228734)
Timeframe: Baseline up to 333 weeks

Interventionpercentage of subjects (Number)
Cetuximab + FOLFOX-466.3
FOLFOX-440.5

[back to top]

Overall Survival (OS) Time

OS was defined as the time (in months) from randomization to death. For subjects who were still alive at the analysis data cut-off date or who lost to follow-up, survival was censored at the last recorded date that the subject was known to be alive. (NCT01228734)
Timeframe: Baseline up to 333 weeks

Interventionmonths (Median)
Cetuximab + FOLFOX-420.8
FOLFOX-416.5

[back to top]

Progression Free Survival (PFS) Time

PFS was defined as the duration (in months) from randomization until the first progressive disease (PD) observation as assessed by the Independent Review Committee (IRC) according to Response Evaluation Criteria for Solid Tumors (RECIST) version 1.0, or death due to any cause when death occurred within 90 days of randomization or the last tumor assessment, whichever was later. PD was defined as at least a 20% increase in the sum of longest diameter (LD) of the target lesions, taking as references the smallest sum LD since the treatment started (including baseline), or appearance of one or more new lesions, and/or unequivocal progression of existing non-target lesions. (NCT01228734)
Timeframe: Baseline up to 333 weeks

Interventionmonths (Median)
Cetuximab + FOLFOX-49.2
FOLFOX-47.4

[back to top]

Time to Treatment Failure (TTF)

TTF was defined as time from randomization to date of the first occurrence of radiologically confirmed PD as determined by IRC, Clinical PD according to the Investigator's assessment (if radiological confirmation of PD by IRC was unavailable), discontinuation of treatment due to progression or adverse event, start of new anticancer therapy, withdrawal of consent, or death within 90 days of last tumor assessment or randomization. Subjects without event were censored on the date of last tumor assessment. (NCT01228734)
Timeframe: Baseline up to 333 weeks

Interventionmonths (Median)
Cetuximab + FOLFOX-49.2
FOLFOX-45.6

[back to top]

Number of Subjects With Curative Surgery of Liver Metastases

The number of subjects who underwent liver metastatic surgery after start of treatment and the outcome of surgery with respect to residual tumor after surgery (R0, R1, R2, not evaluable) were summarized. In case of resection of more than one metastasis, the worst outcome of surgery defined the overall status of a subject. R0 = No residual tumor after resection (all lesions resected completely); R1 = Metastases not resected completely with microscopic residual lesions; and R2 = Metastases not resected completely with macroscopic residual lesions. (NCT01228734)
Timeframe: Baseline up to 333 weeks

,
Interventionsubjects (Number)
Subjects with liver surgerySubjects with liver surgery outcome: R0Subjects with liver surgery outcome: R1Subjects with liver surgery outcome: R2Subjects not evaluable
Cetuximab + FOLFOX-497100
FOLFOX-462200

[back to top]

Progression Free Survival

Time in months that evaluable subjects survived progression free (NCT01229111)
Timeframe: Up to 3 years

InterventionMonths (Median)
Treatment (Cediranib Maleate and Modified FOLFOX)14.4

[back to top]

Estimation of Overall Survival

Time of overall response (NCT01229111)
Timeframe: Up to 3 years

InterventionMonths (Median)
Treatment (Cediranib Maleate and Modified FOLFOX)19.2

[back to top]

Tabulation of the Toxicity Profile of the Combination Therapy

Number of patients that experienced >/= grade 3 treatment related toxicities (definite, probable, possible). (NCT01229111)
Timeframe: Up to 3 years

Interventionparticipants (Number)
Treatment (Cediranib Maleate and Modified FOLFOX)11

[back to top]

The Response Rate of Patients Evaluated Using the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

The number of patients with a Complete Response (CR): Disappearance of all target lesions; Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters; Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions); Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. (NCT01229111)
Timeframe: Up to 3 years

Interventionparticipants (Number)
Partial Response (PR)Stable Disease (SD)Progressive Disease (PD)
Treatment (Cediranib Maleate and Modified FOLFOX)461

[back to top]

Number of Subject With Overall Response

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR (NCT01231399)
Timeframe: Up to 5 years

Interventionparticipants (Number)
Dose Level 1 - 2.5 mg Everolimus Daily5

[back to top]

Maximum Tolerated Dose (MTD) of Everolimus

The highest dose tested in which fewer than 33% of patients experience an attributable DLT to the study drug, when at least 6 patients are treated at that dose and are evaluable for toxicity. Toxicities will be assessed using Common Terminology Criteria for Adverse Events (CTCAE) v4.0. (NCT01231399)
Timeframe: Course 1 (first 28 days)

Interventionmg (Number)
Dose Level 1 - 2.5 mg Everolimus2.5

[back to top]

Progression-free Survival

Estimated using the product-limit method of Kaplan and Meier. From the date treatment started until the date of first documented progression or date of death from any cause, whichever came first. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT01231399)
Timeframe: up to 5 years

InterventionMonths (Median)
Dose Level 1 - 2.5 mg Everolimus Daily14.5

[back to top]

Overall Survival

Estimated using the product-limit method of Kaplan and Meier. From the date treatment started until the date of death from any cause. (NCT01231399)
Timeframe: Up to 5 years.

InterventionMonths (Median)
Dose Level 1 - 2.5 mg Everolimus Daily20.3

[back to top]

Progression-Free Survival (PFS)

PFS was defined using Response Evaluation Criteria in Solid Tumors [RECIST version (v.) 1.1] as the time from randomization to the first observation of progressive disease (PD) or death due to any cause, whichever came first. PD was a ≥20% increase in the sum of the diameters of target lesions with the sum demonstrating an absolute increase of ≥5 millimeters (mm); the appearance of ≥1 new lesions or unequivocal progression of non-target lesions. If a participant did not have a baseline disease assessment, PFS time was censored at the randomization date, regardless of whether or not PD or death was observed. Participants not known to have died or have objective PD were censored at the last post-baseline radiological assessment date. (NCT01246960)
Timeframe: Randomization to measured PD or date of death from any cause (up to Month 25.0)

Interventionmonths (Median)
Ramucirumab and mFOLFOX66.4
Placebo and mFOLFOX66.7

[back to top]

Duration of Response

Duration of response was defined using RECIST v. 1.1 criteria as the time from the date criteria were met for the first objectively recorded CR or PR until the first date criteria for PD were met or death from any cause. CR was the disappearance of all lesions and pathological lymph node reduction in the short axis to <10 mm. PR was a ≥30% decrease in the sum of the diameters of target lesions. PD was a ≥20% increase in the sum of the diameters of target lesions with the sum demonstrating an absolute increase of ≥5 mm; the appearance of ≥1 new lesions or unequivocal progression of non-target lesions. Participants who were not known to have died and who did not have PD were censored at the date of the last tumor assessment prior to the date of any subsequent systemic anticancer therapy. (NCT01246960)
Timeframe: Time of first response to measured PD (up to Month 23.0)

Interventionmonths (Median)
Ramucirumab and mFOLFOX67.4
Placebo and mFOLFOX65.8

[back to top]

Time to Disease Progression (TTP)

TTP was defined using RECIST v. 1.1 as the time from study randomization to the first date of PD. PD was a ≥20% increase in the sum of the diameters of target lesions with the sum demonstrating an absolute increase of ≥5 mm; the appearance of ≥1 new lesions or unequivocal progression of non-target lesions. TTP was censored at the date of last adequate tumor assessment if death was due to causes other than PD. (NCT01246960)
Timeframe: Randomization to measured PD (up to Month 25.0)

Interventionmonths (Median)
Ramucirumab and mFOLFOX68.7
Placebo and mFOLFOX67.1

[back to top]

Number of Participants With Adverse Events (AEs)

Reported are the number of participants who had ramucirumab/placebo-related: AEs, serious AEs (SAEs), AEs based on common terminology criteria for adverse events (CTCAE) ≥Grade 3, AEs = CTCAE Grade 5, as well as, AEs leading to treatment discontinuation and AEs resulting in death. A summary of serious and other non-serious AEs regardless of causality is located in the Reported Adverse Events module. (NCT01246960)
Timeframe: Baseline through study completion (up to Month 28.3)

,
Interventionparticipants (Number)
Any Ramucirumab/Placebo-Related AEAny Ramucirumab/Placebo-Related SAEAny Ramucirumab/Placebo-Related ≥Grade 3 AEAny Ramucirumab/Placebo-Related Grade 5 AEAny AE Leading to Treatment DiscontinuationAny AE with Outcome of Death
Placebo and mFOLFOX6641233352
Ramucirumab and mFOLFOX66410360185

[back to top]

Number of Participants With Treatment-Emergent Anti-Ramucirumab Antibodies

Participants with treatment-emergent anti-ramucirumab antibodies were participants with a 4-fold increase (2 dilution increase) in immunogenicity titer over baseline titer, or participants who tested negative at baseline and positive post-baseline (at titer of ≥1:20). (NCT01246960)
Timeframe: Months 1, 2, 4, 6, and 8

Interventionparticipants (Number)
Ramucirumab and mFOLFOX60
Placebo and mFOLFOX61

[back to top]

Overall Survival (OS)

OS was defined as the time from randomization to death due to any cause. OS was censored at the date of the last follow-up visit for participants who were alive or lost to follow-up. (NCT01246960)
Timeframe: Randomization to date of death from any cause (up to Month 28.3)

Interventionmonths (Median)
Ramucirumab and mFOLFOX611.7
Placebo and mFOLFOX611.5

[back to top]

Percentage of Participants Achieving an Objective Response (Objective Response Rate)

The percentage of participants who achieved a best overall response of partial response (PR) or complete response (CR) is reported. Response was defined using RECIST, v. 1.1 criteria. CR was the disappearance of all lesions and pathological lymph node reduction in the short axis to <10 mm. PR was a ≥30% decrease in the sum of the diameters of target lesions. The percentage of participants with objective response=(number of participants whose best overall response achieved was CR or PR/number of participants treated)*100. (NCT01246960)
Timeframe: Randomization to measured PD (up to Month 23.0)

Interventionpercentage of participants (Number)
Ramucirumab and mFOLFOX645.2
Placebo and mFOLFOX646.4

[back to top]

Response

Proportion of patients reaching a CR. A CR requires the following: an absolute neutrophil count (segs and bands) >1000/μL, no circulating blasts, platelets >100,000/μL; adequate bone marrow cellularity with trilineage hematopoiesis, and <5% marrow leukemia blast cells. All previous extramedullary manifestations of disease must be absent (e.g., lymphadenopathy, splenomegaly, skin or gum infiltration, testicular masses, or CNS involvement). (NCT01256398)
Timeframe: 10 years

Interventionproportion of participants (Number)
Treatment (Chemotherapy, Transplant).9846

[back to top]

Disease Free Survival Defined From the Date of First Induction Complete Response (CR) to Relapse or Death Due to Any Cause

Estimated using the Kaplan-Meier estimator. Proportions will be estimated using point as well as interval estimators. All interval estimators will be constructed using the finite sample size sampling distribution at the unadjusted two-sided level of 0.05. (NCT01256398)
Timeframe: At 3 years after CR

Interventionpercentage of patients (Number)
Treatment (Chemotherapy, Transplant)52.6

[back to top]

Feasibility of Maintenance Therapy in This Patient Population (Restricted to Those Patients Achieving a CR). Feasibility Will be Defined as the Number of Deaths Ocuring.

Proportions will be estimated based on the combined and individual cohorts. (NCT01256398)
Timeframe: 10 years

InterventionParticipants (Count of Participants)
Treatment (Chemotherapy, Transplant)5

[back to top]

Probability of Being BCR-ABL Negative in the Bone Marrow and Peripheral Blood at the Completion of the CNS Prophylaxis Course (Restricted to Those Patients Achieving a CR)

Proportions will be estimated based on the combined and individual cohorts. (NCT01256398)
Timeframe: 10 years

Interventionproportion of participants (Number)
Treatment (Chemotherapy, Transplant)0.667

[back to top]

Overall Survival (OS)

Estimated using the Kaplan-Meier estimator. Proportions will be estimated using point as well as interval estimators. All interval estimators will be constructed using the finite sample size sampling distribution at the unadjusted two-sided level of 0.05. (NCT01256398)
Timeframe: 10 years

InterventionMonths (Median)
Treatment (Chemotherapy, Transplant)55.9

[back to top]

Disease Free Survival (DFS)

Estimated using the Kaplan-Meier estimator. Proportions will be estimated using point as well as interval estimators. All interval estimators will be constructed using the finite sample size sampling distribution at the unadjusted two-sided level of 0.05. (NCT01256398)
Timeframe: 10 years

InterventionMonths (Median)
Treatment (Chemotherapy, Transplant)29.7

[back to top]

Response Duration

Duration of the partial or total response to the treatment. Evaluation and classification according to RECIST 1.1 criteria (Response Evaluation Criteria in Solid Tumors) (NCT01276379)
Timeframe: 4 years

InterventionMonths (Median)
FOLFIRI (m) or FOLFOX-6 (m) + Cetuximab8.66

[back to top]

Overall Survival

"Measured as time in months from start of study treatment to death or lost to follow up.~Results are reported by subgroups to compare outcome measure according to BRAF mutation. All patients belong to same treatment/study arm." (NCT01276379)
Timeframe: 4 years

InterventionMonths (Median)
WT BRAF - FOLFIRI (m) or FOLFOX-6 (m) + Cetuximab32.6
Mutant BRAF - FOLFIRI (m) or FOLFOX-6 (m) + Cetuximab9.3

[back to top]

Frequency of Adverse Events

"Frequency and type of adverse events (AEs). AEs were coded according to NCI CTCAE V3.0 and classified by frequency, relatedness to study treatment (related/not related) and severity (Grade).~Severity ranges from grade 1 (low intensity) to Grade 5 (max. intensity, death)" (NCT01276379)
Timeframe: 4 years

InterventionParticipants (Count of Participants)
Any AEs72100462Grade 3 or higher AEs72100462Grade 5 AEs72100462Treatment related AEs of any grade72100462Treatment related AEs grade 3 or higher72100462
noyes
FOLFIRI (m) or FOLFOX-6 (m) + Cetuximab198
FOLFIRI (m) or FOLFOX-6 (m) + Cetuximab20
FOLFIRI (m) or FOLFOX-6 (m) + Cetuximab138
FOLFIRI (m) or FOLFOX-6 (m) + Cetuximab80
FOLFIRI (m) or FOLFOX-6 (m) + Cetuximab5
FOLFIRI (m) or FOLFOX-6 (m) + Cetuximab213
FOLFIRI (m) or FOLFOX-6 (m) + Cetuximab176
FOLFIRI (m) or FOLFOX-6 (m) + Cetuximab42
FOLFIRI (m) or FOLFOX-6 (m) + Cetuximab101
FOLFIRI (m) or FOLFOX-6 (m) + Cetuximab117

[back to top]

Progression Free Survival

"Measurements according to RECIST 1.1 criteria (Response Evaluation Criteria in Solid Tumors). Main techniques: CT-scan. Two groups will be defined based on the score built from the proposed clinical variables and biomarkers. Instead of a binomial distribution, a Log-rank method has been used to calculate the sample size in order to include all the incidents during the follow-up. Expecting a minimum 20% difference (60 vs. 40%) on PFS at 12 months between groups and with the following assumptions:~Alpha error (bilateral): 5% Beta error: 20% Results are reported by subgroups to compare outcome measure according to BRAF mutation. All patients belong to same treatment/study arm." (NCT01276379)
Timeframe: 4 years

InterventionMonths (Median)
WT BRAF - FOLFIRI (m) or FOLFOX-6 (m) + Cetuximab11.4
Mutant BRAF - FOLFIRI (m) or FOLFOX-6 (m) + Cetuximab5.9

[back to top]

Secondary Biomarkers Analysis

The secondary biomarkers in serum and tumoral tissue will be analysed in order to predict the acquired resistance. (NCT01276379)
Timeframe: 4 years

InterventionParticipants (Count of Participants)
PI3K and PTEN72100462IGF-1RP/MMP772100462
UKWTMutant
FOLFIRI (m) or FOLFOX-6 (m) + Cetuximab69
FOLFIRI (m) or FOLFOX-6 (m) + Cetuximab98
FOLFIRI (m) or FOLFOX-6 (m) + Cetuximab14
FOLFIRI (m) or FOLFOX-6 (m) + Cetuximab158
FOLFIRI (m) or FOLFOX-6 (m) + Cetuximab23
FOLFIRI (m) or FOLFOX-6 (m) + Cetuximab0

[back to top] [back to top]

Response Rate, Defined as the Percentage of Patients in Each Arm Who Have an Objective Status of Complete Response or Partial Response, Confirmed by a Second Assessment Measured at Least 6 Weeks From the Initial Assessment

"Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria:~Complete Response (CR): disappearance of all target lesions;~Partial Response (PR) 30% decrease in sum of longest diameter of target lesions;~Progressive Disease (PD): 20% increase in sum of longest diameter of target lesions;~Stable Disease (SD): small changes that do not meet above criteria.~Response rate is reported as the percentage of participants who achieved Complete Response or Partial Response." (NCT01279681)
Timeframe: Up to 5 years

Interventionpercentage of participants (Number)
Arm A [Fluoropyrimidine + Bevacizumab (BEV)]47
Arm B [Fluoropyrimidine/Oxaliplatin (OXAL) + BEV]38

[back to top]

Progression-Free Survival

Progression was defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Progression free survival was defined as the time (in months) from the date of randomization to the date of documented disease progression or death, whichever occurs first. Patients were followed until progression (and progression was declared) regardless of whether the patient was on the first line treatment or not. Patients who progress following a missed scan will have their date of progression back-dated to the date of missing scan. Patients without a progression who are still alive at the time of analysis will be censored at the date of last follow-up. (NCT01279681)
Timeframe: Up to 5 years

Interventionmonths (Median)
Arm A [Fluoropyrimidine + Bevacizumab (BEV)]6.7
Arm B [Fluoropyrimidine/Oxaliplatin (OXAL) + BEV]6.7

[back to top]

Overall Survival

Overall survival was defined as the time (in months) from randomization to death. (NCT01279681)
Timeframe: Up to 5 years

Interventionmonths (Median)
Arm A [Fluoropyrimidine + Bevacizumab (BEV)]18.8
Arm B [Fluoropyrimidine/Oxaliplatin (OXAL) + BEV]15.4

[back to top]

Steady State Volume of Distribution (Vss) of Ramucirumab

Vss is the theoretical volume in which the total amount of study drug would need to be uniformly distributed during steady state to produce the same concentration as it is in plasma/serum. (NCT01286818)
Timeframe: Day 1, Cycle 1 and Day 1, Cycle 5 (1 cycle=14 days)

InterventionLiters (L) (Geometric Mean)
Day 1, Cycle 1 (n=4)Day 1, Cycle 5 (n=2)
FOLFIRI Plus Ramucirumab (IMC-1121B)2.513.06

[back to top]

Number of Participants With Serum Anti-IMC-1121B Antibodies (Immunogenicity)

(NCT01286818)
Timeframe: Day 1 of Cycle 5 (Week 9), Cycle 6 (Week 11), Cycle 7 (Week 13), and Cycle 9 (Week 17) [(1 cycle=14 days)]

Interventionparticipants (Number)
Day 1, Cycle 5 (n=5)Day 1, Cycle 6 (n=1)Day 1, Cycle 7 (n=3)Day 1, Cycle 9 (n=4)
FOLFIRI Plus Ramucirumab (IMC-1121B)0000

[back to top] [back to top]

Maximum Concentration (Cmax) of Ramucirumab

The Cmax of ramucirumab in serum on Day 1, Cycle 1 and on Day 1, Cycle 5, which was also considered Cmax at steady state (Cmax,ss), is reported. (NCT01286818)
Timeframe: Day 1, Cycle 1 and Day 1, Cycle 5 (1 cycle=14 days)

Interventionmicrograms per milliliter (mcg/mL) (Geometric Mean)
Day 1, Cycle 1 (n=6)Day 1, Cycle 5 (n=2)
FOLFIRI Plus Ramucirumab (IMC-1121B)245267

[back to top]

Half Life (t1/2) of Ramucirumab

t1/2 is the time required for the plasma/serum concentration to decrease 50%. (NCT01286818)
Timeframe: Day 1, Cycle 1 and Day 1, Cycle 5 (1 cycle=14 days)

Interventiondays (Geometric Mean)
Day 1, Cycle 1 (n=6)Day 1, Cycle 5 (n=2)
FOLFIRI Plus Ramucirumab (IMC-1121B)7.388.55

[back to top]

Clearance (CL) of Ramucirumab

The total body CL of ramucirumab on Day 1, Cycle 1 and on Day 1, Cycle 5, which was also considered CL at steady state (CLss), is reported. (NCT01286818)
Timeframe: Day 1, Cycle 1 and Day 1, Cycle 5 (1 cycle=14 days)

Interventionmilliliters per hour (mL/hr) (Geometric Mean)
Day 1, Cycle 1 (n=4)Day 1, Cycle 5 (n=2)
FOLFIRI Plus Ramucirumab (IMC-1121B)11.410.4

[back to top]

Area Under the Curve (AUC) of Ramucirumab

Reported for Day 1, Cycle 1 is AUC from time 0 extrapolated to infinity [AUC(0-inf)] and for Day 1, Cycle 5 is AUC over the dosing interval at steady state AUC(tau,ss). (NCT01286818)
Timeframe: Day 1, Cycle 1 and Day 1, Cycle 5 (1 cycle=14 days)

Interventionmicrograms*day/milliliter (mcg*day/mL) (Geometric Mean)
Day 1, Cycle 1 (n=4)Day 1, Cycle 5 (n=2)
FOLFIRI Plus Ramucirumab (IMC-1121B)16001690

[back to top]

Best Overall Response [Anti-Tumor Activity of FOLFIRI Plus Ramucirumab (IMC-1121B)]

Best overall response evaluated using Response Evaluation Criteria In Solid Tumors (RECIST, version 1.1) criteria. Complete Response (CR): disappearance of all non-nodal target lesions, with the short axes of any target lymph nodes reduced to <10 millimeters (mm). Partial Response (PR): at least a 30% decrease in the sum of the diameters of target lesions (including the short axes of any target lymph nodes), taking as reference the baseline sum diameter. Progressive Disease (PD): an increase of at least 20% in the sum of the diameters of target lesions, taking as reference the smallest sum on study (included baseline sum if that was the smallest on study). In addition, the sum must have demonstrated an absolute increase of at least 5 mm (the appearance of 1 or more new lesions was considered progression). Stable Disease (SD): neither sufficient shrinkage to qualify as PR nor sufficient increase to qualify as PD, taking as reference the smallest sum diameter since treatment started. (NCT01286818)
Timeframe: Every 8 weeks until PD (up to 49 weeks)

Interventionparticipants (Number)
Complete Response (CR)Partial Response (PR)Stable Disease (SD)Progressive Disease (PD)
FOLFIRI Plus Ramucirumab (IMC-1121B)0141

[back to top]

Number of Participants That Experienced Any Dose-Limiting Toxicities (DLT) During the DLT Assessment Period

DLTs were adverse events (AEs) possibly related to study drug that met the National Cancer Institute's Common Terminology Criteria for AEs (NCI CTCAE, version 4.03): Grade 4 neutropenia ≥7 days or ≥Grade 3 with bacteremia or sepsis; Absolute neutrophil count <1.0x10^9/Liters with fever ≥38.3°Celsius requiring intravenous antibiotic therapy; Grade 4 thrombocytopenia or ≥Grade 3 with bleeding requiring platelet transfusion; ≥Grade 3 altered coagulation tests and no anticoagulation; ≥Grade 4 or uncontrolled hypertension; ≥Grade 3 non-hematologic toxicity (except non-clinically significant Grade 3 events like electrolyte abnormality, hypersensitivity, and arthralgia/myalgia); urine protein >3 grams/24 hours; study drug-related toxicity causing Cycle 3, Day 1 treatment delay until Day 44 or later. Grade 3 or Grade 4 infusion-related reaction (hypersensitivity) due to ramucirumab or FOLFIRI, not a DLT. (NCT01286818)
Timeframe: Day 1, Cycle 1 through Day 1, Cycle 3 (1 cycle=14 days)

Interventionparticipants (Number)
FOLFIRI Plus Ramucirumab (IMC-1121B)1

[back to top]

Duration of Response (DOR)

DOR was defined as the time from the date of first documented objective response of PR or CR, whichever was noted earlier, to first subsequent disease progression or death (if death occurred before progression was documented). DOR was defined for responders only (that is, subjects with CR or PR). DOR for subjects without disease progression or death before progression was right censored at the date of their last tumor assessment. (NCT01289821)
Timeframe: From start of treatment until 30 days after the last dose of study treatment, assessed by every 8 weeks

InterventionDays (Median)
Regorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6)257

[back to top]

Overall Survival (OS)

OS was calculated as the time from first date of receiving study treatment to date of death due to any cause. Participants alive at the time of analysis were censored at their last date of follow-up. (NCT01289821)
Timeframe: From start of treatment until 30 days after the last dose of study treatment, assessed by every 8 weeks

InterventionDays (Median)
Regorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6)772

[back to top]

Progression-free Survival (PFS)

PFS was defined as time from the date of start of study treatment to the date of first observed disease progression (radiological according to central assessment or clinical), or death due to any cause, if death occurred before progression was documented. PFS for participants without disease progression or death at the date of database cutoff were right-censored at the last date of tumor assessment. Participants who had no tumor evaluation after baseline and no clinical progression post baseline and who did not die were censored at Day 1 in the analysis. PD = At least a 20% increase in the sum of diameters of target lesions taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of existing non target lesions or the appearance of one or more new lesions will also constitute PD. (NCT01289821)
Timeframe: From start of treatment until 30 days after the last dose of study treatment, assessed by every 8 weeks

InterventionDays (Median)
Regorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6)258

[back to top]

Duration of Stable Disease (DOSD)

DOSD was only evaluated in participants failing to achieve a best response of CR or PR, but who achieved SD. DOSR was defined as the time (in days) from date of start of study treatment to the date at which disease progression or death (if death occurred before progression was first documented). The date the tumor scan was performed was used for this calculation. DOSD for participants without disease progression or death before progression at the time of analysis were censored at the date of their last tumor assessment. (NCT01289821)
Timeframe: From start of treatment until 30 days after the last dose of study treatment, assessed by every 8 weeks

InterventionDays (Median)
Regorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6)231

[back to top]

Objective Response (OR)

OR was defined as the best tumor response (confirmed complete response [CR] or partial response [PR]) observed by MRI or CT scan assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria, version 1.1. CR and PR were confirmed not earlier than 4 weeks following the initial detection of response. CR = Disappearance of all clinical and radiological evidence of tumor (both target and no-target). Any pathological lymph nodes (whether target or non target) must have a reduction in short axis to < 10 mm. PR = At least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum, no unequivocal progression of existing nontarget lesions and no appearance of new lesions. (NCT01289821)
Timeframe: From start of treatment until 30 days after termination of study medication, an average of 47 weeks. Assessed every 8 weeks.

InterventionProportion of participants (Number)
Regorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6)0.4390

[back to top]

Disease Control (DC)

DC was defined as the proportion of participants who had a best response rating of CR, PR, or stable disease (SD) according to RECIST criteria that was achieved during treatment or within 30 days after termination of study treatment. CR and PR were confirmed not earlier than 4 weeks following the initial detection of response. A minimum of 8 weeks (allowing a minus 7-day time window) between start of study treatment and the first follow-up tumor assessment with SD as response was required to assign SD as best overall response. (NCT01289821)
Timeframe: From start of treatment until 30 days after the last dose of study treatment, assessed by every 8 weeks

InterventionProportion of participants (Number)
Regorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6)0.8537

[back to top]

Percentage of Patients With Severe Adverse Events

Toxicity Assessments were made according to NCI CTCAE v. 4.0 . Severe events (grades 3-4) that occurred in a higher percentage of regorafenib treated participants as compared to placebo are reported below. (NCT01298570)
Timeframe: 3 years

,
Interventionpercentage of participants (Number)
neutropeniadiarrheahypophosphatemiahypertensionelevated lipase
Arm A41151488
Arm B305023

[back to top]

Progression Free Survival (PFS)

To compare PFS between regorafenib + FOLFIRI chemotherapy (ARM A) versus placebo + FOLFIRI (ARM B) in patients failing one prior oxaliplatin-containing regimen for metastatic colorectal cancer. PFS is defined as the time from randomization until metastatic colorectal cancer (mCRC) progression or death as a result of any cause. Radiographic response will be measured by RECIST, Response Evaluation Criteria In Solid Tumors Criteria, indicating if subject experienced a Complete Response (CR), disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), no response or less response than Partial or Progressive; or Progressive Disease (PD), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT01298570)
Timeframe: 5.5 years

InterventionMonths (Median)
Arm A6.1
Arm B5.3

[back to top]

Overall Survival (OS)

To compare overall survival (OS) between ARM A and ARM B. OS is defined as the time from randomization until death as a result of any cause. (NCT01298570)
Timeframe: 5.5 years

InterventionMonths (Median)
Arm A13.8
Arm B11.7

[back to top]

Drug Metabolism

To compare the pharmacokinetic (PK) profile of FOLFIRI between a subset of patients receiving regorafenib (ARM A) and patients receiving placebo (Arm B). The Area Under the Curve (AUC) levels of the irinotecan metabolite SN-38 were compared. (NCT01298570)
Timeframe: 28 days

,
InterventionAUC/dose=(ng/mL*h)/(mg/m^2) (Median)
Cycle 1Cycle 2
Arm A0.680.59
Arm B0.630.72

[back to top]

Complete Pathological Response (pCR) Rate

Based on the proportion who achieve pCR based on the first 4 courses of protocol treatment. Evaluated using the Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 guidelines. Means (with associated standard errors), medians (with ranges), percentages and 95% confidence intervals will be reported as appropriate. (NCT01307956)
Timeframe: Up to 8 weeks

InterventionParticipants (Count of Participants)
Treatment (Panitumumab, Chemotherapy, Radiation)3

[back to top]

Number of Patients Who Can Undergo Resection

Restaging with repeat imaging studies will be performed. If no contraindication for surgical resection is identified, resection will be performed. Means (with associated standard errors), medians (with ranges), percentages and 95% confidence intervals will be reported as appropriate. (NCT01307956)
Timeframe: 4 weeks after completion of the radiation

InterventionParticipants (Count of Participants)
Treatment (Panitumumab, Chemotherapy, Radiation)11

[back to top]

Overall Survival

Descriptively summarized using the method of Kaplan-Meier. (NCT01307956)
Timeframe: From the first date of therapy until the date the patient dies, assessed up to 100 months

Interventiondays (Median)
Treatment (Panitumumab, Chemotherapy, Radiation)596

[back to top]

Progression-free Survival

Descriptively summarized using the method of Kaplan-Meier. Response and disease progression were assessed using RECIST criteria version 1.1 (NCT01307956)
Timeframe: Patients were followed from time of consent until the date of first documented progession or date of death from any cause, whichever came first, assessed up to 100 months.

Interventiondays (Median)
Treatment (Panitumumab, Chemotherapy, Radiation)409

[back to top]

Number of Participants Alive and Free of Progression at 4 Months (Patients Who Have Undergone Prior Therapy) and 10 Months (Untreated Patients)

Clinical benefit rate is defined as the proportion of patients alive and free of progression at 4 Months (Patients Who Have Undergone Prior Therapy) and 10 Months (Untreated Patients), assessed from first treatment with GI-4000. Progression is defined as CR (complete response) = disappearance of all target lesions; PR (partial response) = 30% decrease in the sum of the longest diameter of the target lesions; PD (progressive disease) = 20% increase in the sum of the longest diameter of the target lesions; or SD (stable disease) = small changes that do not meet the above criteria. (NCT01322815)
Timeframe: 4 Months for patients who had undergone prior 1st-line therapy, and 10 months for previously untreated patients

Interventionparticipants (Number)
Chemotherapy and GI-40004
GI-4000 and Bevacizumab2

[back to top]

Number of Participants With CTCAE Grade 3 or Higher Clinical Laboratory Toxicities

Laboratory toxicities were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. (NCT01327612)
Timeframe: From first dose of study drug in the extension study to 30 days after last dose; median duration of treatment with conatumumab was 1190.5 days and 1163.0 days for ganitumab.

InterventionParticipants (Count of Participants)
20050118: Ganitumab 20 mg/kg0
20050171: Conatumumab 0.45 mg/kg0
20060295: Conatumumab 3 mg/kg1
20060340: Conatumumab 5 mg/kg0
20060464: Conatumumab 2 mg/kg + mFOLFOX6 + Bevacizumab2
20060464: Conatumumab 10 mg/kg + mFOLFOX6 ± Bevacizumab2
20070411: Conatumumab 15 mg/kg + Ganitumab 18 mg/kg1

[back to top]

Maximum Change From Baseline in Blood Pressure

Maximum change from baseline is defined for each participant as the maximum change from baseline value observed across all visits. (NCT01327612)
Timeframe: Baseline and day 1 of each treatment cycle (every 2, 3, or 4 weeks depending on dosing schedule) up to 30 days after last dose; median duration of treatment with conatumumab was 1190.5 days and 1163.0 days for ganitumab.

,,,,,,
InterventionmmHg (Mean)
Systolic blood pressureDiastolic blood pressure
20050118: Ganitumab 20 mg/kg5.57.5
20050171: Conatumumab 0.45 mg/kg7.01.0
20060295: Conatumumab 3 mg/kg54.010.0
20060340: Conatumumab 5 mg/kg37.013.0
20060464: Conatumumab 10 mg/kg + mFOLFOX6 ± Bevacizumab26.014.7
20060464: Conatumumab 2 mg/kg + mFOLFOX6 + Bevacizumab42.027.5
20070411: Conatumumab 15 mg/kg + Ganitumab 18 mg/kg32.523.5

[back to top]

Minimum Change From Baseline in Blood Pressure

Minimum change from baseline is defined for each participant as the minimum change from baseline value observed across all visits. (NCT01327612)
Timeframe: Baseline and day 1 of each treatment cycle (every 2, 3, or 4 weeks depending on dosing schedule) up to 30 days after last dose; median duration of treatment with conatumumab was 1190.5 days and 1163.0 days for ganitumab.

,,,,,,
InterventionmmHg (Mean)
Systolic blood pressureDiastolic blood pressure
20050118: Ganitumab 20 mg/kg-28.5-19.5
20050171: Conatumumab 0.45 mg/kg-45.0-27.0
20060295: Conatumumab 3 mg/kg-20.0-20.0
20060340: Conatumumab 5 mg/kg-21.0-25.0
20060464: Conatumumab 10 mg/kg + mFOLFOX6 ± Bevacizumab-29.0-14.3
20060464: Conatumumab 2 mg/kg + mFOLFOX6 + Bevacizumab-22.5-8.5
20070411: Conatumumab 15 mg/kg + Ganitumab 18 mg/kg-12.0-10.0

[back to top]

Number of Participants With Disease Progression or Death Due to Disease Progression

(NCT01327612)
Timeframe: From first dose of study drug in the extension study to 30 days after last dose; median duration of treatment with conatumumab was 1190.5 days and 1163.0 days for ganitumab.

,,,,,,
InterventionParticipants (Count of Participants)
Disease progressionDeath due to disease progression
20050118: Ganitumab 20 mg/kg10
20050171: Conatumumab 0.45 mg/kg10
20060295: Conatumumab 3 mg/kg10
20060340: Conatumumab 5 mg/kg00
20060464: Conatumumab 10 mg/kg + mFOLFOX6 ± Bevacizumab20
20060464: Conatumumab 2 mg/kg + mFOLFOX6 + Bevacizumab21
20070411: Conatumumab 15 mg/kg + Ganitumab 18 mg/kg20

[back to top]

Number of Participants With Adverse Events

An adverse event is defined as any untoward medical occurrence in a clinical trial participant, including worsening of a pre-existing medical condition. The event does not necessarily have a causal relationship with study treatment. (NCT01327612)
Timeframe: From first dose of study drug in the extension study to 30 days after last dose; median duration of treatment with conatumumab was 1190.5 days and 1163.0 days for ganitumab.

InterventionParticipants (Count of Participants)
20050118: Ganitumab 20 mg/kg2
20050171: Conatumumab 0.45 mg/kg1
20060295: Conatumumab 3 mg/kg1
20060340: Conatumumab 5 mg/kg1
20060464: Conatumumab 2 mg/kg + mFOLFOX6 + Bevacizumab2
20060464: Conatumumab 10 mg/kg + mFOLFOX6 ± Bevacizumab3
20070411: Conatumumab 15 mg/kg + Ganitumab 18 mg/kg2

[back to top]

Number of Participants With Serious Adverse Events

"A serious adverse event is defined as an adverse event that met at least 1 of the following serious criteria:~fatal,~life threatening (places the participant at immediate risk of death),~required in-patient hospitalization or prolongation of existing hospitalization,~resulted in persistent or significant disability/incapacity,~congenital anomaly/birth defect, and/or~other medically important serious event." (NCT01327612)
Timeframe: From first dose of study drug in the extension study to 30 days after last dose; median duration of treatment with conatumumab was 1190.5 days and 1163.0 days for ganitumab.

InterventionParticipants (Count of Participants)
20050118: Ganitumab 20 mg/kg1
20050171: Conatumumab 0.45 mg/kg0
20060295: Conatumumab 3 mg/kg1
20060340: Conatumumab 5 mg/kg0
20060464: Conatumumab 2 mg/kg + mFOLFOX6 + Bevacizumab1
20060464: Conatumumab 10 mg/kg + mFOLFOX6 ± Bevacizumab3
20070411: Conatumumab 15 mg/kg + Ganitumab 18 mg/kg2

[back to top]

Complete Pathological Response (pCR) of PET/CT Non-responders

The primary endpoint of this study is the percentage of PET/CT non-responders within each induction treatment group reporting a pCR. A pCR is defined as having no tumor found on pathology review at surgery in all resected lymph nodes and tissue. All tissues sampled must have NO viable tumor. (NCT01333033)
Timeframe: Up to 5 years

Interventionpercentage of participants with a pCR (Number)
FOLFOX Non-Responder17.95
CP Non-Responder20

[back to top]

Progression Free Survival (PFS) Among PET/CT Non-responders Within Each Induction Treatment Group

"A non-responder was defined as having a PET/CT SUV (standard uptake value) decrease of less than 35% after induction.~Among the patients who completed induction therapy and did not respond, the progression free survival in each arm were compared. PFS will be measured from study entry until documented progression or death from any cause. PFS will be estimated using the method of Kaplan and Meier." (NCT01333033)
Timeframe: Up to 5 years

Interventionmonths (Median)
FOLFOX Regimen Non-ResponderNA
CP Non-Responder33.4

[back to top]

PET/CT Response Between Treatment Arms

A PET/CT response to induction therapy is defined as metabolic activity of the tumor decreasing by >=35%, as measured by maximum standardized uptake value (SUVmax). (NCT01333033)
Timeframe: Up to 5 years

Interventionpercentage of patients with a response (Number)
FOLFOX Regimen64.86
CP (Carboplatin + Paclitaxel + Radiation)56.14

[back to top]

pCR Compared Between Induction Treatment Arms Among PET/CT Responders

"A PET/CT response to induction therapy is defined as metabolic activity of the tumor decreasing by >=35%, as>~>>~>>~>> measured by maximum standardized uptake value (SUVmax). A pCR is defined as having no tumor found on pathology review at surgery in all resected lymph nodes and tissue. All tissues sampled must have NO viable tumor." (NCT01333033)
Timeframe: Up to 5 years

Interventionpercentage of participants with a pCR (Number)
FOLFOX Responder40.28
CP (Carboplatin + Paclitaxel + Radiation) Responder14.06

[back to top]

pCR Compared Among Non-responders Between Induction Treatment Arms if Treatment Regimens Are Found to be Efficacious

"A Complete Pathological Response (pCR) is defined as having no tumor found on pathology review at surgery in all resected lymph nodes and tissue. All tissues sampled must have NO viable tumor. A non-responder was defined as having a PET/CT SUV (standard uptake value) decrease of less than 35% after induction.>~>>>~>~>>> Among the patients who completed induction therapy and did not respond, the percentage of patients reporting a pCR in each arm were compared." (NCT01333033)
Timeframe: Up to 5 years

Interventionpercentage of participants with a pCR (Number)
FOLFOX Regimen Non-Responders17.95
CP (Carboplatin + Paclitaxel + Radiation) Non-Responders20

[back to top]

Number of Participants Who Experienced Toxicity

(NCT01359007)
Timeframe: 2 years

InterventionParticipants (Count of Participants)
FOLFIRINOX2

[back to top]

Evaluate the Toxicity of Study Therapy

"Evaluate the toxicity of induction FOLFOX and subsequent infusional 5-FU or capecitabine/radiation. Results show number of patients who experienced a SAE. This does not mean all SAEs were deemed related to treatment.~•Secondary efficacy measures include the clinical response rate, as measured endorectal ultrasound or pelvic MRI, and incidence and severity of toxicities seen during the various phases of study treatment, including treatment delays, bleeding and post-op complications. Each visit will have a toxicity assessment completed" (NCT01363843)
Timeframe: approx 1 year

InterventionParticipants (Count of Participants)
Study Arm Only13

[back to top]

Incidence of Complete Resection

The primary objective of this study is to determine the incidence of pCRs and complete (R0) resections at surgery after induction chemotherapy with 8 cycles of modified FOLFOX6 followed by standard chemoradiation with IMRT with concurrent infusional 5-FU or capecitabine (NCT01363843)
Timeframe: approx 6 months

Interventionparticipants (Number)
Study Arm Only13

[back to top]

OS in Participants With High ERCC-1 Levels

Death on study included death from any cause occurring no later than 3 months after the last component of study treatment. OS was defined as the time from randomization to death. The median duration of OS was estimated by Kaplan-Meier analysis and expressed in months. The 95% CI was computed using the method of Brookmeyer and Crowley. (NCT01374425)
Timeframe: From Baseline until death (maximum up to 45 months overall)

Interventionmonths (Median)
Bevacizumab + mFOLFOX6 (ERCC-1 High)22.54
Bevacizumab + FOLFIRI (ERCC-1 High)26.51

[back to top]

OS in Participants With High ERCC-1 Levels Versus Participants With Low ERCC-1 Levels

Death on study included death from any cause occurring no later than 3 months after the last component of study treatment. OS was defined as the time from randomization to death. The median duration of OS was estimated by Kaplan-Meier analysis and expressed in months. The 95% CI was computed using the method of Brookmeyer and Crowley. (NCT01374425)
Timeframe: From Baseline until death (maximum up to 45 months overall)

Interventionmonths (Median)
Bevacizumab + mFOLFOX/FOLFIRI (ERCC-1 High)23.23
Bevacizumab + mFOLFOX/FOLFIRI (ERCC-1 Low)27.27

[back to top]

OS in Participants With High VEGF-A Levels Versus Participants With Low VEGF-A Levels

Death on study included death from any cause occurring no later than 3 months after the last component of study treatment. OS was defined as the time from randomization to death. The median duration of OS was estimated by Kaplan-Meier analysis and expressed in months. The 95% CI was computed using the method of Brookmeyer and Crowley. (NCT01374425)
Timeframe: From Baseline until death (maximum up to 45 months overall)

Interventionmonths (Median)
Bevacizumab + mFOLFOX/FOLFIRI (VEGF-A High)22.83
Bevacizumab + mFOLFOX/FOLFIRI (VEGF-A Low)27.93

[back to top]

OS in Participants With Low ERCC-1 Levels

Death on study included death from any cause occurring no later than 3 months after the last component of study treatment. OS was defined as the time from randomization to death. The median duration of OS was estimated by Kaplan-Meier analysis and expressed in months. The 95% CI was computed using the method of Brookmeyer and Crowley. (NCT01374425)
Timeframe: From Baseline until death (maximum up to 45 months overall)

Interventionmonths (Median)
Bevacizumab + mFOLFOX6 (ERCC-1 Low)25.53
Bevacizumab + FOLFIRI (ERCC-1 Low)27.93

[back to top]

OS in Participants With Wild-Type KRAS Versus Participants With Mutant KRAS

Death on study included death from any cause occurring no later than 3 months after the last component of study treatment. OS was defined as the time from randomization to death. The median duration of OS was estimated by Kaplan-Meier analysis and expressed in months. The 95% CI was computed using the method of Brookmeyer and Crowley. (NCT01374425)
Timeframe: From Baseline until death (maximum up to 45 months overall)

Interventionmonths (Median)
Bevacizumab + mFOLFOX/FOLFIRI (KRAS Wild-Type)28.75
Bevacizumab + mFOLFOX/FOLFIRI (KRAS Mutant)24.64

[back to top]

Overall Survival (OS)

Death on study included death from any cause occurring no later than 3 months after the last component of study treatment. OS was defined as the time from randomization to death. The median duration of OS was estimated by Kaplan-Meier analysis and expressed in months. The 95% CI was computed using the method of Brookmeyer and Crowley. (NCT01374425)
Timeframe: From Baseline until death (maximum up to 45 months overall)

Interventionmonths (Median)
Bevacizumab + mFOLFOX623.85
Bevacizumab + FOLFIRI27.47

[back to top]

Percentage of Participants With Complete Liver Metastasis Resection

The timing of resective surgery was not defined in the protocol and was left at the discretion of the Investigator. Resection was classified as R0, R1, or R2 following surgery. R0 was defined as complete resection with clear margins ≥1 mm. The percentage of participants with R0 resection of liver or liver plus lymph node metastases was reported. The 95% CI was computed using normal approximation to the binomial distribution. (NCT01374425)
Timeframe: At time of resective surgery during study (maximum up to 45 months overall)

Interventionpercentage of participants (Number)
Bevacizumab + mFOLFOX611.9
Bevacizumab + FOLFIRI5.5

[back to top]

Percentage of Participants With Complete Liver Metastasis Resection in Participants With High ERCC-1 Levels

The timing of resective surgery was not defined in the protocol and was left at the discretion of the Investigator. Resection was classified as R0, R1, or R2 following surgery. R0 was defined as complete resection with clear margins ≥1 mm. The percentage of participants with R0 resection of liver or liver plus lymph node metastases was reported. The 95% CI was computed using normal approximation to the binomial distribution. (NCT01374425)
Timeframe: At time of resective surgery during study (maximum up to 45 months overall)

Interventionpercentage of participants (Number)
Bevacizumab + mFOLFOX6 (ERCC-1 High)17.6
Bevacizumab + FOLFIRI (ERCC-1 High)6.7

[back to top]

Percentage of Participants With Disease Control According to RECIST Version 1.1 in Participants With High VEGF-A Levels Versus Participants With Low VEGF-A Levels

Disease control was defined as CR, PR, or SD according to RECIST Version 1.1. CR was defined as disappearance of all target lesions and short-axis reduction to <10 mm of any pathological lymph nodes. PR was defined as ≥30% decrease in sum of LD of target lesions in reference to sum of LD at Baseline. Confirmation of response at a consecutive assessment was not required. SD was defined as neither sufficient shrinkage to quality for PR nor sufficient increase to qualify for disease progression (≥20% increase in sum of LD of target lesions plus absolute increase ≥5 mm) in reference to the smallest sum of LD on study. The percentage of participants with CR, PR, or SD was reported. The 95% CI was computed using normal approximation to the binomial distribution. (NCT01374425)
Timeframe: From Baseline until disease progression; assessed every 6 weeks (maximum up to 45 months overall)

Interventionpercentage of participants (Number)
Bevacizumab + mFOLFOX/FOLFIRI (VEGF-A High)91.9
Bevacizumab + mFOLFOX/FOLFIRI (VEGF-A Low)93.0

[back to top]

Percentage of Participants With Disease Control According to RECIST Version 1.1 in Participants With High ERCC-1 Levels Versus Participants With Low ERCC-1 Levels

Disease control was defined as CR, PR, or SD according to RECIST Version 1.1. CR was defined as disappearance of all target lesions and short-axis reduction to <10 mm of any pathological lymph nodes. PR was defined as ≥30% decrease in sum of LD of target lesions in reference to sum of LD at Baseline. Confirmation of response at a consecutive assessment was not required. SD was defined as neither sufficient shrinkage to quality for PR nor sufficient increase to qualify for disease progression (≥20% increase in sum of LD of target lesions plus absolute increase ≥5 mm) in reference to the smallest sum of LD on study. The percentage of participants with CR, PR, or SD was reported. The 95% CI was computed using normal approximation to the binomial distribution. (NCT01374425)
Timeframe: From Baseline until disease progression; assessed every 6 weeks (maximum up to 45 months overall)

Interventionpercentage of participants (Number)
Bevacizumab + mFOLFOX/FOLFIRI (ERCC-1 High)89.3
Bevacizumab + mFOLFOX/FOLFIRI (ERCC-1 Low)93.9

[back to top]

Percentage of Participants With Disease Control According to RECIST Version 1.1 in Participants With High ERCC-1 Levels

Disease control was defined as CR, PR, or SD according to RECIST Version 1.1. CR was defined as disappearance of all target lesions and short-axis reduction to <10 mm of any pathological lymph nodes. PR was defined as ≥30% decrease in sum of LD of target lesions in reference to sum of LD at Baseline. Confirmation of response at a consecutive assessment was not required. SD was defined as neither sufficient shrinkage to quality for PR nor sufficient increase to qualify for disease progression (≥20% increase in sum of LD of target lesions plus absolute increase ≥5 mm) in reference to the smallest sum of LD on study. The percentage of participants with CR, PR, or SD was reported. The 95% CI was computed using normal approximation to the binomial distribution. (NCT01374425)
Timeframe: From Baseline until disease progression; assessed every 6 weeks (maximum up to 45 months overall)

Interventionpercentage of participants (Number)
Bevacizumab + mFOLFOX6 (ERCC-1 High)93.8
Bevacizumab + FOLFIRI (ERCC-1 High)85.1

[back to top]

Percentage of Participants With Objective Response According to RECIST Version 1.1 in Participants With Low ERCC-1 Levels

Objective response was defined as CR or PR according to RECIST Version 1.1. CR was defined as disappearance of all target lesions and short-axis reduction to <10 mm of any pathological lymph nodes. PR was defined as ≥30% decrease in sum of LD of target lesions in reference to sum of LD at Baseline. Confirmation of response at a consecutive assessment was not required. The percentage of participants with CR or PR was reported. The 95% CI was computed using normal approximation to the binomial distribution. (NCT01374425)
Timeframe: From Baseline until disease progression; assessed every 6 weeks (maximum up to 45 months overall)

Interventionpercentage of participants (Number)
Bevacizumab + mFOLFOX6 (ERCC-1 Low)63.7
Bevacizumab + FOLFIRI (ERCC-1 Low)65.8

[back to top]

Percentage of Participants With Disease Control According to RECIST Version 1.1

Disease control was defined as CR, PR, or stable disease (SD) according to RECIST Version 1.1. CR was defined as disappearance of all target lesions and short-axis reduction to <10 mm of any pathological lymph nodes. PR was defined as ≥30% decrease in sum of LD of target lesions in reference to sum of LD at Baseline. Confirmation of response at a consecutive assessment was not required. SD was defined as neither sufficient shrinkage to quality for PR nor sufficient increase to qualify for disease progression (≥20% increase in sum of LD of target lesions plus absolute increase ≥5 mm) in reference to the smallest sum of LD on study. The percentage of participants with CR, PR, or SD was reported. The 95% CI was computed using normal approximation to the binomial distribution. (NCT01374425)
Timeframe: From Baseline until disease progression; assessed every 6 weeks (maximum up to 45 months overall)

Interventionpercentage of participants (Number)
Bevacizumab + mFOLFOX693.1
Bevacizumab + FOLFIRI91.0

[back to top]

Percentage of Participants With Objective Response According to RECIST Version 1.1 in Participants With Wild-Type KRAS Versus Participants With Mutant KRAS

Objective response was defined as CR or PR according to RECIST Version 1.1. CR was defined as disappearance of all target lesions and short-axis reduction to <10 mm of any pathological lymph nodes. PR was defined as ≥30% decrease in sum of LD of target lesions in reference to sum of LD at Baseline. Confirmation of response at a consecutive assessment was not required. The percentage of participants with CR or PR was reported. The 95% CI was computed using normal approximation to the binomial distribution. (NCT01374425)
Timeframe: From Baseline until disease progression; assessed every 6 weeks (maximum up to 45 months overall)

Interventionpercentage of participants (Number)
Bevacizumab + mFOLFOX/FOLFIRI (KRAS Wild-Type)66.3
Bevacizumab + mFOLFOX/FOLFIRI (KRAS Mutant)60.9

[back to top]

PFS According to RECIST Version 1.1 in Participants With High ERCC-1 and High VEGF-A Levels

Tumor assessments were performed according to RECIST Version 1.1. Disease progression was defined as ≥20% increase in sum of LD of target lesions in reference to the smallest sum of LD on study, in addition to an absolute increase ≥5 mm. Disease progression was further defined as the last documented progression determined by the Investigator no later than 1 day before initiation of second-line therapy. Death on study included death from any cause occurring no later than 3 months after the last component of study treatment. PFS was defined as the time from randomization to death or disease progression, whichever occurred first. The median duration of PFS was estimated by Kaplan-Meier analysis and expressed in months. The 95% CI was computed using the method of Brookmeyer and Crowley. (NCT01374425)
Timeframe: From Baseline until death or disease progression; assessed every 6 weeks (maximum up to 45 months overall)

Interventionmonths (Median)
Bevacizumab + mFOLFOX6 (ERCC-1 High, VEGF-A High)8.80
Bevacizumab + FOLFIRI (ERCC-1 High, VEGF-A High)11.17

[back to top]

Percentage of Participants With Complete Liver Metastasis Resection in Participants With Low ERCC-1 Levels

The timing of resective surgery was not defined in the protocol and was left at the discretion of the Investigator. Resection was classified as R0, R1, or R2 following surgery. R0 was defined as complete resection with clear margins ≥1 mm. The percentage of participants with R0 resection of liver or liver plus lymph node metastases was reported. The 95% CI was computed using normal approximation to the binomial distribution. (NCT01374425)
Timeframe: At time of resective surgery during study (maximum up to 45 months overall)

Interventionpercentage of participants (Number)
Bevacizumab + mFOLFOX6 (ERCC-1 Low)8.9
Bevacizumab + FOLFIRI (ERCC-1 Low)3.3

[back to top]

Percentage of Participants With Complete Liver Metastasis Resection in Participants With High VEGF-A Levels Versus Participants With Low VEGF-A Levels

The timing of resective surgery was not defined in the protocol and was left at the discretion of the Investigator. Resection was classified as R0, R1, or R2 following surgery. R0 was defined as complete resection with clear margins ≥1 mm. The percentage of participants with R0 resection of liver or liver plus lymph node metastases was reported. The 95% CI was computed using normal approximation to the binomial distribution. (NCT01374425)
Timeframe: At time of resective surgery during study (maximum up to 45 months overall)

Interventionpercentage of participants (Number)
Bevacizumab + mFOLFOX/FOLFIRI (VEGF-A High)3.2
Bevacizumab + mFOLFOX/FOLFIRI (VEGF-A Low)8.1

[back to top]

Percentage of Participants With Complete Liver Metastasis Resection in Participants With High ERCC-1 Levels Versus Participants With Low ERCC-1 Levels

The timing of resective surgery was not defined in the protocol and was left at the discretion of the Investigator. Resection was classified as R0, R1, or R2 following surgery. R0 was defined as complete resection with clear margins ≥1 mm. The percentage of participants with R0 resection of liver or liver plus lymph node metastases was reported. The 95% CI was computed using normal approximation to the binomial distribution. (NCT01374425)
Timeframe: At time of resective surgery during study (maximum up to 45 months overall)

Interventionpercentage of participants (Number)
Bevacizumab + mFOLFOX/FOLFIRI (ERCC-1 High)4.6
Bevacizumab + mFOLFOX/FOLFIRI (ERCC-1 Low)6.1

[back to top]

PFS According to RECIST Version 1.1 in Participants With High ERCC-1 and Low VEGF-A Levels

Tumor assessments were performed according to RECIST Version 1.1. Disease progression was defined as ≥20% increase in sum of LD of target lesions in reference to the smallest sum of LD on study, in addition to an absolute increase ≥5 mm. Disease progression was further defined as the last documented progression determined by the Investigator no later than 1 day before initiation of second-line therapy. Death on study included death from any cause occurring no later than 3 months after the last component of study treatment. PFS was defined as the time from randomization to death or disease progression, whichever occurred first. The median duration of PFS was estimated by Kaplan-Meier analysis and expressed in months. The 95% CI was computed using the method of Brookmeyer and Crowley. (NCT01374425)
Timeframe: From Baseline until death or disease progression; assessed every 6 weeks (maximum up to 45 months overall)

Interventionmonths (Median)
Bevacizumab + mFOLFOX6 (ERCC-1 High, VEGF-A Low)12.52
Bevacizumab + FOLFIRI (ERCC-1 High, VEGF-A Low)12.68

[back to top]

PFS According to RECIST Version 1.1 in Participants With High ERCC-1 Levels

Tumor assessments were performed according to RECIST Version 1.1. Disease progression was defined as ≥20% increase in sum of LD of target lesions in reference to the smallest sum of LD on study, in addition to an absolute increase ≥5 mm. Disease progression was further defined as the last documented progression determined by the Investigator no later than 1 day before initiation of second-line therapy. Death on study included death from any cause occurring no later than 3 months after the last component of study treatment. PFS was defined as the time from randomization to death or disease progression, whichever occurred first. The median duration of PFS was estimated by Kaplan-Meier analysis and expressed in months. The 95% CI was computed using the method of Brookmeyer and Crowley. (NCT01374425)
Timeframe: From Baseline until death or disease progression; assessed every 6 weeks (maximum up to 45 months overall)

Interventionmonths (Median)
Bevacizumab + mFOLFOX6 (ERCC-1 High)9.92
Bevacizumab + FOLFIRI (ERCC-1 High)11.17

[back to top]

PFS According to RECIST Version 1.1 in Participants With High ERCC-1 Levels Versus Participants With Low ERCC-1 Levels

Tumor assessments were performed according to RECIST Version 1.1. Disease progression was defined as ≥20% increase in sum of LD of target lesions in reference to the smallest sum of LD on study, in addition to an absolute increase ≥5 mm. Disease progression was further defined as the last documented progression determined by the Investigator no later than 1 day before initiation of second-line therapy. Death on study included death from any cause occurring no later than 3 months after the last component of study treatment. PFS was defined as the time from randomization to death or disease progression, whichever occurred first. The median duration of PFS was estimated by Kaplan-Meier analysis and expressed in months. The 95% CI was computed using the method of Brookmeyer and Crowley. (NCT01374425)
Timeframe: From Baseline until death or disease progression; assessed every 6 weeks (maximum up to 45 months overall)

Interventionmonths (Median)
Bevacizumab + mFOLFOX/FOLFIRI (ERCC-1 High)10.87
Bevacizumab + mFOLFOX/FOLFIRI (ERCC-1 Low)11.56

[back to top]

PFS According to RECIST Version 1.1 in Participants With High Vascular Endothelial Growth Factor (VEGF)-A Levels Versus Participants With Low VEGF-A Levels

Tumor assessments were performed according to RECIST Version 1.1. Disease progression was defined as ≥20% increase in sum of LD of target lesions in reference to the smallest sum of LD on study, in addition to an absolute increase ≥5 mm. Disease progression was further defined as the last documented progression determined by the Investigator no later than 1 day before initiation of second-line therapy. Death on study included death from any cause occurring no later than 3 months after the last component of study treatment. PFS was defined as the time from randomization to death or disease progression, whichever occurred first. The median duration of PFS was estimated by Kaplan-Meier analysis and expressed in months. The 95% CI was computed using the method of Brookmeyer and Crowley. (NCT01374425)
Timeframe: From Baseline until death or disease progression; assessed every 6 weeks (maximum up to 45 months overall)

Interventionmonths (Median)
Bevacizumab + mFOLFOX/FOLFIRI (VEGF-A High)10.02
Bevacizumab + mFOLFOX/FOLFIRI (VEGF-A Low)12.68

[back to top]

PFS According to RECIST Version 1.1 in Participants With Low ERCC-1 and High VEGF-A Levels

Tumor assessments were performed according to RECIST Version 1.1. Disease progression was defined as ≥20% increase in sum of LD of target lesions in reference to the smallest sum of LD on study, in addition to an absolute increase ≥5 mm. Disease progression was further defined as the last documented progression determined by the Investigator no later than 1 day before initiation of second-line therapy. Death on study included death from any cause occurring no later than 3 months after the last component of study treatment. PFS was defined as the time from randomization to death or disease progression, whichever occurred first. The median duration of PFS was estimated by Kaplan-Meier analysis and expressed in months. The 95% CI was computed using the method of Brookmeyer and Crowley. (NCT01374425)
Timeframe: From Baseline until death or disease progression; assessed every 6 weeks (maximum up to 45 months overall)

Interventionmonths (Median)
Bevacizumab + mFOLFOX6 (ERCC-1 Low, VEGF-A High)9.76
Bevacizumab + FOLFIRI (ERCC-1 Low, VEGF-A High)11.07

[back to top]

PFS According to RECIST Version 1.1 in Participants With Low ERCC-1 and Low VEGF-A Levels

Tumor assessments were performed according to RECIST Version 1.1. Disease progression was defined as ≥20% increase in sum of LD of target lesions in reference to the smallest sum of LD on study, in addition to an absolute increase ≥5 mm. Disease progression was further defined as the last documented progression determined by the Investigator no later than 1 day before initiation of second-line therapy. Death on study included death from any cause occurring no later than 3 months after the last component of study treatment. PFS was defined as the time from randomization to death or disease progression, whichever occurred first. The median duration of PFS was estimated by Kaplan-Meier analysis and expressed in months. The 95% CI was computed using the method of Brookmeyer and Crowley. (NCT01374425)
Timeframe: From Baseline until death or disease progression; assessed every 6 weeks (maximum up to 45 months overall)

Interventionmonths (Median)
Bevacizumab + mFOLFOX6 (ERCC-1 Low, VEGF-A Low)11.10
Bevacizumab + FOLFIRI (ERCC-1 Low, VEGF-A Low)14.32

[back to top]

PFS According to RECIST Version 1.1 in Participants With Low ERCC-1 Levels

Tumor assessments were performed according to RECIST Version 1.1. Disease progression was defined as ≥20% increase in sum of LD of target lesions in reference to the smallest sum of LD on study, in addition to an absolute increase ≥5 mm. Disease progression was further defined as the last documented progression determined by the Investigator no later than 1 day before initiation of second-line therapy. Death on study included death from any cause occurring no later than 3 months after the last component of study treatment. PFS was defined as the time from randomization to death or disease progression, whichever occurred first. The median duration of PFS was estimated by Kaplan-Meier analysis and expressed in months. The 95% CI was computed using the method of Brookmeyer and Crowley. (NCT01374425)
Timeframe: From Baseline until death or disease progression; assessed every 6 weeks (maximum up to 45 months overall)

Interventionmonths (Median)
Bevacizumab + mFOLFOX6 (ERCC-1 Low)10.97
Bevacizumab + FOLFIRI (ERCC-1 Low)12.68

[back to top]

PFS According to RECIST Version 1.1 in Participants With Wild-Type V-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Versus Participants With Mutant KRAS

Tumor assessments were performed according to RECIST Version 1.1. Disease progression was defined as ≥20% increase in sum of LD of target lesions in reference to the smallest sum of LD on study, in addition to an absolute increase ≥5 mm. Disease progression was further defined as the last documented progression determined by the Investigator no later than 1 day before initiation of second-line therapy. Death on study included death from any cause occurring no later than 3 months after the last component of study treatment. PFS was defined as the time from randomization to death or disease progression, whichever occurred first. The median duration of PFS was estimated by Kaplan-Meier analysis and expressed in months. The 95% CI was computed using the method of Brookmeyer and Crowley. (NCT01374425)
Timeframe: From Baseline until death or disease progression; assessed every 6 weeks (maximum up to 45 months overall)

Interventionmonths (Median)
Bevacizumab + mFOLFOX/FOLFIRI (KRAS Wild-Type)12.45
Bevacizumab + mFOLFOX/FOLFIRI (KRAS Mutant)10.94

[back to top]

Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1

Tumor assessments were performed according to RECIST Version 1.1. Disease progression was defined as greater than or equal to (≥) 20 percent (%) increase in sum of largest diameters (LD) of target lesions in reference to the smallest sum of LD on study, in addition to an absolute increase ≥5 millimeters (mm). Disease progression was further defined as the last documented progression determined by the Investigator no later than 1 day before initiation of second-line therapy. Death on study included death from any cause occurring no later than 3 months after the last component of study treatment. PFS was defined as the time from randomization to death or disease progression, whichever occurred first. The median duration of PFS was estimated by Kaplan-Meier analysis and expressed in months. The 95% confidence interval (CI) was computed using the method of Brookmeyer and Crowley. (NCT01374425)
Timeframe: From Baseline until death or disease progression; assessed every 6 weeks (maximum up to 45 months overall)

Interventionmonths (Median)
Bevacizumab + mFOLFOX610.09
Bevacizumab + FOLFIRI12.55

[back to top]

Percentage of Participants With Objective Response According to RECIST Version 1.1 in Participants With High ERCC-1 Levels Versus Participants With Low ERCC-1 Levels

Objective response was defined as CR or PR according to RECIST Version 1.1. CR was defined as disappearance of all target lesions and short-axis reduction to <10 mm of any pathological lymph nodes. PR was defined as ≥30% decrease in sum of LD of target lesions in reference to sum of LD at Baseline. Confirmation of response at a consecutive assessment was not required. The percentage of participants with CR or PR was reported. The 95% CI was computed using normal approximation to the binomial distribution. (NCT01374425)
Timeframe: From Baseline until disease progression; assessed every 6 weeks (maximum up to 45 months overall)

Interventionpercentage of participants (Number)
Bevacizumab + mFOLFOX/FOLFIRI (ERCC-1 High)61.1
Bevacizumab + mFOLFOX/FOLFIRI (ERCC-1 Low)64.8

[back to top]

Percentage of Participants With Objective Response According to RECIST Version 1.1 in Participants With High VEGF-A Levels Versus Participants With Low VEGF-A Levels

Objective response was defined as CR or PR according to RECIST Version 1.1. CR was defined as disappearance of all target lesions and short-axis reduction to <10 mm of any pathological lymph nodes. PR was defined as ≥30% decrease in sum of LD of target lesions in reference to sum of LD at Baseline. Confirmation of response at a consecutive assessment was not required. The percentage of participants with CR or PR was reported. The 95% CI was computed using normal approximation to the binomial distribution. (NCT01374425)
Timeframe: From Baseline until disease progression; assessed every 6 weeks (maximum up to 45 months overall)

Interventionpercentage of participants (Number)
Bevacizumab + mFOLFOX/FOLFIRI (VEGF-A High)60.5
Bevacizumab + mFOLFOX/FOLFIRI (VEGF-A Low)66.5

[back to top]

Percentage of Participants With Objective Response According to RECIST Version 1.1 in Participants With High ERCC-1 Levels

Objective response was defined as CR or PR according to RECIST Version 1.1. CR was defined as disappearance of all target lesions and short-axis reduction to <10 mm of any pathological lymph nodes. PR was defined as ≥30% decrease in sum of LD of target lesions in reference to sum of LD at Baseline. Confirmation of response at a consecutive assessment was not required. The percentage of participants with CR or PR was reported. The 95% CI was computed using normal approximation to the binomial distribution. (NCT01374425)
Timeframe: From Baseline until disease progression; assessed every 6 weeks (maximum up to 45 months overall)

Interventionpercentage of participants (Number)
Bevacizumab + mFOLFOX6 (ERCC-1 High)56.3
Bevacizumab + FOLFIRI (ERCC-1 High)65.7

[back to top]

Percentage of Participants With Objective Response According to RECIST Version 1.1

Objective response was defined as complete response (CR) or partial response (PR) according to RECIST Version 1.1. CR was defined as disappearance of all target lesions and short-axis reduction to less than (<) 10 mm of any pathological lymph nodes. PR was defined as ≥30% decrease in sum of LD of target lesions in reference to sum of LD at Baseline. Confirmation of response at a consecutive assessment was not required. The percentage of participants with CR or PR was reported. The 95% CI was computed using normal approximation to the binomial distribution. (NCT01374425)
Timeframe: From Baseline until disease progression; assessed every 6 weeks (maximum up to 45 months overall)

Interventionpercentage of participants (Number)
Bevacizumab + mFOLFOX661.2
Bevacizumab + FOLFIRI65.4

[back to top]

Percentage of Participants With Liver Metastasis Resection in Participants With Low ERCC-1 Levels

The timing of resective surgery was not defined in the protocol and was left at the discretion of the Investigator. Resection was classified as R0, R1, or R2 following surgery. R0 was defined as complete resection with clear margins ≥1 mm. R1 was defined as the presence of exposed tumor or histologically detected tumor cells at the line of transection, or <1 mm microscopic margins. In the case of use of radiofrequency ablation or cryotherapy, the resection was considered as R1. R2 was defined as macroscopic positive margins or incomplete resection at time of surgery. The percentage of participants with resection of liver or liver plus lymph node metastases was reported. The 95% CI was computed using normal approximation to the binomial distribution. (NCT01374425)
Timeframe: At time of resective surgery during study (maximum up to 45 months overall)

Interventionpercentage of participants (Number)
Bevacizumab + mFOLFOX6 (ERCC-1 Low)10.5
Bevacizumab + FOLFIRI (ERCC-1 Low)7.5

[back to top]

Percentage of Participants With Liver Metastasis Resection in Participants With High VEGF-A Levels Versus Participants With Low VEGF-A Levels

The timing of resective surgery was not defined in the protocol and was left at the discretion of the Investigator. Resection was classified as R0, R1, or R2 following surgery. R0 was defined as complete resection with clear margins ≥1 mm. R1 was defined as the presence of exposed tumor or histologically detected tumor cells at the line of transection, or <1 mm microscopic margins. In the case of use of radiofrequency ablation or cryotherapy, the resection was considered as R1. R2 was defined as macroscopic positive margins or incomplete resection at time of surgery. The percentage of participants with resection of liver or liver plus lymph node metastases was reported. The 95% CI was computed using normal approximation to the binomial distribution. (NCT01374425)
Timeframe: At time of resective surgery during study (maximum up to 45 months overall)

Interventionpercentage of participants (Number)
Bevacizumab + mFOLFOX/FOLFIRI (VEGF-A High)5.9
Bevacizumab + mFOLFOX/FOLFIRI (VEGF-A Low)9.2

[back to top]

Percentage of Participants With Liver Metastasis Resection in Participants With High ERCC-1 Levels Versus Participants With Low ERCC-1 Levels

The timing of resective surgery was not defined in the protocol and was left at the discretion of the Investigator. Resection was classified as R0, R1, or R2 following surgery. R0 was defined as complete resection with clear margins ≥1 mm. R1 was defined as the presence of exposed tumor or histologically detected tumor cells at the line of transection, or <1 mm microscopic margins. In the case of use of radiofrequency ablation or cryotherapy, the resection was considered as R1. R2 was defined as macroscopic positive margins or incomplete resection at time of surgery. The percentage of participants with resection of liver or liver plus lymph node metastases was reported. The 95% CI was computed using normal approximation to the binomial distribution. (NCT01374425)
Timeframe: At time of resective surgery during study (maximum up to 45 months overall)

Interventionpercentage of participants (Number)
Bevacizumab + mFOLFOX/FOLFIRI (ERCC-1 High)4.6
Bevacizumab + mFOLFOX/FOLFIRI (ERCC-1 Low)9.0

[back to top]

Percentage of Participants With Liver Metastasis Resection in Participants With High ERCC-1 Levels

The timing of resective surgery was not defined in the protocol and was left at the discretion of the Investigator. Resection was classified as R0, R1, or R2 following surgery. R0 was defined as complete resection with clear margins ≥1 mm. R1 was defined as the presence of exposed tumor or histologically detected tumor cells at the line of transection, or <1 mm microscopic margins. In the case of use of radiofrequency ablation or cryotherapy, the resection was considered as R1. R2 was defined as macroscopic positive margins or incomplete resection at time of surgery. The percentage of participants with resection of liver or liver plus lymph node metastases was reported. The 95% CI was computed using normal approximation to the binomial distribution. (NCT01374425)
Timeframe: At time of resective surgery during study (maximum up to 45 months overall)

Interventionpercentage of participants (Number)
Bevacizumab + mFOLFOX6 (ERCC-1 High)17.6
Bevacizumab + FOLFIRI (ERCC-1 High)6.7

[back to top]

Percentage of Participants With Liver Metastasis Resection

The timing of resective surgery was not defined in the protocol and was left at the discretion of the Investigator. Resection was classified as R0, R1, or R2 following surgery. R0 was defined as complete resection with clear margins ≥1 mm. R1 was defined as the presence of exposed tumor or histologically detected tumor cells at the line of transection, or <1 mm microscopic margins. In the case of use of radiofrequency ablation or cryotherapy, the resection was considered as R1. R2 was defined as macroscopic positive margins or incomplete resection at time of surgery. The percentage of participants with resection of liver or liver plus lymph node metastases was reported. The 95% CI was computed using normal approximation to the binomial distribution. (NCT01374425)
Timeframe: At time of resective surgery during study (maximum up to 45 months overall)

Interventionpercentage of participants (Number)
Bevacizumab + mFOLFOX614.9
Bevacizumab + FOLFIRI10.9

[back to top]

Percentage of Participants With Disease Control According to RECIST Version 1.1 in Participants With Low ERCC-1 Levels

Disease control was defined as CR, PR, or SD according to RECIST Version 1.1. CR was defined as disappearance of all target lesions and short-axis reduction to <10 mm of any pathological lymph nodes. PR was defined as ≥30% decrease in sum of LD of target lesions in reference to sum of LD at Baseline. Confirmation of response at a consecutive assessment was not required. SD was defined as neither sufficient shrinkage to quality for PR nor sufficient increase to qualify for disease progression (≥20% increase in sum of LD of target lesions plus absolute increase ≥5 mm) in reference to the smallest sum of LD on study. The percentage of participants with CR, PR, or SD was reported. The 95% CI was computed using normal approximation to the binomial distribution. (NCT01374425)
Timeframe: From Baseline until disease progression; assessed every 6 weeks (maximum up to 45 months overall)

Interventionpercentage of participants (Number)
Bevacizumab + mFOLFOX6 (ERCC-1 Low)92.7
Bevacizumab + FOLFIRI (ERCC-1 Low)95.0

[back to top]

Progression-Free Survival (PFS)

PFS was defined as the time from the date of first study drug administration to the date of disease progression or death due to any cause, whichever came first. Progression was defined according to RECIST, v1.1 as at least a 20% increase in the sum of diameters of target lesions with an absolute increase of at least 5 mm or the appearance of one or more new lesions. Participants, who did not progress were censored at the date of the last assessment performed. Participants who withdrew from the study without documented progression and for whom an electronic case report form (eCRF) existed as evidence that evaluations had been made, were censored at the date of the last tumor assessment when the participant was known to be progression-free. Participants without post-baseline tumor assessments, but known to be alive were censored at the time of first study drug administration. PFS was calculated: PFS (months) = ([Date of Event - Date of first study drug administration] + 1)/30. (NCT01383707)
Timeframe: End of study up to approximately 3 years

Interventionmonths (Median)
Bevacizumab + mFOLFOX-611.7

[back to top]

Percentage of Participants Achieving No Residual Tumor (R0)/Surgical Margin With Microscopic Residual Tumor (R1) Liver Resection

The percentage of participants achieving R0/R1 liver resection was defined as the percentage of participants achieving R0 surgery (no residual tumor) plus percentage of participants achieving R1 surgery (surgical margin with microscopic residual tumor). (NCT01383707)
Timeframe: End of study up to approximately 3 years

Interventionpercentage of participants (Number)
Bevacizumab + mFOLFOX-629.9

[back to top]

Overall Survival (OS)

OS was defined as the time from the date of first study drug administration to the date of death due to any cause. Participants who were alive at the time of the analysis were censored at the last date the participant was known to be alive. OS was calculated as follows: OS (months) = ([Date of Death - first study drug administration] + 1)/30 (NCT01383707)
Timeframe: End of study up to approximately 3 years

Interventionmonths (Median)
Bevacizumab + mFOLFOX-6NA

[back to top]

Objective Response Rate (ORR) in the Per-protocol Analysis Set (PPAS)

ORR was defined as the percentage of participants with shrinkage (PR) or disappearance of cancer (CR). Tumor response was evaluated according to the RECIST v1.1. The same method of tumor measurement and assessment had to be used to characterize each lesion throughout the study. Tumor assessment consisted of CT scan (abdomen + pelvis + chest) or CE-MRI (abdomen + pelvis) + non CE-CT (chest) according to the choice of the center. CR, Disappearance of all target lesions; PR, >=30% decrease in the sum of the longest diameter of target lesions; OR = CR + PR. (NCT01383707)
Timeframe: Up to 11 cycles of treatment (up to Week 22)

Interventionpercentage of participants (Number)
Bevacizumab + mFOLFOX-664.1

[back to top]

Disease-free Interval (DFI)

DFI was defined as the time from the date of R0/R1 surgery to the date of disease relapse or death due to any cause. Participants who did not progress were considered censored at the date of the last assessment performed. For participants receiving two-stage resection, the date of R0/R1 surgery was the date of the second surgery. Participants, who did not receive surgery and participants without R0/R1 surgery were censored at Day 1. DFI was calculated as follows: DFI (months) = ([Date of R0/R1 surgery - Date of 1st relapse/Death] + 1)/30 (NCT01383707)
Timeframe: End of study up to approximately 3 years

Interventionmonths (Median)
Bevacizumab + mFOLFOX-610.8

[back to top]

Objective Response Rate (ORR) in the Intent-to-treat (ITT) Analysis Set

ORR was defined as the percentage of participants with shrinkage (partial response [PR]) or disappearance of cancer (complete response [CR]). Tumor response was evaluated according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). The same method of tumor measurement and assessment had to be used to characterize each lesion throughout the study. Tumor assessment consisted of computerized tomography (CT) scan (abdomen + pelvis + chest) or contrast-enhanced magnetic resonance imaging (CE-MRI) (abdomen + pelvis) + non CE-CT (chest) according to the choice of the center. CR, Disappearance of all target lesions; PR, >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. (NCT01383707)
Timeframe: Up to 11 cycles of treatment (up to Week 22)

Interventionpercentage of participants (Number)
Bevacizumab + mFOLFOX-654.5

[back to top]

Progression-Free Survival (PFS) at 2 Years

Disease progression is defined using the 2007 revised Cheson et al. criteria that is at least 50% increase in sum of the product of the diameters (SPD) of target measurable nodal lesions over the smallest sum observed, or >= 50% increase in greatest transverse diameter (GTD) of any nodal > 1 cm in shortest axis, or >= 50% increase in the SPD of other target measurable lesions over the smallest sum observed, any new bone marrow involvement, any new lesion, lymph node with long axis is > 1.5 cm or if both long and short axes are > 1 cm, PET positive if patients with no pretreatment PET scan or when PET scan was positive before therapy. Progression-free survival is measured from date of registration to date of first observation of progressive disease, or death due to any cause. Patients last known to be alive and progression-free are censored at date of last contact. (NCT01412879)
Timeframe: Up to 2 years

Interventionpercentage of participants (Number)
Arm 1: R-HCVAD/MTX/Ara-C (Induction Therapy)82
Arm 2: R-Bendamustine (Induction Therapy)81

[back to top] [back to top]

5-year Overall Survival (OS)

Measured from date of registration to date of death due to any cause. Patients last known to be alive and are censored at date of last contact. (NCT01412879)
Timeframe: Up to 5 years

Interventionpercentage of participants (Number)
Arm 1: R-HCVAD/MTX/Ara-C (Induction Therapy)81
Arm 2: R-Bendamustine (Induction Therapy)79

[back to top]

Response Rate (Complete and Partial Response)

Complete Response (CR) is a complete disappearance of all disease with the exception of the following. If no PET scan or when the PET scan was positive before therapy, a post-treatment residual mass of any size is permitted if it is PET negative. If the PET scan was negative before therapy, all nodal masses at baseline must have regressed. No new lesions. Previously enlarged organs must have regressed and not be palpable. Bone marrow (BM) must be negative if positive at baseline. Normalization of markers. Partial Response (PR) is a 50% decrease in the sum of products of greatest diameters (SPD) for up to 6 identified dominant lesions, including spleenic and hepatic nodules from baseline. No new lesions and no increase in the size of liver, spleen or other nodes. If PET scan or when the PET scan was positive before therapy, PET should be positive in at least one previously involved site. (NCT01412879)
Timeframe: Up to 9 months

Interventionpercentage of participants (Number)
Arm 1: R-HCVAD/MTX/Ara-C (Induction Therapy)94.1
Arm 2: R-Bendamustine (Induction Therapy)82.9

[back to top]

Progression Free Survival (PFS)

The PFS was defined as the time from the date of randomization to the earliest event time of: a) death regardless of cause, or b) first indication of disease progression. PFS was analyzed using Kaplan-Meier (KM) estimates. (NCT01479465)
Timeframe: Randomization up to 27 months

Interventionmonths (Median)
FOLFIRI + SIM 700 mg (Part A)5.7
FOLFIRI + Placebo (Part B)5.8
FOLFIRI + SIM 200 mg (Part B)5.4
FOLFIRI + SIM 700 mg (Part B)5.5

[back to top]

Objective Response Rate (ORR)

Objective response was assessed using the Response Evaluation Criteria in Solid Tumors (RECIST) criteria (version 1.1) as Complete Response (CR), Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD). The ORR was defined as the percentage of participants who achieved a CR or PR. (NCT01479465)
Timeframe: Randomization up to 27 months

Interventionpercentage of participants (Number)
FOLFIRI + SIM 700 mg (Part A)9.1
FOLFIRI + Placebo (Part B)10.0
FOLFIRI + SIM 200 mg (Part B)5.9
FOLFIRI + SIM 700 mg (Part B)11.9

[back to top]

Overall Survival (OS)

The OS is measured as time from date of randomization to death regardless of cause. The OS was analyzed using KM estimates. (NCT01479465)
Timeframe: Randomization up to 33 months

Interventionmonths (Median)
FOLFIRI + SIM 700 mg (Part A)9.8
FOLFIRI + Placebo (Part B)16.3
FOLFIRI + SIM 200 mg (Part B)10.5
FOLFIRI + SIM 700 mg (Part B)11.4

[back to top]

Number of Participants With Adverse Events

Number of Participants with Adverse Events as a Measure of Safety and Tolerability (NCT01481545)
Timeframe: Up to 8 weeks after surgery

InterventionParticipants (Count of Participants)
Concomitant - Schedule A7
Sequential - Schedule B22

[back to top]

Clinical Response Rate

"Clinical response was assessed before surgery with the same imaging modalities that were used for the inclusion in the study.~Clinical response rate was the ratio between complete and partial response, evaluated by RECIST CRITERIA, and total of patients evaluated, expressed in percentage of patients.~Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR." (NCT01481545)
Timeframe: 7 weeks after chemoradiation therapy up to 11 weeks

Interventionpercentage of participants (Number)
Sequential - Schedule B40
Concomitant - Schedule A20

[back to top]

Percentage of Patients With Complete Tumor Regression Rate (TRG1)

"Complete tumor regression rate (TRG1) was the ratio of patients with TRG1, graded at surgical resection, and total patients included in the study, expressed in percentage.~Tumor regression grade (TRG) was misured according to the Mandard Scale. Briefly,TRG1 was a complete tumor regression (regardless of the presence of acellular mucine lakes), and TRG2 was a nearly complete tumor regression with extensive fibrosis; TRG3 presented with clear evidence of residual cancer cells but with predominant fibrosis;TRG4 was a residual of cancer cells outgrowing fibrosis; TRG5 was the absence of regressive changes." (NCT01481545)
Timeframe: In 8 weeks after completion of chemoradiotherapy

Interventionpercentage of participants (Number)
Concomitant - Schedule A12.5
Sequential - Schedule B50

[back to top]

Progression Free Survival (PFS)

"PFS was calculated from the date of the initial treatment until tumor progression or relapse, death for any cause or last follow up.~Progression was defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions." (NCT01481545)
Timeframe: 10 years

Interventionparticipants (Number)
Sequential - Schedule B37
Concomitant - Schedule A11

[back to top]

Patients With Metastatic Lymphnodes at Pathology Exam After Surgery

Number of patients with metastatic lymphnodes at pathology exam after surgery. (NCT01481545)
Timeframe: In 8 weeks after chemoradiation therapy completion

Interventionparticipants (Number)
Sequential - Schedule B14
Concomitant - Schedule A5

[back to top]

Overall Survival (OS)

OS was calculated from the date of initial treatment to the date of death for any cause or last follow up. (NCT01481545)
Timeframe: 10 years

Interventionparticipants (Number)
Sequential - Schedule B40
Concomitant - Schedule A11

[back to top]

Number of Patients With Sphincter Preservation

Sphincter preservation in patients with tumor < 5 cm from anal verge in 8 weeks after chemoradiation therapy (NCT01481545)
Timeframe: In 8 weeks after chemoradiation therapy

InterventionParticipants (Count of Participants)
Concomitant - Schedule A13
Sequential - Schedule B41

[back to top]

Overall Survival (OS)

Defined as the time from first treatment until death from any cause. (NCT01490866)
Timeframe: every 8 weeks until progression then every 3 months for up to 5 years.

Interventionmonths (Median)
FOLFOX/Bevacizumab and Axitinib24.2

[back to top]

Progression-free Survival

Defined as the time from first treatment until objective tumor progression or death from any cause, assessed according to Response Evaluation Criteria for Solid Tumors (RECIST) v1.1. (NCT01490866)
Timeframe: 24 months

Interventionmonths (Median)
FOLFOX/Bevacizumab and Axitinib8.3

[back to top]

Time To Progression (TTP)

Defined as the time after a disease is diagnosed (or treated) until worsening of the disease. (NCT01490866)
Timeframe: every 8 weeks, assessed approximately up to 24 months

Interventionmonths (Median)
FOLFOX/Bevacizumab and Axitinib8.8

[back to top]

Frequency of Adverse Events as a Measure of Safety

The frequency of adverse events (AEs) was analyzed in 2 groups of patients, those receiving FOLFOX/bevacizumab (N=70), and patients who received axitinib maintenance (N = 48). AEs were assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0. (NCT01490866)
Timeframe: Every 4 weeks plus 30 days during treatment and up to 5 years thereafter.

,
Interventionparticipants (Number)
FatigueNauseaDiarrheaPeripheral neuropathyNeutropeniaThrombocytopeniaLeukopeniaAnorexiaMucositisProteinuriaAnemiaConstipationPainVomitingHypertensionHeadacheMyalgiaDizzinessSkin changesArthralgiaHand-foot skin reactionDyspneaHoarsenessAST increased
Axitinib241516160871451270110227100067775
FOLFOX/Bevacizumab403734342522211918161615141411988770000

[back to top]

Objective Response Rate

Defined as the percentage of evaluable patients showing a complete or partial response (CR or PR) per RECIST v1.1 criteria. CR = disappearance of all lesions. PR = at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. Stable disease (SD) = neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest (nadir) sum LD since start of treatment. (NCT01490866)
Timeframe: every 8 weeks, assessed up to approximately 24 months

Interventionpercentage of participants (Number)
Objective ResponseStable Disease
FOLFOX/Bevacizumab and Axitinib3457

[back to top]

EORTC-QLQ-C30

This patient recorded outcome consists of 15 subscales in 3 independent domains: global health-related quality of life (HRQoL), functional scales (cognitive, emotional, physical, role and social functioning), and symptom scales (appetite loss, constipation, diarrhea, dyspnea, fatigue, insomnia, nausea and vomiting, and pain). For each subscale, patients were classified as improved, worsened or stable. Improvement is indicated by achievement of subscale score at least 10% improved from baseline and maintained for at least 6 weeks. Worsened is indicated by subscale score at least 10% worse than baseline. Stable is indicated by neither improvement nor worsened. Achievement of improvement prior to worsening was classified as improvement. (NCT01494506)
Timeframe: Baseline to treatment discontinuation every 6 weeks; The maximum time in follow up was 25 months

,,,
Interventionpercent of patients in category (Number)
Global Health Status: ImprovedGlobal Health Status: StableGlobal Health Status: WorsenedPhysical Functioning: ImprovedPhysical Functioning: StablePhysical Functioning: WorsenedRole Functioning: ImprovedRole Functioning: StableRole Functioning: WorsenedEmotional Functioning:ImprovedEmotional Functioning:StableEmotional Functioning:WorsenedCognitive Functioning:ImprovedCognitive Functioning:StableCognitive Functioning:WorsenedSocial Functioning:ImprovedSocial Functioning:StableSocial Functioning:WorsenedFatigue:ImprovedFatigue:StableFatigue:WorsenedNausea and Vomiting:ImprovedNausea and Vomiting:StableNausea and Vomiting:WorsenedPain:ImprovedPain:StablePain:WorsenedDyspnoea:ImprovedDyspnoea:StableDyspnoea:WorsonedInsomnia:ImprovedInsomnia:StableInsomnia:WorsenedAppetite Loss:ImprovedAppetite Loss:StableAppetite Loss:WorsenedConstipation:ImprovedConstipation:StableConstipation:WorsenedDiarrhoea:ImprovedDiarrhoea: StableDiarrhoea: WorsenedFinancial Difficulties: ImprovedFinancial Difficulties: StableFinancial Difficulties: Worsened
5-FU + Leucovorin (Arm B) (Mono Therapy Comparison)114148113752103952859336425211434611305964252103753669244494764252463344583916731
5-FU + Leucovorin (Combo Therapy Comparison)124444114049113753958337444911474212335444651114049568255494654649467304583907426
MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison173845104149153252204634114841133454142066133255273439751421834481145441356316395585141
MM-398 Arm A (Mono Therapy Comparison)103157102961629661032561232541126621318695375820305010474494348938531347394355965142

[back to top]

Time to Treatment Failure

Time from randomization to discontinuation of treatment for any reason, including disease progression, treatment toxicity or death. (NCT01494506)
Timeframe: Randomization to treatment discontinuation (any cause). The maximum time in follow up was 25 months

Interventionmonths (Median)
MM-398 Arm A (Mono Therapy Comparison)1.7
5-FU + Leucovorin (Arm B) (Mono Therapy Comparison)1.4
MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison2.3
5-FU + Leucovorin (Combo Therapy Comparison)1.4

[back to top]

Progression Free Survival

"Progression-free survival was defined as the time from the date of randomization to the date of disease progression, or death (any cause) on or prior to the clinical cutoff date, whichever occurred earlier. Participants who did not have disease progression or had not died were censored at the date of the last tumor assessment. Patients with two or more consecutive missing response assessments prior to a visit with documented progression (or death) were censored at the last date of tumor assessment when the patient was documented to be progression free. PFS was summarized using Kaplan-Meier methods.~The comparison of Arm C is based only on patients who were randomized under the 3-arm version of the protocol. Consequently, the 5-FU+Leucovorin (Combo Therapy Comparison) group is a subset of all patients randomized to 5-FU+Leucovorin, which is the Mono Therapy Comparison control and contains patients randomized under both the 2-arm and 3-arm versions of the protocol." (NCT01494506)
Timeframe: Randomization until disease progression or death from any cause; Until the data cut off of 14 Feb 2014. The maximum time in follow up was 25 months.

Interventionmonths (Median)
MM-398 Arm A (Mono Therapy Comparison)2.7
5-FU + Leucovorin (Arm B) (Mono Therapy Comparison)1.6
MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison3.1
5-FU + Leucovorin (Combo Therapy Comparison)1.5

[back to top]

Pharmacokinetic Measurements of Total Irinotecan

Plasma concentration-time data for MM-398 will be analyzed using population pharmacokinetic methods. (NCT01494506)
Timeframe: 6 weeks after first study drug administration

,
InterventionTotal irinotecan = ug/L; SN38= ug/L (Geometric Mean)
Total Irinotecan-CavgTotal Irinotecan-CmaxTotal SN38-CavgTotal SN38-Cmax
MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison2120.0028460.000.682.58
MM-398 Arm A (Mono Therapy Comparison)2550.0040550.000.823.93

[back to top]

Objective Response Rate

The objective response rate was a secondary efficacy endpoint of the study and was defined by the percentage of patients in the study population with a best overall response of Complete Response (CR) or Partial Response (PR) as assessed by the investigator. Best overall response was defined per RECIST (version 1.1) recorded from randomization until progression or end of study. RECIST (v 1.1) criteria does not require confirmation of response, but an additional, more stringent analysis was also conducted, with designation of CR (or PR) requiring confirmation of response at least 4 weeks following the initial assessment of CR (or PR). Stable disease (SD) required an assessment of SD at least 6 weeks after starting treatment. Subjects with insufficient data for response classification were classified as Not Evaluable for best overall response, and as a non-responder for objective response, in the ITT population. Treatment groups are as indicated for the primary outcome of OS. (NCT01494506)
Timeframe: Assessment every 6 weeks after initial response; Day 1 to data cut off of 14 Feb 2014; maximum time on study 25 months.

Interventionpercentage with confirmed response (Number)
MM-398 Arm A (Mono Therapy Comparison)3.31
5-FU + Leucovorin (Arm B) (Mono Therapy Comparison)0.67
MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison7.69
5-FU + Leucovorin (Combo Therapy Comparison)0.84

[back to top]

Overall Survival

"Overall survival was the primary efficacy endpoint of the study and was defined as the time from the date of patient randomization to the date of death or the date the patient was last known to be alive. OS was summarized by Kaplan-Meier methodology for each treatment group. Pairwise treatment group comparisons were carried out using unstratified log rank analyses on the ITT population. Hazard ratio estimates are from Cox regression analysis.~The comparison of Arm C is based only on patients who were randomized under the 3-arm version of the protocol. Consequently, the 5-FU+Leucovorin (Combo Therapy Comparison) group is a subset of all patients randomized to 5-FU+Leucovorin, which is the Mono Therapy Comparison control and contains patients randomized under both the 2-arm and 3-arm versions of the protocol." (NCT01494506)
Timeframe: From randomization to death; until the data cut off 14 Feb 2014. The maximum time in follow up was 25 months.

Interventionmonths (Median)
MM-398 Arm A (Mono Therapy Comparison)4.9
5-FU + Leucovorin (Arm B) (Mono Therapy Comparison)4.2
MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison6.1
5-FU + Leucovorin (Combo Therapy Comparison)4.2

[back to top]

Percentage of Patients With Clinical Benefit Response

"Composite measure based on patient-reported pain (per VAS), patient-reported pain medication, KPS, and weight. Clinical benefit is indicated by either:~(a) improvement in pain (less pain intensity with stable or decreased pain medication; or less pain medication with stable or decreased pain intensity) with stable or improved KPS; or (b) improvement in KPS with stable or improved pain.~With stable for KPS and pain, clinical benefit may be indicated with an observation of positive weight change.~Clinical benefit response (CBR) was classified weekly and a patient was considered a clinical benefit responder if clinical benefit was observed and maintained over a 4 week period." (NCT01494506)
Timeframe: Randomization to treatment discontinuation.The maximum time in follow up was 25 months

Interventionpercentage of participants with CBR (Number)
MM-398 Arm A (Mono Therapy Comparison)14
5-FU + Leucovorin (Arm B) (Mono Therapy Comparison)13
MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison14
5-FU + Leucovorin (Combo Therapy Comparison)12

[back to top]

Percentage of Patients With Tumor Marker (CA 19-9) Response

Tumor marker response (TMR) was evaluated by the change in CA19-9 serum levels. Response was defined as a decrease of 50% of CA19-9 in relation to the baseline level at least once during the treatment period. (NCT01494506)
Timeframe: Baseline to treatment discontinuation every 6 weeks; The maximum time in follow up was 25 months

Interventionpercent of participants with TMR (Number)
MM-398 Arm A (Mono Therapy Comparison)23.6
5-FU + Leucovorin (Arm B) (Mono Therapy Comparison)11.4
MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison28.9
5-FU + Leucovorin (Combo Therapy Comparison)8.6

[back to top]

PFS Variation by ERCC1

"Progression-free survival is the length of time between protocol registration and disease progression or death, whichever occurs first.~Participants were divided into subgroups according to ERCC1 quartiles to assess whether the differences in PFS between the two treatment arms varied by ERCC1 levels." (NCT01498289)
Timeframe: up to 3 years after registration

,
Interventionmonths (Median)
Q1 ERCC1 (0.20-0.80)Q2 ERCC1 (0.81-1.10)Q3 ERCC1 (1.11-1.42)Q4 ERCC1 (1.43-5.71)
Arm I5.67.45.64.6
Arm II2.83.02.92.6

[back to top] [back to top]

Overall Response Rate (ORR)

"ORR (complete response, unconfirmed complete response, partial response, unconfirmed partial response) in patients with measurable disease were assessed in each arm and compared between arms using Chi-squared test.~Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR." (NCT01498289)
Timeframe: Up to 3 years after registration

Interventionpercentage of evaluable participants (Number)
Arm I42
Arm II30

[back to top]

Overall Survival (OS)

OS is the length of time between protocol registration and patient death (NCT01498289)
Timeframe: Up to 3 years after registration

Interventionmonths (Median)
Arm I11.4
Arm II8.7

[back to top]

PFS in Low-ERCC1 Participants

Progression-free survival is the length of time between protocol registration and disease progression or death, whichever occurs first. (NCT01498289)
Timeframe: Up to 3 years after registration

Interventionmonths (Median)
Arm I5.9
Arm II2.8

[back to top]

Progression-free Survival (PFS) in High-ERCC1 Patients

Progression-free survival is the length of time between protocol registration and disease progression or death, whichever occurs first. (NCT01498289)
Timeframe: Up to 3 years after registration

Interventionmonths (Median)
Arm I FOLFOX4.7
Arm II IT5.3

[back to top]

Plasma 25-hydroxyvitamin D Levels

Plasma 25-hydroxyvitamin D [25(OH)D] levels as measured in one batch per established methods by an independent laboratory. (NCT01516216)
Timeframe: Plasma samples were collected at 4 timepoints on study: baseline, first restaging (cycle 5, day 1), second restaging (cycle 9, day 1) and at treatment discontinuation. Median (maximum) treatment duration was 7.3 (28.5) months.

,
Interventionng/mL (Median)
Baseline plasma 25(OH)D levelsFirst restaging plasma 25(OH)D levelsSecond restaging plasma 25(OH)D levelsAt treatment discontinuation plasma 25(OH)D levels
Chemotherapy + Higher Dose Vitamin D16.13235.234.9
Chemotherapy + Standard Dose Vitamin D18.718.718.518.7

[back to top] [back to top]

Hazard Ratio Between Baseline Plasma 25(OH)D Level and PFS

Plasma 25-hydroxyvitamin D [25(OH)D] levels as measured in one batch per established methods by an independent laboratory. Plasma 25(OH)D Level is used as continuous data. PFS is estimated based on Kaplan-Meier method (see outcome measure 1). The PFS hazard ratio associated with one unit increase of 25()H)D. (NCT01516216)
Timeframe: Baseline Plasma 25(OH)D Level and up to 28.5m for evaluation of PFS.

Interventionhazard ratio (Number)
All Participants With Baseline Plasma 25 (OH) D Level1.00

[back to top]

Hazard Ratio Between Baseline Plasma 25(OH)D Levels and OS

Plasma 25-hydroxyvitamin D [25(OH)D] levels as measured in one batch per established methods by an independent laboratory. Plasma 25(OH)D Level is used as continuous data. OS is estimated based on Kaplan-Meier method (see outcome measure 2). The OS hazard ratio associated with one unit increase of 25()H)D. (NCT01516216)
Timeframe: Baseline Plasma 25(OH)D Level and up to maximum 56.7 months for evaluation of OS.

Interventionhazard ratio (Number)
All Participants of the Study0.995

[back to top]

Median Overall Survival (OS)

OS based on the Kaplan-Meier method is defined as the time from study entry to death or censored at date last known alive. Patients who discontinued treatment to pursue potentially curative resection were censored for progression-free survival at the time of surgery. Patients who had not experienced cancer progression or died were censored at their last known follow-up date. (NCT01516216)
Timeframe: Participants were followed for survival by clinic visit or telephone every 3 months post-treatment discontinuation up to 36 months from the date that the last participant was enrolled. Median follow-up was 22.9 months with maximum 56.7 months.

InterventionMonths (Median)
Chemotherapy + Standard Dose Vitamin D24.3
Chemotherapy + Higher Dose Vitamin D24.3

[back to top]

Median Progression-free Survival (PFS)

"Progression-free survival based on the Kaplan-Meier method is defined as the duration of time from study entry to documented disease progression (PD) or death. Per RECIST 1.1 criteria: progressive disease (PD) is at least a 20% increase in the sum of longest diameter (LD) of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. PD for the evaluation of non-target lesions is the appearance of one or more new lesions and/or unequivocal progression of non-target lesions.~Patients who discontinued treatment to pursue potentially curative resection were censored for progression-free survival at the time of surgery. Patients who had not experienced cancer progression or died were censored at their last known follow-up date." (NCT01516216)
Timeframe: Disease was evaluated every 4 cycles on treatment and off treatment every 8-16 weeks until PD or non-protocol therapy start if discontinued for reason other than PD. Participants were observed up to 28.5 months with maximum follow-up of 56.7 months.

InterventionMonths (Median)
Chemotherapy + Standard Dose Vitamin D11
Chemotherapy + Higher Dose Vitamin D13

[back to top]

Number of Participants With Vitamin D Deficiency at Baseline

Vitamin D deficiency was defined as plasma 25-hydroxyvitamin D [25(OH)D] level <20 ng/mL as measured in one batch per established methods by an independent laboratory. (NCT01516216)
Timeframe: Baseline

InterventionParticipants (Count of Participants)
Chemotherapy + Standard Dose Vitamin D39
Chemotherapy + Higher Dose Vitamin D48

[back to top]

Objective Response Rate

The objective response rate (ORR) was defined as the percentage of participants achieving complete response (CR) or partial response (PR) based on RECIST 1.1 criteria on treatment. Per RECIST 1.1 for target lesions: CR is complete disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD. PR or better overall response assumes at a minimum incomplete response/stable disease (SD) for the evaluation of non-target lesions and absence of new lesions. (NCT01516216)
Timeframe: Disease was evaluated every 4 cycles on treatment. Median (maximum) treatment duration was 7.3 (28.5) months.

Interventionpercentage of participants (Number)
Chemotherapy + Standard Dose Vitamin D63
Chemotherapy + Higher Dose Vitamin D58

[back to top]

Vitamin D Sufficiency Rate

Percentage of participants that achieve Vitamin D sufficiency defined as plasma 25(OH)D >=30 ng/mL on treatment as measured in one batch per established methods by an independent laboratory. (NCT01516216)
Timeframe: Plasma samples were collected at 3 timepoints on treatment: first restaging (cycle 5, day 1), second restaging (cycle 9, day 1) and at treatment discontinuation. Median (maximum) treatment duration was 7.3 (28.5) months.

Interventionpercentage of participants (Number)
Chemotherapy + Standard Dose Vitamin D9.8
Chemotherapy + Higher Dose Vitamin D71.4

[back to top]

Percentage of Participants With Complete Response

Complete Response is defined as 3 consecutive bi-weekly values of hCG<5 over a minimum of 4 weeks of normal hCG values with no values greater than 5 mIU/ml (NCT01535053)
Timeframe: hCG testing is performed prior to each cycle to treatment until treatment is completed, up to 10 months. For patients who have responded to treatment hCG must be obtained every 4 weeks for 1 year after completing treatment.

Interventionpercentage of participants (Number)
Regimen I (Dactinomycin)78.6
Regimen II (Methotrexate)88.5

[back to top]

The Number of Participants With Post Protocol Multi-agent Chemotherapy Treatment for Each Arm.

(NCT01535053)
Timeframe: Anytime during post treatment follow-up for up to 2 years from study entry.

Interventionparticipants (Number)
Regimen I (Dactinomycin)0
Regimen II (Methotrexate)0

[back to top]

The Number of Participants With Post Protocol Surgical Treatment for Each Arm.

(NCT01535053)
Timeframe: Anytime during post treatment follow-up for up to 2 years from study entry.

Interventionparticipants (Number)
Regimen I (Dactinomycin)0
Regimen II (Methotrexate)0

[back to top]

Number of Participants With CTCAE v4 Graded Adverse Events With Low-risk Gestational Trophoblastic Neoplasia by Arm

Maximum grade of physician assessed adverse events reported during treatment (NCT01535053)
Timeframe: Assessed throughout the treatment period and within 2-4 weeks after discontinuation of treatment

,
Interventionparticipants (Number)
Grade 1Grade 2Grade 3Grade 4Grade 5
Regimen I (Dactinomycin)714600
Regimen II (Methotrexate)4101000

[back to top]

Patient-reported Quality of Life (QOL) After Baseline Visit.

Patient reported quality of life was measured with the Functional Assessment of Cancer Therapy - Generic (FACT-G). The FACT-G is a scale for assessing general QOL of cancer patients. It consists of four subscales: Physical Well Being, Functional Well Being, Social/Family Well-Being, and Emotional Well-Being. Each item in the FACT-G was scored using a 5-point scale (0=not at all; 1=a little bit; 2=somewhat; 3=quite a bit; 4=very much). For the negative statements, reversal was performed prior to score calculation. According to the FACIT measurement system, a subscale score was the summation of the individual item scores if more than 50% of subscale items were answered. When unanswered items existed, a subscale score was prorated by multiplying the mean of the answered item scores by the number of items in the subscale. The FACT-G score is calculated as the sum of the subscale scores. The FACT-G score ranges 0-108. A larger score suggests better QOL. (NCT01535053)
Timeframe: Prior to cycle 3 (4 weeks after cycle 1 if off study treatment prior to cycle 3). Prior to cycle 5, Prior to cycle 7, 26 weeks after starting study treatment.

,
Interventionunits on a scale (Least Squares Mean)
Pre-cycle 3Pre-cycle 5Pre-cycle 726 weeks
Regimen I (Dactinomycin)78.375.585.091.2
Regimen II (Methotrexate)81.678.984.590.9

[back to top]

Patient-reported Quality of Life (QOL) at Baseline

Patient reported quality of life was measured with the Functional Assessment of Cancer Therapy - Generic (FACT-G). The FACT-G is a scale for assessing general QOL of cancer patients. It consists of four subscales: Physical Well Being, Functional Well Being, Social/Family Well-Being, and Emotional Well-Being. Each item in the FACT-G was scored using a 5-point scale (0=not at all; 1=a little bit; 2=somewhat; 3=quite a bit; 4=very much). For the negative statements, reversal was performed prior to score calculation. According to the FACIT measurement system, a subscale score was the summation of the individual item scores if more than 50% of subscale items were answered. When unanswered items existed, a subscale score was prorated by multiplying the mean of the answered item scores by the number of items in the subscale. The FACT-G score is calculated as the sum of the subscale scores. The FACT-G score ranges 0-108. A larger score suggests better QOL. (NCT01535053)
Timeframe: Prior to cycle 1

Interventionunits on a scale (Mean)
Regimen I (Dactinomycin)82.3
Regimen II (Methotrexate)81.9

[back to top]

GMDS (Griffiths Mental Development Scale)

GMDS for testing and estimate babies psychomotor development from birth to 2 years trough six subscales : Locomotor, Personal-social, Hearing and language, Eye-Hand coordination, Performance.Sub- and General Quotients (GDQ) standard score are based on a mean of 100 and a standard deviation of 16. For children with delayed development, which is the case for children with Down Syndrome, Quotient tables could be not used because sub- and General quotient floors at 50. For each subscale, a raw score was derived from the contributing items. Total raw score was obtained by adding subscale raw scores. Sum of all subscale raw scores was converted into a development age using correspondence table. Subscale and global development quotients were computed by dividing the development age by the chronological age multiplied by 100. For preterm infants, chronological age was corrected taking into account the gestational term. Higher QD's scores show a better psychomotor development outcome (NCT01576705)
Timeframe: 12 months

Interventiondeveloppement quotient (Mean)
Thyroxin + Folinic Acid51.96
Thyroxin+Folinic Acid Placebo51.27
Thyroxin Placebo+ Folinic Acid51.66
Thyroxin Placebo+ Folinic Acid Placebo51.67

[back to top]

BL (Brunet Lezine Revised Scale)

BL includes 4 subscales : Locomotor, Coordination, Language, Sociability. Subscale and global developpemental quotients were computed by dividing the developpemental age by the chronological age multiplied by 100. This kind of formula do not give a min-max outcome. Higher QD's scores show a better psychomotor developpement outcome. (NCT01576705)
Timeframe: 12 months

Interventiondeveloppement quotient (Mean)
Thyroxin + Folinic Acid51.18
Thyroxin+Folinic Acid Placebo50.64
Thyroxin Placebo+ Folinic Acid51.24
Thyroxin Placebo+ Folinic Acid Placebo51.36

[back to top]

Overall Response Rate (ORR)

The overall response: ORR = complete response (CR) + partial response (PR). Rate will be summarized using both point estimates and exact confidence intervals based on the binomial distribution by groups. (NCT01581307)
Timeframe: Up to 29 months

InterventionParticipants (Count of Participants)
Complete ResponsePartial Response
2nd Line Chemotherapy With Radiotherapy05

[back to top]

Median Overall Survival (OS)

OS, defined as the time from study enrollment to death from any cause, will be analyzed and summarized with the survival probabilities over time using Kaplan-Meier method. Confidence intervals for the median OS rates at different time points will be constructed when appropriate. (NCT01581307)
Timeframe: Up to 29 months

Interventionmonths (Median)
2nd Line Chemotherapy With Radiotherapy14.09

[back to top]

Rate of Progression Free Survival (PFS)

PFS defined as the time from study enrollment to progression in the liver by modified Response Evaluation Criteria in Solid Tumors (RECIST) or death, whichever occurs first will be analyzed and summarized with the survival probabilities over time using Kaplan-Meier method. Confidence intervals for the median PFS rates at different time points will be constructed when appropriate. (NCT01581307)
Timeframe: Up to 29 months

InterventionParticipants (Count of Participants)
2nd Line Chemotherapy With Radiotherapy3

[back to top]

PFS Until Second Disease Progression as Assessed by the Investigator Based on Routine Clinical Practice: Phase B

PFS in Phase B (PFS-B) was defined as the time from the start of Phase B treatment to documentation of second disease progression or death from any cause, whichever occurred first. Disease progression was determined according to standard practice based on radiological, biochemical (CEA) or clinical factors. Determination of disease progression was to be unequivocal and was defined as any of the following: an unequivocal and clinically meaningful increase in the size of known tumors, the appearance of one or more new lesions, death due to disease without prior objective documentation of progression, elevated CEA accompanied by other radiological or clinical evidence of progression, or symptomatic deterioration. Kaplan-Meier methodology was used to estimate PFS. (NCT01588990)
Timeframe: From the start of Phase B treatment to disease progression, death or end of study (up to 4 years)

Interventionmonths (Median)
Bevacizumab: Phase B6.7

[back to top]

OS: Phase B

Overall Survival in Phase B was defined as the time from the start of treatment in Phase B to death due to any cause. Kaplan-Meier methodology was used to estimate OS. (NCT01588990)
Timeframe: From the start of Phase B treatment death or end of study (up to 4 years)

Interventionmonths (Median)
Bevacizumab: Phase B14.9

[back to top]

Functional Assessment of Cancer Therapy-Colorectal (FACT-C) Score: Phase A

FACT-C is one part of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, which comprehensively assesses the health-related QoL of cancer participants and participants with other chronic illnesses. It is composed of 27 items of the general version of the FACT-C as a general core QoL measure and has a disease-specific subscale containing 9 colorectal cancer-specific items. It consists of total 36 items, summarized to 5 subscales: physical well-being (7 items), functional well-being (7 items), social/family well-being (7 items); all 3 subscales range from 0 to 28, emotional well-being (6 items) range from 0 to 24, colorectal cancer subscale (9 items) range from 0 to 36; higher subscale score=better QoL. All single-item measures range from 0='Not at all' to 4='Very much'. Total possible score range: 0 to 144. High scale score represents a better QoL. (NCT01588990)
Timeframe: Baseline, every 8-9 weeks thereafter, EOT (30 days after disease progression [up to 4 years]), survival follow-up 12-weekly visits (up to 4 years) [Detailed time points are presented in the category titles]

Interventionunits on a scale (Mean)
Phase A BaselinePhase A Visit 2 (Weeks 8-9)Phase A Visit 3 (Weeks 16-17)Phase A Visit 4 (Weeks 24-25)Phase A Visit 5 (Weeks 32-33)Phase A Visit 6 (Weeks 40-41)Phase A Visit 7 (Weeks 48-49)Phase A Visit 8 (Weeks 56-57)Phase A Visit 9 (Weeks 64-65)Phase A Visit 10 (Weeks 72-73)Phase A Visit 11 (Weeks 80-81)Phase A Visit 12 (Weeks 88-89)Phase A Visit 13 (Weeks 96-97)Phase A Visit 14 (Weeks 104-105)Phase A Visit 15 (Weeks 112-113)Phase A Visit 16 (Weeks 120-121)Phase A Visit 17 (Weeks 128-129)Phase A Visit 18 (Weeks 136-137)Phase A Visit 19 (Weeks 144-145)Phase A Visit 20 (Weeks 152-153)Phase A Visit 21 (Weeks 160-161)Phase A Visit 22 (Weeks 168-169)Phase A Visit 23 (Weeks 176-177)Phase A EOT Visit (up to 4 years)Survival Follow-Up 1 (up to 4 years)Survival Follow-Up 2 (up to 4 years)Survival Follow-Up 3 (up to 4 years)Survival Follow-Up 4 (up to 4 years)Survival Follow-Up 5 (up to 4 years)Survival Follow-Up 6 (up to 4 years)Survival Follow-Up 7 (up to 4 years)
Bevacizumab: Phase A103.84103.33106.34109.66109.39111.30111.40113.51113.92115.11114.00115.99113.54112.36119.48116.38113.69112.94117.55115.86106.00112.00105.00103.94102.89104.00105.50109.00119.00103.61115.00

[back to top]

Percentage of Participants With Confirmed Complete or Partial Response as Assessed by the Investigator Based on Routine Clinical Practice: Overall

Percentage of participants with best overall response of confirmed complete response or partial response based on the investigator assessment of the response as per routine clinical practice was reported. The confirmation of response must be no less than 4 weeks after initial assessment. (NCT01588990)
Timeframe: Baseline up to disease progression, death or end of study (up to 4 years)

Interventionpercentage of participants (Number)
Complete responsePartial response
Bevacizumab: Phase A and Phase B3.18.6

[back to top]

Percentage of Participants With Confirmed Complete or Partial Response as Assessed by the Investigator Based on Routine Clinical Practice: Phase A

Percentage of participants with best overall response of confirmed complete response or partial response based on the investigator assessment of the response as per routine clinical practice was reported. The confirmation of response must be no less than 4 weeks after initial assessment. (NCT01588990)
Timeframe: Baseline up to disease progression, death or end of study (up to 4 years)

Interventionpercentage of participants (Number)
Complete responsePartial response
Bevacizumab: Phase A3.18.6

[back to top]

Percentage of Participants With Confirmed Complete or Partial Response as Assessed by the Investigator Based on Routine Clinical Practice: Phase B

Percentage of participants with best overall response of confirmed complete response or partial response based on the investigator assessment of the response as per routine clinical practice was reported. The confirmation of response must be no less than 4 weeks after initial assessment. (NCT01588990)
Timeframe: From the start of Phase B treatment to disease progression, death or end of study (up to 4 years)

Interventionpercentage of participants (Number)
Complete responsePartial response
Bevacizumab: Phase B00

[back to top]

Duration of Disease Control (DDC) as Assessed by the Investigator Based on Routine Clinical Practice: Overall

DDC was defined as PFS + PFS-B. In cases where a participant did not enter Phase B, then DDC was defined as PFS. PFS was defined as time from start of initial treatment to documentation of first disease progression or death from any cause, whichever occurred first. PFS-B was time from start of Phase B treatment to documentation of second disease progression or death from any cause, whichever occurred first. Disease progression was determined according to standard practice based on radiological, biochemical (CEA) or clinical factors. Determination of disease progression was to be unequivocal and was defined as any of the following: an unequivocal and clinically meaningful increase in the size of known tumors, appearance of one or more new lesions, death due to disease without prior objective documentation of progression, elevated CEA accompanied by other radiological or clinical evidence of progression, or symptomatic deterioration. Kaplan-Meier methodology was used to estimate DDC. (NCT01588990)
Timeframe: Baseline up to disease progression, death or end of study (up to 4 years)

Interventionmonths (Median)
Bevacizumab: Phase A and Phase B14.0

[back to top]

Association Between NLR Normalization (First NLR Post-Baseline ≤5 Versus NLR >5) and PFS as Assessed by Hazard Ratio

NLR was calculated from laboratory values as ratio of Neutrophils to Lymphocytes. NLR normalization was assessed by adding first post-baseline measurement of NLR to the primary model. This is equivalent to testing whether first change in NLR is significantly associated with outcome. PFS was defined as time from start of initial treatment to documentation of first disease progression or death from any cause. Disease progression was determined according to standard practice based on radiological, biochemical (CEA) or clinical factors. Determination of disease progression was defined as: an unequivocal and clinically meaningful increase in size of known tumors, appearance of ≥1 new lesions, death due to disease without prior objective documentation of progression, elevated CEA accompanied by other radiological or clinical evidence of progression, or symptomatic deterioration.The association between NLR normalization (first NLR post-baseline ≤5 vs >5) and PFS was reported as hazard ratio. (NCT01588990)
Timeframe: Baseline up to disease progression, death or end of study (up to 4 years)

Interventionhazard ratio (Number)
Bevacizumab: Phase A and Phase B0.9

[back to top]

Association Between Longitudinal NLR (Longitudinal NLR ≤5 Versus NLR >5) and OS as Assessed by Hazard Ratio

NLR was calculated from the laboratory values as the ratio of Neutrophils to Lymphocytes. Longitudinal NLR was assessed by treating the NLR measurements taken over the time-course of treatment as a time-dependent covariate. OS was defined as the time from the start of initial treatment to the date of death, regardless of the cause of death. The association between longitudinal NLR (longitudinal NLR ≤5 vs NLR >5) and OS was reported as hazard ratio. (NCT01588990)
Timeframe: Baseline up to death or end of study (up to 4 years)

Interventionhazard ratio (Number)
Bevacizumab: Phase A and Phase B2.2

[back to top]

Association Between NLR (NLR ≤5 Versus NLR >5) and OS as Assessed by Hazard Ratio

NLR was calculated from the laboratory values as the ratio of Neutrophils to Lymphocytes. OS was defined as the time from the start of initial treatment to the date of death, regardless of the cause of death. The association between NLR (NLR ≤ 5 vs > 5) and OS was reported as hazard ratio. (NCT01588990)
Timeframe: Baseline up to disease progression, death or end of study (up to 4 years)

Interventionhazard ratio (Number)
Bevacizumab: Phase A and Phase B1.6

[back to top]

Association Between Neutrophil to Lymphocyte Ratio (NLR) [NLR ≤5 Versus NLR >5] and Progression-Free Survival (PFS) as Assessed by Hazard Ratio

NLR was calculated from the laboratory values as the ratio of Neutrophils to Lymphocytes. PFS was defined as the time from the start of initial treatment to documentation of first disease progression or death from any cause, whichever occurred first. Disease progression was determined according to standard practice based on radiological, biochemical (carcinoembryonic antigen [CEA]) or clinical factors. Determination of disease progression was to be unequivocal and was defined as any of the following: an unequivocal and clinically meaningful increase in the size of known tumors, the appearance of one or more new lesions, death due to disease without prior objective documentation of progression, elevated CEA accompanied by other radiological or clinical evidence of progression, or symptomatic deterioration. The association between NLR (NLR less than or equal to [≤] 5 vs greater than [>] 5) and PFS was reported as hazard ratio. (NCT01588990)
Timeframe: Baseline up to disease progression, death or end of study (up to 4 years)

Interventionhazard ratio (Number)
Bevacizumab: Phase A and Phase B1.4

[back to top]

Overall Survival (OS) From the Start of Treatment to Study Completion: Overall

OS was defined as the time from the start of initial treatment to the date of death, regardless of the cause of death. Kaplan-Meier methodology was used to estimate OS. (NCT01588990)
Timeframe: Baseline until death or end of study (up to 4 years)

Interventionmonths (Median)
Bevacizumab: Phase A and Phase B25.0

[back to top]

Percentage of Participants Who Underwent Liver Resection: Overall

The results include percentage of participants who underwent potentially curative liver resection. (NCT01588990)
Timeframe: Baseline up to disease progression, death or end of study (up to 4 years)

Interventionpercentage of participants (Number)
Bevacizumab: Phase A and Phase B1.6

[back to top]

PFS Until First Disease Progression as Assessed by the Investigator Based on Routine Clinical Practice: Phase A

PFS until first progression was defined as the time from the start of initial treatment to documentation of first disease progression or death from any cause, whichever occurred first. Disease progression was determined according to standard practice based on radiological, biochemical (CEA) or clinical factors. Determination of disease progression was to be unequivocal and was defined as any of the following: an unequivocal and clinically meaningful increase in the size of known tumors, the appearance of one or more new lesions, death due to disease without prior objective documentation of progression, elevated CEA accompanied by other radiological or clinical evidence of progression, or symptomatic deterioration. Kaplan-Meier methodology was used to estimate PFS. (NCT01588990)
Timeframe: Baseline up to first disease progression, death or end of study (up to 4 years)

Interventionmonths (Median)
Bevacizumab: Phase A9.2

[back to top]

Association Between Longitudinal NLR (Longitudinal NLR ≤5 Versus NLR >5) and PFS as Assessed by Hazard Ratio

NLR was calculated from the laboratory values as the ratio of Neutrophils to Lymphocytes. Longitudinal NLR was assessed by treating the NLR measurements taken over the time-course of treatment as a time-dependent covariate. PFS was defined as time from the start of initial treatment to documentation of first disease progression or death from any cause, whichever occurred first. Disease progression was determined according to standard practice based on radiological, biochemical (CEA) or clinical factors. Determination of disease progression was to be unequivocal and was defined as: an unequivocal and clinically meaningful increase in size of known tumors, appearance of one or more new lesions, death due to disease without prior objective documentation of progression, elevated CEA accompanied by other radiological or clinical evidence of progression, or symptomatic deterioration. The association between longitudinal NLR (longitudinal NLR ≤5 vs N>5) and PFS was reported as hazard ratio. (NCT01588990)
Timeframe: Baseline up to disease progression, death or end of study (up to 4 years)

Interventionhazard ratio (Number)
Bevacizumab: Phase A and Phase B1.3

[back to top]

Survival Beyond First Disease Progression: Overall

Survival beyond first progression was defined as the time from the date of first disease progression to death due to any cause. Disease progression was determined according to standard practice based on radiological, biochemical (CEA) or clinical factors. Determination of disease progression was to be unequivocal and was defined as any of the following: an unequivocal and clinically meaningful increase in the size of known tumors, the appearance of one or more new lesions, death due to disease without prior objective documentation of progression, elevated CEA accompanied by other radiological or clinical evidence of progression, or symptomatic deterioration. Kaplan-Meier methodology was used to estimate survival beyond first disease progression. (NCT01588990)
Timeframe: Baseline until death or end of study (up to 4 years)

Interventionmonths (Median)
Bevacizumab: Phase A and Phase B12.6

[back to top]

Time to Failure of Strategy (TFS): Overall

TFS was defined as time from the start of initial treatment to documentation of first disease progression without entering Phase B, or second disease progression having entered Phase B. Disease progression was determined according to standard practice based on radiological, biochemical (CEA) or clinical factors. Determination of disease progression was to be unequivocal and was defined as any of the following: an unequivocal and clinically meaningful increase in the size of known tumors, the appearance of one or more new lesions, death due to disease without prior objective documentation of progression, elevated CEA accompanied by other radiological or clinical evidence of progression, or symptomatic deterioration. Kaplan-Meier methodology was used to estimate TFS. (NCT01588990)
Timeframe: Baseline up to disease progression, death or end of study (up to 4 years)

Interventionmonths (Median)
Bevacizumab: Phase A and Phase B14.8

[back to top]

AQoL-8D Global Utility Score: Phase B

AQoL-8D provides a global utility score and consists of 8 separately scored dimensions including Independent Living, Life Satisfaction, Mental Health, Coping, Relationships, Self Worth, Pain, and Senses. Each of the 8 scales is calculated based on the answers to 3 questions. Each question is given an answer dependent utility score (0 [worst] to 1 [best]) and then these scores are combined using a multiplicative model to get the normalized scale score value, each scale ranging between 0.0 (representing death) and 1.0 (representing full health). (NCT01588990)
Timeframe: Baseline, every 8-9 weeks thereafter, EOT (30 days after disease progression [up to 4 years]), survival follow-up 12-weekly visits (up to 4 years) [Detailed time points are presented in the category titles]

Interventionunits on a scale (Mean)
Phase B BaselinePhase B Visit 2 (up to 4 years)Phase B Visit 3 (up to 4 years)Phase B Visit 4 (up to 4 years)Phase B Visit 5 (up to 4 years)Phase B Visit 6 (up to 4 years)Phase B Visit 7 (up to 4 years)Phase B Visit 8 (up to 4 years)Phase B Visit 9 (up to 4 years)Phase B Visit 10 (up to 4 years)Phase B Visit 11 (up to 4 years)Phase B Visit 12 (up to 4 years)Phase B Visit 13 (up to 4 years)Phase B Visit 14 (up to 4 years)Phase B Visit 15 (up to 4 years)Phase B Visit 16 (up to 4 years)Phase B Visit 17 (up to 4 years)Phase B Visit 18 (up to 4 years)Phase B Visit 19 (up to 4 years)Phase B Visit 20 (up to 4 years)Phase B Visit 21 (up to 4 years)Phase B Visit 22 (up to 4 years)Phase B Visit 23 (up to 4 years)Phase B Visit 24 (up to 4 years)Phase B EOT Visit (up to 4 years)Survival Follow-Up 1 (up to 4 years)Survival Follow-Up 2 (up to 4 years)Survival Follow-Up 3 (up to 4 years)Survival Follow-Up 4 (up to 4 years)Survival Follow-Up 6 (up to 4 years)
Bevacizumab: Phase B0.7360.7730.8130.8780.8080.8090.8250.9100.8190.8560.7300.9600.9650.9580.9670.9420.9270.9310.8660.8870.9400.9190.9370.9500.7080.7880.7910.9890.9810.875

[back to top]

FACT-C Score: Phase B

FACT-C is one part of the FACIT Measurement System, which comprehensively assesses the health-related QoL of cancer participants and participants with other chronic illnesses. It is composed of 27 items of the general version of the FACT-C as a general core QoL measure and has a disease-specific subscale containing 9 colorectal cancer-specific items. It consists of total 36 items, summarized to 5 subscales: physical well-being (7 items), functional well-being (7 items), social/family well-being (7 items); all 3 subscales range from 0 to 28, emotional well-being (6 items) range from 0 to 24, colorectal cancer subscale (9 items) range from 0 to 36; higher subscale score=better QoL. All single-item measures range from 0='Not at all' to 4='Very much'. Total possible score range: 0 to 144. High scale score represents a better QoL. (NCT01588990)
Timeframe: Baseline, every 8-9 weeks thereafter, EOT (30 days after disease progression [up to 4 years]), survival follow-up 12-weekly visits (up to 4 years) [Detailed time points are presented in the category titles]

Interventionunits on a scale (Mean)
Phase B BaselinePhase B Visit 2 (up to 4 years)Phase B Visit 3 (up to 4 years)Phase B Visit 4 (up to 4 years)Phase B Visit 5 (up to 4 years)Phase B Visit 6 (up to 4 years)Phase B Visit 7 (up to 4 years)Phase B Visit 8 (up to 4 years)Phase B Visit 9 (up to 4 years)Phase B Visit 10 (up to 4 years)Phase B Visit 11 (up to 4 years)Phase B Visit 12 (up to 4 years)Phase B Visit 13 (up to 4 years)Phase B Visit 14 (up to 4 years)Phase B Visit 15 (up to 4 years)Phase B Visit 16 (up to 4 years)Phase B Visit 17 (up to 4 years)Phase B Visit 18 (up to 4 years)Phase B Visit 19 (up to 4 years)Phase B Visit 20 (up to 4 years)Phase B Visit 21 (up to 4 years)Phase B Visit 22 (up to 4 years)Phase B Visit 23 (up to 4 years)Phase B Visit 24 (up to 4 years)Phase B EOT Visit (up to 4 years)Survival Follow-Up 1 (up to 4 years)Survival Follow-Up 2 (up to 4 years)Survival Follow-Up 3 (up to 4 years)Survival Follow-Up 4 (up to 4 years)Survival Follow-Up 6 (up to 4 years)
Bevacizumab: Phase B103.47108.71108.19114.89110.60111.28114.78120.39108.08110.50109.33125.00119.00117.00126.00123.00127.00126.00127.00126.00123.00124.00126.00130.00101.6798.72102.50126.33125.00124.67

[back to top]

EuroQol-5D Utility Score: Phase B

"EQ-5D is a standardized generic preference based health related quality of life instrument. It records how one's health is today and consists of a descriptive system. The descriptive system is comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Each dimension on the EQ-5D involves a 3-point response scale which indicates the level of impairment (level 1 = no problem; level 2 = some or moderate problem[s] and level 3 = unable, or extreme problems). Level of problem reported in each EQ-5D dimension determines a unique health state which is converted into a weighted health state index by applying scores from EQ-5D preference weights elicited from general population samples. This generates a unique description of the subjects' health status, which is valued between 0 (representing death) and 1 (representing perfect health). Higher the score, the better the quality of life." (NCT01588990)
Timeframe: Baseline, every 8-9 weeks thereafter, EOT (30 days after disease progression [up to 4 years]), survival follow-up 12-weekly visits (up to 4 years) [Detailed time points are presented in the category titles]

Interventionunits on a scale (Mean)
Phase B BaselinePhase B Visit 2 (up to 4 years)Phase B Visit 3 (up to 4 years)Phase B Visit 4 (up to 4 years)Phase B Visit 5 (up to 4 years)Phase B Visit 6 (up to 4 years)Phase B Visit 7 (up to 4 years)Phase B Visit 8 (up to 4 years)Phase B Visit 9 (up to 4 years)Phase B Visit 10 (up to 4 years)Phase B Visit 11 (up to 4 years)Phase B Visit 12 (up to 4 years)Phase B Visit 13 (up to 4 years)Phase B Visit 14 (up to 4 years)Phase B Visit 15 (up to 4 years)Phase B Visit 16 (up to 4 years)Phase B Visit 17 (up to 4 years)Phase B Visit 18 (up to 4 years)Phase B Visit 19 (up to 4 years)Phase B Visit 20 (up to 4 years)Phase B Visit 21 (up to 4 years)Phase B Visit 22 (up to 4 years)Phase B Visit 23 (up to 4 years)Phase B Visit 24 (up to 4 years)Phase B EOT Visit (up to 4 years)Survival Follow-Up 1 (up to 4 years)Survival Follow-Up 2 (up to 4 years)Survival Follow-Up 3 (up to 4 years)Survival Follow-Up 4 (up to 4 years)Survival Follow-Up 6 (up to 4 years)
Bevacizumab: Phase B0.8140.8590.8940.8970.8660.8370.8760.8740.9080.8110.8060.8441.0001.0000.8440.8330.8440.8330.8270.8160.8440.8440.8270.8440.8090.7400.7720.8270.8271.000

[back to top]

European Quality of Life 5-Dimension (EuroQol-5D) Utility Score: Phase A

"EQ-5D is a standardized generic preference based health related quality of life instrument. It records how one's health is today and consists of a descriptive system. The descriptive system is comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Each dimension on the EQ-5D involves a 3-point response scale which indicates the level of impairment (level 1 = no problem; level 2 = some or moderate problem[s] and level 3 = unable, or extreme problems). Level of problem reported in each EQ-5D dimension determines a unique health state which is converted into a weighted health state index by applying scores from EQ-5D preference weights elicited from general population samples. This generates a unique description of the subjects' health status, which is valued between 0 (representing death) and 1 (representing perfect health). Higher the score, the better the quality of life." (NCT01588990)
Timeframe: Baseline, every 8-9 weeks thereafter, end of treatment (EOT) (30 days after disease progression [up to 4 years]), survival follow-up 12-weekly visits (up to 4 years) [Detailed time points are presented in the category titles]

Interventionunits on a scale (Mean)
Phase A BaselinePhase A Visit 2 (Weeks 8-9)Phase A Visit 3 (Weeks 16-17)Phase A Visit 4 (Weeks 24-25)Phase A Visit 5 (Weeks 32-33)Phase A Visit 6 (Weeks 40-41)Phase A Visit 7 (Weeks 48-49)Phase A Visit 8 (Weeks 56-57)Phase A Visit 9 (Weeks 64-65)Phase A Visit 10 (Weeks 72-73)Phase A Visit 11 (Weeks 80-81)Phase A Visit 12 (Weeks 88-89)Phase A Visit 13 (Weeks 96-97)Phase A Visit 14 (Weeks 104-105)Phase A Visit 15 (Weeks 112-113)Phase A Visit 16 (Weeks 120-121)Phase A Visit 17 (Weeks 128-129)Phase A Visit 18 (Weeks 136-137)Phase A Visit 19 (Weeks 144-145)Phase A Visit 20 (Weeks 152-153)Phase A Visit 21 (Weeks 160-161)Phase A Visit 22 (Weeks 168-169)Phase A Visit 23 (Weeks 176-177)Phase A EOT Visit (up to 4 years)Survival Follow-Up 1 (up to 4 years)Survival Follow-Up 2 (up to 4 years)Survival Follow-Up 3 (up to 4 years)Survival Follow-Up 4 (up to 4 years)Survival Follow-Up 5 (up to 4 years)Survival Follow-Up 6 (up to 4 years)Survival Follow-Up 7 (up to 4 years)
Bevacizumab: Phase A0.8300.8570.8650.8530.8690.8920.8720.8810.8940.8430.8980.9150.8440.8990.8780.8990.8730.9090.9470.8520.9330.8130.9000.8170.7680.9010.8190.8431.0000.8350.816

[back to top]

Assessment of Quality of Life - Eight Dimensions (AQoL-8D) Global Utility Score: Phase A

AQoL-8D provides a global utility score and comprised of 35 questions from which 8 dimensions (Independent Living, Life Satisfaction, Mental Health, Coping, Relationships, Self Worth, Pain, and Senses) are derived. Each of the 8 scales is calculated based on the answers to 3 questions. Each question is given an answer dependent utility score (0 [worst] to 1 [best]) and then these scores are combined using a multiplicative model to get the normalized scale score value, each scale ranging between 0.0 (representing death) and 1.0 (representing full health). (NCT01588990)
Timeframe: Baseline, every 8-9 weeks thereafter, EOT (30 days after disease progression [up to 4 years]), survival follow-up 12-weekly visits (up to 4 years) [Detailed time points are presented in the category titles]

Interventionunits on a scale (Mean)
Phase A BaselinePhase A Visit 2 (Weeks 8-9)Phase A Visit 3 (Weeks 16-17)Phase A Visit 4 (Weeks 24-25)Phase A Visit 5 (Weeks 32-33)Phase A Visit 6 (Weeks 40-41)Phase A Visit 7 (Weeks 48-49)Phase A Visit 8 (Weeks 56-57)Phase A Visit 9 (Weeks 64-65)Phase A Visit 10 (Weeks 72-73)Phase A Visit 11 (Weeks 80-81)Phase A Visit 12 (Weeks 88-89)Phase A Visit 13 (Weeks 96-97)Phase A Visit 14 (Weeks 104-105)Phase A Visit 15 (Weeks 112-113)Phase A Visit 16 (Weeks 120-121)Phase A Visit 17 (Weeks 128-129)Phase A Visit 18 (Weeks 136-137)Phase A Visit 19 (Weeks 144-145)Phase A Visit 20 (Weeks 152-153)Phase A Visit 21 (Weeks 160-161)Phase A Visit 22 (Weeks 168-169)Phase A Visit 23 (Weeks 176-177)Phase A EOT Visit (up to 4 years)Survival Follow-Up 1 (up to 4 years)Survival Follow-Up 2 (up to 4 years)Survival Follow-Up 3 (up to 4 years)Survival Follow-Up 4 (up to 4 years)Survival Follow-Up 5 (up to 4 years)Survival Follow-Up 6 (up to 4 years)Survival Follow-Up 7 (up to 4 years)
Bevacizumab: Phase A0.7470.7600.7670.7960.8000.8310.8180.8510.8220.8270.8390.8560.8310.8150.8710.8690.8590.8800.9150.8640.8060.8110.7090.7390.7180.7920.6960.6200.8000.8100.874

[back to top]

Progression Free Survival in Phase II Dose Expansion

Defined as the time from first treatment until objective tumor progression or death from any cause. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT01611857)
Timeframe: every 8 weeks until treatment discontinuation, projected 18 months and then every 3 months thereafter up to 5 years from start of treatment.

Interventionmonths (Median)
Tivantinib + FOLFOX Dose Expansion6.1

[back to top]

The Incidence of Dose Limiting Toxicities (DLT) in Phase I Dose Escalation

Using a standard 3+3 design participants were enrolled in dose-escalating cohorts to determine the maximum tolerated dose (MTD) of tivantinib when given with FOLFOX (5-FU 400 mg/m^2, continuous IV 5-FU 2400 mg/m^2 over 46 hours, leucovorin 400 mg/m^2 IV, and oxaliplatin 85 mg/m^2). MTD is defined as the highest dose level at which no more than 1 of 6 patients experiences a DLT, assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4. (NCT01611857)
Timeframe: 14 Days (1 cycle)

Interventionparticipants (Number)
Tivantinib 120 mg (PO BID) + FOLFOX0
Tivantinib 240 mg (PO BID) + FOLFOX0
Tivantinib 360 mg (PO BID) + FOLFOX1

[back to top]

Time to Progression in Phase II Dose Expansion

Defined as the time from first treatment until objective tumor progression. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT01611857)
Timeframe: every 8 weeks until progressive disease, expected 18 months.

Interventionmonths (Median)
Tivantinib + FOLFOX Dose Expansion7.0

[back to top]

Overall Survival in Phase II Dose Expansion

Defined as the time from first treatment until death from any cause. (NCT01611857)
Timeframe: every 8 weeks until treatment discontinuation, an expected average of 18 months, then every 12 weeks thereafter up to 5 years from start of treatment.

Interventionmonths (Median)
Tivantinib + FOLFOX Dose Expansion9.6

[back to top]

Objective Response Rate

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Objective Response Rate =Proportion of (CR + PR) observed over all randomized patients. (NCT01622543)
Timeframe: 19 months

InterventionParticipants (Count of Participants)
Folfox Plus Bevacizumab and Reolysin27
Folfox Plus Bevacizumab18

[back to top]

Changes in CEA Levels

Changes in CEA level from baseline to week 28 during treatment. (NCT01622543)
Timeframe: Baseline and at 28 weeks

Interventionng/mL (Mean)
Folfox Plus Bevacizumab and Reolysin-14209.4
Folfox Plus Bevacizumab-1107.99

[back to top]

Overall Survival

Time from randomization to death from any cause or censored at the time of last known alive (NCT01622543)
Timeframe: From date of randomization to death from any cause or censored at the time of last known alive, assessed up to 49 months

InterventionMonths (Median)
Folfox Plus Bevacizumab and Reolysin19.3
Folfox Plus Bevacizumab20.0

[back to top]

Progression Free Survival

Time from the day of randomization until the first observation of objective disease relapse or progression, or the appearance of new lesions or death due to any cause. If a patient had not relapsed/progressed or died, PFS was censored on the date of last disease assessment defined as the earliest test date of target lesion or non-target lesions (if patient had no target lesions). Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT01622543)
Timeframe: 19 months

InterventionMonths (Median)
Folfox Plus Bevacizumab and Reolysin7.33
Folfox Plus Bevacizumab9.13

[back to top]

Progression Free Survival (PFS)

PFS was as the time from enrollment to the earliest documented evidence of disease progression or death,whatever comes first. (NCT01632306)
Timeframe: Baseline to Disease Progression Up to 18 Months

InterventionMonths (Median)
LY2090314 + Gemcitabine1.8
LY2090314 + FOLFOX3.4

[back to top]

Percentage of Participants With Complete Response (CR) or Partial Response (PR) [Overall Response Rate (ORR)]

"Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST v1.1) criteria. CR was defined as the disappearance of all target and non-target lesions and all target and non-target lymph nodes were non-pathological or normal in size [<10 millimeter (mm) short axis]. PR was defined as having at least a 30% decrease in sum of longest diameter of target lesions taking as reference the baseline sum diameters. ORR calculated as: (sum of the number of participants with PRs and CRs) divided by (number of evaluable participants) multiplied by 100.~A CR or PR noted as the objective status on 2 consecutive evaluations at least 4 weeks apart." (NCT01632306)
Timeframe: Baseline Up to 6 Months

InterventionPercentage of Participants (Number)
LY2090314 + Gemcitabine0
LY2090314 + FOLFOX10.0

[back to top]

Overall Survival (OS)

(NCT01632306)
Timeframe: Baseline to Date of Death Due to any Cause Up to 21 Months

InterventionMonths (Median)
LY2090314 + Gemcitabine1.8
LY2090314 + FOLFOX7.7

[back to top]

Percentage of Participants Who Survived at 6 Months

(NCT01632306)
Timeframe: Baseline to Date of Death to any cause Up to 6 Months

InterventionPercentage of participants (Number)
LY2090314 + Gemcitabine0
LY2090314 + FOLFOX50.0

[back to top]

Pharmacokinetics: Dose-Normalized Maximum Observed Drug Concentration (Cmax) of Irinotecan and Its Metabolite SN-38 in Cycle 1

Dose-normalized Cmax was calculated from Cmax divided by the dose. Data presented are Geo LS means. Geo LS means were adjusted for cycle, participant and random error. (NCT01634555)
Timeframe: Cycle 1: 0, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 22, 25, 28, 31, 34, 48, 72, 96 and 168 hours post-irinotecan infusion

Interventionnanograms/milliliter/milligram (Least Squares Mean)
IrinotecanMetabolite SN-38
FOLFIRI (Cycle 1)3.180.05

[back to top]

Pharmacokinetics: Dose-Normalized Area Under the Concentration Versus Time Curve of Irinotecan and Its Metabolite SN-38 From Time Zero to Infinity [AUC(0-∞)] in Cycle 1

Dose-normalized AUC(0-∞) was calculated from AUC(0-∞) divided by the dose. Data presented are Geometric Least Squares (Geo LS) means. Geo LS means were adjusted for cycle, participant and random error. (NCT01634555)
Timeframe: Cycle 1: 0, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 22, 25, 28, 31, 34, 48, 72, 96 and 168 hours post-irinotecan infusion

Interventionnanograms*hour/milliliter/milligram (Least Squares Mean)
IrinotecanMetabolite SN-38
FOLFIRI (Cycle 1)22.120.81

[back to top]

Pharmacokinetics: Cmax of Ramucirumab (IMC-1121B)

(NCT01634555)
Timeframe: Cycle 2: -2, -1, -0.5, 0, 2, 3, 4, 5, 8, 10, 25, 48, 72, 96, 168, 264, 336 hours post-ramucirumab (IMC-1121B) infusion

Interventionmicrograms/milliliter (µg/mL) (Geometric Mean)
Ramucirumab + FOLFIRI (Cycle 2)201.6

[back to top]

Pharmacokinetics: Dose-Normalized Cmax of Irinotecan and Its Metabolite SN-38 in Cycle 2

Dose-normalized Cmax was calculated from Cmax divided by the dose. Data presented are Geo LS means. Geo LS means were adjusted for cycle, participant and random error. (NCT01634555)
Timeframe: Cycle 2: 0, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 22, 25, 28, 31, 34, 48, 72, 96 and 168 hours post-irinotecan infusion

Interventionnanograms/milliliter/milligram (Least Squares Mean)
IrinotecanMetabolite SN-38
Ramucirumab + FOLFIRI (Cycle 2)3.310.05

[back to top]

Pharmacokinetics: Dose-Normalized AUC(0-∞) of Irinotecan and Its Metabolite SN-38 in Cycle 2

Dose-normalized AUC(0-∞) was calculated from AUC(0-∞) divided by the dose. Data presented are Geo LS means. Geo LS means were adjusted for cycle, participant and random error. (NCT01634555)
Timeframe: Cycle 2: 0, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 22, 25, 28, 31, 34, 48, 72, 96 and 168 hours post-irinotecan infusion

Interventionnanograms*hour/milliliter/milligram (Least Squares Mean)
IrinotecanMetabolite SN-38
Ramucirumab + FOLFIRI (Cycle 2)20.560.77

[back to top]

Number of Participants With Treatment Emergent Anti-Drug Antibodies (TE-ADA)

Number of participants with positive treatment emergent anti-ramucirumab antibodies was summarized by treatment group. (NCT01634555)
Timeframe: Up To 2 Years

InterventionParticipants (Count of Participants)
Ramucirumab + FOLFIRI (Cycle 2)0

[back to top]

Progression Free Survival (PFS)

Determine activity of 5-Fluorouracil, leucovorin, and oxaliplatin (FOLFOX) plus dasatinib on progression free survival (PFS) in patients with metastatic pancreatic adenocarcinoma (NCT01652976)
Timeframe: 3 years

Interventionmonths (Median)
Dasatinib and mFOLFOX64

[back to top]

Median Time To Progression

To determine the median time to progression (TTP). TTP is defined as the time (in months) from when a subject achieves either a complete or partial response by RECIST 1.1 criteria until progressive disease (by RECIST 1.1 criteria) or death occurs. (NCT01652976)
Timeframe: 3 years

Interventionmonths (Median)
Dasatinib and mFOLFOX69.8

[back to top]

Median Overall Survival

To determine median overall survival (OS) in months (NCT01652976)
Timeframe: 4 years

Interventionmonths (Median)
Dasatinib and mFOLFOX610.6

[back to top]

Freedom From Metastasis

To determine the rate of freedom from metastasis (FFM), which is defined as the percentage of subjects with documented progressive disease (by RECIST 1.1 criteria) who had no new lesions. RECIST 1.1 criteria defines progressive disease as the appearance of one or more new lesions and/or the increase of the sum of the largest diameter of the target lesions by at least 20% from the smallest sum collected (the sum must also have increased by at least 5 mm). (NCT01652976)
Timeframe: 3 years

Interventionpercentage of subjects (Number)
Dasatinib and mFOLFOX665.5

[back to top]

Drug Compliance

To determine patient compliance with oral therapy. For this outcome measure, compliance with oral therapy is defined as the percentage of subjects that took dasatinib for at least one cycle. Compliance with oral therapy was documented with a medication diary that subjects were asked to complete to document whether each dose of dasatinib was taken. (NCT01652976)
Timeframe: 3 years

Interventionpercentage of subjects (Number)
Dasatinib and mFOLFOX693.2

[back to top]

Clinical Benefit Rate

To determine the clinical benefit rate (CBR). The CBR is defined as the percentage of subjects who achieved either a complete or partial response or stable disease by RECIST 1.1 criteria. RECIST 1.1 criteria defines a partial response as a decrease of the sum of the largest diameter each target lesion by at least 30%. A complete response is defined as the disappearance of all target lesions (except lymph nodes, whose short axis must measure 10 mm or less). By RECIST 1.1 criteria, a subject is considered to have stable disease when the sum of the largest diameter of the target lesions has neither decreased enough to qualify as a partial response not increased enough to qualify as progressive disease. (NCT01652976)
Timeframe: 3 years

Interventionpercentage of subjects (Number)
Dasatinib and mFOLFOX656.82

[back to top]

Safety and Tolerability

To determine the safety profile and tolerability of this regimen in this population by evaluating acute treatment related toxicities using CTCAE v4.0 criteria. Using the CTCAE v4.0, the severity of each adverse event reported was graded on a scale of 1 (mild severity) to 5 (fatal). For this outcome measure the percentage of subjects experiencing any adverse event of each CTCAE grade was tabulated. (NCT01652976)
Timeframe: 3 years

Interventionpercentage of subjects (Number)
Percent of subjects experiencing a Grade 1 eventPercent of subjects experiencing a grade 2 eventPercent of subjects experiencing a Grade 3 eventPercent of subjects experiencing a Grade 4 eventPercent of subjects experiencing a grade 5 event
Dasatinib and mFOLFOX688.690.986.422.79.1

[back to top]

Quality of Life, as Measured by the Cancer Therapy Satisfaction Questionnaire (CTSQ), 2007

To determine the quality of life (QOL) of patients receiving this therapy using the CTSQ questionnaire. The CTSQ consists of 16 questions where subjects respond with a score on a scale of 0 (worst)-4 (best). The responses to the questions are used to calculate 3 subscores: Expectations of Therapy (ET), Feelings about Side Effects (FSE), and Satisfaction with Therapy (SWT). Each subscore is calculated by multiplying the mean response value for the questions used to calculate that subscore by 25. The maximum value is 100 and the minimum value is 0 for all 3 subscores. A higher subscore indicates better QOL in that area. The mean difference in each of the 3 subscores from baseline and 95% confidence interval for the entire study population is reported here. A negative mean difference indicates a decrease from baseline in QOL for that area. (NCT01652976)
Timeframe: 3 years

Interventionscore on a scale (Mean)
Subscore difference for ETSubscore difference for FSESubscore difference for SWT
Dasatinib and mFOLFOX6-8.42.1-0.5

[back to top]

Quality of Life, as Measured by the Functional Assessment of Chronic Illness Therapy; Hepatobiliary Cancer (FACT-Hep) Questionnaire (Version 4.0)

The FACT-Hep consists of 45 questions where subjects respond with a score on a scale of 0 (worst)-4 (best). The responses to the questions are summed to calculate 5 subscores: Physical Well-Being (PWB), Social Well-Being (SWB), Emotional Well-Being (EWB), Functional Well-Being (FWB), and Hepatobiliary Cancer Subscale (HCS). The mean difference in each of the 5 subscores from baseline, as well as the total score of the 5 subscores (the FACT-Hep Total Score) for the entire study population is reported here. The mean difference in the FACT-G Total Score (calculated by summing the PWB, SWB, EWB, and FWB subscores) is also reported here. A negative mean difference indicates a decrease from baseline in QOL. Score ranges- PWB subscore: 0-28, SWB subscore: 0-28, EWB subscore: 0-24, FWB subscore: 0-28, HCS subscore: 0-72, FACT-G Total Score: 0-108, and FACT-Hep Total Score: 0-180. A higher value for each subscore or total score indicates better QOL. (NCT01652976)
Timeframe: 3 years

Interventionscore on a scale (Mean)
Subscore difference for PWBSubscore difference for SWBSubscore difference for EWBSubscore difference for FWBSubscore difference for HCSDifference in FACT-G Total ScoreDifference in FACT-Hep Total Score
Dasatinib and mFOLFOX6-4.4-0.90.6-2.8-6.3-7.4-13.7

[back to top]

Site of Failure

To determine the site of failure of this regimen in this population. The site of failure is the anatomical site(s) where disease progression by RECIST 1.1 criteria was noted on imaging. (NCT01652976)
Timeframe: 3 years

InterventionParticipants (Count of Participants)
Left pleural effusionLiverLungsPancreas/liverPeritoneal carcinomatosisperitoneal carcinomatosis/liverSpleen/liver
Dasatinib and mFOLFOX611234111

[back to top]

Response Rate

To determine the response rate (RR) by RECIST 1.1 criteria. The response rate is the number of subjects who had either a complete or partial response by RECIST 1.1 criteria. RECIST 1.1 criteria defines a partial response as a decrease of the sum of the largest diameter each target lesion by at least 30%. A complete response is defined as the disappearance of all target lesions (except lymph nodes, whose short axis must measure 10 mm or less). The imaging modality used for all RECIST assessments in this study was CT. (NCT01652976)
Timeframe: 3 years

Interventionpercentage of subjects (Number)
Dasatinib and mFOLFOX625

[back to top]

Percentage Able to Complete Full Course of Preoperative Chemotherapy

The percentage of participants able to complete the full course of preoperative chemotherapy and undergo a resection. This will be the primary determinant of success for this pilot study. - Early withdrawals due to toxicity, disease progression, or intercurrent illness will be considered failures. (NCT01660711)
Timeframe: Following completion of all planned therapy, an expected average of 4 months

InterventionParticipants (Count of Participants)
FOLFIRINOX Chemotherapy22

[back to top]

Percentage Able to Complete Full Course of Therapy

The percentage of participants able to complete the full course of therapy, including preoperative chemotherapy, surgical resection and postoperative chemotherapy. (NCT01660711)
Timeframe: On completion of all planned therapy, an expected average of 8 months

InterventionParticipants (Count of Participants)
FOLFIRINOX Chemotherapy14

[back to top]

Median Overall Survival (OS)

Calculated using Kaplan Meier methods and the median will be estimated assuming an exponential distribution. (NCT01666730)
Timeframe: Time from first day of treatment to death from any cause, assessed up to 1 year

InterventionMonths (Median)
Treatment (Metformin Hydrochloride, FOLFOX)7.1

[back to top]

Response Rate (RR) Objective Tumor Response Based on Computed Tomography (CT) Scans or Magnetic Resonance Imaging (MRI) Scans According to Response Evaluation Criteria in Solid Tumors (RECIST)

"CBR is the number of participants of the total analysis population who experience confirmed complete (CR) or partial response (PR) per RECIST~CR = all detectable tumor has disappeared PR = a >=30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum Stable Disease (SD) = small changes that do not meet previously given criteria. Progressive disease (PD) = a >=20% increase in target lesions~The true response rate of the combination therapy for this patient population will be estimated based on the number of response using a binomial distribution and its confidence intervals will be estimated using Wilson's method." (NCT01666730)
Timeframe: 1 year

InterventionParticipants (Count of Participants)
Treatment (Metformin Hydrochloride, FOLFOX)4

[back to top]

Number of Grade 3 and 4 Toxicities According to NCI CTCAE Version 4.0

The toxicity profile of the combination will be tabulated. (NCT01666730)
Timeframe: Up to 1 year

InterventionEvents (Number)
Grade 3Grade 4
Treatment (Metformin Hydrochloride, FOLFOX)602

[back to top]

Progression Free Survival According to RECIST 1.1 Criteria

Calculated using Kaplan Meier methods and the median will be estimated assuming an exponential distribution. (NCT01666730)
Timeframe: Time from first day of treatment received to the earlier documented disease progression or death from any cause, assessed up to 1 year

InterventionMonths (Median)
Treatment (Metformin Hydrochloride, FOLFOX)5.1

[back to top]

Clinical Benefit Rate (CBR) Based on Computed Tomography (CT) Scans or Magnetic Resonance Imaging (MRI) Scans According to RECIST

"CBR is the number of participants of the total analysis population who experience a CR, PR, or SD per RECIST~CR = all detectable tumor has disappeared PR = a >=30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum SD = small changes that do not meet previously given criteria. PD = a >=20% increase in target lesions" (NCT01666730)
Timeframe: 1 year

InterventionParticipants (Count of Participants)
Treatment (Metformin Hydrochloride, FOLFOX)14

[back to top] [back to top]

Change From Baseline in HRQL EQ-5D-3L VAS Score

EQ-5D VAS was used to record a participant's rating for his/her current health-related quality of life state and captured on a vertical VAS (0-100), where 0 = worst imaginable health state and 100 = best imaginable health state. Baseline corresponded to last evaluable assessment before treatment administration. (NCT01670721)
Timeframe: Pre-dose at Baseline, Day 1 of every odd cycle; and at end of treatment (30 days after last study treatment) (maximum exposure: 99 weeks)

Interventionunits on a scale (Mean)
Baseline (n=125)At cycle 3 (n=94)At cycle 5 (n=76)At cycle 7 (n=57)At cycle 9 (n=38)At cycle 11 (n=36)At cycle 13 (n=22)At cycle 15 (n=22)At cycle 17 (n=13)At cycle 19 (n=10)At cycle 21 (n=8)At cycle 23 (n=5)At cycle 25 (n=2)At cycle 27 (n=3)At cycle 29 (n=2)At cycle 31 (n=1)At cycle 37 (n=1)At cycle 39 (n=1)At cycle 41 (n=1)At cycle 43 (n=1)At cycle 45 (n=1)At end of study treatment (n=55)
Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)69.48-6.23-7.62-7.79-7.55-8.67-8.95-12.41-10.31-15.70-15.13-8.80-13.00-15.67-17.50-15.00-15.00-15.00-15.00-15.00-15.00-13.05

[back to top]

Percentage of Participants With Adverse Events (AEs)

Any untoward medical occurrence in a participant who received investigational medicinal product (IMP) was considered an AE without regard to possibility of causal relationship with this treatment. Treatment-emergent adverse events (TEAEs) were defined as AEs that developed or worsened or became serious during on-treatment period. On-treatment period was defined as the time from the first dose of treatment to 30 days after the last dose of treatment (either Aflibercept or FOLFIRI). A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious AEs. (NCT01670721)
Timeframe: Baseline upto 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure:723 days)

InterventionPercentage of participants (Number)
Any TEAEAny serious TEAEAny serious related TEAEAny TEAE leading to deathAny TEAE (permanent treatment discontinuation)Any TEAE (premature treatment discontinuation)
Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)100.0040.621.19.123.416.0

[back to top]

Change From Baseline in HRQL European-Quality of Life-5 Dimension Instrument-3 Levels (EQ-5D-3L) Index Score

EQ-5D was a standardized HRQL questionnaire consisting of EQ-5D descriptive system and Visual Analogue Scale (VAS). EQ-5D descriptive system comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression measured on 3 levels (no problem, some problems & severe problems) within a particular EQ-5D dimension. 5 dimensional 3-level system was converted into single index utility score. Possible values for single index utility score ranged from -0.594 (severe problems in all dimensions) to 1.0 (no problem in all dimensions) on scale where 1 represented best possible health state. (NCT01670721)
Timeframe: Pre-dose at Baseline, Day 1 of every odd cycle; and at end of treatment (30 days after last study treatment) (maximum exposure: 99 weeks)

Interventionunits on a scale (Mean)
Baseline (n=148)At Cycle 3 (n=127)At Cycle 5 (n=96)At Cycle 7 (n=72)At Cycle 9 (n=49)At Cycle 11 (n=43)At Cycle 13 (n=24)At Cycle 15 (n=25)At Cycle 17 (n=14)At Cycle 19 (n=12)At Cycle 21 (n=10)At Cycle 23 (n=6)At Cycle 25 (n=3)At Cycle 27 (n=3)At Cycle 29 (n=2)At Cycle 31 (n=1)At Cycle 37 (n=1)At Cycle 39 (n=1)At Cycle 41 (n=1)At Cycle 43 (n=1)At Cycle 45 (n=1)At end of study treatment (n=71)
Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)0.78-0.04-0.08-0.05-0.09-0.06-0.09-0.10-0.03-0.10-0.03-0.080.04-0.09-0.180.00-0.150.000.000.000.00-0.20

[back to top]

Concentration of [6S]-5-THF in Adjacent Mucosa Tissue

Comparison of concentration of the metabolite [6S]-5-THF in mucosa adjacent to the tumor after the different treatments. (NCT01681472)
Timeframe: Sample taken Day 1 (Day of surgery) at 0 min (before anesthetics) and 5, 10, 20, 40, 60, 90, 120, 180, 240, 360 min after study drug administration, and 24 h after study drug administration

Interventionpmol/g (Mean)
Levoleucovorin 200 mg/m21333
Levoleucovorin 60 mg/m2626
Modufolin 200 mg/m25099
Modufolin 60 mg/m23481

[back to top]

Concentration of [6S]-5-methyl-THF in Tumor Tissue

Comparison of concentration of the metabolite [6S]-5-methyl-THF in tumor after the different treatments. (NCT01681472)
Timeframe: Sample taken Day 1 (Day of surgery) at 0 min (before anesthetics) and 5, 10, 20, 40, 60, 90, 120, 180, 240, 360 min after study drug administration, and 24 h after study drug administration

Interventionpmol/g (Mean)
Levoleucovorin 200 mg/m23574
Levoleucovorin 60 mg/m21904
Modufolin 200 mg/m24396
Modufolin 60 mg/m21882

[back to top]

Concentration of [6S]-5-methyl-THF in Adjacent Mucosa Tissue

Comparison of concentration of the metabolite [6S]-5-methyl-THF in mucosa adjacent to the tumor after the different treatments. (NCT01681472)
Timeframe: Sample taken Day 1 (Day of surgery) at 0 min (before anesthetics) and 5, 10, 20, 40, 60, 90, 120, 180, 240, 360 min after study drug administration, and 24 h after study drug administration

Interventionpmol/g (Mean)
Levoleucovorin 200 mg/m23667
Levoleucovorin 60 mg/m21216
Modufolin 200 mg/m22494
Modufolin 60 mg/m22066

[back to top]

Concentration of [6S]-5-formyl-THF in Tumor Tissue

Comparison of concentration of the metabolite [6S]-5-formyl-THF in tumor after the different treatments. (NCT01681472)
Timeframe: Sample taken Day 1 (Day of surgery) at 0 min (before anesthetics) and 5, 10, 20, 40, 60, 90, 120, 180, 240, 360 min after study drug administration, and 24 h after study drug administration

Interventionpmol/g (Mean)
Levoleucovorin 200 mg/m23611
Levoleucovorin 60 mg/m2512
Modufolin 200 mg/m2100
Modufolin 60 mg/m257

[back to top]

Concentration of [6S]-5-formyl-THF in Adjacent Mucosa Tissue

Comparison of concentration of the metabolite [6S]-5-formyl-THF in mucosa adjacent to the tumor after the different treatments. (NCT01681472)
Timeframe: Sample taken Day 1 (Day of surgery) at 0 min (before anesthetics) and 5, 10, 20, 40, 60, 90, 120, 180, 240, 360 min after study drug administration, and 24 h after study drug administration

Interventionpmol/g (Mean)
Levoleucovorin 200 mg/m25456
Levoleucovorin 60 mg/m21403
Modufolin 200 mg/m282
Modufolin 60 mg/m242

[back to top]

Concentration of [6R]-5,10-methylene-THF in Tumor Tissue

Comparison of concentration of the active substance in Modufolin: [6R]-5,10-methylene-THF in tumor tissue after the different treatments. (NCT01681472)
Timeframe: Sample taken Day 1 (Day of surgery) at 0 min (before anesthetics) and 5, 10, 20, 40, 60, 90, 120, 180, 240, 360 min after study drug administration, and 24 h after study drug administration

Interventionpmol/g (Mean)
Levoleucovorin 200 mg/m21871
Levoleucovorin 60 mg/m2959
Modufolin 200 mg/m24725
Modufolin 60 mg/m22393

[back to top]

Concentration of [6R]-5,10-methylene-THF in Adjacent Mucosa Tissue

Comparison of concentration of the active substance in Modufolin: [6R]-5,10-methylene-THF in mucosa adjacent to the tumor after the different treatments. (NCT01681472)
Timeframe: Sample taken Day 1 (Day of surgery) at 0 min (before anesthetics) and 5, 10, 20, 40, 60, 90, 120, 180, 240, 360 min after study drug administration, and 24 h after study drug administration

Interventionpmol/g (Mean)
Levoleucovorin 200 mg/m21333
Levoleucovorin 60 mg/m2626
Modufolin 200 mg/m25099
Modufolin 60 mg/m23481

[back to top]

Cmax of [6S]-5-THF in Plasma

Maximum concentration (Cmax) in plasma of the metabolite [6S]-5-THF (NCT01681472)
Timeframe: Samples taken Day 1 (Day of surgery) and Day 2

Interventionµg/L (Mean)
L-LV(200)577.6250
L-LV(60)335.0000
Mod(200)13372.5000
Mod(60)5015.7143

[back to top]

Cmax of [6S]-5-methyl-THF in Plasma

Maximum concentration (Cmax) in plasma of the metabolite [6S]-5-methyl-THF (NCT01681472)
Timeframe: Samples taken Day 1 (Day of surgery) and Day 2

Interventionµg/L (Mean)
L-LV(200)2786.25000
L-LV(60)1078.00000
Mod(200)2020.50000
Mod(60)800.42857

[back to top]

Cmax of [6S]-5-formyl-THF in Plasma

Maximum concentration (Cmax) in plasma of the active substance in Modufolin: [6R] 5,10- methylene-THF and the metabolites: [6S]-5-THF, [6S]-5-methyl-THF, and [6S]-5-formyl-THF (NCT01681472)
Timeframe: Samples taken Day 1 (Day of surgery) and Day 2

Interventionµg/L (Mean)
L-LV(200)32962.5000
L-LV(60)10168.3333
Mod(200)252.7500
Mod(60)261.0000

[back to top]

AUC(Last) of [6R]-5,10-methylene-THF

Area under the plasma concentration versus time curve, from time 0 to the last time point, for the active substance in Modufolin: [6R]-5,10-methylene-THF (NCT01681472)
Timeframe: Samples taken Day 1 (Day of surgery) and Day 2

Interventionmcg*h/L (Mean)
L-LV(200)462.10746
L-LV(60)239.90076
Mod(200)7910.61038
Mod(60)2272.78010

[back to top]

Cmax of [6R]-5,10-methylene-THF

Maximum concentration (Cmax) in plasma of the active substance in Modufolin: [6R]-5,10-methylene-THF (NCT01681472)
Timeframe: Samples taken Day 1 (Day of surgery) and Day 2

Interventionµg/L (Mean)
L-LV(200)195.0000
L-LV(60)123.0000
Mod(200)22087.5000
Mod(60)6452.8571

[back to top]

Gene Expression Ratios (Mucosa:Tumor)

Concentration of different genes involved in folate transport and metabolism were analysed in both tumor and adjacent mucosa. The concentration in mucosa was divided by the concentration in tumor. A value above 1 indicate that the gene expression was higher in mucosa than in tumor and a value below 1 that the gene expression was higher in tumor than in mucosa. (NCT01681472)
Timeframe: Sample taken Day 1 (Day of Surgery)

,,,
InterventionRatio (Number)
AMTPCFTFPGSMTHFSABCC3GGHABCC1MTHFD1LSHMT1SHMT2RFC-1
Levoleucovorin 200 mg/m23.332.450.830.724.150.310.430.352.260.481.18
Levoleucovorin 60 mg/m21.862.920.630.832.480.350.770.290.720.380.53
Modufolin 200 mg/m25.602.750.700.873.370.470.550.241.130.340.66
Modufolin 60 mg/m21.352.030.470.511.830.500.410.150.890.310.48

[back to top]

Correlation of Gene Expression in Tumor and Adjacent Mucosa

Concentration of the gene expression was analysed in both tumor and adjacent mucosa. The presence of any correlation between the results (i.e., concentration of the gene expression in tumor versus adjacent mucosa) was evaluated for each treatment. No evaluation was done between treatments. (NCT01681472)
Timeframe: Sample taken Day 1 (Day of Surgery)

,,,
InterventionNormalized concentration (Number)
AMTPCFTFPGSMTHFSABCC3GGHABCC1MTHFD1LSHMT1SHMT2RFC-1
Levoleucovorin 200 mg/m2-0.471930.114970.176640.958400.003220.789280.747570.744590.591830.555080.64565
Levoleucovorin 60 mg/m2-0.707300.89976-0.647430.584190.77700-0.097370.144360.209550.05531-0.71666-0.02450
Modufolin 200 mg/m20.754040.585020.886820.43194-0.258910.46883-0.167240.371600.678530.862660.23312
Modufolin 60 mg/m20.429720.881280.976240.94364-0.389870.937110.829630.321130.509660.810400.31800

[back to top]

Correlation Between Plasma and Tissue Concentration (Tumor and Mucosa) for [6S]-5-THF

Correlation between the exposure of [6S]-5-THF following 2 hours after dosing (AUC[0-2h]) and the concentration of [6S]-5-THF in the tumor or adjacent mucosa at surgery. (NCT01681472)
Timeframe: Samples taken Day 1 (Day of surgery)

,,,
Interventioncorrelation coefficient (Number)
AUC(0-2h) vs. conc in tumorAUC(0-2h) vs. conc in adjacent mucosa
Levoleucovorin 200 mg/m2-0.021880.07937
Levoleucovorin 60 mg/m2NANA
Modufolin 200 mg/m20.270180.34905
Modufolin 60 mg/m20.382980.45404

[back to top]

Correlation Between Plasma and Tissue Concentration (Tumor and Mucosa) for [6S]-5-methyl-THF

Correlation between the exposure of [6S]-5-methyl-THF following 2 hours after dosing (AUC[0-2h]) and the concentration of [6S]-5-methyl-THF in the tumor or adjacent mucosa at surgery. (NCT01681472)
Timeframe: Samples taken Day 1 (Day of surgery)

,,,
Interventioncorrelation coefficient (Number)
AUC(0-2h) vs. conc in tumorAUC(0-2h) vs. conc in adjacent mucosa
Levoleucovorin 200 mg/m20.737430.76502
Levoleucovorin 60 mg/m20.447570.34496
Modufolin 200 mg/m20.03292-0.66295
Modufolin 60 mg/m20.090330.36854

[back to top]

Correlation Between Plasma and Tissue Concentration (Tumor and Mucosa) for [6S]-5-formyl-THF

Correlation between the exposure of [6S]-5-formyl-THF following 2 hours after dosing (AUC[0-2h]) and the concentration of [6S]-5-formyl-THF in the tumor or adjacent mucosa at surgery. (NCT01681472)
Timeframe: Samples taken Day 1 (Day of surgery)

,
Interventioncorrelation coefficient (Number)
AUC(0-2h) vs. conc in tumorAUC(0-2h) vs. conc in adjacent mucosa
Levoleucovorin 200 mg/m20.687780.23512
Levoleucovorin 60 mg/m20.115120.02576

[back to top]

Correlation Between Plasma and Tissue Concentration (Tumor and Mucosa) for [6R]-5,10-methylene-THF

Correlation between the exposure of [6R]-5,10-methylene-THF following 2 hours after dosing (AUC[0-2h]) and the concentration of [6R]-5,10-methylene-THF in the tumor or adjacent mucosa at surgery. (NCT01681472)
Timeframe: Samples taken Day 1 (Day of surgery)

,,
Interventioncorrelation coefficient (Number)
AUC(0-2h) vs. conc in tumorAUC(0-2h) vs. conc in adjacent mucosa
Levoleucovorin 200 mg/m20.540390.68223
Levoleucovorin 60 mg/m2NANA
Modufolin 200 mg/m2-0.216660.27618

[back to top]

Change in S-Folate Concentration From Screening

Blood samples for folate biomarker (S-folate) analysis were collected at Screening, Day 2 and Day 5 (End of study visit). Changes from screening to later visits were counted. (NCT01681472)
Timeframe: Samples taken at Screening visit, Day 2 and End of Study (Day 5)

,,,
InterventionParticipants (Count of Participants)
Shift from Normal at Screen to High at Day 2Missing data Screen to Day 2Normal at Screening and Normal at Day 5Shift from Normal at Screen to High at Day 5Missing data Screen to Day 5
Levoleucovorin 200 mg/m280080
Levoleucovorin 60 mg/m251141
Modufolin 200 mg/m280161
Modufolin 60 mg/m270340

[back to top]

Change in Homocystein Concentration From Screening

"Blood samples for folate biomarker (homocystein) analysis were collected at Screening, Day 2 and Day 5 (End of study visit). Changes from screening to later visits were counted.~The criteria for assessment categories normal, low and high were based on the reference ranges for plasma-Homocystein as follows: low <4,7 mcmol/L; normal => 4,7 and <=16 mcmol/L; high >16 mcmol/L. Values were applicable for both male and female adults." (NCT01681472)
Timeframe: Samples taken at Screening visit, Day 2 and End of Study (Day 5)

,,,
InterventionParticipants (Count of Participants)
Normal at Screen and Normal at Day 2Shift from Normal at Screen to Low at Day 2Shift from High at Screen to Normal at Day 2Normal at Screen and Normal at Day 5Shift from Normal at Screen to Low at Day 5Shift from High at Screen and Normal at Day 5Missing data Screen to Day 5
Levoleucovorin 200 mg/m24226020
Levoleucovorin 60 mg/m24204101
Modufolin 200 mg/m24135030
Modufolin 60 mg/m25025020

[back to top]

Tmax of [6S]-5-THF

Timepoint (tmax) when Cmax in plasma occurs for the metabolite [6S]-5-THF (NCT01681472)
Timeframe: Samples taken Day 1 (Day of surgery) and Day 2

Interventionh (Mean)
L-LV(200)2.02083375
L-LV(60)1.50000000
Mod(200)0.38541750
Mod(60)0.09523571

[back to top]

Tmax of [6S]-5-methyl-THF

Timepoint (tmax) when Cmax in plasma occurs for the metabolite [6S]-5-methyl-THF (NCT01681472)
Timeframe: Samples taken Day 1 (Day of surgery) and Day 2

Interventionh (Mean)
L-LV(200)4.75000000
L-LV(60)2.41666667
Mod(200)3.75000000
Mod(60)2.92857143

[back to top]

Tmax of [6S]-5-formyl-THF

Timepoint (tmax) when Cmax in plasma occurs for the metabolite [6S]-5-formyl-THF (NCT01681472)
Timeframe: Samples taken Day 1 (Day of surgery) and Day 2

Interventionh (Mean)
L-LV(200)0.12499750
L-LV(60)0.08333000
Mod(200)0.10416500
Mod(60)0.08333000

[back to top]

Tmax of [6R]-5,10-methylene-THF

Timepoint (tmax) when Cmax in plasma occurs of the active substance in Modufolin: [6R]-5,10-methylene-THF (NCT01681472)
Timeframe: Samples taken Day 1 (Day of surgery) and Day 2

Interventionh (Mean)
L-LV(200)1.14285857
L-LV(60)1.00000000
Mod(200)0.08333000
Mod(60)0.08333000

[back to top]

T(Last) of [6S]-5-THF

The time-point for the last measurable concentration for the metabolite [6S]-5-TH in plasma (NCT01681472)
Timeframe: Samples taken Day 1 (Day of surgery) and Day 2

Interventionh (Mean)
L-LV(200)4.75000000
L-LV(60)2.00000000
Mod(200)5.75000000
Mod(60)3.42857143

[back to top]

T(Last) of [6S]-5-methyl-THF

The time-point for the last measurable concentration for the metabolite [6S]-5-methyl-THF in plasma (NCT01681472)
Timeframe: Samples taken Day 1 (Day of surgery) and Day 2

Interventionh (Mean)
L-LV(200)24.0000000
L-LV(60)12.0000000
Mod(200)15.0000000
Mod(60)8.5714286

[back to top]

AUC(0-2h) of [6R]-5,10-methylene-THF

Area under the plasma concentration versus time curve from time 0 to 2 hours, for the active substance in Modufolin: [6R]-5,10-methylene-THF (NCT01681472)
Timeframe: Samples taken Day 1 (Day of surgery)

Interventionmcg*h/L (Mean)
L-LV(200)326.40261
L-LV(60)239.90076
Mod(200)7734.09113
Mod(60)0

[back to top]

AUC(0-2h) of [6S]-5-methyl-THF

Area under the plasma concentration versus time curve from time 0 to 2 hours, for the metabolite: [6S]-5-methyl-THF (NCT01681472)
Timeframe: Samples taken Day 1 (Day of surgery)

Interventionmcg*h/L (Mean)
L-LV(200)2336.24432
L-LV(60)1258.60184
Mod(200)2277.89290
Mod(60)997.74091

[back to top]

AUC(0-2h) of [6S]-5-THF

Area under the plasma concentration versus time curve from time 0 to 2 hours, for the metabolite [6S]-5-THF (NCT01681472)
Timeframe: Samples taken Day 1 (Day of surgery)

Interventionmcg*h/L (Mean)
L-LV(200)827.1083
L-LV(60)640.0489
Mod(200)19408.1712
Mod(60)5639.2700

[back to top]

AUC(0-2h) of [6SR]-5-formyl-THF

Area under the plasma concentration versus time curve from time 0 to 2 hours, for the metabolite [6S]-5-formyl-THF (NCT01681472)
Timeframe: Samples taken Day 1 (Day of surgery)

Interventionmcg*h/L (Mean)
L-LV(200)29911.9184
L-LV(60)7595.4599
Mod(200)0
Mod(60)0

[back to top]

AUC(Last) of [6S]-5-THF

Area under the plasma concentration versus time curve, from time 0 to the last time point, for the metabolite [6S]-5-THF (NCT01681472)
Timeframe: Samples taken Day 1 (Day of surgery) and Day 2

Interventionmcg*h/L (Mean)
L-LV(200)2231.1443
L-LV(60)640.0489
Mod(200)28466.5389
Mod(60)6766.9104

[back to top]

AUC(Last) of [6S]-5-methyl-THF

Area under the plasma concentration versus time curve, from time 0 to the last time point, for the metabolite [6S]-5-methyl-THF (NCT01681472)
Timeframe: Samples taken Day 1 (Day of surgery) and Day 2

Interventionmcg*h/L (Mean)
L-LV(200)32206.2771
L-LV(60)7689.0921
Mod(200)21737.2428
Mod(60)5495.1924

[back to top]

AUC(Last) of [6S]-5-formyl-THF

Area under the plasma concentration versus time curve, from time 0 to the last time point, for the metabolite [6S]-5-formyl-THF (NCT01681472)
Timeframe: Samples taken Day 1 (Day of surgery) and Day 2

Interventionmcg*h/L (Mean)
L-LV(200)43429.1885
L-LV(60)9637.0308
Mod(200)75.6174
Mod(60)50.1858

[back to top]

T(Last) of [6S]-5-formyl-THF

The time-point for the last measurable concentration for the metabolite [6S]-5-formyl-THF in plasma (NCT01681472)
Timeframe: Samples taken Day 1 (Day of surgery) and Day 2

Interventionh (Mean)
L-LV(200)6.00000000
L-LV(60)8.33333333
Mod(200)0.33333500
Mod(60)0.16667000

[back to top]

T(Last) of [6R]-5,10-methylene-THF

The time-point for the last measurable concentration of the active substance in Modufolin: [6R]-5,10-methylene-THF (NCT01681472)
Timeframe: Samples taken Day 1 (Day of surgery) and Day 2

Interventionh (Mean)
L-LV(200)3.00000000
L-LV(60)2.00000000
Mod(200)3.25000000
Mod(60)1.35714286

[back to top]

T(1/2) of [6S]-5-THF

Terminal plasma elimination half-life time for the metabolite [6S]-5-THF (NCT01681472)
Timeframe: Samples taken Day 1 (Day of surgery) and Day 2

Interventionh (Mean)
L-LV(200)5.59459251
L-LV(60)0
Mod(200)1.24808943
Mod(60)0.96378070

[back to top]

T(1/2) of [6S]-5-methyl-THF

Terminal plasma elimination half-life time for the metabolite [6S]-5-methyl-THF (NCT01681472)
Timeframe: Samples taken Day 1 (Day of surgery) and Day 2

Interventionh (Mean)
L-LV(200)7.0955575
L-LV(60)10.7281060
Mod(200)9.0743346
Mod(60)8.5121573

[back to top]

T(1/2) of [6S]-5-formyl-THF

Terminal plasma elimination half-life time for the metabolite [6S]-5-formyl-THF (NCT01681472)
Timeframe: Samples taken Day 1 (Day of surgery) and Day 2

Interventionh (Mean)
L-LV(200)1.51328500
L-LV(60)0.98944069
Mod(200)0.23180085
Mod(60)0

[back to top]

T(1/2) of [6R]-5,10-methylene-THF

Terminal plasma elimination half-life time for the active substance in Modufolin: [6R]-5,10-methylene-THF (NCT01681472)
Timeframe: Samples taken Day 1 (Day of surgery) and Day 2

Interventionh (Mean)
L-LV(200)3.07069184
L-LV(60)9.12204918
Mod(200)0.90893994
Mod(60)0.34368840

[back to top]

Concentration of [6S]-5-THF in Tumor Tissue

Comparison of concentration of the metabolite [6S]-5-THF in tumor after the different treatments. (NCT01681472)
Timeframe: Sample taken Day 1 (Day of surgery) at 0 min (before anesthetics) and 5, 10, 20, 40, 60, 90, 120, 180, 240, 360 min after study drug administration, and 24 h after study drug administration

Interventionpmol/g (Mean)
Levoleucovorin 200 mg/m21329
Levoleucovorin 60 mg/m2933
Modufolin 200 mg/m24175
Modufolin 60 mg/m22219

[back to top]

S-Folate Concentration

Blood samples for folate biomarker (S-folate) analysis were collected at Screening, Day 2 and Day 5 (End of study visit). (NCT01681472)
Timeframe: Samples taken at Screening visit, Day 2 and End of Study (Day 5)

,,,
Interventionnmol/L (Mean)
Concentration at ScreeningConcentration at Day 2Concentration at Day 5
Levoleucovorin 200 mg/m221.7545.0044.75
Levoleucovorin 60 mg/m221.0045.0040.80
Modufolin 200 mg/m215.0345.0044.14
Modufolin 60 mg/m218.7145.0040.29

[back to top]

Number of AEs Per Severity

Number of reported AEs per treatment with respect to severity (NCT01681472)
Timeframe: Screening visit until end of study, Day 5

,,,
InterventionEvents (Number)
AEs of mild severityAEs of moderate severityAEs of severe severity
Levoleucovorin 200 mg/m2130
Levoleucovorin 60 mg/m2001
Modufolin 200 mg/m2172
Modufolin mg/m2522

[back to top]

Homocystein Concentration

Blood samples for folate biomarker (homocystein) analysis were collected at Screening, Day 2, and Day 5 (End of study visit). (NCT01681472)
Timeframe: Samples taken at Screening visit, Day 2, and End of Study (Day 5)

,,,
Interventionμmol/L (Mean)
Concentration at ScreeningConcentration at Day 2Concentration at Day 5
Levoleucovorin 200 mg/m212.596.419.04
Levoleucovorin 60 mg/m211.276.409.18
Modufolin 200 mg/m214.537.0610.20
Modufolin 60 mg/m213.808.1410.10

[back to top]

Progression Free Survival (PFS)

Progression free survival will be measured from D1 of treatment until evidence of tumor progression (including clinical deterioration related to the underlying pancreatic cancer, as assessed by the investigator) or death from any cause. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Patients that are lost to follow-up will be censored (NCT01688336)
Timeframe: the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years

InterventionMonths (Median)
FOLFIRINOX10.7

[back to top]

Overall Survival for Borderline Resectable Patients

All patients who receive at least Day 1 of FOLFIRINOX treatment will be evaluable and followed up for up to 3 years for the outcome of overall survival (OS) (NCT01688336)
Timeframe: Up to 3 years

InterventionMonths (Median)
FOLFIRINOX9.0

[back to top]

Objective Response Rate

"All patients who have received at least one cycle of treatment will be evaluated. Disease will be evaluated per Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1) for target lesions and assessed by CT and/or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions.~Patients who drop out of the study prior to disease evaluation will not be evaluable for response unless the patient undergoes radiologic evaluation or their disease progresses clinically." (NCT01688336)
Timeframe: Up to 3 years

Interventionpercentage of patients (Number)
FOLFIRINOX11

[back to top]

Median Overall Survival (OS) of FOLFIRINOX in Patients With Unresectable Locally Advanced (ULA) Pancreatic Cancer

All patients who receive at least Day 1 of FOLFIRINOX treatment will be evaluable and followed up for up to 3 years for the primary outcome of overall survival (OS). (NCT01688336)
Timeframe: Up to 3 years

Interventionmonths (Median)
FOLFIRINOX28.5

[back to top]

Disease Control Rate (DCR)

Disease control rate will be measured by the percentage of patients with responses (CR) and partial responses (PR) and stable disease (SD), per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI and/or CT: Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for a Partial Response nor sufficient increase to qualify for Progression of Disease (POD); Complete Response (CR), Disappearance of all target lesions. (NCT01688336)
Timeframe: Up to 3 years

Interventionpercentage of patients (Number)
FOLFIRINOX89

[back to top]

Rate of Resectability (RR)

Rate of resectability will be evaluated by determining the percentage of patients who were initially deemed to have ULA or borderline resectable (BR) disease and, following any period of treatment, were subsequently deemed to have resectable disease and undergo surgical resection. The denominator will reflect all patients with ULA or BR disease. (NCT01688336)
Timeframe: Up to 3 years

Interventionpercentage of patients (Number)
FOLFIRINOX22

[back to top]

Response

Number of participants treated with mDCF with progressive disease (PD), stable disease (SD), partial response (PR), non-complete response and non-progressive disease (non-CR/non-PD), and partial response with progressive disease clinically (PR/PD) as defined by RECIST criteria. Response is compared based on CHFR-methylation status. (NCT01715233)
Timeframe: 4 months

InterventionParticipants (Count of Participants)
CHFR-methylated72174376CHFR-unmethylated72174376Unknown methylation status72174376
SDnon-CR/non-PDPR/PDPRPD
Metastatic Esophageal, Gastroesophageal & Gastric Cancer.3
Metastatic Esophageal, Gastroesophageal & Gastric Cancer.2
Metastatic Esophageal, Gastroesophageal & Gastric Cancer.1
Metastatic Esophageal, Gastroesophageal & Gastric Cancer.5
Metastatic Esophageal, Gastroesophageal & Gastric Cancer.0

[back to top]

CHFR Methylation Status

Number of participants with advanced esophagogastric cancer that are CHFR-methylated or unmethylated at baseline. (NCT01715233)
Timeframe: Baseline

InterventionParticipants (Count of Participants)
CHFR-methylatedCHFR-unmethylated
Metastatic Esophageal, Gastroesophageal & Gastric Cancer.612

[back to top]

Overall Survival

Number of participants alive at 2 years. (NCT01715233)
Timeframe: 2 Years

InterventionParticipants (Count of Participants)
Metastatic Esophageal, Gastroesophageal And Gastric Cancer.2

[back to top]

Objective Response Rate

"Objective response rate (ORR), according to Response Evaluation Criteria in Solid Tumors (RECIST),version 1.1, was the primary end point and was defined as the number of complete plus partial responses divided by the number of enrolled patients.~Per RECIST v 1.1 for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR." (NCT01718873)
Timeframe: Objective response was assessed by computed tomographic scan or other appropriate imaging at weeks 12 and 24 from randomization, and every 3 months thereafter, assessed up to 90 months.

Interventionparticipants (Number)
Bevacizumab Before Chemotherapy65
Bevacizumab With Chemotherapy66

[back to top]

Overall Survival

Overall survival was defined as the time from randomization to the date of death. Patients alive at the time of the final analysis were censored on the date of the last follow-up information available. (NCT01718873)
Timeframe: assessed up to 90 months

Interventionmonths (Median)
Bevacizumab Before Chemotherapy29.8
Bevacizumab With Chemotherapy24.1

[back to top]

Progression-free Survival (PFS)

"Progression-free survival was defined as the time from randomization to the date of progression or death, whichever occurred first. Patients without progression were censored on the date of the last follow-up visit.~Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions." (NCT01718873)
Timeframe: assessed up to 90 months

Interventionmonths (Median)
Bevacizumab Before Chemotherapy11.7
Bevacizumab With Chemotherapy10.5

[back to top]

Toxic Effects

Toxic effects were scored according to the National Cancer Institute Common Toxicity Criteria for Adverse Events (CTCAE), version 4.0. For the National Cancer Institute Common Toxicity Criteria for Adverse Events (CTCAE), version 4.0 scale score range from 1 to 4. A high score, that is 3 and 4, represents a high level of toxicity, whereas the minimum values, that is 1 and 2, represents a mild/modest level of toxicity. (NCT01718873)
Timeframe: up to 4 weeks after the end of the treatment

InterventionParticipants (Count of Participants)
Bevacizumab Before Chemotherapy108
Bevacizumab With Chemotherapy113

[back to top]

Disease Control Rate

Disease control rate was calculated by adding complete and partial responses and stable disease. (NCT01718873)
Timeframe: At weeks 12 and 24 from randomization and every 3 months thereafter, assessed up to 90 months

InterventionParticipants (Count of Participants)
Bevacizumab Before Chemotherapy107
Bevacizumab With Chemotherapy103

[back to top]

Number of Subjects Completing Therapy Including Surgical Resection.

This outcome measure is the number of subjects completing therapy up to and including surgical resection. In this context, surgical excision of residual tumor is an option in the progression of usual care. Surgery was contraindicated for some participants. This measure is the number of subject who were eligible for and completed the surgical procedure. (NCT01726582)
Timeframe: At time of surgery (approximately 10 to 20 weeks after screening)

InterventionParticipants (Count of Participants)
Milestones Related to Usual Therapy107

[back to top]

Overall Survival in Months

This measure is the median time of survival (in months) at five years from the initiation of therapy. Results will be presented for two cohorts: subjects completing neoadjuvant therapy and surgical resection; and subjects completing neoadjuvant therapy but without surgical resection. (NCT01726582)
Timeframe: 5 years

InterventionMonths (Median)
Milestones Related to Therapy (Resected)45
Milestones Related to Therapy (Non-Resected)11

[back to top]

Progression-free Survival

This measure is the number of subjects not experiencing tumor progression at five years from initiating therapy. (NCT01726582)
Timeframe: 5 years

InterventionParticipants (Count of Participants)
Milestones Related to Usual Therapy36

[back to top]

Use of Biomarkers to Determine Course of Treatment

The number of subjects for whom a biomarker (i.e., molecular profile) was used to determine the course of treatment. (NCT01726582)
Timeframe: Initiation of therapy (approximately 4 to 12 weeks after screening) until surgery (approximately 10 to 20 weeks after screening)

InterventionParticipants (Count of Participants)
Milestones Related to Usual Therapy92

[back to top]

Objective Response Rate (ORR)

ORR was defined as the percentage of patients achieving complete response (CR) or partial response (PR) on treatment based on RECIST 1.1 criteria. Per RECIST 1.1 for target lesions: CR is complete disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD. PR or better overall response assumes at a minimum incomplete response/stable disease (SD) for the evaluation of non-target lesions and absence of new lesions. (NCT01747551)
Timeframe: Tumor assessments were performed every 8 weeks and evaluated by independent, blinded radiologists. Patients received a median (range) treatment duration (m) of 6.9 (0-23.3) and 6.4 (0-43.9) for mFOLFOX6/ziv-aflibercept and mFOLFOX6/placebo, respectively.

Interventionpercentage of patients (Number)
mFOLFOX6 + Ziv-aflibercept61.1
mFOLFOX6 + Placebo75.0

[back to top]

6-month Progression-free Survival (PFS)

6-month PFS is the percent probability of patients remaining alive and progression-free at 6-months from randomization estimated using Kaplan-Meier methods. PFS was measured as the time from randomization to 1st documented disease progression (PD) or death. Patients alive without PD were censored at the earliest of the date of last progression-free disease assessment or start of non-protocol therapy. Per RECIST 1.1 criteria: progressive disease (PD) is at least a 20% increase in the sum of longest diameter (LD) of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. PD for the evaluation of non-target lesions is the appearance of one or more new lesions and/or unequivocal progression of non-target lesions. (NCT01747551)
Timeframe: Tumor assessments were performed every 8 weeks and evaluated by independent, blinded radiologists. Patient follow-up was 6 months.

Interventionpercent probability (Number)
mFOLFOX6 + Ziv-aflibercept60.5
mFOLFOX6 + Placebo57.1

[back to top]

Duration of Objective Response

Duration of response is the time from date of first documented confirmed objective response to date of first documented progressive disease. Per RECIST 1.1 for target lesions: PD is at least a 20% increase in sum LD, taking as reference the smallest sum on study with at least 5 mm absolute increase. For non-target lesions, progression-free means no new lesions or unequivocal progression on existing non-target lesions or not evaluated. (NCT01747551)
Timeframe: Tumor assessments were performed every 8 weeks and evaluated by independent, blinded radiologists. Patient follow-up (months) median (range) was 14.5 (1.1-49.8) and 18.8 (0.6-49.8) for mFOLFOX6/ziv-aflibercept and mFOLFOX6/placebo, respectively.

Interventionmonths (Mean)
mFOLFOX6 + Ziv-aflibercept9.0
mFOLFOX6 + Placebo8.0

[back to top] [back to top]

Disease-Free Survival

(NCT01749956)
Timeframe: Patients without evidence of progression will be followed every 3 months (±1 month) from date of last dose of study drug during Years 1-2, every 6 months during Years 3-4, and annually thereafter or until disease progression, estimated 5 years.

Interventionpercentage of participants (Median)
FOLFOX6/Aflibercept/Radation/SurgeryNA

[back to top]

The Number of Participants Who Experienced Serious or Non-Serious Adverse Events as a Measure of Safety.

Adverse events and serious adverse events (AEs and SAEs) were graded according to National Cancer Institute Common Technology Criteria for Adverse Events (NCI CTCAE) v4.0. Specific AE and SAE terms are provided in the Adverse Event module. (NCT01749956)
Timeframe: weekly for 6 weeks pre-op then every 2 weeks post-op, approximately 36 weeks

Interventionparticipants (Number)
AEsSAEs
FOLFOX6/Aflibercept/Radiation/Surgery389

[back to top]

Overall Survival Probability at 6 and 12 Months

The probability of overall survival at 6 months and 12 months from date of first protocol treatment until date of death. (NCT01749956)
Timeframe: up to 1 year

Interventionprobability (Number)
6-month OS probability12 month OS probability
FOLFOX6/Aflibercept/Radiation/Surgery0.970.94

[back to top]

Disease Free Survival Probability at 6 and 12 Months

The probability of disease free survival at 6 and 12 months after initiating protocol treatment. (NCT01749956)
Timeframe: Up to 1 year

Interventionprobability (Number)
6-month DFS probability12-month DFS probability
FOLFOX6/Aflibercept/Radiation/Surgery0.950.87

[back to top]

Sphincter Preservation Rate

The percentage of patients who had Low Anterior Resection during surgery.. (NCT01749956)
Timeframe: Between days 57 and 98 after preoperative chemotherapy.

Interventionpercentage of patients (Number)
FOLFOX6/Aflibercept/Radation/Surgery62

[back to top]

Pathologic Complete Response Rate

The Pathologic Complete Response (pCR) Rate is defined as the number of pathologic complete responders among all patients evaluable for response, including evaluable patients who did not proceed to surgery. A pCR is defined as the absence of any residual abnormality detected in a pathological specimen. (NCT01749956)
Timeframe: Between days 57 and 98 after preoperative chemotherapy

Interventionparticipants (Number)
FOLFOX6/Aflibercept/Radiation/Surgery7

[back to top]

Overall Survival

Measured from date of first protocol treatment until date of death. (NCT01749956)
Timeframe: Every 3 months (±1 month) following documented progression, up to 5 years or death, whichever comes first.

Interventionparticipants (Median)
FOLFOX6/Aflibercept/Radiation/SurgeryNA

[back to top]

Proportion of Participants Who Underwent Liver Metastases Resections

Reported here is the proportion of participants who underwent liver metastases resections calculated as follows: number of participants who underwent liver metastases resections divided by total number of participants in each arm. (NCT01765582)
Timeframe: Randomization up to approximately 3 years

InterventionProportion of participants (Number)
Arm A: Concurrent FOLFOXIRI + Bevacizumab0.17
Arm B: Sequential FOLFOXIRI + Bevacizumab0.10
Arm C: FOLFOX + Bevacizumab0.08
Arms A + B: Pooled FOLFOXIRI + Bevacizumab0.14

[back to top]

Time to PFS2

Time to PFS2 was defined as time from randomization to the first occurrence of disease progression after reinduction of second-line therapy, as assessed by the Investigator using RECIST v1.1, or death from any cause, whichever occurs first. Disease progression was defined as sum of longest diameters increased by at least 20% from the smallest value on study. The sum of longest diameters must also demonstrate an absolute increase of at least 5mm. (NCT01765582)
Timeframe: Randomization up to disease progression during second-line therapy or death, whichever occurs first (up to approximately 3 years)

Interventionmonths (Median)
Arm A: Concurrent FOLFOXIRI + Bevacizumab18.76
Arm B: Sequential FOLFOXIRI + Bevacizumab13.17
Arm C: FOLFOX + Bevacizumab14.75
Arms A + B: Pooled FOLFOXIRI + Bevacizumab15.08

[back to top]

Overall Survival (OS)

OS was defined as the time from the date of randomization to the date of death from any cause. (NCT01765582)
Timeframe: Randomization until death due to any cause (up to approximately 3 years)

Interventionmonths (Median)
Arm A: Concurrent FOLFOXIRI + Bevacizumab33.97
Arm B: Sequential FOLFOXIRI + Bevacizumab28.32
Arm C: FOLFOX + Bevacizumab30.65
Arms A + B: Pooled FOLFOXIRI + Bevacizumab28.32

[back to top]

Percentage of Participants With Adverse Events

An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. (NCT01765582)
Timeframe: Randomization up to approximately 3 years

InterventionPercentage of participants (Number)
Arm A: Concurrent FOLFOXIRI + Bevacizumab100
Arm B: Sequential FOLFOXIRI + Bevacizumab98.9
Arm C: FOLFOX + Bevacizumab100
Arms A + B: Pooled FOLFOXIRI + Bevacizumab99.4

[back to top]

Percentage of Participants With Overall Response During First-Line Therapy (ORR1)

ORR1 was the percentage of participants with complete response (CR) or partial response (PR) during first-line therapy as assessed by investigator according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v.1.1). CR was defined as disappearance of all extranodal target lesions and all pathological lymph nodes had to have decreased to <10 millimeter (mm) in short axis. PR was defined as at least a 30% decrease in the sum of longest diameters of target lesions, taking as reference the baseline sum diameters. ORR1 = CR + PR (NCT01765582)
Timeframe: Randomization up to disease progression during first-line therapy or death, whichever occurs first (up to approximately 3 years)

InterventionPercentage of participants (Number)
Arm A: Concurrent FOLFOXIRI + Bevacizumab72.0
Arm B: Sequential FOLFOXIRI + Bevacizumab72.8
Arm C: FOLFOX + Bevacizumab62.1
Arms A + B: Pooled FOLFOXIRI + Bevacizumab72.4

[back to top]

Progression-Free Survival During First-Line Therapy (PFS1)

PFS1 was defined as time from randomization to the first occurrence of disease progression during first-line therapy, as assessed by the Investigator using RECIST v1.1, or death from any cause, whichever occurs first. Disease progression was defined as sum of longest diameters increased by at least 20% from the smallest value on study. The sum of longest diameters must also demonstrate an absolute increase of at least 5 mm. (NCT01765582)
Timeframe: Randomization up to disease progression during first-line therapy or death, whichever occurs first (up to approximately 3 years)

Interventionmonths (Median)
Arm A: Concurrent FOLFOXIRI + Bevacizumab11.86
Arm B: Sequential FOLFOXIRI + Bevacizumab11.37
Arm C: FOLFOX + Bevacizumab9.46
Arms A + B: Pooled FOLFOXIRI + Bevacizumab11.70

[back to top]

Proportion of Participants Considered by the Investigator to be Unresectable on Study Enrollment Who Subsequently Underwent Attempted Curative Resections of Metastases

The proportion of participants considered by the investigator to be unresectable at study enrollment who subsequently underwent attempted curative resections of metastases was calculated as follows: number of participants considered by the investigator to be unresectable at study enrollment who subsequently underwent attempted curative resections of metastases divided by total number of participants in each arm. This outcome represents a measure of the rate of conversion from unresectable to resectable disease. (NCT01765582)
Timeframe: Randomization up to approximately 3 years

InterventionProportion of participants (Number)
Arm A: Concurrent FOLFOXIRI + Bevacizumab0.24
Arm B: Sequential FOLFOXIRI + Bevacizumab0.17
Arm C: FOLFOX + Bevacizumab0.14
Arms A + B: Pooled FOLFOXIRI + Bevacizumab0.21

[back to top]

Time to Progression

"The median amount of time from the time of registration until disease progression. Disease progression was assessed using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.~Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression)." (NCT01775501)
Timeframe: The amount of time from registration until disease progression or death, median duration 7.7 months

InterventionMonths (Median)
FOLFOX + Sorafenib7.7

[back to top]

Overall Response Rate

"Overall response rate is the number of participants that achieved either a complete or partial response according to RECIST 1.1 criteria.~Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm.~Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters." (NCT01775501)
Timeframe: 2 years

InterventionParticipants (Count of Participants)
FOLFOX + Sorafenib7

[back to top]

Duration of Response

The median amount of time from achieving a response (partial or complete) until disease progression, death, or loss to follow-up. (NCT01775501)
Timeframe: From the time of treatment response until death or disease progression (median duration 172 days)

InterventionDays (Median)
FOLFOX + Sorafenib172

[back to top]

Median Overall Survival

The duration of time from study registration until death. (NCT01775501)
Timeframe: From registration until death, median duration of 15.1 months

InterventionMonths (Median)
FOLFOX + Sorafenib15.1

[back to top]

Median Progression Free Survival

The median duration of time from the start of treatment until disease progression or death (NCT01775501)
Timeframe: From the start of treatment until disease progression or death, median duration of 232 days

InterventionDays (Median)
FOLFOX + Sorafenib232

[back to top]

Number of Patients Experiencing Adverse Events

To evaluate the tolerability and toxicities of FOLFOX-S regimen in this population of patients. (NCT01775501)
Timeframe: From the start of treatment until 30 days after the end of treatment, median duration of 10.7 months

InterventionParticipants (Count of Participants)
FOLFOX + Sorafenib40

[back to top]

Percentage of Participants Experiencing Laboratory Abnormalities

Treatment-emergent laboratory abnormalities were defined as values that increase at least one toxicity grade from baseline. Participants with any laboratory abnormality were reported. (NCT01803282)
Timeframe: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days

,,,,,,,,,,,
Interventionpercentage of participants (Number)
Any Laboratory abnormalities: HematologyAny Laboratory abnormalities: Serum ChemistryAny Laboratory abnormalities: Coagulation
Part A: ADX 1800 mg33.383.333.3
Part A: ADX 200 mg0.0100.025.0
Part A: ADX 600 mg33.366.70.0
Part B: BRCA, ADX 800 mg86.766.740.0
Part B: EGC, ADX 800 mg87.587.535.0
Part B: FL CRC, ADX 800 mg+BEV 10 mg/kg90.981.836.4
Part B: FL CRC, ADX 800 mg+BEV 5 mg/kg84.495.637.8
Part B: LAC, ADX 1200 mg90.060.010.0
Part B: LSC, ADX 1200 mg80.070.010.0
Part B: PAC, ADX 800 mg97.288.938.9
Part B: SL CRC, ADX 800 mg+BEV 10 mg/kg100.087.537.5
Part B: SL CRC, ADX 800 mg+BEV 5 mg/kg95.586.445.5

[back to top]

Percentage of Participants Experiencing Treatment-Emergent Adverse Events

(NCT01803282)
Timeframe: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days

Interventionpercentage of participants (Number)
Part A: ADX 200 mg100.0
Part A: ADX 600 mg100.0
Part A: ADX 1800 mg83.3
Part B: PAC, ADX 800 mg100.0
Part B: LAC, ADX 1200 mg100.0
Part B: LSC, ADX 1200 mg100.0
Part B: EGC, ADX 800 mg100.0
Part B: FL CRC, ADX 800 mg+BEV 5 mg/kg100.0
Part B: FL CRC, ADX 800 mg+BEV 10 mg/kg100.0
Part B: SL CRC, ADX 800 mg+BEV 5 mg/kg100.0
Part B: SL CRC, ADX 800 mg+BEV 10 mg/kg100.0
Part B: BRCA, ADX 800 mg100.0

[back to top]

Number of Participants With R0 Resection

The number of participants that received treatment with proton radiation along with FOLFIRINOX-Losartan and then subsequently underwent attempted surgery and achieved R0 resection. R0 resection means that no cancer cells were seen microscopically at the resection margin. (NCT01821729)
Timeframe: At the time of surgery (approximately 4 months after the start of treatment)

InterventionParticipants (Count of Participants)
Experimental Arm34

[back to top]

Progression-Free Survival

"To determine the progression free survival of patients with locally advanced disease who receive FOLFIRINOX-Losartan and proton beam radiation therapy. Disease progression was assessed using Response Evaluation Criteria in Solid Tumors (RECIST 1.1).~Progressive disease (PD): At least a 20% increase in the sum of the longest diameter (LD) of target lesion, taking as reference the smal lest sum LD recorded since the treatment started or the appearance of one or more new lesions (new lesions must be > slice thickness)." (NCT01821729)
Timeframe: From the start of treatment until death or progression, median duration of 17.5 months

InterventionMonths (Median)
Experimental Arm17.5

[back to top]

Maximum Observed Plasma Concentration (Cmax) for Free and Vascular Endothelial Growth Factor (VEGF)-Bound Aflibercept: Participants With Additional Blood Sampling for Detailed PK Analysis

In 10 participants of ITT population, additional blood samples were obtained for detailed non-compartmental PK analysis of free and VEGF-bound aflibercept in combination with irinotecan and 5-FU in Cycle 1. (NCT01882868)
Timeframe: Predose (prior to aflibercept infusion), 1, 2, 4, 8, 24, 48, 168 and 336 hours post aflibercept infusion on Day 1 of Cycle 1

Interventionmcg/mL (Mean)
Plasma Free-Aflibercept (n=10)Plasma VEGF-Bound Aflibercept (n=8)
Aflibercept + FOLFIRI90.82.83

[back to top]

Area Under the Concentration Time Curve From Time 0 to the Time of Last Quantifiable Concentration (AUClast) for Irinotecan and Its Active Metabolite SN-38: Participants With Additional Blood Sampling for Detailed PK Analysis

In 10 participants of ITT population, additional blood samples were obtained for detailed non-compartmental PK analysis of irinotecan and SN-38 in combination with aflibercept and 5-FU in Cycle 1. (NCT01882868)
Timeframe: Pre-dose (prior to aflibercept infusion), 1.5, 2, 4.5 and 23 hours post irinotecan infusion on Day 1 of Cycle 1

Interventionng*h/mL (Mean)
Plasma IrinotecanPlasma SN-38
Aflibercept + FOLFIRI16900344

[back to top]

Area Under the Concentration Time Curve From Time 0 to the Time of Last Quantifiable Concentration (AUClast) for Free and VEGF-Bound Aflibercept: Participants With Additional Blood Sampling for Detailed PK Analysis

In 10 participants of ITT population, additional blood samples were obtained for detailed non-compartmental PK analysis of free and VEGF-bound aflibercept in combination with irinotecan and 5-FU in Cycle 1. (NCT01882868)
Timeframe: Predose (prior to aflibercept infusion), 1, 2, 4, 8, 24, 48, 168 and 336 hours post aflibercept infusion on Day 1 of Cycle 1

Interventionmcg*day/mL (Mean)
Plasma Free-Aflibercept (n=10)Plasma VEGF-Bound Aflibercept (n=8)
Aflibercept + FOLFIRI32124.4

[back to top]

Area Under the Concentration Time Curve From Time 0 to 14 Days Post Start of Infusion (AUC0-14 Day) for Free and VEGF-Bound Aflibercept: Participants With Additional Blood Sampling for Detailed PK Analysis

In 10 participants of ITT population, additional blood samples were obtained for detailed non-compartmental PK analysis of free and VEGF-bound aflibercept in combination with irinotecan and 5-FU in Cycle 1. (NCT01882868)
Timeframe: Predose (prior to aflibercept infusion), 1, 2, 4, 8, 24, 48, 168 and 336 hours post aflibercept infusion on Day 1 of Cycle 1

Interventionmcg*day/mL (Mean)
Plasma Free-Aflibercept (n=10)Plasma VEGF-Bound Aflibercept (n=5)
Aflibercept + FOLFIRI31223.3

[back to top]

Area Under the Concentration Time Curve (AUC) for Irinotecan and Its Active Metabolite SN-38: Participants With Additional Blood Sampling for Detailed PK Analysis

In 10 participants of ITT population, additional blood samples were obtained for detailed non-compartmental PK analysis of irinotecan and SN-38 in combination with aflibercept and 5-FU in Cycle 1. (NCT01882868)
Timeframe: Pre-dose (prior to aflibercept infusion), 1.5, 2, 4.5 and 23 hours post irinotecan infusion on Day 1 of Cycle 1

Interventionng*h/mL (Mean)
Plasma Irinotecan (n=10)Plasma SN-38 (n=4)
Aflibercept + FOLFIRI17700341

[back to top]

Aflibercept Immunogenicity Assessment: Number of Participants With Positive Sample(s) in the Anti-drug Antibodies (ADA) Assay and in the Neutralizing Anti-drug Antibodies (NAb) Assay

Blood samples of participants were analyzed by using a titer-based, bridging immunoassay developed and validated to detect aflibercept ADA in human serum. Samples with positive antibody levels were further analyzed using a validated, non-quantitative, competitive ligand binding assay to detect NAb. (NCT01882868)
Timeframe: Baseline, at any time post baseline and 90 days after the last dose of aflibercept

Interventionparticipants (Number)
At baseline in the ADA assay (n=62)At any time post-baseline in the ADA assay (n=62)At any time post-baseline in the NAb assay (n=62)At 90 days after last dose in the ADA assay (n=50)At 90 days after last dose in NAb assay (n=50)
Aflibercept + FOLFIRI10000

[back to top]

Volume of Distribution at the Steady State (Vss) for Irinotecan: Participants With Additional Blood Sampling for Detailed PK Analysis

In 10 participants of ITT population, additional blood samples were obtained for detailed non-compartmental PK analysis of irinotecan in combination with aflibercept and 5-FU in Cycle 1. (NCT01882868)
Timeframe: Predose (prior to aflibercept infusion), 1.5, 2, 4.5 and 23 hours post irinotecan infusion on Day 1 of Cycle 1

Interventionliter (Mean)
Aflibercept + FOLFIRI92.5

[back to top]

Volume of Distribution at the Steady State (Vss) for Free Aflibercept: Participants With Additional Blood Sampling for Detailed PK Analysis

In 10 participants of ITT population, additional blood samples were obtained for detailed non-compartmental PK analysis of free aflibercept in combination with irinotecan and 5-FU in Cycle 1. (NCT01882868)
Timeframe: Pre-dose (prior to aflibercept infusion), 1, 2, 4, 8, 24, 48, 168 and 336 hours post aflibercept infusion on Day 1 of Cycle 1

Interventionliters (Mean)
Aflibercept + FOLFIRI3.53

[back to top]

Volume of Distribution at the Steady State (Vss) for Free Aflibercept: ITT Population

Sparse blood sampling was performed on 52 participants and additional blood sampling for detailed PK analysis was performed on 10 participants as per protocol. A population PK analysis was performed and an overall data is reported for all the participants. (NCT01882868)
Timeframe: Pre-dose, 1, 4, 24, 336 hours post aflibercept infusion on Day 1 of Cycle 1 for participants with sparse sampling & pre-dose, 1, 2, 4, 8, 24, 48, 168, 336 hours post aflibercept infusion on Day 1 of Cycle 1 for participants with additional sampling

Interventionliters (Mean)
Aflibercept + FOLFIRI6.197

[back to top]

Total Body Clearance (CL) for Irinotecan: Participants With Additional Blood Sampling for Detailed PK Analysis

In 10 participants of ITT population, additional blood samples were obtained for detailed non-compartmental PK analysis of irinotecan in combination with aflibercept and 5-FU in Cycle 1. (NCT01882868)
Timeframe: Pre-dose (prior to aflibercept infusion), 1.5, 2, 4.5 and 23 hours post irinotecan infusion on Day 1 of Cycle 1

Interventionliter/hour (Mean)
Aflibercept + FOLFIRI18.3

[back to top]

Total Body Clearance (CL) for Free Aflibercept: ITT Population

Sparse blood sampling was performed on 52 participants and additional blood sampling for detailed PK analysis was performed on 10 participants as per protocol. A population PK analysis was performed and an overall data is reported for all the participants. (NCT01882868)
Timeframe: Pre-dose, 1, 4, 24, 336 hours post aflibercept infusion on Day 1 of Cycle 1 for participants with sparse sampling & pre-dose, 1, 2, 4, 8, 24, 48, 168, 336 hours post aflibercept infusion on Day 1 of Cycle 1 for participants with additional sampling

Interventionliter/day (Mean)
Aflibercept + FOLFIRI0.8053

[back to top]

Terminal Elimination Half-life (t1/2z) for Free Aflibercept: Participants With Additional Blood Sampling for Detailed PK Analysis

In 10 participants of ITT population, additional blood samples were obtained for detailed non-compartmental PK analysis of free aflibercept in combination with irinotecan and 5-FU in Cycle 1. (NCT01882868)
Timeframe: Pre-dose (prior to aflibercept infusion), 1, 2, 4, 8, 24, 48, 168 and 336 hours post aflibercept infusion on Day 1 of Cycle 1

Interventiondays (Mean)
Aflibercept + FOLFIRI4.47

[back to top]

Steady State Drug Concentration (Css) for 5-FU: Participants With Additional Blood Sampling for Detailed PK Analysis

In 10 participants of ITT population, additional blood samples were obtained for detailed non-compartmental PK analysis of 5-FU in combination with aflibercept and irinotecan in Cycle 1. (NCT01882868)
Timeframe: Pre-dose (prior to aflibercept infusion), 2.5, 21 and 45 hours post 5-FU infusion on Day 1 of Cycle 1

Interventionng/mL (Mean)
Aflibercept + FOLFIRI930

[back to top]

Percentage of Participants With Overall Response

Overall response in participants was defined as the percentage of participants with confirmed complete response (CR) or partial response (PR) assessed by an independent radiological review committee (IRRC) according to response evaluation criteria in solid tumors (RECIST) version 1.1. CR was defined as disappearance of all target lesions; any lymph node (target or non-target) must have reduction in the short axis to <10 mm; PR was defined as at least 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters. Percentage of participants with overall response and the 95% confidence interval (CI) were provided. The 95% CI was calculated using normal approximation. (NCT01882868)
Timeframe: Baseline and every 6 weeks until DP (maximum duration: 16.4 months)

Interventionpercentage of participants (Number)
Aflibercept + FOLFIRI8.3

[back to top]

Area Under the Concentration Time Curve (AUC) for Free Aflibercept: ITT Population

Sparse blood sampling was performed on 52 participants and additional blood sampling for detailed PK analysis was performed on 10 participants as per protocol. A population PK analysis was performed and an overall data is reported for all the participants. (NCT01882868)
Timeframe: Pre-dose, 1, 4, 24, 336 hours post aflibercept infusion on Day 1 of Cycle 1 for participants with sparse sampling & pre-dose, 1, 2, 4, 8, 24, 48, 168, 336 hours post aflibercept infusion on Day 1 of Cycle 1 for participants with additional sampling

Interventionmcg*day/mL (Mean)
Aflibercept + FOLFIRI304.6

[back to top]

Progression Free Survival (PFS)

PFS was defined as the time interval from the date of first study drug administration to the date of first observation of DP or death due to any cause, whichever came first. If death or progression was not observed, the participant was censored at the date of participant's last valid progression-free tumor assessment prior to the study cut-off date. DP for PFS was assessed by the IRRC based on tumor imaging according to RECIST 1.1. Progression in disease was defined as at least 20% increase in the sum of diameters of target lesions compared to smallest sum of diameters on-study with absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions. PFS was estimated by Kaplan-Meier estimates. (NCT01882868)
Timeframe: Baseline and every 6 weeks until DP or death, due to any cause (maximum duration: 16.4 months)

Interventionmonths (Median)
Aflibercept + FOLFIRI5.42

[back to top]

Number of Participants With Treatment Emergent Adverse Events (TEAEs)

Adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily have to have a causal relationship with the treatment. TEAEs were defined as AEs that developed or worsened during the on--treatment period which was defined as the period from the time of first dose of study treatment until 30 days after the last dose of study treatment. (NCT01882868)
Timeframe: First dose (Day 1 of Cycle 1) of study treatment up to end of treatment visit (30 days after last dose of study treatment) (maximum duration: 77 weeks)

Interventionparticipants (Number)
Aflibercept + FOLFIRI62

[back to top]

Total Body Clearance (CL) for Free Aflibercept: Participants With Additional Blood Sampling for Detailed PK Analysis

In 10 participants of ITT population, additional blood samples were obtained for detailed non-compartmental PK analysis of free aflibercept in combination with irinotecan and 5-FU in Cycle 1. (NCT01882868)
Timeframe: Pre-dose (prior to aflibercept infusion), 1, 2, 4, 8, 24, 48, 168 and 336 hours post aflibercept infusion on Day 1 of Cycle 1

Interventionliter/day (Mean)
Aflibercept + FOLFIRI0.716

[back to top]

Time to Reach Maximum Plasma Concentration Observed (Tmax) for Free and VEGF-Bound Aflibercept in Cycle 1: Participants With Additional Blood Sampling for Detailed PK Analysis

In 10 participants of ITT population, additional blood samples were obtained for detailed non-compartmental PK analysis of free and VEGF-bound aflibercept in combination with irinotecan and 5-FU in Cycle 1. (NCT01882868)
Timeframe: Predose (prior to aflibercept infusion), 1, 2, 4, 8, 24, 48, 168 and 336 hours post aflibercept infusion on Day 1 of Cycle 1

Interventiondays (Median)
Plasma Free-Aflibercept (n=10)Plasma VEGF-Bound Aflibercept (n=8)
Aflibercept + FOLFIRI0.0713.97

[back to top]

Terminal Elimination Half-life (t1/2z) for Irinotecan and Its Active Metabolite SN-38: Participants With Additional Blood Sampling for Detailed PK Analysis

In 10 participants of ITT population, additional blood samples were obtained for detailed non-compartmental PK analysis of irinotecan and SN-38 in combination with aflibercept and 5-FU in Cycle 1. (NCT01882868)
Timeframe: Pre-dose (prior to aflibercept infusion), 1.5, 2, 4.5 and 23 hours post irinotecan infusion on Day 1 of Cycle 1

Interventionhours (Mean)
Plasma Irinotecan (n=10)Plasma SN-38 (n=5)
Aflibercept + FOLFIRI5.1910.3

[back to top]

Overall Survival (OS)

OS was defined as the time interval from the date of first study drug administration to the date of death due to any cause. If death was not observed, the participant was censored at the last date the participant was known to be alive or the study cut-off date, whichever was first. OS was estimated by Kaplan-Meier estimates. (NCT01882868)
Timeframe: Baseline up to death or study cut--off (maximum duration: 24.7 months)

Interventionmonths (Median)
Aflibercept + FOLFIRI15.59

[back to top]

Maximum Observed Plasma Concentration (Cmax) for Free Aflibercept: ITT Population

Sparse blood sampling was performed on 52 participants and additional blood sampling for detailed pharmacokinetic (PK) analysis was performed on 10 participants as per protocol. A population PK analysis was performed and an overall data is reported for all the participants. (NCT01882868)
Timeframe: Pre-dose, 1, 4, 24, 336 hours post aflibercept infusion on Day 1 of Cycle 1 for participants with sparse sampling & pre-dose, 1, 2, 4, 8, 24, 48, 168, 336 hours post aflibercept infusion on Day 1 of Cycle 1 for participants with additional sampling

Interventionmcg/mL (Mean)
Aflibercept + FOLFIRI73.19

[back to top]

Clearance at Steady State (CLss) for 5-FU: Participants With Additional Blood Sampling for Detailed PK Analysis

In 10 participants of ITT population, additional blood samples were obtained for detailed non-compartmental PK analysis of 5-FU in combination with aflibercept and irinotecan in Cycle 1. (NCT01882868)
Timeframe: Pre-dose (prior to aflibercept infusion), 2.5, 21 and 45 hours post 5-FU infusion on Day 1 of Cycle 1

Interventionliter/hour (Mean)
Aflibercept + FOLFIRI122

[back to top]

Area Under the Concentration Time Curve From Time 0 to 14 Days Post Start of Infusion (AUC0-14 Day) for Free Aflibercept: ITT Population

Sparse blood sampling was performed on 52 participants and additional blood sampling for detailed PK analysis was performed on 10 participants as per protocol. A population PK analysis was performed and an overall data is reported for all the participants. (NCT01882868)
Timeframe: Pre-dose, 1, 4, 24, 336 hours post aflibercept infusion on Day 1 of Cycle 1 for participants with sparse sampling & pre-dose, 1, 2, 4, 8, 24, 48, 168, 336 hours post aflibercept infusion on Day 1 of Cycle 1 for participants with additional sampling

Interventionmcg*day/mL (Mean)
Aflibercept + FOLFIRI246.9

[back to top]

Area Under the Concentration Time Curve (AUC) for Free Aflibercept: Participants With Additional Blood Sampling for Detailed PK Analysis

In 10 participants of ITT population, additional blood samples were obtained for detailed non-compartmental PK analysis of free aflibercept in combination with irinotecan and 5-FU in Cycle 1. (NCT01882868)
Timeframe: Pre-dose (prior to aflibercept infusion), 1, 2, 4, 8, 24, 48, 168 and 336 hours post aflibercept infusion on Day 1 of Cycle 1

Interventionmcg*day/mL (Mean)
Aflibercept + FOLFIRI355

[back to top]

Maximum Observed Plasma Concentration (Cmax) for Irinotecan and Its Active Metabolite SN-38: Participants With Additional Blood Sampling for Detailed PK Analysis

In 10 participants of ITT population, additional blood samples were obtained for detailed non-compartmental PK analysis of irinotecan and SN-38 in combination with aflibercept and 5-FU in Cycle 1. (NCT01882868)
Timeframe: Predose (prior to aflibercept infusion), 1.5, 2, 4.5 and 23 hours post irinotecan infusion on Day 1 of Cycle 1

Interventionng/mL (Mean)
Plasma IrinotecanPlasma SN-38
Aflibercept + FOLFIRI222032.2

[back to top]

Active Metabolite SN-38 / Irinotecan Ratio on Area Under the Concentration Time Curve (Rmet): Participants With Additional Blood Sampling for Detailed PK Analysis

In 10 participants of ITT population, additional blood samples were obtained for detailed non - compartmental PK analysis of irinotecan and SN-38 in combination with aflibercept and 5-FU in Cycle 1. (NCT01882868)
Timeframe: Pre-dose (prior to aflibercept infusion), 1.5, 2, 4.5 and 23 hours post irinotecan infusion on Day 1 of Cycle 1

Interventionratio (Mean)
Aflibercept + FOLFIRI0.0313

[back to top]

Serum Concentration of Ipatasertib

(NCT01896531)
Timeframe: Day 1 at 1 hour and 4 hours post-dose; Day 5, pre-dose and 2 hours post-dose

Interventionng/mL (Mean)
Day 1: 1 hour post-doseDay 1: 4 hours post-doseDay 5: pre-doseDay 5: 2 hours post-dose
Ipatasertib + mFOLFOX650638990.7557

[back to top]

Progression-Free Survival (PFS) in All Randomized Participants and Participants With PTEN Loss Tumors at Primary Analysis

PFS was defined as the time from randomization to the first occurrence of disease progression (as determined using RECIST Version 1.1 and assessed by the investigator), or death from any cause on study. Progressive disease (PD): At least a 20% increase in the sum of diameters of target lesions, and the sum must also demonstrate an absolute increase of at least 5 mm or progression of non-target lesions. Death on study was defined as death from any cause within 30 days of the last dose of study treatment regimen. Kaplan-Meier estimates were used for evaluation. (NCT01896531)
Timeframe: Screening, at the end of Cycle 4 (cycle = 14 days) and every fourth cycle thereafter until disease progression or death, whichever occurred first, assessed up to approximately 1.75 years

,
Interventionmonths (Median)
All Randomized ParticipantsParticipants With PTEN Loss Tumors
Ipatasertib + mFOLFOX66.577.10
Placebo + mFOLFOX67.527.39

[back to top]

Overall Survival (OS)

OS was defined as the time from the date of randomization to the date of death from any cause. Kaplan-Meier estimates were used for evaluation. (NCT01896531)
Timeframe: Baseline up to end of study (up to approximately 7.5 years)

,
Interventionmonths (Median)
RandomizedPTEN Loss TumorsAkt Dx+
Ipatasertib + mFOLFOX611.9614.8211.66
Placebo + mFOLFOX615.3121.7817.22

[back to top]

Objective Response Rate (ORR)

Objective Response Rate was defined as the percentage of participants achieving either a complete response (CR) or a partial response (PR) based on the investigator assessment using RECIST v 1.1. CR: disappearance of all target lesions and all pathological lymph nodes below 10 mm. Partial response (PR): At least a 30% decrease in the sum of diameters of target lesions. (NCT01896531)
Timeframe: Screening, at the end of Cycle 4 (cycle = 14 days) and every fourth cycle thereafter until disease progression or death, whichever occurred first, up to end of study (up to approximately 7.5 years)

,
Interventionpercentage of participants (Number)
RandomizedPTEN Loss TumorsAkt Dx+
Ipatasertib + mFOLFOX652.150.052.2
Placebo + mFOLFOX657.373.356.5

[back to top]

Duration of Objective Tumor Response

Duration of objective tumor response in participants with measurable soft tissue disease at baseline was defined as the time from first observation of an objective tumor response until first observation of disease progression, as assessed by the investigator per modified RECIST Version 1.1. PD: At least a 20% increase in the sum of diameters of target lesions, and the sum must also demonstrate an absolute increase of at least 5 mm or progression of non-target lesions. (NCT01896531)
Timeframe: Screening, at the end of Cycle 4 (cycle = 14 days) and every fourth cycle thereafter until disease progression or death, whichever occurred first, up to end of study (up to approximately 7.5 years)

,
Interventionmonths (Median)
RandomizedPTEN Loss TumorAkt Dx+
Ipatasertib + mFOLFOX64.634.704.70
Placebo + mFOLFOX65.855.986.80

[back to top]

Number of Participants With Adverse Events (AEs)

An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. Death on study was defined as death from any cause within 30 days of the last dose of study treatment regimen. (NCT01896531)
Timeframe: Baseline until end of study (up to approximately 7.5 years)

InterventionParticipants (Count of Participants)
Ipatasertib + mFOLFOX670
Placebo + mFOLFOX680

[back to top]

Percentage of Participants Achieving R0 Resection (R0 Resection Rate)

The percentage of participants achieving R0 resection, defined as the absence of gross and microscopic tumor involvement in the resection margins, will be determined for those participants who receive at least one cycle of FOLFIRINOX chemotherapy. A 90% confidence interval will be determined. (NCT01897454)
Timeframe: Up to 30 months

InterventionPercentage of Participants (Number)
Treatment (FOLFIRINOX, IMRT, and Gemcitabine Hydrochloride)55.6

[back to top]

Progression Free Survival (PFS)

Progression-free Survival defined as the duration of time from start of treatment to time of disease progression will be analyzed. Median progression free survival will be presented. (NCT01897454)
Timeframe: From start of treatment to time of progression, assessed up to 60 months

InterventionMonths (Median)
Treatment (FOLFIRINOX, IMRT, and Gemcitabine Hydrochloride)34

[back to top]

Percentage of Patients Able to Undergo Resection

The percentage of participants with resectable or borderline resectable disease to undergo resection will be determined. The ability for patients to complete preoperative therapy and undergo resection is correlated with more favorable overall survival outcomes. (NCT01897454)
Timeframe: Up to 30 months

InterventionParticipants (Count of Participants)
Treatment (FOLFIRINOX, IMRT, and Gemcitabine Hydrochloride)15

[back to top]

Overall Response Rate

Overall Response Rate, defined as the percentage of patients that achieved Partial Response (PR) or Complete Response (CR) as per the Response evaluation in solid tumors criteria, was assessed using RECIST Version 1.1 criteria. Complete Response (CR) is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. Partial Response (PR) is defined as having at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Higher percentages of PR and CR are associated with more favorable outcomes (NCT01897454)
Timeframe: Up to 30 months

InterventionParticipants (Count of Participants)
Treatment (FOLFIRINOX, IMRT, and Gemcitabine Hydrochloride)4

[back to top]

Overall Survival (OS)

Median Overall Survival defined as the the duration of time from diagnosis to the time of death from any cause will be determined. (NCT01897454)
Timeframe: Up to 60 months

InterventionMonths (Median)
Treatment (FOLFIRINOX, IMRT, and Gemcitabine Hydrochloride)35.1

[back to top]

Toxicities Associated With Chemotherapy and Radiotherapy

The number of patients who experienced treatment related adverse events will be determined for all patients who received at least one cycle of FOLFIRINOX chemotherapy. These events will be graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. (NCT01897454)
Timeframe: Up to 30 months

InterventionParticipants (Count of Participants)
Treatment (FOLFIRINOX, IMRT, and Gemcitabine Hydrochloride)22

[back to top]

Vascular Reconstruction

The percentage of patients who underwent pancreaticoduodenectomy requiring vascular reconstruction will be evaluated. (NCT01897454)
Timeframe: Up to 30 months

InterventionParticipants (Count of Participants)
Treatment (FOLFIRINOX, IMRT, and Gemcitabine Hydrochloride)5

[back to top]

Change From Baseline in Central Retinal Thickness (CRT) At Week 16

CRT was measured by spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. All images were transmitted to the central reading center. SD-OCT was performed in the study eye after pupil dilation. LS mean was calculated using MMRM model with treatment groups, randomization strata of VH level (<4, >=4), visits and visit-by-treatment groups interaction as fixed categorical effects, as well as, fixed continuous covariate of baseline CRT. (NCT01900431)
Timeframe: Baseline to Week 16

Interventionµm (microns) (Least Squares Mean)
Placebo (Part A)-8.9
Sarilumab 200 mg q2w (Part A)-35.4

[back to top]

Percentage of Participants With Anterior Chamber (AC) Cell Score = 0 or At Least 2-step Reduction in Score at Week 16

Participants with AC cell score = 0 or with ≥2 step reduction from baseline at Week 16 were evaluated. Slit lamp examinations were conducted at each visit to assess AC cell count. The number of AC cells observed within a 1 mm × 1 mm slit beam was used to determine the grade according to the Standardization of Uveitis Nomenclature (SUN) criteria: grade 0 = no cells; grade +0.5 = 1 - 5 cells; grade +1 = 6 - 25 cells; grade +2= 26 - 50 cells; grade +3 = too many to count. (NCT01900431)
Timeframe: Week 16

InterventionPercentage of participants (Number)
Placebo (Part A)86.7
Sarilumab 200 mg q2w (Part A)86.2

[back to top]

Pharmacokinetics (PK) Assessment: Serum Functional Sarilumab Concentration

Serum functional (unbound) sarilumab concentrations were determined using an enzyme-linked immunosorbent assay (ELISA) method with a lower limit of quantification (LLOQ) of 294 ng/mL. Concentrations below LLOQ were set to zero for samples at predose. Post-treatment concentrations below LLOQ were replaced by LLOQ/2. The samples were considered non-eligible for the analysis if the previous dosing time was <11 days or >17 days before the sampling time for every other week regimens. (NCT01900431)
Timeframe: Predose on Day 1 (Baseline), Week 2, 4, 8, 12, 16, 24, 36, 52, and end of study (EOS) (Week 56)

Interventionng/mL (Mean)
At BaselineAt Week 2At Week 4At Week 8At Week 12At Week 16At Week 24At Week 36At Week 52EOS (Week 56)
Sarilumab 200 mg q2w (Part A + Part B)0.07383.39876.615958.919705.219598.422406.824375.425046.01730.0

[back to top]

Percentage of Participants With Prednisone Dose of ≤5 mg/Day (or Equivalent Oral Corticosteroid) at Week 16

Participants with prednisone dose ≤5 mg/day (or equivalent oral corticosteroid) at Week 16 were evaluated. (NCT01900431)
Timeframe: Week 16

InterventionPercentage of participants (Number)
Placebo (Part A)40.0
Sarilumab 200 mg q2w (Part A)41.4

[back to top]

Percentage of Participants With at Least 2-step Reduction in Vitreous Haze (VH) or Prednisone Dose <10 mg/Day at Week 16

At least 2-step reduction in VH per central review from baseline was evaluated on Miami 9-step scale. VH is the obscuration of fundus by vitreous cells and protein exudation. Each of the 9-step scale (from grade 0 [low opacity] to 8 [more opacity]) images (in increasing order of opacity) are equivalent to approximately 0.3 log units of degradation in visual acuity based on the Bangerter calibration. Participants with prednisone dose <10 mg/day (or equivalent oral corticosteroid) were also evaluated. (NCT01900431)
Timeframe: Week 16

InterventionPercentage of participants (Number)
Placebo (Part A)30.0
Sarilumab 200 mg q2w (Part A)46.1

[back to top]

Change From Baseline in Best Corrected Visual Acuity (BCVA) Score at Week 16

BCVA score is based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters, and then at 1 meter. The range of ETDRS is 0 to 100 letters. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. LS mean was calculated using MMRM model with treatment groups, randomization strata of VH level (<4, >=4), visits and visit-by-treatment groups interaction as fixed categorical effects, as well as, fixed continuous covariate of baseline BCVA. (NCT01900431)
Timeframe: Baseline to Week 16

Interventionunits on a scale (Least Squares Mean)
Placebo (Part A)3.5
Sarilumab 200 mg q2w (Part A)9.3

[back to top]

Change From Baseline in VH Scale at Week 16

Change from baseline in VH scale was evaluated on Miami 9-step scale. VH is the obscuration of fundus by vitreous cells and protein exudation. Each of the 9-step scale (from grade 0 [low opacity] to 8 [more opacity]) images (in increasing order of opacity) were equivalent to approximately 0.3 log units of degradation in visual acuity based on the Bangerter calibration. Least squares (LS) mean was calculated using mixed model for repeated measurements (MMRM) model with treatment groups, visits and visit-by-treatment groups interaction as fixed categorical effects as well as fixed continuous covariate of baseline adjudicated VH. (NCT01900431)
Timeframe: Baseline to Week 16

Interventionunits on a scale (Least Squares Mean)
Placebo (Part A)-0.1
Sarilumab 200 mg q2w (Part A)-0.9

[back to top]

Percent Change From Baseline in CRT at Week 16

CRT was measured by SD-OCT, a non-invasive diagnostic system providing high-resolution imaging sections of the retina. All images were transmitted to the central reading center. SD-OCT was performed in the study eye after pupil dilation. LS mean was calculated using MMRM model with treatment groups, randomization strata of VH level (<4, >=4), visits and visit-by-treatment groups interaction as fixed categorical effects, as well as, fixed continuous covariate of baseline CRT. (NCT01900431)
Timeframe: Baseline to Week 16

Interventionpercent change (Least Squares Mean)
Placebo (Part A)0.0
Sarilumab 200 mg q2w (Part A)-6.4

[back to top]

Progression Free Survival (PFS)

(NCT01913639)
Timeframe: 6 months

Interventionpercentage of participants (Number)
FOLFOX Plus Regorafenib53

[back to top]

Participants Evaluated for Toxicity

Adverse events will be determined as per the NCI Common Toxicity Criteria, version 4.0. Toxicity during cycle 1 and subsequent cycles will be reported. (NCT01913639)
Timeframe: 1 year

InterventionParticipants (Count of Participants)
FOLFOX Plus Regorafenib39

[back to top]

Overall Survival (OS)

Overall survival will be measured from the start of treatment to death or last follow-up and will be estimated using the Kaplan-Meier method (NCT01913639)
Timeframe: 2 years

Interventionmonths (Median)
FOLFOX Plus Regorafenib14.2

[back to top]

Overall Response Rate

This is defined as the percentage of patients who have achieved either an objective complete or partial target lesion response that is confirmed on the RECIST 1.1 criteria. Complete or partial responses will be confirmed with repeat CT evaluation after 4 weeks. (NCT01913639)
Timeframe: 4 weeks

Interventionpercentage of participants with CR or PR (Number)
FOLFOX Plus Regorafenib54

[back to top]

Progression-free Survival (PFS) at 1 Year

"Progression-free survival (PFS) means the period of time that a participant remains alive without tumor progression either locally or at a distant site in the body (metastasis). The effect of the study treatments was assessed as the number of participants in each treatment group that remained alive without tumor progression, at 1 year after treatment.~The outcome is reported as a number without dispersion." (NCT01926197)
Timeframe: 1 year

InterventionParticipants (Count of Participants)
Modified FOLFIRINOX5
Modified FOLFIRINOX Plus Stereotactic Body Radiotherapy2

[back to top]

Grade 2 or Greater Gastrointestinal (GI) Toxicity

"Toxicity means an adverse event related to the study treatment. Toxicity was assessed between treatment groups as the number of treatment-related , ≥ grade 2 events of gastritis, fistula, enteritis, or ulcer; plus any other Grade 3 to 5 gastrointestinal (GI) toxicity. The outcome is reported as the number of defined adverse events by preferred term for each treatment group, occurring within 3 months of the start of treatment. These adverse events by definition are all within the Common Terminology Criteria for Adverse Events (CTCAE) version 4.01 Gastrointestinal Body System. The outcome is reported as numbers without dispersion.~All-cause Mortality mFFX 7 SBRT 8" (NCT01926197)
Timeframe: 3 months

,
InterventionRelated adverse events (Number)
Blood in stool (melena)ColitisColonic obstructionDiarrheaDuodenal perforationFistula, analFluid in abdomen (ascites)Gastrointestinal bleed (hemorrhage)Gastrointestinal bleed (hemorrhage), upperGastrointestinal inflammation (enterocolitis)NauseaPain, abdominalPain, intractable (due to disease progression)Stool discolored, clay colorVomited blood (hematemesis)
Modified FOLFIRINOX111300010133010
Modified FOLFIRINOX Plus Stereotactic Body Radiotherapy000013213014104

[back to top]

Local Progression-free Survival (Local PFS)

Local progression-free survival (PFS) means the period of time that a participant remains alive without recurrence or advancement of the disease at the baseline sites of the tumor (local progression). The effect of the study treatments was assessed as the median local PFS of participants in the treatment groups. The outcome is reported as the median local PFS with standard deviation. (NCT01926197)
Timeframe: 38 months

Interventionmonths (Median)
Modified FOLFIRINOX6.5
Modified FOLFIRINOX Plus Stereotactic Body Radiotherapy8.4

[back to top]

Metastasis-free Survival (MFS)

Metastasis-free survival (MFS) means the period of time that a participant remains alive without the appearance of new tumor lesions a distant site in the body (metastasis). The effect of the study treatments was assessed as the median MFS of participants in the treatment groups. The outcome is reported as the median PFS with standard deviation. (NCT01926197)
Timeframe: 62 months

Interventionmonths (Median)
Modified FOLFIRINOX12.9
Modified FOLFIRINOX Plus Stereotactic Body Radiotherapy10.8

[back to top]

Overall Survival (OS)

The effect of the study treatments was assessed as the length of time participants in each treatment group that remained alive. The outcome is reported as the median OS with standard deviation. (NCT01926197)
Timeframe: 62 months

Interventionmonths (Median)
Modified FOLFIRINOX12.9
Modified FOLFIRINOX Plus Stereotactic Body Radiotherapy13.4

[back to top]

Progression-free Survival (PFS)

Progression-free survival (PFS) means the period of time that a participant remains alive without tumor progression either locally or at a distant site in the body (metastasis). The effect of the study treatments was assessed as the median PFS of participants in the treatment groups. The outcome is reported as the median PFS with standard deviation. (NCT01926197)
Timeframe: 38 months

Interventionmonths (Median)
Modified FOLFIRINOX6.5
Modified FOLFIRINOX Plus Stereotactic Body Radiotherapy8.4

[back to top]

Toxicity and Tolerability (Arm A and Arm B) as Measured by the Number of Participants With Grade 3 or Higher Adverse Events

(NCT01928290)
Timeframe: 30 days after completion of treatment (estimated to be 5 months)

,
Interventionparticipants (Number)
AnemiaFebrile neutropeniaAnal FistulaDiarrheaHematemesisNauseaPeripheral ischemiaVomitingFatigueLaparoscopy surgeryPainSepsisLung infectionPneumoniaHypernatremiaNeutrophil count decreasedPlatelet count decreasedAnorexiaDehydrationHypokalemiaBack painPeripheral sensory neuropathySyncopeDyspneaPleural embolismSkin infectionThromboembolic eventAbdominal painEnterocolitisHemorrhoidsG-tube infectionNeutropenic entercolitisAlkaline phosphatase increased
Arm A: FOLFIRINOX (HER2-negative)1214121341111111933411211114000000
Arm B: FOLFIRINOX & Trastuzumab (HER2-positive)000502010000000800020010000111111

[back to top]

Progression Free Survival

Duration of time from start of treatment to time of progression or death, whichever occurs first. (NCT01928290)
Timeframe: Through 1 year after completion of treatment (median follow-up 16.2 months - 95% CI 4.7-42.5 months)

Interventionmonths (Median)
Arm A: FOLFIRINOX (HER2-negative)8.4
Arm B: FOLFIRINOX & Trastuzumab (HER2-positive)13.8

[back to top]

Overall Survival (OS)

Overall survival is defined as the time interval from date of diagnosis to date of death from any cause. (NCT01928290)
Timeframe: Through 1 year after completion of treatment (median follow-up 16.2 months - 95% CI 4.7-42.5 months)

Interventionmonths (Median)
Arm A: FOLFIRINOX (HER2-negative)15.5
Arm B: FOLFIRINOX & Trastuzumab (HER2-positive)19.6

[back to top]

Number of Participants With an Objective Response

"Objective response (defined as complete response (CR) + partial response (PR) by RECIST 1.1 criteria)~CR: Disappearance of all target lesions, non-target lesions, and normalization of tumor marker level. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm.~PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters." (NCT01928290)
Timeframe: Through completion of treatment (estimated to be 4 months)

InterventionParticipants (Count of Participants)
Arm A: FOLFIRINOX (HER2-negative)25
Arm B: FOLFIRINOX & Trastuzumab (HER2-positive)22

[back to top]

Duration of Response

Time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (NCT01928290)
Timeframe: Through 1 year after completion of treatment (median follow-up 16.2 months - 95% CI 4.7-42.5 months)

Interventionmonths (Median)
Arm A: FOLFIRINOX (HER2-negative)5.8
Arm B: FOLFIRINOX & Trastuzumab (HER2-positive)10.5

[back to top]

Clinical Benefit Rate

"Clinical benefit rate is the percentage of combined patients who have achieved complete response (CR), partial response (PR), and stable disease (SD)~CR: Disappearance of all target lesions, non-target lesions, and normalization of tumor marker level. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm~PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters~SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study." (NCT01928290)
Timeframe: Through completion of treatment (estimated to be 4 months)

InterventionParticipants (Count of Participants)
Arm A: FOLFIRINOX (HER2-negative)33
Arm B: FOLFIRINOX & Trastuzumab (HER2-positive)22

[back to top]

Time to Progression (TTP)

Duration of time from start of treatment to time of progression. Progression is defined as At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (NCT01928290)
Timeframe: Through 1 year after completion of treatment (median follow-up 16.2 months - 95% CI 4.7-42.5 months)

Interventionmonths (Median)
Arm A: FOLFIRINOX (HER2-negative)8.0
Arm B: FOLFIRINOX & Trastuzumab (HER2-positive)13.9

[back to top]

Progression Free Survival (PFS) (Phase II)

Time from date of registration to date of first documentation of progression or symptomatic deterioration or death due to any cause. Participants last known to be alive without report of progression are censored at date of last contact. (NCT01959139)
Timeframe: From date of registration to date of death due to any cause, assessed up to 3 years

Interventionmonths (Median)
Phase II: mFOLFIRINOX6.2
Phase II: mFOLFIRINOX + PEGPH204.3

[back to top]

Phase II: Overall Survival

"Time from date of registration to date of death due to any cause. Participants last known to be alive are censored at date of last contact.~Assessed using the logrank test." (NCT01959139)
Timeframe: From date of registration to date of death due to any cause, assessed up to 3 years

Interventionmonths (Median)
Phase II: mFOLFIRINOX14.4
Phase II: mFOLFIRINOX + PEGPH207.7

[back to top] [back to top]

Objective Tumor Response Rate (Confirmed and Unconfirmed, Complete and Partial)

"Objective tumor response rate (complete response, unconfirmed complete response, partial response, unconfirmed partial response) in patients with measurable disease were assessed in each arm and compared between arms using Chi-squared test.~Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions" (NCT01959139)
Timeframe: Up to 3 years

Interventionpercent of participants (Number)
Phase II: mFOLFIRINOX45
Phase II: mFOLFIRINOX + PEGPH2033

[back to top]

Phase I: Maximum Tolerated Dose (MTD) of PEGPH20 in Combination With mFOLFIRINOX

"Assess safety of mFOLFIRINOX in combination with PEGPH20 and select the optimal dose of PEGPH20 for the Phase II portion.~MTD of PEGPH20 in combination with mFOLFORINOX was evaluated by testing decreasing doses of PEGPH20 from 3mcg/kg on Day 1 and Day 3/4, to 3mcg/kg on Day 1 only and to 1.6 mcg/kg on Day 1 only.~MTD reflects the highest dose that had a dose-limiting toxicity (DLT) rate of ≤ 17%. DLTs were defined as treatment regimen related: grade ≥ 3 non-hematologic toxicity; grade 4 absolute neutrophil count (ANC) anemia or thrombocytopenia; grade 4 ANC lasting > 7 days; grade ≥ 3 febrile neutropenia; grade ≥ 3 elevation of aspartate aminotransferase (AST)/alanine aminotransferase (ALT), total bilirubin, and creatinine; delay in starting the 2nd cycle of mFOLFIRINOX by > 2 weeks due to drug related toxicity.~DLT were graded using the NCI CTCAE version 4. Note: the third and lowest dose level was not reached." (NCT01959139)
Timeframe: 2 cycles of 14 days

Interventionug/kg (Number)
Phase I: mFOLFIRINOX + PEGPH20, 3 ug/kg on Day 1 and Day 3/40
Phase I: mFOLFIRINOX + PEGPH20, 3 ug/kg on Day 13
All Phase 1 Participants3

[back to top]

Distant Failure-free Survival

Analyzed using Kaplan-Meier plots, medians and ranges. (NCT01959672)
Timeframe: Date of administration study drug to the date of first appearance of tumor lesions by imaging, or death, assessed up to 5 years

Interventionmonths (Median)
Treatment (Chemotherapy, Oregovomab, SBRT, Surgery)11

[back to top]

Number of Participants With CA-125-Specific T-cell Signal.

The percentage of patients responding will be summarized using frequencies and percentages. (NCT01959672)
Timeframe: Baseline to up to week 12

InterventionParticipants (Count of Participants)
Treatment (Chemotherapy, Oregovomab, SBRT, Surgery)2

[back to top]

Number of Participants With Progressive Disease,

Rate of progressive disease defined as at least a 25% increase in the longest diameter of a lesion, taking as reference the longest diameter recorded since the treatment started. An exact one-sided 90% confidence interval will be constructed round the progressive disease rate. (NCT01959672)
Timeframe: Up to 4 months

InterventionParticipants (Count of Participants)
Treatment (Chemotherapy, Oregovomab, SBRT, Surgery)2

[back to top]

Overall Survival

Analyzed using Kaplan-Meier plots, medians and ranges. (NCT01959672)
Timeframe: Date of first of study drug to the date of death, assessed up to 5 years

Interventionmonths (Median)
Treatment (Chemotherapy, Oregovomab, SBRT, Surgery)14.4

[back to top]

Surgical Complete Resection (Negative Margin) Rate

The percentage of patients who will undergo R0 resection (NCT01959672)
Timeframe: Up to week 18

InterventionParticipants (Count of Participants)
Treatment (Chemotherapy, Oregovomab, SBRT, Surgery)4

[back to top] [back to top]

One-year Rate of Overall Survival

Rate of overall survival of study participants at one year since initiation of protocol therapy. Overall survival (OS) will be measured from the date of initiation of study treatment until date of death from any cause. In the absence of death, the follow-up will be censored at date of last contact (censored observation). Kaplan-Meier estimate of overall survival at one-year. (NCT01964755)
Timeframe: 12 months

Interventionpercentage of participants (Number)
Chemotherapy + Antiviral-Based Therapy83.3

[back to top]

T-Cell Subset Levels in Peripheral Blood in Positive Participants Before, During and After Protocol Therapy

Measurement of T-cell subset levels (CD4, CD8) in peripheral blood before, during and after protocol therapy to assess the effect of protocol therapy on immune re-constitution or exhaustion. (NCT01964755)
Timeframe: From Baseline Up to 1 Year Post-Therapy

Interventioncells/mm^3 (Mean)
CD4 count, Before TherapyCD4 count, During TherapyCD4 count, After TherapyCD8 count, Before TherapyCD8 count, During TherapyCD8 count, After Thaerapy
Chemotherapy + Antiviral-Based Therapy328285323.5124610061006

[back to top]

One-Year Rate of Failure-Free Survival (FFS)

Rate of failure-free survival of study participants one-year after start of protocol therapy. Failure-free survival (FFS) will be measured from the date of treatment initiation until date of documented disease progression, relapse after response, or death from any cause. For patients alive and free of relapse or progression, follow-up time will be censored at the last documented date of failure-free status. Kaplan-Meier estimate of failure-free survival at one-year. (NCT01964755)
Timeframe: 12 months

Interventionpercentage of participants (Number)
Chemotherapy + Antiviral-Based Therapy37.5

[back to top]

Rate of Complete Response to Protocol Therapy

"Complete Response (CR) rate in study participants to protocol therapy. Response will be assessed via CT Scan and bone marrow aspirate/biopsy, if applicable. Complete response criteria include:~Complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy, and normalization of those biochemical abnormalities definitely assignable to Non Hodgkin's Lymphoma (NHL);~All lymph nodes and tumor masses disappeared or regressed to normal size (≤ 1.5 cm in their greatest transverse diameters for nodes > 1.5 cm before therapy);~Previously involved nodes that were 1.1 to 1.5 cm in their greatest transverse diameter (GTD) before treatment must have decreased to ≤ 1 cm in their GTD after treatment, or by more than 75% bin the sum of the products of the greatest diameters (SPD);~No new sites of disease." (NCT01964755)
Timeframe: About 21 days

InterventionParticipants (Count of Participants)
Chemotherapy + Antiviral-Based Therapy3

[back to top]

HIV Viral Load in Positive Subjects Before, During and After Protocol Therapy

Measurement of HIV Viral Load in positive subjects before, during and after protocol therapy to assess the effect of protocol therapy on immune reconstitution or exhaustion. (NCT01964755)
Timeframe: From Baseline Up to 1 Year Post-Therapy

Interventioncopies/ml (Number)
Before TherapyDuring TherapyAfter Therapy
Chemotherapy + Antiviral-Based Therapy333NANA

[back to top] [back to top]

Number of Ongoing AEs Per HDMTX Course

Characterization (frequency and severity grade) of toxicity reported for each course of HDMTX treatment with folate rescue therapy and continuing until eight (8) days after start of HDMTX administration, per NCI CTCAE v4.0 (Grade refers to the severity of the AE). The CTCAE displays Grades 1 through 5 with unique clinical descriptions of severity for each AE; Grade 1 Mild, Grade 2 Moderate, Grade 3 Severe, Grade 4 Life-threatening, and Grade 5 Death related to AE. (NCT01987102)
Timeframe: From the start of HDMTX administration through 8 days post dose for each course of HDMTX

,
InterventionNumber of AEs (Number)
Course 1 (SOC)Course 2 (SOC)Course 1 (MOD)Course 2 (MOD)
Cohort 11419614
Cohort 210101016

[back to top] [back to top]

Time to Successful MTX Elimination (Definition C)

Definition C: Time to successful MTX elimination = Time from start of MTX treatment until serum MTX level is ≤ 0.1 μmol/L (NCT01987102)
Timeframe: Time from start of MTX treatment until serum MTX level is ≤ 0.1 μmol/L

,
Interventionhours (Mean)
Time (h) Course SOC 1Time (h) Course SOC 2Time (h) Course MOD 1Time (h) Course MOD 2
Cohort 184.5277.074.0072.50
Cohort 262.7562.7565.7588.0

[back to top]

Number of AEs Per Severity (All Courses)

Characterization (number and severity grade) of toxicity reported for each course of HDMTX treatment with folate rescue therapy and continuing until eight (8) days after start of HDMTX administration, per NCI CTCAE v4.0 (Grade refers to the severity of the AE). The CTCAE displays Grades 1 through 5 with unique clinical descriptions of severity for each AE; Grade 1 Mild, Grade 2 Moderate, Grade 3 Severe, Grade 4 Life-threatening, and Grade 5 Death related to AE. (NCT01987102)
Timeframe: From the start of HDMTX administration through 8 days post dose for each course of HDMTX in total

,
InterventionNumber of AEs (Number)
Grade 1Grade 2Grade 3Grade 4
Cohort 1408113
Cohort 2271561

[back to top]

Characterization (Number/Severity) of All Reported AEs During the ENTIRE STUDY PERIOD.

The severity of AEs have been done using NCI CTCAE v4.0. Total number of AEs per severity grade are presented for all AEs and for AEs related to MTX. For AEs related to MTX the number of AEs occurring per preferred term and severity grade are detailed.The CTCAE displays Grades 1 through 5 with unique clinical descriptions of severity for each AE; Grade 1 Mild, Grade 2 Moderate, Grade 3 Severe, Grade 4 Life-threatening, and Grade 5 Death related to AE. (NCT01987102)
Timeframe: From the start of HDMTX administration through 8 days post dose for all 4 courses of HDMTX in total

,
InterventionNumber of AEs (Number)
Grade 1 (ALL AEs)Grade 2 (ALL AEs)Grade 3 (ALL AEs)Grade 4 (ALL AEs)Any Grade (ALL AEs)Grade 1 (AEs Related to MTX)Grade 2 (AEs Related to MTX)Grade 3 (AEs Related to MTX)Grade 4 (AEs Related to MTX)Any Grade (AEs Related to MTX)ALAT increase (Related to MTX) Grade 1ALAT increase (Related to MTX) Grade 2ALAT increase (Related to MTX) Grade 3ALAT increase (Related to MTX) Grade 4ALAT increase (Related to MTX) Any GradeAnemia (Related to MTX) Grade 1Anemia (Related to MTX) Grade 2Anemia (Related to MTX) Grade 3Anemia (Related to MTX) Grade 4Anemia (Related to MTX) Any GradeASAT increased (Related to MTX) Grade 1ASAT increased (Related to MTX) Grade 2ASAT increased (Related to MTX) Grade 3ASAT increased (Related to MTX) Grade 4ASAT increased (Related to MTX) Any GradeCheilitis (Related to MTX) Grade 1Cheilitis (Related to MTX) Grade 2Cheilitis (Related to MTX) Grade 3Cheilitis (Related to MTX) Grade 4Cheilitis (Related to MTX) Any GradeConvulsion (Related to MTX) Grade 1Convulsion (Related to MTX) Grade 2Convulsion (Related to MTX) Grade 3Convulsion (Related to MTX) Grade 4Convulsion (Related to MTX) Any GradeDiarrhoea (Related to MTX) Grade 1Diarrhoea (Related to MTX) Grade 2Diarrhoea (Related to MTX) Grade 3Diarrhoea (Related to MTX) Grade 4Diarrhoea (Related to MTX) Any GradeDrug clearance decreased (Related to MTX) Grade 1Drug clearance decreased (Related to MTX) Grade 2Drug clearance decreased (Related to MTX) Grade 3Drug clearance decreased (Related to MTX) Grade 4Drug clearance decreased (Related to MTX) AnyGradeFebrile neutropenia (Related to MTX) Grade 1Febrile neutropenia (Related to MTX) Grade 2Febrile neutropenia (Related to MTX) Grade 3Febrile neutropenia (Related to MTX) Grade 4Febrile neutropenia (Related to MTX) Any GradeHeadache (Related to MTX) Grade 1Headache (Related to MTX) Grade 2Headache (Related to MTX) Grade 3Headache (Related to MTX) Grade 4Headache (Related to MTX) Any GradeNausea (Related to MTX) Grade 1Nausea (Related to MTX) Grade 2Nausea (Related to MTX) Grade 3Nausea (Related to MTX) Grade 4Nausea (Related to MTX) Any GradeNephropathy (Related to MTX) Grade 1Nephropathy (Related to MTX) Grade 21Nephropathy (Related to MTX) Grade 3Nephropathy (Related to MTX) Grade 4Nephropathy (Related to MTX) Any GradeNeutropenia (Related to MTX) Grade 1Neutropenia (Related to MTX) Grade 2Neutropenia (Related to MTX) Grade 3Neutropenia (Related to MTX) Grade 4Neutropenia (Related to MTX) Any GradeNeutrophil count decrease (Related to MTX) Grade 1Neutrophil count decrease (Related to MTX) Grade 2Neutrophil count decrease (Related to MTX) Grade 3Neutrophil count decrease (Related to MTX) Grade 4Neutrophil count decrease (Related to MTX)AnyGradePyrexia (Related to MTX) Grade 1Pyrexia (Related to MTX) Grade 2Pyrexia (Related to MTX) Grade 3Pyrexia (Related to MTX) Grade 4Pyrexia (Related to MTX) Any GradeStomatitis (Related to MTX) Grade 1Stomatitis (Related to MTX) Grade 2Stomatitis (Related to MTX) Grade 3Stomatitis (Related to MTX) Grade 4Stomatitis (Related to MTX) Any GradeVomiting (Related to MTX) Grade 1Vomiting (Related to MTX) Grade 2Vomiting (Related to MTX) Grade 3Vomiting (Related to MTX) Grade 4Vomiting (Related to MTX) Any GradeWBC count decreased (Related to MTX) Grade 1WBC count decreased (Related to MTX) Grade 2WBC count decreased (Related to MTX) Grade 3WBC count decreased (Related to MTX) Grade 4WBC count decreased (Related to MTX) Any Grade
Cohort 14081136225661382141834007502070000000000210030000000000100012000200000000000000010001000009000900000
Cohort 2271569492012513803003000002000212000001010000010001001010100142006100010001100101000003210682001000101

[back to top]

Number of Administered HDMTX Courses Classified as Having Met the Criteria for Successful Advancement According to Definition A and/or Definition B

"Definition A: Successful advancement from 1st to 2nd HDMTX course within the same MAP cycle. Fulfilling all of the following criteria 8 days after start of first HDMTX course within the same MAP cycle:~Serum MTX: ≤0.1μmol/L~Neutrophils: ≥0.25x109/L~Platelets: ≥50x109/L~Serum bilirubin: ≤1.25 x upper limit of normal (ULN)~Glomerular filtration rate (GFR) ≥70 mL/min/1.73m2~No AE Grade 2 or more related to HDMTX hindering a potential HDMTX administration, at the discretion of the investigator~Definition B: Successful advancement to next MAP cycle~Fulfilling all of the following criteria 8 days after start of the second HDMTX course in previous MAP cycle:~Serum MTX: ≤0.1μmol/L~Neutrophils: ≥ 0.75 x 109/L~Platelets: ≥75x109/L~Serum bilirubin: ≤1.25xULN~GFR ≥70 mL/min/1.73m2~No AE Grade 2 or more related to HDMTX hindering a potential Adriamycin/Doxorubicin and Cisplatin (AP) administration, at the discretion of the investigator" (NCT01987102)
Timeframe: 8 days after start of first and/or second HDMTX course in a MAP cycle

,
InterventionNumber of courses (Number)
Successful Course SOC 1Unsuccessful Course SOC 1Successful Course SOC 2Unsuccessful Course SOC 2Successful Course MOD 1Unsuccessful Course MOD 1Successful Course MOD 2Unsuccessful Course MOD 2
Cohort 140404040
Cohort 240403121

[back to top]

Number of Administered MAP Cycles Classified as Having Met the Criteria for Successful Advancement From First to Second HDMTX Course Within the Same MAP Cycle According to Definition A.

"Definition A: Successful advancement from first to second HDMTX course within the same MAP cycle~Fulfilling all of the following criteria 8 days after start of first HDMTX course within the same MAP cycle:~Serum MTX: ≤ 0.1 μmol/L~Neutrophils: ≥ 0.25 x 109/L~Platelets: ≥ 50 x 109/L~Serum bilirubin: ≤ 1.25 x ULN~GFR ≥ 70 mL/min/1.73 m2~No AE Grade 2 or more (NCI CTCAE v4.0) related to HDMTX hindering a potential HDMTX administration, at the discretion of the investigator" (NCT01987102)
Timeframe: 8 days after start of first HDMTX course in a MAP cycle

,
InterventionNumber of courses (Number)
Successful Course SOC 1Unsuccessful Course SOC 1Successful Course MOD 1Unsuccessful Course MOD 1
Cohort 14040
Cohort 24031

[back to top] [back to top]

Number of Grade A1, Grade A2, Grade B, Grade C, or Grade D Excretion Toxicities as Listed in the MTX-toxicity Management Instructions

The MTX-toxicity management instructions provided in the protocol are based on the Children's Oncology Group (COG) treatment management recommendations used in study protocol AOST0331, EURAMOS 1. The COG recommend changes in the hydration and the rescue frequency and/or dose to be done if pre-specified toxicities of different severity grades occur. (NCT01987102)
Timeframe: Time from start of MTX treatment until serum MTX level is ≤ 0.1 μmol/L

,
InterventionNumber of MTX excretion toxicities (Number)
Grade A2 (24h) SOC 1Grade A2 (24h) SOC 2Grade A2 (24h) MOD 1Grade A2 (24h) MOD 2Grade B (24h) SOC 1Grade B (24h) SOC 2Grade B (24h) MOD 1Grade B (24h) MOD 2None (24h) SOC 1None (24h) SOC 2None (24h) MOD 1None (24h) MOD 2Grade A2 (48h) SOC 1Grade A2 (48h) SOC 2Grade A2 (48h) MOD 1Grade A2 (48h) MOD 2Grade B (48h) SOC 1Grade B (48h) SOC 2Grade B (48h) MOD 1Grade B (48h) MOD 2None (48h) SOC 1None (48h) SOC 2None (48h) MOD 1None (48h) MOD 2Grade A1 (72h) SOC 1Grade A1 (72h) SOC 2Grade A1 (72h) MOD 1Grade A1 (72h) MOD 2Grade A2 (72h) SOC 1Grade A2 (72h) SOC 2Grade A2 (72h) MOD 1Grade A2 (72h) MOD 2Grade B (72h) SOC 1Grade B (72h) SOC 2Grade B (72h) MOD 1Grade B (72h) MOD 2None (72h) SOC 1None (72h) SOC 2None (72h) MOD 1None (72h) MOD 2
Cohort 12212101112211122100023222212111000001122
Cohort 22231000122112121000123210110000000014332

[back to top]

Number of HDMTX Courses in Which the Initial Hydration Was Increased

(NCT01987102)
Timeframe: Time from start of MTX treatment until serum MTX level is ≤ 0.1 μmol/L

,
InterventionHDMTX courses (Number)
Hydration change in Course SOC 1Unchanged hydration Course SOC 1Hydration change in Course SOC 2Unchanged hydration Course SOC 2Hydration change in Course MOD 1Unchanged hydration Course MOD 1Hydration change in course MOD 2Unchanged hydration Course MOD 2
Cohort 122132222
Cohort 204042212

[back to top]

Number of HDMTX Courses With Delayed Early MTX Elimination (Definition E).

"Definition E: Delayed early MTX elimination (according to US label for Calcium Folinate)~S-MTX levels of:~50 μmol/L at 24 hours after start of MTX administration, OR~5 μmol/L at 48 hours after start of MTX administration OR An increase in S-Creatinine level of 100% or greater at 24 hours after start of MTX administration." (NCT01987102)
Timeframe: Time from start of MTX treatment until serum MTX level is ≤ 0.1 μmol/L

,
InterventionNumber of courses (Number)
Delayed early MTX elimination in Course SOC 1Undelayed early MTX elimination in Course SOC 1Delayed early MTX elimination in Course SOC 2Undelayed early MTX elimination in Course SOC 2Delayed early MTX elimination in Course MOD 1Undelayed early MTX elimination in Course MOD 1Delayed early MTX elimination in Course MOD 2Undelayed early MTX elimination in Course MOD 2
Cohort 104040404
Cohort 204040403

[back to top]

Number of HDMTX Courses With Delayed Late MTX Elimination (Definition F).

"Definition F: Delayed late MTX elimination (according to US label for Calcium Folinate)~S-MTX level:~> 0.2 μmol/L at 72 hours AND > 0.1 μmol/L at 96 hours after start of MTX administration." (NCT01987102)
Timeframe: Time from start of MTX treatment until serum MTX level is ≤ 0.1 μmol/L

,
InterventionNumber of courses (Number)
Delayed late MTX elimination in Course SOC 1Undelayed late MTX elimination in Course SOC 1Delayed late MTX elimination in Course SOC 2Undelayed late MTX elimination in Course SOC 2Delayed late MTX elimination in Course MOD 1Undelayed late MTX elimination in Course MOD 1Delayed late MTX elimination in Course MOD 2Undelayed late MTX elimination in Course MOD 2
Cohort 103030202
Cohort 201010110

[back to top]

Number of HDMTX Courses With Delayed MTX Elimination (Definition D).

"Definition D: Delayed MTX elimination (according to COGs excretion toxicity management instructions)~S-MTX levels of:~> 10 μmol/L at 24 h after start of MTX administration, OR > 1 μmol/L at 48 h after start of MTX administration, OR > 0.1 μmol/L at 72 h after start of MTX administration or later" (NCT01987102)
Timeframe: Time from start of MTX treatment until serum MTX level is ≤ 0.1 μmol/L

,
InterventionNumber of courses (Number)
Delayed MTX elimination in Course SOC 1Undelayed MTX elimination in Course SOC 1Delayed MTX elimination in Course SOC 2Undelayed MTX elimination in Course SOC 2Delayed MTX elimination in Course MOD 1Undelayed MTX elimination in Course MOD 1Delayed MTX elimination in Course MOD 2Undelayed MTX elimination in Course MOD 2
Cohort 131312222
Cohort 204131312

[back to top]

Comparison of 5-FC in the Brain to 5-FC in the Plasma

PK data from the patients who undergo intracerebral microdialysis (dose level 4) will be summarized using the mean ratio of average brain interstitial 5-FC concentrations to the average steady-state plasma levels. (NCT02015819)
Timeframe: The ratio of average brain interstitial 5-FC and 5-FU concentrations to average plasma steady-state levels was calculated using all measured data.

Interventionratio (Mean)
Dose Level 4 (NSC 1.5x10^8 and 5-FC 37.5 mg/kg) + Leucovorin + Microdialysis29

[back to top]

Average Steady State Levels of 5-FC Concentrations in Plasma

PK data from the patients who undergo intracerebral microdialysis (dose level 4) will be summarized using descriptive statistics. (NCT02015819)
Timeframe: Samples were obtained prior to the first dose of 5-FC then every 30 minutes for 3 hours, additional samples at 4 and 6 hours after the morning doses on days 4, 5. On days 6, 7, 8 blood samples were collected just before morning dose and 90 minutes later

Interventionµmol/L (Mean)
Dose Level 4 (NSC 1.5x10^8 and 5-FC 37.5 mg/kg) + Leucovorin + Microdialysis748

[back to top]

Number of Participants With Mechanical Issues With Repeat Administrations of NSCs Via Rickham

Number of participants with mechanical issues with repeat administrations of NSCs via Rickham. (NCT02015819)
Timeframe: 28 days after last infusion of NSCs, up to 6 months total

InterventionParticipants (Count of Participants)
Dose Level 1 (NSC 5x10^7 and 5-FC 37.5 mg/kg)0
Dose Level 2 (NSC 1x10^8 and 5-FC 37.5 mg/kg)0
Dose Level 3 (NSC 1.5x10^8 and 5-FC 37.5 mg/kg)0
Dose Level 4 (NSC 1.5x10^8 and 5-FC 37.5 mg/kg) + Leucovorin + Microdialysis0

[back to top]

Average Steady State Levels of 5-FC and 5-FU in the Brain

Pharmacokinetic (PK) data from the patients who undergo intracerebral microdialysis (dose level 4) will be summarized using descriptive statistics. All summaries will be exploratory in spirit. (NCT02015819)
Timeframe: Following the first dose of 5-FC, samples were collected every hour for 24 hours and then every 3 hours thereafter until the end of the 7-day course of 5-FC or until the microdialysis catheter stopped functioning.

Interventionµmol/L (Mean)
average steady state levels of 5-FC in the brainaverage steady state levels of 5-FU in the brain
Dose Level 4 (NSC 1.5x10^8 and 5-FC 37.5 mg/kg) + Leucovorin + Microdialysis2130.03

[back to top]

Number of Participants Developing Antibodies Against NSCs

Development of a antibody response to the NSCs will be evaluated by flow cytometry. Data from assessing for possible development of NSC immunogenicity with repeat exposure will be presented in an exploratory fashion using descriptive statistics. (NCT02015819)
Timeframe: While receiving treatment, up to 6 months.

InterventionParticipants (Count of Participants)
Dose Level 1 (NSC 5x10^7 and 5-FC 37.5 mg/kg)0
Dose Level 2 (NSC 1x10^8 and 5-FC 37.5 mg/kg)2
Dose Level 3 (NSC 1.5x10^8 and 5-FC 37.5 mg/kg)0
Dose Level 4 (NSC 1.5x10^8 and 5-FC 37.5 mg/kg) + Leucovorin + Microdialysis1

[back to top]

Number of Participants With Dose Limiting Toxicities (DLTs) and Maximum Tolerated Dose (MTD)

Number of DLTs per dose level and the MTD/MFD. (NCT02015819)
Timeframe: Day 28 of course 1

InterventionParticipants (Count of Participants)
Dose Level 1: (NSC 5x10^7 and 5-FC 37.5 mg/kg)0
Dose Level 2: (NSC 1x10^8 and 5-FC 37.5 mg/kg)0
Dose Level 3 (NSC 1.5x10^8 and 5-FC 37.5 mg/kg)0
Dose Level 4 (NSC 1.5x10^8 and 5-FC 37.5 mg/kg + Leucovorin + Microdialysis1

[back to top]

Number of Patients With Pathologic Complete Response

"Pathologic complete response rate is reported as the number of patients who achieve pathologic complete response after the treatment for each arm.~As per the NCCN guidelines, pathologic response is graded by the system recommended by the AJCC Cancer Staging Manual and CAP guidelines:~Complete response - no remaining viable cancer cells~Moderate response - only small clusters/single cancer cells remain~Minimal response - residual cancer remaining, but with predominant fibrosis~Poor response - minimal/no tumor kills, extensive residual cancer" (NCT02017704)
Timeframe: Up to 60 months

InterventionParticipants (Count of Participants)
IMRT and Capecitabine0
Endo-HDR2

[back to top]

Change in EORTC QLQ-C30 Global Health Status Score

"Patients were given the EORTC QLQ-C30 at baseline, preop, postop, and at follow ups Y1-5. The forms were scored as per the manual available at EORTC. Raw scores are transformed to fall in a range of 0-100. Generally, higher scores on QoL scales represent higher levels of QoL.~The scores are reported as the mean of the Global Health Status/QoL scale score when more than 1 patient completed the form for a time point. If only 1 form was available for a time point, then the score for that form is reported." (NCT02017704)
Timeframe: baseline, preop, postop, and at follow ups Y1-5

Interventionscore on a scale (Mean)
baselinepre-oppost-opyear 2year 3year 4
IMRT and Capecitabine8333545066.583

[back to top]

Change in EORTC QLQ-C30 Global Health Status Score

"Patients were given the EORTC QLQ-C30 at baseline, preop, postop, and at follow ups Y1-5. The forms were scored as per the manual available at EORTC. Raw scores are transformed to fall in a range of 0-100. Generally, higher scores on QoL scales represent higher levels of QoL.~The scores are reported as the mean of the Global Health Status/QoL scale score when more than 1 patient completed the form for a time point. If only 1 form was available for a time point, then the score for that form is reported." (NCT02017704)
Timeframe: baseline, preop, postop, and at follow ups Y1-5

Interventionscore on a scale (Mean)
baselinepre-oppost-opyear 1year 2year 3year 4year 5
Endo-HDR71.249.672.57366.377.39191.5

[back to top]

Number of Participants With Grade 3 or Higher Adverse Events

"Number of participants with grade 3 or higher adverse events will be listed by relationship.~Grading is by CTCAE 4 guidelines.~Relationship, as determined by PI, is unrelated/unlikely/possible/probable/definite." (NCT02017704)
Timeframe: Up to 60 months

,
InterventionParticipants (Count of Participants)
Grade: 3; Relationship: probableGrade: 3; Relationship: possibleGrade 3; Relationship: Unlikely
Endo-HDR110
IMRT and Capecitabine111

[back to top]

Number of Participants With Adverse Events and Serious Adverse Events

Assessment of safety of napabucasin administered in combination with either FOLFOX6 with and without bevacizumab, or CAPOX, or FOLFIRI with and without bevacizumab, or regorafenib, or irinotecan in participants with advanced gastrointestinal malignancies by reporting of adverse events and serious adverse events (NCT02024607)
Timeframe: The time from the date of first treatment, while the patient is taking napabucasin, and for 30 days after stopping therapy, an average of 4 months.

InterventionParticipants (Count of Participants)
Napabucasin Plus FOLFOX6115
Napabucasin Plus FOLFOX6 Plus Bevacizumab41
Napabucasin Plus CAPOX87
Napabucasin Plus FOLFIRI156
Napabucasin Plus FOLFIRI Plus Bevacizumab40
Napabucasin Plus Regorafenib54
Napabucasin Plus Irinotecan2

[back to top]

Disease Control Rate

To determine the anti-tumor activity (specifically the disease control rate) of napabucasin administered in combination with either FOLFOX6 with and without bevacizumab, or CAPOX, or FOLFIRI with and without bevacizumab, or regorafenib, or irinotecan. Percentage of participants with a documented complete response, partial response and stable disease based on RECIST 1.1. (NCT02024607)
Timeframe: From the date of first treatment, every 8 weeks, until the date of first documented objective disease progression, up to 24 months.

Interventionpercentage of participants (Number)
Napabucasin Plus FOLFOX654.7
Napabucasin Plus FOLFOX6 Plus Bevacizumab76.2
Napabucasin Plus CAPOX55.3
Napabucasin Plus FOLFIRI65.7
Napabucasin Plus FOLFIRI Plus Bevacizumab87.0
Napabucasin Plus Regorafenib34.4
Napabucasin Plus Irinotecan100

[back to top]

Disease Control Rate of Patients With FOLFIRI/XELIRI-refractory Metastatic Colorectal Cancer

To determine the disease control rate of napabucasin administered in combination with FOLFIRI in patients with FOLFIRI/XELIRI-refractory metastatic colorectal cancer. Percentage of participants with a documented complete response, partial response and stable disease based on RECIST 1.1. (NCT02024607)
Timeframe: From the date of first treatment, every 8 weeks, until the date of first documented objective disease progression, up to 24 months

Interventionpercentage of participants (Number)
Napabucasin Plus FOLFIRI56.9

[back to top]

The Objective Response Rate of Napabucasin Administered in Combination in FOLFIRI in Patients With FOLFIRI/XELIRI-refractory Metastatic Colorectal Cancer

Assessment of the objective response rate (ORR) of napabucasin administered in combination with FOLFIRI in patients with FOLFIRI/XELIRI-refractory metastatic colorectal cancer. The Objective Response Rate (ORR) is the proportion of participants with a complete response or partial response who have measurable disease at baseline imaging. (NCT02024607)
Timeframe: From the date of first treatment, every 8 weeks, until the date of first documented objective disease progression, up to 24 months

Interventionpercentage of participants (Number)
Napabucasin Plus FOLFIRI0

[back to top]

Progression Free Survival of Patients With FOLFIRI/XELIRI-refractory Metastatic Colorectal Cancer

The effect of napabucasin given in combination with FOLFIRI on Progression Free Survival (PFS) of patients with FOLFIRI/XELIRI-refractory metastatic colorectal cancer. PFS of patients with FOLFIRI/XELIRI-refractory metastatic colorectal cancer. (NCT02024607)
Timeframe: The time from the date of first treatment to the date of first documentation of disease progression or death due to any cause, up to thirty six months

Interventionmonths (Number)
Napabucasin Plus FOLFIRI20.82

[back to top]

Overall Survival of Patients With FOLFIRI/XELIRI-refractory Metastatic Colorectal Cancer

The effect of napabucasin given in combination with FOLFIRI on Overall Survival (OS) of patients with FOLFIRI/XELIRI-refractory metastatic colorectal cancer. (NCT02024607)
Timeframe: 4 weeks after the patient has been off study treatment, every 3 months thereafter until death, the study closes, up to 36 months.

Interventionmonths (Median)
Napabucasin Plus FOLFIRI8.97

[back to top] [back to top]

Objective Response Rate

Confirmed response (CR) is two or more objective statuses of CR a minimum of four weeks apart documented before progression or symptomatic deterioration. Partial response (PR) is two or more objective statuses of PR or better a minimum of four weeks apart documented before progression or symptomatic deterioration. Unconfirmed CR is one objective status of CR documented before progression or symptomatic deterioration but not qualifying as CR or PR. Unconfirmed PR is one objective status of PR documented before progression or symptomatic deterioration but not qualifying as CR, PR or unconfirmed CR. (NCT02042443)
Timeframe: Up to 2 years from registration

,
InterventionParticipants (Count of Participants)
Partial ResponseUnconfirmed Partial ResponseStable/No ResponseIncreasing DiseaseSymptomatic Deterioration
Chemotherapy20981
Trametinib022191

[back to top]

Progression-free Survival

From date of registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause. Patients last known to be alive and progression free are censored at date of last contact. (NCT02042443)
Timeframe: Up to 2 years from registration

Interventionmonths (Median)
Trametinib1.3
Chemotherapy2.8

[back to top]

Overall Survival

From date of registration to date of death due to any cause. Patients last known to be alive are censored at date of last contact. (NCT02042443)
Timeframe: Up to 2 years from registration

Interventionmonths (Median)
Trametinib4.3
Chemotherapy7.9

[back to top]

PK:Area Under the Concentration-Time Curve (AUC[0-∞]) of Ramucirumab

Area under the concentration-time curve. (NCT02069041)
Timeframe: Cycle 1 and Cycle 3: 0,1.0,1.5,2.0,3.0,5.0,24.0,48.0,168.0,336.0 hours

Interventionmicrogram*day / milliliter)(ug*day/mL) (Geometric Mean)
Cycle 1Cycle 3
Ramucirumab + FOLFOX49401190

[back to top]

Pharmacokinetics (PK): Maximum Concentration (Cmax) of Ramucirumab

Maximum Concentration (Cmax) (NCT02069041)
Timeframe: Cycle 1 and Cycle 3: 0,1.0,1.5,2.0,3.0,5.0,24.0,48.0,168.0,336.0 hours

Interventionug/mL(microgram / milliliter) (Geometric Mean)
Cycle 1Cycle 3
Ramucirumab + FOLFOX4155190

[back to top]

Percentage of Participants With Best Response of Complete Response (CR) or Partial Response (PR) (Overall Response Rate [ORR])

"Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST, version[v] 1.1) criteria.CR was defined as the disappearance of all target and non-target lesions and all target and non-target lymph nodes were non-pathological or normal in size [<10 millimeter (mm) short axis]. PR is at least a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters. Progressive Disease(PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (including the baseline sum if that is the smallest).In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression.~Percentage of participants with CR or PR= (number of participants whose best overall response was CR or PR)/(number of participants treated)*100." (NCT02069041)
Timeframe: Response to Disease Progression or Death (Up To 7 Months)

Interventionpercentage of Participants (Number)
Ramucirumab + FOLFOX425

[back to top] [back to top]

Number of Participants With Anti-Ramucirumab Antibodies

(NCT02069041)
Timeframe: Baseline through 6.1 Months

InterventionParticipants (Count of Participants)
Ramucirumab + FOLFOX40

[back to top]

Elimination Half-life (t1/2) of BEVZ92 and Avastin®

Secondary PK endpoints included the t1/2 calculated at Cycle 7 (NCT02069704)
Timeframe: t1/2: 0 to 336 hours after the administration of the Cycle 7 infusion.

Interventionh (Geometric Least Squares Mean)
Bevacizumab Biosimilar (BEVZ92)294
Avastin® (Bevacizumab, Ref. Product).289

[back to top]

Ctrough,sd of BEVZ92 and Avastin®

Secondary PK endpoints included the Ctrough calculated at Cycle 1 (Ctrough,sd ) (NCT02069704)
Timeframe: Ctrough, sd: 0 to 336 hours after start of the first infusion.

Interventionng/mL (Geometric Least Squares Mean)
Bevacizumab Biosimilar (BEVZ92)344
Avastin® (Bevacizumab, Ref. Product).349

[back to top]

Cmax,ss of BEVZ92 and Avastin®

Secondary PK endpoints included the Cmax calculated at Cycle 7 (Cmax, ss ) (NCT02069704)
Timeframe: Cmax, ss: 0 to 336 hours post-dose after the administration of Cycle 7 infusion (Week 13)

Interventionng/mL (Geometric Least Squares Mean)
Bevacizumab Biosimilar (BEVZ92)195000
Avastin® (Bevacizumab, Ref. Product).200000

[back to top]

Cmax,sd of BEVZ92 and Avastin®

Secondary PK endpoints included the Cmax calculated at Cycle 1 (Cmax,sd ) (NCT02069704)
Timeframe: Cmax, sd: 0 to 336 hours after start of the first infusion.

Interventionng/mL (Geometric Least Squares Mean)
Bevacizumab Biosimilar (BEVZ92)120000
Avastin® (Bevacizumab, Ref. Product).123000

[back to top]

AUC at Steady State (AUCss) of BEVZ92 and Avastin®

"To compare the PK profile of BEVZ92 and Avastin®, both administered in combination with FOLFOX (any) or FOLFIRI, by means of comparing the truncated area under the concentration-versus-time curve calculated over a dosage interval at steady state (i.e. at Cycle 7; AUCss).~For the PK similarity assessments, regulatory guidelines on bioequivalence were followed whereby two treatments are judged not to be different from one another if the 90% CI of the ratio of a log-transformed exposure measure (AUC) falls completely within the range 80-125%." (NCT02069704)
Timeframe: AUCss: 0 to 336 hours after the administration of Cycle 7 infusion (Week 13).

Interventionng.h/mL (Geometric Least Squares Mean)
Bevacizumab Biosimilar (BEVZ92)35900000
Avastin® (Bevacizumab, Ref. Product).35700000

[back to top]

Area Under the Concentration-versus-time Curve (AUC) at Cycle 1 (AUC0-336h) of BEVZ92 and Avastin®

"To compare the pharmacokinetic (PK) profile of BEVZ92 and Avastin®, both administered in combination with FOLFOX (any) or FOLFIRI, by means of comparing the truncated AUC calculated from start of the first infusion until start of the second infusion (i.e. at Cycle 1; AUC0-336h)~For the PK similarity assessments, regulatory guidelines on bioequivalence were followed whereby two treatments are judged not to be different from one another if the 90% confidence interval (CI) of the ratio of a log-transformed exposure measure (AUC) falls completely within the range 80-125%." (NCT02069704)
Timeframe: AUC0-336 hrs: 0 to 336 hours after start of the first infusion

Interventionng.h/mL (Geometric Least Squares Mean)
Bevacizumab Biosimilar (BEVZ92)16500000
Avastin® (Bevacizumab, Ref. Product).16600000

[back to top]

Ctrough,ss of BEVZ92 and Avastin®

Secondary PK endpoints included the Ctrough calculated at Cycle 7 (Ctrough,ss) (NCT02069704)
Timeframe: Ctrough, ss: 0 to 336 hours after the administration of the Cycle 7 infusion.

Interventionng/mL (Geometric Least Squares Mean)
Bevacizumab Biosimilar (BEVZ92)69600
Avastin® (Bevacizumab, Ref. Product).69300

[back to top]

Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) Reported With BEVZ92 and Avastin®

Compare the safety profile by means of the frequency and severity of TEAEs and SAEs reported in each treatment arm. (NCT02069704)
Timeframe: From first study dose and up to 30 days after the end of study treatment for each patient, for an average of 11 months

,
Interventionparticipants (Number)
Any TEAE (any causality)Any grade>=3 TEAEAny TEAE leading to discontinuationAny treatment-related TEAEAny grade >=3 treatment-related TEAEAny serious TEAEAny bleeding event
Avastin® (Bevacizumab, Ref. Product)7149670702119
Bevacizumab Biosimilar (BEVZ92)66441363631914

[back to top]

Objective Response Rate (ORR) of BEVZ92 and Avastin®

"To compare efficacy in terms of ORR between arms. Clinical and radiological tumor assessments were performed according to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 using computed tomography (CT) or magnetic resonance imaging (MRI) scans.~Objective response (OR) is defined as a best overall response of partial response (PR) or complete response (CR) as defined by RECIST v1.1. All participants who did not meet the criteria for CR or PR by the end of the study were considered non-responders." (NCT02069704)
Timeframe: Every four weeks. Up to 48 weeks

,
InterventionParticipants (Count of Participants)
ORR (CR+PR)Stable diseaseProgressive diseaseunevaluable
Avastin® (Bevacizumab, Ref. Product)402524
Bevacizumab Biosimilar (BEVZ92)352745

[back to top]

Anti-Drug Antibody (ADA) of BEVZ92 and Avastin®

Immunogenicity profile by means of measurement of ADA developed de novo (seroconversion) after cycle 5, cycle 8, and 12 months after first drug administration (pre-dose). (NCT02069704)
Timeframe: At baseline, and on Day 1 (pre-dose) of Cycles: 1, 5 and 8, and 12 months after first drug administration

,
Interventionparticipants (Number)
SeroconversionNo seroconversion
Avastin® (Bevacizumab, Ref. Product)071
Bevacizumab Biosimilar (BEVZ92)267

[back to top]

Volume of Distribution (Vd) of BEVZ92 and Avastin®

Secondary PK endpoints included the Vd calculated at Cycle 7 (NCT02069704)
Timeframe: Vd: 0 to 336 hours after the administration of the Cycle 7 infusion.

InterventionL (Geometric Least Squares Mean)
Bevacizumab Biosimilar (BEVZ92)4.06
Avastin® (Bevacizumab, Ref. Product).3.86

[back to top]

Progression-free Survival (PFS) of BEVZ92 and Avastin®

"Compare PFS between the randomized treatment arms. Progression-free survival (PFS) was defined as the time from the randomization date to the date of disease progression using RECIST v1.1, or death. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions plus 5 mm absolute increase, and/or unequivocal progression of known non-target lesion, and/or the appearance of new lesions." (NCT02069704)
Timeframe: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 weeks.

Interventionmonths (Median)
Bevacizumab Biosimilar (BEVZ92)10.8
Avastin® (Bevacizumab, Ref. Product)11.1

[back to top]

Elimination Rate Constant (Kel) of BEVZ92 and Avastin®

Secondary PK endpoints included the Kel calculated at Cycle 7 (Ctrough,ss) (NCT02069704)
Timeframe: Kel: 0 to 336 hours after the administration of the Cycle 7 infusion.

Interventionl/h (Geometric Least Squares Mean)
Bevacizumab Biosimilar (BEVZ92)0.00236
Avastin® (Bevacizumab, Ref. Product).0.00240

[back to top]

Survival for Patients With Metastatic Pancreatic Cancer With First-line Treatment With FOLFOX-A as Compared to Historical Controls of Gemcitabine Alone.

(NCT02080221)
Timeframe: Every 3 months for up to 5 years

Interventionmonths (Median)
Progression- free survivalOverall survival
FOLFOXA511

[back to top]

Overall Survival (OS) of LR Relapse Patients

OS rates of LR relapse B-ALL patients who are randomized following Block 1 chemotherapy to receive either chemotherapy alone or chemotherapy plus blinatumomab (LR Randomization). OS is calculated as the time from randomization to date of death or date of last contact. Three-year OS estimates will be calculated from date of randomization for both Arm C and Arm D. Two-sided 95% confidence intervals will be calculated. (NCT02101853)
Timeframe: Up to 3 years from date of randomization

Interventionpercentage of participants (Number)
Arm C (LR Control)88.29
Arm D (LR Blinatumomab)90.37

[back to top]

Disease Free Survival (DFS) of High-risk (HR) and Intermediate-risk (IR) Relapse Patients

DFS rates of HR and IR relapse B-ALL patients who are randomized following Induction Block 1 chemotherapy to receive either two intensive chemotherapy blocks or two 5-week blocks of blinatumomab (HR/IR Randomization). DFS is calculated as the time from randomization to date of first event (treatment failure, relapse, second malignancy, remission death) or date of last contact. Two-year DFS estimates will be calculated from date of randomization for both Arm A and Arm B. Two-sided 95% confidence intervals will be calculated. (NCT02101853)
Timeframe: Up to 2 years from date of randomization

Interventionpercentage of participants (Number)
Arm A (HR and IR Control)39.04
Arm B (HR and IR Blinatumomab)54.44

[back to top]

Disease Free Survival (DFS) of Low Risk (LR) Relapse Patients

DFS rates of LR relapse B-ALL patients who are randomized following Block 1 chemotherapy to receive either chemotherapy alone or chemotherapy plus blinatumomab (LR Randomization). DFS is calculated as the time from randomization to date of first event (relapse, second malignancy, remission death) or date of last contact. Three-year DFS estimates will be calculated from date of randomization for both Arm C and Arm D. Two-sided 95% confidence intervals will be calculated. (NCT02101853)
Timeframe: Up to 3 years from date of randomization

Interventionpercentage of participants (Number)
Arm C (LR Control)58.94
Arm D (LR Blinatumomab)67.00

[back to top]

Overall Survival (OS) of HR and IR Relapse Patients

OS rates of HR and IR relapse B-ALL patients who are randomized following Induction Block 1 chemotherapy to receive either two intensive chemotherapy blocks or two 5-week blocks of blinatumomab (HR/IR Randomization). OS is calculated as the time from randomization to date of death or date of last contact. Two-year OS estimates will be calculated from date of randomization for both Arm A and Arm B. Two-sided 95% confidence intervals will be calculated. (NCT02101853)
Timeframe: Up to 2 years from date of randomization

Interventionpercentage of participants (Number)
Arm A (HR and IR Control)58.40
Arm B (HR and IR Blinatumomab)71.33

[back to top]

Cumulative Incidence Rates of Isolated Central Nervous System (CNS) Relapse for SR and IR T-ALL Patients on the Non-bortezomib Containing Arm on This Study (no CRT) and Similar Patients on AALL0434 (Receive CRT)

Cumulative incidence of isolated CNS relapse adjusting for competing risks using the method of: Gray R, A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1141:1154, 1988 (NCT02112916)
Timeframe: 3 years

,
InterventionPercentage of participants (Number)
Isolated CNS RelapseIsolated Bone Marrow RelapseCombined Bone Marrow Relapse
AALL0434 T-ALL Patients2.23.01.8
AALL1231 T-ALL Patients3.61.41.3

[back to top]

Toxicity Rates Associated With Modified Standard Therapy, Including Dexamethasone and Additional Pegaspargase

Percentage of patients who experienced Grade 3 or higher Toxicity Assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 (NCT02112916)
Timeframe: 3 years from start of therapy by patient

InterventionPercentage of participants (Number)
Total Patients78.0

[back to top]

Event-free Survival (EFS) for Modified Augmented Berlin-Frankfurt-Munster Backbone With or Without Bortezomib in All Randomized Patients

EFS is calculated as time from randomization at study entry to first event (induction failure, induction death, relapse, second malignancy, remission death) or date of last contact. Three-year EFS rates will be calculated for both groups. (NCT02112916)
Timeframe: 3 years

InterventionPercentage of participants (Number)
Arm A (Combination Chemotherapy)81.7
Arm B (Combination Chemotherapy, Bortezomib)85.1

[back to top]

EFS for Very High Risk (VHR) T-ALL Patients Treated With High Risk (HR) Berlin-Frankfurt-Munster (BFM) Intensification Blocks Who Become Minimal Residual Disease (MRD) Negative and Those Who Remain MRD Positive at the End of HR Block 3

EFS will be calculated as time from the end of the three high-risk blocks of therapy to first event (relapse, second malignancy, remission death) or date of last contact. (NCT02112916)
Timeframe: 3 years

InterventionPercentage of participants (Number)
VHR T-ALL MRD Undetectable25.0
VHR T-ALL MRD Detectable88.9

[back to top]

EFS for Very High Risk (VHR) T-LLy Patients Treated With HR Berlin-Frankfurt-Munster (BFM) Intensification Blocks Who Have Complete or Partial Remission and Those Who do Not Respond

EFS for very high risk (VHR) T-LLy patients treated with HR Berlin-Frankfurt-Munster (BFM) intensification blocks who have complete or partial remission and those who do not respond (NCT02112916)
Timeframe: 3 years

InterventionPercentage of participants (Number)
VHR T-LLy (CR/PR)0

[back to top]

EFS for Standard (SR) and Intermediate Risk (IR) T-ALL Patients on the Non-bortezomib Containing Arm on This Study (no Cranial Radiation Therapy [CRT]) and Similar Patients on AALL0434 (Received CRT)

EFS is calculated as time from randomization at study entry to first event (induction failure, induction death, relapse, second malignancy, remission death) or date of last contact. (NCT02112916)
Timeframe: 3 years

InterventionPercentage of participants (Number)
AALL1231 T-ALL Patients88.3
AALL0434 T-ALL Patients88.8

[back to top]

Percentage of Participants With Objective Response (ORR) as Assessed Using RECIST v. 1.1

Efficacy of vanucizumab was evaluated in terms of Percentage of Participants With ORR as Investigator-Assessed Using RECIST v. 1.1. Best Overall Confirmed Response. (NCT02141295)
Timeframe: Baseline (within 28 days prior to Day 1), then every 8 weeks until progressive disease (PD), start of other anticancer therapy, withdrawal of consent, or death (up to approximately 29 months)

InterventionPercentage of Participants (Number)
Safety Run-In62.5
Vanucizumab + mFOLFOX-643.6
Bevacizumab + mFOLFOX-651.6

[back to top]

Overall Survival (OS)

Efficacy of vanucizumab was evaluated in terms of OS as the time from randomization until death from any cause. 99999 = data not estimable due to the low number of deaths. (NCT02141295)
Timeframe: Baseline until death from any cause (maximum up to approximately 3.5 years)

Interventiondays (Median)
Vanucizumab + mFOLFOX-6746.0
Bevacizumab + mFOLFOX-6NA

[back to top]

Number of Participants With Human Anti-human Antibodies (HAHAs) Against Vanucizumab

Safety is evaluated in terms of number of participants with Human Anti-human Antibodies (HAHAs) Against Vanucizumab. (NCT02141295)
Timeframe: End of study (EoS, within 28 to 42 days after last dose, latest at 29 months)

InterventionParticipants (Count of Participants)
Safety Run-In2
Vanucizumab + mFOLFOX-61

[back to top]

Time to Reach Cmax (Tmax) of Vanucizumab

PK profile of vanucizumab was evaluated in terms of Tmax (NCT02141295)
Timeframe: Cycles 1 and 8 of parts 1 and 2

,
Interventionhr (Median)
Cycle 1Cycle 8
Safety Run-In2.794.04
Vanucizumab + mFOLFOX-62.051.58

[back to top]

Duration of Objective Response, as Assessed Using RECIST v. 1.1

Efficacy of vanucizumab was evaluated in terms of duration of objective response as assessed using RECIST v. 1.1. This was computed using the PFS definition with death on study (deaths that occurred outside the 30 days window from the last study treatment are excluded). (NCT02141295)
Timeframe: Baseline (within 28 days prior to Day 1), then every 8 weeks until PD, start of other anticancer therapy, withdrawal of consent, or death (up to approximately 29 months)

Interventiondays (Median)
Vanucizumab + mFOLFOX-6342
Bevacizumab + mFOLFOX-6304

[back to top]

Cmax Accumulation Ratio (AR) of Vanucizumab

PK profile of vanucizumab was evaluated in terms of Cmax Ratio, values are reported for cycle 8 of both part 1 (safety run-in) and part 2 of the study. (NCT02141295)
Timeframe: Cycle 8

InterventionRatio (Geometric Mean)
Safety Run-In1.51
Vanucizumab + mFOLFOX-61.63

[back to top]

Plasma Clearance at Steady State (CLss) of Vanucizumab

PK profile of vanucizumab was evaluated in terms of CLss, values are reported for cycle 8 of both part 1 (safety run-in) and part 2 of the study. (NCT02141295)
Timeframe: Cycle 8

Interventionml/hr (Geometric Mean)
Safety Run-In15.3
Vanucizumab + mFOLFOX-618.0

[back to top]

Plasma Terminal Half-Life (t1/2) of Vanucizumab

PK profile of vanucizumab was evaluated in terms of t1/2, values are reported for cycle 8 of both part 1 (safety run-in) and part 2 of the study. (NCT02141295)
Timeframe: Cycle 8

Interventionhr (Geometric Mean)
Safety Run-In202
Vanucizumab + mFOLFOX-6157

[back to top]

Progression-free Survival (PFS), Time to Event

Efficacy of vanucizumab was evaluated in terms of PFS as Investigator-Assessed Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1). PFS was defined as the time between randomization and the date of first documented disease progression or death from any cause on study, whichever occurred first. Death on study was defined as death from any cause within 30 days of the last study treatment. (NCT02141295)
Timeframe: Baseline, every 8 weeks, up to approximately 29 months

Interventiondays (Median)
Vanucizumab + mFOLFOX-6338.0
Bevacizumab + mFOLFOX-6309.0

[back to top]

Volume of Distribution at Steady State (Vss) of Vanucizumab

PK profile of vanucizumab was evaluated in terms of Vss, values are reported for cycle 8 of both part 1 (safety run-in) and part 2 of the study. (NCT02141295)
Timeframe: Cycle 8

Interventionml (Geometric Mean)
Safety Run-In4400
Vanucizumab + mFOLFOX-64140

[back to top]

Area Under the Plasma Concentration-Time Curve (AUC) of Vanucizumab

PK profile of vanucizumab was evaluated in terms of AUC (NCT02141295)
Timeframe: Cycles 1 and 8 of parts 1 and 2

,
Interventionhr*ug/ml (Geometric Mean)
Cycle 1Cycle 8
Safety Run-In73600112000
Vanucizumab + mFOLFOX-66350082100

[back to top]

Maximum Observed Plasma Concentration (Cmax) of Vanucizumab

PK profile of vanucizumab was evaluated in terms of Cmax (NCT02141295)
Timeframe: Cycles 1 and 8 of parts 1 and 2

,
Interventionug/ml (Geometric Mean)
Cycle 1Cycle 8
Safety Run-In463685
Vanucizumab + mFOLFOX-6500794

[back to top]

Minimum Observed Plasma Concentration (Clast) of Vanucizumab

PK profile of vanucizumab was evaluated in terms of Clast (NCT02141295)
Timeframe: Cycles 1 and 8 of parts 1 and 2

Interventionug/ml (Geometric Mean)
Cycle 1Cycle 8
Vanucizumab + mFOLFOX-6103361

[back to top]

Percentage of Participants With Adverse Events (AEs)

Safety is evaluated in terms of percentage of participants with at least one serious adverse event and percentage of participants with at least one adverse event. (NCT02141295)
Timeframe: Up to approximately 29 months

,,
InterventionPercentage of Participants (Number)
Serious Adverse eventsAdverse events
Bevacizumab + mFOLFOX-643.2100.0
Safety Run-In37.5100
Vanucizumab + mFOLFOX-649.5100.0

[back to top]

Disease Free Survival

Disease free survival is defined as the time from on study date to evidence of tumor recurrence or death from any cause. Patients who remained alive and disease free were censored at their date of last disease evaluation. (NCT02178709)
Timeframe: Up to 3 years

Interventionmonths (Median)
FOLFIRINOX8.6

[back to top]

Objective Response Rate (Percentage of Patients With Complete Response or Partial Response)

"Measured by RECIST v1.1 Complete response: Disappearance of all target lesions Partial response: At least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter~The percentage of patients with objective response and its 95% confidence interval will be provided." (NCT02178709)
Timeframe: Up to 4 months

Interventionpercentage of participants (Number)
FOLFIRINOX17.7

[back to top]

Disease Control Rate (Percentage of Patients With Complete Response, Partial Response, or Stable Disease)

"Measured by RECIST v1.1~Complete response: Disappearance of all target lesions Partial response: At least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter Stable disease: Neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum longest diameter since the treatment started~The percentage of patients with objective response and its 95% confidence interval will be provided." (NCT02178709)
Timeframe: Up to 4 months

Interventionpercentage of participants (Number)
FOLFIRINOX88.2

[back to top] [back to top]

Overall Survival

Overall survival was defined as the time from on study date to death due to any cause. Patients who remained alive were censored at their last known alive date. The Kaplan-Meier method was used to determine the median and 95% confidence interval. (NCT02178709)
Timeframe: Up to 4 years

Interventionmonths (Median)
FOLFIRINOX15.7

[back to top]

Percentage of Patients Who Successfully Underwent Surgery After Neoadjuvant FOLFIRINOX

The percentage of patients who successfully underwent surgery after neoadjuvant FOLFIRINOX and its 95% confidence interval will be provided. (NCT02178709)
Timeframe: Up to 4 months

Interventionpercentage of participants (Number)
FOLFIRINOX76.7

[back to top]

Percentage of Patients With Pathologic Complete Response

"Pathologic complete response was evaluated using MRI or CT and Evan's criteria for pathologic response following neoadjuvant therapy:~I: <10% to no tumor cells destroyed IIa: 10-50% of tumor cells destroyed IIb: 50-90% of tumor cells destroyed III: >90% of tumor cells destroyed IIIM: sizable pools of cellular mucin IV: No viable tumor cells (complete pathologic response) IVM: Acellular pools of mucin" (NCT02178709)
Timeframe: Up to 4 months

Interventionpercentage of participants (Number)
FOLFIRINOX0

[back to top]

Rate of R0 Resection

The percentage of patients with a final margin status of R0 after resection of their primary tumor and its 95% confidence interval will be provided. R0 resection indicates a microscopically margin-negative resection, in which no cancer cells seen microscopically at the primary tumor site. (NCT02178709)
Timeframe: Up to 4 months

Interventionpercentage of participants (Number)
FOLFIRINOX75.8

[back to top]

Peritoneal Recurrence Free Survival at 18 Months

Peritoneal recurrence-free survival at 18 months determined by CT and CEA. If CEA was normal and CT did not show any signs of peritoneal metastase at 18 months, a diagnostic laparoscopy was performed in those patients who consented to this intervention. Complete peritoneal staging was performed during laparoscopy, and biopsies were taken from suspicious lesions. If no peritoneal lesions were seen or biopsies were negative, this indicated that the patient was free from peritoneal recurrence. (NCT02231086)
Timeframe: 18 months

Interventionparticipants (Number)
Standard Adjuvant Systemic Chemotherapy79
Adjuvant HIPEC (Open/Laparoscopic)80

[back to top] [back to top]

Secondary Outcome Measure (Number of Adverse Events)

Number of adverse events caused from the administration of neoadjuvant concurrent LDFRT-FOLFOX while maintaining a high rate of pelvic R0 resection compared to standard preoperative chemoradiation and total mesorectal excision surgery. (NCT02319304)
Timeframe: 1 year

InterventionAdverse Events (Number)
Pelvic Radiotherapy With Concurrent Neoadjuvant FOLFOX7

[back to top]

Primary Outcome Measure (Overall Survival Rate)

Overall survival rate of patients who receive a neoadjuvant full dose FOLFOX plus the addition of concurrent LDFRT result in a pCR response rate of at least 35%. (NCT02319304)
Timeframe: 1 year

InterventionParticipants (Count of Participants)
Pelvic Radiotherapy With Concurrent Neoadjuvant FOLFOX3

[back to top]

Overall Survival (OS)

OS was defined as the time from the day of randomization (Day 0) until death by all causes. (NCT02337946)
Timeframe: Up to approximately 31 months

Interventionmonths (Median)
Group ANA
Group BNA

[back to top]

Response Rate (RR)

RR was defined as the percentage of participants who had shown complete response (CR) or partial response (PR) as the best overall response in accordance with the RECIST 1.1 criteria after randomization. The best overall response was CR, followed by PR, stable disease (SD), progressive disease (PD), and not evaluable (NE). CR: disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to <10 mm. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters as the best overall response after randomization., SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). (NCT02337946)
Timeframe: Up to approximately 31 months

Interventionpercentage of participants (Number)
Group A80.4
Group B87.7

[back to top]

Time to Treatment Failure (TTF)

TTF was defined as the time from the day of randomization (Day 0) until the day of protocol treatment discontinuation determination, the day of PD decision during protocol treatment, or death from any cause, whichever came the earliest. (NCT02337946)
Timeframe: Up to approximately 31 months

Interventionmonths (Median)
Group A8.1
Group B6.1

[back to top]

Percentage of Participants With Grade 3 or Higher Skin Toxicity

"Skin toxicity was defined as events classified with an system organ class of Skin and subcutaneous tissue disorders or a preferred term of paronychia." (NCT02337946)
Timeframe: Up to 28 days after discontinuation of study drug or start of subsequent therapy (data cut off: 31 August 2017; Overall study completion date)

,
Interventionpercentage of participants (Number)
Skin and subcutaneous tissue disordersParonychia
Group A17.97.1
Group B18.59.3

[back to top]

Percentage of Participants With Grade 2 or Higher Peripheral Neuropathy

"Peripheral neuropathy was defined as events classified with a preferred term (PT) of peripheral neuropathy according to Standardized MedDRA Queries." (NCT02337946)
Timeframe: Up to 28 days after discontinuation of study drug or start of subsequent therapy (data cut off: 31 August 2017; Overall study completion date)

Interventionpercentage of participants (Number)
Group A30.4
Group B3.7

[back to top]

Percentage of Participants With Adverse Events

Safety population was defined as all participants who received at least one dose of protocol treatment after randomization. (NCT02337946)
Timeframe: Up to 28 days after discontinuation of study drug or start of subsequent therapy (data cut off: 31 August 2017; Overall study completion date)

Interventionpercentage of participants (Number)
Group A100
Group B100

[back to top]

Progression-Free Survival (PFS)

The PFS is the period from the date of randomization (Day 0) until the date of judgment of progression from the date of randomization, or until death by all causes, whichever comes first. The presence/absence of progressive disease (PD) was determined based on imaging, consideration of clinical PD, or survival research results. PD based on response evaluation criteria in solid tumors (RECIST) is at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (NCT02337946)
Timeframe: Up to approximately 31 months

Interventionmonths (Median)
Group A9.1
Group B9.3

[back to top]

Percentage of Participants With Adverse Events by Severity Graded Using the Common Terminology Criteria for Adverse Events (CTCAE) Grade

An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medical treatment or procedure that may or may not be considered related to the medical treatment or procedure. Grade refers to the severity of the AE. The CTCAE displays Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL). Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL. Grade 4 Life-threatening consequences; urgent intervention indicated. Grade 5 Death related to AE. (NCT02337946)
Timeframe: Up to 28 days after discontinuation of study drug or start of subsequent therapy (data cut off: 31 August 2017; Overall study completion date)

,
Interventionpercentage of participants (Number)
Grade 1Grade 2Grade 3, 4 and 5
Group A019.680.4
Group B027.872.2

[back to top]

Progression-Free Survival Rate (PFS Rate) at 9 Months After Randomization

PFS rate was defined as the gross percentage of participants who survived with no evidence of progression from the day of randomization (Day 0) until 9 months after Day 0. The presence/absence of progressive disease (PD) was determined based on imaging, consideration of clinical PD, or survival research results. PD based on response evaluation criteria in solid tumors (RECIST) is at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (NCT02337946)
Timeframe: Up to 9 months after randomization

Interventionpercentage of participants (Number)
Group A46.4
Group B47.4

[back to top]

Number of Patients Reporting Adverse Events (AEs)

The safety and tolerability of the study therapy were assessed by means of AEs and changes in laboratory data. AEs were coded and evaluated using the NCI-CTCAE v4.0 toxicity criteria (if NCI-CTCAE are not applicable, MedDRA was used). (NCT02340949)
Timeframe: From baseline until 2 years and 2 months

InterventionParticipants (Count of Participants)
At least one AE71941053At least one AE71941054At least one Grade 3-4 AE71941054At least one Grade 3-4 AE71941053At least one AE that lead to treatment discontinuation71941054At least one AE that lead to treatment discontinuation71941053At least one AE that lead to death71941054At least one AE that lead to death71941053At least one Serious Adverse Event (SAE)71941054At least one Serious Adverse Event (SAE)71941053At least one treatment-related AE71941053At least one treatment-related AE71941054At least one treatment-related AE Grade 3-471941054At least one treatment-related AE Grade 3-471941053At least one treatment-related AE that led to death71941053At least one treatment-related AE that led to death71941054At least one treatment-related AE that led to permanent treatment discontinuation71941054At least one treatment-related AE that led to permanent treatment discontinuation71941053At least one treatment-related Serious Adverse Event (SAE)71941054At least one treatment-related Serious Adverse Event (SAE)71941053
YesNo
mFOLFOX6 + Aflibercept83
mFOLFOX631
mFOLFOX6 + Aflibercept32
mFOLFOX634
mFOLFOX6 + Aflibercept20
mFOLFOX64
mFOLFOX6 + Aflibercept95
mFOLFOX661
mFOLFOX6 + Aflibercept3
mFOLFOX6 + Aflibercept112
mFOLFOX6 + Aflibercept45
mFOLFOX616
mFOLFOX6 + Aflibercept70
mFOLFOX649
mFOLFOX6 + Aflibercept105
mFOLFOX659
mFOLFOX6 + Aflibercept10
mFOLFOX66
mFOLFOX6 + Aflibercept64
mFOLFOX617
mFOLFOX6 + Aflibercept51
mFOLFOX648
mFOLFOX6 + Aflibercept0
mFOLFOX60
mFOLFOX6 + Aflibercept115
mFOLFOX665
mFOLFOX6 + Aflibercept17
mFOLFOX63
mFOLFOX6 + Aflibercept98
mFOLFOX662
mFOLFOX6 + Aflibercept25
mFOLFOX6 + Aflibercept90

[back to top]

Disease Free Survival (DFS) Rate at 3 Years

DFS rate is defined as the percentage of participants without local recurrences at 3-years post study treatment. Here we report the DFS rate at 3-years after completing the Study treatment. (NCT02340949)
Timeframe: At 3 years after study treatment completion, within a general time frame of 5 years and two months

Interventionpercentage of participants (Number)
mFOLFOX6 + Aflibercept75.2
mFOLFOX681.5

[back to top]

Number of Patients Reporting Surgical Complications

Surgical complications will be assessed by means of AEs reported during 30 days post surgery. (NCT02340949)
Timeframe: From surgical intervention up to 30 days post-surgery, within a general time frame of 2 years and 2 months per study protocol

InterventionParticipants (Count of Participants)
Postoperative AEs71941053Postoperative AEs71941054Postoperative AEs Grade 3-471941053Postoperative AEs Grade 3-471941054Complications71941053Complications71941054Anastomosis fistula71941054Anastomosis fistula71941053wound infection71941053wound infection71941054intraabdominal infection71941053intraabdominal infection71941054Stoma complications71941053Stoma complications71941054Reoperation71941053Reoperation71941054
YesNo
mFOLFOX6 + Aflibercept3
mFOLFOX6 + Aflibercept112
mFOLFOX6 + Aflibercept2
mFOLFOX60
mFOLFOX6 + Aflibercept113
mFOLFOX6 + Aflibercept60
mFOLFOX630
mFOLFOX6 + Aflibercept55
mFOLFOX635
mFOLFOX6 + Aflibercept4
mFOLFOX6 + Aflibercept111
mFOLFOX6 + Aflibercept5
mFOLFOX6 + Aflibercept110
mFOLFOX6 + Aflibercept10
mFOLFOX61
mFOLFOX6 + Aflibercept105
mFOLFOX664
mFOLFOX665
mFOLFOX6 + Aflibercept9
mFOLFOX65
mFOLFOX6 + Aflibercept106
mFOLFOX660

[back to top]

Number of Patients Achieving Pathological Parameters of Efficacy: R0 Resection, Tumor Regression Grade, and Circular Radial Margin Rate

"R0 resection is defined as complete tumor removal, and correlates with good prognosis.~Tumor regression grade (TRG) is defined as presence of residual tumor after preoperative therapy. This was assessed by magnetic resonance imaging (MRI) according to the 5-point regression grading scale established by Mandard: TRG1 (complete response with no residual cancer), TRG2 (rare residual cancer), TRG3 (fibrosis outgrowing residual cancer), TRG4 (residual cancer outgrowing fibrosis) and TRG5 (absence of regression).~Circular Radial Margin (CRM) is defined as the distance from the margin of normal tissue to the edge of tumor tissue in the resected primary tumor the measured by histopathology study after surgery. A margin of ≤1 mm is considered to be a negative prognostic factor for local recurrence." (NCT02340949)
Timeframe: From baseline until 2 years and 2 months

InterventionParticipants (Count of Participants)
R0 rate71941053R0 rate71941054TRG1-271941053TRG1-271941054CRM ≤ 171941053CRM ≤ 171941054
Not availableYesNo
mFOLFOX6 + Aflibercept101
mFOLFOX660
mFOLFOX6 + Aflibercept2
mFOLFOX62
mFOLFOX6 + Aflibercept12
mFOLFOX6 + Aflibercept59
mFOLFOX630
mFOLFOX6 + Aflibercept56
mFOLFOX635
mFOLFOX6 + Aflibercept0
mFOLFOX60
mFOLFOX6 + Aflibercept3
mFOLFOX63
mFOLFOX6 + Aflibercept96
mFOLFOX656
mFOLFOX6 + Aflibercept16
mFOLFOX66

[back to top]

The Number of Patients With Tumor Size Reduction (Objective Response Rate)

Objective response rate is the sum of partial responses plus complete responses and will be assessed per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions. (NCT02358863)
Timeframe: 1 year

InterventionParticipants (Count of Participants)
Chemotherapy0

[back to top]

ACR Numeric (N) Index (ACRn) at Week 24

ACRn is defined as the lowest % improvement for TJC68, SJC66 and the median of 5 ACR components. These are • Patient's Assessment of Pain over previous 24 hours using a VAS; left end of line 0=no pain to right end of line 100=unbearable pain • Patient's Global Assessment of Disease Activity • Physician's Global Assessment of Disease Activity over previous 24 hours using a VAS where left end of line 0=no disease activity to right end of line 100=maximum disease activity • Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do • Acute-phase reactant: CRP. A positive % change indicates improvement. MMRM model with main effects for study site, treatment, visit, and previously failed medication with interactions between visit and treatment and visit and previously failed medication and participant used as a random effect with an unstructured covariance structure. (NCT02379091)
Timeframe: Baseline and Week 24

Interventionpercentage change (Mean)
Placebo34.04
Namilumab 20 mg/mL35.35
Namilumab 80 mg/mL44.66
Namilumab 150 mg/mL36.57

[back to top]

Change From Baseline in DAS28-CRP at Week 24

The DAS28-CRP score is a measure of the participant's disease activity calculated using the tender joint count (TJC) [28 joints], swollen joint count (SJC) [28 joints], general health: patient's global assessment of disease activity [visual analog scale: 0=no disease activity to 100=maximum disease activity] and acute phase response: C-Reactive Protein (CRP) for a total possible score of 0 (best) to approximately 10 (worst). Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. A negative change from Baseline indicates improvement. (NCT02379091)
Timeframe: Baseline and Week 24

Interventionscore on a scale (Mean)
Placebo-1.75
Namilumab 20 mg/mL-2.37
Namilumab 80 mg/mL-2.20
Namilumab 150 mg/mL-2.26

[back to top]

ACR Numeric (N) Index (ACRn) at Week 12

ACRn is defined as the lowest % improvement for TJC68, SJC66 and the median of 5 ACR components. These are • Patient's Assessment of Pain over previous 24 hours using a VAS; left end of line 0=no pain to right end of line 100=unbearable pain • Patient's Global Assessment of Disease Activity • Physician's Global Assessment of Disease Activity over previous 24 hours using a VAS where left end of line 0=no disease activity to right end of line 100=maximum disease activity • Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do • Acute-phase reactant: CRP. A positive % change indicates improvement. MMRM model with main effects for study site, treatment, visit, and previously failed medication with interactions between visit and treatment and visit and previously failed medication and participant used as a random effect with an unstructured covariance structure. (NCT02379091)
Timeframe: Baseline and Week 12

Interventionpercentage change (Least Squares Mean)
Placebo-17.25
Namilumab 20 mg/mL3.97
Namilumab 80 mg/mL19.68
Namilumab 150 mg/mL17.14

[back to top]

Change From Baseline in Disease Activity Score 28 C-Reactive Protein (DAS28-CRP) at Week 12

The DAS28-CRP score is a measure of the participant's disease activity calculated using the tender joint count (TJC) [28 joints], swollen joint count (SJC) [28 joints], general health: patient's global assessment of disease activity [visual analog scale: 0=no disease activity to 100=maximum disease activity] and acute phase response: C-Reactive Protein (CRP) for a total possible score of 0 (best) to approximately 10 (worst). Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. A negative change from Baseline indicates improvement. A mixed model repeated measures (MMRM) model with main effects for study site, treatment, visit, and previously failed medication with interactions between visit and treatment, visit and previously failed medication, and visit and baseline value as a covariate and participant as a random effect with an unstructured covariance structure was used for analysis. (NCT02379091)
Timeframe: Baseline and Week 12

Interventionscore on a scale (Least Squares Mean)
Placebo-0.77
Namilumab 20 mg/mL-1.38
Namilumab 80 mg/mL-1.36
Namilumab 150 mg/mL-1.69

[back to top]

Change From Baseline in DAS28-CRP at Weeks 2, 6, and 10

The DAS28-CRP score is a measure of the participant's disease activity calculated using the tender joint count (TJC) [28 joints], swollen joint count (SJC) [28 joints], general health: patient's global assessment of disease activity [visual analog scale: 0=no disease activity to 100=maximum disease activity] and acute phase response: C-Reactive Protein (CRP) for a total possible score of 0 (best) to approximately 10 (worst). Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. A negative change from Baseline indicates improvement. A MMRM model with main effects for study site, treatment, visit, and previously failed medication with interactions between visit and treatment, visit and previously failed medication, and visit and baseline value as a covariate and participant as a random effect with an unstructured covariance structure was used for analysis. (NCT02379091)
Timeframe: Baseline and Weeks 2, 6 and 10

,,,
Interventionscore on a scale (Least Squares Mean)
Change at Week 2Change at Week 6Change at Week 10
Namilumab 150 mg/mL-0.95-1.42-1.51
Namilumab 20 mg/mL-0.58-1.13-1.19
Namilumab 80 mg/mL-0.84-1.37-1.39
Placebo-0.33-0.70-0.75

[back to top]

Percentage of Participants Achieving American College of Rheumatology 20% (ACR20), 50% (ACR 50) and 70% (ACR70) Response at Weeks 12 and 24

"ACR20/50/70 response is defined as a ≥20/50/70% reduction from Baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), and the following:~Patient's Assessment of Pain over the previous 24 hours using a Visual Analog Scale (VAS); left end of the line 0=no pain to right end of the line 100=unbearable pain~Patient's Global Assessment of Disease Activity~Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity~Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do~Acute-phase reactant: C-reactive Protein (CRP)." (NCT02379091)
Timeframe: Baseline and Weeks 12 and 24

,,,
Interventionpercentage of participants (Number)
ACR 20, Week 12ACR 50, Week 12ACR 70, Week 12ACR 20, Week 24ACR 50, Week 24ACR 70, Week 24
Namilumab 150 mg/mL53.838.515.456.036.020.0
Namilumab 20 mg/mL72.020.04.065.234.813.0
Namilumab 80 mg/mL52.230.421.747.847.830.4
Placebo37.516.78.333.323.819.0

[back to top]

Percentage of Participants With a Reduction of Pain as Measured Using a Visual Analog Scale (VAS) at Weeks 2, 12 and 24

Reduction of Pain, defined as a ≥40% change from Baseline as measured using a 100 mm Visual Analog Scale (VAS); left end of the line 0=no pain to right end of the line 100=unbearable pain at weeks 2, 12 and 24. (NCT02379091)
Timeframe: Baseline and Week 2, 12 and 24

,,,
Interventionpercentage of participants (Number)
Week 2Week 12Week 24
Namilumab 150 mg/mL3.630.824.0
Namilumab 20 mg/mL14.344.043.5
Namilumab 80 mg/mL8.739.147.8
Placebo7.720.822.7

[back to top]

Numbers of Patients With Dose Limiting Toxicities

"Primary objective is the determination of the maximum tolerated dose (MTD) of selinexor in combination with mFOLFOX6 in patients with metastatic colorectal cancer.~Criteria to assess MTD was the experience of AEs > grade 3, discontinuation from study treatment due to adverse events or withdrawal of consent by the patients." (NCT02384850)
Timeframe: 28 days of treatment

,
InterventionParticipants (Count of Participants)
Discontinuation due to Adverse eventsDiscontinuation due to Withdrawal of ConsentDiscontinuation due to Progressive Disease
Selinexor 20mg + mFOLFOX6222
Selinexor 40 mg+ mFOLFOX6220

[back to top]

Number of Patients Experiencing Adverse Events

"Secondary objectives are to determine the efficacy and tolerability of selinexor in combination with mFOLFOX6 in patients with metastatic colorectal cancer by~- Toxicity (acc. to NCI Common Terminology Criteria for Adverse Events (CTC AE) v4.03)" (NCT02384850)
Timeframe: treatment start to up to 30 days after last dose

,
InterventionParticipants (Count of Participants)
Patients with AEs of any CTCAE GradePatients with AEs of at least CTCAE Grade 3Patients with Selinexor related AEs of any GradePatients with Selinexor related AEs of at least Grade 3Patients with chemotherapy related AEs of any GradePatients with chemotherapy related AEs of at least Grade 3Patients with AEs leading to discontinuationPatients with at least 1 SAEPatients with at least 1 SAE related to SelinexorPatients with at least 1 SAE related to chemotherapy
Selinexor 20mg + mFOLFOX66645632313
Selinexor 40 mg+ mFOLFOX64444442211

[back to top]

Progression Free Survival (PFS)

"Secondary objectives are to determine the efficacy and tolerability of selinexor in combination with mFOLFOX6 in patients with metastatic colorectal cancer by~- Progression free survival (PFS) The disease status was measured by CT/MRI and evaluated according to RECIST 1.1 criteria every 8 weeks during treatment, at End of Treatment and every 3 weeks during Follow-up to determine time until patient has Progressive Disease (PD). PD is defined according to RECIST v1.1 at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression." (NCT02384850)
Timeframe: 2 years

Interventionmonths (Mean)
Selinexor 40 mg+ mFOLFOX6NA
Selinexor 20mg + mFOLFOX6NA

[back to top]

Number of Patients Still Alive at End of Study (Overall Survival)

"Secondary objectives are to determine the efficacy and tolerability of selinexor in combination with mFOLFOX6 in patients with metastatic colorectal cancer by~- Overall survival (OS)~Overall survial is defined as length of time from start of treatment that patients are still alive. For this time-to-event variables the Kaplan-Meier method was intended to be used" (NCT02384850)
Timeframe: 2 years

InterventionParticipants (Count of Participants)
Selinexor 40 mg+ mFOLFOX60
Selinexor 20mg + mFOLFOX62

[back to top]

Overall Response Rate

"Secondary objectives are to determine the efficacy and tolerability of selinexor in combination with mFOLFOX6 in patients with metastatic colorectal cancer by~- Overall response rate (RR) (acc. to RECIST v1.1)~Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed byCT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR." (NCT02384850)
Timeframe: 2 years

InterventionParticipants (Count of Participants)
Selinexor 40 mg+ mFOLFOX60
Selinexor 20mg + mFOLFOX61

[back to top]

Progression-Free Survival (PFS) in All Participants

PFS was defined as the time from the date of randomization to the earlier of Progressive Disease (PD) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 or death due to any cause. (NCT02394795)
Timeframe: Up to approximately 60 months

InterventionMonths (Median)
Group P; mFOLFOX6 + Panitumumab Combination Therapy12.91
Group B; mFOLFOX6 + Bevacizumab Combination Therapy11.99

[back to top]

Progression-Free Survival (PFS) in Participants With Left-sided Tumors

PFS was defined as the time from the date of randomization to the earlier of Progressive Disease (PD) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 or death due to any cause. The left-sided tumors were defined as primary tumors occupying a left-sided site include the descending colon, sigmoid colon, and rectum. (NCT02394795)
Timeframe: Up to approximately 60 months

InterventionMonths (Median)
Group P; mFOLFOX6 + Panitumumab Combination Therapy13.70
Group B; mFOLFOX6 + Bevacizumab Combination Therapy13.24

[back to top]

Duration of Response (DOR)

DOR means that the period from the day when either CR or PR is first confirmed until the day of documented PD or the day of death due to all causes, whichever occurs earlier. (NCT02394795)
Timeframe: Up to approximately 60 months

InterventionMonths (Median)
Group P; mFOLFOX6 + Panitumumab Combination Therapy11.86
Group B; mFOLFOX6 + Bevacizumab Combination Therapy10.74

[back to top]

Number of Participants With Treatment-emergent Adverse Events (TEAE)

Adverse event (AE) was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have a causal relationship with this treatment. A TEAE was defined as an adverse event with an onset that occurred in the treatment period after receiving the protocol treatment. (NCT02394795)
Timeframe: Up to approximately 60 months

InterventionParticipants (Count of Participants)
Group P; mFOLFOX6 + Panitumumab Combination Therapy402
Group B; mFOLFOX6 + Bevacizumab Combination Therapy398

[back to top]

Overall Survival (OS) in All Participants

OS was measured as the time from the date of randomization to the date of death due to any cause. (NCT02394795)
Timeframe: Up to approximately 60 months

InterventionMonths (Median)
Group P; mFOLFOX6 + Panitumumab Combination Therapy36.24
Group B; mFOLFOX6 + Bevacizumab Combination Therapy31.28

[back to top]

OS in Participants With Left-sided Tumors

OS was measured as the time from the date of randomization to the date of death due to any cause. The left-sided tumors were defined as primary tumors occupying a left-sided site include the descending colon, sigmoid colon, and rectum. (NCT02394795)
Timeframe: Up to approximately 60 months

InterventionMonths (Median)
Group P; mFOLFOX6 + Panitumumab Combination Therapy37.85
Group B; mFOLFOX6 + Bevacizumab Combination Therapy34.30

[back to top]

Number of Participants Treated With Curative Surgical Resection After Chemotherapy

Curative surgical resection was defined as complete resection. (NCT02394795)
Timeframe: Up to approximately 60 months

InterventionParticipants (Count of Participants)
Group P; mFOLFOX6 + Panitumumab Combination Therapy66
Group B; mFOLFOX6 + Bevacizumab Combination Therapy44

[back to top]

Overall Survival

Time from date of treatment start until date of death due to any cause or last Follow-up. (NCT02420717)
Timeframe: Up to 4 years 7 months

InterventionMonths (Median)
Phase I Ruxolitinib 15mg4.8
Phase I Ruxolitinib 20mg5.4
Phase I Ruxolitinib 25mg38.5

[back to top]

Participants With Complete Response (Complete Response [CR]/CR With Incomplete Marrow Recovery [CRi]) (Phase II)

Complete Response (CR) is disappearance of all clinical and/or radiologic evidence of disease, Neutrophil count ≥ 1.0 x 10^9/L, Platelet count ≥ 100 x 10^9/L, Normal bone marrow differential (≤ 5% blasts), No extra-medullary leukemia. Complete Remission with Incomplete Blood Count Recovery (CRi) is CR except for ANC < 1.0 x 10^9/L and/or platelets < 100 x 10^9/L. (NCT02420717)
Timeframe: 42 days

InterventionParticipants (Count of Participants)
Phase I Ruxolitinib 15mg0
Phase I Ruxolitinib 20mg1
Phase I Ruxolitinib 25mg0

[back to top]

Progression-free Survival

Time from date of treatment start until the date of first objective documentation of disease-relapse. (NCT02420717)
Timeframe: Up to 4 years 7 months

InterventionMonths (Median)
Phase I Ruxolitinib 15mg2.3
Phase I Ruxolitinib 20mg1.8
Phase I Ruxolitinib 25mg1.9

[back to top]

Maximal Tolerated Dose (MTD) of Ruxolitinib in Combination With Chemotherapy Defined as the Highest Dose Level at Which no More Than 1 Out of 6 Patients Experience a Dose Limiting Toxicity (Phase I)

The method of Thall, Simon and Estey will be used for toxicity monitoring for this study. The severity of the toxicities will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 whenever possible. Safety data will be summarized by category, severity and frequency. (NCT02420717)
Timeframe: 42 days

InterventionMilligrams (mg) (Number)
Phase I Ruxolitinib 15mg25

[back to top]

4-month Progression-free Survival (PFS) Rate

PFS is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first. Will be estimated using the product-limit method of Kaplan and Meier. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum on study (including baseline sum), or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT02508077)
Timeframe: At 4 months

Interventionpercentage of participants (Number)
Treatment (Panitumumab and FOLFIRI)0

[back to top]

Objective Response Rate (ORR)

ORR was defined as the percentage of participants who achieve a complete response (CR) or partial response (PR) as assessed by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1. CR was defined as the disappearance of all target lesions and disappearance of all non-target lesions and normalization of tumor marker level. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. (NCT02545504)
Timeframe: Up to 135.4 weeks at the time of final analysis

Interventionpercentage of participants (Number)
Andecaliximab + mFOLFOX650.5
Placebo + mFOLFOX641.1

[back to top]

Percentage of Participants With Clinically Relevant Treatment-emergent Laboratory Abnormalities

Treatment-emergent laboratory abnormalities were graded per Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03 where 0=None, 1=Mild, 2=Moderate, 3=Severe, 4=Potentially Life Threatening. Treatment-emergent laboratory abnormalities are defined as values that increase at least 1 toxicity grade from baseline at any post-baseline time point, up to 30 days after the last dose of all study treatment, or 55 days after the last dose of andecaliximab/placebo for participants who permanently discontinued all study treatments. If the relevant baseline laboratory value is missing, then any abnormality of at least Grade 1 was considered treatment-emergent. (NCT02545504)
Timeframe: First dose date up to the last dose date (maximum: 161.7 weeks) plus 30 to 55 days

,
Interventionpercentage of participants (Number)
HematologySerum ChemistryCoagulation
Andecaliximab + mFOLFOX694.491.77.4
Placebo + mFOLFOX689.592.93.3

[back to top]

Progression-free Survival (PFS)

PFS was defined as the interval of time from the date of randomization to the earlier of the first documentation of definitive disease progression or death from any cause. (NCT02545504)
Timeframe: Andecaliximab + mFOLFOX6 median follow-up at the time of the final analysis: 18.64 months; Placebo + mFOLFOX6 median follow-up at the time of the final analysis: 18.74 months

Interventionmonths (Median)
Andecaliximab + mFOLFOX67.46
Placebo + mFOLFOX67.06

[back to top]

Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)

An adverse event (AE) is any untoward medical occurrence in a clinical study participant administered a medicinal product, which does not necessarily have a causal relationship with the treatment. TEAEs are events in a given study period that meet any of the following criteria: Any AE with onset date of on or after andecalizimab/placebo start date and no later than 30 days after permanent discontinuation of all study treatment (andecaliximab/placebo and chemotherapy) or Any AEs with onset date of on or after the andecaliximab/placebo start date and no later than 55 days after permanent discontinuation of andecaliximab/placebo or AEs leading to discontinuation of andecaliximab/placebo. (NCT02545504)
Timeframe: First dose date up to the last dose date (maximum:161.7 weeks) plus 30 to 55 days

Interventionpercentage of participants (Number)
Andecaliximab + mFOLFOX699.1
Placebo + mFOLFOX699.5

[back to top]

Overall Survival (OS)

OS was defined as the time interval from the date of randomization to death from any cause. (NCT02545504)
Timeframe: Andecaliximab + mFOLFOX6 median follow-up at the time of final analysis: 19.43 months; Placebo + mFOLFOX6 median follow-up at the time of the final analysis: 19.45 months

Interventionmonths (Median)
Andecaliximab + mFOLFOX612.52
Placebo + mFOLFOX611.76

[back to top]

Median Overall Survival (OS)

The OS was the time from date of first study treatment to the date of death from any cause. Participant survival data were collected from all available sources. The OS was calculated using Kaplan-Meier technique. (NCT02551991)
Timeframe: RECIST assessments performed at baseline (within 28 days before start of study treatment), every 8 weeks after first dose, EoT visit, then every 2 months thereafter (maximum of 278 weeks).

Interventionmonths (Median)
Dose Exploration: Cohort 112.6
Dose Exploration: Cohort -112.5
Dose Exploration: Cohort -2B16.6
Dose Exploration: Cohort -35.8
Dose Expansion: Cohort -112.7
Cohort -1: Pooled12.6

[back to top]

Median Progression Free Survival (PFS)

The PFS was defined as the time from date of first study treatment to the first documented radiographical progression of disease (PD), per investigator using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1, or death from any cause, whichever comes first. The PFS was calculated using Kaplan-Meier technique. (NCT02551991)
Timeframe: RECIST assessments performed at baseline (within 28 days before start of study treatment), every 8 weeks after first dose, end of treatment (EoT) visit, then every 2 months thereafter (maximum of 278 weeks).

Interventionmonths (Median)
Dose Exploration: Cohort 19.7
Dose Exploration: Cohort -132.3
Dose Exploration: Cohort -2B9.2
Dose Exploration: Cohort -33.8
Dose Expansion: Cohort -19.2
Cohort -1: Pooled9.2

[back to top]

Overall Response Rate (ORR)

The ORR was defined as the percentage of participants with a BOR characterized as either a CR or PR relative to the total number of evaluable participants using RECIST Version 1.1. Evaluable participants were defined as treated participants with measurable disease at baseline. (NCT02551991)
Timeframe: RECIST assessments performed at baseline (within 28 days before start of study treatment), every 8 weeks after first dose, EoT visit, then every 2 months thereafter (maximum of 278 weeks).

Interventionpercentage of participants (Number)
Dose Exploration: Cohort 10
Dose Exploration: Cohort -142.9
Dose Exploration: Cohort -2B30.0
Dose Exploration: Cohort -314.3
Dose Expansion: Cohort -132.0
Cohort -1: Pooled34.4

[back to top]

Median Duration of Response (DoR)

The DoR was defined as the time from the first date of response (CR or PR) to first date of documented radiographical PD, per investigator using RECIST Version 1.1. This only applied to participants with CR or PR. If a participant was given a new anticancer therapy prior to first response, DoR was not calculated. The DoR was calculated using Kaplan-Meier technique. (NCT02551991)
Timeframe: RECIST assessments performed at baseline (within 28 days before start of study treatment), every 8 weeks after first dose, EoT visit, then every 2 months thereafter (maximum of 278 weeks).

Interventionmonths (Median)
Dose Exploration: Cohort -128.4
Dose Exploration: Cohort -2BNA
Dose Expansion: Cohort -19.4
Cohort -1: Pooled9.4

[back to top]

Part 1A: Number of Participants With Dose-Limiting Toxicities (DLT)

Adverse events (AEs) were considered to be DLTs if they occurred during the safety evaluation period (i.e, 28 days of Cycle 1; or 14 days after the second dose of study treatment if there was a treatment delay) and were deemed related to the study treatment regimen. Any AE that was related to disease progression was not considered a DLT. (NCT02551991)
Timeframe: From the start of the first study treatment (Cycle 1 Day 1) up to 14 days after the second dose of study treatment, maximum of 42 days

InterventionParticipants (Count of Participants)
Dose Exploration: Cohort 12
Dose Exploration: Cohort -11
Dose Exploration: Cohort -2B2
Dose Exploration: Cohort -30

[back to top]

Disease Control Rate (DCR)

The DCR was defined as percentage of participants with CR or PR or SD or Non-PD/Non-CR, per RECIST Version 1.1 relative to total number of treated participants with measurable disease at baseline. (NCT02551991)
Timeframe: At Week 16

Interventionpercentage of participants (Number)
Dose Exploration: Cohort 142.9
Dose Exploration: Cohort -171.4
Dose Exploration: Cohort -2B40.0
Dose Exploration: Cohort -328.6
Dose Expansion: Cohort -172.0
Cohort -1: Pooled71.9

[back to top]

Best Overall Response (BOR)

The BOR was defined as the best response (complete response [CR] + partial response [PR] + stable disease [SD]) recorded from the start of study treatment until disease progression or start of new anticancer therapy using RECIST Version 1.1. (NCT02551991)
Timeframe: RECIST assessments performed at baseline (within 28 days before start of study treatment), every 8 weeks after first dose, EoT visit, then every 2 months thereafter (maximum of 278 weeks).

InterventionParticipants (Count of Participants)
Dose Exploration: Cohort 12
Dose Exploration: Cohort -16
Dose Exploration: Cohort -2B4
Dose Exploration: Cohort -34
Dose Expansion: Cohort -120
Cohort -1: Pooled26

[back to top] [back to top]

Number of Participants With Adverse Events (AEs) by Nature, Severity, and Occurrence Measured From Baseline to End of Trial Participation, as Assessed by the Common Terminology Criteria for AEs (Version 4.03) (CTCAE v4.03).

AEs were coded according to the Medical Dictionary for Regulatory Activities (MedDRA) classification. The incidence and type of AEs (e.g., treatment-emergent AE [TEAE]) were summarized according to MedDRA system organ classes and preferred terms. An AE was considered as treatment-emergent if it occurred after the first treatment administration. (NCT02568046)
Timeframe: 15 months

,
InterventionParticipants (Count of Participants)
At least 1 TEAEAt least 1 Serious TEAEAt least 1 Serious TEAE related to Sym004 onlyAt least 1 TEAE leading to Sym004 dose reductionAt least 1 TEAE leading to interruption of Sym004At least 1 TEAE leading to Sym004 withdrawalAt least 1 TEAE leading to FOLFIRI withdrawalAt least 1 TEAE leading to trial terminationAt least 1 TEAE related to Sym004 + FOLFIRIAt least 1 TEAE related to Sym004 onlyAt least 1 TEAE related to FOLFIRI onlyAt least 1 TEAE Grade ≥3 related to Sym004+FOLFIRIAt least 1 TEAE Grade ≥ 3 related to Sym004 onlyAt least 1 TEAE Grade ≥ 3 related to FOLFIRI onlyAt least 1 dermatologic toxicityAt least 1 TEAE of hypomagnesaemiaAt least 1 Infusion related reaction TEAEAt least 1 TEAE resulting in death
Dose Level -1: Sym004 9 mg/kg + FOLFIRI520252213542215030
Dose Level 1: Sym004 12 mg/kg + FOLFIRI530132104442013330

[back to top]

Response Rate of FOLFOX-A for Patients With Locally Advanced Pancreatic Cancer.

(NCT02578732)
Timeframe: From date of start of treatment, until the date of first documented progression, whichever came first, assessed up to 3 years

InterventionParticipants (Count of Participants)
Complete ResponsePartial ResponseStable DiseaseProgressive Disease
FOLFOXA012124

[back to top]

Overall Survival for Patients With Locally Advanced Pancreatic Cancer Treated With FOLFOX-A

(NCT02578732)
Timeframe: During treatment (approximately every 2 weeks for up to 6 months), then approximately every 4 months for for a maximum of 5 years

Interventionmonths (Mean)
FOLFOXA12.3

[back to top]

Progression Free Survival (PFS)

Descriptive statistics (point and exact 90% confidence interval estimates from the resultant Kaplan-Meier curve) will be generated for PFS. The median PFS will be estimated on an intention-to-treat basis (using all registered patients), and on a response-evaluable basis (using all patients who completed all BAT infusions) using the Kaplan-Meier method. (NCT02620865)
Timeframe: Up to 18 months

InterventionYears (Median)
Treatment (Anti-CD3 x Anti-EGFR BATs)0.934

[back to top]

Incidence of Toxicity (CTCAE Version 4.0)

Toxicity rates will be estimated using all treated patients. (NCT02620865)
Timeframe: Up to 18 months

InterventionParticipants (Count of Participants)
AnorexiaAnxietyChillsDepressionDiarrheaDizzinessDry MouthFatigueFeverGastroesophageal reflux diseaseHeadacheMyalgiaNauseaRash maculo-papularVomiting
Treatment (Anti-CD3 x Anti-EGFR BATs)112121122121221

[back to top]

Median Overall Survival (OS)

Descriptive statistics (point and exact 90% confidence interval estimates from the resultant Kaplan-Meier curve) will be generated for OS. The median OS will be estimated on an intention-to-treat basis (using all registered patients), and on a response-evaluable basis (using all patients who completed all BAT infusions) using the Kaplan-Meier method. (NCT02620865)
Timeframe: Up to 18 months

Interventionyears (Median)
Treatment (Anti-CD3 x Anti-EGFR BATs)0.934

[back to top]

Change From Baseline in European Quality of Life 5-dimensions Health Outcome Questionnaire Through Visual Analogue Scale up to Safety Follow-up (Up to 152.3 Weeks)

EQ-5D-5L is comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive overall score using a visual analog scale (VAS) that ranged from 0 to 100 millimeter (mm), where 0 is the worst health you can imagine and 100 is the best health you can imagine. (NCT02625610)
Timeframe: Baseline, Week 3/4, Week 7, Week 13, Week 19, Week 25, Week 31, Week 37, Week 43, Week 49, Week 55, Week 61, Week 67, End of Treatment ( EOT up to 148 weeks) and Safety Follow-up (Up to 152.3 Weeks)

,
InterventionMillimeter (Mean)
Week 3/4Week 7Week 13Week 19Week 25Week 31Week 37Week 43Week 49Week 55Week 61Week 67End Of TreatmentSafety Follow-Up
Avelumab0.6-2.1-0.7-0.1-1.41.40.93.22.13.43.54.9-10.3-9.6
Chemotherapy + Best Supportive Care (BSC)0.9-0.5-3.2-3.5-4.5-2.3-1.7-4.4-2.9-9.4-6.4-7.3-12.2-8.0

[back to top]

Overall Survival (OS)

Overall Survival was defined as the time from randomization to the date of death due to any cause. For participants who were still alive at the time of data analysis or who were lost to follow-up, OS time was censored at the date of last contact. OS was measured using Kaplan-Meier (KM) estimates. (NCT02625610)
Timeframe: From randomization into maintenance phase up to 1276 days

Interventionmonths (Median)
Chemotherapy + Best Supportive Care (BSC)10.9
Avelumab10.4

[back to top]

Objective Response Rate (ORR) by Investigator Assessment

The ORR defined as the percentage of all randomized participants with a confirmed best overall response (BOR) of partial response (PR),or complete response (CR) according to RECIST v1.1 and as per Investigator assessment. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in sum of longest diameter (SLD) of all lesions. (NCT02625610)
Timeframe: From randomization into maintenance phase up to 1276 days

Interventionpercentage of participants (Number)
Chemotherapy + Best Supportive Care (BSC)14.4
Avelumab13.3

[back to top]

Maintenance Phase: Number of Participants With Grade Change From Baseline to Worst On-Treatment Grade 4 Hematology Values

Blood samples were collected for the analysis of following hematology parameters: lymphocyte count, neutrophil count, white blood cells, platelet count, lipase, serum amylase, creatinine phosphokinase and creatinine. The hematology parameters were graded according to National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. An increase is defined as an increase in CTCAE grade relative to Baseline grade. Data for worst-case (Grade 4) post Baseline is presented. Only those participants with increase to grade 4 have been presented. (NCT02625610)
Timeframe: From baseline up to 1276 days

,
InterventionParticipants (Count of Participants)
lymphocyte count decreasedneutrophil count decreasedwhite blood cells decreasedplatelet count decreasedlipase increasedserum amylase increasedcreatinine phosphokinase increasedcreatinine increased
Avelumab11008221
Chemotherapy + Best Supportive Care (BSC)06216300

[back to top]

Maintenance Phase: Number of Participants With Shift in Eastern Cooperative Oncology Group (ECOG) Performance Status Score to 1 or Higher Than 1

ECOG PS score is widely used by doctors and researchers to assess how a participants' disease is progressing, and is used to assess how the disease affects the daily living abilities of the participant, and determine appropriate treatment and prognosis. The score ranges from Grade 0 to Grade 5, where Grade 0 = Fully active, able to carry on all pre-disease performance without restriction, Grade 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature (like light house work, office work), Grade 2 = Ambulatory and capable of all self-care but unable to carry out any work activities, Grade 3 = Capable of only limited self-care, confined to bed or chair more than 50% of waking hours and Grade 4 = Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair, Grade 5 = Death. Number of participants with shift in ECOG PS Score to 1 or Higher Than 1 were reported. (NCT02625610)
Timeframe: From randomization into maintenance phase up to 1276 days

InterventionParticipants (Count of Participants)
Chemotherapy + Best Supportive Care (BSC)140
Avelumab144

[back to top]

Progression Free Survival (PFS) by Independent Review Committee (IRC)

The PFS time was defined as the time from date of randomization until date of the first documentation of progressive disease (PD) or death due to any cause (whichever occurs first). PFS was assessed as per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) as per IRC. PD was defined as at least a 20 percent (%) increase in the sum of longest diameter (SLD), taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions. PFS was measured using Kaplan-Meier (KM) estimates. (NCT02625610)
Timeframe: From randomization into maintenance phase up to 1276 days

Interventionmonths (Median)
Chemotherapy + Best Supportive Care (BSC)4.4
Avelumab3.2

[back to top]

Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30) Global Health Status Scale Score up to Safety Follow-up (Up to 152.3 Weeks)

European Organization for the Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life (QoL) in cancer participants. It consisted of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, role, cognitive, emotional, social), and 9 symptom scales/items (Fatigue, nausea and vomiting, pain, dyspnoea, sleep disturbance, appetite loss, constipation, diarrhea, financial impact. The EORTC QLQ-C30 GHS/QoL score ranges from 0 to 100; High score indicates better GHS/QoL. Score 0 represents: very poor physical condition and QoL. Score 100 represents: excellent overall physical condition and QoL. (NCT02625610)
Timeframe: Baseline, Week 3/4, Week 7, Week 13, Week 19, Week 25, Week 31, Week 37, Week 43, Week 49, Week 55, Week 61, Week 67, End of Treatment ( EOT up to 148 weeks) and Safety Follow-up (Up to 152.3 Weeks)

,
Interventionunits on a scale (Mean)
Week 3/4Week 7Week 13Week 19Week 25Week 31Week 37Week 43Week 49Week 55Week 61Week 67End Of TreatmentSafety Follow-Up
Avelumab0.85-1.010.241.370.411.851.773.334.014.002.384.90-11.67-9.29
Chemotherapy + Best Supportive Care (BSC)1.30-1.44-2.50-5.85-4.43-3.09-1.39-1.191.520.00-5.000.00-11.54-7.51

[back to top]

Change From Baseline in European Quality of Life 5-dimensions (EQ-5D-5L) Health Outcome Questionnaire Through Composite Index Score up to Safety Follow-up (Up to 152.3 Weeks)

EQ-5D-5L is comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive overall composite health state index score, with scores ranging from -0.594 to 1. A higher score indicates better health state. (NCT02625610)
Timeframe: Baseline, Week 3/4, Week 7, Week 13, Week 19, Week 25, Week 31, Week 37, Week 43, Week 49, Week 55, Week 61, Week 67, End of Treatment ( EOT up to 148 weeks) and Safety Follow-up (Up to 152.3 Weeks)

,
InterventionUnits on Scale (Mean)
Week 3/4Week 7Week 13Week 19Week 25Week 31Week 37Week 43Week 49Week 55Week 61Week 67End Of TreatmentSafety Follow-Up
Avelumab0.004-0.009-0.017-0.0110.0140.0130.0130.0580.0260.0280.0310.039-0.138-0.099
Chemotherapy + Best Supportive Care (BSC)-0.002-0.032-0.053-0.039-0.049-0.023-0.035-0.046-0.100-0.164-0.091-0.076-0.125-0.062

[back to top]

Maintenance Phase: Number of Participants With Potentially Clinically Significant Abnormalities in Vital Signs

Vital signs assessment included Systolic blood pressure (SBP), Diastolic blood pressure (DBP) and Pulse Rate (PR). Number of Participants with any potentially clinically significant abnormalities in vital signs were reported. Clinical significance was determined by the investigator. (NCT02625610)
Timeframe: From randomization into maintenance phase up to 1276 days

,
InterventionParticipants (Count of Participants)
Increased in Systolic blood pressureDecreased in Systolic blood pressureIncreased in Diastolic blood pressureDecreased in Diastolic blood pressureIncreased in pulse rateDecreased in pulse rate
Avelumab626924264830
Chemotherapy + Best Supportive Care (BSC)574314214632

[back to top]

Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Stomach Cancer Specific (EORTC QLQ-STO22 ) Questionnaire Scores up to Safety Follow-up (Up to 152.3 Weeks)

European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Stomach Cancer Specific (EORTC QLQ-STO22 ) supplements the EORTC QLQ-C30 to assess symptoms and treatment-related side effects commonly reported in participants. There are 22 questions which comprise 5 scales (dysphagia, pain, reflux symptom, dietary restrictions, and anxiety) and 4 single items (dry mouth, hair loss, taste, body image). Most questions use 4-point scale (1 'Not at all' to 4 'Very much'; 1 question was a yes or no answer). A linear transformation was used to standardize all scores and single-items to a scale of 0 to 100; higher score=better level of functioning or greater degree of symptoms. (NCT02625610)
Timeframe: Baseline, Week 3/4, Week 7, Week 13, Week 19, Week 25, Week 31, Week 37, Week 43, Week 49, Week 55, Week 61, Week 67, End of Treatment ( EOT up to 148 weeks) and Safety Follow-up (Up to 152.3 Weeks)

,
Interventionunits on a scale (Mean)
Dysphagia: Week 3/4Dysphagia Week 7Dysphagia Week 13Dysphagia Week 19Dysphagia Week 25Dysphagia Week 31Dysphagia Week 37Dysphagia Week 43Dysphagia Week 49Dysphagia Week 55Dysphagia Week 61Dysphagia Week 67Dysphagia End Of TreatmentDysphagia Safety Follow-UpPain Week 3/4Pain Week 7Pain Week 13Pain Week 19Pain Week 25Pain Week 31Pain Week 37Pain Week 43Pain Week 49Pain Week 55Pain Week 61Pain Week 67Pain End Of TreatmentPain Safety Follow-UpReflux Week 3/4Reflux Week 7Reflux Week 13Reflux Week 19Reflux Week 25Reflux Week 31Reflux Week 37Reflux Week 43Reflux Week 49Reflux Week 55Reflux Week 61Reflux Week 67Reflux End of TreatmentReflux Safety Follow-upEating Restrictions Week 3/4Eating Restrictions Week 7Eating Restrictions Week 13Eating Restrictions Week 19Eating Restrictions Week 25Eating Restrictions Week 31Eating Restrictions Week 37Eating Restrictions Week 43Eating Restrictions Week 49Eating Restrictions Week 55Eating Restrictions Week 61Eating Restrictions Week 67Eating Restrictions EOTEating Restrictions Safety Follow-upAnxiety Week 3/4Anxiety Week 7Anxiety Week 13Anxiety Week 19Anxiety Week 25Anxiety Week 31Anxiety Week 37Anxiety Week 43Anxiety Week 49Anxiety Week 55Anxiety Week 61Anxiety Week 67Anxiety End of TreatmentAnxiety Safety Follow-Up
Avelumab0.601.340.651.521.694.39-0.67-2.591.230.891.061.318.217.25-0.042.600.16-0.51-1.550.97-1.26-1.94-0.62-1.00-1.59-0.499.4510.990.120.50-1.09-1.681.69-1.29-4.38-5.56-2.06-3.56-6.350.004.732.900.13-0.270.00-0.63-1.550.39-3.28-3.89-5.25-6.00-5.56-2.4510.0111.59-4.06-1.20-2.83-1.68-1.69-0.52-1.01-1.11-6.17-4.00-4.76-1.965.894.99
Chemotherapy + Best Supportive Care (BSC)0.762.841.60-0.58-1.390.82-7.19-4.76-3.030.000.00-1.857.279.391.512.532.963.22-1.564.01-4.901.791.520.003.330.009.258.221.040.310.991.750.69-2.06-6.54-3.171.012.226.677.413.431.560.730.981.02-2.34-2.08-2.47-8.82-4.760.763.330.001.398.277.04-0.28-1.30-0.86-1.56-2.784.12-3.92-3.970.002.22-4.449.264.585.48

[back to top]

Maintenance Phase: Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Abnormalities

ECG parameters included heart rate, pulse rate intervals, QRS interval, QT interval corrected based on Fridericia's formula (QTcF) intervals and QTcB intervals. Clinical significance was determined by the investigator. Number of participants with potentially clinically significant ECG abnormalities were reported. (NCT02625610)
Timeframe: From randomization into maintenance phase up to 1276 days

,
InterventionParticipants (Count of Participants)
Decreased heart rateIncreased heart rateIncreased Pulse Rate intervalIncreased QRS intervalQTcF interval greater than (>)450milisecond (ms)less than or equal to(<=)480msQTcF interval: > 480 ms <= 500 msQTcF interval: > 500 msQTcB Interval: > 450 msec <= 480 msecQTcB Interval: > 480 msec <= 500 msecQTcB Interval: > 500 msec
Avelumab12389311823
Chemotherapy + Best Supportive Care (BSC)02159231925

[back to top]

Maintenance Phase: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs According to National Cancer Institute-Common Terminology Criteria for Adverse Events Version 4.03 (NCI-CTCAE v4.03)

Adverse event (AE) was defined as any untoward medical occurrence in a participant, which does not necessarily have causal relationship with treatment. A serious AE was defined as an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged in participant hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. The term TEAE is defined as AEs starting or worsening after the first intake of the study drug. TEAEs included both serious TEAEs and non-serious TEAEs. Number of participants with TEAEs and serious TEAEs were reported. (NCT02625610)
Timeframe: From randomization into maintenance phase up to 1276 days

,
InterventionParticipants (Count of Participants)
Any TEAEsAny Serious TEAE
Avelumab22389
Chemotherapy + Best Supportive Care (BSC)21475

[back to top]

Prospective Patient Reported Outcomes as Measured by FACT-C Questionnaire

-The FACT-C questionnaire is broken down into physical well-being, social/family well-being, emotional well-being, and functional well-being. The answers range from 0 (not at all) to 4 (very much). (NCT02641691)
Timeframe: Completion of chemoradiation (approximately 112 days)

,,,,,
InterventionParticipants (Count of Participants)
I have a lack of energyI have nauseaBecause of my physical condition, I have trouble meeting the needs of my familyI have painI am bothered by side effects of treatmentI feel illI am forced to spend time in bedI feel close to my friendsI get emotional support from my familyI get support from my friendsMy family has accepted my illnessI am satisfied with family communication about my illnessI feel close to my partner (or the person who is my main support)I am satisfied with my sex lifeI feel sadI am satisfied with how I am coping with my illnessI am losing hope in the fight against my illnessI feel nervousI worry about dyingI worry that my condition will get worseI am able to work (include work at home)My work (include work at home) is fulfillingI am able to enjoy lifeI have accepted my illnessI am sleeping wellI am enjoying the things I usually do for funI am content with the quality of my life right nowI have swelling or cramps in my stomach areaI am losing weightI have control of my bowelsI can digest my food wellI have diarrhea (diarrhoea)I have a good appetiteI like the appearance of my bodyI am embarrassed by my ostomy applianceCaring for my ostomy appliance is difficult
0=Not at All316811616130011101103165124100100013111041211
1=A Little Bit338372611000015011161144222324642101300
2=Somewhat1102430011112283423033531346116325800
3=Quite a Bit200020032132011800113276665104327300
4=Very Much0010100141516141417504000088797660041014300
Prefer Not to Answer/No Answer/No00010100000003000000000010001010101818

[back to top]

Prospective Patient Reported Outcomes as Measured by FACT-C Questionnaire

-The FACT-C questionnaire is broken down into physical well-being, social/family well-being, emotional well-being, and functional well-being. The answers range from 0 (not at all) to 4 (very much). (NCT02641691)
Timeframe: 10-14 months after chemoradiation (approximately 16-20 months)

,,,,,
InterventionParticipants (Count of Participants)
I have a lack of energyI have nauseaBecause of my physical condition, I have trouble meeting the needs of my familyI have painI am bothered by side effects of treatmentI feel illI am forced to spend time in bedI feel close to my friendsI get emotional support from my familyI get support from my friendsMy family has accepted my illnessI am satisfied with family communication about my illnessI feel close to my partner (or the person who is my main support)I am satisfied with my sex lifeI feel sadI am satisfied with how I am coping with my illnessI am losing hope in the fight against my illnessI feel nervousI worry about dyingI worry that my condition will get worseI am able to work (include work at home)My work (include work at home) is fulfillingI am able to enjoy lifeI have accepted my illnessI am sleeping wellI am enjoying the things I usually do for funI am content with the quality of my life right nowI have swelling or cramps in my stomach areaI am losing weightI have control of my bowelsI can digest my food wellI have diarrhea (diarrhoea)I have a good appetiteI like the appearance of my bodyI am embarrassed by my ostomy applianceCaring for my ostomy appliance is difficult
0=Not at All41710951514000000593156105110010012152061311
1=A Little Bit504522200000006016572010145122160202
2=Somewhat514361121221223414253655445207523810
3=Quite a Bit400030142221120401113255563205224200
4=Very Much00012001215131415154071100997763411210210310
Prefer Not to Answer/No Answer/No00000000010105000000000111100000001515

[back to top]

Number of Any Grade 3 or Higher Toxicities

-The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for all toxicity reporting. (NCT02641691)
Timeframe: From start of radiation treatment through 30 days after completion of treatment (approximately 18 weeks)

InterventionParticipants (Count of Participants)
AnemiaFebrile neutropeniaCardiac arrestMyocardial infarctionVentricular fibrillationAbdominal painDiarrheaPancreatitisFeverCholectystitisLung infectionFallActivated partial thromboplastin time prolongedAspartate aminotransferase increasedCardiac troponin I increasedCardiac troponin T increasedLymphocyte count decreasedNeutrophil count decreasedWhite blood cell decreasedDehydrationHyperglycemiaHypokalemiaHyponatremiaGeneralized muscle weaknessPeripheral sensory neuropathySyncopeRespiratory failureAspirationDyspneaHypoxiaPalmar-plantar erythrodysesthesia syndromeCellulitisHypertensionHypotensionThromboembolic event
Arm 1: Radiation/Oxaliplatin/Leucovorin/5-FU22111131111111113522122121112111121

[back to top]

Number of Post Chemotherapy Grade 3 or Higher Toxicities

-The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for all toxicity reporting. (NCT02641691)
Timeframe: Post-chemotherapy through 1 year follow-up (approximately 1 year and 4 months)

InterventionParticipants (Count of Participants)
AnemiaFebrile neutropeniaCardiac arrestMyocardial infarctionVentricular fibrillationAbdominal painDiarrheaFeverCholecystitisLung infectionActivated partial thromboplastin time prolongedAspartate aminotransferase increasedCardiac troponin I increasedCardiac troponin T increasedLymphocyte count decreasedNeutrophil count decreasedWhite blood cell count decreasedDehydrationHyperglycemiaHypokalemiaHyponatremiaGeneralized muscle weaknessPeripheral sensory neuropathySyncopeRespiratory failureAspirationDyspneaHypoxiaCellulitisHypotensionThromboembolic event
Arm 1: Radiation/Oxaliplatin/Leucovorin/5-FU2211113211111135211221211111111

[back to top]

Complete Response Rate

"Criteria for complete clinical response:~No residual gross tumor at procto/sigmoidoscopy, or only erythematous scar or ulcer~No radiographic evidence of tumor on DRE~Substantial downsizing on MRI~No suspicious mesorectal lymph nodes on MRI~Negative biopsy from scar, ulcer, or former tumor site (if necessary according to surgeon's judgment)~Criteria for no significant clinical response:~Residual disease by DRE, endoscopy or MR.~Increase in primary tumor size upon clinical exam or imaging~Any new lesions" (NCT02641691)
Timeframe: 1 year

InterventionParticipants (Count of Participants)
Arm 1: Radiation/Oxaliplatin/Leucovorin/5-FU12

[back to top]

Quality of Anorectal Function as Measured by the FACT-C Questionnaire

-The FACT-C questionnaire has 2 statements about anorectal function and the participant answers 0 (not at all) to 4 (very much) (NCT02641691)
Timeframe: Completion of chemoradiation (approximately 112 days)

,,,,
InterventionParticipants (Count of Participants)
I have control of my bowelsI have diarrhea (diarrhoea)
0=Not at All14
1=A Little Bit410
2=Somewhat62
3=Quite a Bit42
4=Very Much41

[back to top]

Quality of Anorectal Function as Measured by the FACT-C Questionnaire

-The FACT-C questionnaire has 2 statements about anorectal function and the participant answers 0 (not at all) to 4 (very much) (NCT02641691)
Timeframe: Baseline

,,,,
InterventionParticipants (Count of Participants)
I have control of my bowelsI have diarrhea (diarrhoea)
0=Not at All19
1=A Little Bit05
2=Somewhat54
3=Quite a Bit30
4=Very Much112

[back to top]

Quality of Anorectal Function as Measured by the FACT-C Questionnaire

-The FACT-C questionnaire has 2 statements about anorectal function and the participant answers 0 (not at all) to 4 (very much) (NCT02641691)
Timeframe: 10-14 months after chemoradiation (approximately 16-20 months)

,,,,
InterventionParticipants (Count of Participants)
I have control of my bowelsI have diarrhea (diarrhoea)
0=Not at All26
1=A Little Bit26
2=Somewhat72
3=Quite a Bit52
4=Very Much22

[back to top]

Prospective Patient Reported Outcomes as Measured by FACT-C Questionnaire

-The FACT-C questionnaire is broken down into physical well-being, social/family well-being, emotional well-being, and functional well-being. The answers range from 0 (not at all) to 4 (very much). (NCT02641691)
Timeframe: Baseline

,,,,,
InterventionParticipants (Count of Participants)
I have a lack of energyI have nauseaBecause of my physical condition, I have trouble meeting the needs of my familyI have painI am bothered by side effects of treatmentI feel illI am forced to spend time in bedI feel close to my friendsI get emotional support from my familyI get support from my friendsMy family has accepted my illnessI am satisfied with family communication about my illnessI feel close to my partner (or the person who is my main support)I am satisfied with my sex lifeI feel sadI am satisfied with how I am coping with my illnessI am losing hope in the fight against my illnessI feel nervousI worry about dyingI worry that my condition will get worseI am able to work (include work at home)My work (include work at home) is fulfillingI am able to enjoy lifeI have accepted my illnessI am sleeping wellI am enjoying the things I usually do for funI am content with the quality of my life right nowI have swelling or cramps in my stomach areaI am losing weightI have control of my bowelsI can digest my food wellI have diarrhea (diarrhoea)I have a good appetiteI like the appearance of my bodyI am embarrassed by my ostomy applianceCaring for my ostomy appliance is difficult
0=Not at All9191711191917000000082196122000020014101091000
1=A Little Bit302600100000018214491000001550050200
2=Somewhat611201110000164404253522646025240400
3=Quite a Bit200100010121010504244336676033406800
4=Very Much0000000182019181919807020012111512697101113213600
Prefer Not to Answer/No Answer/No00001010000004000000010000000010002020

[back to top]

Pathological Complete Response (PathCR) Rate

Defined as number of patients with pathologic complete responses (pCR) divided by total evaluable patients. pCR is defined as no recognized cancer and margins free of tumor as found by the pathologist following resection of the esophageal specimen and accompanying lymph nodes. (NCT02730546)
Timeframe: Up to 3 years

Interventionpercentage of patients (Number)
Treatment (Pembrolizumab, Chemotherapy, Radiation, Surgery)22.6

[back to top]

Progression-Free Survival (PFS)

PFS is defined as the time from randomization to the first objective documentation of disease progression per RECIST 1.1 (PD) or death, whichever comes first. (NCT02753127)
Timeframe: Randomization to Date of Death or until the date of first documented objective disease progression or database cutoff date (28 Apr 2020) (Approximately 43 months)

,
Interventionmonths (Median)
Progression-Free Survival (PFS), General Population(GP)Progression-Free Survival (PFS) , ITT-pSTAT3(+)
FOLFIRI ± Bevacizumab5.625.55
Napabucasin + FOLFIRI ± Bevacizumab5.555.39

[back to top]

Number of Patients With Adverse Events in the General Population

All patients who have received at least one dose of either BBI-608 or FOLFIRI will be included in the safety analysis according to the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) version 4.0. The incidence of adverse events will be summarized by type of adverse event and severity. (NCT02753127)
Timeframe: All adverse event are collected from date of signed informed consent until 30 days after protocol treatment discontinuation. Outcome followed until study discontinuation up to 4 years

,
InterventionParticipants (Count of Participants)
Number of Patients with Adverse Events in the General PopulationNumber of Patients with Adverse Events in the pSTAT3(+) Subpopulation
FOLFIRI ± Bevacizumab602266
Napabucasin + FOLFIRI ± Bevacizumab619275

[back to top]

Overall Survival (OS)

"Overall survival was defined as the time from randomization until death from any cause.~Patients who are alive at the time of the interim or the final analyses or who have become lost to follow-up will be censored on the date the patient was last known to be alive." (NCT02753127)
Timeframe: Randomization to Date of Death from any cause or database cutoff date (28 Apr 2020) (Approximately 43 months)

,
Interventionmonths (Median)
Overall Survival (OS), General Population(GP)Overall Survival (OS), ITT-pSTAT3(+)
FOLFIRI ± Bevacizumab13.8312.12
Napabucasin + FOLFIRI ± Bevacizumab14.2913.17

[back to top]

Disease Control Rate (DCR)

DCR is defined as the percentage of patients with a documented complete response, partial response, and stable disease (CR + PR + SD) based on RECIST 1.1. The primary estimate of DCR will be based on patients with measurable disease by RECIST 1.1 at randomization (NCT02753127)
Timeframe: Randomization to Date of Death or until the date of first documented objective disease progression or database cutoff date (28 Apr 2020) (Approximately 43 months)

,
Interventionpercentage of participants (Number)
Disease Control Rate (DCR), General Population(GP)Disease Control Rate (DCR), ITT-pSTAT3(+)
FOLFIRI ± Bevacizumab69.170.3
Napabucasin + FOLFIRI ± Bevacizumab69.667.2

[back to top]

Mean Change From Baseline for Global Health Status at Time 2 (Cycle 5 Day 1) and Time 4 (Cycle 9 Day 1).

The Quality of Life (QoL) of patients will be assessed using European Organization for Research and Treatment of Cancer Quality of Life questionnaire (EORTC-QLQ-C30) (EORTC QLQ-30) while the patient remains on study treatment (FOLFIRI with or without BBI-608). EORTC QLQ-30 is used to assess the overall quality of life in cancer patients using 28 questions with a 4 point scale. (1 'Not at all' to 4'Very Much'); 2 questions use a 7-point sale (1 'Very Poor' to 7 'Excellent'). Scores are averaged and transformed to 0-100 scale; higher overall score = better quality of life. (NCT02753127)
Timeframe: From baseline at Time 2 (Cycle 5 Day 1), approximately 57 days and Time 4 (Cycle 9 Day 1), approximately 113 days

,
Interventionscore on a scale (Mean)
Mean Change From Baseline for Global Health status at Time 2 (Cycle 5 Day 1). General PopulationMean Change From Baseline for Global Health status at Time 4 (Cycle 9 Day 1). General Population
FOLFIRI ± Bevacizumab-5.45-5.58
Napabucasin + FOLFIRI ± Bevacizumab-7.07-7.70

[back to top]

Mean Change From Baseline for Physical Functioning Status at Time 2 (Cycle 5 Day 1) and Time 4 (Cycle 9 Day 1).

The Quality of Life (QoL) of patients will be assessed using European Organization for Research and Treatment of Cancer Quality of Life questionnaire (EORTC-QLQ-C30) (EORTC QLQ-30) while the patient remains on study treatment (FOLFIRI with or without BBI-608). EORTC QLQ-30 is used to assess the overall quality of life in cancer patients using 28 questions with a 4 point scale. (1 'Not at all' to 4'Very Much'); 2 questions use a 7-point sale (1 'Very Poor' to 7 'Excellent'). Scores are averaged and transformed to 0-100 scale; higher overall score = better quality of life. (NCT02753127)
Timeframe: From baseline at Time 2 (Cycle 5 Day 1) and Time 4 (Cycle 9 Day 1)

,
InterventionQOL score on a scale (Mean)
Mean Change From Baseline for Physical Functioning at Time 2 (Cycle 5 Day 1). General PopulationMean Change From Baseline for Physical Functioning at Time 4 (Cycle 9 Day 1). General Population
FOLFIRI ± Bevacizumab-3.94-4.22
Napabucasin + FOLFIRI ± Bevacizumab-5.86-6.37

[back to top]

Objective Response Rate (ORR)

ORR is defined as the proportion of patients with a documented complete response and partial response (CR + PR) based on RECIST 1.1. The primary estimate for ORR will be based on patients with measurable disease by RECIST 1.1 at randomization. (NCT02753127)
Timeframe: Randomization to Date of Death or until the date of first documented objective disease progression or database cutoff date (28 Apr 2020) (Approximately 43 months)

,
Interventionpercentage of participants (Number)
Objective Response Rate (ORR), General Population(GP)Objective Response Rate (ORR), ITT-pSTAT3(+)
FOLFIRI ± Bevacizumab14.613.9
Napabucasin + FOLFIRI ± Bevacizumab13.811.9

[back to top]

Biologic Activity, Defined as Global Deoxyribonucleic Acid (DNA) Methylation Change in Peripheral Blood Mononuclear Cells (PBMC)s; Day 5 of Second Course of Azacitidine

Will calculate the percentage of CpG site methylation for all patients after the second course of azacitidine. Mean and standard deviation will be reported. (NCT02828358)
Timeframe: Week 13, Day 5 (Following induction phase (5 weeks), the first course of Azacitidine (1 week), and consolidation (6 weeks), the second course of Azacitidine began around Week 13 of therapy)

InterventionPercentage of CpG methylation (Mean)
KMT2A-Rearranged74.52

[back to top]

Biologic Activity, Defined as Global Deoxyribonucleic Acid (DNA) Methylation Change in Peripheral Blood Mononuclear Cells (PBMC)s; Day 5 of First Course of Azacitidine

Will calculate the percentage of CpG site methylation for all patients after the first course of azacitidine. Mean and standard deviation will be reported. (NCT02828358)
Timeframe: Week 6, Day 5 (Following the induction phase (35 days), the first course of Azacitidine began around Week 6 of therapy)

InterventionPercentage of CpG methylation (Mean)
KMT2A-Rearranged75.54

[back to top]

Biologic Activity, Defined as Global Deoxyribonucleic Acid (DNA) Methylation Change in Peripheral Blood Mononuclear Cells (PBMC)s; Day 1 Prior to Second Course of Azacitidine

Will calculate the percentage of CpG site methylation for all patients before the second course of azacitidine. Mean and standard deviation will be reported. (NCT02828358)
Timeframe: Week 13, Day 1 (Following induction phase (5 weeks), the first course of Azacitidine (1 week), and consolidation (6 weeks), the second course of Azacitidine began around Week 13 of therapy)

InterventionPercentage of CpG methylation (Mean)
KMT2A-Rearranged76.5

[back to top]

Biologic Activity, Defined as Global Deoxyribonucleic Acid (DNA) Methylation Change in Peripheral Blood Mononuclear Cells (PBMC)s; Day 1 Prior to First Course of Azacitidine

Will calculate the percentage of CpG site methylation for all patients before the first course of azacitidine. Mean and standard deviation will be reported. (NCT02828358)
Timeframe: Week 6, Day 1 (Following the induction phase (35 days), the first course of Azacitidine began around Week 6 of therapy)

InterventionPercentage of CpG methylation (Mean)
KMT2A-Rearranged78.17

[back to top]

Tolerability of Azacitidine in Combination With Interfant-06 Standard Chemotherapy in Evaluable Infant Patients With Newly Diagnosed ALL With KMT2A Gene Rearrangement (KMT2A-R). KMT2A Gene Rearrangement (KMT2A-R)

Proportion of KMT2A-Rearranged patients treated with azacitidine with Dose Limiting Toxicities (DLTs) from the first course of azacitidine administration up to fourth course of azacitidine administration. (NCT02828358)
Timeframe: 6 months

Interventionpercentage of participants (Number)
KMT2A-Rearranged6.45

[back to top]

Progression Free Survival (PFS) in Participants Treated With Nivolumab Plus Chemotherapy vs Chemotherapy With PD-L1 CPS ≥ 5

Progression Free Survival (PFS) is defined as the time from randomization to the date of the first documented PD or death due to any cause. PD is determined by blinded independent committee review (BICR) per RECIST1.1 criteria in participants treated with Nivolumab plus Chemotherapy vs Chemotherapy with PD-L1 CPS ≥ 5. Progressive disease (PD) is defined as at least a 20% increase in the sum of diameters of target lesions, taking in reference the smallest sum on study that also demonstrated an absolute increase of at least 5 mm. CPS is defined as the number of PD-L1 staining cells (tumor cells, lymphocytes, macrophages) divided by the total number of viable tumor cells, multiplied by 100. (NCT02872116)
Timeframe: From randomization to the date of the first documented progressive disease (PD) per BICR or death due to any cause (up to approximately 10 months)

InterventionMonths (Median)
Arm 1: Nivolumab + Chemotherapy (XELOX or FOLFOX)7.69
Arm 2a: Chemotherapy (XELOX or FOLFOX)6.05

[back to top]

OS in Participants Treated With Nivolumab Plus Ipilimumab vs Chemotherapy

Overall survival (OS), defined as the time from randomization to the time of death, in participants treated with Nivolumab plus Ipilimumab vs Chemotherapy with PD-L1 CPS (combined positive score) ≥ 1, 5, 10, and all randomized participants. CPS is defined as the number of PD-L1 staining cells (tumor cells, lymphocytes, macrophages) divided by the total number of viable tumor cells, multiplied by 100. (NCT02872116)
Timeframe: From the date of randomization up to the date of death, up to approximately 14 months

,
InterventionMonths (Median)
All randomized participantsParticipants with CPS ≥ 1Participants with CPS ≥ 5Participants with CPS ≥ 10
Arm 2b: Chemotherapy (XELOX or FOLFOX)11.8311.4711.6311.33
Arm 3: Nivolumab + Ipilimumab11.7311.7311.2411.63

[back to top]

Overall Survival (OS) in Participants Treated With Nivolumab Plus Chemotherapy vs Chemotherapy With PD-L1 CPS ≥ 5

Overall survival (OS), defined as the time from randomization to the time of death, in participants treated with Nivolumab plus Chemotherapy vs Chemotherapy with PD-L1 CPS (combined positive score) ≥ 5. CPS is defined as the number of PD-L1 staining cells (tumor cells, lymphocytes, macrophages) divided by the total number of viable tumor cells, multiplied by 100. (NCT02872116)
Timeframe: From the date of randomization up to the date of death, up to approximately 17 months

InterventionMonths (Median)
Arm 1: Nivolumab + Chemotherapy (XELOX or FOLFOX)14.39
Arm 2a: Chemotherapy (XELOX or FOLFOX)11.10

[back to top]

OS in Participants Treated With Nivolumab Plus Chemotherapy vs Chemotherapy

Overall survival (OS), defined as the time from randomization to the time of death, in participants treated with Nivolumab plus Chemotherapy vs Chemotherapy with PD-L1 CPS ≥ 1, 10, and all randomized participants. CPS is defined as the number of PD-L1 staining cells (tumor cells, lymphocytes, macrophages) divided by the total number of viable tumor cells, multiplied by 100. (NCT02872116)
Timeframe: From the date of randomization up to the date of death, up to approximately 17 months

,
InterventionMonths (Median)
All randomized participantsParticipants with CPS ≥ 1Participants with PD-L1 CPS ≥ 10
Arm 1: Nivolumab + Chemotherapy (XELOX or FOLFOX)13.8313.9615.01
Arm 2a: Chemotherapy (XELOX or FOLFOX)11.5611.3310.87

[back to top]

Objective Response Rate

Objective response rate (ORR) as assessed by BICR in participants with PD-L1 CPS ≥ 10, 5, 1, or all randomized participants. ORR is a percentage of participants determined by the number of participants with a best overall response (BOR) of complete response (CR) or partial response (PR) divided by the number of measurable participants with target lesion at baseline. BOR is defined as the best response designation as determined by the BICR, recorded between the date of randomization and the date of objectively documented progression (per RECIST 1.1 as determined by the BICR) or the date of subsequent anti-cancer therapy, whichever occurs first. CR is defined as the disappearance of all target lesions. PR is define as at 30% decrease in the sum of diameters of target lesions. The 806 chemotherapy treated participants are split into two separate arms (Arm 2a and Arm 2b) to act as comparison groups to the other treatment arms. (NCT02872116)
Timeframe: From randomization to the date of objectively documented progression or the date of subsequent anti-cancer therapy, whichever occurs first (up to approximately 43 months)

,,,
InterventionPercentage of Participants (Number)
Participants with CPS ≥ 1Participants with CPS ≥ 5Participants with CPS ≥ 10All randomized participants
Arm 1: Nivolumab + Chemotherapy (XELOX or FOLFOX)59.559.858.346.9
Arm 2a: Chemotherapy (XELOX or FOLFOX)46.445.344.237.0
Arm 2b: Chemotherapy (XELOX or FOLFOX)37.337.735.934.9
Arm 3: Nivolumab + Ipilimumab21.723.124.320.8

[back to top]

PFS in Participants Treated With Nivolumab Plus Ipilimumab vs Chemotherapy

Progression Free Survival (PFS) is defined as the time from randomization to the date of the first documented PD or death due to any cause. PD is determined by blinded independent committee review (BICR) per RECIST1.1 criteria in participants treated with Nivolumab plus Ipilumab vs Chemotherapy with PD-L1 CPS ≥ 10, 5, 1 or all randomized participants. Progressive disease (PD) is defined as at least a 20% increase in the sum of diameters of target lesions, taking in reference the smallest sum on study that also demonstrated an absolute increase of at least 5 mm. CPS is defined as the number of PD-L1 staining cells (tumor cells, lymphocytes, macrophages) divided by the total number of viable tumor cells, multiplied by 100. (NCT02872116)
Timeframe: From randomization to the date of the first documented progressive disease (PD) per BICR or death due to any cause (up to approximately 9 months)

,
InterventionMonths (Median)
All randomized participantsPD-L1 CPS ≥ 1PD-L1 CPS ≥ 5PD-L1 CPS ≥ 10
Arm 2b: Chemotherapy (XELOX or FOLFOX)7.066.936.286.28
Arm 3: Nivolumab + Ipilimumab2.832.792.832.89

[back to top]

PFS in Participants Treated With Nivolumab Plus Chemotherapy vs Chemotherapy

Progression free survival (PFS), defined as the time from randomization to the date of the first documented progressive disease (PD) or death due to any cause, in participants treated with Nivolumab plus Chemotherapy vs Chemotherapy by BICR per RECIST1.1 in participants with PD-L1 CPS ≥ 10, 1, or all randomized subjects. Progreessive disease (PD) is defined as at least a 20% increase in the sum of diameters of target lesions, taking in reference the smallest sum on study that also demonstrated an absolute increase of at least 5 mm. CPS is defined as the number of PD-L1 staining cells (tumor cells, lymphocytes, macrophages) divided by the total number of viable tumor cells, multiplied by 100. (NCT02872116)
Timeframe: From randomization to the date of the first documented progressive disease (PD) per BICR or death due to any cause (up to approximately 10 months)

,
InterventionMonths (Median)
All randomized participantsParticipants with CPS ≥ 1Participants with CPS ≥ 10
Arm 1: Nivolumab + Chemotherapy (XELOX or FOLFOX)7.667.498.31
Arm 2a: Chemotherapy (XELOX or FOLFOX)6.936.905.78

[back to top] [back to top]

Disease Control Rate

Disease control rate (DCR) is defined as the proportion of participants who have a confirmed and unconfirmed, partial, complete or stable response to therapy. (NCT02890355)
Timeframe: Up to 3 years post registration

Interventionproportion of participants (Number)
Arm I (Veliparib and mFOLFIRI)0.32
Arm II (FOLFIRI)0.47

[back to top]

Duration of Response (DoR)

"DoR: time from date of first documentation of response (complete response, CR, or partial response, PR) to date of first documentation of progression or symptomatic deterioration, or death due to any cause among participants, who achieve a response (CR or PR).~The distribution of DoR in each treatment arm will be estimated using the Kaplan-Meier method." (NCT02890355)
Timeframe: Up to 3 years post registration

Interventionmonths (Median)
Arm I (Veliparib and mFOLFIRI)3.4
Arm II (FOLFIRI)5.1

[back to top]

Overall Response Rate, ORR

Overall response rate (ORR) is defined as the proportion of participants who have a confirmed and unconfirmed, partial or complete response to therapy. (NCT02890355)
Timeframe: Up to 3 years post registration

Interventionproportion of participants (Number)
Arm I (Veliparib and mFOLFIRI)0.09
Arm II (FOLFIRI)0.10

[back to top]

Overall Survival (OS)

"OS: time to death by any cause from randomized treatment arm assignment.~The log-rank test with stratification was used by prior systemic treatment for metastatic disease. Distributions of overall survival in arms 1 and 2 were estimated using the method of Kaplan-Meier." (NCT02890355)
Timeframe: Up to 3 years

Interventionmonths (Median)
Arm I (Veliparib and mFOLFIRI)5.4
Arm II (FOLFIRI)6.5

[back to top]

Progression Free Survival (PFS)

From date of registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause. Patients last known to be alive without report of progression are censored at date of last contact. (NCT02890355)
Timeframe: From date of registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause, assessed up to 3 years

Interventionmonths (Median)
Arm I (Veliparib and mFOLFIRI)2.1
Arm II (FOLFIRI)2.9

[back to top]

Change in Quality of Life as Defined by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C-30

Change in quality of life over the six measurement times will be modeled using mixed effects linear regression to account for correlation among repeated measurements from the same subjects. Average change in QoL from baseline to follow-up will be computed. (NCT02896907)
Timeframe: Baseline to up to 28 days after the last treatment

Interventionscore on a scale (Mean)
Treatment (FOLFIRINOX, Ascorbic Acid)NA

[back to top]

Neoadjuvant Rectal Cancer (NAR) Score

A linear regression model that controls for the stratification factors (cT-stage and cN-stage) will be used. Mean NAR scores along with standard errors and confidence intervals will be reported by treatment. The NAR score ranges from zero to 100 with lower values corresponding to better prognosis. (NCT02921256)
Timeframe: Baseline to up to 3 years

Interventionscore on a scale (Mean)
Arm Ia (mFOLFOX6, RT, Capecitabine)12.6
Arm II (mFOLFOX6, RT, Capecitabine, Veliparib)13.7
Arm Ib (mFOLFOX6, RT, Capecitabine)14.1
Arm III (mFOLFOX6, RT, Capecitabine, Pembrolizumab)11.5

[back to top]

Rate of Pathologic Complete Response (Nodes and Tumor) ypT0 and ypN0

Pathologic Complete Response means no remaining cancer detectable in the pathology sample. Analyzed by a logistic regression model that controls for the stratification factors (cT-stage and cN-stage). Observed proportions along with confidence intervals will be presented by treatment. (NCT02921256)
Timeframe: Up to 3 years

Interventionpercentage of participants (Mean)
Arm Ia (mFOLFOX6, RT, Capecitabine)21.6
Arm II (mFOLFOX6, RT, Capecitabine, Veliparib)33.8
Arm Ib (mFOLFOX6, RT, Capecitabine)29.4
Arm III (mFOLFOX6, RT, Capecitabine, Pembrolizumab)31.9

[back to top]

Rate of Sphincter Preservation

Sphincter preservation means that the surgical procedure used to remove the tumor did not disturb the sphincter muscle. Analyzed by a logistic regression model that controls for the stratification factors (cT-stage and cN-stage). Observed proportions along with confidence intervals will be presented by treatment. (NCT02921256)
Timeframe: Up to 3 years

Interventionpercentage of participants (Mean)
Arm Ia (mFOLFOX6, RT, Capecitabine)52.5
Arm II (mFOLFOX6, RT, Capecitabine, Veliparib)59.3
Arm Ib (mFOLFOX6, RT, Capecitabine, Pembrolizumab)71.0
Arm III (mFOLFOX6, RT, Capecitabine, Pembrolizumab)59.4

[back to top]

Percentage of Participants Alive at 1 Year (12-Month Survival Rate)

The 12-month survival rate is defined as the percentage of participants who have not died 12 months after the date of randomization. (NCT02923921)
Timeframe: From randomization to until the date of first documented date of death from any cause within 12 months

InterventionPercentage of participants (Number)
Pegilodecakin + FOLFOX14.7
FOLFOX19.1

[back to top]

Percentage of Participants With a Best Overall Response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD): Disease Control Rate (DCR)

Disease Control Rate (DCR) was the percentage of participants with a best overall response of CR, PR, or Stable Disease (SD) as per Response using RECIST v1.1 criteria. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions. PD was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. (NCT02923921)
Timeframe: Randomization to Objective Progressive Disease or Start of New Anti-Cancer Therapy (Up To 30 Months)

InterventionPercentage of participants (Number)
Pegilodecakin + FOLFOX42.8
FOLFOX36.6

[back to top]

Progression Free Survival

PFS defined as the time from the date of randomization to the first evidence of disease progression as defined by response evaluation criteria in solid tumors (RECIST) v1.1 or death from any cause. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a participant does not have a complete baseline disease assessment, then the PFS time was censored at the date of randomization, regardless of whether or not objectively determined disease progression or death has been observed for the participant. If a participant did not have a complete baseline disease assessment, then PFS was censored at the enrollment date, regardless whether or not objectively determined PD or death had been observed for the participant. (NCT02923921)
Timeframe: Randomization to Progressive Disease (PD) or Date of Death (Up To 30 Months)

InterventionMonths (Median)
Pegilodecakin + FOLFOX2.14
FOLFOX2.10

[back to top]

Duration of Response (DOR)

DOR was the time from the date of first evidence of complete response or partial response to the date of objective progression or the date of death due to any cause, whichever is earlier. CR and PR were defined using the RECIST v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. If a responder was not known to have died or have objective progression as of the data inclusion cutoff date, duration of response was censored at the last adequate tumor assessment date. PD was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. (NCT02923921)
Timeframe: Randomization to Progressive Disease (PD) or Date of Death (Up To 30 Months)

InterventionMonths (Median)
Pegilodecakin + FOLFOX4.99
FOLFOX5.17

[back to top]

Overall Survival

Overall survival is defined as the time from date of randomization to the date of death (due to any cause). For participants whose last known status is alive at the data cutoff date for the analysis, time will be censored as the last contact date prior to the data cutoff date. (NCT02923921)
Timeframe: Randomization to date of death from any cause (Up To 30 Months)

InterventionMonths (Median)
Pegilodecakin + FOLFOX5.78
FOLFOX6.28

[back to top]

Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) [Objective Response Rate (ORR)] That Assessed by Investigator

ORR was the percentage of participants achieving a best overall response (BOR) of complete response (CR) or partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. Participants who discontinued study treatment (for reasons other than progression) before entering concurrent phase were considered to have non-evaluable response. (NCT02923921)
Timeframe: Randomization to PD (Up To 30 Months)

InterventionPercentage of participants (Number)
Pegilodecakin + FOLFOX4.6
FOLFOX5.6

[back to top]

(Phase 3) Change From Baseline in the Participant Global Impression of Change (PGIC) in Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet

"The PGIC is a measure of participant's perceptions of change in their symptoms over time that can be used as an anchoring method to determine the minimal clinically important difference for other participant reported outcome (PROs). For this assessment, participants answered the following question: Since starting treatment, my colorectal cancer symptoms are: (1) very much improved, (2) much improved, (3) minimally improved, (4) no change, (5) minimally worse, (6) much worse or (7) very much worse." (NCT02928224)
Timeframe: Baseline,Cycle (C)1 Day (D)1, C2 D1, C3 D1, C4 D1, C5 D1, C6 D1, C7 D1, C8 D1, C9 D1, C10 D1, C11 D1, C12 D1, C13 D1, C14 D1, C15 D1, C16 D1, C17 D1, C18 D1, C19 D1, C20 D1, C21 D1, C22 D1, C23 D1, End of Treatment, 30 Day Follow Up(each cycle of 28 days)

InterventionUnits on a scale (Mean)
BaselineChange at Cycle 1 Day 1Change at Cycle 2 Day 1Change at Cycle 3 Day 1Change at Cycle 4 Day 1Change at Cycle 5 Day 1Change at Cycle 6 Day 1Change at Cycle 7 Day 1Change at Cycle 8 Day 1Change at Cycle 9 Day 1Change at Cycle 10 Day 1Change at Cycle 11 Day 1Change at Cycle 12 Day 1Change at Cycle 13 Day 1Change at Cycle 14 Day 1Change at Cycle 15 Day 1Change at Cycle 16 Day 1Change at Cycle 17 Day 1Change at Cycle 18 Day 1Change at Cycle 19 Day 1Change at Cycle 20 Day 1Change at Cycle 21 Day 1Change at End of TreatmentChange at 30 Day Follow Up
Phase 3: Triplet Arm3.8-0.1-0.7-0.9-0.9-0.9-0.8-1.1-1.2-0.8-0.5-0.9-0.9-1.3-1.1-1.2-2.0-1.3-2.0-3.0-3.0-3.00.3-0.1

[back to top]

(Phase 3) Change From Baseline in the Participant Global Impression of Change (PGIC) in Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet

"The PGIC is a measure of participant's perceptions of change in their symptoms over time that can be used as an anchoring method to determine the minimal clinically important difference for other participant reported outcome (PROs). For this assessment, participants answered the following question: Since starting treatment, my colorectal cancer symptoms are: (1) very much improved, (2) much improved, (3) minimally improved, (4) no change, (5) minimally worse, (6) much worse or (7) very much worse." (NCT02928224)
Timeframe: Baseline,Cycle (C)1 Day (D)1, C2 D1, C3 D1, C4 D1, C5 D1, C6 D1, C7 D1, C8 D1, C9 D1, C10 D1, C11 D1, C12 D1, C13 D1, C14 D1, C15 D1, C16 D1, C17 D1, C18 D1, C19 D1, C20 D1, C21 D1, C22 D1, C23 D1, End of Treatment, 30 Day Follow Up(each cycle of 28 days)

InterventionUnits on a scale (Mean)
BaselineChange at Cycle 1 Day 1Change at Cycle 2 Day 1Change at Cycle 3 Day 1Change at Cycle 4 Day 1Change at Cycle 5 Day 1Change at Cycle 6 Day 1Change at Cycle 7 Day 1Change at Cycle 8 Day 1Change at Cycle 9 Day 1Change at Cycle 10 Day 1Change at Cycle 11 Day 1Change at Cycle 12 Day 1Change at Cycle 13 Day 1Change at End of TreatmentChange at 30 Day Follow Up
Phase 3:Control Arm3.90.0-0.3-0.5-0.5-0.7-0.8-1.1-1.0-1.0-0.30.0-0.5-1.00.40.7

[back to top]

(Phase 3) Change From Baseline in the Functional Assessment of Cancer Therapy-Colon Cancer (FACT-C) in Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet

FACT-C= Functional Assessment of Chronic Illness Therapy (FACIT), which assessed HRQoL of cancer participants & participants with other chronic illnesses. It consists of total 36 items (27 items of general version of FACT-C and disease-specific subscale containing 9 CRC-specific items), summarized to 5 subscales: physical well-being (7 items), functional well-being (7 items), social/family well-being (7 items); all 3 subscales range:0-28, emotional well-being (6 items) range: 0-24, colorectal cancer subscale (9 items) range: 0-36; higher subscale score= better QoL. All single-item measures range: 0= 'Not at all' to 4= 'Very much'. Table summarizes functional well-being subscale, individual questions are linearly scaled & combined to form functional well-being subscale score (range 0-28). High score represents better QoL. (NCT02928224)
Timeframe: Baseline,Cycle (C)1 Day (D)1, C2 D1, C3 D1, C4 D1, C5 D1, C6 D1, C7 D1, C8 D1, C9 D1, C10 D1, C11 D1, C12 D1, C13 D1, C14 D1, C15 D1, C16 D1, C17 D1, C18 D1, C19 D1, C20 D1, C21 D1, C22 D1, C23 D1, End of Treatment, 30 Day Follow Up(each cycle of 28 days)

InterventionUnits on a scale (Mean)
BaselineChange at Cycle 1 Day 1Change at Cycle 2 Day 1Change at Cycle 3 Day 1Change at Cycle 4 Day 1Change at Cycle 5 Day 1Change at Cycle 6 Day 1Change at Cycle 7 Day 1Change at Cycle 8 Day 1Change at Cycle 9 Day 1Change at Cycle 10 Day 1Change at Cycle 11 Day 1Change at Cycle 12 Day 1Change at Cycle 13 Day 1Change at Cycle 14 Day 1Change at Cycle 15 Day 1Change at Cycle 16 Day 1Change at Cycle 17 Day 1Change at Cycle 18 Day 1Change at Cycle 19 Day 1Change at Cycle 20 Day 1Change at Cycle 21 Day 1Change at Cycle 22 Day 1Change at Cycle 23 Day 1Change at End of TreatmentChange at 30 Day Follow Up
Phase 3:Doublet Arm16.2-0.9-0.6-0.2-0.1-0.20.6-0.10.2-0.8-1.3-0.5-1.1-3.2-4.0-1.5-0.7-0.7-3.0-6.0-5.0-5.0-12.0-9.0-2.2-0.8

[back to top]

(Phase 3) Change From Baseline in the Functional Assessment of Cancer Therapy-Colon Cancer (FACT-C) in Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet

FACT-C= Functional Assessment of Chronic Illness Therapy (FACIT), which assessed HRQoL of cancer participants & participants with other chronic illnesses. It consists of total 36 items (27 items of general version of FACT-C and disease-specific subscale containing 9 CRC-specific items), summarized to 5 subscales: physical well-being (7 items), functional well-being (7 items), social/family well-being (7 items); all 3 subscales range:0-28, emotional well-being (6 items) range: 0-24, colorectal cancer subscale (9 items) range: 0-36; higher subscale score= better QoL. All single-item measures range: 0= 'Not at all' to 4= 'Very much'. Table summarizes functional well-being subscale, individual questions are linearly scaled & combined to form functional well-being subscale score (range 0-28). High score represents better QoL. (NCT02928224)
Timeframe: Baseline,Cycle (C)1 Day (D)1, C2 D1, C3 D1, C4 D1, C5 D1, C6 D1, C7 D1, C8 D1, C9 D1, C10 D1, C11 D1, C12 D1, C13 D1, C14 D1, C15 D1, C16 D1, C17 D1, C18 D1, C19 D1, C20 D1, C21 D1, C22 D1, C23 D1, End of Treatment, 30 Day Follow Up(each cycle of 28 days)

InterventionUnits on a scale (Mean)
BaselineChange at Cycle 1 Day 1Change at Cycle 2 Day 1Change at Cycle 3 Day 1Change at Cycle 4 Day 1Change at Cycle 5 Day 1Change at Cycle 6 Day 1Change at Cycle 7 Day 1Change at Cycle 8 Day 1Change at Cycle 9 Day 1Change at Cycle 10 Day 1Change at Cycle 11 Day 1Change at Cycle 12 Day 1Change at Cycle 13 Day 1Change at Cycle 14 Day 1Change at Cycle 15 Day 1Change at Cycle 16 Day 1Change at Cycle 17 Day 1Change at Cycle 18 Day 1Change at Cycle 19 Day 1Change at Cycle 20 Day 1Change at Cycle 21 Day 1Change at End of TreatmentChange at 30 Day Follow Up
Phase 3: Triplet Arm16.3-0.2-0.3-0.20.40.70.70.50.9-1.9-1.7-1.5-1.5-2.0-2.4-2.3-4.2-6.7-5.0-7.0-6.0-9.0-2.4-3.5

[back to top]

(Phase 3) Change From Baseline in the Functional Assessment of Cancer Therapy-Colon Cancer (FACT-C) in Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet

FACT-C= Functional Assessment of Chronic Illness Therapy (FACIT), which assessed HRQoL of cancer participants & participants with other chronic illnesses. It consists of total 36 items (27 items of general version of FACT-C and disease-specific subscale containing 9 CRC-specific items), summarized to 5 subscales: physical well-being (7 items), functional well-being (7 items), social/family well-being (7 items); all 3 subscales range:0-28, emotional well-being (6 items) range: 0-24, colorectal cancer subscale (9 items) range: 0-36; higher subscale score= better QoL. All single-item measures range: 0= 'Not at all' to 4= 'Very much'. Table summarizes functional well-being subscale, individual questions are linearly scaled & combined to form functional well-being subscale score (range 0-28). High score represents better QoL. (NCT02928224)
Timeframe: Baseline,Cycle (C)1 Day (D)1, C2 D1, C3 D1, C4 D1, C5 D1, C6 D1, C7 D1, C8 D1, C9 D1, C10 D1, C11 D1, C12 D1, C13 D1, C14 D1, C15 D1, C16 D1, C17 D1, C18 D1, C19 D1, C20 D1, C21 D1, C22 D1, C23 D1, End of Treatment, 30 Day Follow Up(each cycle of 28 days)

InterventionUnits on a scale (Mean)
BaselineChange at Cycle 1 Day 1Change at Cycle 2 Day 1Change at Cycle 3 Day 1Change at Cycle 4 Day 1Change at Cycle 5 Day 1Change at Cycle 6 Day 1Change at Cycle 7 Day 1Change at Cycle 8 Day 1Change at Cycle 9 Day 1Change at Cycle 10 Day 1Change at Cycle 11 Day 1Change at Cycle 12 Day 1Change at Cycle 13 Day 1Change at End of TreatmentChange at 30 Day Follow Up
Phase 3:Control Arm16.8-1.4-0.9-0.7-1.8-1.6-1.9-0.5-2.1-2.60.5-4.5-4.5-8.0-3.1-4.2

[back to top]

(Phase 3) Change From Baseline in the EuroQol-5D-5L Visual Analog Scale (EQ-5D-5L VAS) in Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet

The EQ-5D-5L contains 1 item for each of 5 dimensions of health-related QoL (i.e., mobility, self-care, usual activities, pain or discomfort and anxiety or depression). Response options for each item varied from having no problems to moderate problems or extreme problems. The EQ-5D-5L (v4.0) is a standardized measure of health utility that provides a single index value for one's health status. The EQ-5D-5L is frequently used for economic evaluations of health care and has been recognized as a valid and reliable instrument for this purpose. The EQ visual analog scale (VAS) is a score that is directly reported by the participant and ranges from 0 to 100 (higher is better quality health). (NCT02928224)
Timeframe: Baseline,Cycle (C)1 Day (D)1, C2 D1, C3 D1, C4 D1, C5 D1, C6 D1, C7 D1, C8 D1, C9 D1, C10 D1, C11 D1, C12 D1, C13 D1, C14 D1, C15 D1, C16 D1, C17 D1, C18 D1, C19 D1, C20 D1, C21 D1, C22 D1, C23 D1, End of Treatment, 30 Day Follow Up(each cycle of 28 days)

InterventionUnits on a scale (Mean)
BaselineChange at Cycle 1 Day 1Change at Cycle 2 Day 1Change at Cycle 3 Day 1Change at Cycle 4 Day 1Change at Cycle 5 Day 1Change at Cycle 6 Day 1Change at Cycle 7 Day 1Change at Cycle 8 Day 1Change at Cycle 9 Day 1Change at Cycle 10 Day 1Change at Cycle 11 Day 1Change at Cycle 12 Day 1Change at Cycle 13 Day 1Change at Cycle 14 Day 1Change at Cycle 15 Day 1Change at Cycle 16 Day 1Change at Cycle 17 Day 1Change at Cycle 18 Day 1Change at Cycle 19 Day 1Change at Cycle 20 Day 1Change at Cycle 21 Day 1Change at Cycle 22 Day 1Change at Cycle 23 Day 1Change at End of TreatmentChange at 30 Day Follow Up
Phase 3:Doublet Arm66.5-0.91.94.25.65.12.93.62.0-4.0-8.1-0.1-0.6-4.1-0.44.23.31.7-3.3-5.52.0-5.0-5.0-5.0-8.0-5.9

[back to top]

(Phase 3) Change From Baseline in the EuroQol-5D-5L Visual Analog Scale (EQ-5D-5L VAS) in Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet

The EQ-5D-5L contains 1 item for each of 5 dimensions of health-related QoL (i.e., mobility, self-care, usual activities, pain or discomfort and anxiety or depression). Response options for each item varied from having no problems to moderate problems or extreme problems. The EQ-5D-5L (v4.0) is a standardized measure of health utility that provides a single index value for one's health status. The EQ-5D-5L is frequently used for economic evaluations of health care and has been recognized as a valid and reliable instrument for this purpose. The EQ visual analog scale (VAS) is a score that is directly reported by the participant and ranges from 0 to 100 (higher is better quality health). (NCT02928224)
Timeframe: Baseline,Cycle (C)1 Day (D)1, C2 D1, C3 D1, C4 D1, C5 D1, C6 D1, C7 D1, C8 D1, C9 D1, C10 D1, C11 D1, C12 D1, C13 D1, C14 D1, C15 D1, C16 D1, C17 D1, C18 D1, C19 D1, C20 D1, C21 D1, C22 D1, C23 D1, End of Treatment, 30 Day Follow Up(each cycle of 28 days)

InterventionUnits on a scale (Mean)
BaselineChange at Cycle 1 Day 1Change at Cycle 2 Day 1Change at Cycle 3 Day 1Change at Cycle 4 Day 1Change at Cycle 5 Day 1Change at Cycle 6 Day 1Change at Cycle 7 Day 1Change at Cycle 8 Day 1Change at Cycle 9 Day 1Change at Cycle 10 Day 1Change at Cycle 11 Day 1Change at Cycle 12 Day 1Change at Cycle 13 Day 1Change at Cycle 14 Day 1Change at Cycle 15 Day 1Change at Cycle 16 Day 1Change at Cycle 17 Day 1Change at Cycle 18 Day 1Change at Cycle 19 Day 1Change at Cycle 20 Day 1Change at Cycle 21 Day 1Change at End of TreatmentChange at 30 Day Follow Up
Phase 3: Triplet Arm69.00.81.43.04.03.31.31.44.10.30.20.2-4.0-3.0-4.0-3.4-10.4-18.37.08.08.08.0-8.5-11.1

[back to top]

(Phase 3) Change From Baseline in the EuroQol-5D-5L Visual Analog Scale (EQ-5D-5L VAS) in Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet

The EQ-5D-5L contains 1 item for each of 5 dimensions of health-related QoL (i.e., mobility, self-care, usual activities, pain or discomfort and anxiety or depression). Response options for each item varied from having no problems to moderate problems or extreme problems. The EQ-5D-5L (v4.0) is a standardized measure of health utility that provides a single index value for one's health status. The EQ-5D-5L is frequently used for economic evaluations of health care and has been recognized as a valid and reliable instrument for this purpose. The EQ visual analog scale (VAS) is a score that is directly reported by the participant and ranges from 0 to 100 (higher is better quality health). (NCT02928224)
Timeframe: Baseline,Cycle (C)1 Day (D)1, C2 D1, C3 D1, C4 D1, C5 D1, C6 D1, C7 D1, C8 D1, C9 D1, C10 D1, C11 D1, C12 D1, C13 D1, C14 D1, C15 D1, C16 D1, C17 D1, C18 D1, C19 D1, C20 D1, C21 D1, C22 D1, C23 D1, End of Treatment, 30 Day Follow Up(each cycle of 28 days)

InterventionUnits on a scale (Mean)
BaselineChange at Cycle 1 Day 1Change at Cycle 2 Day 1Change at Cycle 3 Day 1Change at Cycle 4 Day 1Change at Cycle 5 Day 1Change at Cycle 6 Day 1Change at Cycle 7 Day 1Change at Cycle 8 Day 1Change at Cycle 9 Day 1Change at Cycle 10 Day 1Change at Cycle 11 Day 1Change at Cycle 12 Day 1Change at Cycle 13 Day 1Change at End of TreatmentChange at 30 Day Follow Up
Phase 3:Control Arm68.3-2.1-2.4-1.4-0.42.5-3.62.4-2.8-8.1-1.84.01.5-2.0-12.7-11.0

[back to top]

(Phase 3) Change From Baseline in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire for Cancer Participants (QLQ-C30) Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet

The EORTC QLQ-C30 questionnaire consisted of 30 questions generating 5 functional scores (physical, role, cognitive, emotional, & social); a global health (GH) status/global quality of life scale score; 3 symptom scale scores (fatigue, pain, & nausea & vomiting); & 6 standalone one-item scores that capture additional symptoms (dyspnea, appetite loss, sleep disturbance, constipation, & diarrhea) & perceived financial burden. All items were graded by severity experienced during previous week & used 4-point-scale (1: not at all, 2: a little, 3: quite a bit, 4: very much). The scores were converted to health-related quality of life (HRQoL) scale ranging from 0-100. Higher scores indicating higher response levels (i.e., higher functioning, higher symptom severity). (NCT02928224)
Timeframe: Baseline, Cycle(C)1 Day(D)1 , C2 D1, C3 D1, C4 D1, C5 D1, C6 D1, C7 D1, C8 D1, C9 D1, C10 D1, C11 D1, C12 D1, C13 D1, C14 D1, C15 D1, C16 D1, C17 D1, C18 D1, C19 D1, C20 D1, C21 D1, C22 D1, C23 D1, End of Treatment, 30 Day Follow Up(each cycle of 28 days)

InterventionUnits on a scale (Mean)
BaselineChange at Cycle 1 Day 1Change at Cycle 2 Day 1Change at Cycle 3 Day 1Change at Cycle 4 Day 1Change at Cycle 5 Day 1Change at Cycle 6 Day 1Change at Cycle 7 Day 1Change at Cycle 8 Day 1Change at Cycle 9 Day 1Change at Cycle 10 Day 1Change at Cycle 11 Day 1Change at Cycle 12 Day 1Change at Cycle 13 Day 1Change at Cycle 14 Day 1Change at Cycle 15 Day 1Change at Cycle 16 Day 1Change at Cycle 17 Day 1Change at Cycle 18 Day 1Change at Cycle 19 Day 1Change at Cycle 20 Day 1Change at Cycle 21 Day 1Change at Cycle 22 Day 1Change at Cycle 23 Day 1Change at End of TreatmentChange at 30 Day Follow Up
Phase 3:Doublet Arm60.7-4.33.83.54.24.35.64.34.2-5.6-2.83.9-4.6-3.2-6.02.8-5.6-2.8-8.3-8.3-8-16.7-16.70.0-13.1-10.4

[back to top]

(Phase 3) Change From Baseline in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire for Cancer Participants (QLQ-C30) Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet

The EORTC QLQ-C30 questionnaire consisted of 30 questions generating 5 functional scores (physical, role, cognitive, emotional, & social); a global health (GH) status/global quality of life scale score; 3 symptom scale scores (fatigue, pain, & nausea & vomiting); & 6 standalone one-item scores that capture additional symptoms (dyspnea, appetite loss, sleep disturbance, constipation, & diarrhea) & perceived financial burden. All items were graded by severity experienced during previous week & used 4-point-scale (1: not at all, 2: a little, 3: quite a bit, 4: very much). The scores were converted to health-related quality of life (HRQoL) scale ranging from 0-100. Higher scores indicating higher response levels (i.e., higher functioning, higher symptom severity). (NCT02928224)
Timeframe: Baseline, Cycle(C)1 Day(D)1 , C2 D1, C3 D1, C4 D1, C5 D1, C6 D1, C7 D1, C8 D1, C9 D1, C10 D1, C11 D1, C12 D1, C13 D1, C14 D1, C15 D1, C16 D1, C17 D1, C18 D1, C19 D1, C20 D1, C21 D1, C22 D1, C23 D1, End of Treatment, 30 Day Follow Up(each cycle of 28 days)

InterventionUnits on a scale (Mean)
BaselineChange at Cycle 1 Day 1Change at Cycle 2 Day 1Change at Cycle 3 Day 1Change at Cycle 4 Day 1Change at Cycle 5 Day 1Change at Cycle 6 Day 1Change at Cycle 7 Day 1Change at Cycle 8 Day 1Change at Cycle 9 Day 1Change at Cycle 10 Day 1Change at Cycle 11 Day 1Change at Cycle 12 Day 1Change at Cycle 13 Day 1Change at Cycle 14 Day 1Change at Cycle 15 Day 1Change at Cycle 16 Day 1Change at Cycle 17 Day 1Change at Cycle 18 Day 1Change at Cycle 19 Day 1Change at Cycle 20 Day 1Change at Cycle 21 Day 1Change at End of TreatmentChange at 30 Day Follow Up
Phase 3: Triplet Arm62.8-2.4-1.60.70.2-1.1-4.0-2.5-2.6-5.8-3.3-5.20.00.0-1.23.6-16.7-27.8-16.70.0-250.0-14.1-17.4

[back to top]

(Phase 3) Change From Baseline in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire for Cancer Participants (QLQ-C30) Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet

The EORTC QLQ-C30 questionnaire consisted of 30 questions generating 5 functional scores (physical, role, cognitive, emotional, & social); a global health (GH) status/global quality of life scale score; 3 symptom scale scores (fatigue, pain, & nausea & vomiting); & 6 standalone one-item scores that capture additional symptoms (dyspnea, appetite loss, sleep disturbance, constipation, & diarrhea) & perceived financial burden. All items were graded by severity experienced during previous week & used 4-point-scale (1: not at all, 2: a little, 3: quite a bit, 4: very much). The scores were converted to health-related quality of life (HRQoL) scale ranging from 0-100. Higher scores indicating higher response levels (i.e., higher functioning, higher symptom severity). (NCT02928224)
Timeframe: Baseline, Cycle(C)1 Day(D)1 , C2 D1, C3 D1, C4 D1, C5 D1, C6 D1, C7 D1, C8 D1, C9 D1, C10 D1, C11 D1, C12 D1, C13 D1, C14 D1, C15 D1, C16 D1, C17 D1, C18 D1, C19 D1, C20 D1, C21 D1, C22 D1, C23 D1, End of Treatment, 30 Day Follow Up(each cycle of 28 days)

InterventionUnits on a scale (Mean)
BaselineChange at Cycle 1 Day 1Change at Cycle 2 Day 1Change at Cycle 3 Day 1Change at Cycle 4 Day 1Change at Cycle 5 Day 1Change at Cycle 6 Day 1Change at Cycle 7 Day 1Change at Cycle 8 Day 1Change at Cycle 9 Day 1Change at Cycle 10 Day 1Change at Cycle 11 Day 1Change at Cycle 12 Day 1Change at Cycle 13 Day 1Change at End of TreatmentChange at 30 Day Follow Up
Phase 3:Control Arm62.8-3.4-1.9-0.21.4-2.2-4.51.70.0-4.82.133.34.20.0-15.5-24.6

[back to top]

Phase 3: Number of Participants With Clinically Notable Shifts in Urinalysis Laboratory Parameters

Clinically notable shifts was defined as worsening by at least 2 grades or to >= Grade 3 based on CTCAE version 4.03 where Grade 1: mild, Grade 2: moderate, Grade 3: severe, Grade 4: life threatening and Grade 5: death. (NCT02928224)
Timeframe: From start of study treatment until 30 days post last dose of study treatment (for triplet arm: maximum treatment exposure of 277.4 weeks; for doublet arm: maximum treatment exposure of 268 weeks; for Control arm: maximum treatment exposure of 108 weeks)

InterventionParticipants (Count of Participants)
Phase 3: Triplet Arm8
Phase 3: Doublet Arm8
Phase 3: Control Arm5

[back to top]

(Safety Lead-in) Time to Response by Investigator

Time to response was defined as the time from first dose to first radiographic evidence of response. (NCT02928224)
Timeframe: From first dose to first radiographic evidence of response (maximum treatment exposure of 280 weeks)

InterventionMonths (Median)
Combined Safety Lead-in1.45

[back to top]

(Safety Lead-in) Time to Response by BICR

Time to response was defined as the time from first dose to first radiographic evidence of response. (NCT02928224)
Timeframe: From first dose to first radiographic evidence of response (maximum treatment exposure of 280 weeks)

InterventionMonths (Median)
Combined Safety Lead-in1.45

[back to top]

(Safety Lead-in) Progression-Free Survival (PFS) by Investigator

PFS was defined as the time from first dose to the earliest documented PD or death due to any cause. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated. (NCT02928224)
Timeframe: From first dose to the earliest documented PD or death due to any cause (maximum treatment exposure of 280 weeks)

InterventionMonths (Median)
Combined Safety Lead-in8.08

[back to top]

(Safety Lead-in) Progression-Free Survival (PFS) by BICR

PFS was defined as the time from first dose to the earliest documented PD or death due to any cause. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated. (NCT02928224)
Timeframe: From first dose to the earliest documented PD or death due to any cause (maximum treatment exposure of 280 weeks)

InterventionMonths (Median)
Combined Safety Lead-in5.59

[back to top]

(Safety Lead-in) Objective Response Rate (ORR) by Investigator

ORR per RECIST, v1.1, was defined as the percentage of participants achieving an overall best response of CR or PR, where CR: disappearance of all target and non-target lesions and normalization of tumor marker level, all lymph nodes must be non-pathological in size (<10 mm short axis), and PR: at least 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters persistence of one or more non-target lesions and/or maintenance of tumor marker level above the normal limits. (NCT02928224)
Timeframe: From start of study treatment until 30 days post last dose of study treatment (maximum treatment exposure of 280 weeks)

InterventionPercentage of participants (Number)
Combined Safety Lead-in52.8

[back to top]

(Safety Lead-in) Objective Response Rate (ORR) by BICR

ORR per RECIST, v1.1, was defined as the percentage of participants achieving an overall best response of CR or PR, where CR: disappearance of all target and non-target lesions and normalization of tumor marker level, all lymph nodes must be non-pathological in size (<10 mm short axis), and PR: at least 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters persistence of one or more non-target lesions and/or maintenance of tumor marker level above the normal limits. (NCT02928224)
Timeframe: From start of study treatment until 30 days post last dose of study treatment (maximum treatment exposure of 280 weeks)

InterventionPercentage of participants (Number)
Combined Safety Lead-in41.7

[back to top]

(Safety Lead-in) Number of Participants With Dose-Limiting Toxicities (DLTs)

(NCT02928224)
Timeframe: Cycle 1 (up to 28 days)

InterventionParticipants (Count of Participants)
Combined Safety Lead-in (CSLI)5

[back to top]

(Safety Lead-in) Number of Participants With Adverse Events (AEs)

An AE is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study drug, whether or not considered related to the study drug. Number of participants reporting AEs were reported in this outcome measure. (NCT02928224)
Timeframe: Duration of safety lead-in, approximately 6 months (up to 28 days per cycle)

InterventionParticipants (Count of Participants)
Combined Safety Lead-in37

[back to top]

(Safety Lead-in) Incidence of Dose Interruptions, Dose Modifications and Discontinuations Due to Adverse Events (AEs) - Interim Analysis

An AE is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study drug, whether or not considered related to the study drug. Number of participants with dose interruptions, dose modifications and dose discontinuations due to AEs were reported in this outcome measure. (NCT02928224)
Timeframe: Duration of safety lead-in, approximately 6 months (up to 28 days per cycle)

InterventionParticipants (Count of Participants)
Combined Safety Lead-in26

[back to top] [back to top] [back to top] [back to top]

(Safety Lead-in) Incidence of Dose Interruptions, Dose Modifications and Discontinuations Due to Adverse Events (AEs) - Final Analysis

An AE is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study drug, whether or not considered related to the study drug. Number of participants according to incidence of dose interruptions, dose modifications and dose discontinuations due to AEs were reported in this outcome measure. (NCT02928224)
Timeframe: From start of study treatment until 30 days post last dose of study treatment (maximum treatment exposure of 280 weeks)

InterventionParticipants (Count of Participants)
Dose interruptionsDose modificationsDiscontinuation due to AEs
Combined Safety Lead-in30168

[back to top]

(Safety Lead-in) Duration of Response (DOR) by Investigator

DOR was defined as the time from first radiographic evidence of response to the earliest documented disease progression (PD) or death due to underlying disease. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated. (NCT02928224)
Timeframe: From time of response to the earliest documented PD or death due to underlying disease (maximum treatment exposure of 280 weeks)

InterventionMonths (Median)
Combined Safety Lead-in6.47

[back to top]

(Safety Lead-in) Duration of Response (DOR) by BICR

DOR was defined as the time from first radiographic evidence of response to the earliest documented PD or death due to underlying disease. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated. (NCT02928224)
Timeframe: From time of response to the earliest documented PD or death due to underlying disease (maximum treatment exposure of 280 weeks)

InterventionMonths (Median)
Combined Safety Lead-in8.15

[back to top]

(Phase 3) Overall Survival (OS) of Triplet Arm vs. Control Arm - Interim Analysis

OS was defined as the time from randomization to death due to any cause. (NCT02928224)
Timeframe: From randomization to death due to any cause until 204 deaths were observed (maximum treatment exposure of 89.1 weeks for triplet arm and 52.4 weeks for control arm)

InterventionMonths (Median)
Phase 3: Triplet Arm9.03
Phase 3: Control Arm5.42

[back to top]

(Phase 3) Overall Survival (OS) of Triplet Arm vs. Control Arm - Final Analysis

OS was defined as the time from randomization to death due to any cause. (NCT02928224)
Timeframe: From randomization to death due to any cause (maximum treatment exposure of 277.4 weeks for triplet arm and 108 weeks for control arm)

InterventionMonths (Median)
Phase 3: Triplet Arm9.82
Phase 3:Control Arm5.88

[back to top]

(Phase 3) Overall Survival (OS) in Triplet Arm vs. Doublet Arm

OS was defined as the time from randomization to death due to any cause. (NCT02928224)
Timeframe: From randomization to death due to any cause until 204 deaths were observed (maximum treatment exposure of 89.7 weeks for doublet arm and 89.1 weeks for triplet arm)

InterventionMonths (Median)
Phase 3: Triplet Arm9.82
Phase 3: Doublet Arm9.40

[back to top] [back to top]

(Phase 3) Overall Survival (OS) in Doublet Arm vs. Control Arm

OS was defined as the time from randomization to death due to any cause. (NCT02928224)
Timeframe: From randomization to death due to any cause until 204 deaths were observed (maximum treatment exposure of 89.7 weeks for doublet arm and 52.4 weeks for control arm)

InterventionMonths (Median)
Phase 3: Doublet Arm9.40
Phase 3:Control Arm5.88

[back to top]

(Phase 3) Objective Response Rate (ORR) by Blinded Independent Central Review (BICR) Per Response Evaluation Criteria in Solid Tumors (RECIST), v1.1 of Triplet Arm vs. Control Arm

ORR per RECIST, v1.1, was defined as the percentage of participants achieving an overall best response of complete response (CR) or partial response (PR), where CR: disappearance of all target and non-target lesions and normalization of tumor marker level, all lymph nodes must be non-pathological in size (<10 millimeter [mm] short axis), and PR: at least 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters persistence of one or more non-target lesions and/or maintenance of tumor marker level above the normal limits. (NCT02928224)
Timeframe: Duration of Phase 3, approximately 6 months (up to 28 days per cycle)

InterventionPercentage of participants (Number)
Phase 3: Triplet Arm26.1
Phase 3:Control Arm1.9

[back to top]

(Phase 3) Evaluation of the Model-Based Oral Clearance (CL/F) for Encorafenib

The reported cross-arm CL/F value is a fixed-effect parameter determined from a population PK analysis. The analysis included pooled data from participants enrolled in multiple studies including those who were not enrolled in this study. The NCTID include: NCT01719380, NCT01543698, and NCT01436656. An additional study ARRAY-162-105 is not required to register. (NCT02928224)
Timeframe: 2 and 6 hours post-dose on Day 1 of Cycle 1, Predose and 2 hours post-dose on Day 1 of Cycle 2 (each cycle of 28 days)

InterventionLiter/hour (Geometric Mean)
Pharmacokinetic Population of Encorafenib16.4

[back to top]

(Phase 3) Evaluation of the Model-Based Oral Clearance (CL/F) for Binimetinib

The reported cross-arm CL/F value is a fixed-effect parameter determined from a population PK analysis. The analysis included pooled data from participants enrolled in multiple studies including those who were not enrolled in this study. The NCTID include: NCT01719380, NCT01543698, and NCT01436656. An additional study ARRAY-162-105 is not required to register. (NCT02928224)
Timeframe: 2 and 6 hours post-dose on Day 1 of Cycle 1, Predose and 2 hours post-dose on Day 1 of Cycle 2 (each cycle of 28 days)

InterventionLiter/hour (Geometric Mean)
Pharmacokinetic Population of Encorafenib19.0

[back to top]

(Phase 3) Evaluation of the Model-Based Clearance (CL) for Cetuximab

The reported cross-arm CL/F value is a fixed-effect parameter determined from a population PK analysis. The analysis included pooled data from participants enrolled in multiple studies including those who were not enrolled in this study. The NCTID include: NCT01719380, NCT01543698, and NCT01436656. An additional study ARRAY-162-105 is not required to register. (NCT02928224)
Timeframe: 2 and 6 hours post-dose on Day 1 of Cycle 1, Predose and 2 hours post-dose on Day 1 of Cycle 2 (each cycle of 28 days)

InterventionLiter/hour (Geometric Mean)
Pharmacokinetic Population of Encorafenib0.0154

[back to top]

(Phase 3) Comparison of Time to Response in Triplet Arm vs Doublet Arm Per Investigator

Time to response was defined as the time from first dose to first radiographic evidence of response. (NCT02928224)
Timeframe: From first dose to first radiographic evidence of response (maximum treatment exposure of 277.4 weeks for triplet arm and 268 weeks for doublet arm)

InterventionMonths (Median)
Phase 3: Triplet Arm1.48
Phase 3:Doublet Arm1.48

[back to top]

(Phase 3) Comparison of Time to Response in Triplet Arm vs Doublet Arm Per BICR

Time to response was defined as the time from first dose to first radiographic evidence of response. (NCT02928224)
Timeframe: From first dose to first radiographic evidence of response (maximum treatment exposure of 277.4 weeks for triplet arm and 268 weeks for doublet arm)

InterventionMonths (Median)
Phase 3: Triplet Arm1.43
Phase 3:Doublet Arm1.48

[back to top]

(Phase 3) Comparison of Time to Response in Triplet Arm vs Control Arm Per Investigator

Time to response was defined as the time from first dose to first radiographic evidence of response. (NCT02928224)
Timeframe: From first dose to first radiographic evidence of response (maximum treatment exposure of 277.4 weeks for triplet arm and 108 weeks for control arm)

InterventionMonths (Median)
Phase 3: Triplet Arm1.48
Phase 3:Control Arm2.63

[back to top]

(Phase 3) Comparison of Time to Response in Triplet Arm vs Control Arm Per BICR

Time to response was defined as the time from first dose to first radiographic evidence of response. (NCT02928224)
Timeframe: From first dose to first radiographic evidence of response (maximum treatment exposure of 277.4 weeks for triplet arm and 108 weeks for control arm)

InterventionMonths (Median)
Phase 3: Triplet Arm1.43
Phase 3:Control Arm1.45

[back to top]

(Phase 3) Comparison of Time to Response in Doublet Arm vs Control Arm Per Investigator

Time to response was defined as the time from first dose to first radiographic evidence of response. (NCT02928224)
Timeframe: From first dose to first radiographic evidence of response (maximum treatment exposure of 268 weeks for doublet arm and 108 weeks for control arm)

InterventionMonths (Median)
Phase 3: Doublet Arm1.48
Phase 3:Control Arm2.63

[back to top]

(Phase 3) Comparison of Time to Response in Doublet Arm vs Control Arm Per BICR

Time to response was defined as the time from first dose to first radiographic evidence of response. (NCT02928224)
Timeframe: From first dose to first radiographic evidence of response (maximum treatment exposure of 268 weeks for doublet arm and 108 weeks for control arm)

InterventionMonths (Median)
Phase 3: Doublet Arm1.48
Phase 3:Control Arm1.45

[back to top]

(Phase 3) Comparison of Progression-Free Survival (PFS) in Triplet Arm vs Doublet Arm Per Investigator

PFS was defined as the time from first dose to the earliest documented PD or death due to any cause. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated. (NCT02928224)
Timeframe: From first dose to the earliest documented PD or death due to any cause (maximum treatment exposure of 277.4 weeks for triplet arm and 268 weeks for doublet arm)

InterventionMonths (Median)
Phase 3: Triplet Arm4.47
Phase 3: Doublet Arm4.27

[back to top]

(Phase 3) Comparison of Progression-Free Survival (PFS) in Triplet Arm vs Doublet Arm Per BICR

PFS was defined as the time from first dose to the earliest documented PD or death due to any cause. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated. (NCT02928224)
Timeframe: From first dose to the earliest documented PD or death due to any cause (maximum treatment exposure of 277.4 weeks for triplet arm and 268 weeks for doublet arm)

InterventionMonths (Median)
Phase 3: Triplet Arm4.30
Phase 3: Doublet Arm4.21

[back to top]

(Phase 3) Comparison of Progression-Free Survival (PFS) in Triplet Arm vs Control Arm Per BICR

PFS was defined as the time from first dose to the earliest documented PD or death due to any cause. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated. (NCT02928224)
Timeframe: From first dose to the earliest documented PD or death due to any cause (maximum treatment exposure of 277.4 weeks for triplet arm and 108 weeks for control arm)

InterventionMonths (Median)
Phase 3: Triplet Arm4.30
Phase 3:Control Arm1.51

[back to top]

(Phase 3) Comparison of Progression-Free Survival (PFS) in Doublet Arm vs Control Arm Per Investigator

PFS was defined as the time from first dose to the earliest documented PD or death due to any cause. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated. (NCT02928224)
Timeframe: From first dose to the earliest documented PD or death due to any cause (maximum treatment exposure of 268 weeks for doublet arm and 108 weeks for control arm)

InterventionMonths (Median)
Phase 3: Doublet Arm4.27
Phase 3:Control Arm1.58

[back to top]

(Phase 3) Comparison of Progression-Free Survival (PFS) in Doublet Arm vs Control Arm Per BICR

PFS was defined as the time from first dose to the earliest documented PD or death due to any cause. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated. (NCT02928224)
Timeframe: From first dose to the earliest documented PD or death due to any cause (maximum treatment exposure of 268 weeks for doublet arm and 108 weeks for control arm)

InterventionMonths (Median)
Phase 3: Doublet Arm4.21
Phase 3:Control Arm1.51

[back to top]

(Phase 3) Comparison of Objective Response Rate (ORR) in Triplet Arm vs Doublet Arm Per Investigator

ORR per RECIST, v1.1, was defined as the percentage of participants achieving an overall best response of CR or PR, where CR: disappearance of all target and non-target lesions and normalization of tumor marker level, all lymph nodes must be non-pathological in size (<10 mm short axis), and PR: at least 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters persistence of one or more non-target lesions and/or maintenance of tumor marker level above the normal limits. (NCT02928224)
Timeframe: Duration of Phase 3, approximately 6 months (up to 28 days per cycle)

InterventionPercentage of participants (Number)
Phase 3: Triplet Arm26.1
Phase 3: Doublet Arm15.9

[back to top]

(Phase 3) Comparison of Objective Response Rate (ORR) in Triplet Arm vs Doublet Arm Per BICR

ORR per RECIST, v1.1, was defined as the percentage of participants achieving an overall best response of CR or PR, where CR: disappearance of all target and non-target lesions and normalization of tumor marker level, all lymph nodes must be non-pathological in size (<10 mm short axis), and PR: at least 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters persistence of one or more non-target lesions and/or maintenance of tumor marker level above the normal limits. (NCT02928224)
Timeframe: Duration of Phase 3, approximately 6 months (up to 28 days per cycle)

InterventionPercentage of participants (Number)
Phase 3: Triplet Arm26.1
Phase 3: Doublet Arm20.4

[back to top]

(Phase 3) Comparison of Progression-free Survival (PFS) in Triplet Arm vs Control Arm Per Investigator

PFS was defined as the time from first dose to the earliest documented PD or death due to any cause. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated. (NCT02928224)
Timeframe: From first dose to the earliest documented PD or death due to any cause (maximum treatment exposure of 277.4 weeks for triplet arm and 108 weeks for control arm)

InterventionMonths (Median)
Phase 3: Triplet Arm4.47
Phase 3:Control Arm1.58

[back to top]

Phase 3: Number of Participants With Shifts in Left Ventricular Ejection Fraction (LVEF) From Baseline to Maximum Grade On-treatment

Left ventricular ejection fraction (LVEF) abnormalities were defined according to CTCAE version 4.03 where Grade 0: Non-missing value below Grade 2, Grade 2: LVEF between 40% and 50% or absolute change from baseline between -10% and < -20%, Grade 3: LVEF between 20% and 39% or absolute change from baseline <= -20%, Grade 4: LVEF lower than 20%. Categories with at least 1 non-zero data values showing any shift in Grade from baseline to 1 day after dose 1 (post-baseline) were reported. Participants whose grade category was unchanged (e.g. Grade 0 to Grade 0) were not reported. (NCT02928224)
Timeframe: From start of study treatment until 30 days post last dose of study treatment (for triplet arm: maximum treatment exposure of 277.4 weeks; for doublet arm: maximum treatment exposure of 268 weeks; for Control arm: maximum treatment exposure of 108 weeks)

,,
InterventionParticipants (Count of Participants)
Baseline Grade 0 to Grade 2 post baselineBaseline Grade 0 to Grade 3 post baselineBaseline Grade 0 to missing gradeBaseline Grade 2 to missing gradeBaseline missing grade to Grade 0 post baseline
Phase 3: Control Arm0018620
Phase 3: Doublet Arm0120530
Phase 3: Triplet Arm2711701

[back to top]

Phase 3: Number of Participants With Shift in Visual Acuity Logarithm of the Minimum Angle of Resolution (LogMAR) Score

Visual acuity was measured using the Snellen visual acuity conversion chart. This was determined by establishing the smallest optotypes that could be identified correctly by the participant at a given observation distance. Snellen visual acuity was reported as a Snellen fraction (m/M) in which the numerator (m) indicated the test distance and the denominator (M) indicated the distance at which the gap of the equivalent Landolt ring subtends 1 minute of arc. The LogMAR score was calculated as - log(m/M). The maximum increase in score of <= 0, 0 to < 0.1, 0.1 to < 0.2, 0.2 to < 0.3 and >=0.3 relative to baseline in LogMAR were reported in this endpoint. (NCT02928224)
Timeframe: From start of study treatment until 30 days post last dose of study treatment (for triplet arm: maximum treatment exposure of 277.4 weeks; for doublet arm: maximum treatment exposure of 268 weeks; for Control arm: maximum treatment exposure of 108 weeks)

,,
InterventionParticipants (Count of Participants)
Baseline <=0 to >0-<0.1Baseline <=0 to 0.1-<0.2Baseline <=0 to 0.2-<0.3Baseline <=0 to >=0.3Baseline <=0 to missing scoreBaseline >0-<0.1 to <=0Baseline >0-<0.1 to 0.1-<0.2Baseline >0-<0.1 to 0.2-<0.3Baseline >0-<0.1 to >=0.3Baseline >0-<0.1 to missing scoreBaseline 0.1-<0.2 to <=0Baseline 0.1-<0.2 to >0-<0.1Baseline 0.2-<0.3 to <=0Baseline 0.2-<0.3 to >0-<0.1Baseline 0.2-<0.3 to 0.1-<0.2Baseline 0.2-<0.3 to missing scoreBaseline >=0.3 to <=0Baseline >=0.3 to >0-<0.1Baseline >=0.3 to 0.1-<0.2Baseline >=0.3 to 0.2-<0.3Baseline >=0.3 to missing scoreBaseline 0.1-<0.2 to 0.2-<0.3Baseline 0.1-<0.2 to missing score
Phase 3: Control Arm000012900003000000500001307
Phase 3: Doublet Arm83018662102510001420101939
Phase 3: Triplet Arm33154691774335113319412100

[back to top]

Phase 3: Number of Participants With Newly Occurring Clinically Notable Vital Sign Abnormalities

Newly occurring clinically notable changes was defined as participants not meeting the criterion at baseline and meeting criterion post-baseline. The criterion included: low/high systolic blood pressure (SBP): <= 90 millimeters of mercury (mmHg) with decrease from baseline of >= 20mmHg or >= 160mmHg with increase from baseline of >= 20mmHg, low or high diastolic blood pressure (DBP): <= 50mmHg with decrease from baseline of >= 15mmHg or >= 100mmHg with increase from baseline of >= 15mmHg, low or high pulse: <= 50 beats/min with decrease from baseline of >= 15 beats/min or >= 120 beats/min with increase from baseline of >= 15 beats/min, low or high temperature: <= 36 degree Celsius (deg C) or >= 37.5 deg C. (NCT02928224)
Timeframe: From start of study treatment until 30 days post last dose of study treatment (for triplet arm: maximum treatment exposure of 277.4 weeks; for doublet arm: maximum treatment exposure of 268 weeks; for Control arm: maximum treatment exposure of 108 weeks)

,,
InterventionParticipants (Count of Participants)
Diastolic Blood Pressure - HighDiastolic Blood Pressure - LowPulse Rate - HighPulse Rate - LowSystolic Blood Pressure - HighSystolic Blood Pressure - LowTemperature - HighTemperature - Low
Phase 3: Control Arm752035102555
Phase 3: Doublet Arm62714413282384
Phase 3: Triplet Arm82123319373393

[back to top]

Phase 3: Number of Participants With Newly Occurring Clinically Notable Electrocardiogram (ECG) Values

Newly occurring clinically notable changes was defined as participants not meeting the criterion at baseline and meeting criterion post-baseline. The criterion included: heart rate- decrease from baseline > 25% and to a value < 50 and increase from baseline > 25% and to a value > 100. QT interval- new > 450 (millisecond) msec, new > 480 msec, new > 500 msec, increase from baseline > 30 msec and increase from baseline > 60 msec. QTcF- new > 450 msec, new > 480 msec, new > 500 msec, increase from baseline > 30 msec and increase from baseline > 60 msec. (NCT02928224)
Timeframe: From start of study treatment until 30 days post last dose of study treatment (for triplet arm: maximum treatment exposure of 277.4 weeks; for doublet arm: maximum treatment exposure of 268 weeks; for Control arm: maximum treatment exposure of 108 weeks)

,,
InterventionParticipants (Count of Participants)
Heart Rate - Decrease from baseline > 25% and to a value < 50Heart Rate - Increase from baseline > 25% and to a value > 100QT Interval - New > 450 millisecond (msec)QT Interval - New > 480 msecQT Interval - New > 500 msecQT Interval - increase from baseline > 30 msecQT Interval - increase from baseline > 60 msecQTcF - New > 450 msecQTcF - New > 480 msecQTcF - New > 500 msecQTcF - increase from baseline > 30 msecQTcF - increase from baseline > 60 msec
Phase 3: Control Arm02872032102352245
Phase 3: Doublet Arm42430759921511867520
Phase 3: Triplet Arm1271743972239915912

[back to top]

Phase 3: Number of Participants With Clinically Notable Shifts in Serum Chemistry Laboratory Parameters

Clinically notable shifts was defined as worsening by at least 2 grades or to >= Grade 3 based on CTCAE version 4.03 where Grade 1: mild, Grade 2: moderate, Grade 3: severe, Grade 4: life threatening and Grade 5: death. (NCT02928224)
Timeframe: From start of study treatment until 30 days post last dose of study treatment (for triplet arm: maximum treatment exposure of 277.4 weeks; for doublet arm: maximum treatment exposure of 268 weeks; for Control arm: maximum treatment exposure of 108 weeks)

,,
InterventionParticipants (Count of Participants)
Alanine Aminotransferase - HyperAlbumin - HypoAlkaline Phosphatase - HyperAspartate Aminotransferase - HyperBilirubin - HyperCalcium - HyperCalcium - HypoCreatine Kinase - HyperCreatinine - HyperGlucose - HyperGlucose - HypoMagnesium - HyperMagnesium - HypoPotassium - HyperPotassium - HypoSodium - HyperSodium - HypoTroponin I - HyperUrate - Hyper
Phase 3: Control Arm10171891207364129592501
Phase 3: Doublet Arm7161271308111160141071402
Phase 3: Triplet Arm115013111111518458401114511004

[back to top]

Phase 3: Number of Participants With Clinically Notable Shifts in Hematology and Coagulation Laboratory Parameters

Clinically notable shifts was defined as worsening by at least 2 grades or to more than or equal to (>=) Grade 3 based on Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 where Grade 1: mild, Grade 2: moderate, Grade 3: severe, Grade 4: life threatening and Grade 5: death. (NCT02928224)
Timeframe: From start of study treatment until 30 days post last dose of study treatment (for triplet arm: maximum treatment exposure of 277.4 weeks; for doublet arm: maximum treatment exposure of 268 weeks; for Control arm: maximum treatment exposure of 108 weeks)

,,
InterventionParticipants (Count of Participants)
Activated Partial Thromboplastin Time - HyperHemoglobin - HyperHemoglobin - HypoLeukocytes - HyperLeukocytes - HypoLymphocytes - HyperLymphocytes - HypoNeutrophils - HypoPlatelets - HypoProthrombin Intl. Normalized Ratio - Hyper
Phase 3: Doublet Arm903009347852
Phase 3: Triplet Arm9097021225413
Phase 3:Control Arm40170514576542

[back to top]

(Safety Lead-in) Evaluation of the Time of Maximum Observed Concentration (Tmax) for Metabolite of Binimetinib (AR00426032)

(NCT02928224)
Timeframe: Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 (each cycle of 28 days)

InterventionHours (Median)
Cycle 1Cycle 2
Combined Safety Lead-in2.001.58

[back to top]

(Safety Lead-in) Evaluation of the Time of Maximum Observed Concentration (Tmax) for Encorafenib

(NCT02928224)
Timeframe: Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 (each cycle of 28 days)

InterventionHours (Median)
Cycle 1Cycle 2
Combined Safety Lead-in2.002.00

[back to top]

(Safety Lead-in) Evaluation of the Time of Maximum Observed Concentration (Tmax) for Cetuximab

(NCT02928224)
Timeframe: Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 (each cycle of 28 days)

InterventionHours (Median)
Cycle 1Cycle 2
Combined Safety Lead-in3.773.05

[back to top]

(Safety Lead-in) Evaluation of the Time of Maximum Observed Concentration (Tmax) for Binimetinib

(NCT02928224)
Timeframe: Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 (each cycle of 28 days)

InterventionHours (Median)
Cycle 1Cycle 2
Combined Safety Lead-in1.981.04

[back to top]

(Safety Lead-in) Evaluation of the Maximum Concentration (Cmax) for Metabolite of Binimetinib (AR00426032)

(NCT02928224)
Timeframe: Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 (each cycle of 28 days)

InterventionNanogram/milliliter (Geometric Mean)
Cycle 1Cycle 2
Combined Safety Lead-in59.920.5

[back to top]

(Safety Lead-in) Evaluation of the Maximum Concentration (Cmax) for Encorafenib

(NCT02928224)
Timeframe: Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 (each cycle of 28 days)

InterventionNanogram/milliliter (Geometric Mean)
Cycle 1Cycle 2
Combined Safety Lead-in33602490

[back to top]

(Safety Lead-in) Evaluation of the Maximum Concentration (Cmax) for Cetuximab

(NCT02928224)
Timeframe: Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 (each cycle of 28 days)

InterventionNanogram/milliliter (Geometric Mean)
Cycle 1Cycle 2
Combined Safety Lead-in195000199000

[back to top]

(Safety Lead-in) Evaluation of the Maximum Concentration (Cmax) for Binimetinib

(NCT02928224)
Timeframe: Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 (each cycle of 28 days)

InterventionNanogram/milliliter (Geometric Mean)
Cycle 1Cycle 2
Combined Safety Lead-in654524

[back to top]

(Safety Lead-in) Evaluation of the Area Under the Concentration-time Curve From Zero to the Last Measurable Time Point (AUClast) for Metabolite of Binimetinib (AR00426032)

(NCT02928224)
Timeframe: Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 (each cycle of 28 days)

InterventionNanogram/milliliter *hour (Geometric Mean)
Cycle 1Cycle 2
Combined Safety Lead-in20670.0

[back to top]

(Safety Lead-in) Evaluation of the Area Under the Concentration-Time Curve From Zero to the Last Measurable Time Point (AUClast) for Encorafenib

(NCT02928224)
Timeframe: Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 (each cycle of 28 days)

InterventionNanogram/milliliter *hour (Geometric Mean)
Cycle 1Cycle 2
Combined Safety Lead-in113006660

[back to top]

(Safety Lead-in) Evaluation of the Area Under the Concentration-Time Curve From Zero to the Last Measurable Time Point (AUClast) for Cetuximab

(NCT02928224)
Timeframe: Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 (each cycle of 28 days)

InterventionNanogram/milliliter *hour (Geometric Mean)
Cycle 1Cycle 2
Combined Safety Lead-in841000970000

[back to top]

(Phase 3) Comparison of Duration of Response (DOR) in Doublet Arm vs Control Arm Per BICR

DOR was defined as the time from first radiographic evidence of response to the earliest documented PD or death due to underlying disease. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated. (NCT02928224)
Timeframe: From time of response to PD or death due to underlying disease (maximum treatment exposure of 268 weeks for doublet arm and 108 weeks for control arm)

InterventionMonths (Median)
Phase 3: Doublet Arm6.06
Phase 3:Control ArmNA

[back to top]

(Safety Lead-in) Evaluation of the Area Under the Concentration-Time Curve From Zero to the Last Measurable Time Point (AUClast) for Binimetinib

(NCT02928224)
Timeframe: Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 (each cycle of 28 days)

InterventionNanogram/milliliter *hour (Geometric Mean)
Cycle 1Cycle 2
Combined Safety Lead-in19601540

[back to top]

(Phase 3) Comparison of Objective Response Rate (ORR) in Triplet Arm vs Control Arm Per Investigator

ORR per RECIST, v1.1, was defined as the percentage of participants achieving an overall best response of CR or PR, where CR: disappearance of all target and non-target lesions and normalization of tumor marker level, all lymph nodes must be non-pathological in size (<10 mm short axis), and PR: at least 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters persistence of one or more non-target lesions and/or maintenance of tumor marker level above the normal limits. (NCT02928224)
Timeframe: Duration of Phase 3, approximately 6 months (up to 28 days per cycle)

InterventionPercentage of participants (Number)
Phase 3: Triplet Arm26.1
Phase 3:Control Arm3.7

[back to top]

(Phase 3) Comparison of Objective Response Rate (ORR) in Doublet Arm vs Control Arm Per Investigator

ORR per RECIST, v1.1, was defined as the percentage of participants achieving an overall best response of CR or PR, where CR: disappearance of all target and non-target lesions and normalization of tumor marker level, all lymph nodes must be non-pathological in size (<10 mm short axis), and PR: at least 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters persistence of one or more non-target lesions and/or maintenance of tumor marker level above the normal limits. (NCT02928224)
Timeframe: Duration of Phase 3, approximately 6 months (up to 28 days per cycle)

InterventionPercentage of participants (Number)
Phase 3: Doublet Arm15.9
Phase 3:Control Arm3.7

[back to top]

(Phase 3) Comparison of Objective Response Rate (ORR) in Doublet Arm vs Control Arm Per BICR

ORR per RECIST, v1.1, was defined as the percentage of participants achieving an overall best response of CR or PR, where CR: disappearance of all target and non-target lesions and normalization of tumor marker level, all lymph nodes must be non-pathological in size (<10 mm short axis), and PR: at least 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters persistence of one or more non-target lesions and/or maintenance of tumor marker level above the normal limits. (NCT02928224)
Timeframe: Duration of Phase 3, approximately 6 months (up to 28 days per cycle)

InterventionPercentage of participants (Number)
Phase 3: Doublet Arm20.4
Phase 3:Control Arm1.9

[back to top]

(Phase 3) Comparison of Duration of Response (DOR) in Triplet Arm vs Doublet Arm by Investigator

DOR was defined as the time from first radiographic evidence of response to the earliest documented PD or death due to underlying disease. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated. (NCT02928224)
Timeframe: From time of response to PD or death due to underlying disease (maximum treatment exposure of 277.4 weeks for triplet arm and 268 weeks for doublet arm)

InterventionMonths (Median)
Phase 3: Triplet Arm4.80
Phase 3:Doublet Arm5.70

[back to top]

(Phase 3) Comparison of Duration of Response (DOR) in Triplet Arm vs Doublet Arm by BICR

DOR was defined as the time from first radiographic evidence of response to the earliest documented PD or death due to underlying disease. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated. (NCT02928224)
Timeframe: From time of response to PD or death due to underlying disease (maximum treatment exposure of 277.4 weeks for triplet arm and 268 weeks for doublet arm)

InterventionMonths (Median)
Phase 3: Triplet Arm4.80
Phase 3:Doublet Arm6.06

[back to top]

(Phase 3) Comparison of Duration of Response (DOR) in Triplet Arm vs Control Arm Per Investigator

DOR was defined as the time from first radiographic evidence of response to the earliest documented disease progression (PD) or death due to underlying disease. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated. (NCT02928224)
Timeframe: From time of response to PD or death due to underlying disease (maximum treatment exposure of 277.4 weeks for triplet arm and 108 weeks for control arm)

InterventionMonths (Median)
Phase 3: Triplet Arm4.80
Phase 3:Control Arm5.75

[back to top]

(Phase 3) Comparison of Duration of Response (DOR) in Triplet Arm vs Control Arm Per BICR

DOR was defined as the time from first radiographic evidence of response to the earliest documented PD or death due to underlying disease. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated. (NCT02928224)
Timeframe: From time of response to PD or death due to underlying disease (maximum treatment exposure of 277.4 weeks for triplet arm and 108 weeks for control arm)

InterventionMonths (Median)
Phase 3: Triplet Arm4.80
Phase 3:Control ArmNA

[back to top]

(Phase 3) Comparison of Duration of Response (DOR) in Doublet Arm vs Control Arm Per Investigator

DOR was defined as the time from first radiographic evidence of response to the earliest documented PD or death due to underlying disease. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated. (NCT02928224)
Timeframe: From time of response to PD or death due to underlying disease (maximum treatment exposure of 268 weeks for doublet arm and 108 weeks for control arm)

InterventionMonths (Median)
Phase 3: Doublet Arm5.70
Phase 3:Control Arm5.75

[back to top]

(Phase 3) Change From Baseline in the Participant Global Impression of Change (PGIC) in Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet

"The PGIC is a measure of participant's perceptions of change in their symptoms over time that can be used as an anchoring method to determine the minimal clinically important difference for other participant reported outcome (PROs). For this assessment, participants answered the following question: Since starting treatment, my colorectal cancer symptoms are: (1) very much improved, (2) much improved, (3) minimally improved, (4) no change, (5) minimally worse, (6) much worse or (7) very much worse." (NCT02928224)
Timeframe: Baseline,Cycle (C)1 Day (D)1, C2 D1, C3 D1, C4 D1, C5 D1, C6 D1, C7 D1, C8 D1, C9 D1, C10 D1, C11 D1, C12 D1, C13 D1, C14 D1, C15 D1, C16 D1, C17 D1, C18 D1, C19 D1, C20 D1, C21 D1, C22 D1, C23 D1, End of Treatment, 30 Day Follow Up(each cycle of 28 days)

InterventionUnits on a scale (Mean)
BaselineChange at Cycle 1 Day 1Change at Cycle 2 Day 1Change at Cycle 3 Day 1Change at Cycle 4 Day 1Change at Cycle 5 Day 1Change at Cycle 6 Day 1Change at Cycle 7 Day 1Change at Cycle 8 Day 1Change at Cycle 9 Day 1Change at Cycle 10 Day 1Change at Cycle 11 Day 1Change at Cycle 12 Day 1Change at Cycle 13 Day 1Change at Cycle 14 Day 1Change at Cycle 15 Day 1Change at Cycle 16 Day 1Change at Cycle 17 Day 1Change at Cycle 18 Day 1Change at Cycle 19 Day 1Change at Cycle 20 Day 1Change at Cycle 21 Day 1Change at Cycle 22 Day 1Change at Cycle 23 Day 1Change at End of TreatmentChange at 30 Day Follow Up
Phase 3:Doublet Arm3.80.1-0.8-1.2-1.1-1.1-1.2-1.0-1.1-0.9-0.6-1.1-0.8-0.9-1.5-1.6-0.7-1.0-1.0-0.5-2.0-2.0-2.0-2.00.10.5

[back to top]

Number of Participants That Are Hospitalized Because of Adverse Events Attributed to Disease Progression

Participants hospitalized because of adverse events measured by the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 attributed to disease progression. Progression was measured by the Response Evaluation Criteria in Solid Tumors (RECIST) and is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. The appearance of one or more new lesions is also considered progressions. (NCT03050814)
Timeframe: Up to 51.5 months

InterventionParticipants (Count of Participants)
Standard of Care (SOC) - Arm A4
Standard of Care (SOC) - Arm B + Lead in4

[back to top]

Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)

Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT03050814)
Timeframe: Date treatment consent signed to date off study, approximately 33 months and 20 days for Arm A and 51 months and 7 days for Arm B.

InterventionParticipants (Count of Participants)
Standard of Care (SOC) - Arm A10
Standard of Care (SOC) - Arm B + Lead in16

[back to top]

Progression Free Survival Between the Standard of Care (SOC) Arm A, and Standard of Care (SOC) Arm B + lead-in

Progression free survival is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first. Progression was measured by the Response Evaluation Criteria in Solid Tumors (RECIST) and is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. The appearance of one or more new lesions is also considered progressions. (NCT03050814)
Timeframe: Up to 1.5 years

InterventionMonths (Median)
Standard of Care (SOC) - Arm A8.8
Standard of Care (SOC) - Arm B + Lead in10.1

[back to top]

Phases 1 and 2: Number of Participants With Dose Limiting Toxicities (DLTs)

A DLT was defined as the occurrence of any of the protocol-specified toxicities occurring up to and including Day 28 for the cohorts where mFOLFOX6 and nab-paclitaxel/gemcitabine are administered and Day 21 for all other chemotherapy regimens in Phase 1, except those with a clear alternative explanation (eg, disease progression) or transient (≤ 72 hours) abnormal laboratory values without associated clinically significant signs or symptoms based on investigator determination. (NCT03085914)
Timeframe: 28 days

InterventionParticipants (Count of Participants)
Group A: Epa + Pembrolizumab + mFOLFOX62
Group B: Epa + Pembrolizumab + Nab-Paclitaxel and Gemcitabine0
Group C: Epa + Pembrolizumab + Paclitaxel and Carboplatin0
Group D: Epa + Pembrolizumab + Pemetrexed and Platinum Agent0
Group E: Epa + Pembrolizumab + Cyclophosphamide0
Group F: Epa + Pembrolizumab + Gemcitabine and Platinum Agent3
Group G: Epa + Pembrolizumab + 5-FU and Platinum Agent0

[back to top]

Phases 1 and 2: Objective Response Rate (ORR)

ORR was defined as the percentage of participants having a complete response (CR) or partial response (PR) as determined by investigator assessment of radiographic disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. (NCT03085914)
Timeframe: Up to Week 18

,,,,,,
InterventionParticipants (Count of Participants)
Complete ResponsePartial Response
Group A: Epa + Pembrolizumab + mFOLFOX605
Group B: Epa + Pembrolizumab + Nab-Paclitaxel and Gemcitabine12
Group C: Epa + Pembrolizumab + Paclitaxel and Carboplatin03
Group D: Epa + Pembrolizumab + Pemetrexed and Platinum Agent02
Group E: Epa + Pembrolizumab + Cyclophosphamide03
Group F: Epa + Pembrolizumab + Gemcitabine and Platinum Agent01
Group G: Epa + Pembrolizumab + 5-FU and Platinum Agent05

[back to top]

Phases 1 & 2: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs

A TEAE is any AE either reported for the first time or worsening of a pre-existing event after first dose of epacadostat, pembrolizumab, or chemotherapy. Serious adverse event is defined as an event that meets 1 of the following criteria: is fatal or life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability, incapacity, or a substantial disruption of a person's ability to conduct normal life functions, constitutes a congenital anomaly or birth defect,is a medically important event that may jeopardize the participant or may require medical or surgical intervention to prevent 1 of the outcomes listed above. (NCT03085914)
Timeframe: Up to 21 months

,,,,,,
InterventionParticipants (Count of Participants)
TEAESerious TEAE
Group A: Epa + Pembrolizumab + mFOLFOX695
Group B: Epa + Pembrolizumab + Nab-Paclitaxel and Gemcitabine95
Group C: Epa + Pembrolizumab + Paclitaxel and Carboplatin113
Group D: Epa + Pembrolizumab + Pemetrexed and Platinum Agent96
Group E: Epa + Pembrolizumab + Cyclophosphamide134
Group F: Epa + Pembrolizumab + Gemcitabine and Platinum Agent86
Group G: Epa + Pembrolizumab + 5-FU and Platinum Agent115

[back to top]

Grade 3 or Greater Acute and Late Gastrointestinal Toxicity

To determine rates of grade 3 or greater gastrointestinal toxicity, including acute toxicities occurring within 3 months of treatment, and late toxicities occurring over 3 months after completion of radiation. This outcome was clarified when results were entered. The number of patients that experienced at least 1 grade 3 (or greater) event are presented. (NCT03099265)
Timeframe: Up to 40 weeks

InterventionParticipants (Count of Participants)
Patients With Borderline Resectable Pancreatic Adenocarcinoma5

[back to top]

Best Overall Response

This will be calculated from the day of first treatment dose until disease progression or death, whichever occurs earlier (NCT03099486)
Timeframe: 1-2 years

InterventionParticipants (Count of Participants)
Regorafenib + 5FU/LV Treatment ArmNA

[back to top]

Number of Toxicities Due to Regorafenib and 5-FU/LV Combination Therapy

Number of toxicities due to combination therapy will be summarized by frequencies and grades of toxicities due to the combination therapy according to CTCAE 4.03 criteria (NCT03099486)
Timeframe: 1-2 years

Interventiontoxicities (Number)
Regorafenib + 5FU/LV Treatment ArmNA

[back to top]

Overall Survival Rate

Overall survival will be calculated from the day of first treatment until death (NCT03099486)
Timeframe: 1 years

Interventionmonths (Median)
Regorafenib + 5FU/LV Treatment ArmNA

[back to top]

Progression Free Survival (PFS) at 2 Months

PFS at 2 months in mCRC patients who progress on regorafenib monotherapy and are treated with regorafenib and 5-FU/LV combination therapy. (NCT03099486)
Timeframe: 2 months

Interventionmonths (Median)
Regorafenib + 5FU/LV Treatment ArmNA

[back to top]

Change From Baseline of Clinical Chemistry Parameters: Alkaline Phosphatase, Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST)

Blood samples were collected for the analysis of clinical chemistry parameters including alkaline phosphatase, ALT and AST at indicated time points. Day -1 value was defined as Baseline for clinical chemistry parameters. Change from Baseline was defined as difference between post-dose visit values minus Baseline value. (NCT03258762)
Timeframe: Baseline (Day -1), 24, 96, 168, 336 hours and follow up (504 hours)

,
InterventionInternational units per liter (Mean)
Alkaline Phosphatase, 24 hours, n=7, 7Alkaline Phosphatase, 96 hours, n=7, 7Alkaline Phosphatase, 168 hours, n=7, 7Alkaline Phosphatase, 336 hours, n=7, 7Alkaline Phosphatase, Follow-up (504 hours), n=7,6ALT, 24 hours, n=7, 7ALT, 96 hours, n=7, 7ALT, 168 hours, n=7, 7ALT, 336 hours, n=7, 7ALT, Follow up (504 hours), n=7, 6AST, 24 hours, n=7, 7AST, 96 hours, n=7, 7AST, 168 hours, n=7, 7AST, 336 hours, n=7, 7AST, Follow up (504 hours), n=7, 6
Healthy Caucasian Participants-3.3-3.1-4.1-2.9-9.3-3.3-5.1-4.4-3.9-5.3-1.9-4.3-3.0-2.4-1.5
Healthy Japanese Participants-9.0-6.7-7.0-11.0-9.6-3.0-2.10.70.90.4-3.4-3.7-2.00.30.0

[back to top]

Change From Baseline of Clinical Chemistry Parameters: Direct Bilirubin, Bilirubin, Creatinine.

Blood samples were collected for the analysis of clinical chemistry parameters including direct bilirubin, bilirubin and creatinine at indicated time points. Day -1 value was defined as Baseline for clinical chemistry parameters. Change from Baseline was defined as difference between post-dose visit values minus Baseline value. (NCT03258762)
Timeframe: Baseline (Day -1), 24, 96, 168, 336 hours and follow up (504 hours)

,
InterventionMicromoles per liter (Mean)
Direct bilirubin, 24 hours, n=7, 7Direct bilirubin, 96 hours, n=7, 7Direct bilirubin, 168 hours, n=7, 7Direct bilirubin, 336 hours, n=7, 7Direct bilirubin, Follow-up (504 hours), n=7, 6Bilirubin, 24 hours, n=7, 7Bilirubin, 96 hours, n=7, 7Bilirubin, 168 hours, n=7, 7Bilirubin, 336 hours, n=7, 7Bilirubin, Follow up (504 hours), n=7, 6Creatinine, 24 hours, n=7, 7Creatinine, 96 hours, n=7, 7Creatinine, 168 hours, n=7, 7Creatinine, 336 hours, n=7, 7Creatinine, Follow up (504 hours), n=7, 6
Healthy Caucasian Participants0.60.70.90.90.33.12.41.0-0.3-1.726.630.124.614.99.5
Healthy Japanese Participants0.70.40.6-0.3-0.31.4-0.60.7-4.0-3.421.724.420.914.15.6

[back to top]

Change From Baseline of Clinical Chemistry Parameters: Glucose, Sodium, Calcium, Potassium, and Urea.

Blood samples were collected for the analysis of clinical chemistry parameters including glucose, sodium, calcium, potassium, and urea at indicated time points. Day -1 value was defined as Baseline for clinical chemistry parameters. Change from Baseline was defined as difference between post-dose visit values minus Baseline value. (NCT03258762)
Timeframe: Baseline (Day -1), 24, 96, 168, 336 hours and follow up (504 hours)

,
InterventionMillimoles per liter (Mean)
Glucose, 24 hours, n=7, 7Glucose, 96 hours, n=7, 7Glucose, 168 hours, n=7, 7Category title 4. : Glucose, 336 hours, n=7, 7Glucose, Follow-up (504 hours), n= 7, 6Calcium, 24 hours, n=7, 7Calcium, 96 hours, n=7, 7Calcium, 168 hours, n=7, 7Calcium, 336 hours, n=7, 7Calcium, Follow up (504 hours), n=7, 6Potassium, 24 hours, n=7, 7Potassium, 96 hours, n=7, 7Potassium, 168 hours, n=7, 7Potassium, 336 hours, n=7, 7Potassium, Follow up (504 hours), n=7, 6Sodium, 24 hours, n=7, 7Sodium, 96 hours, n=7, 7Sodium, 168 hours, n=7, 7Sodium, 336 hours, n=7, 7Sodium, Follow up (504 hours), n=7, 6Urea, 24 hours, n=7, 7Urea, 96 hours, n=7, 7Urea, 168 hours, n=7, 7Urea, 336 hours, n=7, 7Urea, Follow up,(504 hours) n=7, 6
Healthy Caucasian Participants-0.26-0.10-0.37-0.090.00-0.054-0.033-0.033-0.040-0.0420.00-0.11-0.21-0.21-0.220.01.01.7-0.3-0.51.01-0.03-0.261.061.27
Healthy Japanese Participants-0.33-0.43-0.60-0.43-0.24-0.116-0.006-0.006-0.083-0.100-0.030.000.01-0.100.09-0.3-0.6-1.30.3-0.10.330.260.41-0.160.99

[back to top]

Change From Baseline of Clinical Chemistry Parameters: Protein

Blood samples were collected for the analysis of clinical chemistry parameter including protein at indicated time points. Day -1 value was defined as Baseline for clinical chemistry parameters. Change from Baseline was defined as difference between post-dose visit values minus Baseline value. (NCT03258762)
Timeframe: Baseline (Day -1), 24, 96, 168, 336 hours and follow up (504 hours)

,
InterventionGram per liter (Mean)
24 hours, n=7, 796 hours, n=7, 7168 hours, n=7, 7336 hours, n=7, 7Follow-up (504 hours), n=7, 6
Healthy Caucasian Participants-2.3-2.9-4.1-2.4-4.2
Healthy Japanese Participants-4.9-4.6-3.6-4.4-5.4

[back to top]

Change From Baseline of ECG Parameter: ECG Mean Heart Rate

A single 12-lead ECG was obtained at indicated time points using an ECG machine that automatically calculates mean ECG heart rate. Day 1 (Pre-dose) value was defined as Baseline for ECG parameters. Change from Baseline was defined as difference between post-dose visit values minus Baseline value. (NCT03258762)
Timeframe: Baseline (Pre-dose on Day 1), 4, 12, 24, 48, and 504 hours

,
InterventionBeats per minute (Mean)
4 hours, n=7, 712 hours, n=7, 724 hours, n=7, 748 hours, n=7, 7504 hours, n=7, 6
Healthy Caucasian Participants6.07.13.15.03.2
Healthy Japanese Participants-2.32.3-5.36.7-7.1

[back to top]

Change From Baseline of Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval, and QT Interval Corrected for Heart Rate by Fredericia's Formula (QTcF) Interval

A single 12-lead ECG was obtained at indicated time points using an ECG machine that automatically measures PR, QRS, QT, and QTcF intervals. Day 1 (Pre-dose) value was defined as Baseline for ECG parameters. Change from Baseline was defined as difference between post-dose visit values minus Baseline value. (NCT03258762)
Timeframe: Baseline (Pre-dose on Day 1), 4, 12, 24, 48, and 504 hours

,
InterventionMillisecond (Mean)
PR Interval, 4 hours, n=7, 7PR Interval, 12 hours, n=7, 7PR Interval, 24 hours, n=7, 7PR Interval, 48 hours, n=7, 7PR Interval, 504 hours, n=7, 6QRS duration, 4 hours, n=7, 7QRS duration, 12 hours, n=7, 7QRS duration, 24 hours, n=7, 7QRS duration, 48 hours, n=7, 7QRS duration, 504 hours, n=7, 6QT interval, 4 hours, n=7, 7QT interval, 12 hours, n=7, 7QT interval, 24 hours, n=7, 7QT interval, 48 hours, n=7, 7QT interval, 504 hours, n=7, 6QTcF interval, 4 hours, n=7, 7QTcF interval, 12 hours, n=7, 7QTcF interval, 24 hours, n=7, 7QTcF interval, 48 hours, n=7, 7QTcF interval, 504 hours, n=7, 6
Healthy Caucasian Participants-4.6-5.9-0.10.32.2-2.1-0.6-2.00.4-0.8-20.4-21.7-7.3-14.7-9.2-6.6-5.7-0.1-2.9-2.2
Healthy Japanese Participants-5.3-8.7-3.1-17.0-7.3-1.6-0.30.33.1-0.3-4.0-17.94.32.314.7-4.9-7.7-0.911.66.7

[back to top]

Number of Participants With Abnormal Urinalysis Parameter

The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters of can be read as Trace, + and ++ indicating proportional concentrations in the urine sample. Only participants with abnormal findings for urinalysis at any visit has been presented. (NCT03258762)
Timeframe: Day -1, 24, 96, 168, 336 and follow up (504 hours)

,
InterventionParticipants (Count of Participants)
Ketones, 336 hours, ++Ketones, 336 hours, traceKetones, follow up (504 hours), +Occult blood, 336 hours, +Occult blood, follow up, traceProtein, Day -1, traceProtein, 24 hours, traceProtein, 96 hours, traceProtein, 168 hours, traceProtein, 336 hours, trace
Healthy Caucasian Participants0100113413
Healthy Japanese Participants2011002223

[back to top]

Change From Baseline in Hematology Parameter: Mean Corpuscular Hemoglobin

Blood samples were collected for the analysis of hematology parameter including mean corpuscular hemoglobin at indicated time points. Day -1 value was defined as Baseline for hematology parameters. Change from Baseline was defined as difference between post-dose visit values minus Baseline value. (NCT03258762)
Timeframe: Baseline (Day -1), 24, 96, 168, 336 hours and follow up (504 hours)

,
InterventionPicogram (Mean)
24 hours, n= 7, 796 hours, n=7, 7168 hours, n=7, 7336 hours, n= 7, 7Follow up (504 hours), n=7, 6
Healthy Caucasian Participants0.00.0-0.1-0.3-0.2
Healthy Japanese Participants0.0-0.40.00.10.0

[back to top]

Change From Baseline in Hematology Parameter: Hemoglobin

Blood samples were collected for the analysis of hematology parameter including hemoglobin at indicated time points. Day -1 value was defined as Baseline for hematology parameters. Change from Baseline was defined as difference between post-dose visit values minus Baseline value. (NCT03258762)
Timeframe: Baseline (Day -1), 24, 96, 168, 336 hours and follow up (504 hours)

,
InterventionGram per liter (Mean)
24 hours, n= 7, 796 hours, n=7, 7168 hours, n=7, 7336 hours, n= 7, 7Follow up (504 hours), n=7, 6
Healthy Caucasian Participants3.00.0-1.7-3.6-6.0
Healthy Japanese Participants2.02.60.0-4.9-12.1

[back to top]

Change From Baseline in Hematology Parameter: Hematocrit

Blood samples were collected for the analysis of hematology parameter including hematocrit at indicated time points. Day -1 value was defined as Baseline for hematology parameters. Change from Baseline was defined as difference between post-dose visit values minus Baseline value. (NCT03258762)
Timeframe: Baseline (Day -1), 24, 96, 168, 336 hours and follow up (504 hours)

,
InterventionProportion of red blood cells in blood (Mean)
24 hours, n= 7, 796 hours, n=7, 7168 hours, n=7, 7336 hours, n= 7, 7Follow up (504 hours), n=7, 6
Healthy Caucasian Participants0.007-0.006-0.006-0.016-0.025
Healthy Japanese Participants0.0010.009-0.004-0.014-0.036

[back to top]

Change From Baseline in Hematology Parameter: Erythrocytes

Blood samples were collected for the analysis of hematology parameter including erythrocytes at indicated time points. Day -1 value was defined as Baseline for hematology parameters. Change from Baseline was defined as difference between post-dose visit values minus Baseline value. (NCT03258762)
Timeframe: Baseline (Day -1), 24, 96, 168, 336 hours and follow up (504 hours)

,
Intervention10^12 cells per liter (Mean)
24 hours, n= 7, 796 hours, n=7, 7168 hours, n=7, 7336 hours, n= 7, 7Follow up (504 hours), n=7, 6
Healthy Caucasian Participants0.1000.006-0.021-0.079-0.183
Healthy Japanese Participants0.0260.101-0.024-0.187-0.411

[back to top]

Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)

An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment or events associated with liver injury and impaired liver function were categorized as SAE. All participants who take at least one dose of study treatment were included in Safety Population. (NCT03258762)
Timeframe: Up to Day 23

,
InterventionParticipants (Count of Participants)
Any AEsAny SAEs
Healthy Caucasian Participants60
Healthy Japanese Participants20

[back to top]

Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)

Blood pressure of participants were measured at indicated time points in semi-supine position after 5 minutes rest. Day 1 (Pre-dose) value was defined as Baseline for vital sign parameters. Change from Baseline was defined as difference between post-dose visit values minus Baseline value. (NCT03258762)
Timeframe: Baseline (Pre-dose on Day 1), 4, 12, 24, 48, 72, 96, 120, 144, 168, 336 and 504 hours

,
InterventionMillimeter of mercury (mmHg) (Mean)
DBP, 4 hours, n=7, 7DBP, 12 hours, n=7, 7DBP, 24 hours, n=7, 7DBP, 48 hours, n=7, 7DBP, 72 hours, n=7, 7DBP, 96 hours, n=7, 7DBP, 120 hours, n=7, 7DBP, 144 hours, n=7, 7DBP, 168 hours, n=7, 7DBP, 336 hours, n=7, 7DBP, 504 hours, n=7, 6SBP, 4 hours, n=7, 7SBP, 12 hours, n=7, 7SBP, 24 hours, n=7, 7SBP, 48 hours, n=7, 7SBP, 72 hours, n=7, 7SBP, 96 hours, n=7, 7SBP, 120 hours, n=7, 7SBP,144 hours, n=7, 7SBP, 168 hours, n=7, 7SBP, 336 hours, n=7, 7SBP, 504 hours, n=7, 6
Healthy Caucasian Participants-0.7-0.3-2.92.0-4.6-2.7-3.4-5.4-1.0-5.3-0.71.31.0-3.4-1.1-4.62.60.9-3.30.9-2.6-1.5
Healthy Japanese Participants-7.0-5.4-3.9-3.4-4.0-5.9-4.1-7.6-5.1-5.7-7.3-0.11.4-1.0-1.9-1.0-1.4-6.3-6.60.4-3.9-5.0

[back to top]

Vd/F of Pyrimethamine in Healthy Caucasian Male Participants

Blood samples were collected at indicated time points. The PK parameters were calculated by non-compartmental analysis. (NCT03258762)
Timeframe: Pre-dose, 1, 2, 4, 6, 12 hours post-dose on Day 1, Day 2, Day 3, Day 4, Day 6, Day 8, Day 15 and Day 22

InterventionMilliliters (Geometric Mean)
Healthy Caucasian Participants157125.8

[back to top]

Time to Maximum Observed Concentration (Tmax) of Pyrimethamine in Healthy Japanese Male Participants

Blood samples were collected at indicated time points. The PK parameters were calculated by non-compartmental analysis. (NCT03258762)
Timeframe: Pre-dose, 1, 2, 4, 6, 12 hours post-dose on Day 1, Day 2, Day 3, Day 4, Day 6, Day 8, Day 15 and Day 22

InterventionHours (Median)
Healthy Japanese Participants2.000

[back to top]

Terminal Half-life (t1/2) of Pyrimethamine in Healthy Japanese Male Participants

Blood samples were collected at indicated time points. The PK parameters were calculated by non-compartmental analysis. (NCT03258762)
Timeframe: Pre-dose, 1, 2, 4, 6, 12 hours post-dose on Day 1, Day 2, Day 3, Day 4, Day 6, Day 8, Day 15 and Day 22

InterventionHours (Geometric Mean)
Healthy Japanese Participants122.75

[back to top]

T1/2 of Pyrimethamine in Healthy Caucasian Male Participants

Blood samples were collected at indicated time points. The PK parameters were calculated by non-compartmental analysis. (NCT03258762)
Timeframe: Pre-dose, 1, 2, 4, 6, 12 hours post-dose on Day 1, Day 2, Day 3, Day 4, Day 6, Day 8, Day 15 and Day 22

InterventionHours (Mean)
Healthy Caucasian Participants99.46

[back to top]

Specific Gravity at Indicated Time Points

Urine samples were collected for analysis of specific gravity of urine. Urinary specific gravity is a measure of the concentration of solutes in the urine. It measures the ratio of urine density compared with water density and provides information on the kidney's ability to concentrate urine. (NCT03258762)
Timeframe: Day -1, 24, 96, 168, 336 hours and follow up (504 hours)

,
InterventionRatio (Mean)
Day -1, n=7, 724 hours, n=7, 796 hours, n=7, 7168 hours, n=7, 7336 hours, n=7, 7Follow up (504 hours), n=7, 6
Healthy Caucasian Participants1.01771.02561.02361.02071.02461.0222
Healthy Japanese Participants1.01271.02141.02111.02111.01931.0183

[back to top]

Urine Potential of Hydrogen (pH) at Indicated Time Points

Urine samples were collected for analysis of urine pH. pH is calculated on a scale of 0 to 14, values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0). (NCT03258762)
Timeframe: Day -1, 24, 96, 168, 336 hours and follow up (504 hours)

,
InterventionpH (Mean)
Day -1, n=7, 724 hours, n=7, 796 hours, n=7, 7168 hours, n=7, 7336 hours, n=7, 7Follow up (504 hours), n=7, 6
Healthy Caucasian Participants6.865.796.076.076.006.08
Healthy Japanese Participants6.215.865.795.936.006.43

[back to top]

Maximum Observed Concentration (Cmax) of Pyrimethamine in Healthy Japanese Male Participants

Blood samples were collected at indicated time points. The Pharmacokinetic (PK) parameters were calculated by non-compartmental analysis. PK Population is defined as all participants who administered at least one dose of study treatment and who have PK sample taken and analyzed. (NCT03258762)
Timeframe: Pre-dose, 1, 2, 4, 6, 12 hours post-dose on Day 1, Day 2, Day 3, Day 4, Day 6, Day 8, Day 15 and Day 22

InterventionNanogram per milliliter (Geometric Mean)
Healthy Japanese Participants430.5

[back to top]

Cmax of Pyrimethamine in Healthy Caucasian Male Participants

Blood samples were collected at indicated time points. The PK parameters were calculated by non-compartmental analysis. (NCT03258762)
Timeframe: Pre-dose, 1, 2, 4, 6, 12 hours post-dose on Day 1, Day 2, Day 3, Day 4, Day 6, Day 8, Day 15 and Day 22

InterventionNanogram per milliliter (Geometric Mean)
Healthy Caucasian Participants371.1

[back to top]

CL/F of Pyrimethamine in Healthy Caucasian Male Participants

Blood samples were collected at indicated time points. The PK parameters were calculated by non-compartmental analysis. (NCT03258762)
Timeframe: Pre-dose, 1, 2, 4, 6, 12 hours post-dose on Day 1, Day 2, Day 3, Day 4, Day 6, Day 8, Day 15 and Day 22

InterventionMilliliters per hour (Geometric Mean)
Healthy Caucasian Participants1114.4

[back to top]

AUC (0-t) of Pyrimethamine in Healthy Caucasian Male Participants

Blood samples were collected at indicated time points. The PK parameters were calculated by non-compartmental analysis. (NCT03258762)
Timeframe: Pre-dose, 1, 2, 4, 6, 12 hours post-dose on Day 1, Day 2, Day 3, Day 4, Day 6, Day 8, Day 15 and Day 22

InterventionHours* nanogram per milliliter (Geometric Mean)
Healthy Caucasian Participants41582.0

[back to top]

AUC (0-inf) of Pyrimethamine in Healthy Caucasian Male Participants

Blood samples were collected at indicated time points. The PK parameters were calculated by non-compartmental analysis. (NCT03258762)
Timeframe: Pre-dose, 1, 2, 4, 6, 12 hours post-dose on Day 1, Day 2, Day 3, Day 4, Day 6, Day 8, Day 15 and Day 22

InterventionHours* nanogram per milliliter (Geometric Mean)
Healthy Caucasian Participants44869.1

[back to top]

AUC (0-24) of Pyrimethamine in Healthy Caucasian Male Participants

Blood samples were collected at indicated time points. The PK parameters were calculated by non-compartmental analysis. (NCT03258762)
Timeframe: Pre-dose, 1, 2, 4, 6, 12 hours post-dose on Day 1, Day 2, Day 3, Day 4, Day 6, Day 8, Day 15 and Day 22

InterventionHours* nanogram per milliliter (Geometric Mean)
Healthy Caucasian Participants6930.8

[back to top]

Change From Baseline in Hematology Parameter: Mean Corpuscular Volume

Blood samples were collected for the analysis of hematology parameter including mean corpuscular volume at indicated time points. Day -1 value was defined as Baseline for hematology parameters. Change from Baseline was defined as difference between post-dose visit values minus Baseline value. (NCT03258762)
Timeframe: Baseline (Day -1), 24, 96, 168, 336 hours and follow up (504 hours)

,
InterventionFemtoliter (Mean)
24 hours, n= 7, 796 hours, n=7, 7168 hours, n=7, 7336 hours, n= 7, 7Follow up (504 hours), n=7, 6
Healthy Caucasian Participants-0.7-1.4-1.1-1.9-1.7
Healthy Japanese Participants-0.60.1-0.30.40.4

[back to top]

Area Under the Concentration-time Curve From Time 0 to Infinity (AUC[0-inf]) of Pyrimethamine in Healthy Japanese Male Participants

Blood samples were collected at indicated time points. The PK parameters were calculated by non-compartmental analysis. (NCT03258762)
Timeframe: Pre-dose, 1, 2, 4, 6, 12 hours post-dose on Day 1, Day 2, Day 3, Day 4, Day 6, Day 8, Day 15 and Day 22

InterventionHours* nanogram per milliliter (Geometric Mean)
Healthy Japanese Participants64670.3

[back to top]

Area Under the Concentration-time Curve From Time 0 to t (AUC[0-t]) of Pyrimethamine in Healthy Japanese Male Participants

Blood samples were collected at indicated time points. The PK parameters were calculated by non-compartmental analysis. (NCT03258762)
Timeframe: Pre-dose, 1, 2, 4, 6, 12 hours post-dose on Day 1, Day 2, Day 3, Day 4, Day 6, Day 8, Day 15 and Day 22

InterventionHours* nanogram per milliliter (Geometric Mean)
Healthy Japanese Participants59013.1

[back to top]

Area Under the Concentration-time Curve From Time 0 to 24 (AUC[0-24]) of Pyrimethamine in Healthy Japanese Male Participants

Blood samples were collected at indicated time points. The PK parameters were calculated by non-compartmental analysis. (NCT03258762)
Timeframe: Pre-dose, 1, 2, 4, 6, 12 hours post-dose on Day 1, Day 2, Day 3, Day 4, Day 6, Day 8, Day 15 and Day 22

InterventionHours* nanogram per milliliter (Geometric Mean)
Healthy Japanese Participants8756.3

[back to top]

Apparent Volume of Distribution Following Oral Dosing (Vd/F) of Pyrimethamine in Healthy Japanese Male Participants

Blood samples were collected at indicated time points. The PK parameters were calculated by non-compartmental analysis. (NCT03258762)
Timeframe: Pre-dose, 1, 2, 4, 6, 12 hours post-dose on Day 1, Day 2, Day 3, Day 4, Day 6, Day 8, Day 15 and Day 22

InterventionMilliliter (Geometric Mean)
Healthy Japanese Participants135330.9

[back to top]

Apparent Clearance Following Oral Dosing (CL/F) of Pyrimethamine in Healthy Japanese Male Participants

Blood samples were collected at indicated time points. The PK parameters were calculated by non-compartmental analysis. (NCT03258762)
Timeframe: Pre-dose, 1, 2, 4, 6, 12 hours post-dose on Day 1, Day 2, Day 3, Day 4, Day 6, Day 8, Day 15 and Day 22

InterventionMilliliter per hour (Geometric Mean)
Healthy Japanese Participants773.2

[back to top]

Tmax of Pyrimethamine in Healthy Caucasian Male Participants

Blood samples were collected at indicated time points. The PK parameters were calculated by non-compartmental analysis. (NCT03258762)
Timeframe: Pre-dose, 1, 2, 4, 6, 12 hours post-dose on Day 1, Day 2, Day 3, Day 4, Day 6, Day 8, Day 15 and Day 22

InterventionHours (Median)
Healthy Caucasian Participants1.000

[back to top]

Change From Baseline in Temperature

Temperature of participants were measured at indicated time points in semi-supine position after 5 minutes rest. Day 1 (Pre-dose) value was defined as Baseline for vital sign parameters. Change from Baseline was defined as difference between post-dose visit values minus Baseline value. (NCT03258762)
Timeframe: Baseline (Pre-dose on Day 1), 4, 12, 24, 48, 72, 96, 120, 144, 168, 336 and 504 hours

,
InterventionCelsius (Mean)
4 hours, n=7, 712 hours, n=7, 724 hours, n=7, 748 hours, n=7, 772 hours, n=7, 796 hours, n=7, 7120 hours, n=7, 7144 hours, n=7, 7168 hours, n=7, 7336 hours, n=7, 7504 hours, n=7, 6
Healthy Caucasian Participants0.270.26-0.01-0.04-0.10-0.04-0.17-0.090.01-0.13-0.07
Healthy Japanese Participants-0.010.04-0.07-0.16-0.10-0.11-0.10-0.14-0.09-0.27-0.26

[back to top]

Change From Baseline in Pulse Rate

Pulse rate of participants were measured at indicated time points in semi-supine position after 5 minutes rest. Day 1 (Pre-dose) value was defined as Baseline for vital sign parameters. Change from Baseline was defined as difference between post-dose visit values minus Baseline value. (NCT03258762)
Timeframe: Baseline (Pre-dose on Day 1), 4, 12, 24, 48, 72, 96, 120, 144, 168, 336 and 504 hours

,
InterventionBeats per minute (Mean)
4 hours, n=7, 712 hours, n=7, 724 hours, n=7, 748 hours, n=7, 772 hours, n=7, 796 hours, n=7, 7120 hours, n=7, 7144 hours, n=7, 7168 hours, n=7, 7336 hours, n=7, 7504 hours, n=7, 6
Healthy Caucasian Participants4.710.1-5.0-0.3-0.30.62.0-0.17.11.62.2
Healthy Japanese Participants3.65.03.43.44.91.41.10.14.41.0-2.1

[back to top]

Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet and Leukocytes

Blood samples were collected for the analysis of hematology parameters including basophils, eosinophils, lymphocytes, monocytes, neutrophils, platelet and leukocytes at indicated time points. Day -1 value was defined as Baseline for hematology parameters. Change from Baseline was defined as difference between post-dose visit values minus Baseline value. Data was not available as all basophil values were below the detection limit. Hence, the change from baseline in basophil values were not calculated. (NCT03258762)
Timeframe: Baseline (Day -1), 24, 96, 168, 336 hours and follow up (504 hours)

,
Intervention10^9 cells per liter (Mean)
Eosinophils, 24 hours, n=4, 3Eosinophils, 96 hours, n=4, 3Eosinophils, 168 hours, n=4, 3Eosinophils, 336 hours, n=3, 3Eosinophils, Follow up (504 hours), n=4, 2Lymphocytes, 24 hours, n=7, 7Lymphocytes, 96 hours, n=7, 7Lymphocytes, 168 hours, n=7, 7Lymphocytes, 336 hours, n=7, 7Lymphocytes, Follow up (504 hours), n=7, 6Monocytes, 24 hours, n=7, 7Monocytes, 96 hours, n=7, 7Monocytes, 168 hours, n=7, 7Monocytes, 336 hours, n=7, 7Monocytes, Follow up (504 hours), n=7, 6Neutrophils, 24 hours, n=7, 7Neutrophils, 96 hours, n=7, 7Neutrophils, 168 hours, n=7, 7Neutrophils, 336 hours, n=7, 7Neutrophils, Follow up (504 hours), n=7, 6Platelet, 24 hours, n=7, 7Platelet, 96 hours, n=7, 7Platelet, 168 hours, n=7, 7Platelet, 336 hours, n=7, 7Platelet, Follow up (504 hours), n=7, 6Leukocytes, 24 hours, n=7, 7Leukocytes, 96 hours, n=7, 7Leukocytes, 168 hours, n=7, 7Leukocytes, 336 hours, n=7, 7Leukocytes, Follow up (504 hours), n=7, 6
Healthy Caucasian Participants0.070.000.000.00-0.050.360.300.260.090.000.04-0.010.000.00-0.03-0.54-0.79-0.69-0.96-0.97-11.6-6.3-13.3-27.3-24.3-0.09-0.46-0.36-0.77-0.97
Healthy Japanese Participants-0.03-0.030.000.00-0.05-0.27-0.11-0.10-0.50-0.41-0.11-0.040.01-0.09-0.06-0.63-0.76-0.61-0.93-1.09-18.3-15.1-20.0-22.4-22.9-1.00-0.89-0.67-1.50-1.59

[back to top]

Change From Baseline in Hematology Parameter: Reticulocytes

Blood samples were collected for the analysis of hematology parameter including reticulocytes at indicated time points. Day -1 value was defined as Baseline for hematology parameters. Change from Baseline was defined as difference between post-dose visit values minus Baseline value. (NCT03258762)
Timeframe: Baseline (Day -1), 24, 96, 168, 336 hours and follow up (504 hours)

,
InterventionProportion of reticulocytes in blood (Mean)
24 hours, n= 7, 796 hours, n=7, 7168 hours, n=7, 7336 hours, n= 7, 7Follow up (504 hours), n=7, 6
Healthy Caucasian Participants0.0003-0.00060.00090.00030.0017
Healthy Japanese Participants-0.00160.00170.0013-0.0011-0.0013

[back to top] [back to top]

Clinical Response Rate

"The number of participants that achieved a clinical response following treatment. Clinical response is defined as achieving a best overall response of a complete response (CR) or a partial response (PR).~Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm.~Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters." (NCT03279237)
Timeframe: After 4 and 8 cycles of FOLFIRINOX (8 and 16 weeks); and 3-4 weeks after chemo radiation (24-25 weeks)

InterventionParticipants (Count of Participants)
FOLFIRINOX + Pre-operative Radiation20

[back to top]

Pathologic Complete Response Rate

The number of participants that achieve a pathologic complete response at surgery following FOLFIRINOX and chemoradiation. All patients will undergo a full pathological review of their surgical specimen according to the American Joint Committee on Cancer (AJCC) Staging Classification, 6th edition. Initial gross evaluation and identification of resection margins will be performed jointly by the surgeon and the pathologist. Pathological complete response will be defined as the absence of any viable tumor cells within the pathologic specimen. (NCT03279237)
Timeframe: 29 Weeks

InterventionParticipants (Count of Participants)
FOLFIRINOX + Pre-operative Radiation7

[back to top]

The Completion Rate of Chemotherapy in Combination With Chemoradiation

The number of participants that complete the assigned study intervention. (NCT03279237)
Timeframe: 21 weeks

InterventionParticipants (Count of Participants)
FOLFIRINOX + Pre-operative Radiation23

[back to top]

Number of Positive Anti-drug Antibody (ADA) Samples Among Patients (Immunogenicity)

Anti-drug antibody assessment (NCT03288987)
Timeframe: Up to 12 months

InterventionParticipants (Count of Participants)
Bevacizumab + FOLFIRI-3 (AryoGen Pharmed Bevacizumab)1
Bevacizumab + FOLFIRI-3 (Roche Bevacizumab)1

[back to top]

Progression Free Survival (PFS)

PFS is defined as the time from the date of randomization to the first date of documentation progression (per investigator assessment) or death as a result of any cause. (NCT03288987)
Timeframe: PFS was measured from the start of chemotherapy to the date of disease progression or to the date of death if no progression whichever came first, assessed up to 12 months

InterventionDay (Median)
Bevacizumab + FOLFIRI-3 (AryoGen Pharmed Bevacizumab)232
Bevacizumab + FOLFIRI-3 (Roche Bevacizumab)210

[back to top]

Incidence of the Adverse Events

Safety was assessed on the basis of reports of adverse events, laboratory-test results, and vital sign measurements. Adverse events were categorized According to the Common Toxicity Criteria of the National Cancer Institute, version 5.0, in which a grade of 1 indicates mild adverse events, a grade of 2 moderate adverse events, a grade of 3 serious adverse events, and a grade of 4 life-threatening adverse events (NCT03288987)
Timeframe: Up to 12 months

InterventionParticipants (Count of Participants)
Bevacizumab + FOLFIRI-3 (AryoGen Pharmed Bevacizumab)76
Bevacizumab + FOLFIRI-3 (Roche Bevacizumab)44

[back to top]

Objective Response Rate

Tumor response was defined as partial and complete responses, according to the RECIST criteria ( version 1.1). The definitions were as follows: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), decrease of at least 30% in the lesion that has the largest diameter; Objective Response Rate (ORR) = CR + PR. (NCT03288987)
Timeframe: Up to 12 months

InterventionParticipants (Count of Participants)
Bevacizumab + FOLFIRI-3 (AryoGen Pharmed Bevacizumab)17
Bevacizumab + FOLFIRI-3 (Roche Bevacizumab)5

[back to top]

Overall Survival (OS)

Overall survival OS was defined as the time from date of randomization to date of death due to any cause (NCT03288987)
Timeframe: Up to 12 months

InterventionParticipants (Count of Participants)
Bevacizumab + FOLFIRI-3 (AryoGen Pharmed Bevacizumab)30
Bevacizumab + FOLFIRI-3 (Roche Bevacizumab)17

[back to top]

Time to Treatment Failure

"Time to treatment failure was defined as the time from the date of randomization to the date of each of the following,~The treatment modalities did not destroy or modify the cancer cells,~The tumor either became larger (disease progression) or stayed the same size after treatment,~Death due to any cause,~Discontinuation of treatment" (NCT03288987)
Timeframe: Up to 12 months

InterventionDay (Median)
Bevacizumab + FOLFIRI-3 (AryoGen Pharmed Bevacizumab)73
Bevacizumab + FOLFIRI-3 (Roche Bevacizumab)73

[back to top]

Tmax of INCB001158 in Participants Treated With INCB001158 in Combination With Chemotherapy Following the First Dose on Cycle 1 Day 1 and on Cycle 2 Day 1 Following Repeated Dose Administration

tmax was defined as the time to the maximum concentration. Extensive sample collection was used for the first 12 participants enrolled in each chemotherapy regimen. Sparse sample collection was used for the 13th participant enrolled and onward. (NCT03314935)
Timeframe: Day 1 of Cycles 1 and 2: predose; 0.5, 1, 2, 4, 6, and 8-10 hours post-dose for extensive sample collection. Day 1 of Cycles 1 and 2: predose; 1 and 4 hours post-dose for sparse sample collection

,,,,,
Interventionhours (Median)
Cycle 1 Day 1Cycle 2 Day 1
Phase 2: INCB001158 100 mg + Gemcitabine + Cisplatin: BTC (Cohort B1)4.074.00
Phase 2: INCB001158 100 mg + Gemcitabine + Cisplatin: OC (Cohort B2)4.084.06
Phase 2: INCB001158 100 mg + mFOLFOX6: MSS-CRC (Cohort A1)4.134.00
Phase 2: INCB001158 100 mg + Paclitaxel: EC (Cohort C2)4.093.85
Phase 2: INCB001158 100 mg + Paclitaxel: GC (Cohort C1)5.054.13
Phase 2: INCB001158 100 mg + Paclitaxel: OC (Cohort C3)3.973.95

[back to top]

Phase 1: ORR

ORR was defined as the percentage of participants with a confirmed best overall response of CR or PR, as determined by investigator assessment of radiographic disease as per RECIST v1.1. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to <10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the Baseline sum diameters, no new lesions, and no progression of non-target lesions. (NCT03314935)
Timeframe: up to 580 days

Interventionpercentage of participants (Number)
Phase 1: INCB001158 50 mg + mFOLFOX612.5
Phase 1: INCB001158 75 mg + mFOLFOX60.0
Phase 1: INCB001158 100 mg + mFOLFOX60.0
Phase 1: INCB001158 50 mg + Gemcitabine + Cisplatin0.0
Phase 1: INCB001158 75 mg + Gemcitabine + Cisplatin25.0
Phase 1: INCB001158 100 mg + Gemcitabine + Cisplatin0.0
Phase 1: INCB001158 50 mg + Paclitaxel14.3
Phase 1: INCB001158 75 mg + Paclitaxel0.0
Phase 1: INCB001158 100 mg + Paclitaxel28.6

[back to top]

Cmin of INCB001158 in Participants Treated With INCB001158 in Combination With Chemotherapy on Cycle 2 Day 1 Following Repeated Dose Administration

Cmin was defined as the minimum observed plasma concentration over the dose interval. Extensive sample collection was used for the first 12 participants enrolled in each chemotherapy regimen. Sparse sample collection was used for the 13th participant enrolled and onward. (NCT03314935)
Timeframe: Day 1 of Cycle 2: predose; 0.5, 1, 2, 4, 6, and 8-10 hours post-dose for extensive sample collection. Day 1 of Cycle 2: predose; 1 and 4 hours post-dose for sparse sample collection

Interventionnanograms per milliliter (ng/mL) (Geometric Mean)
Phase 2: INCB001158 100 mg + mFOLFOX6: MSS-CRC (Cohort A1)747
Phase 2: INCB001158 100 mg + Gemcitabine + Cisplatin: BTC (Cohort B1)407
Phase 2: INCB001158 100 mg + Gemcitabine + Cisplatin: OC (Cohort B2)268
Phase 2: INCB001158 100 mg + Paclitaxel: GC (Cohort C1)542
Phase 2: INCB001158 100 mg + Paclitaxel: EC (Cohort C2)1020
Phase 2: INCB001158 100 mg + Paclitaxel: OC (Cohort C3)633

[back to top]

Tlast of INCB001158 in Participants Treated With INCB001158 in Combination With Chemotherapy Following the First Dose on Cycle 1 Day 1 and on Cycle 2 Day 1 Following Repeated Dose Administration

tlast was defined as the time of the last sample collected from which a concentration was measured. Extensive sample collection was used for the first 12 participants enrolled in each chemotherapy regimen. Sparse sample collection was used for the 13th participant enrolled and onward. (NCT03314935)
Timeframe: Day 1 of Cycles 1 and 2: predose; 0.5, 1, 2, 4, 6, and 8-10 hours post-dose for extensive sample collection. Day 1 of Cycles 1 and 2: predose; 1 and 4 hours post-dose for sparse sample collection

,,,,,
Interventionhours (Median)
Cycle 1 Day 1Cycle 2 Day 1
Phase 2: INCB001158 100 mg + Gemcitabine + Cisplatin: BTC (Cohort B1)7.737.58
Phase 2: INCB001158 100 mg + Gemcitabine + Cisplatin: OC (Cohort B2)7.537.60
Phase 2: INCB001158 100 mg + mFOLFOX6: MSS-CRC (Cohort A1)7.537.50
Phase 2: INCB001158 100 mg + Paclitaxel: EC (Cohort C2)7.537.55
Phase 2: INCB001158 100 mg + Paclitaxel: GC (Cohort C1)7.507.57
Phase 2: INCB001158 100 mg + Paclitaxel: OC (Cohort C3)7.657.58

[back to top]

Cmax of INCB001158 in Participants Treated With INCB001158 in Combination With Chemotherapy Following the First Dose on Cycle 1 Day 1 and on Cycle 2 Day 1 Following Repeated Dose Administration

Cmax was defined as the maximum observed plasma concentration over the dose interval. Extensive sample collection was used for the first 12 participants enrolled in each chemotherapy regimen. Sparse sample collection was used for the 13th participant enrolled and onward. (NCT03314935)
Timeframe: Day 1 of Cycles 1 and 2: predose; 0.5, 1, 2, 4, 6, and 8-10 hours post-dose for extensive sample collection. Day 1 of Cycles 1 and 2: predose; 1 and 4 hours post-dose for sparse sample collection

,,,,,
Interventionng/mL (Geometric Mean)
Cycle 1 Day 1Cycle 2 Day 1
Phase 2: INCB001158 100 mg + Gemcitabine + Cisplatin: BTC (Cohort B1)13501860
Phase 2: INCB001158 100 mg + Gemcitabine + Cisplatin: OC (Cohort B2)21602250
Phase 2: INCB001158 100 mg + mFOLFOX6: MSS-CRC (Cohort A1)12901960
Phase 2: INCB001158 100 mg + Paclitaxel: EC (Cohort C2)17602390
Phase 2: INCB001158 100 mg + Paclitaxel: GC (Cohort C1)11001600
Phase 2: INCB001158 100 mg + Paclitaxel: OC (Cohort C3)16402100

[back to top]

Phase 1: Number of Participants With Any Dose-limiting Toxicity (DLT)

A DLT was defined as the occurrence of any protocol-defined toxicity occurring up to and including Day 28, except those with a clear alternative explanation (e.g., disease progression) or transient (≤72 hours) abnormal laboratory values without associated clinically significant signs or symptoms based on investigator determination. All DLTs were assessed by the investigator using Common Terminology Criteria for Adverse Events (CTCAE) v4.03 criteria. (NCT03314935)
Timeframe: up to Day 28

InterventionParticipants (Count of Participants)
Phase 1: INCB001158 50 mg + mFOLFOX60
Phase 1: INCB001158 75 mg + mFOLFOX60
Phase 1: INCB001158 100 mg + mFOLFOX60
Phase 1: INCB001158 50 mg + Gemcitabine + Cisplatin1
Phase 1: INCB001158 75 mg + Gemcitabine + Cisplatin0
Phase 1: INCB001158 100 mg + Gemcitabine + Cisplatin0
Phase 1: INCB001158 50 mg + Paclitaxel0
Phase 1: INCB001158 75 mg + Paclitaxel0
Phase 1: INCB001158 100 mg + Paclitaxel0

[back to top]

Phases 1 and 2: Disease Control Rate

DCR was defined as the percentage of participants with an overall response of CR, PR, or stable disease (SD), as determined by investigator assessment of radiographic disease as per RECIST v1.1, for at least 8 weeks. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to <10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. PD: progression of a target or non-target lesion or presence of a new lesion. SD: no change in target lesions to qualify for CR, PR, or PD. (NCT03314935)
Timeframe: up to 1385 days

Interventionpercentage of participants (Number)
Phase 1: INCB001158 50 mg + mFOLFOX662.5
Phase 1: INCB001158 75 mg + mFOLFOX683.3
Phase 1: INCB001158 100 mg + mFOLFOX616.7
Phase 1: INCB001158 50 mg + Gemcitabine + Cisplatin57.1
Phase 1: INCB001158 75 mg + Gemcitabine + Cisplatin75.0
Phase 1: INCB001158 100 mg + Gemcitabine + Cisplatin100.0
Phase 1: INCB001158 50 mg + Paclitaxel42.9
Phase 1: INCB001158 75 mg + Paclitaxel60.0
Phase 1: INCB001158 100 mg + Paclitaxel85.7
Phase 2: INCB001158 100 mg + mFOLFOX6: MSS-CRC (Cohort A1)100.0
Phase 2: INCB001158 100 mg + Gemcitabine + Cisplatin: BTC (Cohort B1)66.7
Phase 2: INCB001158 100 mg + Gemcitabine + Cisplatin: OC (Cohort B2)88.9
Phase 2: INCB001158 100 mg + Paclitaxel: GC (Cohort C1)54.5
Phase 2: INCB001158 100 mg + Paclitaxel: EC (Cohort C2)80.0
Phase 2: INCB001158 100 mg + Paclitaxel: OC (Cohort C3)66.7

[back to top]

Phases 1 and 2: Progression-free Survival

According to RECIST 1.1, PFS was defined as the length of time from the date of the first dose study of drug until the earliest date of disease progression, as determined by investigator assessment of radiographic disease per RECIST v1.1, or death due to any cause, if it occurred sooner than progression. (NCT03314935)
Timeframe: up to 1385 days

Interventionmonths (Median)
Phase 1: INCB001158 50 mg + mFOLFOX63.7
Phase 1: INCB001158 75 mg + mFOLFOX66.6
Phase 1: INCB001158 100 mg + mFOLFOX61.7
Phase 1: INCB001158 50 mg + Gemcitabine + Cisplatin3.9
Phase 1: INCB001158 75 mg + Gemcitabine + Cisplatin5.3
Phase 1: INCB001158 100 mg + Gemcitabine + Cisplatin6.4
Phase 1: INCB001158 50 mg + Paclitaxel3.9
Phase 1: INCB001158 75 mg + Paclitaxel3.7
Phase 1: INCB001158 100 mg + Paclitaxel11.8
Phase 2: INCB001158 100 mg + mFOLFOX6: MSS-CRC (Cohort A1)3.7
Phase 2: INCB001158 100 mg + Gemcitabine + Cisplatin: BTC (Cohort B1)8.5
Phase 2: INCB001158 100 mg + Gemcitabine + Cisplatin: OC (Cohort B2)7.8
Phase 2: INCB001158 100 mg + Paclitaxel: GC (Cohort C1)3.5
Phase 2: INCB001158 100 mg + Paclitaxel: EC (Cohort C2)7.1
Phase 2: INCB001158 100 mg + Paclitaxel: OC (Cohort C3)3.7

[back to top] [back to top]

AUC0-t of INCB001158 in Participants Treated With INCB001158 in Combination With Chemotherapy Following the First Dose on Cycle 1 Day 1 and on Cycle 2 Day 1 Following Repeated Dose Administration

AUC0-t was defined as the area under the plasma concentration-time curve from time = 0 to the last measurable concentration at time = t. Extensive sample collection was used for the first 12 participants enrolled in each chemotherapy regimen. Sparse sample collection was used for the 13th participant enrolled and onward. (NCT03314935)
Timeframe: Day 1 of Cycles 1 and 2: predose; 0.5, 1, 2, 4, 6, and 8-10 hours post-dose for extensive sample collection. Day 1 of Cycles 1 and 2: predose; 1 and 4 hours post-dose for sparse sample collection

,,,,,
Interventionhours x ng/mL (Geometric Mean)
Cycle 1 Day 1Cycle 2 Day 1
Phase 2: INCB001158 100 mg + Gemcitabine + Cisplatin: BTC (Cohort B1)724010600
Phase 2: INCB001158 100 mg + Gemcitabine + Cisplatin: OC (Cohort B2)1060012200
Phase 2: INCB001158 100 mg + mFOLFOX6: MSS-CRC (Cohort A1)691011000
Phase 2: INCB001158 100 mg + Paclitaxel: EC (Cohort C2)929014400
Phase 2: INCB001158 100 mg + Paclitaxel: GC (Cohort C1)468010000
Phase 2: INCB001158 100 mg + Paclitaxel: OC (Cohort C3)884012800

[back to top]

Phase 2: Objective Response Rate (ORR)

ORR was defined as the percentage of participants with a best overall response of complete response (CR) or partial response (PR), as determined by investigator assessment of radiographic disease as per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1). CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to <10 millimeters (mm). PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. Analysis was conducted by cohort (tumor type) in Phase 2 because different tumor types could have different response criteria or different background response rates. (NCT03314935)
Timeframe: up to 1385 days

Interventionpercentage of participants (Number)
Phase 2: INCB001158 100 mg + mFOLFOX6: MSS-CRC (Cohort A1)0.0
Phase 2: INCB001158 100 mg + Gemcitabine + Cisplatin: BTC (Cohort B1)24.2
Phase 2: INCB001158 100 mg + Gemcitabine + Cisplatin: OC (Cohort B2)22.2
Phase 2: INCB001158 100 mg + Paclitaxel: GC (Cohort C1)9.1
Phase 2: INCB001158 100 mg + Paclitaxel: EC (Cohort C2)30.0
Phase 2: INCB001158 100 mg + Paclitaxel: OC (Cohort C3)16.7

[back to top]

Phases 1 and 2: Duration of Response

DOR was defined as the time from initial objective response (CR or PR) (as determined by investigator assessment of radiographic disease assessment per RECIST v1.1) until the earliest date of disease progression or death due to any cause, if it occurred sooner than disease progression. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to <10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. PD: progression of a target or non-target lesion or presence of a new lesion. (NCT03314935)
Timeframe: up to 368 days

Interventionmonths (Median)
Phase 2: INCB001158 100 mg + Gemcitabine + Cisplatin: BTC (Cohort B1)5.8

[back to top]

Phases 1 and 2: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)

An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurred after a participant provided informed consent. Abnormal laboratory values or test results occurring after informed consent constituted AEs only if they induced clinical signs or symptoms, were considered clinically meaningful, required therapy (e.g., hematologic abnormality that required transfusion), or required changes in the study drug(s). A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug. (NCT03314935)
Timeframe: up to 1385 days

InterventionParticipants (Count of Participants)
Phase 1 and Phase 2: INCB001158 50 mg + mFOLFOX68
Phase 1 and Phase 2: INCB001158 75 mg + mFOLFOX66
Phase 1 and Phase 2: INCB001158 100 mg + mFOLFOX613
Phase 1 and Phase 2: INCB001158 50 mg + Gemcitabine + Cisplatin7
Phase 1 and Phase 2: INCB001158 75 mg + Gemcitabine + Cisplatin4
Phase 1 and Phase 2: INCB001158 100 mg + Gemcitabine + Cisplatin46
Phase 1 and Phase 2: INCB001158 50 mg + Paclitaxel7
Phase 1 and Phase 2: INCB001158 75 mg + Paclitaxel5
Phase 1 and Phase 2: INCB001158 100 mg + Paclitaxel51

[back to top]

Overall Survival (OS)

OS is defined as the time from randomization until death from any cause. (NCT03368859)
Timeframe: Follow up continued until the first occurrence of radiographic progression, death from any cause or termination of the study; median follow-up time was 25.6(0.3-64.4) and 37.6(0.3-66.3) weeks in ABT-165 plus FOLFIRI and Bevacizumab + FOLFIRI, respectively

InterventionMonths (Median)
ABT-165 Plus FOLFIRI7.95
Bevacizumab Plus FOLFIRINA

[back to top]

Objective Response Rate (ORR)

ORR is defined as the proportion of participants with a complete response (CR) or partial response (PR) as determined by a investigator assessment based on Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1. (NCT03368859)
Timeframe: From randomization up to 30 days after last dose of study drug; median time on follow-up was 25.6 (0.3 - 64.4) and 37.6 (0.3 - 66.3) weeks in ABT-165 plus FOLFIRI and Bevacizumab plus FOLFIRI, respectively

Interventionpercentage of participants (Number)
ABT-165 Plus FOLFIRI5.6
Bevacizumab Plus FOLFIRI14.7

[back to top]

Progression Free Survival (PFS)

PFS is defined as the time from randomization until the first occurrence of radiographic progression determined by investigator assessment or death from any cause. (NCT03368859)
Timeframe: Follow up continued until the first occurrence of radiographic progression, death from any cause or termination of the study; median follow-up time was 25.6(0.3-64.4) and 37.6(0.3-66.3) weeks in ABT-165 plus FOLFIRI and Bevacizumab + FOLFIRI, respectively

InterventionMonths (Median)
ABT-165 Plus FOLFIRI3.78
Bevacizumab Plus FOLFIRI7.36

[back to top]

Overall Survival (OS)

Overall Survival (OS) is defined as the time between the date of randomization and the date of death. For those without documentation of death, OS will be censored on the last date the participant was known to be alive. (NCT03414983)
Timeframe: From the date of randomization up to the date of death (up to 44 months)

InterventionMonths (Median)
Arm A: NIV+mFOLFOX+BEV30.52
Arm B: mFOLFOX+BEV31.77

[back to top]

Objective Response Rate (ORR) Per Investigator Assessment

ORR is defined as the percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR). BOR is defined as the best response designation as determined by tumor assessments by the Investigator per RECIST 1.1, recorded between the date of randomization and the date of objectively documented progression per RECIST 1.1 or the date of subsequent anticancer therapy (including tumor-directed radiotherapy and tumor-directed surgery), whichever occurs first. PR is defined as at least a 30% decrease in the sum of diameters of target lesions. CR is defined as the disappearance of all target lesions and the reduction of any pathological lymph nodes to <10 mm. (NCT03414983)
Timeframe: From the date of randomization up to the date of objectively documented progression or the date of subsequent anticancer therapy, whichever occurs first (up to approximately 44 months)

InterventionPercentage of participants (Number)
Arm A: NIV+mFOLFOX+BEV60.6
Arm B: mFOLFOX+BEV52.9

[back to top]

Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR)

ORR is defined as the percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR). BOR is defined as the best response designation as determined by BICR per RECIST 1.1, recorded between the date of randomization and the date of objectively documented progression per RECIST 1.1 or the date of subsequent anticancer therapy (including tumor-directed radiotherapy and tumor-directed surgery), whichever occurs first. PR is defined as at least a 30% decrease in the sum of diameters of target lesions. CR is defined as the disappearance of all target lesions and the reduction of any pathological lymph nodes to <10 mm. (NCT03414983)
Timeframe: From the date of randomization up to the date of objectively documented progression or the date of subsequent anticancer therapy, whichever occurs first (up to approximately 44 months)

InterventionPercentage of Participants (Number)
Arm A: NIV+mFOLFOX+BEV60.6
Arm B: mFOLFOX+BEV45.6

[back to top]

Number of Participants With Serious Adverse Events (SAEs)

Number of participants with any grade of serious adverse events (SAEs) graded by Common Terminology Criteria for Adverse Events (CTCAE v4.0) to determine safety and tolerability. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening (defined as an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe), requires inpatient hospitalization or causes prolongation of existing hospitalization. (NCT03414983)
Timeframe: From first dose to 30 days post last dose (up to 45 months)

InterventionParticipants (Count of Participants)
Arm A: NIV+mFOLFOX+BEV57
Arm B: mFOLFOX+BEV20

[back to top]

Number of Participants With Adverse Events (AEs)

An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal. (NCT03414983)
Timeframe: From first dose to 30 days post last dose (up to 45 months)

InterventionParticipants (Count of Participants)
Arm A: NIV+mFOLFOX+BEV122
Arm B: mFOLFOX+BEV61

[back to top]

Number of Participants Experiencing Death

The number of participants who died during the treatment period (NCT03414983)
Timeframe: From first dose up to 6 weeks post last dose (up to 46 months)

InterventionParticipants (Count of Participants)
Arm A: NIV+mFOLFOX+BEV87
Arm B: mFOLFOX+BEV42

[back to top]

Duration of Response (DoR) Per Investigator Assessment

Duration of objective response (DoR) is defined as the time between the date of first confirmed complete response (CR) or partial response (PR) to the date of the first documented tumor progression as assessed by the investigator based on RECIST 1.1 criteria or death due to any cause, whichever occurs first. PR is defined as at least a 30% decrease in the sum of diameters of target lesions. CR is defined as the disappearance of all target lesions and the reduction of any pathological lymph nodes to <10 mm. (NCT03414983)
Timeframe: From randomization up to the date of the first documented progression (per RECIST 1.1) or death due to any cause, whichever occurs first (up to 44 months)

InterventionMonths (Median)
Arm A: NIV+mFOLFOX+BEV12.48
Arm B: mFOLFOX+BEV11.07

[back to top]

Duration of Response (DoR) Per Blinded Independent Central Review (BICR)

Duration of objective response (DoR) is defined as the time between the date of first confirmed complete response (CR) or partial response (PR) to the date of the first documented tumor progression as assessed by the BICR based on RECIST 1.1 criteria or death due to any cause, whichever occurs first. PR is defined as at least a 30% decrease in the sum of diameters of target lesions. CR is defined as the disappearance of all target lesions and the reduction of any pathological lymph nodes to <10 mm. (NCT03414983)
Timeframe: From randomization up to the date of the first documented progression (per RECIST 1.1) or death due to any cause, whichever occurs first (up to 44 months)

InterventionMonths (Median)
Arm A: NIV+mFOLFOX+BEV12.88
Arm B: mFOLFOX+BEV9.26

[back to top]

Disease Control Rate (DCR) Per Investigator

Disease Control Rate (DCR) is defined as the percentage of participants whose Best Overall Response (BOR) is complete response (CR) or partial response (PR) or stable disease (SD). CR is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD is defined as neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum diameters while on study. (NCT03414983)
Timeframe: From the date of randomization up to the date of objectively documented progression or the date of subsequent anticancer therapy, whichever occurs first (up to approximately 44 months)

InterventionPercentage of participants (Number)
Arm A: NIV+mFOLFOX+BEV85.8
Arm B: mFOLFOX+BEV77.9

[back to top]

Disease Control Rate (DCR) Per Blinded Independent Central Review (BICR)

Disease Control Rate (DCR) is defined as the percentage of participants whose Best Overall Response (BOR) is complete response (CR) or partial response (PR) or stable disease (SD). CR is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD is defined as neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum diameters while on study. (NCT03414983)
Timeframe: From the date of randomization up to the date of objectively documented progression or the date of subsequent anticancer therapy, whichever occurs first (up to approximately 44 months)

InterventionPercentage of participants (Number)
Arm A: NIV+mFOLFOX+BEV91.3
Arm B: mFOLFOX+BEV83.8

[back to top]

Number of Participants With Laboratory Abnormalities in Specific Thyroid Tests

The number of participants with laboratory abnormalities in specific thyroid tests based on SI conventional units. TSH = Thyroid Stimulating Hormone LLN = Lower Limit of Normal ULN = Upper Limit of Normal (NCT03414983)
Timeframe: From first dose up to 30 days post last dose (up to 45 months)

,
InterventionParticipants (Number)
TSH > ULNTSH > ULN WITH TSH <= ULN AT BASELINETSH > ULN WITH AT LEAST ONE FT3/FT4 TEST VALUE < LLNTSH > ULN WITH ALL OTHER FT3/FT4 TEST VALUES >= LLNTSH > ULN WITH FT3/FT4 TEST MISSINGTSH < LLNTSH < LLN WITH TSH >= LLN AT BASELINETSH < LLN WITH AT LEAST ONE FT3/FT4 TEST VALUE > ULNTSH < LLN WITH ALL OTHER FT3/FT4 TEST VALUES <= ULNTSH < LLN WITH FT3/FT4 TEST MISSING
Arm A: NIV+mFOLFOX+BEV453720111425221384
Arm B: mFOLFOX+BEV2316291233021

[back to top]

Number of Participants With Laboratory Abnormalities in Specific Liver Tests

The number of participants with laboratory abnormalities in specific liver tests based on SI conventional units. ALT = Alanine Aminotransferase AST = Aspartate Aminotransferase ULN = Upper Limit of Normal (NCT03414983)
Timeframe: From first dose up to 30 days post last dose (up to 45 months)

,
InterventionParticipants (Number)
ALT OR AST > 3XULNALT OR AST > 5XULNALT OR AST > 10XULNALT OR AST > 20XULNTOTAL BILIRUBIN > 2XULNALP > 1.5XULNCONCURRENT ALT OR AST ELEVATION > 3XULN WITH TOTAL BILIRUBIN > 1.5XULN WITHIN ONE DAYCONCURRENT ALT OR AST ELEVATION > 3XULN WITH TOTAL BILIRUBIN > 1.5XULN WITHIN 30 DAYSCONCURRENT ALT OR AST ELEVATION > 3XULN WITH TOTAL BILIRUBIN > 2XULN WITHIN ONE DAYCONCURRENT ALT OR AST ELEVATION > 3XULN WITH TOTAL BILIRUBIN > 2XULN WITHIN 30 DAYS
Arm A: NIV+mFOLFOX+BEV167200392200
Arm B: mFOLFOX+BEV62001201111

[back to top]

Time to Objective Response Per Investigator Assessment

TTR is defined as the time from the randomization date to the date of the first confirmed complete response (CR) or partial response (PR) as assessed by investigator. PR is defined as at least a 30% decrease in the sum of diameters of target lesions. CR is defined as the disappearance of all target lesions and the reduction of any pathological lymph nodes to <10 mm. TTR is derived for responders only. (NCT03414983)
Timeframe: From the randomization date up to the date of the first confirmed CR or PR (up to 44 months)

InterventionMonths (Median)
Arm A: NIV+mFOLFOX+BEV2.83
Arm B: mFOLFOX+BEV2.83

[back to top]

Time to Objective Response Per Blinded Independent Central Review (BICR)

Time to objective response (TTR) is defined as the time from the randomization date to the date of the first confirmed complete response (CR) or partial response (PR) as assessed by BICR. PR is defined as at least a 30% decrease in the sum of diameters of target lesions. CR is defined as the disappearance of all target lesions and the reduction of any pathological lymph nodes to <10 mm. TTR is derived for responders only. (NCT03414983)
Timeframe: From the randomization date up to the date of the first confirmed CR or PR (up to approximately 44 months)

InterventionMonths (Median)
Arm A: NIV+mFOLFOX+BEV2.83
Arm B: mFOLFOX+BEV2.83

[back to top]

Progression Free Survival (PFS) Per Investigator Assessment

Progression Free Survival (PFS) is defined as the time from randomization to the date of the first documented progression, as determined by Investigator Assessment, or death due to any cause, whichever occurs first. Baseline tumor assessment is defined as tumor scans prior to or on randomization date. Participants who did not have documented progression per Investigator Assessment and who did not die or participants who started any subsequent anti-cancer therapy without a prior reported progression will be censored at the date of the last tumor assessment on or prior to initiation of the subsequent anticancer therapy, if any. Participants who die without a reported prior progression per Investigator Assessment will be considered to have progressed on the date of death. Participants who did not have any baseline or post baseline tumor assessments and did not die (or died after initiation of the subsequent anti-cancer therapy) will be censored at the randomization date. (NCT03414983)
Timeframe: From randomization up to the date of the first documented progression (up to approximately 44 months)

InterventionMonths (Median)
Arm A: NIV+mFOLFOX+BEV13.77
Arm B: mFOLFOX+BEV12.19

[back to top]

Progression Free Survival (PFS) Per Blinded Independent Central Review (BICR) - Extended Collection

PFS is the time from randomization to the date of first documented progression, as determined by BICR, or death due to any cause, whichever occurs first. Baseline tumor assessment is defined as tumor scans prior to or on randomization date. Participants who did not have documented progression and did not die or participants who started any subsequent anti-cancer therapy without a prior reported progression were censored on date of last tumor assessment on or prior to initiation of the subsequent anticancer therapy, if any. Participants who died without prior progression were considered to have progressed on the date of death. Participants who did not have any baseline assessments and did not die (or died after initiation of the subsequent anti-cancer therapy) were censored at the randomization date. Note: This outcome measure represents an updated version of the primary endpoint to include additional data collection that has occurred after the primary completion date. (NCT03414983)
Timeframe: From randomization to up to the date of the first documented progression (up to 44 months)

InterventionMonths (Median)
Arm A: NIV+mFOLFOX+BEV11.99
Arm B: mFOLFOX+BEV12.02

[back to top]

Progression Free Survival (PFS) Per Blinded Independent Central Review (BICR)

Progression Free Survival (PFS) is defined as the time from randomization to the date of the first documented progression, as determined by BICR (per RECIST 1.1), or death due to any cause, whichever occurs first. Baseline tumor assessment is defined as tumor scans prior to or on randomization date. Participants who did not have documented progression per BICR and who did not die or participants who started any subsequent anti-cancer therapy without a prior reported progression per BICR will be censored at the date of the last tumor assessment on or prior to initiation of the subsequent anticancer therapy, if any. Participants who die without a reported prior progression per BICR will be considered to have progressed on the date of death. Participants who did not have any baseline or post baseline tumor assessments and did not die (or died after initiation of the subsequent anti-cancer therapy) will be censored at the randomization date. (NCT03414983)
Timeframe: From randomization to up to the date of the first documented progression (up to 16 months)

InterventionMonths (Median)
Arm A: NIV+mFOLFOX+BEV11.86
Arm B: mFOLFOX+BEV11.93

[back to top]

Event-Free Survival

Event-free survival defined as the time interval from date of treatment start until the date of death, disease progression or relapse. (NCT03488225)
Timeframe: Start of treatment up to 2 years

InterventionMonths (Median)
Treatment (Hyper-CVAD, Inotuzumab Ozogamicin)24

[back to top]

Number of Participants With Minimal Residual Disease (MRD) Negativity

MRD levels continuously assessed during induction and consolidation therapy by 6-color multiparameter flow. MRD negativity defined by a value of at least 10-4 and confirmed on a second bone marrow aspiration/biopsy performed after a subsequent cycle. (NCT03488225)
Timeframe: Start of treatment up to 2 years

InterventionParticipants (Count of Participants)
Treatment (Hyper-CVAD, Inotuzumab Ozogamicin)4

[back to top]

Number of Participants With Adverse Events

For the purpose of toxicity monitoring, toxicities are defined as any treatment -related grade 3 or 4 non-hematologic AEs occurred any time during the trial.NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 utilized for adverse event reporting. (NCT03488225)
Timeframe: Start of treatment up to 30 days after last dose received.

InterventionParticipants (Count of Participants)
Neutropenic FeverPeripheral Sensory NeuropathyAllergic ReactionMuscle Weakness
Treatment (Hyper-CVAD, Inotuzumab Ozogamicin)2111

[back to top]

Participants to Achieve Complete Remission (CR):

Complete Remission (CR) is defined as - Normalization of the peripheral blood and bone marrow blasts /= 100X10^9/L and complete resolution of all sites of extramedullary disease. (NCT03488225)
Timeframe: Start of treatment up to 2 years

InterventionParticipants (Count of Participants)
Treatment (Hyper-CVAD, Inotuzumab Ozogamicin)4

[back to top]

Overall Survival

Time from date of treatment start until date of death due to any cause or last Follow-up. (NCT03488225)
Timeframe: Start of treatment up to 2 years

InterventionMonths (Median)
Treatment (Hyper-CVAD, Inotuzumab Ozogamicin)24

[back to top]

Progression Free Survival (PFS)

"Defined as the duration from the date of randomization to the date of progressive disease or death from any cause.~Progressive Disease is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as at least 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must have also demonstrated an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered progression." (NCT03504423)
Timeframe: 38 months

Interventionmonths (Median)
CPI-613, mFolfirinox7.82
Folfirinox7.98

[back to top]

Overall Response Rate (ORR)

Defined as the rate of Complete Response (CR) plus Partial Response (PR): Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), at least 30% decrease in the sum of diameters of target lesions; (NCT03504423)
Timeframe: 38 months

InterventionParticipants (Count of Participants)
CPI-613, mFolfirinox104
Folfirinox90

[back to top]

Overall Survival (OS)

Defined as the duration from the date of randomization to the date of death from any cause (NCT03504423)
Timeframe: 38 months

Interventionmonths (Median)
CPI-613, mFolfirinox11.10
Folfirinox11.73

[back to top]

Median Time to Recurrence

Disease recurrence will be defined as radiographic tumor evidence detected by surveillance imaging. Confirmation of recurrence by biopsy will be at the discretion of the treating physician. This study closed early on June 18, 2020. It was earlier than one planned because of the lack of accrual. (NCT03515941)
Timeframe: From the end of completion of assigned therapy, subjects undergo follow-up every 3 months for a total of 36 months(planned) after the date of surgery or until the study closure

Interventionmonths (Median)
Arm 1: Adjuvant ChemotherapyNA
Arm 2: Adjuvant ChemoradiationNA

[back to top] [back to top]

Duration of Response

"Response date to loss of response or last follow up. Complete Remission (CR): Normalization of the peripheral blood and bone marrow with 5% or less blasts in normocellular or hypercellular marrow with a granulocyte count of 1 x 10^9/L or above, and platelet count of 100 x 10^9/L. Complete resolution of all sites of extramedullary disease is required for CR.~Complete remission without recovery of counts (CRi): Peripheral blood and marrow results as for CR, but with incomplete recover of counts (platelets < 100 x 10^9/L; neutrophils < 1 x 10^9/L).~Partial Response (PR): As above for CR except for the presence of 6-25% marrow blasts." (NCT03518112)
Timeframe: Time from the first day of treatment assessed up to 3 years, 1 month

InterventionMonths (Median)
Treatment (Blinatumomab, Combination Chemotherapy)4.4

[back to top]

Number of Participants Negative for Minimal Residual Disease (MRD)

Minimal Residual Disease (MRD) was assessed by flow cytometry. MRD negativity: Absence of detectable leukemia using multiparameter flow cytometry with a sensitivity of NCT03518112)
Timeframe: Up to 3 years

InterventionParticipants (Count of Participants)
Treatment (Blinatumomab, Combination Chemotherapy)4

[back to top]

Overall Survival

Time from date of treatment start until date of death due to any cause or last Follow-up. (NCT03518112)
Timeframe: Time from the first day of treatment assessed up to 3 years, 1 month

InterventionMonths (Median)
Treatment (Blinatumomab, Combination Chemotherapy)16.7

[back to top]

Participants With a Response

"defined as the percentage of patients achieving complete response (CR) or CR with inadequate count recovery (CRi). Complete Remission (CR): Normalization of the peripheral blood and bone marrow with 5% or less blasts in normocellular or hypercellular marrow with a granulocyte count of 1 x 10^9/L or above, and platelet count of 100 x 10^9/L. Complete resolution of all sites of extramedullary disease is required for CR.~Complete remission without recovery of counts (CRi): Peripheral blood and marrow results as for CR, but with incomplete recover of counts (platelets < 100 x 10^9/L; neutrophils < 1 x 10^9/L)." (NCT03518112)
Timeframe: Up to 3 years

InterventionParticipants (Count of Participants)
Treatment (Blinatumomab, Combination Chemotherapy)4

[back to top]

Event Free Survival (EFS) Where Events Defined as no Response, Loss of Response, or Death

"Time from date of treatment start until the date of first objective documentation of disease-relapse. Relapse and resistant disease will be defined based on morphological assessment of bone marrow and peripheral blood.~Complete Remission (CR): Normalization of the peripheral blood and bone marrow with 5% or less blasts in normocellular or hypercellular marrow with a granulocyte count of 1 x 10^9/L or above, and platelet count of 100 x 10^9/L. Complete resolution of all sites of extramedullary disease is required for CR.~Complete remission without recovery of counts (CRi): Peripheral blood and marrow results as for CR, but with incomplete recover of counts (platelets < 100 x 10^9/L; neutrophils < 1 x 10^9/L).~Partial Response (PR): As above for CR except for the presence of 6-25% marrow blasts." (NCT03518112)
Timeframe: Time from the first day of treatment assessed up to 3 years, 1 month

InterventionMonths (Median)
Treatment (Blinatumomab, Combination Chemotherapy)5.7

[back to top]

Serum Concentrations of Durvalumab

Serum concentrations of durvalumab are reported. (NCT03611556)
Timeframe: Ten mins (± 5 mins) post EOI, approximately 1 hour (+ 15 mins) after start of infusion on C1D1 and C5D1; and pre-dose on C2D1 and C5D1

,,,
Interventionμg/mL (Geometric Mean)
C1D1 (EOI)C2D1 (pre-dose)C5D1 (pre-dose)C5D1 (EOI)
Dose-escalation, Oleclumab 1500 mg + Durvalumab + Gemcitabine + Nab-paclitaxel292.535.97NANA
Dose-escalation, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel374.514.3974.52522.1
Dose-escalation, Oleclumab 3000 mg + Durvalumab + mFOLFOX380.759.97175.9664.5
Dose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel345.886.20137.9597.9

[back to top]

Serum Concentrations of Oleclumab

Serum concentrations of oleclumab are reported. (NCT03611556)
Timeframe: Ten minutes (mins) (± 5 mins) post end of infusion (EOI), approximately 1 hour (+ 15 mins) after start of infusion on C1D1, C3D1, and C5D1; and pre-dose on C3D1 and C5D1

Interventionμg/mL (Geometric Mean)
C1D1 (EOI)C3D1 (pre-dose)C3D1 (EOI)
Dose-escalation, Oleclumab 1500 mg + Durvalumab + mFOLFOX412.7134.3571.1

[back to top]

Serum Concentrations of Oleclumab

Serum concentrations of oleclumab are reported. (NCT03611556)
Timeframe: Ten minutes (mins) (± 5 mins) post end of infusion (EOI), approximately 1 hour (+ 15 mins) after start of infusion on C1D1, C3D1, and C5D1; and pre-dose on C3D1 and C5D1

,,,,
Interventionμg/mL (Geometric Mean)
C1D1 (EOI)C3D1 (pre-dose)C3D1 (EOI)C5D1 (pre-dose)C5D1 (EOI)
Dose-escalation, Oleclumab 1500 mg + Durvalumab + Gemcitabine + Nab-paclitaxel297.6128.6NANANA
Dose-escalation, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel710.2211.5870.373.19948.3
Dose-escalation, Oleclumab 3000 mg + Durvalumab + mFOLFOX734.6368.91181235.71057
Dose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel725.9226.8894.4116.4753.2
Dose-expansion, Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxel704.4164.8893.085.99852.8

[back to top]

Number of Participants With TEAEs and TESAEs in Dose Expansion Phase

An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. The TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug. (NCT03611556)
Timeframe: Day 1 through 172.1 weeks (maximum observed duration)

,,
InterventionParticipants (Count of Participants)
Any TEAEsAny TESAEs
Dose-expansion, Gemcitabine + Nab-paclitaxel6234
Dose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel7037
Dose-expansion, Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxel3724

[back to top]

Serum Concentrations of Durvalumab

Serum concentrations of durvalumab are reported. (NCT03611556)
Timeframe: Ten mins (± 5 mins) post EOI, approximately 1 hour (+ 15 mins) after start of infusion on C1D1 and C5D1; and pre-dose on C2D1 and C5D1

Interventionμg/mL (Geometric Mean)
C1D1 (EOI)C2D1 (pre-dose)
Dose-escalation, Oleclumab 1500 mg + Durvalumab + mFOLFOX309.050.52

[back to top]

Progression-free Survival According to RECIST v1.1 in Dose Expansion Phase

The PFS is defined as the time from randomization until the first documentation of a PD or death due to any cause, whichever occurred first, regardless of whether the participant received subsequent anticancer treatment prior to progression. The PD is defined as at least a 20% increase in sum of the diameters of target lesions, taking as reference the smallest sum on study and an absolute increase of at least 5 mm of sum of the diameters, or unequivocal progression of existing non-target lesions, or the appearance of new lesion/s. Participants who had no documented progression and were still alive at the time of analysis were censored at the time of the latest date of assessment from their last evaluable RECIST v1.1 assessment. The PFS is assessed using the Kaplan-Meier method. (NCT03611556)
Timeframe: Baseline (Days -28 to -1) through 36.1 months (maximum observed duration)

InterventionMonths (Median)
Dose-expansion, Gemcitabine + Nab-paclitaxel6.7
Dose-expansion, Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxel5.6
Dose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel7.5

[back to top]

Number of Participants With Positive Anti-drug Antibodies (ADA) to Oleclumab

Number of participants with positive ADA to oleclumab are reported. Persistent positive is defined as positive at >= 2 post-baseline assessments (with >=16 weeks between first and last positive) or positive at last post-baseline assessment. Transient positive is defined as negative at last post-baseline assessment and positive at only one post-baseline assessment or at >= 2 post-baseline assessments (with <16 weeks between first and last positive). Treatment-boosted ADA is defined as baseline ADA positive titer that was boosted to a 4-fold or higher level following drug administration. (NCT03611556)
Timeframe: Day 1 through 172.1 weeks (Pre-dose on Cycle [C] 1 Day [D] 1, C2D1, C3D1, Day 1 of every 3 cycles starting with C5, through 12 weeks post last dose of oleclumab)

,,,,,
InterventionParticipants (Count of Participants)
ADA positive at baselineADA positive post-baselinePersistent PositiveTransient PositiveTreatment-boosted ADA
Dose-escalation, Oleclumab 1500 mg + Durvalumab + Gemcitabine + Nab-paclitaxel01100
Dose-escalation, Oleclumab 1500 mg + Durvalumab + mFOLFOX00000
Dose-escalation, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel00000
Dose-escalation, Oleclumab 3000 mg + Durvalumab + mFOLFOX01100
Dose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel00000
Dose-expansion, Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxel01010

[back to top]

Number of Participants With Positive ADA to Durvalumab

Number of participants with positive ADA to durvalumab are reported. Persistent positive is defined as positive at >= 2 post-baseline assessments (with >=16 weeks between first and last positive) or positive at last post-baseline assessment. Transient positive is defined as negative at last post-baseline assessment and positive at only one post-baseline assessment or at >= 2 post-baseline assessments (with <16 weeks between first and last positive). Treatment-boosted ADA is defined as baseline ADA positive titer that was boosted to a 4-fold or higher level following drug administration. (NCT03611556)
Timeframe: Day 1 through 128 weeks (Pre-dose on C1D1, C2D1, C3D1, Day 1 of every 3 cycles starting with C5, through 12 weeks post last dose of durvalumab)

,,,,
InterventionParticipants (Count of Participants)
ADA positive at baselineADA positive post-baselinePersistent PositiveTransient PositiveTreatment-boosted ADA
Dose-escalation, Oleclumab 1500 mg + Durvalumab + Gemcitabine + Nab-paclitaxel01100
Dose-escalation, Oleclumab 1500 mg + Durvalumab + mFOLFOX00000
Dose-escalation, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel00000
Dose-escalation, Oleclumab 3000 mg + Durvalumab + mFOLFOX02200
Dose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel20000

[back to top]

Number of Participants With Abnormal Vital Signs Reported as TEAEs in Dose Expansion Phase

Number of participants with abnormal vital signs (temperature, blood pressure, pulse rate, and respiratory rate) reported as TEAEs are reported. (NCT03611556)
Timeframe: Day 1 through 172.1 weeks (maximum observed duration)

,,
InterventionParticipants (Count of Participants)
HypothermiaPyrexiaDyspnoeaDyspnoea exertionalHypertensionHypotensionOrthostatic hypotension
Dose-expansion, Gemcitabine + Nab-paclitaxel01571231
Dose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel121821140
Dose-expansion, Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxel01261340

[back to top]

Number of Participants With Abnormal Vital Signs Reported as TEAEs in Dose Escalation Phase

Number of participants with abnormal vital signs (temperature, blood pressure, pulse rate, and respiratory rate) reported as TEAEs are reported. (NCT03611556)
Timeframe: Day 1 through 65.7 weeks (maximum observed duration)

,,,
InterventionParticipants (Count of Participants)
PyrexiaDyspnoeaDyspnoea exertionalHypotensionTemperature intoleranceHypertension
Dose-escalation, Oleclumab 1500 mg + Durvalumab + Gemcitabine + Nab-paclitaxel310200
Dose-escalation, Oleclumab 1500 mg + Durvalumab + mFOLFOX000010
Dose-escalation, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel301100
Dose-escalation, Oleclumab 3000 mg + Durvalumab + mFOLFOX100101

[back to top]

Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs in Dose Escalation Phase

Number of participants with abnormal ECG parameters reported as TEAEs are reported. (NCT03611556)
Timeframe: Day 1 through 65.7 weeks (maximum observed duration)

,,,
InterventionParticipants (Count of Participants)
Atrial fibrillationTachycardiaAtrioventricular block
Dose-escalation, Oleclumab 1500 mg + Durvalumab + Gemcitabine + Nab-paclitaxel000
Dose-escalation, Oleclumab 1500 mg + Durvalumab + mFOLFOX000
Dose-escalation, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel110
Dose-escalation, Oleclumab 3000 mg + Durvalumab + mFOLFOX001

[back to top]

Number of Participants With Abnormal ECG Parameters Reported as TEAEs in Dose Expansion Phase

Number of participants with abnormal ECG parameters reported as TEAEs are reported. (NCT03611556)
Timeframe: Day 1 through 172.1 weeks (maximum observed duration)

,,
InterventionParticipants (Count of Participants)
Supraventricular tachycardiaTachycardia
Dose-expansion, Gemcitabine + Nab-paclitaxel02
Dose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel03
Dose-expansion, Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxel13

[back to top]

Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs in Dose Expansion Phase

Number of participants with abnormal clinical laboratory parameters reported as TEAEs are reported. (NCT03611556)
Timeframe: Day 1 through 172.1 weeks (maximum observed duration)

,,
InterventionParticipants (Count of Participants)
AnaemiaFebrile neutropeniaLeukocytosisLeukopeniaLymphopeniaNeutropeniaThrombocytopeniaThrombocytosisHyperthyroidismHypothyroidismHypertransaminasaemiaAlanine aminotransferase decreasedAlanine aminotransferase increasedAmylase increasedAspartate aminotransferase increasedBlood albumin decreasedBlood alkaline phosphatase increasedBlood bilirubin increasedBlood creatinine increasedBlood glucose increasedBlood lactate dehydrogenase increasedBlood magnesium decreasedBlood oestrogen decreasedGamma-glutamyltransferase increasedHaemoglobin decreasedInternational normalised ratio increasedLipase increasedLiver function test increasedLymphocyte count decreasedNeutrophil countNeutrophil count decreasedPlatelet count decreasedTroponin I increasedWhite blood cell count decreasedWhite blood cell count increasedHyperglycaemiaHyperkalaemiaHypoalbuminaemiaHypocalcaemiaHypoglycaemiaHypokalaemiaHypomagnesaemiaHyponatraemiaHypophosphataemiaHypovolaemiaIron deficiencyType 2 diabetes mellitusProteinuria
Dose-expansion, Gemcitabine + Nab-paclitaxel17011222620001811113320100600014019131604132044811000
Dose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel28313216131370016115082803008112061242001006163286300101
Dose-expansion, Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxel14102015700010908023020111001020890612122023000011

[back to top]

Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs in Dose Escalation Phase

Number of participants with abnormal clinical laboratory parameters reported as TEAEs are reported. (NCT03611556)
Timeframe: Day 1 through 65.7 weeks (maximum observed duration)

,,,
InterventionParticipants (Count of Participants)
AnaemiaNeutropeniaThrombocytopeniaHypothyroidismAlanine aminotransferase increasedAspartate aminotransferase increasedBlood alkaline phosphatase increasedBlood bilirubin increasedBlood creatinine increasedBlood glucose decreasedInternational normalised ratio increasedLymphocyte count decreasedNeutrophil count decreasedPlatelet count decreasedWhite blood cell count decreasedHypoalbuminaemiaHypocalcaemiaHypokalaemiaHypomagnesaemiaHyponatraemiaHypophosphataemiaProteinuriaHyperthyroidismAmylase increasedGamma-glutamyltransferase increasedLipase increased
Dose-escalation, Oleclumab 1500 mg + Durvalumab + Gemcitabine + Nab-paclitaxel32203321011001000010010000
Dose-escalation, Oleclumab 1500 mg + Durvalumab + mFOLFOX12200000000011000000000100
Dose-escalation, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel32214310300123221322100000
Dose-escalation, Oleclumab 3000 mg + Durvalumab + mFOLFOX01112311000232211212001111

[back to top]

Progression-free Survival According to RECIST v1.1 by CD73 Expression at Baseline in Dose Expansion Phase

The PFS is defined as the time from randomization until the first documentation of a PD or death due to any cause, whichever occurred first, regardless of whether the participant receives subsequent anticancer treatment prior to progression. The PD is defined as at least a 20% increase in SoD of TLs, taking as reference the smallest sum on study and an absolute increase of at least 5 mm of SoD, or unequivocal progression of existing NTLs, or the appearance of new lesion/s. Participants who had no documented progression and were still alive at time of analysis were censored at time of latest date of assessment from their last evaluable RECIST v1.1 assessment. PFS is assessed by CD73 expression level either low/high at baseline using Kaplan-Meier method. CD73 low: No CD73 expression in tumor cells/<50% of tumor cells with 2+/3+ intensity. CD73 high: CD73 expression with 2+/3+ intensity in >=50% of tumor cells. (NCT03611556)
Timeframe: Baseline (Days -28 to -1) through 36.1 months (maximum observed duration)

InterventionMonths (Median)
Gemcitabine + Nab-paclitaxel: CD73 Level = High5.6
Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxel: CD73 Level = High5.2
Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel: CD73 Level = High5.5
Gemcitabine + Nab-paclitaxel: CD73 Level = Low10.5
Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxel: CD73 Level = Low7.6
Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel: CD73 Level = Low10.9

[back to top]

Percentage of Participants With OR According to RECIST v1.1 in Dose Escalation Phase

The OR is defined as best overall response of confirmed CR or confirmed PR based on RECIST v1.1 guidelines. The CR is defined as disappearance of all target and non-target lesions, any pathological lymph nodes (target and non-target) must have reduction in short axis < 10 mm, and no new lesions. The PR is defined as at least a 30% decrease in the sum of the diameters of target lesions (compared to baseline) and no new lesions. Confirmation of CR and PR is required by a repeat, consecutive assessment no less than 4 weeks from the date of first documentation. Percentage of participants with OR is reported. (NCT03611556)
Timeframe: Baseline (Days -28 to -1) through 24.5 months (maximum observed duration)

InterventionPercentage of Participants (Number)
Dose-escalation, Oleclumab 1500 mg + Durvalumab + Gemcitabine + Nab-paclitaxel0
Dose-escalation, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel14.3
Dose-escalation, Oleclumab 1500 mg + Durvalumab + mFOLFOX0
Dose-escalation, Oleclumab 3000 mg + Durvalumab + mFOLFOX12.5

[back to top]

Percentage of Participants With OR According to RECIST v1.1 by CD73 Expression at Baseline in Dose Expansion Phase

The OR is defined as best overall response of confirmed CR or confirmed PR based on RECIST v1.1. The CR is defined as disappearance of all TLs and NTLs, any pathological lymph nodes (target and non-target) must have reduction in short axis <10 mm, and no new lesions. The PR is defined as at least a 30% decrease in the SoD of TLs (compared to baseline) and no new lesions. Confirmation of CR and PR is required by a repeat, consecutive assessment no less than 4 weeks from the date of first documentation. The OR is assessed by cluster of differentiation 73 (CD73) expression level either low or high at baseline. The CD73 low is defined as no CD73 expression in tumor cells or <50% of tumor cells with 2+ or 3+ intensity and CD73 high is defined as CD73 expression with 2+ or 3+ intensity in >=50% of tumor cells. (NCT03611556)
Timeframe: Baseline (Days -28 to -1) through 36.1 months (maximum observed duration)

InterventionPercentage of Participants (Number)
Gemcitabine + Nab-paclitaxel: CD73 Level = High23.9
Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxel: CD73 Level = High22.2
Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel: CD73 Level = High31.4
Gemcitabine + Nab-paclitaxel: CD73 Level = Low43.8
Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxel: CD73 Level = Low18.2
Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel: CD73 Level = Low36.8

[back to top]

Percentage of Participants With Objective Response (OR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in Dose Expansion Phase

The OR is defined as best overall response of confirmed complete response (CR) or confirmed partial response (PR) based on RECIST v1.1 guidelines. The CR is defined as disappearance of all target lesions (TLs) and non-target lesions (NTLs), any pathological lymph nodes (target and non-target) must have reduction in short axis < 10 mm, and no new lesions. The PR is defined as at least a 30% decrease in the sum of the diameters (SoD) of TLs (compared to baseline) and no new lesions. Confirmation of CR and PR is required by a repeat, consecutive assessment no less than 4 weeks from the date of first documentation. Percentage of participants with OR is reported. (NCT03611556)
Timeframe: Baseline (Days -28 to -1) through 36.1 months (maximum observed duration)

InterventionPercentage of Participants (Number)
Dose-expansion, Gemcitabine + Nab-paclitaxel29.0
Dose-expansion, Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxel21.1
Dose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel32.9

[back to top]

Percentage of Participants With Disease Control (DC) According to RECIST v1.1 in Dose Escalation Phase

The DC is defined as confirmed CR, PR, or stable disease (SD) (maintained for >=8 weeks). The CR is defined as disappearance of all TLs and NTLs, any pathological lymph nodes (target and non-target) must have reduction in short axis <10 mm, and no new lesions. The PR is defined as at least a 30% decrease in the SoD of TLs (compared to baseline) and no new lesions. Confirmation of CR and PR is required by a repeat, consecutive assessment no less than 4 weeks from date of first documentation. The SD is defined as neither sufficient shrinkage of TLs to qualify for PR nor sufficient increase of TLs to qualify for progressive disease (PD), taking as reference the smallest SoD while on study, and no new lesions. The PD is defined as at least a 20% increase in SoD of TLs, taking as reference the smallest sum on study and an absolute increase of at least 5 mm of SoD, or unequivocal progression of existing NTLs, or the appearance of new lesion/s. Percentage of participants with DC is reported. (NCT03611556)
Timeframe: Baseline (Days -28 to -1) through 24.5 months (maximum observed duration)

InterventionPercentage of Participants (Number)
Dose-escalation, Oleclumab 1500 mg + Durvalumab + Gemcitabine + Nab-paclitaxel42.9
Dose-escalation, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel71.4
Dose-escalation, Oleclumab 1500 mg + Durvalumab + mFOLFOX66.7
Dose-escalation, Oleclumab 3000 mg + Durvalumab + mFOLFOX62.5

[back to top]

Percentage of Participants With DC According to RECIST v1.1 in Dose Expansion Phase

The DC is defined as confirmed CR, PR, or stable disease (SD) (maintained for >=8 weeks). The CR is defined as disappearance of all TLs and NTLs, any pathological lymph nodes (target and non-target) must have reduction in short axis <10 mm, and no new lesions. The PR is defined as at least a 30% decrease in the SoD of TLs (compared to baseline) and no new lesions. Confirmation of CR and PR is required by a repeat, consecutive assessment no less than 4 weeks from date of first documentation. The SD is defined as neither sufficient shrinkage of TLs to qualify for PR nor sufficient increase of TLs to qualify for PD, taking as reference the smallest SoD while on study, and no new lesions. The PD is defined as at least a 20% increase in SoD of TLs, taking as reference the smallest sum on study and an absolute increase of at least 5 mm of SoD, or unequivocal progression of existing NTLs, or the appearance of new lesion/s. Percentage of participants with DC is reported. (NCT03611556)
Timeframe: Baseline (Days -28 to -1) through 36.1 months (maximum observed duration)

InterventionPercentage of Participants (Number)
Dose-expansion, Gemcitabine + Nab-paclitaxel66.1
Dose-expansion, Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxel73.7
Dose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel75.7

[back to top]

Overall Survival in Dose Expansion Phase

The overall survival is defined as the time from the randomization until death due to any cause. For participants who were alive at the time of data cut off, overall survival was censored on the last date when participants were known to be alive. The overall survival is assessed using the Kaplan-Meier method. (NCT03611556)
Timeframe: Baseline (Days -28 to -1) through 38.7 months (maximum observed duration)

InterventionMonths (Median)
Dose-expansion, Gemcitabine + Nab-paclitaxel10.8
Dose-expansion, Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxel8.9
Dose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel12.9

[back to top]

Overall Survival by CD73 Expression at Baseline in Dose Expansion Phase

The overall survival is defined as the time from the randomization until death due to any cause. For participants who were alive at the time of data cut off, overall survival was censored on the last date when participants were known to be alive. The overall survival is assessed by CD73 expression level either low or high at baseline using the Kaplan-Meier method. The CD73 low is defined as no CD73 expression in tumor cells or <50% of tumor cells with 2+ or 3+ intensity and CD73 high is defined as CD73 expression with 2+ or 3+ intensity in >=50% of tumor cells. (NCT03611556)
Timeframe: Baseline (Days -28 to -1) through 38.7 months (maximum observed duration)

InterventionMonths (Median)
Gemcitabine + Nab-paclitaxel: CD73 Level = High9.9
Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxel: CD73 Level = High7.9
Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel: CD73 Level = High12.1
Gemcitabine + Nab-paclitaxel: CD73 Level = Low22.2
Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxel: CD73 Level = Low16.0
Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel: CD73 Level = Low16.1

[back to top]

Number of Participants With Progression-free Survival Events According to RECIST v1.1 in Dose Expansion Phase

Progression-free survival (PFS) is defined as the time from randomization until the first documentation of a PD or death due to any cause, whichever occurred first, regardless of whether the participant received subsequent anticancer treatment prior to progression. The PD is defined as at least a 20% increase in sum of the diameters of target lesions, taking as reference the smallest sum on study and an absolute increase of at least 5 mm of sum of the diameters, or unequivocal progression of existing non-target lesions, or the appearance of new lesion/s. Participants who had no documented progression and were still alive at the time of analysis were censored at the time of the latest date of assessment from their last evaluable RECIST v1.1 assessment. The PFS is assessed using the Kaplan-Meier method. The number of participants with PFS events is reported. (NCT03611556)
Timeframe: Baseline (Days -28 to -1) through 36.1 months (maximum observed duration)

InterventionParticipants with event (Number)
Dose-expansion, Gemcitabine + Nab-paclitaxel43
Dose-expansion, Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxel32
Dose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel51

[back to top]

Number of Participants With Progression-free Survival Events According to RECIST v1.1 by CD73 Expression at Baseline in Dose Expansion Phase

PFS: Time from randomization until first documentation of PD/death due to any cause, whichever occurred first, regardless of whether participant received subsequent anticancer treatment prior to progression. PD:>=20% increase in SoD of TLs and an absolute increase of >= 5 mm of SoD/unequivocal progression of existing NTLs/appearance of new lesion. Participants who had no documented progression and were still alive at the time of analysis were censored at time of latest date of assessment from their last evaluable RECIST v1.1 assessment. PFS is assessed by CD73 expression level either low/high at baseline using Kaplan-Meier method. CD73 low: No CD73 expression in tumor cells/<50% of tumor cells with 2+/3+ intensity. CD73 high: CD73 expression with 2+/3+ intensity in >=50% of tumor cells. Number of participants with PFS events is reported. (NCT03611556)
Timeframe: Baseline (Days -28 to -1) through 36.1 months (maximum observed duration)

InterventionParticipants with event (Number)
Gemcitabine + Nab-paclitaxel: CD73 Level = High35
Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxel: CD73 Level = High23
Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel: CD73 Level = High39
Gemcitabine + Nab-paclitaxel: CD73 Level = Low8
Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxel: CD73 Level = Low9
Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel: CD73 Level = Low12

[back to top]

Number of Participants With Overall Survival Events in Dose Expansion Phase

The overall survival is defined as the time from the randomization until death due to any cause. For participants who were alive at the time of data cut off, overall survival was censored on the last date when participants were known to be alive. The overall survival is assessed using the Kaplan-Meier method. The number of participants with overall survival events (deaths) is reported. (NCT03611556)
Timeframe: Baseline (Days -28 to -1) through 38.7 months (maximum observed duration)

InterventionParticipants with event (Number)
Dose-expansion, Gemcitabine + Nab-paclitaxel47
Dose-expansion, Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxel32
Dose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel53

[back to top]

Number of Participants With Overall Survival Events by CD73 Expression at Baseline in Dose Expansion Phase

The overall survival is defined as the time from the randomization until death due to any cause. For participants who were alive at the time of data cut off, overall survival was censored on the last date when participants were known to be alive. The overall survival is assessed by CD73 expression level either low or high at baseline using the Kaplan-Meier method. The CD73 low is defined as no CD73 expression in tumor cells or <50% of tumor cells with 2+ or 3+ intensity and CD73 high is defined as CD73 expression with 2+ or 3+ intensity in >=50% of tumor cells. The number of participants with overall survival events (deaths) is reported. (NCT03611556)
Timeframe: Baseline (Days -28 to -1) through 38.7 months (maximum observed duration)

InterventionParticipants with event (Number)
Gemcitabine + Nab-paclitaxel: CD73 Level = High37
Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxel: CD73 Level = High22
Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel: CD73 Level = High39
Gemcitabine + Nab-paclitaxel: CD73 Level = Low10
Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxel: CD73 Level = Low10
Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel: CD73 Level = Low14

[back to top]

Number of Participants With Dose-limiting Toxicities (DLTs) in Dose Escalation Phase

DLT: Any study drug related Grade (G)3 or higher toxicity including: any G4 immune-mediated AEs, >=G3 colitis/pneumonitis/interstitial lung disease (ILD), >=G3 nausea/vomiting/diarrhea that does not resolve to G2 or less within 3 days of maximal supportive care (MSC), G2 pneumonitis/ILD that does not resolve within 7 days of initiation of MSC, G4 anemia, G3 anemia with clinical sequelae/requires >2 units of red blood cells transfusion, G4 thrombocytopenia/neutropenia >=7 days, G3/4 thrombocytopenia with >=G3 hemorrhage, G4 febrile neutropenia (FN), G3 FN lasting >=5 days while receiving MSC, isolated G3 liver transaminase elevation (LTE)/ isolated G3 total bilirubin (TBL) that does not downgrade to G1 or less within 14 days of onset, isolated G4 LTE or TBL, elevated aspartate aminotransferase/alanine aminotransferase >3×upper limit of normal (ULN) and concurrent TBL >2×ULN without cholestasis or alternative explanations, any other toxicity judged as a DLT by Dose Escalation Committee. (NCT03611556)
Timeframe: From Day 1 to 28 days after the first dose of study drugs

InterventionParticipants (Count of Participants)
Dose-escalation, Oleclumab 1500 mg + Durvalumab + Gemcitabine + Nab-paclitaxel0
Dose-escalation, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel0
Dose-escalation, Oleclumab 1500 mg + Durvalumab + mFOLFOX0
Dose-escalation, Oleclumab 3000 mg + Durvalumab + mFOLFOX1

[back to top]

Duration of Response (DoR) According to RECIST v1.1 in Dose Expansion Phase

The DoR is defined as the time from the first documentation of an OR until the first documentation of a PD or death due to any cause, whichever occurs first. The OR is defined as best overall response of confirmed CR or PR based on RECIST v1.1 guidelines. The CR is defined as disappearance of all TLs and NTLs, any pathological lymph nodes (target and non-target) must have reduction in short axis < 10 mm, and no new lesions. The PR is defined as at least a 30% decrease in the SoD of TLs (compared to baseline) and no new lesions. Confirmation of CR and PR is required by a repeat, consecutive assessment no less than 4 weeks from the date of first documentation. The PD is defined as at least a 20% increase in SoD of TLs, taking as reference the smallest sum on study and an absolute increase of at least 5 mm of SoD, or unequivocal progression of existing NTLs, or the appearance of new lesion/s. The DoR is assessed using the Kaplan-Meier method. (NCT03611556)
Timeframe: Baseline (Days -28 to -1) through 36.1 months (maximum observed duration)

InterventionMonths (Median)
Dose-expansion, Gemcitabine + Nab-paclitaxel7.2
Dose-expansion, Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxel12.9
Dose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel9.5

[back to top]

Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) in Dose Escalation Phase

An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. The TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug. (NCT03611556)
Timeframe: Day 1 through 65.7 weeks (maximum observed duration)

,,,
InterventionParticipants (Count of Participants)
Any TEAEsAny TESAEs
Dose-escalation, Oleclumab 1500 mg + Durvalumab + Gemcitabine + Nab-paclitaxel74
Dose-escalation, Oleclumab 1500 mg + Durvalumab + mFOLFOX30
Dose-escalation, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel76
Dose-escalation, Oleclumab 3000 mg + Durvalumab + mFOLFOX84

[back to top]

Plasma Concentrations of Gemcitabine and Metabolite 2',2'-Difluorodeoxyuridine (dFdU)

Plasma concentrations of gemcitabine and metabolite dFdU are reported. (NCT03611556)
Timeframe: Ten mins (± 5 mins) post EOI, approximately 30-40 mins after start of infusion on C1D1 and C4D1; and pre-dose on C4D1

,,,,
Interventionng/mL (Geometric Mean)
Gemcitabine C1D1 (EOI)Gemcitabine C4D1 (pre-dose)Gemcitabine C4D1 (EOI)dFdU C1D1 (EOI)dFdU C4D1 (pre-dose)dFdU C4D1 (EOI)
Dose-escalation, Oleclumab 1500 mg + Durvalumab + Gemcitabine + Nab-paclitaxel3194NANA33700NANA
Dose-escalation, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel4659NA353032160434.634550
Dose-expansion, Gemcitabine + Nab-paclitaxel3301NA174829510245.123900
Dose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel4086NA299826300177.527260
Dose-expansion, Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxel3315NA143132350149.921970

[back to top]

Plasma Concentrations of Nab-paclitaxel

Plasma concentrations of nab-paclitaxel are reported. (NCT03611556)
Timeframe: Ten mins (± 5 mins) post EOI, approximately 30-40 mins after start of infusion on C1D1 and C4D1; and pre-dose on C4D1

,,,,
Interventionng/mL (Geometric Mean)
C1D1 (EOI)C4D1 (pre-dose)C4D1 (EOI)
Dose-escalation, Oleclumab 1500 mg + Durvalumab + Gemcitabine + Nab-paclitaxel1711NANA
Dose-escalation, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel2685NA1474
Dose-expansion, Gemcitabine + Nab-paclitaxel2381NA1825
Dose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel2611NA1747
Dose-expansion, Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxel2711NA1445

[back to top]

Disease Control Rate (DCR)

To compare the between the 2 treatment arms (NCT03665441)
Timeframe: ~24 weeks

InterventionParticipants (Count of Participants)
Eryaspase Plus Chemotherapy147
Chemotherapy Alone126

[back to top]

Incidence of Treatment Emergent Adverse Events as Assessed by CTCAE v5.0

To evaluate the safety and tolerability of eryaspase in combination with chemotherapy versus chemotherapy alone by assessing the number of patients with with treatment emergent adverse events per CTCAE v5.0 (NCT03665441)
Timeframe: ~9 months

,
Interventionparticipants (Number)
Number of patients with treatment emergent adverse events (TEAE)number of patients with TEAE >= Grade 3Number of patients with TE SAENumber of patients with TEAEs leading to study drug discontinuationNumber of patients with TE SAE with outcome of death
Chemotherapy Alone246176105419
Eryaspase Plus Chemotherapy2481951224614

[back to top]

Time to Quality of Life Questionnaire EORTC QLQ-C30 First Worsening in Global Health Status Analysis

The time to first Worsening was defined as the date of randomization to the date of first Worsening occurred in patient score on their global health status. Patients who did not have any worsening were censored at date of last measurement or at baseline if no measurement is available post-baseline. (NCT03665441)
Timeframe: ~1 year

Interventionmonths (Median)
Eryaspase Plus Chemotherapy4.0
Chemotherapy Alone3.6

[back to top]

Progression Free Survival (PFS)

To compare PFS between the 2 treatment arm. Progression is determined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT03665441)
Timeframe: ~24 weeks

Interventionmonths (Median)
Eryaspase Plus Chemotherapy3.7
Chemotherapy Alone3.4

[back to top]

Overall Survival (OS)

To determine whether the addition of eryaspase to chemotherapy improves OS when compared to chemotherapy alone (NCT03665441)
Timeframe: ~12 months

Interventionmonths (Median)
Eryaspase Plus Chemotherapy7.5
Chemotherapy Alone6.7

[back to top]

Objective Response Rate (ORR)

To compare the ORR between the 2 treatment arms. ORR is defined as the proportion of patients who achieve objective tumor response (CR or PR) per modified RECIST 1.1: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions. (NCT03665441)
Timeframe: ~24 weeks

InterventionParticipants (Count of Participants)
Eryaspase Plus Chemotherapy41
Chemotherapy Alone32

[back to top]

Duration of Response (DoR)

To compare the DoR between the 2 treatment arms (NCT03665441)
Timeframe: ~24 weeks

Interventionmonths (Median)
Eryaspase Plus Chemotherapy5.7
Chemotherapy Alone6.8

[back to top]

Overall Survival

Will be summarized using standard Kaplan-Meier methods; where estimates of the median time will be obtained with 95% confidence intervals. (NCT03736720)
Timeframe: From first dosing of study treatment combination to time of death or imitation of a new therapy, assessed up to 3 years

Interventionmonths (Median)
Treatment (Liposomal Irinotecan, Leucovorin, Fluorouracil)8.3

[back to top]

Progression-free Survival Assessed by RECIST 1.1

Will be summarized using standard Kaplan-Meier methods; where estimates of the median time will be obtained with 95% confidence intervals. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT03736720)
Timeframe: From first dosing of study treatment combination to disease progression, assessed up to 3 years

Interventionmonths (Median)
Treatment (Liposomal Irinotecan, Leucovorin, Fluorouracil)3.9

[back to top]

Time-to Treatment Failure

Will be summarized using standard Kaplan-Meier methods; where estimates of the median time will be obtained with 90% confidence intervals. (NCT03736720)
Timeframe: From enrollment to discontinuation of treatment, assessed up to 3 years

Interventionmonths (Median)
Treatment (Liposomal Irinotecan, Leucovorin, Fluorouracil)3.9

[back to top]

Quality of Life (QOL) as Assessed by European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30)

Will be treated as quantitative data and summarized by time-point using the mean and standard deviation. The QOL scores at each follow-up time may be compared with base-line levels using the paired t-test or sign test. The overall QoL rating ranges from 0 (poor) to 10 (good). (NCT03736720)
Timeframe: From treatment initiation until treatment completion/progression (up to 3 years).

Interventionunits on a scale (Mean)
Pre Treatment QoLEnd of Treatment QoL
Treatment (Liposomal Irinotecan, Leucovorin, Fluorouracil)5.95.5

[back to top]

Duration of Response

The duration of response is measured from the time measurement criteria are first met for CR/PR until the first date that recurrent or progressive disease is objectively documented. (NCT03750786)
Timeframe: Until disease progression, an average of ten months

Interventionmonths (Median)
Group A12.2
Group B12.9

[back to top]

Progression Free Survival

PFS, defined as the time from randomization to first occurrence of tumor progression based on CT-scans/MRIs. (NCT03750786)
Timeframe: Until disease progression, an average of ten months

Interventionmonths (Median)
Group A12.8
Group B11.6

[back to top]

Social Responsiveness Scale (SRS) - Parent Reported Change

"The Social Responsiveness Scale - parent reported version measures social ability in children and young adults. There are 65 questions. The questions on the scale with anchors 1 (Not True) - 4 (Almost Always True). The scoring of SRS questions can range from 0-3 (with possible reverse scoring) based on scoring instructions for data analysis. The total possible score range for the SRS is 0 - 195. Analysis will be performed for mean of total score change over time.~Anchors Not True = 1 Sometimes True = 2 Often True = 3 Almost Always True = 4~Lower score indicates better performance." (NCT03771560)
Timeframe: Baseline to Week 12

Interventionscore on a scale (Mean)
Folinic Acid Open-label-7.8

[back to top]

Social Responsiveness Scale (SRS) - Teacher Reported Change

"The Social Responsiveness Scale - teacher reported version measures social ability in children and young adults. There are 65 questions. The questions on the scale with anchors 1 (Not True) - 4 (Almost Always True). The scoring of SRS questions can range from 0-3 (with possible reverse scoring) based on scoring instructions for data analysis. The total possible score range for the SRS is 0 - 195. Analysis will be performed for mean of total score change over time.~Anchors Not True = 1 Sometimes True = 2 Often True = 3 Almost Always True = 4~Lower score indicates better performance." (NCT03771560)
Timeframe: Baseline to Week 12

Interventionscore on a scale (Median)
Folinic Acid Open-label-0.5

[back to top]

Aberrant Behavior Checklist (ABC) - Parent Reported Change

"The Aberrant Behavior Checklist - parent reported version measures aberrant behavior in children and young adults. There are 58 questions.The scoring of one question can range from 0 (not a problem) to 3 (severe) points on a Likert scale. The total possible score range for the ABC is 0 - 174. Analysis will be performed for mean of total score change over time.~Scoring from 0-3~Not a problem = 0, Slightly = 1, Moderately Serious =2, Severe =3~Lower score indicates better performance." (NCT03771560)
Timeframe: Baseline to Week 12

Interventionscore on a scale (Mean)
Folinic Acid Open-label-2.4

[back to top]

Aberrant Behavior Checklist (ABC) - Teacher Reported Change

"The Aberrant Behavior Checklist - teacher reported version measures aberrant behavior in children and young adults. There are 58 questions. The scoring of ABC questions can range from 0 (not a problem) to 3 (severe) points on a likert scale. The total possible score range for the ABC is 0 - 174. Analysis will be performed for mean of total score change over time.~Scoring from 0-3~Not a problem = 0, Slightly = 1, Moderately Serious =2, Severe =3~Lower score indicates better performance." (NCT03771560)
Timeframe: Baseline to Week 12

Interventionscore on a scale (Mean)
Folinic Acid Open-label1.2

[back to top]

Pediatric Quality of Life (PedsQL) - Parent Reported Change

"Pediatric Quality of Life is reported by parent only and it assesses improvement of the child's overall quality of life through questions about physical, emotional, social and school functioning. There are 23 questions. The scoring of PedsQL questions can range from 0 (Never) to 4 (Almost Always) points on a Likert scale. Questions are reversed scored and linearly transformed to a 0 - 100 scale for data analysis as follows: 0=100, 1=75, 2=50, 3=23, 4=0. The total score = sum of all the questions over the number of items answered on. The total possible score range for the PedsQL is 0 - 100. Analysis will be performed for mean of total score change over time.~Scoring from 0 to 4~Never = 0, Almost Never = 1, Sometimes = 2, Often = 3, Almost Always =4~Higher score indicates better performance." (NCT03771560)
Timeframe: Baseline to Week 12

Interventionscore on a scale (Mean)
Folinic Acid Open-label-0.8

[back to top]

Disease Control Rate (DCR)

Disease Control Rate (DCR) will be defined as the total number of patients whose best responses are either a CR, PR, or SD divided by the number of response evaluable patients. Patients with best response of SD will need to maintain SD by 24 weeks to be considered to have received clinical benefit from the treatment regimen. (NCT03783936)
Timeframe: Up to a maximum of 11 months.

InterventionPercentage of participants (Number)
Induction and Maintenance55.6

[back to top]

Progression Free Survival (PFS)

"Per RECIST 1.1: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter(LD) of target lesions; Progressive Disease (PD): >= 20% increase in tumor burden relative to nadir or the appearance of one or more new lesions; Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started.~Progression Free Survival (PFS) will be defined as the time from the start date of treatment to the date of documented progression as determined by RECIST 1.1 or death from any cause." (NCT03783936)
Timeframe: Time of treatment start until the criteria for disease progression or death, up to a maximum of 11 months.

Interventionmonths (Median)
Induction and Maintenance8

[back to top]

Progression Free Survival by iRECIST(iPFS)

"Immune-RECIST Criteria(iRECIST): Complete Response(iCR), Disappearance of all measurable and non-measurable lesions; Partial Response (iPR), >=30% decrease in tumor burden relative to baseline; Unconfirmed Progressive Disease (iUPD), >= 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions; Confirmed Progressive Disease (iCPD), confirmation of iUPD (by further growth) at the next assessment; Stable Disease (iSD), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started.~iPFS will be defined as the time from the start date of treatment to the date of documented progression as determined by iRECIST criteria or death from any cause." (NCT03783936)
Timeframe: Time of treatment start until the criteria for disease progression or death, up to a maximum of 11 months.

Interventionmonths (Median)
Induction and Maintenance8

[back to top]

Best Objective Response Rate (bORR)

"Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST): Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter(LD) of target lesions; Progressive Disease (PD): >= 20% increase in tumor burden relative to nadir or the appearance of one or more new lesions; Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started.~The bORR will be defined as the percentage of subjects whose best response by 24 weeks are either a CR or PR according to RECIST 1.1. For confirmed response, PR or CR need to be confirmed by repeat assessments that should be performed no less than 4 weeks. Otherwise, it will be considered as an unconfirmed response." (NCT03783936)
Timeframe: 24 weeks

InterventionPercentage of participants (Number)
Best response rate (confirmed or unconfirmed)Best confirmed response rate
Induction and Maintenance6150

[back to top] [back to top]

Overall Survival (OS)

Overall Survival (OS) will be defined as the time from start of treatment to the date of death from any cause, or date of last contact (censored). (NCT03783936)
Timeframe: Time of treatment start until death or date of last contact, up to a maximum of 20 months

Interventionmonths (Median)
Induction and Maintenance13.1

[back to top]